

EXHIBIT 124

Confidential - Subject to Protective Order

Page 1

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP)
PRODUCTS LIABILITY) MDL No. 2741
LITIGATION)
_____) Case No.
THIS DOCUMENT RELATES) 16-md-02741-VC
TO ALL CASES)

WEDNESDAY, SEPTEMBER 20, 2017

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

- - -

Videotaped deposition of
Christopher Corcoran, Sc.D., held at the
Hampton Inn, 1665 North Main Street, Logan,
Utah, commencing at 9:13 a.m., on the above
date, before Carrie A. Campbell, Registered
Diplomate Reporter, Certified Realtime
Reporter, Illinois, California & Texas
Certified Shorthand Reporter, Missouri &
Kansas Certified Court Reporter.

- - -

GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

Confidential - Subject to Protective Order

Page 6

1 Monsanto.
 2 MR. WISNER: Appearing by
 3 phone, Brent Wisner for the
 4 plaintiffs.
 5
 6 CHRISTOPHER CORCORAN, Sc.D.,
 7 of lawful age, having been first duly sworn
 8 to tell the truth, the whole truth and
 9 nothing but the truth, deposes and says on
 10 behalf of the Plaintiffs, as follows:
 11
 12 DIRECT EXAMINATION
 13 QUESTIONS BY MS. GREENWALD:
 14 Q. Dr. Corcoran, I know we just
 15 introduced ourselves, but I'll do it again.
 16 My name is Robin Greenwald, and
 17 I represent the plaintiffs in this lawsuit.
 18 Just a couple of preliminary
 19 issues before we get into the substance.
 20 I talk fast, first of all. I
 21 live in New York, so if I go too fast, just
 22 tell me to slow down.
 23 Okay?
 24 A. Okay.
 25 Q. So I'm going to be asking you

Page 7

1 several questions today, and if you don't
 2 understand a question I ask, please ask me to
 3 rephrase it.
 4 Okay?
 5 A. Okay.
 6 Q. One of the things you have to
 7 do for the court reporter is you have to
 8 audibly answer. You can't shake your head
 9 because she can't take a shake of the head,
 10 so we have to give audible answers.
 11 A. Okay.
 12 Q. All right?
 13 And the other thing we have to
 14 be careful about is I have to finish my
 15 question before you start to answer, and vice
 16 versa, I can't start a question until you
 17 finish your answer. So we have to try to do
 18 that for the court reporter also.
 19 A. Okay.
 20 Q. Have you ever been deposed
 21 before?
 22 A. I have not.
 23 Q. Okay. So I'm sure you've
 24 learned all about what the deposition is, but
 25 I'm glad I went through those preliminary

Page 8

1 issues with you.
 2 The videographer has to take a
 3 certain break at a certain time because of
 4 the tape, how long a tape will go, but if you
 5 need a break before then, just let me know
 6 and we can take a break. The only rule is
 7 you can't take a break when a question is
 8 pending. But other than that, if you need a
 9 break, this is your deposition, and you
 10 should just tell me you want to take a break
 11 and we'll take one.
 12 Okay?
 13 A. Okay. Thank you very much.
 14 Q. All right. Terrific.
 15 So the first thing I want to do
 16 is mark as -- so we're going to be marking
 17 exhibits also through the course of the day,
 18 so there's just some legal stuff that goes
 19 on.
 20 A. Right.
 21 (Corcoran Exhibit 21-1 marked
 22 for identification.)
 23 QUESTIONS BY MS. GREENWALD:
 24 Q. I'm going to mark as
 25 Exhibit 21-1 a copy of the expert report of

Page 9

1 Dr. Christopher D. Corcoran in this
 2 litigation and give you a copy of that.
 3 Dr. Corcoran, is Exhibit 21-1
 4 the expert report that you prepared in
 5 connection with this litigation?
 6 A. Yes.
 7 Q. Okay. So I'm going to be
 8 asking you a lot of questions about that
 9 today, so we'll just leave it here and we'll
 10 mark this, and so this way it will just be
 11 handy for you.
 12 A. Okay.
 13 (Corcoran Exhibit 21-2 marked
 14 for identification.)
 15 QUESTIONS BY MS. GREENWALD:
 16 Q. Okay. The second document I
 17 want to mark is Exhibit 21-2, which is a copy
 18 of the notice for your deposition today.
 19 Have you seen that before?
 20 A. Yes.
 21 Q. So if you could turn to the
 22 last two pages of Exhibit 21-2, which is a
 23 series of requests for production.
 24 Do you see that?
 25 A. Yes.

Confidential - Subject to Protective Order

<p style="text-align: right;">Page 10</p> <p>1 Q. Okay. When did you receive 2 this, approximately, from -- well, let me 3 strike that. 4 Did you receive this from the 5 Hollingsworth firm? 6 A. I did. 7 Q. Okay. Approximately when did 8 you receive this? 9 A. It's been within the last two 10 weeks, I think. 11 Q. Okay. And how did you go about 12 searching for documents that are responsive 13 to the documents that are requested in the 14 request for production? 15 A. I just read through the list 16 and just, I guess, checked that those things 17 were available. 18 Q. Okay. Do you keep paper files 19 in your office? 20 A. Some. 21 Q. And did you check paper files 22 in connection with responding to the request 23 for production? 24 A. Let's see. Do you mind if I 25 just read through again this one more time --</p>	<p style="text-align: right;">Page 12</p> <p>1 correct? 2 A. That's right, yeah. 3 Q. Okay. Great. Thank you. 4 Can you turn to page 9 of your 5 expert report, please? 6 And I'm going to be referring 7 to the lines on the left, which are actually 8 very useful for this deposition, so I can 9 actually tell you where on the page we're 10 looking. 11 A. Sure. 12 Q. If you look at lines 33 and 13 34 -- 14 A. Uh-huh. 15 Q. -- you state as follows: "As 16 shown in Tables 1 and 2, of the hundreds of 17 individual tumor types evaluated across all 18 12 experiments, 1,016 were observed in at 19 least one mouse or rat." 20 Do you see that? 21 A. Yes. 22 Q. Did I read that accurately? 23 A. Yes. 24 Q. What sources did you use to 25 come up with that number?</p>
<p style="text-align: right;">Page 11</p> <p>1 Q. No. Not at all. 2 A. -- just to make sure? 3 Q. That's fine. 4 A. I would say most everything on 5 this list I keep as electronic files. There 6 were a couple of items that are -- that I 7 have hard copies of. 8 Q. Okay. So you searched your 9 electronic files for documents that would be 10 responsive to the request for production 11 contained in 21-2? 12 A. Yes. 13 Q. Okay. And did you produce to 14 your attorneys everything that you had in 15 your files that were responsive to your 16 request for production? 17 A. Yes. Everything that they -- 18 that they -- that they told me was required, 19 I provided for them. 20 Q. Okay. And do you have an 21 assistant in your job at the university? 22 A. No. 23 Q. Okay. So in other words, if 24 it's not in your electronic file, it doesn't 25 exist for purposes of this work; is that</p>	<p style="text-align: right;">Page 13</p> <p>1 A. The data that I used all came 2 from the supplement that was produced by 3 Greim that I cited in the expert report. 4 Q. And what did you actually do 5 from the Greim -- or what did you actually 6 use from the Greim paper to calculate the 7 1,016? 8 A. The supplement that Greim 9 provided that had all of the data tables, 10 I -- I guess I just transcribed all of those. 11 I made -- I made my own data files, 12 basically, using the tables from Greim, and 13 those were the tables I used to produce that 14 number. 15 Q. So when you refer to the 16 Greim -- so the Greim -- there's the Greim 17 paper and then there are multiple supplements 18 to the Greim paper, correct? 19 A. That's right. 20 Q. And about how many are there? 21 A. I actually don't know. 22 The supplement that I used, I 23 guess I'm looking at the overall body of data 24 tables that were provided by Greim as a 25 supplement to his paper.</p>

Confidential - Subject to Protective Order

Page 14

1 Q. So did you actually look at all
 2 the supplements to the Greim paper, the
 3 multiple hundreds of pages or thousands of
 4 pages of supplemental material to the Greim
 5 paper, or are you talking about something
 6 else?
 7 A. Are you talking about the --
 8 MR. GRIFFIS: Excuse me.
 9 Objection.
 10 THE WITNESS: Okay. Are you
 11 talking about the supplements that
 12 actually had the data printed?
 13 QUESTIONS BY MS. GREENWALD:
 14 Q. Yeah.
 15 A. Yes, I did. I actually went
 16 through every page.
 17 Q. About how many pages is that;
 18 can you approximate?
 19 A. I can't recall. I mean, it's
 20 at least hundreds.
 21 Q. Okay. But not a thousand?
 22 A. I don't know. I can't recall.
 23 Q. Do you know about how many
 24 supplements there are?
 25 A. By supplements, are you talking

Page 15

1 about individual data tables from the other
 2 12 studies?
 3 Q. Right.
 4 So within -- within the 12
 5 studies, there's data tables, correct?
 6 A. Uh-huh.
 7 Q. And did you review all of the
 8 data tables for all of the studies that were
 9 available in the supplements to Greim?
 10 A. I did.
 11 Q. Okay. And can you approximate
 12 how many pages of data that was that you
 13 reviewed?
 14 A. I can't. It was just an
 15 enormous number, but I can't recall exactly
 16 how many pages there were.
 17 Q. But -- well, let me ask it this
 18 way then. You said a couple hundred before,
 19 but it could be more.
 20 It's less than a couple of
 21 thousands, would you say?
 22 I'm just trying to cabin it and
 23 get some sense of what you recall having
 24 looked at.
 25 A. I really don't know. I just

Page 16

1 know that it was a big task going through all
 2 those data tables, and that's -- if I -- I
 3 mean, obviously if I had the supplement in
 4 front of me, I could tell you exactly, but I
 5 can't remember off the top of my head.
 6 Q. I didn't want to kill all those
 7 trees. Way too many trees to put all this in
 8 front of you.
 9 I have the Greim paper, but
 10 let's wait on that for right now.
 11 A. Okay.
 12 Q. So you came up with the number
 13 of 1,016, and you're saying that number is
 14 from a review by you of the supplemental
 15 material to the Greim paper; is that correct?
 16 A. Yes.
 17 Q. Okay. And so what did you
 18 actually do to calculate the 1016?
 19 A. Well, I took the data from the
 20 Greim supplement. I hand-entered it myself
 21 into -- into a format that I could use to
 22 analyze and, you know, checked it,
 23 double-checked it. And then when I actually
 24 did the analysis, I filtered out all of
 25 the -- all of the tumor types, all of the

Page 17

1 sites for which at least one lesion was
 2 observed among the rats or mice. And so
 3 that's where that 1,016 came from.
 4 Q. Prior to working on this case
 5 in connection with your expert report, had
 6 you done any research about glyphosate?
 7 A. No.
 8 Q. Did you even know about
 9 glyphosate before you were retained in this
 10 case?
 11 A. No, not really.
 12 Q. So in other words, you hadn't
 13 read the IARC Monograph 112 before being
 14 retained in this case?
 15 A. That's right.
 16 Q. Okay. Had you ever done any
 17 consulting work for Monsanto before this
 18 case?
 19 A. No, I haven't.
 20 Q. Did you ever do any consulting
 21 work for any other company before this case
 22 that manufactures pesticides?
 23 A. No.
 24 Q. Is this your first consulting
 25 work for industry?

Confidential - Subject to Protective Order

Page 18

1 A. I do do some consulting work
 2 for Cytel Software Corporation in Boston, but
 3 other than that, no. That's mostly to
 4 develop software.
 5 Q. Okay. Right. I won't have a
 6 lot of questions to ask you about that.
 7 A. All right.
 8 Q. So approximately when were you
 9 contacted by -- let me -- is it the
 10 Hollingsworth firm that contacted you --
 11 A. Yes.
 12 Q. -- in connection with
 13 representation in this case?
 14 A. Yes.
 15 Q. And when was that first
 16 contact?
 17 A. It was August, I think, last
 18 year was the first time I heard from
 19 Hollingsworth.
 20 Q. Okay. And that was August
 21 of 2016?
 22 A. I think so. August -- at the
 23 latest it was September. I know for sure it
 24 was no later than September.
 25 Q. I just want to get the year

Page 19

1 right.
 2 It was 2016?
 3 A. Yeah, about a year ago.
 4 Q. Okay. And how long ago before
 5 you actually agreed to act as a consulting
 6 and expert witness in this case did you have
 7 contact from the Hollingsworth firm?
 8 A. I'm not sure exactly how long,
 9 but I know that it was within two months.
 10 Q. Okay. And who contacted you
 11 from Hollingsworth?
 12 A. It was John Kalas.
 13 Q. And what were you asked to do?
 14 A. He asked me to review some data
 15 from the IARC monograph because I had some
 16 expertise in computing the trend test which
 17 was used for the animal toxicology studies,
 18 and so I reviewed their analysis.
 19 (Corcoran Exhibit 21-3 marked
 20 for identification.)
 21 QUESTIONS BY MS. GREENWALD:
 22 Q. Okay. Let me mark -- so I'm
 23 first going to mark as 21-3 a letter dated
 24 August 31, 2016, from the Hollingsworth firm
 25 to you. Hand that to you.

Page 20

1 A. Thanks.
 2 Q. Is this the retention agreement
 3 between you and the Hollingsworth firm in
 4 connection with this case?
 5 A. Yes.
 6 Q. Okay. So if August 31st is the
 7 date you entered into this agreement,
 8 presumably if it was two weeks before that
 9 you first talked to them, you would have been
 10 in contact with them sometime in mid-August
 11 probably; is that right?
 12 A. Yeah. I think that's right.
 13 Q. Of 2016, right?
 14 A. Yeah.
 15 Q. Okay. And is there anything
 16 that the Hollingsworth firm asked you to do
 17 that's not reflected in Exhibit 21-3?
 18 MR. GRIFFIS: Objection to the
 19 extent this calls for confidential
 20 communications between us and
 21 Dr. Corcoran as to things we asked him
 22 to do.
 23 You can ask him about his
 24 expert report and his work in creating
 25 that.

Page 21

1 THE WITNESS: As far as this
 2 letter goes, no --
 3 MR. GRIFFIS: You don't need to
 4 answer.
 5 MS. GREENWALD: Yeah, I think
 6 he's telling -- I think he's saying
 7 it's invading the attorney-client
 8 privilege, so I'll move on to
 9 something else.
 10 THE WITNESS: Okay. Thanks.
 11 MS. GREENWALD: Sorry.
 12 (Corcoran Exhibits 21-4, 21-5
 13 and 21-6 marked for identification.)
 14 QUESTIONS BY MS. GREENWALD:
 15 Q. Okay. So now I'm going to mark
 16 as 21-4 an invoice from you dated January 20,
 17 2017, which covers the period August 16,
 18 2016, through January 1, 2017.
 19 A. Thanks.
 20 Q. Sure.
 21 And just for ease, I'm going to
 22 mark them all right now. I'm going to mark
 23 the next one as 23-4 {sic}, the invoice from
 24 you dated May 20, 2017, that covers -- wait,
 25 that must be 21-5. Yeah, I'm sorry, 21-5.

Confidential - Subject to Protective Order

Page 22	<p>1 That's my fault -- 21-5, the period of</p> <p>2 February 10, 2017, through May 20th of 2017,</p> <p>3 and I think I mentioned the invoice is dated</p> <p>4 May 20, 2017.</p> <p>5 Okay. And then last I'm going</p> <p>6 to mark as 21-6 your invoice dated</p> <p>7 May 20th -- wait a minute. Is this one also</p> <p>8 dated -- just give me one second. I'm sorry.</p> <p>9 I'm just noticing something.</p> <p>10 Yeah, it's also dated May 20,</p> <p>11 2017. That threw me off. This covers the</p> <p>12 period May 21, 2017, through July 20, 2017,</p> <p>13 and again, I'm marking that as 21-6.</p> <p>14 A. Thanks.</p> <p>15 Q. And let me get you yours.</p> <p>16 A. Oh, sorry, I think I put the</p> <p>17 wrong date on here. It was supposed to be</p> <p>18 July 20th.</p> <p>19 Q. Okay. So I can -- I assume</p> <p>20 you've been continuing working on this case</p> <p>21 since July 20, 2017, obviously, right?</p> <p>22 A. Yes. Yeah.</p> <p>23 Q. This is just the last bill that</p> <p>24 you've given so far?</p> <p>25 A. Right.</p>	Page 24	<p>1 Q. Were you asked to give general</p> <p>2 descriptions like this when you were</p> <p>3 retained?</p> <p>4 MR. GRIFFIS: Objection. Don't</p> <p>5 answer that question.</p> <p>6 THE WITNESS: Right.</p> <p>7 QUESTIONS BY MS. GREENWALD:</p> <p>8 Q. All right. Is this the type</p> <p>9 of -- so can you look at this -- these</p> <p>10 exhibits I just gave you, 21-4, -5 and -6,</p> <p>11 and tell me approximately how much time you</p> <p>12 spent reviewing the Greim papers and the</p> <p>13 supplemental materials?</p> <p>14 A. Yes, I think I can. I can tell</p> <p>15 you that I would say that the -- if you look</p> <p>16 at -- from, I'd say, about January to --</p> <p>17 January through the end of May, that would be</p> <p>18 the time that my effort was concentrated on</p> <p>19 the Greim supplement.</p> <p>20 Because of the enormous amount</p> <p>21 of data that I had to -- that I had to enter</p> <p>22 based on the Greim supplements and the volume</p> <p>23 of work, the number of analyses that were</p> <p>24 performed, I'd say that, you know, during</p> <p>25 that period a good proportion of the time</p>
Page 23	<p>1 Q. Okay. Approximately how much</p> <p>2 time -- so I notice on your -- on your</p> <p>3 invoices that you don't actually describe</p> <p>4 what specifically you're analyzing or</p> <p>5 reporting on; is that right?</p> <p>6 A. No.</p> <p>7 Q. So all of your entries are</p> <p>8 actually one of three types, basically.</p> <p>9 A. Uh-huh.</p> <p>10 Q. They're either data, analysis</p> <p>11 and report, or they reference a meeting or a</p> <p>12 teleconference, which I'll bundle as one</p> <p>13 type, or they're specifically mentioning that</p> <p>14 you are looking at a plaintiff expert report</p> <p>15 and again doing research and data analysis;</p> <p>16 is that right?</p> <p>17 A. Yes.</p> <p>18 MR. GRIFFIS: Objection to</p> <p>19 form.</p> <p>20 QUESTIONS BY MS. GREENWALD:</p> <p>21 Q. Okay. So you don't have any --</p> <p>22 you don't have past experience, right, in</p> <p>23 doing consulting work in any kind of</p> <p>24 litigation; is that right?</p> <p>25 A. That's right.</p>	Page 25	<p>1 that was spent on the data analysis and</p> <p>2 report had to do with transcribing the data</p> <p>3 from the Greim supplement and analyzing it.</p> <p>4 Q. Okay. And you said January</p> <p>5 through what month? Did you say May, through</p> <p>6 May?</p> <p>7 A. I'd say the end of May.</p> <p>8 Of course, you know, a lot of</p> <p>9 that had to do with the actual writing as</p> <p>10 well, but the volume of work involving the</p> <p>11 Greim supplement was concentrated during that</p> <p>12 time.</p> <p>13 Q. When did you start working on</p> <p>14 your expert report, the writing of it?</p> <p>15 A. I'm actually not sure exactly</p> <p>16 when I actually, you know, put pen to paper,</p> <p>17 as it were, but I would say probably in</p> <p>18 December-ish, around there, November,</p> <p>19 December, is when I actually started, you</p> <p>20 know, doing a bulk of the writing.</p> <p>21 Q. So if you look at</p> <p>22 Exhibit 21-6 --</p> <p>23 A. Uh-huh.</p> <p>24 Q. -- and you have three entries:</p> <p>25 a May 6th, May 8th, and May 12th, plaintiff</p>

Confidential - Subject to Protective Order

Page 26

1 expert report, research and data analysis.
 2 A. 21-6. Do you mean 21-5?
 3 Q. I must have written the wrong
 4 number on here. I'm sorry.
 5 A. The one I have with May 5th,
 6 6th -- and 6th is on 21-5.
 7 Q. I think I messed up because the
 8 date's the same on the invoice. It's my
 9 fault.
 10 A. Yeah, sorry, that's --
 11 Q. No, no, no, that's my fault. I
 12 could have gotten it right. I didn't.
 13 Okay. All right. So let me
 14 ask the question again.
 15 So if you look at 21-5, there's
 16 three entries from May 6th, May 8th, and
 17 May 12th of this year --
 18 A. Uh-huh.
 19 Q. -- and it says, "plaintiff
 20 expert report - research and data analysis."
 21 Do you see those?
 22 A. Yes.
 23 Q. And those are the only entries
 24 that reference plaintiff expert report,
 25 correct?

Page 27

1 A. Well, there's the one on the
 2 4th.
 3 Q. On 21-5.
 4 A. There's also the one on the
 5 4th.
 6 Q. Oh, I'm sorry, you're
 7 absolutely right. Thank you for catching
 8 that. So on May 4th also.
 9 So those are the only four; is
 10 that correct?
 11 A. Those are the only four listed
 12 on this invoice, yeah.
 13 Q. Okay. Does that mean those are
 14 the four times that you were reviewing and --
 15 or researching and analyzing the data of the
 16 plaintiff expert reports in this case?
 17 A. I wouldn't say that those are
 18 the only times I actually referred to the
 19 plaintiff expert report, but I think that
 20 that reflects the fact that during that time
 21 I had just received the plaintiff expert
 22 report. And so the bulk of the time that I
 23 spent reviewing it was -- was on those four
 24 days.
 25 But, you know, I've referred to

Page 28

1 it since, on and off, not in as significant a
 2 way -- in a way that I did during that time,
 3 but -- but that was where I spent the bulk of
 4 my time, initially studying his expert
 5 report.
 6 Q. Okay. And if you look at all
 7 three invoices that you have produced in this
 8 case, which is 21-4, -5 and -6, am I right
 9 that those are the only four entries that you
 10 have in any of these invoices that reflect
 11 research -- I'm sorry, plaintiff expert
 12 report - research and data analysis?
 13 MR. GRIFFIS: Objection to
 14 form. Misstates what he just said.
 15 THE WITNESS: Those are the
 16 only four entries I have in my
 17 invoices, that's true, but I've
 18 referred to the plaintiff expert
 19 report many times on and off since.
 20 That kind of is a natural part
 21 of, you know, data analysis is
 22 iterating. But certainly at that time
 23 I spent, you know, some focused time
 24 actually reading it and looking at his
 25 results.

Page 29

1 QUESTIONS BY MS. GREENWALD:
 2 Q. Okay. When you say "data
 3 analysis and report" in these invoices, what
 4 does that mean?
 5 A. It means analyzing the data
 6 that produced the results of my expert report
 7 and actually writing the expert report.
 8 Q. Okay. And when you mention
 9 research/reading -- so, for example, on 21-4
 10 there's several entries at the top that say
 11 "research/reading."
 12 What does that mean?
 13 A. Well, initially when -- when I
 14 was first given the IARC report and was first
 15 assessing it, I spent some time looking at
 16 the IARC report and also referring to, you
 17 know, some of my references that had to do
 18 with my analysis of that report, particularly
 19 that -- at the time, again, like I told you
 20 before, I was kind of tasked with looking at
 21 what they had to say about the animal
 22 toxicology results, and that was mostly
 23 focused on the study that in my expert report
 24 I list as the Knezevich study.
 25 So that's what I was looking at

Confidential - Subject to Protective Order

Page 30	<p>1 at the time, the IARC report and just related</p> <p>2 materials, to kind of understand what they</p> <p>3 were doing.</p> <p>4 Q. So your recollection is back</p> <p>5 then research/reading meant the IARC report</p> <p>6 and the Knezevich study?</p> <p>7 A. And other material related to</p> <p>8 the issues that I was assessing with their</p> <p>9 computation of P value and the trend test and</p> <p>10 so on.</p> <p>11 Q. And so how did you go about</p> <p>12 deciding what you were going to look at</p> <p>13 besides the IARC Monograph 112, I assume</p> <p>14 we're talking about, right, and the</p> <p>15 Knezevich?</p> <p>16 A. Yeah, well, that's kind of a</p> <p>17 good question is, you know, how does any</p> <p>18 academic decide what they're going read, you</p> <p>19 know, when they're actually assessing, you</p> <p>20 know, the results from somebody else.</p> <p>21 You know, my expertise happens</p> <p>22 to be in categorical data analysis, or that's</p> <p>23 part of my expertise, and so, you know, I was</p> <p>24 kind of relying on the typical sources that I</p> <p>25 use in that research area.</p>	Page 32	<p>1 IARC 112 itself?</p> <p>2 A. I can't really recall exactly</p> <p>3 what I looked at at the time. I just read</p> <p>4 the report. I read about their analysis.</p> <p>5 You know, I have a lot of years</p> <p>6 of experience doing the same kinds of</p> <p>7 analyses working in, you know, statistical</p> <p>8 software, and so that just more or less had</p> <p>9 to do with my evaluation of their analysis</p> <p>10 using, again, my -- my own history, my own</p> <p>11 training.</p> <p>12 Q. So Exhibit 21-1, which is your</p> <p>13 expert report --</p> <p>14 A. Right.</p> <p>15 Q. -- did you write that report in</p> <p>16 its entirety?</p> <p>17 A. Yes.</p> <p>18 Q. Did you have help from anybody</p> <p>19 else in writing that report?</p> <p>20 A. No.</p> <p>21 Q. Is there any language in the</p> <p>22 report that someone else provided to you?</p> <p>23 A. No.</p> <p>24 Q. Do you recall how much time you</p> <p>25 spent analyzing Dr. Portier's expert report?</p>
Page 31	<p>1 Q. So what else would you have</p> <p>2 researched other than -- your expertise is in</p> <p>3 categorical data analysis, so -- so did</p> <p>4 you -- I'm just trying to understand, what</p> <p>5 would you have researched at the time --</p> <p>6 again, I'm going back to September of 2016 --</p> <p>7 besides IARC and, I believe you said, the</p> <p>8 Knezevich study?</p> <p>9 What else did you research in</p> <p>10 those -- the first, appears to be, month,</p> <p>11 month and a half?</p> <p>12 A. Well, what I was reading and</p> <p>13 what I was looking at is what was contained</p> <p>14 in the IARC report, mainly.</p> <p>15 Q. Okay.</p> <p>16 A. As far as, you know, how -- my</p> <p>17 expertise in terms of, you know, the trend</p> <p>18 test and so on, I mean, that arises from just</p> <p>19 kind of the bulk of my training over 20,</p> <p>20 25 years.</p> <p>21 Q. Okay. So when you were</p> <p>22 reviewing the material that was contained in</p> <p>23 the IARC report, did you look at any of the</p> <p>24 underlying materials that were cited in the</p> <p>25 IARC report, or was it just reviewing the</p>	Page 33	<p>1 A. No. I mean, I guess if I pore</p> <p>2 through my invoices for a while, I can, you</p> <p>3 know, try to give you an estimate of that</p> <p>4 again. But like I said, I think that's just</p> <p>5 largely reflected in my billing record.</p> <p>6 Q. But how would you do that?</p> <p>7 Let's -- I mean, I'm not going to have you do</p> <p>8 that because I'm not going to spend the day</p> <p>9 having you pore through them.</p> <p>10 But how would you go about,</p> <p>11 based on these three invoices that we marked</p> <p>12 here 21-4 through 21-6, how would you go</p> <p>13 evaluating, based on these entries, how much</p> <p>14 time you spent evaluating Dr. Portier's</p> <p>15 original report?</p> <p>16 A. Well, part of it is my memory.</p> <p>17 I mean, I've been working on this for a year</p> <p>18 now. I've spent a lot of hours on it. And</p> <p>19 so I think were I to just kind of go through</p> <p>20 these invoices and, you know, recreate the,</p> <p>21 you know, the -- I don't know, I guess my</p> <p>22 sort of internal dialog in looking at his</p> <p>23 expert report and so on, I think I could</p> <p>24 probably give you a pretty good estimate if I</p> <p>25 were to, you know, sit down and kind of go</p>

Confidential - Subject to Protective Order

Page 34

1 through this month by month.
 2 I mean, I worked on it very
 3 hard, personally, over the past several
 4 months, and so -- and so I have a pretty
 5 bright recollection of what I've done, more
 6 or less at a high level, from month to month.
 7 So if you wanted me to actually
 8 kind of go through the invoices and reproduce
 9 that, I could.
 10 Q. I don't want you to do that.
 11 But you're saying reproduce it
 12 from memory. You don't have any handwritten
 13 notes that would more reflect what these
 14 entries mean, correct?
 15 A. I wouldn't say I have a lot of
 16 handwritten notes. I just have -- I just
 17 have my expert report that basically
 18 reflects, you know, what it is that I've
 19 looked at, what I've prioritized.
 20 Q. No, I understand that.
 21 I guess I'm asking a slightly
 22 different question, and maybe I'm not asking
 23 it artfully.
 24 I wanted to know whether you
 25 have any notes that underlie the entries in

Page 35

1 21-4 through 21-6 that would reflect time
 2 spent on, for example, looking at Greim and
 3 the supplemental material or Dr. Portier's
 4 original report. Or when it comes about, the
 5 next invoice, I assume, will show review of
 6 Dr. Portier's rebuttal report.
 7 I wanted to know whether you
 8 keep any notes from which you then generate
 9 these invoices or whether -- or whether you
 10 just keep time, like, okay, today I worked
 11 one hour; tomorrow I worked -- I mean,
 12 yesterday I worked two hours, and that's --
 13 and you don't have anything else but that?
 14 MR. GRIFFIS: Objection. The
 15 discovery of notes is something that
 16 we have addressed in the MDL
 17 agreements in this case are privileged
 18 and not subject to discovery.
 19 Dr. Corcoran, you can -- you
 20 may answer whether you have taken any
 21 notes and not as to the content of
 22 such notes.
 23 THE WITNESS: You know, the
 24 truth of it is that I haven't taken
 25 many notes about what I did

Page 36

1 specifically. I kept these invoices
 2 as a record of work, and so the
 3 invoices reflect the effort from day
 4 to day. But I never took any notes
 5 that actually, you know, specified
 6 what I was doing from minute to
 7 minute.
 8 QUESTIONS BY MS. GREENWALD:
 9 Q. Okay. How about day to day?
 10 I'm not asking for minute to minute.
 11 A. No, outside of these invoices,
 12 I have not.
 13 Q. So your entry would generally
 14 be in a calendar or wherever you kept it --
 15 A. Actually in the --
 16 Q. -- data analysis.
 17 A. Right.
 18 And any invoice, as I was
 19 working, I would just kind of fill in hours
 20 on the certain days.
 21 But the record of my work is in
 22 the expert report. I mean, that's where
 23 the -- that's where the summation of my work
 24 is, and so the expert report reflects
 25 actually what it is that I worked on.

Page 37

1 Q. And you've been paid up till
 2 now \$107,250; is that correct?
 3 A. That's what I've invoiced.
 4 Q. I'm sorry, I should have asked
 5 it that way.
 6 And you have continued to work
 7 since then?
 8 A. Yes.
 9 Q. Okay. Have you performed any
 10 additional analyses since -- sorry.
 11 Have you performed any
 12 additional analyses since reviewing
 13 Dr. Portier's rebuttal report?
 14 A. No.
 15 Q. Have you done any research
 16 since receiving Dr. Portier's rebuttal
 17 report?
 18 MR. GRIFFIS: Objection.
 19 Vague.
 20 THE WITNESS: I haven't outside
 21 of just reviewing, you know, what's
 22 already been available.
 23 QUESTIONS BY MS. GREENWALD:
 24 Q. Did you review each of the 12
 25 studies on glyphosate that you mentioned in

Confidential - Subject to Protective Order

Page 38	<p>1 the summary of your report?</p> <p>2 And if you'd like to refer to</p> <p>3 it, it is line 7 through 9.</p> <p>4 MR. GRIFFIS: Objection. Vague</p> <p>5 as to "studies."</p> <p>6 THE WITNESS: Which page?</p> <p>7 QUESTIONS BY MS. GREENWALD:</p> <p>8 Q. Page -- I'm sorry, page 1 of</p> <p>9 your report. It says, "This report examines</p> <p>10 the rodent studies of glyphosate and cancer</p> <p>11 risk, particularly the seven feeding</p> <p>12 experiments using rats and five using mice</p> <p>13 that were reviewed in the expert report</p> <p>14 prepared by Dr. Chris Portier."</p> <p>15 Do you see that?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. Did you review each of</p> <p>18 the 12 studies that you refer to in line 7</p> <p>19 through 9?</p> <p>20 MR. GRIFFIS: Objection. Vague</p> <p>21 as to the word "studies."</p> <p>22 THE WITNESS: Well, I guess I'm</p> <p>23 wondering what you mean by "review"</p> <p>24 and what you mean by "study."</p> <p>25 Do you mean the published</p>	Page 40	<p>1 analyze the data from that report.</p> <p>2 And I looked at the IARC</p> <p>3 report.</p> <p>4 I've read a lot of the</p> <p>5 background material that was -- that's been</p> <p>6 provided, I think -- well, for example, the</p> <p>7 EPA report, Portier's report.</p> <p>8 I guess in that sense, yes,</p> <p>9 I've reviewed the studies through the various</p> <p>10 sources that were available to me.</p> <p>11 Q. Okay. You're working on behalf</p> <p>12 of Monsanto Corporation in this case, right?</p> <p>13 A. No. I'm working for</p> <p>14 Hollingsworth --</p> <p>15 Q. Sorry.</p> <p>16 A. -- as far as I know.</p> <p>17 Q. But it's on behalf of Monsanto,</p> <p>18 correct?</p> <p>19 A. Well, I'm invoicing</p> <p>20 Hollingsworth, and so...</p> <p>21 Q. Let's go back to Exhibit 21-3,</p> <p>22 which is your retention letter.</p> <p>23 A. Right.</p> <p>24 Q. This first sentence reads:</p> <p>25 "This letter confirms that Hollingsworth,</p>
Page 39	<p>1 results as cited in the Portier</p> <p>2 report?</p> <p>3 QUESTIONS BY MS. GREENWALD:</p> <p>4 Q. No. I'd want to know if you</p> <p>5 reviewed any of the underlying data or</p> <p>6 manuscripts or documents relating to the</p> <p>7 12 -- the seven feeding experiments using</p> <p>8 rats and the five using mice that you</p> <p>9 reference in line 7 through 9, other than the</p> <p>10 summaries in Greim and other than what is</p> <p>11 referenced in Dr. Portier's report and IARC.</p> <p>12 A. I am not sure. I mean, I think</p> <p>13 the bulk of my knowledge about these 12</p> <p>14 studies comes from, you know, the collective</p> <p>15 work that's been cited both by me and</p> <p>16 Dr. Portier.</p> <p>17 So, yes, the Greim -- the Greim</p> <p>18 study or the Greim publication, actually, was</p> <p>19 a comprehensive review that both myself and</p> <p>20 Dr. Portier relied on for expert reports, so</p> <p>21 I reviewed that.</p> <p>22 I've, you know, reviewed every</p> <p>23 page of data in the Greim supplement because</p> <p>24 I, you know, basically hand-entered it since</p> <p>25 that was the only means possible to actually</p>	Page 41	<p>1 LLP, on behalf of Monsanto Company, has</p> <p>2 retained you to provide expert consulting</p> <p>3 services to HLLP for the purposes of</p> <p>4 assisting HLLP in representing Monsanto in</p> <p>5 connection with potential and/or actual</p> <p>6 litigation against Monsanto involving</p> <p>7 injuries allegedly caused by Roundup and/or</p> <p>8 glyphosate, paren, the litigation, close</p> <p>9 paren," close quote.</p> <p>10 Do you see that?</p> <p>11 A. Yes.</p> <p>12 Q. Okay. So is it your</p> <p>13 understanding that your work is on behalf of</p> <p>14 Monsanto in connection with litigation</p> <p>15 brought against Monsanto by various</p> <p>16 plaintiffs?</p> <p>17 A. Well, it's my understanding</p> <p>18 that I'm working for Hollingsworth and that</p> <p>19 they're representing Monsanto, yes.</p> <p>20 Q. So as you sit here today, you</p> <p>21 don't believe you're doing work for the</p> <p>22 benefit of Monsanto?</p> <p>23 MR. GRIFFIS: Objection.</p> <p>24 Argumentative. Asked and answered.</p> <p>25 THE WITNESS: I've just been</p>

Confidential - Subject to Protective Order

Page 42	Page 44
<p>1 asked by Hollingsworth to help them 2 perform an independent data analysis, 3 and that's my understanding, that it's 4 on Monsanto's behalf for the sake of 5 this litigation. But I'm doing this 6 for Hollingsworth -- or I guess in the 7 employment of Hollingsworth. 8 QUESTIONS BY MS. GREENWALD: 9 Q. Have you been paid on any of 10 your invoices yet? 11 A. Yes. 12 Q. Do you get your check from 13 Hollingsworth? 14 A. Yes. 15 Q. But just to be clear, you do 16 understand this work is being done on behalf 17 of Monsanto, correct? 18 MR. GRIFFIS: Objection to 19 form. Argumentative. Asked and 20 answered multiple times. 21 THE WITNESS: Well, you're 22 right, you read the -- you read the 23 letter of retainer, and that's my 24 understanding. 25</p>	<p>1 were Monsanto studies, would that help 2 refresh your recollection? 3 A. I guess that would be 4 interesting. I mean, I'd like to see the 5 source to verify that, but it wouldn't really 6 change any of my conclusions. I mean, 7 they're the -- they're the studies that were 8 analyzed by -- 9 Q. Okay. So -- 10 MR. GRIFFIS: Excuse me, I 11 don't believe Dr. Corcoran was done 12 with his answer. 13 MS. GREENWALD: Oh, I'm sorry, 14 forgive me. 15 THE WITNESS: Oh, I'm sorry. I 16 just didn't know if you were listening 17 to the rest of my answer. 18 I just know that they were the 19 12 studies that were analyzed by 20 Dr. Portier, and so I used the same 12 21 studies that were presented in Greim. 22 (Corcoran Exhibit 21-7 marked 23 for identification.) 24 QUESTIONS BY MS. GREENWALD: 25 Q. Okay. I'm going to mark now --</p>
Page 43	Page 45
<p>1 QUESTIONS BY MS. GREENWALD: 2 Q. Okay. Did you receive the 3 underlying data for any of the studies that 4 are -- any of the 12 studies that were 5 sponsored by Monsanto? 6 A. Well, through the Greim 7 supplement? Yes. 8 Q. No, the actually studies. 9 Do you know whether any of 10 those 12 studies that are referenced in the 11 Greim paper were Monsanto-sponsored studies? 12 A. My understanding is the -- like 13 the initial study I looked at, the Knezevich 14 study, that was a Monsanto-sponsored study, 15 but I haven't actually been in communication 16 with any of the original, you know, 17 scientists who conducted those studies, no. 18 Q. Do you know whether any of the 19 other studies -- any of the other 12 besides 20 Knezevich were Monsanto-sponsored studies? 21 A. I can't recall off the top of 22 my head which ones were sponsored by Monsanto 23 and which ones weren't. 24 Q. Well, if I told you that the 25 Lankas study and the Stout and Ruecker study</p>	<p>1 we have to staple this together. I 2 apologize. The stapling came apart, but 3 we'll use a paperclip or something. 4 I'm going to mark Exhibit 21-7, 5 which is an article from Critical Reviews in 6 Toxicology, and the first author's name is 7 Helmut Greim, and ask you to take a look at 8 that. 9 A. Thanks. 10 Q. Sure. 11 If you can go to the -- so is 12 this the Greim paper that we've been talking 13 about so far this morning? 14 A. Yes. 15 Q. Okay. If you look under table 16 the contents -- 17 A. Uh-huh. 18 Q. -- on the left-hand column -- 19 A. Yes. 20 Q. -- you'll see that it says, 21 "Rat carcinogenicity." 22 Do you see that? 23 A. Yes. 24 Q. And it says, "Study 1, 25 Monsanto, 1981"?</p>

12 (Pages 42 to 45)

Confidential - Subject to Protective Order

Page 46

1 A. Uh-huh.
 2 Q. And it says, "Study 2,
 3 Monsanto, 1990"?
 4 A. Uh-huh.
 5 Q. Do you know which studies those
 6 are?
 7 A. Do you mind if I look?
 8 Q. Not at all.
 9 A. So it looks like that was the
 10 Lankas study, using my own table in my expert
 11 report in the Stout study.
 12 Q. Okay. And then to the right of
 13 that, the remainder of the table of contents
 14 mentions under "mouse" -- do you see that?
 15 A. Uh-huh.
 16 Q. -- study number 10 --
 17 A. Right.
 18 Q. -- and it says "Monsanto,"
 19 correct, "1983"?
 20 A. Right.
 21 Q. And that's Knezevich?
 22 A. That's the Knezevich study,
 23 yes.
 24 Q. Okay. So -- and those are the
 25 only three in the table of contents that

Page 47

1 reference Monsanto as the sponsor of the
 2 study, correct?
 3 A. It looks like it, yeah.
 4 Q. Okay. So you read the Greim
 5 paper, right?
 6 A. Yes.
 7 Q. In fact, you said you spent a
 8 lot of time studying it, right?
 9 A. Yes.
 10 Q. Okay. Did you ever ask
 11 Monsanto for the underlying data for those
 12 three studies?
 13 A. Well, no. I mean, since they
 14 were available in the supplement of this
 15 paper, I didn't think it was necessary to go
 16 and look for the data elsewhere.
 17 I mean, it appeared that, you
 18 know, based on the number of citations that
 19 this paper has received, that most everybody
 20 agrees that data in the Greim supplement are
 21 acceptable.
 22 Q. But, I mean, is that -- as you
 23 sit here today, do you believe that all of
 24 the data in the Greim paper are accurate?
 25 A. Well, I can only make my

Page 48

1 judgment based on what everybody else has
 2 found acceptable. And I know that those were
 3 the same data used in the Portier report and
 4 in some other sources, and so I have to
 5 assume that they're credible.
 6 Q. Well, of course, Dr. Portier
 7 doesn't work on behalf of Monsanto
 8 Corporation, does he?
 9 A. No.
 10 Q. And so he wouldn't have had the
 11 same access to these papers as you might have
 12 had, for example, as a person who is working
 13 with the Hollingsworth firm on behalf of
 14 Monsanto; isn't that right?
 15 MR. GRIFFIS: Objection.
 16 Argumentative. Misstates testimony.
 17 THE WITNESS: Well, I don't
 18 really know. I don't know what kind
 19 of access Hollingsworth has to
 20 Monsanto data. But, you know, if
 21 they've been made freely available
 22 through the Greim paper and other
 23 people have used them besides
 24 Dr. Portier and myself, I have to
 25 assume that they're -- that the data

Page 49

1 are sound.
 2 QUESTIONS BY MS. GREENWALD:
 3 Q. So if you have a choice, just
 4 generally speaking -- take it out of the
 5 context of this litigation and this case,
 6 even your report.
 7 If you have a choice between
 8 reading a paper that summarizes someone
 9 else's data or actually getting the data
 10 itself, the actual study itself, which would
 11 you choose as you do research?
 12 A. Have you seen the Greim
 13 supplement?
 14 Q. I have.
 15 A. Because the data tables are the
 16 original tables from the scientists who
 17 actually produced the data. So as far as
 18 I -- as far as I know, they look like the
 19 original, you know, documents that were
 20 produced by these scientists who actually
 21 carried out the study.
 22 So I don't know that there was
 23 a more original source than what was -- what
 24 seemed to be available through the Greim
 25 supplement. Unless somebody actually used

Confidential - Subject to Protective Order

Page 50	Page 52
<p>1 Wite-Out on those sheets, I think those were 2 the original data tables. 3 Q. Do you know as you sit here 4 today that the supplements to the Greim paper 5 are the actual results from the 12 studies? 6 A. Well, if they aren't, I guess 7 I'm not sure why we're sitting here. 8 Q. I'm just asking -- I'm -- I 9 don't want to -- I'm just asking a simple 10 question, and if you want me to rephrase it, 11 I can. 12 I just want to know, as you sit 13 here today, whether you know that the data 14 that's attached as supplements to the Greim 15 paper are in fact the data from each of those 16 12 studies. 17 A. Well, I assume that based on 18 their use by multiple other scientists, 19 including myself, Dr. Portier and others. 20 Q. Okay. But you don't know; you 21 assumed it. Is that right? Is that fair? 22 I just want to make sure I 23 understand your testimony, that's all. 24 A. All I can say is just I have to 25 assume that because everybody else is</p>	<p>1 that, you know, everybody has relied 2 on who has looked at glyphosate across 3 the 12 studies. 4 And so you're kind of asking 5 two different things. One is, am I 6 relying on the summary? 7 Well, I'm not relying on this 8 summary for the data. I'm relying on 9 the supplements which contain the 10 original data tables. 11 QUESTIONS BY MS. GREENWALD: 12 Q. Which you assume contain the 13 original data tables, correct? 14 A. Of course, yeah. I assume that 15 because, you know, Dr. Portier and other 16 scientists have used the same tables. 17 Q. Okay. So your -- I'm going to 18 go back to my question for a minute. 19 If you're not looking at 20 Greim -- and we're not talking about 21 glyphosate -- 22 A. Uh-huh. 23 Q. -- and you don't know if other 24 people have relied on it, okay, you don't 25 know what other people have done, and you</p>
<p>Page 51</p> <p>1 treating these data as credible, and so it 2 makes sense for me to do the same. 3 Q. Well, okay. I don't know 4 that -- let's move on from that for a minute, 5 but let me go back to the question I 6 originally asked. 7 As a -- if you're working on a 8 subject, whatever that subject is, and you 9 have a choice of looking at an article or a 10 study or a paper that summarizes the works -- 11 of the work of others or getting the actual 12 work that's the underlying work that's 13 summarized in that study, which would you 14 choose? 15 A. Well -- 16 MR. GRIFFIS: Objection. Asked 17 and answered. 18 MS. GREENWALD: No, he never 19 asked that question, actually. 20 THE WITNESS: I'm actually 21 happy to answer it because this paper 22 that you gave me is the summary. The 23 supplement that I used to actually, 24 you know, hand -- hand-enter the data, 25 those supplements are the data tables</p>	<p>Page 53</p> <p>1 have a paper that's a summary paper, and you 2 have a choice of reviewing the summary paper 3 that reviews data of another or actually 4 getting the paper that has the -- of the 5 actual person who conducted the study, which 6 would you choose? 7 A. Well, you know, that's an 8 interesting hypothetical, but that's not what 9 happened here. 10 Q. I understand that's not what 11 happened here. I want to know what you would 12 pick. 13 A. Well, what happened here is I 14 got the original data that was used and cited 15 by, you know, several other scientists, 16 including Dr. Portier, and so that helps to 17 reassure me that these data are credible. 18 That's what happened here. 19 You know, what I would do in 20 another case, I can't say. I mean, you'd 21 have to put me in that position and show me 22 the data, and I'd have to make an independent 23 judgment in that case. 24 In this case, all I can say is 25 everybody's used these data. If they're not</p>

14 (Pages 50 to 53)

Confidential - Subject to Protective Order

Page 54	Page 56
<p>1 credible, then I guess there's no reason for 2 us to really be here.</p> <p>3 Q. So hypothetically speaking, and 4 it doesn't have to be in the context of a 5 litigation, I just want to know if you would 6 choose a summary paper of another person's 7 data over the actual data of this study -- 8 MR. GRIFFIS: Objection.</p> <p>9 QUESTIONS BY MS. GREENWALD: 10 Q. -- if you had access to both. 11 MR. GRIFFIS: Objection. Asked 12 and answered multiple times. 13 MS. GREENWALD: I have not 14 gotten an answer to that question.</p> <p>15 QUESTIONS BY MS. GREENWALD: 16 Q. I just want to know which one 17 you would choose. 18 Outside of the context of this 19 litigation, in any research you're doing, 20 would you not want to get the underlying 21 study over a summary paper that is reviewing 22 that data and other data together? 23 A. Again, as a statistician who 24 has been practicing for over 20 years and 25 looking at people's data, the supplement that</p>	<p>1 pathology report, correct? 2 A. No. 3 Q. Now, if you've answered this 4 before, I'm sorry, but I don't recall that 5 you did. 6 Did you ever ask Monsanto or 7 Hollingsworth for the underlying data for the 8 Lankas study, the Stout and Ruecker or the 9 Knezevich and Hogan? 10 MR. GRIFFIS: Objection. Asked 11 and answered. 12 THE WITNESS: I didn't ask -- 13 QUESTIONS BY MS. GREENWALD: 14 Q. Other than Greim, did you ever 15 ask -- 16 A. I didn't ask for any additional 17 data because the Greim data are the ones that 18 everybody seems to rely on, are the data that 19 everybody seems to rely on. 20 Q. So if you can look at 21 exhibit -- I'm sorry, yeah, Exhibit 21-1. 22 A. Sure. 23 Q. And if you could go to page -- 24 so you have -- first, get past your expert 25 report. So get past page 47.</p>
<p>Page 55</p> <p>1 was provided in Greim is nearly -- you know, 2 it tabulates data in as nearly raw a form as 3 I could imagine. So I have no question that 4 the data in the Greim supplement are credible 5 based on their use by Portier and other 6 scientists. 7 So there's no hypothetical 8 necessary because I'm not using a summary 9 paper. I'm not using this paper for the 10 data. I'm using the supplement to this paper 11 which actually contains the original data 12 tables. 13 Q. Does Greim include the 14 individual animal pathology for each study in 15 its supplements? 16 A. No. 17 Q. Are pathology reports typically 18 part of underlying data of a study? 19 A. Yeah, absolutely. That's why I 20 said there -- that's why I actually said 21 they're nearly as original as -- the tables 22 that are presented are the original tables 23 based on their tabulation of the original 24 animal data. 25 Q. It doesn't contain the</p>	<p>Page 57</p> <p>1 Because of the numbering here, 2 I don't know else how to do it. So go past 3 the expert report and get to the materials 4 considered, which is five pages. It's 1 of 5. 5 And if you go to -- 6 A. 1 of 5? Okay. Got it. 7 Q. If you can go to page 3 of 5? 8 A. Right. 9 Q. And if you can go to entry 39, 10 please? 11 A. Uh-huh. 12 Q. So you reference the Knezevich 13 and Hogan paper here, right? 14 A. Uh-huh, yes. 15 Q. Does that mean you considered 16 the actual underlying study of Knezevich and 17 Hogan, or are you referring to Greim here in 18 39? 19 A. I'm not sure I understand what 20 you're asking. 21 Q. Well, did you have the 22 Knezevich and Hogan paper? 23 A. Yeah, that was available to me. 24 Q. And did you have the underlying 25 data for Knezevich and Hogan?</p>

15 (Pages 54 to 57)

Confidential - Subject to Protective Order

Page 58

1 A. Yeah, through that source, the
 2 individual-level data are available, yes.
 3 Q. Okay. So why did you want it
 4 for Knezevich and Hogan if you had Greim?
 5 MR. GRIFFIS: Objection. Form.
 6 THE WITNESS: I'm not -- again,
 7 I'm not quite sure what you're asking,
 8 but Greim contains the same totals
 9 that you could obtain from Knezevich.
 10 QUESTIONS BY MS. GREENWALD:
 11 Q. Okay. So then let me ask that
 12 question again.
 13 If Greim, if I understand your
 14 answer correctly, contains all of the data
 15 that you needed to do your work, why would
 16 you have consulted the Knezevich and Hogan
 17 study but not any of the other studies that
 18 you -- that were Monsanto studies?
 19 A. Those -- if you're -- are you
 20 asking about individual-level data? Is that
 21 what you're asking me?
 22 Q. I'm just -- so, okay, let
 23 me make it in smaller pieces.
 24 For number 39, did you actually
 25 get the Knezevich and Hogan underlying data?

Page 59

1 A. Those were available, yes.
 2 Q. And available from Monsanto,
 3 correct, or did you get them somewhere else?
 4 A. No, I did not get them from
 5 Monsanto.
 6 Q. Did you get them from
 7 Hollingsworth?
 8 A. I actually don't know. I think
 9 most of -- most of the material I received
 10 was through Hollingsworth, so...
 11 Q. Okay. Did you ask to get the
 12 Knezevich and Hogan study in particular? Did
 13 you ask for that study?
 14 A. No.
 15 MR. GRIFFIS: Objection to
 16 "communications."
 17 Please don't answer questions
 18 about what you asked for and were sent
 19 specifically by us.
 20 THE WITNESS: Oh, okay.
 21 QUESTIONS BY MS. GREENWALD:
 22 Q. Can you estimate about how many
 23 hours you spent reviewing the Greim paper and
 24 the associated supplemental materials?
 25 A. I think you asked that earlier,

Page 60

1 and I -- like I said, I think that based on
 2 my invoices, the bulk of that analysis was --
 3 that examination of the Greim supplement was
 4 probably the first four or five months of
 5 this year, through May.
 6 Q. Did you do any calculations of
 7 the animal bioassay data in Greim using false
 8 data -- I'm sorry, false discovery rate?
 9 A. Did I use --
 10 Q. Did you do any calculations of
 11 the animal bioassay data in Greim using false
 12 discovery rate?
 13 A. I'm sorry, what -- what -- what
 14 calculations are you talking about?
 15 That's kind of a confusing
 16 question.
 17 Q. Well, did you apply the false
 18 discovery rate to any of the animal bioassay
 19 data in Greim?
 20 A. Are you talking about the
 21 animal bioassay data that I analyzed in my
 22 expert report? Is this what we're talking
 23 about?
 24 Q. From -- I'm asking about the
 25 data of Greim, which you said you've

Page 61

1 reviewed.
 2 A. Right. So my expert report,
 3 like I said, those are the data that I used.
 4 I obtained those data from the Greim
 5 supplement.
 6 Q. Uh-huh.
 7 A. Uh-huh.
 8 Q. And did you apply the false
 9 discovery rate to that data?
 10 A. I used false discovery rate --
 11 false discovery rate approach to, you know,
 12 adjust for multiple testing, as I outlined in
 13 my expert report.
 14 Q. So where are those calculations
 15 in your report?
 16 A. There's -- there's a section --
 17 first of all, going to page 6, I guess
 18 pages 5 and 6, I talk about why some sort of
 19 adjustment for multiple testing is necessary
 20 when you're -- when you're looking at
 21 hundreds, in this case, of tumor types
 22 simultaneously.
 23 Q. So let's just stay on that page
 24 for a minute --
 25 A. Okay.

Confidential - Subject to Protective Order

Page 62	Page 64
<p>1 Q. -- okay, because otherwise 2 we'll have to double back. 3 A. All right. 4 Q. Did you do any -- did you do 5 any calculations using the false discovery 6 rate on pages 5 or 6? 7 A. I applied the false discovery 8 rate correction that's mentioned on page 6. 9 I applied that to the data as I describe in 10 Section 4. 11 Q. Okay. Where on page 6? Which 12 lines? 13 A. Page 6 -- I'm sorry, page 6 is 14 where I say I talk about -- I give some 15 context for multiple testing then talk about 16 why it's necessary, but the calculations are 17 not on page 6. 18 Q. Okay. I'm sorry. So let's 19 move on from 6 then. 20 So where else? 21 I'm sorry, you were going to 22 show me where in the report -- 23 A. Oh, I'm sorry. 24 Q. No, it's my fault. I should 25 have gone back to that.</p>	<p>1 make sure I understand this correctly. 2 Appendix C and Appendix D on 3 pages 46 and 47 are the places where you 4 applied -- 5 A. The calculations are not 6 contained here. The results are contained 7 here. The results are summarized in 8 Appendices C and D. 9 Q. All right. So just make sure I 10 understand. Page 5 and 6 where you talk 11 about the content -- or the context of the 12 false discovery rate, right? 13 A. Yes. 14 Q. And then the next page you 15 referred me to was page 9, the paragraph 16 starting at line 15, correct? 17 A. Yeah. So pages 9 and 10, I 18 think that's where the results for the P 19 value analysis are reported. 20 Q. Anywhere else in the report? 21 And I understand -- I 22 understand Appendix C and D -- 23 A. Appendix C and D, right. 24 MR. GRIFFIS: Excuse me. 25 Objection. If this isn't just a test</p>
Page 63	Page 65
<p>1 So where in the report do you 2 show any calculations of the data using the 3 false discovery rate? 4 A. Let's see. On page 9, and this 5 is where I mentioned that these 6 calculations -- I performed these 7 calculations. 8 Q. Can you tell me which line? 9 A. Uh-huh. Starting in the 10 paragraph that starts at line 15. 11 Q. Okay. 12 A. And then I report -- starting 13 on the next paragraph, on line 28, I report 14 kind of the results of that analysis. And 15 then as I -- I adjusted for the false 16 discovery rate for every -- every P value, 17 but to not bulk up the appendix, I focused on 18 those that had -- that had P values less than 19 .05. So those are reported in the appendix, 20 in Appendix C. 21 Q. So Appendix C -- 22 A. It's on page 47. Or I'm sorry, 23 appendix -- yeah, Appendix C and Appendix D. 24 Pages 46 and 47. 25 Q. So make sure -- I just want to</p>	<p>1 of his current memory and you want him 2 to find every single spot, he's going 3 to have to look because there are 4 other pages. 5 THE WITNESS: I guess I'd add 6 that, you know, the multiple testing 7 is also discussed on pages 11 and 12 8 and 13, starting with the beginning of 9 Section 5 and extending through 10 Section 5A. 11 If you're interested in other 12 incidents where I mentioned -- or 13 other occasions where I mention 14 multiple testing, I mention that also 15 in Section 5B with respect to his 16 analysis, Dr. Portier's analysis, of 17 historical controls. 18 And I also mentioned the issue 19 of multiple testing within Section 5C 20 with respect to his pooled analysis. 21 QUESTIONS BY MS. GREENWALD: 22 Q. Those two sections you just 23 talked about, though, don't have any 24 calculation of yours, correct? 25 A. It talks about -- you were</p>

17 (Pages 62 to 65)

Confidential - Subject to Protective Order

Page 66	Page 68
<p>1 saying earlier -- you said there were 2 multiple testing issues, and so I'm just 3 pointing out that those are other places 4 where I mentioned that as well. 5 Q. Okay. Now, number 66 in your 6 consideration material -- 7 A. Uh-huh. 8 Q. -- mentions Weber. 9 A. Uh-huh. 10 Q. Klaus Weber. 11 MR. GRIFFIS: We've been going 12 about an hour, so when you find a good 13 spot, I'd like to take a break. 14 MS. GREENWALD: After this 15 question, we can do that. 16 THE WITNESS: Right, I got it. 17 QUESTIONS BY MS. GREENWALD: 18 Q. So you also reviewed the 19 evaluation done by Klaus Weber; is that 20 right? 21 A. Yes. 22 MS. GREENWALD: Okay. So you 23 want to take a break now? 24 MR. GRIFFIS: Sure, yeah. 25 THE WITNESS: I'm fine if you</p>	<p>1 Q. It's not in your report, I 2 promise you. 3 A. I don't recall off the top of 4 my head -- 5 Q. Okay. 6 A. -- knowing much about that. 7 Q. Okay. Do you know whether 8 Klaus Weber is a consultant for Monsanto? 9 A. I actually don't. 10 Q. Okay. What did you understand 11 to be the purpose underlying the Weber paper? 12 A. My evaluation of it was just 13 that it was -- there was -- you know, there 14 was an additional pathology report, and so 15 some -- as I said in my expert report, it 16 appeared that some of the counts changed for 17 a couple of the tumor types, and so I 18 reevaluated and included a table in my report 19 to address that. 20 Q. Part of the reason for the 21 Weber report was to look at the Kumar study 22 to see if there was a virus in the mice? 23 A. I don't know what the purpose 24 was of the Weber paper. I just know that I, 25 you know, analyzed the data that were kind of</p>
Page 67	Page 69
<p>1 want to continue with the Weber line 2 of questioning. 3 MS. GREENWALD: It's up to you 4 guys. I'll let you discuss it. 5 THE WITNESS: And we can take a 6 break after we discuss Weber. 7 MS. GREENWALD: The post-Weber 8 break. 9 QUESTIONS BY MS. GREENWALD: 10 Q. How did you get the Weber 11 paper? 12 A. I got it through the attorneys 13 at Hollingsworth. 14 Q. Who is Klaus Weber? 15 A. I am not sure exactly where he 16 is from. I mean, I've -- I actually looked 17 at the paper, but I can't remember where he's 18 from or what his affiliation is. 19 Q. Okay. Have you ever heard of 20 the Glyphosate Task Force? 21 A. Affiliated with whom? 22 Q. I just want to know if you've 23 ever heard of the Glyphosate Task Force. 24 A. It's talked about in the 25 information that I've --</p>	<p>1 re-reviewed in that paper. 2 Q. Okay. Did the Weber paper 3 factor into your opinions in your expert 4 report? 5 A. Well, I included it in the 6 expert report. 7 Do you mind if I just turn to 8 it so I can -- 9 Q. No, no, no, your expert report 10 is yours to review and look at any time 11 during this deposition today. 12 A. I think that -- I think on 13 page -- it's page 11, starting at line 3, 14 that kind of summarizes my, you know, use of 15 my opinions based on the Weber analysis. 16 So I -- like I said, some of 17 the reported tumor counts differed slightly 18 from the data in Greim, so I, you know -- I 19 included an additional table. 20 I had -- I had the Kumar mouse 21 table based on what I got from Greim, and 22 then I had an additional table that I 23 included in my appendix based on this Weber 24 reevaluation. But as I said, it didn't 25 really change my overall conclusion.</p>

Confidential - Subject to Protective Order

Page 70	Page 72
<p>1 Q. So you accepted the numbers in 2 the Weber paper over those contained in 3 Greim; is that correct?</p> <p>4 A. Well --</p> <p>5 Q. In reaching -- I'm sorry, in 6 reaching your opinions in this case?</p> <p>7 A. Well, I don't know if I, you 8 know, give one more credence than the other. 9 I think that because that paper was made 10 available, and it was kind of made available 11 late in this process, that I became aware 12 that these data were available.</p> <p>13 I just included that table for 14 the sake of completeness, but I wouldn't say 15 I have an opinion about, you know, which data 16 are the more airtight.</p> <p>17 Q. When you have two different 18 data sets for the same study, how do you 19 decide which one you're going to use?</p> <p>20 A. Well, that's a good question, 21 but the issue with this whole analysis is 22 that we have hundreds and hundreds of tumors 23 that we're looking at.</p> <p>24 Now, in the case of Weber, you 25 know, there were some counts that changed for</p>	<p>1 we, you know, investigating here. I mean, 2 we're investigating hundreds.</p> <p>3 And so the question is, well, 4 okay, if the Weber reanalysis, if that's the 5 one that's accurate, then, you know, let's 6 analyze the data using -- using the Weber 7 data, and let's see what happens.</p> <p>8 And there was no change in the 9 substantive conclusions based on that 10 analysis.</p> <p>11 So whether we used the Weber or 12 whether we used kind of the original Kumar 13 data from Greim, it really didn't make any 14 difference.</p> <p>15 Q. But the Weber study, am I not 16 correct, realized that the study authors in 17 Greim had conflicting numbers; isn't that 18 right?</p> <p>19 A. Again, I would have to go back 20 and read the entire Weber paper to know 21 exactly what motivated the paper. All I know 22 is that I got the data from the Weber 23 reanalysis that I included for the sake of 24 completeness. And either way, using the 25 Kumar data from Greim, using the Weber data,</p>
<p>Page 71</p> <p>1 some of the reported tumors, but we still 2 have the overarching issue that there are 3 hundreds and hundreds of tumors that we're 4 evaluating at the same time. So in other 5 words, there was nothing that changed about 6 the overall analysis accounting for all of 7 these tumors when I actually, just for the 8 sake of, you know -- just for the sake of 9 completeness analyzed those changed tumor 10 counts as well.</p> <p>11 Q. So in reaching your opinion in 12 this case, are you saying it doesn't matter 13 whether you use the numbers from Greim or 14 Weber?</p> <p>15 A. Oh, it matters.</p> <p>16 Q. I just want to make sure -- I 17 want to make sure I understand your 18 testimony.</p> <p>19 A. That's why I included both. 20 That's why I included both, because it does 21 matter which numbers you're using.</p> <p>22 What I am saying is that 23 because of the number of analyses that we're 24 doing, that's the thing that really impacts 25 the bottom line here. How many tumors are</p>	<p>Page 73</p> <p>1 it didn't make any difference.</p> <p>2 Q. Do you recall sitting here 3 today whether Weber reanalyzed the 4 original -- the original histopathological -- 5 histopathological data?</p> <p>6 A. Histopathological.</p> <p>7 Q. Histopathological.</p> <p>8 Wow, I can't get it out today.</p> <p>9 A. No, I don't recall that off the 10 top of my head.</p> <p>11 Q. You don't recall?</p> <p>12 A. But if I -- again, if I had a 13 chance to read the entire paper, I could tell 14 you.</p> <p>15 Q. Well, at the time you wrote 16 your expert report, would it have made a 17 difference to you if you knew that Weber had 18 reanalyzed the original histopathological --</p> <p>19 A. Histopathological.</p> <p>20 Q. -- histopathological data? 21 Would that have made a difference?</p> <p>22 A. I don't know how a court 23 reporter keeps up with a word like that.</p> <p>24 Q. Histopathological. Sorry about 25 that.</p>

19 (Pages 70 to 73)

Confidential - Subject to Protective Order

Page 74	Page 76
<p>1 Would that have made a 2 difference to you? 3 MR. GRIFFIS: Objection. Asked 4 and answered. 5 THE WITNESS: Oh. Well, like I 6 said, I went over the reanalysis of 7 time in my expert report. You know, I 8 analyzed the data, I included the 9 table, and it didn't change my overall 10 opinion. 11 QUESTIONS BY MS. GREENWALD: 12 Q. Did you count the tumors 13 reported by Weber in the Kumar study when you 14 came to your 1,016 that's on page 9 of your 15 expert report? 16 A. You know what, I don't know. I 17 mean, I -- I don't think that given that 18 we're talking about a handful of tumors that 19 it would have changed the discussion. 20 I think on page 9 -- is that 21 what we're talking about? 22 Q. Yeah, of your 1,016 that we 23 talked about earlier, I wanted to know 24 whether you counted the tumors reported by 25 Weber.</p>	<p>1 QUESTIONS BY MS. GREENWALD: 2 Q. Dr. Corcoran, do you recall 3 about how many pages the full Knezevich and 4 Hogan study was that you reviewed? 5 A. No. 6 Q. Do you remember if it was like 7 hundreds of pages? A thousand pages? 8 A. I don't at all. 9 Q. And do you recall how many 10 pages the supplement is to the Greim paper 11 relating to the Knezevich and Hogan? 12 A. Like I told you before, I know 13 it was a ton because I went through them by 14 hand, but I can't remember exactly what the 15 number is. 16 Q. So do you recall sitting here 17 today whether the data set was much larger in 18 the actual Knezevich and Hogan study that you 19 received versus the supplemental material 20 that was attached to Greim? 21 A. So what do you mean by "larger" 22 exactly? 23 Q. Just many more pages, many more 24 pages of data and information when you had 25 the actual Knezevich and Hogan study.</p>
<p>1 A. I think that the 1,016 is based 2 on my analyses of the data from Greim. 3 What I'm basically saying on 4 page 11 is, yes, you know, I didn't change 5 the numbers in the previous paragraphs to 6 reflect the Weber data because the Weber data 7 came to me so late. 8 What I did do is I looked at 9 the Weber data and I did -- I did take that 10 into consideration with regard to the overall 11 numbers of tumors, the 1,016, as well as the 12 345 tumor types that had at least three 13 incidence of tumors. 14 So I weighed that, but that 15 didn't change substantively. 16 MS. GREENWALD: Okay. Break 17 time. 18 THE WITNESS: All right. 19 Thanks. 20 VIDEOGRAPHER: We're going off 21 the record. The time is 10:24. 22 (Off the record at 10:24 a.m.) 23 VIDEOGRAPHER: Okay. Back on 24 the record. The time is 10:43. 25</p>	<p>1 A. Like I said, I don't know how 2 many pages the Knezevich study occupied. 3 Q. I'm asking a different 4 question. So I realize you don't know the 5 number of pages. 6 I'm just asking if you recall 7 as you sit here today whether the -- did the 8 actual materials that were associated with 9 the actual Knezevich and Hogan study that you 10 received, which is in your consideration 11 material, was a much larger set of materials 12 than what's attached as a supplement to the 13 Greim paper. 14 A. Yeah, I don't remember what the 15 relative size was. 16 Q. Okay. So do you recall the 17 Suresh study? 18 A. Yes. 19 Q. Okay. Isn't it true that there 20 was a 48 percent tumor response rate in the 21 controls in the Suresh study? 22 A. You know, if we're going to 23 look at actual data, I think I'd have to 24 have, you know, kind of something in front of 25 me to recall things like that.</p>
Page 75	Page 77

20 (Pages 74 to 77)

Confidential - Subject to Protective Order

Page 78

1 Q. Okay. So what would you --

2 A. I mean, there are like, you

3 know, over a thousand tumors that I entered.

4 I can't remember exactly what the response

5 rates were in every treatment group for every

6 study --

7 Q. Okay. So -- sorry.

8 A. -- every tumor type.

9 That's all right.

10 Q. What could I give you that

11 would help you?

12 So you have Greim, and you have

13 your report. I also have a copy of

14 Dr. Portier's expert report, and I have a

15 copy of his rebuttal report.

16 A. Well, I would need to have

17 something that actually shows me the data

18 from the Suresh study that you're talking

19 about for that particular tumor type. So

20 wherever that is.

21 Q. So I'm going to go back to

22 that --

23 A. Okay.

24 Q. -- so we don't waste time here.

25 Okay. So I'd like to talk a

Page 79

1 little bit about your background.

2 A. Okay.

3 Q. And your CV is contained in

4 your expert report right after your

5 consideration materials.

6 A. I've got it.

7 Q. So it's in Exhibit 21-1, and

8 it's 1 of 28 pages, correct?

9 A. Right.

10 Q. And it says a report generated

11 on July 29, 2017, correct?

12 A. Yes.

13 Q. So is this your most updated

14 CV?

15 A. As of July 29th, yeah.

16 Q. Okay. Nothing substantial has

17 happened in the last two months that would

18 require updating in your CV?

19 A. I'm not -- I mean, in terms of

20 papers published, I'm not totally sure, but,

21 no, nothing in terms of my professional

22 positions or anything.

23 Q. Okay. On pages 4 and 5, you

24 have a section of book chapters that have

25 been published.

Page 80

1 A. Uh-huh.

2 Q. Do any of these publications

3 involve methodology to be employed for

4 evaluating animal bioassays for cancer

5 outcomes?

6 A. Yes. I mean, there are

7 chapters here that could be applied to the

8 analysis of the data that we're talking about

9 here.

10 You know, I suppose that you

11 could say that any one of them, you know, in

12 some sense relates to the analysis of animal

13 toxicology data if these methods are useful

14 for analyzing data from a given experiment.

15 Q. Do they actually contain

16 information about application of these

17 methods to animal toxicology?

18 A. You know, often in my area of

19 research where we're developing or describing

20 methodologies, we'll use examples that

21 illustrate the utility of the methods, and I

22 actually don't know off the top of my head if

23 we used any --

24 (Telephone interruption.)

25 MS. GREENWALD: I apologize. I

Page 81

1 turned it on at the break and I forgot

2 to turn it off.

3 THE WITNESS: No problem.

4 I don't really know if I used

5 any examples from animal toxicology

6 studies, but it's possible.

7 QUESTIONS BY MS. GREENWALD:

8 Q. Okay. So on the top of page 5,

9 you reference analysis of correlated data

10 StatXact, that's S-t-a-t, capital X-a-c-t,

11 version 8.0 user manual, paren, PP 895 to

12 935.

13 A. Per version 8, yeah.

14 Q. Okay. So can you explain what

15 your work has been with StatXact and

16 preparing a user manual?

17 A. Sure. I -- my advisor, Cyrus

18 Mehta, when I was in graduate school, was the

19 founder of Cytel Software Corporation, and so

20 I've worked on research projects with him and

21 other colleagues at Cytel since I was a

22 graduate student in the late '90s. And some

23 of the research that I've conducted in

24 statistical methods has actually been

25 implemented in their software package

Confidential - Subject to Protective Order

Page 82	Page 84
<p>1 StatXact. And so because my work was used, I 2 helped them to write parts of the user 3 manual. 4 Q. So was part of your -- so you 5 said he was your advisor in your Ph.D. 6 program? 7 A. That's right, yeah. 8 Q. Okay. Was part of your work in 9 your Ph.D. program working on StatXact then? 10 A. My doctoral program? 11 Q. Right. 12 A. Not directly. 13 Q. Okay. 14 A. It's just that they found that 15 what I developed was useful, and they felt 16 like it should be made available for other 17 people to use and apply. 18 Q. Do you know what the first 19 version of StatXact was? 20 This says version 8. I don't 21 know -- 22 A. Version 1.0. I mean, that was 23 before I even met my advisor. That was 24 probably in the late '80s that that was 25 developed.</p>	<p>1 A. Sometimes, yeah. 2 Q. -- supplementation or I mean on 3 the new version? 4 A. At times, yeah. 5 Q. Okay. Are you under a 6 consulting agreement with -- let me step back 7 for a minute. 8 StatXact is owned by Cytel, 9 right? 10 A. Yeah. 11 Q. Cytel Corporation? 12 A. Yeah. 13 Q. Okay. Are you under retainer 14 with Cytel Corporation? 15 A. Not right now. 16 Q. Were you ever? 17 A. No, not under -- I never signed 18 any formal retainer. We had grants from the 19 National Institutes of Health to develop 20 software. That's what led to the 21 implementation of some of the modules in 22 StatXact that I helped to, you know, develop 23 and document. And so I was paid as a 24 consultant out of those NIH funds. 25 Q. By Cytel?</p>
Page 83	Page 85
<p>1 Q. Okay. That's what I was 2 wondering. Late '80s. Okay. 3 And this version 8 would have 4 been in approximately what year, 2009? 5 A. Yes, 2009 when the reference -- 6 the date for that reference. 7 Q. So you didn't actually help 8 develop StatXact, correct? 9 A. No. 10 Q. And have you been part of the 11 development of any of its later versions? 12 A. Indirectly. You know, the way 13 that StatXact works is it's just a suite of 14 software tools that people use in statistics 15 and data analysis, and so, you know, their 16 versions kind of build, they just add 17 compatibilities. 18 And so, you know, I've served 19 to kind of evaluate later versions. I 20 haven't made, you know, any really huge 21 contributions to -- like new capabilities in 22 that package. 23 Q. Okay. So when they update 24 StatXact, would it be fair to say that you're 25 consulted or you give advice on the --</p>	<p>1 A. By Cytel Software Corporation, 2 yeah. 3 Q. Okay. So if I understand that 4 right, Cytel had a grant from the NIH; is 5 that right? 6 A. Yeah, they've had several. 7 Q. Okay. And one of the grants 8 that Cytel has from the NIH is working on 9 developing and further developing StatXact; 10 is that correct? 11 A. Yeah. That's correct. 12 Q. Okay. 13 A. They're called small business 14 innovation research grants where they try to 15 take innovative technology and make it 16 commercially available. 17 Q. Okay. And so you -- so your 18 consulting work with -- on StatXact then has 19 been through Cytel? 20 A. Right. 21 Q. Okay. Other than your work 22 with Cytel on advising on updated versions of 23 StatXact and preparing the manual, have you 24 done any other work with Cytel relating to 25 StatXact?</p>

22 (Pages 82 to 85)

Confidential - Subject to Protective Order

Page 86	Page 88
<p>1 A. No.</p> <p>2 Q. Did you get paid for writing</p> <p>3 the manual?</p> <p>4 A. No. I mean, through the, you</p> <p>5 know, NIH grant consulting, I guess you could</p> <p>6 say.</p> <p>7 Q. Okay. So the manual update was</p> <p>8 also part of the NIH grant?</p> <p>9 A. I think more or less, yeah.</p> <p>10 Well, I'm -- I think -- I</p> <p>11 wasn't paid directly to write parts of the</p> <p>12 manual. It's just that I did it because, you</p> <p>13 know, as an academic statistician, that's</p> <p>14 what I do, I publish. And so I was</p> <p>15 participating with the documentation of that</p> <p>16 manual.</p> <p>17 Q. But this analysis of correlated</p> <p>18 data that's referenced on the top of page 5</p> <p>19 of your CV is not -- it's not a</p> <p>20 peer-reviewed, published manual, is it?</p> <p>21 A. No. That's why it's under book</p> <p>22 chapters.</p> <p>23 Q. That's what I thought. Okay.</p> <p>24 A. Right. Book chapters are</p> <p>25 separate from peer-reviewed -- or the referee</p>	<p>1 packages such as SAS, StatXact, SPSS or</p> <p>2 whatever, they implement those tools so</p> <p>3 they're available to a wider number of users.</p> <p>4 So in other words, the things</p> <p>5 that I've contributed to StatXact are things</p> <p>6 that I've published that are below, kind of</p> <p>7 in my list of refereed journal articles that</p> <p>8 are now available through a widely used</p> <p>9 software package so that other people can use</p> <p>10 those tools as well.</p> <p>11 Q. About how much money have you</p> <p>12 been paid from Cytel over the course of your</p> <p>13 professional career for your work on</p> <p>14 StatXact?</p> <p>15 A. I have no idea.</p> <p>16 Q. Can you approximate?</p> <p>17 A. No, I can't. I mean, I've</p> <p>18 worked for them for -- since I was a graduate</p> <p>19 student. There was would no way for me to</p> <p>20 approximate that.</p> <p>21 Q. Do you know how much you made</p> <p>22 last year from Cytel?</p> <p>23 A. No. I mean, not off the top of</p> <p>24 my head. I'd have to -- I'd have to go check</p> <p>25 through my records.</p>
<p>Page 87</p> <p>1 journals articles below that, those represent</p> <p>2 peer-reviewed publications.</p> <p>3 Q. Right.</p> <p>4 A. That's why I'm keeping them</p> <p>5 separate from book chapters.</p> <p>6 Q. That's what I thought.</p> <p>7 A. That's --</p> <p>8 Q. I was just a little confused by</p> <p>9 your answer before.</p> <p>10 So you answered, "It's just</p> <p>11 that I did it because, you know, as an</p> <p>12 academic statistician, that's what I do, I</p> <p>13 publish. And so I was participating with the</p> <p>14 documentation of that manual."</p> <p>15 But you don't mean that you've</p> <p>16 done publications for peer-reviewed journals</p> <p>17 with respect to your work with StatXact,</p> <p>18 right?</p> <p>19 A. No.</p> <p>20 Q. Okay.</p> <p>21 A. I mean, just to be clear, you</p> <p>22 know, that's kind of what happens in academic</p> <p>23 statistics. If you -- you know, if you</p> <p>24 develop something that is -- that has high</p> <p>25 utility, then often, you know, software</p>	<p>Page 89</p> <p>1 Q. Can you give me a range?</p> <p>2 Are we talking about \$10,000?</p> <p>3 \$50,000?</p> <p>4 A. I really don't know. I mean,</p> <p>5 I'd have to go back and check my records, you</p> <p>6 know, my invoicing records with them, but I</p> <p>7 wouldn't want to venture a guess off the top</p> <p>8 of my head.</p> <p>9 Q. I'm not asking you to guess.</p> <p>10 So you're saying as you sit</p> <p>11 here today, you can't even give me a range of</p> <p>12 how much you made in payments from Cytel in</p> <p>13 the year 2016?</p> <p>14 MR. GRIFFIS: Objection. Asked</p> <p>15 and answered.</p> <p>16 QUESTIONS BY MS. GREENWALD:</p> <p>17 Q. I'll make sure I understand</p> <p>18 your answer.</p> <p>19 A. Yeah, that's what I'm saying.</p> <p>20 I'm saying I'm not sure that I can give you a</p> <p>21 range without going and checking.</p> <p>22 Q. You said you've been paid by</p> <p>23 them since you were doing your doctoral</p> <p>24 thesis, right?</p> <p>25 A. To varying -- in varying</p>

23 (Pages 86 to 89)

Confidential - Subject to Protective Order

Page 90

1 amounts, yeah, depending on, you know, what
 2 projects we have going on.
 3 Q. Would you say it's been every
 4 year that you've had a project from them that
 5 you've been paid by them?
 6 A. No, it hasn't been every year.
 7 Q. In the last ten years, have you
 8 been you paid by them every year?
 9 A. No. I'd say no.
 10 Q. In the last --
 11 A. But again, I mean, I -- I
 12 wasn't prepared to answer questions about my
 13 invoicing history with Cytel, so I'd have to
 14 go back and actually recreate that billing
 15 history to know for sure.
 16 Q. Have you ever been an employee
 17 of Cytel?
 18 A. No.
 19 Q. Have you ever served as a board
 20 member?
 21 A. No.
 22 (Corcoran Exhibit 21-8 marked
 23 for identification.)
 24 QUESTIONS BY MS. GREENWALD:
 25 Q. Let me mark as Exhibit 21-8 a

Page 91

1 PowerPoint presentation that says -- that's
 2 titled "New StatXact Toolkit for Correlated
 3 Data," Chris Corcoran, Utah State University
 4 and -- I'm not going to try to pronounce his
 5 name, the other person from Cytel Software
 6 Corporation.
 7 A. Pralay Senchaudhuri. I'm
 8 excited you found this.
 9 Q. I did. The Internet is an
 10 amazing thing.
 11 Do you recall any prepared
 12 document -- by the way, have you seen this
 13 before?
 14 A. Yeah, I prepared it.
 15 Q. Okay. So this looks to be the
 16 PowerPoint presentation that you prepared?
 17 A. Yes, I created this.
 18 Q. Okay. Well, I just want to
 19 make sure, since I got it off the Internet,
 20 that it looks like it's an accurate copy.
 21 A. Yep.
 22 Q. Okay. Do you recall when you
 23 prepared this?
 24 A. Yes.
 25 Q. When was that?

Page 92

1 A. I'm not sure exactly which year
 2 I gave this presentation because I've given
 3 other presentations related to the same
 4 topic.
 5 Q. Last five years?
 6 A. Likely. I'm not sure. Like I
 7 said, I've given different presentations
 8 about this, so I'm not sure what -- I'd have
 9 to go to the site where you found this to
 10 know exactly what the context was.
 11 Q. Who did you give this
 12 presentation to?
 13 A. This one? I am not sure
 14 because I've given similar presentations on a
 15 couple of occasions, so I can't remember
 16 which group this was for.
 17 Q. Because I noticed there's four
 18 organizations mentioned in the four corners
 19 of the document. One says Utah State
 20 University.
 21 A. Yes.
 22 Q. Do you see that?
 23 A. Yes.
 24 Q. Do you do this work on behalf
 25 of Utah State University?

Page 93

1 A. I do this work as an academic
 2 statistician with Utah State. So, you know,
 3 the funding comes from the National
 4 Institutes of Health, and the funding was to
 5 support Cytel and to support me as well.
 6 Q. Okay. And that's why the logo
 7 for Utah State University appears here?
 8 A. That's right.
 9 Q. Okay.
 10 A. Because I work for Utah State
 11 University.
 12 Q. Okay. And is that sort of your
 13 university policy, that when you do work like
 14 this you're supposed to put your university
 15 logo? I'm curious.
 16 A. I don't know if we have a
 17 policy about it. I just know that since I
 18 work for Utah State, you know, in academics,
 19 when we go and give presentations, that's
 20 something that we want to kind of maintain a
 21 record of because it -- you know, whatever
 22 helps us helps the university, and so the
 23 university wants us to keep a record of the
 24 presentations that we make. And our own
 25 employment in our roles, we get credit for

Confidential - Subject to Protective Order

Page 94	Page 96
<p>1 that.</p> <p>2 Q. So that would be in part, am I</p> <p>3 correct -- and correct me if I am wrong --</p> <p>4 because you're doing this work indirectly</p> <p>5 through an NIH grant because Cytel is being</p> <p>6 paid by an NIH grant? Is that part of the</p> <p>7 reason why?</p> <p>8 A. No, I was -- I was -- I was</p> <p>9 directly -- I was, you know, listed as key</p> <p>10 personnel for that grant, so there's nothing</p> <p>11 indirect about it.</p> <p>12 Q. Okay. For this grant here, for</p> <p>13 doing this PowerPoint?</p> <p>14 A. For the grant that supported</p> <p>15 the work that we are talking about here.</p> <p>16 Q. Okay. Maybe you can tell me</p> <p>17 which grant that is. So it's page 37.</p> <p>18 Which grant would that be?</p> <p>19 It's page 27 I think your</p> <p>20 grants are on.</p> <p>21 A. I think for some reason it</p> <p>22 looks like only current grants are listed</p> <p>23 here, not past. It must have just been, you</p> <p>24 know, the setting when I generated this</p> <p>25 report.</p>	<p>1 led to this toolkit, yes.</p> <p>2 Q. Okay. And why is SBA on there?</p> <p>3 A. It's the Small Business</p> <p>4 Administration, because they're the ones that</p> <p>5 sponsor the Small Business Innovation and</p> <p>6 Research grants. They're called -- they're</p> <p>7 referred to as SBIR grants.</p> <p>8 Q. And you said you've given other</p> <p>9 presentations besides the one that's</p> <p>10 reflected in 21-8, correct?</p> <p>11 A. I've given, yeah, a lot of</p> <p>12 presentations about -- about correlated --</p> <p>13 exact tests for correlated data.</p> <p>14 Q. Okay.</p> <p>15 A. So starting when I was a</p> <p>16 doctoral student and, you know, until</p> <p>17 relatively recently.</p> <p>18 Q. So give me some examples of the</p> <p>19 audiences to which you give these</p> <p>20 presentations.</p> <p>21 A. Mostly other academic</p> <p>22 statisticians and students.</p> <p>23 Q. So it's usually in a university</p> <p>24 setting?</p> <p>25 A. Usually in a university</p>
<p>Page 95</p> <p>1 Q. So you have more grants from</p> <p>2 NIH than appear on page 27?</p> <p>3 A. Yeah, I have a history of</p> <p>4 grants, but these are -- these were, I guess,</p> <p>5 in some sense current grants.</p> <p>6 Q. Okay. Well, that will help</p> <p>7 answer some of the questions I had about the</p> <p>8 distinction between your expert report and</p> <p>9 some of the grants mentioned here, but we'll</p> <p>10 wait a minute to get there.</p> <p>11 A. Okay. It would just take a few</p> <p>12 minutes, actually, to look at the NIH</p> <p>13 database to find, you know, the grant that</p> <p>14 actually funded this work, if you want to</p> <p>15 take the time to do it.</p> <p>16 Q. Well, I'll -- maybe we can do</p> <p>17 that later.</p> <p>18 A. Okay.</p> <p>19 Q. Right now I don't really need</p> <p>20 to.</p> <p>21 Okay. So NIH's logo is on</p> <p>22 there, again, because this was being done by</p> <p>23 you in connection with NIH?</p> <p>24 A. Because they provided the</p> <p>25 support for Cytel that led to the work that</p>	<p>Page 97</p> <p>1 setting. I think one time I, you know, I</p> <p>2 presented at the FDA. So in other words,</p> <p>3 there were other statisticians, analysts, who</p> <p>4 work for the FDA who were just interested in</p> <p>5 knowing kind of more about the toolkit.</p> <p>6 Q. Is there a different cost</p> <p>7 structure for having the software for</p> <p>8 StatXact if you are an educational</p> <p>9 institution versus a commercial</p> <p>10 establishment?</p> <p>11 A. I actually don't know.</p> <p>12 Q. So you don't know anything</p> <p>13 about the pricing structure for StatXact?</p> <p>14 A. Not really. I haven't looked</p> <p>15 at it for a while, I mean, because I -- you</p> <p>16 know, because of my close connection to them,</p> <p>17 I -- so it's not an issue that I've dealt</p> <p>18 with.</p> <p>19 Q. So I know I asked you the</p> <p>20 question if you know the differential.</p> <p>21 Do you know anything about the</p> <p>22 pricing structure at all for StatXact,</p> <p>23 regardless of who's using it, who the user</p> <p>24 is?</p> <p>25 A. Not currently.</p>

25 (Pages 94 to 97)

Confidential - Subject to Protective Order

Page 98	Page 100
<p>1 Q. Did you ever know it?</p> <p>2 A. I think I've probably seen the</p> <p>3 prices at some point in my life, but I can't</p> <p>4 remember what they are off the top of my head</p> <p>5 or at what time that was.</p> <p>6 I -- well, nevermind.</p> <p>7 Q. For what use is StatXact</p> <p>8 marketed?</p> <p>9 A. It's marketed to, you know,</p> <p>10 statisticians and analysts and academics and</p> <p>11 biopharmaceuticals and federal agencies.</p> <p>12 Q. What kind of federal agencies</p> <p>13 would --</p> <p>14 A. Well, like I said, for example,</p> <p>15 I gave a talk at the FDA, so there are</p> <p>16 statisticians there at the FDA who apparently</p> <p>17 use it.</p> <p>18 I don't know what the -- what</p> <p>19 their numbers are, but I think that -- I</p> <p>20 think -- at least I know that there are some</p> <p>21 users there.</p> <p>22 Q. Do you know that they use it,</p> <p>23 or were you there to market it?</p> <p>24 A. I have no idea who is actually</p> <p>25 using it from day to day. I was there to --</p>	<p>1 academics at least know what StatXact is, but</p> <p>2 I don't know what the actual numbers are.</p> <p>3 Q. Do you know if StatXact also --</p> <p>4 I'm sorry, if Cytel also lists corporate</p> <p>5 users of StatXact?</p> <p>6 A. I think that they probably do,</p> <p>7 but I haven't looked at their website for a</p> <p>8 while.</p> <p>9 Q. Okay. So the last entry of</p> <p>10 your book chapters mentions Cytel but not</p> <p>11 StatXact. It says Egret.</p> <p>12 What is Egret?</p> <p>13 A. Oh, Egret was a package that I</p> <p>14 think they no longer produce. It was a</p> <p>15 package that they -- that they -- that they</p> <p>16 made available, I think, that was -- I can't</p> <p>17 remember what the acronym stood for.</p> <p>18 Q. Okay.</p> <p>19 A. But it was a package that was</p> <p>20 used, I think -- I think it was more focused</p> <p>21 on epidemiology. But that was kind of in the</p> <p>22 late '90s when I was a student that I helped</p> <p>23 out with that a little bit.</p> <p>24 Q. Okay. All right. So if you</p> <p>25 look at pages 5 through 16 of your CV that's</p>
<p>Page 99</p> <p>1 they were interested in having some people</p> <p>2 connected with Cytel to come and kind of show</p> <p>3 them, you know, what the capabilities were,</p> <p>4 what the new tools were for the new version,</p> <p>5 so that was -- that's what I did was just</p> <p>6 show them examples how to analyze data and so</p> <p>7 on.</p> <p>8 Q. Right.</p> <p>9 So you don't actually know</p> <p>10 whether FDA uses this. You just know that</p> <p>11 you presented its capabilities to the FDA?</p> <p>12 A. Well, I know that on Cytel's</p> <p>13 website they -- they present, you know, a</p> <p>14 list of people who actually use StatXact,</p> <p>15 so...</p> <p>16 Q. Okay. And you've looked at</p> <p>17 that recently?</p> <p>18 A. Not really recently. I've</p> <p>19 looked at it in the past.</p> <p>20 Q. Any other federal agency that</p> <p>21 you recall as a user of StatXact besides the</p> <p>22 FDA?</p> <p>23 A. Not off the top of my head, but</p> <p>24 most -- you know, most all statisticians who</p> <p>25 work for, you know, the government or in</p>	<p>Page 101</p> <p>1 attached to your report, which is</p> <p>2 Exhibit 21-1 --</p> <p>3 A. Uh-huh.</p> <p>4 Q. -- those appear to be the pages</p> <p>5 where you list your peer-reviewed journal</p> <p>6 articles, right?</p> <p>7 A. Right.</p> <p>8 Q. Okay. So Dr. Corcoran, my</p> <p>9 review of the titles of these articles</p> <p>10 suggest that there are about a hundred</p> <p>11 peer-reviewed journal articles in which you</p> <p>12 are an author or a coauthor.</p> <p>13 Does that sound about right?</p> <p>14 A. I don't know. I'd have to go</p> <p>15 through and count them.</p> <p>16 Q. I actually counted them.</p> <p>17 Just generally, does that sound</p> <p>18 about right? I'm not going to hold you to</p> <p>19 the hundred.</p> <p>20 A. It looks like dozens.</p> <p>21 Q. Unless I'm a bad counter, I</p> <p>22 think it's a hundred.</p> <p>23 So we'll say roughly a hundred,</p> <p>24 okay, just for purposes of some of these</p> <p>25 questions.</p>

26 (Pages 98 to 101)

Confidential - Subject to Protective Order

Page 102	Page 104
<p>1 For the articles here, which, 2 as I say, I counted about a hundred, isn't it 3 true that all but a few relate to issues of 4 dementia, Alzheimer's and cognitive, 5 age-related issues? 6 A. What do you mean by "a few"? 7 Q. Five or less. 8 A. I don't know. I guess I'd have 9 to go through and count that up. 10 Q. Okay. Well, then I'm actually 11 going to ask you to do something for me. 12 A. Okay. 13 Q. Other than if you exclude 14 peer-reviewed articles on dementia, 15 Alzheimer's and other cognitive, age-related 16 health issues, and you exclude articles 17 relating to religion and depression, how many 18 of your peer-reviewed articles -- how many 19 peer-reviewed articles have you published? 20 A. I haven't the faintest clue. I 21 mean, I'd have to go through this entire list 22 and comment about that. 23 Q. Well, as you sit here today, 24 can you tell me any peer-reviewed article 25 that you published that does not relate to</p>	<p>1 A. Yes, in large part. I mean, 2 it's an observational study of, you know, of 3 aging in this area, in this geographic area. 4 Q. Have you ever designed a rodent 5 carcinogenicity study to assess the ability 6 of a chemical to cause cancer? 7 A. No, I haven't. 8 Q. Have you ever performed or 9 overseen any rodent carcinogenicity study to 10 assess the ability of a chemical to cause 11 cancer? 12 A. Carcinogenicity study? 13 Q. Carcinogenicity. Boy, I'm 14 really tripping over my words today. 15 A. No, I haven't. 16 Q. Have you ever designed a study 17 that addresses the optimal dosing pattern for 18 rodent carcinogenicity studies -- I'm doing 19 it again -- to assess the ability of a 20 chemical to cause cancer? 21 A. No, I haven't. 22 Q. So I think I'm going to know 23 the answer to this because of the grants. 24 You stated in your expert 25 report that you received over \$25 million in</p>
Page 103	Page 105
<p>1 either dementia, Alzheimer's, cognitive, age, 2 health-related issues or religion and 3 depression? 4 A. Just off the top of my head, 5 no. 6 Q. What's the -- is it Cache or 7 Cache -- how do you say the name of this -- 8 A. It's Cache. 9 Q. What is the Cache study? 10 A. It's a large study of memory in 11 old age and Alzheimer's disease. 12 Q. Okay. 13 A. It represents actually several 14 studies that were kind of coordinated. 15 Q. Is that being coordinated 16 through Utah State University? 17 A. Mostly. 18 Q. Okay. And are you one of the 19 coordinators of that study? 20 A. I wouldn't call myself a 21 coordinator. I'm kind of a lead statistician 22 on a lot of the efforts that they have 23 initiated. 24 Q. Is that an epidemiological 25 study?</p>	<p>1 NIH grants, correct? 2 A. That I've helped -- I've 3 assisted as an analyst in studies that total 4 that amount, yeah. 5 Q. Okay. So the 25 million is not 6 grants that went directly to you; is that 7 correct? 8 A. That's right. 9 Q. All right. And am I correct 10 then -- so let me rephrase that. 11 A. No federal grant, like an NIH 12 grant for a large, complex study, no amount 13 of funding goes to one person. These -- 14 these studies are complex and involve a lot 15 of personnel across different universities. 16 They're very interdisciplinary. 17 Q. Is the Cache County study an 18 NIH-funded grant? 19 A. Yes, it was funded by several 20 grants from the NIH. 21 Q. Okay. And is that part of the 22 \$25 million figure you're using -- I can find 23 it. Just give me a second. I'm sorry -- on 24 page 2 of your expert report? 25 A. Yeah, I'm talking about all</p>

Confidential - Subject to Protective Order

Page 106

1 grants that I've -- that I served.
 2 Q. Okay. Now, you say -- back
 3 to -- back to your CV.
 4 A. Uh-huh.
 5 Q. Sorry. Go back to your grants.
 6 Give me a second.
 7 I believe it's page 27. Just
 8 give me a second before I take you there.
 9 Yeah, page 27.
 10 I know you said this -- this
 11 didn't have the full numbers of grants that
 12 you've received. I just want to ask you
 13 about one in particular.
 14 A. Sure.
 15 Q. You mentioned the top one, and
 16 you're named as, I think, grant recipient.
 17 The second person is the supporting.
 18 Does that mean that your name
 19 would or would not appear on a grant
 20 application?
 21 A. I think it would --
 22 Q. It would. Okay.
 23 A. -- appear.
 24 Q. And that's the one that the NIH
 25 funded in the amount of \$1,067,869; is that

Page 107

1 right?
 2 A. That's right.
 3 Q. And that's for epidemiology of
 4 Alzheimer's disease, resilience and risk
 5 pedigrees?
 6 A. Yes.
 7 Q. And that is from September 1,
 8 2016, through August 31, 2021?
 9 A. Yeah.
 10 Q. Okay.
 11 A. That's what the dates are.
 12 Q. Okay. You signed your
 13 retention agreement with the Hollingsworth
 14 firm in August of 2016, right?
 15 A. Yes.
 16 Q. August 31st, the day before you
 17 received this grant; is that right?
 18 A. I don't know if that's exactly
 19 how the grant awards work. I mean, you get a
 20 notice of award, but the funding period is
 21 something that's determined separate from the
 22 notice of the award, so --
 23 Q. Okay. So when you would have
 24 gotten notice --
 25 A. So it's not like you get a

Page 108

1 phone call that says your grant is starting
 2 tomorrow. I mean, you're told that months in
 3 advance, and then they set -- once they
 4 actually have their budget set, then they
 5 tell you when the award starts.
 6 Q. So you probably would have
 7 gotten the green light on the request for the
 8 grant months before September 1, correct?
 9 A. Yes.
 10 Q. Do you know whether NIH has any
 11 ongoing requirement or obligation on
 12 researchers to update potential conflicts of
 13 interest?
 14 A. I don't know.
 15 I know that our university has
 16 requirements, and so I try to, you know,
 17 adhere to those. They actually have us --
 18 they actually have us update, you know, our
 19 own contacts, and so they -- I think that
 20 just kind of happens annually. And so I
 21 usually update what's going on in terms of my
 22 research and consulting work then.
 23 Q. Have you disclosed to your
 24 university that you're a consultant to
 25 Hollingsworth and Monsanto in this

Page 109

1 litigation?
 2 MR. GRIFFIS: Objection.
 3 Misstates prior testimony with regard
 4 to Monsanto.
 5 THE WITNESS: I -- I'm actually
 6 just consulting for Hollingsworth, but
 7 I --
 8 QUESTIONS BY MS. GREENWALD:
 9 Q. Okay. So I'll ask it that way.
 10 Did you disclose to your
 11 university that you are a consultant for the
 12 Hollingsworth firm on behalf of Monsanto
 13 Corporation?
 14 MR. GRIFFIS: Objection to
 15 form.
 16 THE WITNESS: I don't -- I
 17 don't know if I've actually -- if
 18 they've actually kind of sent through
 19 that update recently, so I don't know
 20 if I've actually filed that.
 21 QUESTIONS BY MS. GREENWALD:
 22 Q. So you don't have an ongoing
 23 obligation at your university to update
 24 information as it -- as it occurs?
 25 A. We do, and we -- they actually

Confidential - Subject to Protective Order

Page 110	Page 112
<p>1 send us something every year, like a reminder 2 that helps us to kind of make sure that we're 3 updated. 4 Q. So help me understand how this 5 works. 6 If you are -- if you get your 7 update, let's say, January 1st, but 8 February 1st you become a consultant for a 9 corporation in connection with some private 10 consultancy work, are you saying that you at 11 that point are supposed to update your 12 information to the university at that time, 13 or do you wait until the following January? 14 A. I'm not actually certain what 15 their timing requirements are. 16 Q. Okay. But as you sit here 17 today, you haven't informed your university, 18 is that correct, about your consulting work 19 with Hollingsworth? 20 A. I'm not sure. Like I said, 21 I -- you know, those things get updated 22 periodically, and I'd have to go back and 23 check. 24 Q. Well, would anyone update it 25 but you?</p>	<p>1 materials considered list. I should use the 2 right term -- right after your expert report 3 text, does this accurately list all the 4 materials you have reviewed in preparation as 5 an expert in this case up to the present day? 6 A. Yes. 7 Q. Did you perform any analysis 8 that's not set forth in your report? 9 A. No -- 10 MR. GRIFFIS: Objection to 11 form. 12 Yeah, to the extent that we've 13 asked him to do things outside the 14 scope of the expert report, such 15 request would be privileged. 16 Don't answer with regard to 17 other analyses we've asked you to 18 perform or other consultations we've 19 asked you to do. 20 You may answer with regard to 21 the subject matter of your expert 22 report, whether there were analyses 23 concerning contents therein that 24 aren't disclosed in the expert report, 25 so...</p>
Page 111	Page 113
<p>1 A. No. 2 Q. Okay. So do you recall, 3 sitting here today, whether you have updated 4 any information with the university -- with 5 the Utah State -- let finish my question. 6 A. Oh, I'm sorry. 7 Q. -- with the Utah State 8 University about your consultancy work for 9 Hollingsworth corporate -- Hollingsworth, 10 LLP, on behalf of Monsanto Corporation? 11 A. No. 12 MR. GRIFFIS: Objection to 13 form. 14 THE WITNESS: Like I said, I -- 15 I -- I'm updating things constantly. 16 I mean, I get dozens of requests per 17 month to file papers, and so I would 18 just have to go back to see if that's 19 something I've done. 20 QUESTIONS BY MS. GREENWALD: 21 Q. So I'm almost finished with 22 this part of questioning. 23 The reference materials that 24 are pages 1 through 6 -- 1 through 5 that are 25 attached right after your -- I'm sorry,</p>	<p>1 THE WITNESS: Well, what I was 2 going to say is no. I mean, I think 3 what's in my expert report is fairly 4 comprehensive. 5 You know, at the same time I 6 received Dr. Portier's rebuttal 7 report. I haven't done any initial -- 8 or like additional analyses based on 9 that, but I do have -- I do have some 10 concerns about what he -- what he 11 reported in his -- especially in his 12 deposition, but I haven't done any 13 analyses to follow up on that. 14 QUESTIONS BY MS. GREENWALD: 15 Q. So are your concerns about what 16 Dr. Portier testified about in his deposition 17 part of what you deem to be part of your 18 opinions in this case? 19 A. Pending, you know, some further 20 exploration, yes, because he talked in his 21 deposition about -- he gave some details that 22 were not really provided before about how he 23 conducted his dose response analyses for the 24 pooled -- for his pooled procedures. 25 Q. Okay. So let's do it now. Why</p>

Confidential - Subject to Protective Order

<p style="text-align: right;">Page 114</p> <p>1 don't you tell me everything that you -- let 2 me use your words. 3 Why don't you tell me all the 4 concerns that you have about what Dr. Portier 5 testified about in his deposition, which in 6 this case was taken on September 5, 2017. 7 A. Sure. 8 MR. GRIFFIS: That are beyond 9 what's already stated in the expert 10 report, do you mean? 11 MS. GREENWALD: Correct. Yes. 12 If it's in the expert report, correct. 13 Thank you for that clarification. 14 Sorry about that. 15 THE WITNESS: Besides what I've 16 said in my expert report, he -- he 17 talked in his deposition about how he 18 actually did the dose response 19 analyses for the -- for his pooled 20 data procedures, and he, you know, 21 conducted those in a way that I think 22 was flawed. 23 QUESTIONS BY MS. GREENWALD: 24 Q. Stay there for a second. 25 A. Okay.</p>	<p style="text-align: right;">Page 116</p> <p>1 It's kind of like if -- you 2 know, if Bill Gates walked in here and we 3 computed our average salary with him present, 4 what would -- you know, how that would kind 5 of inflate -- that would inflate all of our 6 salaries on average. That's kind of what is 7 happening with these extreme dose groups. 8 They place more -- they give more prominence, 9 basically, to tumors that are found in higher 10 dose groups. 11 So I have a concern about that, 12 but I actually haven't done an analysis to -- 13 you know, to really better understand exactly 14 what kind of impact that's having on his P 15 value computation. 16 Q. What else? 17 A. That's all I have to add to my 18 expert report. 19 Q. So everything in your expert 20 report, plus what you just explained -- what 21 you just testified about relating to his 22 testimony at his deposition about dose 23 response for pooled procedures, right -- 24 A. Right. 25 Q. -- that you just testified</p>
<p style="text-align: right;">Page 115</p> <p>1 Q. In what way is it flawed? 2 A. Well, I already expressed my 3 concern in my expert report about him 4 combining data sets from different sources 5 into the same table without accounting for 6 study differences. 7 On top of that, he's also -- 8 he's also combined them in a way that -- that 9 places studies that have extreme doses, I 10 mean, upper treatment groups, he kind of 11 combines them with studies that actually have 12 relatively lower doses, and they're higher 13 treatment groups. 14 He does that in a way that I 15 think influences the P values that he's 16 computing when he pools the data sets 17 together. Because it turns out that when 18 you -- when you actually have extreme dose 19 groups and you're conducting a trend test to 20 compute a P value for dose response effects, 21 that those higher doses actually have more 22 influence. So any incidence of tumor that 23 you see in the higher dose groups then has -- 24 places greater influence on the result, undue 25 influence.</p>	<p style="text-align: right;">Page 117</p> <p>1 about? 2 A. So in addition to the other 3 flaws in his pooled procedure, that's one 4 that could be fairly significant. 5 Q. Did Dr. Portier do pooling in 6 his deposition different than he did in his 7 expert report? 8 A. Well, I think in his deposition 9 he explained how he did it in his expert 10 report, and that's something that was not -- 11 that I didn't pick up from his expert report 12 because he didn't explain it. 13 So once he explained it in his 14 deposition, it was clear to me, you know, 15 that that was a problem. 16 Q. What are the study differences 17 you're referring to among these studies? 18 For example, let's talk about 19 the rat studies first. 20 A. Uh-huh. 21 So what are the study 22 differences? 23 Q. Uh-huh. 24 A. You mean -- 25 Q. I mean, other than I understand</p>

Confidential - Subject to Protective Order

Page 118	Page 120
<p>1 the dose treatment. Let's put dose -- let's 2 talk about rats first, and let's put aside 3 dose. 4 A. Uh-huh. 5 Q. What are the study differences 6 that you have knowledge about? 7 A. Well, do you mind if I just 8 refer to my report? 9 Q. No, it's there for you all day. 10 A. Let me just point this out. 11 Kind of starting in the -- starting in the 12 summary. 13 Q. What page are you on? 14 Oh, the summary of your report. 15 Okay. 16 A. Yeah. 17 Q. Uh-huh. 18 A. So at the very end, starting 19 in -- on line 28, I point out that his 20 combining or pooling of data from across 21 several sources, that these are the 22 differences I'm talking about: using 23 experiments carried out during different 24 years and in different laboratories, under 25 different conditions, without appropriately</p>	<p>1 those would not be appropriately compared? 2 A. Yeah, that's -- that's a good 3 question. But it's fairly common statistical 4 knowledge that if you have different 5 experiments -- different experiments that are 6 carried out at different times and different 7 locations under different conditions, that in 8 spite of your best efforts to try to control 9 those, even using in this case, you know, 10 rats or mice from the same strain, that there 11 will be variations in the environment that 12 will lead to different underlying tumor 13 rates. 14 Q. Okay. But I just want to 15 understand. 16 My one, I hope, simple question 17 is that if you have same period of time, same 18 mouse strain -- we were talking about rats, 19 but we can go to mice, doesn't matter -- same 20 mouse strain, two different places but the 21 laboratories themselves where the mice are 22 being studied have controlled environments, 23 are you saying that those could not be 24 compared? 25 A. I think I lost track of what</p>
Page 119	Page 121
<p>1 accounting for these studies' unique 2 characteristics. 3 So those are kinds of 4 differences I'm talking about. 5 Q. Okay. So what are the 6 different conditions, the different 7 laboratory conditions, among the seven rat 8 studies that you looked at in connection with 9 your expert report? 10 MR. GRIFFIS: Objection to 11 form. 12 THE WITNESS: They were not 13 carried out in the same lab. Those 14 are the differences. 15 QUESTIONS BY MS. GREENWALD: 16 Q. Okay. So is it possible to 17 control environment in different labs so that 18 the -- do you mean just like different 19 buildings? 20 A. Well, different places, 21 different times, under different conditions. 22 Q. So do you believe that if you 23 have different buildings or different places 24 but they otherwise control the environment 25 within the research laboratory the same, that</p>	<p>1 you were saying. 2 You're saying at the same time 3 in two different labs? Is that what you 4 said? 5 Q. Well, within a two to three 6 year period that you otherwise control for 7 the environment within the laboratory. 8 Are you saying that those -- 9 A. What do you mean by "control"? 10 Q. Well, temperature, light -- 11 A. Oh, so -- you know, in terms of 12 controlling the conditions? 13 Q. Well, let me -- rather than 14 answering that question, why don't you tell 15 me what do you mean by different conditions? 16 Let's go through your sentence. 17 Let's parse it out. 18 "In addition, Dr. Portier 19 violated conventional statistical practice in 20 his use of historical controls and in 21 combining or pooling data from across several 22 sources - using experiments carried out 23 during different years" -- that I 24 understand -- "and in different 25 laboratories" --</p>

Confidential - Subject to Protective Order

Page 122	Page 124
<p>1 Do you mean by that like 2 different actual buildings, like different 3 laboratories? Like one might be the -- 4 A. Physical. Yes, different 5 physical -- 6 Q. -- Utah State -- 7 A. Facilities, yeah. 8 Q. Okay. 9 -- "and under different 10 conditions." 11 So what do you mean by "under 12 different conditions"? 13 A. I mean the conditions that are 14 inherent to the environment. 15 Q. Like? 16 A. That laboratory. 17 Q. Give me some examples, please. 18 A. I think that, you know, it 19 would be best to, you know, actually cite 20 some of the sources that Dr. Portier used 21 himself. I think they explain this even 22 better than I could off the top of my head. 23 Q. Okay. I'm not asking you right 24 now for any specific conditions in any 25 particular laboratory with respect to the 12</p>	<p>1 times and different locations, using 2 different -- you know, even the same strains 3 of mice, that there is variability that can't 4 be entirely controlled. 5 Now, what those things are are 6 a matter of conjecture. We don't know them. 7 If we did know them, then the people who 8 designed the experiments could control those 9 things. But you can't control everything. 10 So what you do as a 11 statistician is that you control for those 12 things as a part of the analysis, and that -- 13 again, that's very well-understood, as I've 14 outlined in my expert report, and that's what 15 Dr. Portier didn't do. 16 So whether or not you're 17 actually controlling every little thing and 18 what those things are is kind of immaterial. 19 The point is, as a statistician, my job is to 20 control those things as a part of my 21 analysis. 22 Q. So when you use the word 23 "different conditions" in line 29, you're not 24 thinking of any particular concrete 25 conditions?</p>
Page 123	Page 125
<p>1 studies that are at issue in this case. 2 I'm really merely asking you 3 when you use this sentence here, and you use 4 that phrase on line 29 of page 1 of your 5 report, what did you mean when you said 6 "different conditions"? 7 What do you mean by the words 8 "different conditions"? 9 A. Well, I'm not in the job, as 10 you pointed out, of actually, you know, 11 conducting animal toxicology experiments. 12 I'm a statistician. So what I'm hired to do 13 is to analyze data that come from the types 14 of studies that, you know, say, a 15 toxicologist would produce. 16 And what I know is that based 17 on the, you know, the literature, the 18 literature that Chris Portier cited, the, you 19 know, materials that I cite in my own list, 20 what I know is it's accepted across, you 21 know, the toxicology community as well as 22 across the statistical community that in 23 spite of your best efforts to control 24 environmental conditions from lab to lab 25 across different -- you know, at different</p>	<p>1 A. No. What I'm saying is the 2 data demonstrate from, you know, thousands 3 and countless studies in toxicology and in 4 all other fields of science that when you -- 5 that when you try to combine data from 6 different experiments that were carried at 7 different times, different locations, there 8 are things that make those studies different 9 that are not measurable, in spite of 10 everything that they do to try to control 11 that. And so what you do is you control it 12 as part of the statistical analysis. 13 So that's what Dr. Portier is 14 not doing in his expert report. What he's 15 doing is he's just combining data into tables 16 as though they came from the same experiment 17 and the same study, and that is an absolute 18 violation of statistical practice. That's 19 where, as a statistician, I control those 20 things since I'm not involved in the design 21 of the experiments themselves. 22 (Corcoran Exhibit 21-9 marked 23 for identification.) 24 QUESTIONS BY MS. GREENWALD: 25 Q. I'm going to mark as</p>

Confidential - Subject to Protective Order

Page 126	<p>1 Exhibit 21-9 the expert report of 2 Dr. Christopher J. Portier. 3 A. Thanks. 4 Q. Sure. 5 And you've read that report 6 before, right? 7 A. Yes. 8 Q. Can you turn to page 33? 9 A. (Witness complies.) 10 Q. For example, the paragraph that 11 starts out with "Brammer 2001" sort of in the 12 top part of the page? 13 A. Yes. 14 Q. Can you -- you want to take a 15 look at that for a minute, that paragraph? 16 A. Okay. I've read it. 17 Q. Okay. Is it still your 18 testimony that Dr. Portier didn't describe 19 and explain in his expert report how he was 20 comparing the data among the rat -- the rat 21 studies? 22 A. Yes, that is my testimony. 23 Q. Do you also want to go to 24 page 19 and 20 of the same report? 25 A. Before we turn to pages 19 and</p>	Page 128	<p>1 it. 2 Secondly, there's no reason to 3 simply exclude a study even if he had 4 formally tested it. So if his test was 5 formal and he decided that Suresh had a 6 larger -- a larger response rate, then there 7 would be no statistical reason for him to 8 just simply exclude it from his pool 9 analysis. That's what I'm pointing out in my 10 expert report. 11 So notice how he says further 12 on, "All three studies use different diets 13 and were conducted in different facilities; 14 thus, there is no obvious explanation for the 15 dramatically different rates." 16 So in other words, that -- you 17 were asking me before is it possible to do 18 studies in different laboratories under 19 different -- you know, even trying to control 20 environmental conditions and still -- and 21 still observe studies that are markedly 22 different. 23 And the answer is yes. This 24 paragraph explains, you know, how -- for 25 things that he has no explanation for that</p>
Page 127	<p>1 20, can I -- I point out here that 2 Dr. Portier says -- he says, "Given different 3 doses and different sample sizes" -- this is 4 on page 33 in the middle of the paragraph you 5 just had me read. 6 Q. Uh-huh. 7 A. "Given different doses and 8 different sample sizes, we need to formally 9 test for consistency in these studies." 10 Q. Correct. 11 A. There is no formal test in this 12 paragraph. So he has not formally tested for 13 any differences. He's eyeballed it, and he's 14 decided that he -- you know, he's decided 15 that they're different just based on his -- 16 these eyeballed proportions. And on top of 17 that, there's no reason for him to... 18 Q. Oh, I'm sorry. 19 A. I'm sorry, I was answering your 20 question. I just ---- 21 Q. No. No. I'm listening. I'm 22 listening. No, I'm listening. I'm sorry, we 23 multi-task. 24 A. Okay. What I'm saying here is 25 that he, first of all, didn't formally test</p>	Page 129	<p>1 can't be controlled in the laboratory. 2 Q. Dr. Corcoran, did you read the 3 sentence that says, "Suresh saw 48 percent 4 response" -- 5 A. Uh-huh. 6 Q. -- "of hepatocellular adenomas 7 in controls, whereas the other two studies 8 saw no tumors in the control animals"? 9 A. Yes. 10 Q. Okay. Do you think that's one 11 of the reasons why the Suresh study was not 12 included in this combining of data? 13 A. But what I point out in my 14 expert report is that there's no reason to 15 exclude studies for having these different 16 baseline rates. 17 The thing that you're studying 18 is not what the -- not what the kind of 19 spontaneous rate of tumors is in mice and 20 rats. That's not what you're trying to 21 study. 22 What you're studying is whether 23 or not there's, you know, some sort of 24 compound-related effect. That's what you're 25 studying.</p>

Confidential - Subject to Protective Order

Page 130	Page 132
<p>1 So in other words, had he used 2 kind of one of the standard methods for 3 analyzing data that come from different 4 studies that allow you to look at dose 5 response, even if they do come from different 6 places and have different rates, then there 7 was no reason for him to exclude that study. 8 That's a very arbitrary 9 decision, and there was no -- you know, even 10 though, yes, you eyeball that and you say, 11 well, a 48 response rate compared to zero, 12 that appears to be, you know, significantly 13 different, but there was no formal test done. 14 He never actually carried out a statistical 15 procedure that told him that. 16 Q. What's the purpose of having a 17 control animal in a bioassay? 18 A. What's the purpose of having a 19 control animal in a bioassay? 20 Q. Uh-huh. 21 A. So you can compare treatment to 22 animals that were not exposed. 23 Q. Okay. If you go to page 19 and 24 20, the bottom of 19, top of 20, starting 25 with -- well, he doesn't have lines.</p>	<p>1 sources that he cited and the materials I use 2 in my material list, the truth is, in spite 3 of your best efforts to control everything, 4 you cannot control everything in terms of the 5 animals' environment. That's why they end up 6 with these, you know, different -- these 7 different tumor rates amongst controls. 8 That's one of the main reasons. That cannot 9 be completely controlled for. 10 And so on page 33, you know, 11 the page that, you know, you just pointed out 12 to me, he's illustrating exactly why that 13 happens. I mean, even though the studies try 14 to use the same environmental conditions, you 15 still have a tumor response rate in one group 16 that's nearly 50 percent and the other group 17 zero percent. 18 Q. So are you saying this Suresh 19 study saw a 48 percent tumor rate in the 20 controls because of the difference in the 21 animals' food type, water and how often the 22 animals were handled? 23 A. I have no concrete explanation 24 for that, but what I'm saying is as a 25 statistician that is an easy thing to control</p>
Page 131	Page 133
<p>1 So if you go to the last full 2 sentence on 19 and the carryover on 20? 3 A. Okay. 4 Q. Starts with "these studies are 5 conducted." 6 A. Yeah, you know, he's -- do you 7 want me to read that out loud, first of all? 8 Q. No. 9 I mean, do you have any reason 10 to believe that the animals were not -- 11 sorry, let me strike that. I'm going to 12 start over. 13 Do you have any reason as you 14 sit here today to believe that the studies 15 were not conducted in a way that controlled 16 for the animals' food type, water quality and 17 how often the animals are handled? 18 A. This is the whole problem with 19 Dr. Portier's pool analysis, because he's 20 right. He's saying that you're trying to 21 control everything in the environment that 22 you can control, so he's absolutely right 23 about that. 24 But the key word is "trying." 25 And the truth is that even based on his own</p>	<p>1 for, and it's something that Dr. Portier 2 didn't. 3 Q. So that's easy to control for, 4 but it's not easy to control for food type, 5 water quality and how often an animal is 6 handled; is that you're saying? 7 A. It's the beauty of a 8 statistical model is that you can control 9 for -- you can control for conditions like 10 that even though they weren't -- 11 Q. So as you sit -- 12 A. Sorry, I just want to finish my 13 answer. 14 That's the beauty of using a 15 statistical analysis that does control for 16 things like that. I mean, using the right 17 statistical analysis, you can control for 18 those factors. 19 Q. Okay. So I want to ask my one 20 question again because I still don't think 21 I've gotten an answer for it. 22 As you sit here today, do you 23 know whether the food type, water quality and 24 how often the animals were handled in these 25 rat studies were different?</p>

Confidential - Subject to Protective Order

Page 134	Page 136
<p>1 Do you know -- do you know</p> <p>2 factually whether there was a difference --</p> <p>3 A. What I'm telling you --</p> <p>4 Q. -- among those studies?</p> <p>5 A. -- is that as a statistician,</p> <p>6 it doesn't really matter because -- because</p> <p>7 what I do as a statistician is I say, well,</p> <p>8 here are data from different studies. How do</p> <p>9 I account for those potential differences</p> <p>10 through my statistical analysis?</p> <p>11 And that's using the approach</p> <p>12 that I talk about in my expert report that</p> <p>13 Dr. Portier doesn't use at all.</p> <p>14 Q. So how do you account for those</p> <p>15 factors in your methodology?</p> <p>16 A. Do you want to refer to my</p> <p>17 expert report? Because I think I explain it</p> <p>18 in there.</p> <p>19 So if you go to page 15 of my</p> <p>20 expert report in Section 5C.</p> <p>21 Q. Uh-huh.</p> <p>22 A. First go to line 15.</p> <p>23 So my point is, "First and most</p> <p>24 critically, Dr. Portier's pool procedures</p> <p>25 flout statistical standards by making no such</p>	<p>1 Second, you have to actually</p> <p>2 account for those differences within the</p> <p>3 model, which his own sources tell us to do,</p> <p>4 because, again, that's fairly conventional</p> <p>5 statistical practice.</p> <p>6 So instead of actually</p> <p>7 accounting for those differences, what he did</p> <p>8 was he just put all the data together in the</p> <p>9 same table, which is really grievously wrong</p> <p>10 in statistical practice.</p> <p>11 And then the third thing is</p> <p>12 that you have to make sure not only that</p> <p>13 you're accounting for those differences but</p> <p>14 that the different dose response effects</p> <p>15 across the studies are accounted for as well,</p> <p>16 and that he didn't do either.</p> <p>17 Q. But what did you do?</p> <p>18 I'm still trying to understand.</p> <p>19 Tell me what you did with this data.</p> <p>20 What analysis -- what are you</p> <p>21 doing different or what are you proposing or</p> <p>22 what -- yeah, help me under -- I'm still</p> <p>23 trying to understand what you did.</p> <p>24 I understand your criticism of</p> <p>25 Dr. Portier.</p>
Page 135	Page 137
<p>1 adjustments at all for differences between</p> <p>2 experiments or for the similarities among</p> <p>3 mice within each study. Dr. Portier simply</p> <p>4 aggregates data across various subsets of rat</p> <p>5 and mouse studies treating rodents born and</p> <p>6 raised in different environments, fed from</p> <p>7 different sources, measured using different</p> <p>8 tools by different researchers over a 30-year</p> <p>9 span as though they were all included within</p> <p>10 a single experiment at the same time."</p> <p>11 So -- and then below that -- I</p> <p>12 mean, I won't read the entire thing, but</p> <p>13 below that paragraph I outline exactly how</p> <p>14 one would conduct that kind of analysis, and</p> <p>15 it's a very common approach when you're</p> <p>16 actually looking at data that arise from</p> <p>17 different studies.</p> <p>18 The first step is to determine</p> <p>19 formally whether or not the studies do have</p> <p>20 those kind of differences.</p> <p>21 Now, he said that he did that</p> <p>22 on page 33 with, you know, those -- those rat</p> <p>23 studies, but he actually carried out no</p> <p>24 formal test. He just eyeballed it. So</p> <p>25 that's one checkmark.</p>	<p>1 A. Are we talking about the pooled</p> <p>2 analyses?</p> <p>3 MR. GRIFFIS: Objection.</p> <p>4 Compound.</p> <p>5 QUESTIONS BY MS. GREENWALD:</p> <p>6 Q. I'm trying to understand what</p> <p>7 your approach is -- well, let me ask it this</p> <p>8 way.</p> <p>9 Are you testifying that none of</p> <p>10 these studies should be compared?</p> <p>11 A. I'm testifying that they should</p> <p>12 be -- if they're going to be compared, there</p> <p>13 are steps that you have to take to make sure</p> <p>14 that it's done properly. And I'm testifying</p> <p>15 that he took none of them when he was</p> <p>16 actually pooling data.</p> <p>17 Q. What steps did you take to</p> <p>18 determine whether they should be compared?</p> <p>19 A. Well, you know, the steps I</p> <p>20 took in analyzing the data were to first look</p> <p>21 at, you know, the 12 studies in total, in</p> <p>22 other words, you know, to actually look at</p> <p>23 the evidence across all tumor types, across</p> <p>24 all studies, and to actually account for the</p> <p>25 fact that we're doing many, many tests as</p>

Confidential - Subject to Protective Order

Page 138	Page 140
<p>1 opposed to just cherry-picking P values. 2 So my task was to kind of 3 evaluate, well, is there any evidence of, you 4 know, a compound-related effect. 5 And after having assessed all 6 of the -- all of these trend tests over many 7 hundreds of tumor types across all 12 8 studies, seven rat and five mice, my decision 9 was that there was no compound-related 10 effect. 11 My evaluation -- my evaluation 12 of the pool analyses had more to do with what 13 Dr. Portier was trying to do to assess the 14 evidence on his own. 15 Q. Okay. Can you tell me where in 16 your report you explain the steps you took to 17 compare the data? Give me a page number. 18 A. To -- the steps that should be 19 taken if you're going to combine data? 20 Q. No, what steps you took to 21 decide that there was no compound effect. 22 What steps did you take with 23 respect to the rat studies, for example, on 24 whether they could or could not be compared? 25 A. Well, the --</p>	<p>1 many data sets, that's in Section 5B. 2 That's what's required. 3 QUESTIONS BY MS. GREENWALD: 4 Q. You didn't do that analysis, 5 though, with this data set, did you? 6 A. What I did was I looked at what 7 he did, and I pointed out how it was flawed. 8 And I also, as an example -- you know, since 9 you brought up page 33 in his report, as an 10 example, I addressed -- I addressed that very 11 example, page 14 -- on page 14. 12 Q. But you didn't -- did you or 13 did you not do an analysis -- 14 A. Oh, I'm sorry, not on page 14. 15 It's page 18, sorry. 16 Q. 18 of whose report? Yours? 17 A. Yes. 18 Q. That's where you did an 19 analysis of the data? 20 A. That's where I addressed the 21 example that you just showed me from page 33 22 of his report. 23 So I outlined the steps before 24 that, and then I actually applied it to 25 illustrate why what he was doing was so</p>
Page 139	Page 141
<p>1 MR. GRIFFIS: Objection. 2 Compound. 3 THE WITNESS: Well, this is 4 the -- kind of the bulk of, you know, 5 my first four sections. I step 6 through, starting with my summary, you 7 know, my own background, you know, 8 talking about -- talking kind of more 9 generally about -- about the 10 background of the problem, what 11 happens when you actually conduct a 12 study that has hundreds and hundreds 13 of P values. So I gave some context 14 for that. I carried out my own 15 analysis based on those P values. 16 My -- you know, the material 17 that you're referring to in Section 4 18 is then my assessment of -- I'm sorry, 19 in Section 5 is my assessment of what 20 Dr. Portier did to, you know, 21 demonstrate what he thought was 22 evidence of a compound-related effect. 23 So in other words, if you're 24 asking, you know, what it requires to 25 do a proper combined analysis across</p>	<p>1 deeply flawed. 2 Q. And you're saying that's on 18, 3 lines 3 through 29 -- 28? 4 A. That's where I look at the 5 example that you just cited on page 33 in 6 this report. 7 Q. And how in your analysis here 8 do you account for the 48 percent tumor rates 9 in the control in Suresh? 10 A. So looking down -- looking down 11 in the paragraph below, starting on line 31, 12 my own -- 13 MR. GRIFFIS: Let's pause one 14 moment. We just had a knock on the 15 door. 16 MS. GREENWALD: Right. 17 VIDEOGRAPHER: We're going off 18 the record. The time is 11:51. 19 (Off the record at 11:51 a.m.) 20 VIDEOGRAPHER: We're back on 21 the record. The time is 11:51. 22 THE WITNESS: Yeah, I can 23 finish that answer. 24 QUESTIONS BY MS. GREENWALD: 25 Q. Were you in the middle of an</p>

Confidential - Subject to Protective Order

Page 142	Page 144
<p>1 answer? Yeah, sorry. 2 A. So that's okay. 3 Starting on line 31, "My own 4 analysis of the liver adenoma data first 5 demonstrated definitively that there is 6 higher -- highly significant correlation 7 among rats within each study." 8 So I actually did conduct a 9 formal test of differences between the 10 groups, which he didn't. 11 And then -- and then I looked 12 at the dose response effects across the three 13 studies that he was discussing, and what I 14 found was that the Brammer study, you know, 15 had a 21 percent increase in odds for 16 every -- you know, every unit of dose, 17 hundred milligrams per kilogram of body 18 weight per day, whereas the other two 19 studies, the Suresh and Wood studies, had 20 only 1 percent increase each. 21 And so in other words, that 22 would be -- the first step is actually 23 adjusting for those differences. 24 The second step is looking for 25 differences in dose response effect.</p>	<p>1 Q. How do you do that with the 2 controls when you have two studies that have 3 no tumors in the controls and one that has 4 48 percent? 5 MR. GRIFFIS: Objection. Asked 6 and answered. 7 THE WITNESS: The way that you 8 do that is pretty easy. 9 QUESTIONS BY MS. GREENWALD: 10 Q. Not for me. 11 A. Well, yeah, I mean, I'm talking 12 about for a statistician, but it's not -- 13 it's not that complicated in a statistical 14 model because, you know, you fit the model 15 that fits a line that helps you to model dose 16 response. 17 And then, you know, essentially 18 what you're doing is you're adding another 19 term in the model that accounts for study 20 type. So in other words, it's allowing -- 21 you know, it's allowing that dose response to 22 vary -- that tumor rate to vary across 23 different studies. 24 Q. What's the name of this model 25 you applied?</p>
Page 143	Page 145
<p>1 Q. Okay. I'm still trying to 2 understand, like, where did you account for 3 the 48 percent tumor rate? 4 I understand your writing. 5 Where did you account for that 6 in your methodology? 7 A. Yeah, when -- when -- in 8 statistics, when you actually fit a model, 9 like in this case logistic regression, which 10 actually not just -- it doesn't just compute 11 a P value. It allows you to actually 12 estimate what the dose response effect is. 13 It's an easy thing -- as 14 Dr. Portier pointed out in his rebuttal 15 report, it's a fairly easy thing to use 16 logistic regression and then add in an effect 17 in the model that actually accounts for these 18 study differences. There are two or three 19 different ways to do it, but they're all 20 fairly well-accepted. 21 And so what I did was I 22 included that kind of effect in my logistic 23 regression model, and that accounts for the 24 fact that you have this variability between 25 the tumor rates across these three studies.</p>	<p>1 A. This is logistic regression. 2 Q. You did not do an analysis of 3 the seven rat studies, correct? 4 A. I did analyze the seven rat 5 studies. 6 Q. Together? 7 A. Well, yeah, those are the 8 tables in my appendices. I analyzed them all 9 together. 10 Q. That's C and D that we talked 11 about earlier? 12 A. Yeah. I mean, I analyze them 13 in the aggregate and actually, you know, 14 looking at the distribution of P values 15 across the trend tests. 16 Q. Am I right, we're talking about 17 C and D, correct, pages 46 and 47? 18 A. We're talking about A, B, C and 19 D. 20 Q. All four. Okay. 21 A. So those are the results of -- 22 those are, you know, the bulk of my results 23 for the analysis across all of these studies. 24 Q. Where in your study do you 25 explain the steps you took to get your</p>

Confidential - Subject to Protective Order

Page 146	Page 148
<p>1 results?</p> <p>2 A. Results for what?</p> <p>3 Q. That are in Appendix A, B, C</p> <p>4 and D.</p> <p>5 A. So go into my expert report,</p> <p>6 starting on page 9, line 28. Trend test</p> <p>7 results for the seven rat studies are</p> <p>8 summarized by the tables in Appendix A, and</p> <p>9 results for the five mouse studies are</p> <p>10 summarized in Appendix B. And my, you know,</p> <p>11 summary of where those results come from are</p> <p>12 in the paragraphs preceding that.</p> <p>13 Q. Preceding what?</p> <p>14 So I understand, you tell us</p> <p>15 where those numbers are.</p> <p>16 Where do you explain how you</p> <p>17 got those numbers?</p> <p>18 A. The trend test P values?</p> <p>19 Q. The numbers that you just</p> <p>20 talked about that you said they're in Tables</p> <p>21 A, B, C and D.</p> <p>22 How do you -- where do you</p> <p>23 explain the methodology that you used to</p> <p>24 derive those numbers?</p> <p>25 MR. GRIFFIS: Objection. Asked</p>	<p>1 A. I've heard his name but I've</p> <p>2 never met him, and I don't know what his role</p> <p>3 is, really, in this case.</p> <p>4 Q. Have you read his expert</p> <p>5 report?</p> <p>6 A. No.</p> <p>7 MR. GRIFFIS: It's almost noon</p> <p>8 and lunch is here. Should we break?</p> <p>9 MS. GREENWALD: Sure.</p> <p>10 VIDEOGRAPHER: We're going off</p> <p>11 the record. The time is 11:58.</p> <p>12 (Off the record at 11:58 a.m.)</p> <p>13 VIDEOGRAPHER: Okay. We are</p> <p>14 back on the record. The time is</p> <p>15 12:37.</p> <p>16 QUESTIONS BY MS. GREENWALD:</p> <p>17 Q. Okay. So a quick question from</p> <p>18 before the lunch, and then we're going to</p> <p>19 move on to something different.</p> <p>20 A. All right.</p> <p>21 Q. What's the basis for your</p> <p>22 assumption that the data from the various</p> <p>23 studies, both the rat studies and the mice</p> <p>24 studies, cannot be tabulated together?</p> <p>25 A. Just the weight of the</p>
<p>1 and answered.</p> <p>2 THE WITNESS: Well, so let's</p> <p>3 start on page 8, line 8.</p> <p>4 QUESTIONS BY MS. GREENWALD:</p> <p>5 Q. Okay.</p> <p>6 A. Actually, look at the first two</p> <p>7 questions preceding that in the preceding</p> <p>8 paragraph.</p> <p>9 First, how do we evaluate the</p> <p>10 dose response effect of glyphosate on a</p> <p>11 single tumor type?</p> <p>12 Second, how do we account for</p> <p>13 many dose response analyses across multiple</p> <p>14 tumor types?</p> <p>15 And then the following</p> <p>16 paragraphs explain where that comes from.</p> <p>17 And then like I say on page 9,</p> <p>18 starting on line 28, I sum that up by</p> <p>19 saying -- so there's where the results come</p> <p>20 from in these appendices.</p> <p>21 Q. Do you know Dr. Foster?</p> <p>22 A. No.</p> <p>23 Q. Do you know that Dr. Foster</p> <p>24 submitted an expert report in this case on</p> <p>25 behalf of Monsanto?</p>	<p>1 literature about, you know, about combining</p> <p>2 data from different sources and including,</p> <p>3 you know, again, some of the sources that</p> <p>4 were cited by Portier and the sources that I</p> <p>5 included in my materials list.</p> <p>6 Q. Okay. So if I understand you</p> <p>7 right, the only authority that you are</p> <p>8 relying on would be either documents or</p> <p>9 articles cited by Dr. Portier in either his</p> <p>10 report or rebuttal report or that's cited in</p> <p>11 your expert report; is that fair?</p> <p>12 A. I'm saying that, you know, with</p> <p>13 the couple of decades of training I have,</p> <p>14 that it's pretty well-accepted that when you</p> <p>15 actually try to analyze data by combining</p> <p>16 them across different studies that, you know,</p> <p>17 data that arise from different sources like</p> <p>18 that, that it's fairly common, in fact, I</p> <p>19 would say it's conventional, to handle those</p> <p>20 analyses in the way that I describe in my</p> <p>21 expert report.</p> <p>22 Now, having said that, the</p> <p>23 specific citations in Dr. Portier's report</p> <p>24 and mine explain why, but there are, you</p> <p>25 know, textbooks written about those.</p>

Confidential - Subject to Protective Order

Page 150	<p>1 Q. Okay. So other than potential</p> <p>2 textbooks and your years of experience and</p> <p>3 the citations in both your consideration</p> <p>4 lists and Dr. Portier's consideration lists,</p> <p>5 that would be the totality of the evidence,</p> <p>6 so to speak, that would be the basis of your</p> <p>7 opinion that these studies cannot be</p> <p>8 combined?</p> <p>9 A. Yeah, that's a big totality,</p> <p>10 but, yes, that's the basis for it.</p> <p>11 Q. I believe that.</p> <p>12 Would you agree that there's a</p> <p>13 difference between primary and secondary</p> <p>14 tumors?</p> <p>15 A. I am not really kind of</p> <p>16 familiar with the differences between primary</p> <p>17 and secondary tumors.</p> <p>18 Q. So you don't know what a</p> <p>19 primary tumor is?</p> <p>20 A. Well, I do. I mean, I wouldn't</p> <p>21 say that I'm an expert in tumor pathology,</p> <p>22 no.</p> <p>23 Q. Okay. What's your</p> <p>24 understanding of what a primary tumor is?</p> <p>25 A. I don't know if I want to</p>	Page 152	<p>1 separately in the Greim supplement by</p> <p>2 the original scientists who produced</p> <p>3 the data, if they were reported as</p> <p>4 primary or secondary tumors, if those</p> <p>5 were distinguished in that way, then,</p> <p>6 you know, they're listed separately in</p> <p>7 my appendices. They're listed as-is.</p> <p>8 QUESTIONS BY MS. GREENWALD:</p> <p>9 Q. I have to mark one more</p> <p>10 document. I thought I was finished with</p> <p>11 marking documents, but I'm incorrect.</p> <p>12 (Corcoran Exhibit 21-10 marked</p> <p>13 for identification.)</p> <p>14 QUESTIONS BY MS. GREENWALD:</p> <p>15 Q. Okay. I'm going to mark as</p> <p>16 21-10 the rebuttal report of Dr. Christopher</p> <p>17 J. Portier in support of general causation on</p> <p>18 behalf of plaintiffs.</p> <p>19 A. Great. Thanks.</p> <p>20 Q. Sure.</p> <p>21 You've seen that before, right,</p> <p>22 Dr. Corcoran?</p> <p>23 A. Yes.</p> <p>24 Q. Give me one second, I'm sorry.</p> <p>25 As you sit here today, do you</p>
Page 151	<p>1 answer as a statistician. I mean, that's not</p> <p>2 really my training is in pathology. I just</p> <p>3 know that, you know, that they -- you know,</p> <p>4 they're kind of diagnosed or assessed</p> <p>5 separately.</p> <p>6 Q. So when you were calculating</p> <p>7 tumors identified in the Greim paper, did you</p> <p>8 distinguish between primary and secondary</p> <p>9 tumors?</p> <p>10 A. The tumors I analyzed from the</p> <p>11 Greim paper were just as reported in the</p> <p>12 tables within the supplement.</p> <p>13 Q. Okay. So the answer to my</p> <p>14 question is you did not distinguish in your</p> <p>15 calculations between primary and secondary</p> <p>16 tumors; is that correct?</p> <p>17 MR. GRIFFIS: Objection.</p> <p>18 Misstates testimony.</p> <p>19 THE WITNESS: Well, that's not</p> <p>20 what I'm saying at all. I'm saying</p> <p>21 that what I reported in my own expert</p> <p>22 report in Appendices A through D,</p> <p>23 that's the way those tumors were</p> <p>24 reported in the Greim supplement.</p> <p>25 And so if they reported</p>	Page 153	<p>1 have reason to disagree -- if you can go to</p> <p>2 page 2, I'm sorry.</p> <p>3 A. Okay.</p> <p>4 Q. Do you have reason to disagree</p> <p>5 with the sentence on page 2 of Dr. Portier's</p> <p>6 rebuttal report that reads, "81 of the tumor</p> <p>7 sites appearing in Dr. Corcoran's tables</p> <p>8 A.1-7 and B.1-5 in his appendix are</p> <p>9 metastatic secondary tumors and should not be</p> <p>10 included in the P value count for this</p> <p>11 analysis"?</p> <p>12 A. Well, I'd say that that's</p> <p>13 his -- that's his own expert opinion, but</p> <p>14 I -- as I said, when I analyze the data, I</p> <p>15 analyze the tumors as they were reported by</p> <p>16 the original scientists who contributed to</p> <p>17 the tables in Greim.</p> <p>18 Q. Okay. Do you understand that</p> <p>19 some tumors in animal bioassays are</p> <p>20 organ-specific?</p> <p>21 Do you understand what that</p> <p>22 means?</p> <p>23 A. Yeah, I have come to understand</p> <p>24 that.</p> <p>25 Q. Okay. And an organ-specific</p>

Confidential - Subject to Protective Order

Page 154	<p>1 tumor is one that develops in a specific</p> <p>2 organ in the body; is that right?</p> <p>3 A. Uh-huh, yes.</p> <p>4 Q. And there are also systematic</p> <p>5 tumors; is that correct?</p> <p>6 A. Yes.</p> <p>7 Q. And an example of a systematic</p> <p>8 tumor is a malignant lymphoma; is that right?</p> <p>9 A. I think that would be an</p> <p>10 example, yes.</p> <p>11 Q. Okay. And the analysis in your</p> <p>12 expert report, which is marked 21-1, does not</p> <p>13 combine systematic tumors, right?</p> <p>14 A. Not unless they were reported</p> <p>15 in any kind of combined way in the Greim</p> <p>16 supplement.</p> <p>17 Q. Okay. But you yourself didn't</p> <p>18 combine any systematic tumors; isn't that</p> <p>19 right?</p> <p>20 Unless it was combined in</p> <p>21 Greim, you're saying?</p> <p>22 A. No, that's right.</p> <p>23 Q. Why not?</p> <p>24 A. Because I -- I wouldn't -- I</p> <p>25 don't think the -- I don't think that that</p>	Page 156	<p>1 incidence of tumor within the study, and then</p> <p>2 that number dropped down to 419 in his</p> <p>3 rebuttal report.</p> <p>4 In other words, it's clear</p> <p>5 that, you know, the -- you know, even in his</p> <p>6 case, he couldn't really decide on what the</p> <p>7 final list was. So the point was not</p> <p>8 necessarily in just deciding on, you know,</p> <p>9 which number that you were going to use, what</p> <p>10 total. The point is that we actually account</p> <p>11 for the number of tests that we're doing</p> <p>12 through some sort of multiplicity</p> <p>13 adjustment -- for accounting for the multiple</p> <p>14 tests that we're doing.</p> <p>15 So in other words, you know, if</p> <p>16 given a chance, you could sit down with a</p> <p>17 pathologist and you could -- or multiple</p> <p>18 pathologists and you could come to some sort</p> <p>19 of consensus about that.</p> <p>20 Q. So I still don't understand why</p> <p>21 you don't think it's appropriate or</p> <p>22 methodologically sound to combine systematic</p> <p>23 tumors in your analyses.</p> <p>24 MR. GRIFFIS: Objection.</p> <p>25 Argumentative.</p>
Page 155	<p>1 was -- I didn't think that that was</p> <p>2 appropriate, I mean, based on my examination</p> <p>3 of the Greim tables.</p> <p>4 I mean, my job was to look at</p> <p>5 the weight of evidence across the -- you</p> <p>6 know, the tumors that are reported in the</p> <p>7 Greim supplement. Some of them were reported</p> <p>8 as combined; some of them were not.</p> <p>9 In this kind of complex</p> <p>10 analysis, what you would do -- and I think</p> <p>11 that, you know, Dr. Portier even mentioned</p> <p>12 this in his own deposition.</p> <p>13 Ideally what you would do is</p> <p>14 that you would -- if you were going to decide</p> <p>15 on those kinds of combinations, what you</p> <p>16 would do is you would sit down with</p> <p>17 pathologists or toxicologists and find out</p> <p>18 whether or not there was some sort of</p> <p>19 consensus.</p> <p>20 I mean, what I do know is that,</p> <p>21 you know, Dr. Portier reported in his</p> <p>22 original expert report that there were -- I</p> <p>23 can't remember the exact number, 450-plus</p> <p>24 tumors that he analyzed or that he considered</p> <p>25 that had three or more -- three or more</p>	Page 157	<p>1 THE WITNESS: Oh, I'm sorry.</p> <p>2 I wouldn't say that it's not --</p> <p>3 that it's not methodologically sound</p> <p>4 at all. I mean, I've worked for over</p> <p>5 20 years on interdisciplinary projects</p> <p>6 involving scientists from all kinds of</p> <p>7 backgrounds, you know, medical</p> <p>8 doctors, psychiatrists, psychologists,</p> <p>9 tomographers, statisticians,</p> <p>10 geneticists, biologists.</p> <p>11 I mean, what you do in a</p> <p>12 setting like this is you don't just</p> <p>13 make an executive decision about what</p> <p>14 you're going to combine based on your</p> <p>15 role as a statistician. You consult</p> <p>16 with pathologists who help you to make</p> <p>17 that determination.</p> <p>18 What I did was I tried to apply</p> <p>19 kind of a consistent methodology. In</p> <p>20 other words, a priori, I decided that</p> <p>21 I was going to look at the Greim</p> <p>22 supplement, then I was going to</p> <p>23 analyze those tumors as reported in</p> <p>24 the Greim supplement, some of which</p> <p>25 were reported as combined, some of</p>

Confidential - Subject to Protective Order

Page 158	Page 160
<p>1 which were not, and then make my 2 analysis based on that. 3 Like I said, I mean, my -- my 4 own take on Dr. Portier's analysis is 5 that his number of tumors change from 6 his, you know, initial analyses prior 7 to his expert report, to his expert 8 report, to his rebuttal report. So 9 that kind of illustrates why it would 10 be important to actually sit down and 11 consult with a pathologist if you're 12 going to decide how to do those. 13 However, the overarching 14 concern is that regardless of which 15 list, you know, Dr. Portier ends up 16 with or me or some -- in some 17 consultation with pathologists, 18 whether you're talking about 450 19 tumors or 419 or whichever number 20 you're going to use, you have to 21 account for the hundreds of tests that 22 you're doing in order to, you know, 23 make an evaluation of the evidence. 24 That's kind of the overarching 25 concern.</p>	<p>1 case where logistic regression analysis was 2 applied to the data? 3 A. I'm sorry, can you clarify 4 that? 5 Q. Sure. 6 There are 12 studies that are 7 reported in Greim, right? 8 A. Right. 9 Q. And those are the 12 studies 10 that have been the subject of your report and 11 all the reports in this deposition today, 12 right? 13 A. That's right. 14 What I'm asking is are you -- 15 are you asking whether or not the original 16 investigators used logistic regression? 17 Q. Correct. Correct. 18 Do you know? 19 A. I'm not sure if they did, but 20 for the individual studies it wouldn't be 21 entirely necessary for somebody who just 22 actually conducted one study. 23 The trend test, in most cases, 24 would often be a sufficient way of 25 assessing -- assessing any kind of, you know,</p>
Page 159	Page 161
<p>1 QUESTIONS BY MS. GREENWALD: 2 Q. Would you also want to sit down 3 and talk to a toxicologist as well in this 4 collaboration? 5 A. You know, if we were going to 6 talk specifically about this issue, you know, 7 what to combine, I think that it's clear 8 from, you know, Dr. Portier's own reports and 9 other, you know, material that I've read 10 related to this case that that would be a 11 natural part of the process. 12 Q. Isn't it true that logistic 13 regression analysis is more commonly applied 14 in epidemiology? 15 A. No, I wouldn't say that at all. 16 Logistic regression is used countless times, 17 I think, every day around the planet for all 18 kinds of different applications across 19 genetics, biology, business, sociology. It 20 probably is, you know, I'd say, easily one of 21 the most commonly {sic} statistical tools 22 that's applied across all different sciences, 23 settings. 24 Q. Okay. Can you give me any 25 example in the 12 studies at issue in this</p>	<p>1 dose response, compound-related effect. 2 What we're talking about here 3 is something different. In other words, none 4 of the other scientists who, you know, 5 originally conducted these studies actually 6 considered combining, you know, information 7 at the time with -- with other studies that 8 have been done. 9 So in other words, that's kind 10 of the issue in this case is that we're 11 talking about combining data from across 12 different studies. And that's specifically 13 what requires logistic regression to take 14 care of the problems that I talked about, 15 that Dr. Portier didn't. 16 Q. Did Greim use logistic 17 regression analysis in his paper? 18 A. I don't recall. 19 Q. You don't recall whether Greim 20 used logistic regression analysis in his 21 paper? 22 A. No, I don't. 23 Q. When's the last time you read 24 Greim? 25 A. I think some weeks ago, I</p>

Confidential - Subject to Protective Order

Page 162	Page 164
<p>1 think, when I read it through completely, but</p> <p>2 that's not -- not -- I'm not sure that that</p> <p>3 was something that he needed, because at the</p> <p>4 time, you know, I think when -- when they</p> <p>5 published that paper, they weren't actually</p> <p>6 trying to combine results to get kind of an</p> <p>7 overall -- evidence of an overall effect.</p> <p>8 Q. The article's entitled</p> <p>9 "Evaluation of carcinogenic potential of the</p> <p>10 herbicide glyphosate drawing on tumor</p> <p>11 incidence data from 14 chronic/ 12 carcinogenicity rodent studies," right?</p> <p>13 A. Yes.</p> <p>14 Q. That's the name of it?</p> <p>15 And your testimony is, if I</p> <p>16 understand it correctly, that you're not sure</p> <p>17 that was something that needed because at the</p> <p>18 time when they published the paper, they</p> <p>19 weren't actually trying to combine results to</p> <p>20 get an overall evidence of an overall effect;</p> <p>21 is that right?</p> <p>22 A. So they weren't -- they weren't</p> <p>23 pooling data sets in the way that --</p> <p>24 that Dr. Portier was.</p> <p>25 Q. What do you understand Greim</p>	<p>1 So in other words, the</p> <p>2 statistical methods -- the statistical</p> <p>3 methods, he says, are contained in the</p> <p>4 tables, but in the tables themselves</p> <p>5 I've not seen anything that says</p> <p>6 logistic regression.</p> <p>7 What I meant by combining is</p> <p>8 that he, you know -- this article</p> <p>9 contains information about each study,</p> <p>10 but he's not actually trying to</p> <p>11 combine the data from the studies</p> <p>12 together to, you know, compute one</p> <p>13 effect or P value in the way that --</p> <p>14 the way that Dr. Portier was.</p> <p>15 QUESTIONS BY MS. GREENWALD:</p> <p>16 Q. Isn't it true that the false</p> <p>17 discovery rate is expected in circumstances</p> <p>18 where one is only rejecting positive findings</p> <p>19 and not rejecting negative findings?</p> <p>20 A. I'm sorry, I don't understand</p> <p>21 that question.</p> <p>22 Could you repeat that, please?</p> <p>23 Q. Sure.</p> <p>24 Isn't it true that the false</p> <p>25 discovery rate --</p>
Page 163	Page 165
<p>1 was doing in this paper?</p> <p>2 A. I think he was just presenting</p> <p>3 a summary of all the findings having to do</p> <p>4 with glyphosate.</p> <p>5 Q. But you don't know if he</p> <p>6 applied logistic regression analysis, right?</p> <p>7 A. Do you want me to take a look</p> <p>8 at the paper and I can tell you?</p> <p>9 Q. Sure.</p> <p>10 A. Is that a paper you gave me</p> <p>11 already?</p> <p>12 Q. I did. It is exhibit --</p> <p>13 MR. GRIFFIS: 7.</p> <p>14 MS. GREENWALD: -- 21 -- thank</p> <p>15 you.</p> <p>16 THE WITNESS: So looking at</p> <p>17 page 190 of the Greim paper, the</p> <p>18 summary paper, if you look at the</p> <p>19 paragraph on the top right column, it</p> <p>20 says, "Statistical methods are noted</p> <p>21 in the manuscript tables where</p> <p>22 statistical significance was attained.</p> <p>23 Statistical differences in neoplasm</p> <p>24 incidence summary tables are reported</p> <p>25 in online data supplements."</p>	<p>1 A. Uh-huh.</p> <p>2 Q. -- is expected in circumstances</p> <p>3 where one is only rejecting a positive</p> <p>4 finding --</p> <p>5 A. Can I just stop you for just</p> <p>6 one second?</p> <p>7 Q. Sure.</p> <p>8 A. Because the first part of your</p> <p>9 question, I think, is the part that's</p> <p>10 confusing.</p> <p>11 Q. Okay.</p> <p>12 A. The false discovery rate is</p> <p>13 expected in certain circumstances.</p> <p>14 The false discovery rate exists</p> <p>15 for any -- in any setting where you're</p> <p>16 talking about computing hundreds or thousands</p> <p>17 or more P values. The false discovery rate,</p> <p>18 it's -- it's something that just kind of is.</p> <p>19 It's a quantity that exists.</p> <p>20 Q. So how do you define it? Maybe</p> <p>21 you should just define "false discovery</p> <p>22 rate."</p> <p>23 A. Sure. Yeah. The false</p> <p>24 discovery rate is the -- I guess you'd say</p> <p>25 the expected ratio of -- of, I guess, of true</p>

Confidential - Subject to Protective Order

Page 166	Page 168
<p>1 findings among those that are actually -- you 2 know, I guess in the case of a -- just to 3 make it more concrete for P values, you know, 4 you have -- you're doing hundreds of analyses 5 or thousands of analyses. The false 6 discovery rate has to do with the proportion 7 of instances where you have P values less 8 than .05 that actually are false positives. 9 Q. So it's the same as a false 10 positive rate; is that fair? 11 A. No, it's not. 12 Q. No. 13 How is it different than a 14 false positive rate? 15 A. A false positive rate in terms 16 of P -- are we talking about P values? 17 So if you set a P value 18 threshold at .05 and you say that if I 19 observe a P value less than .05, then that's 20 statistically significant, in that case the 21 false positive rate would be the rate at 22 which you observed findings of P values less 23 than .05 when, in fact, there's no effect. 24 Q. Okay. Got it. Okay. That was 25 my error for sure.</p>	<p>1 to result in P values less than .05. 2 Now, what the false discovery 3 rate attempts to at least characterize is, 4 okay, well, what proportion of those are -- 5 are results for experiments where there's no 6 evidence of an effect, in other words. 7 So that's what the false 8 discovery rate is -- is trying to measure. 9 Q. Is the false discovery rate 10 more appropriately used in a study for 11 proving or disproving a hypothesis versus 12 screening? 13 A. I don't really know how to 14 answer that question. All I know is that, 15 you know, the false discovery rate is 16 something that's been -- that's been 17 recommended, even within our own profession, 18 in situations where you have hundreds or 19 thousands or even millions of P values and 20 you want to make sure that you are not being 21 too strict about, you know, throwing out 22 potentially interesting findings, basically. 23 Q. Do you know if EPA uses the 24 false discovery rate -- 25 A. I don't.</p>
Page 167	Page 169
<p>1 Okay. So I just want to make 2 sure, I'm going to your last sentence of your 3 answer before my poor question. 4 "The false discovery rate has 5 to do with the proportion of instances where 6 you have P value -- P values less" -- and the 7 answer is cut off. 8 I'm sorry. 9 Okay, "less than .05." 10 Would that be a fair short 11 answer to what the false discovery rate is? 12 A. So suppose that you're using P 13 values. So suppose that that's what we're 14 doing. And suppose that you say that -- that 15 you're actually looking for P values less 16 than .05, that if you see that, you're going 17 to -- you're going to decide that, you know, 18 that's no worth. 19 So what the false discovery 20 rate measures is it says, okay, well, if 21 you're going to carry out hundreds of tests 22 like we are here, we have hundreds of P 23 values that we're computing across all these 24 different tumor types, we're going to expect 25 that a certain proportion of those are going</p>	<p>1 Q. -- in cancer bioassays? 2 A. No. Like I said, what I do 3 know is that it's something that's been 4 recommended within our profession, the 5 American Statistical Association. 6 Q. But you don't know if EPA uses 7 it? 8 A. No, I don't. 9 Q. Do you know what EFSA is? 10 A. No. 11 Q. The European Food Safety 12 Administration? 13 A. Yeah. No, I don't. 14 Q. Okay. Then you won't know if 15 it uses it. 16 Do you know what ECCA is? 17 A. I don't. 18 Q. Okay. Then I'm not going to 19 ask you those questions. 20 A. Okay. 21 Q. Can you cite to a single 22 peer-reviewed article that applies false 23 discovery rate to animal bioassays? 24 A. I don't think so. Not off the 25 top of my head.</p>

Confidential - Subject to Protective Order

Page 170

1 Q. You know, you've mentioned
 2 Dr. Portier quite a few times in the
 3 deposition today and obviously in your expert
 4 report.
 5 Prior to being hired as an
 6 expert in this case, had you ever heard of
 7 Dr. Portier?
 8 A. Yes.
 9 Q. And had you ever met him?
 10 A. No.
 11 Q. How did you hear about him?
 12 A. I think I cited a paper of his
 13 when I published my dissertation.
 14 Q. Other than that time that you
 15 cited one of his papers, have you had any
 16 other interaction with his writings or his
 17 work?
 18 A. No, not that I know of.
 19 Q. Until this case?
 20 A. That's right.
 21 Q. In preparation for your expert
 22 report, did you ask the Hollingsworth firm
 23 for any particular documents to help you
 24 prepare your expert report?
 25 MR. GRIFFIS: Objection.

Page 171

1 THE WITNESS: No.
 2 MR. GRIFFIS: Don't answer that
 3 question.
 4 MS. GREENWALD: I just wanted
 5 to know if he had any documents that
 6 he wanted that he asked you for.
 7 I'm not asking you for
 8 communications that you guys had about
 9 a document.
 10 MR. GRIFFIS: Yeah, our
 11 communications and our exchange of
 12 documents is privileged.
 13 QUESTIONS BY MS. GREENWALD:
 14 Q. In preparation for your report,
 15 were there any documents -- is there any
 16 documents that you felt you needed to prepare
 17 your report that you did not have access to?
 18 A. No.
 19 Q. Okay. You can go to page 3 of
 20 your report.
 21 Just one second. I'm sorry.
 22 I'm sorry. I have a miscite here. Forgive
 23 me. I'm so sorry.
 24 A. That's okay.
 25 Q. I'm going to -- I have to look

Page 172

1 for that cite, sorry.
 2 Okay. So on page 4 now.
 3 A. Okay.
 4 Q. Line 32.
 5 A. Great.
 6 Q. Well, it starts, though, at
 7 line 31. "The tendency of researchers, along
 8 with scientific journals and other media
 9 venues, is a bias towards, quote, positive,
 10 close quote, findings."
 11 Do you see that?
 12 A. Yes.
 13 Q. Can you identify any
 14 publications in the peer-reviewed literature
 15 that report a positive finding for any of the
 16 12 rodent studies that you've discussed in
 17 your report?
 18 A. Not off the top of my head, no.
 19 Q. Okay. So I found the other
 20 one. If you go to the -- sorry, I took you
 21 to the wrong page before. If you can go to
 22 the bottom of page 2 --
 23 A. Okay.
 24 Q. -- and then we're going to flip
 25 over to 3.

Page 173

1 A. Okay.
 2 Q. I'm sorry about that.
 3 A. That's okay.
 4 Q. "This is largely because" -- so
 5 if you want to look -- it's in the
 6 statistical background section.
 7 A. Right. I'm there.
 8 Q. "This is largely because, one,
 9 data are generally full of uncertainty and
 10 variation, particularly when we study complex
 11 diseases or other phenomenon in humans or
 12 animals; two, many questions in health and
 13 medicine have strong statistical
 14 overtones" -- and then there's a
 15 parenthetical -- "and three, the comparison
 16 of different treatments or potential risks
 17 relies heavily on statistical concepts -
 18 especially probability - in both designing
 19 and analyzing experiments."
 20 Do you see that?
 21 A. Yes.
 22 Q. Okay. Is this also the case
 23 for animal chronic toxicity studies?
 24 MR. GRIFFIS: Objection to
 25 form.

Confidential - Subject to Protective Order

Page 174	Page 176
<p>1 THE WITNESS: I think under 2 number one, particularly where we 3 study complex diseases or other 4 phenomena in humans and animals. 5 QUESTIONS BY MS. GREENWALD: 6 Q. But -- sorry, so let me focus 7 on number 3. 8 A. Uh-huh. 9 Q. "The comparison of different 10 treatments or potential risk relies heavily 11 on statistical concepts - especially 12 probability in both designing and analyzing 13 experiments." 14 Is that also the case for 15 animal chronic toxicity studies? 16 A. Well, since, you know, both 17 Dr. Portier and I are using the 18 Cochran-Armitage trend test which is based 19 on, you know, a probability model, then, yes, 20 it applies, you know, when we use a method 21 like that. 22 Q. Isn't it true that general 23 screening studies are not hypothesis-driven 24 in toxicology? 25 A. I'm not sure what you mean by</p>	<p>1 not by a statistician, so I realize -- 2 A. Yeah, and I'm -- you know, I'm 3 sorry if this sounds technical, but any test 4 that you do, you know, statistically 5 speaking, should start with a hypothesis, 6 whether you're -- you know, whether you're 7 looking at, you know, hundreds of things or 8 one. 9 So there has never been an 10 analysis that I've done in my life, you know, 11 over thousands of different analyses and 12 different settings where -- you know, where 13 we actually apply a statistical test there 14 isn't a hypothesis. 15 So that's -- that's why you'll 16 have to forgive me if that question -- I'm 17 not really sure what you're asking, because 18 every statistical test requires a hypothesis. 19 Q. So you would consider a 20 hypothesis just the general question: Is 21 this chemical capable of causing any health 22 outcome; that would be a hypothesis? 23 A. Well, I think my hypothesis is 24 stated, you know, in the expert report. 25 Q. No. No. I'm asking a</p>
Page 175	Page 177
<p>1 "general screening studies" because that's 2 kind of a -- that's a broad term, I guess, in 3 statistical practice. 4 Q. So I'm not a statistician. I'm 5 going to try to put it in a framework of -- 6 the only way I can do it. 7 So you are looking at a 8 chemical to find out its outcome. You have 9 no preconceived notion one way or the other 10 of what that outcome's going to be versus a 11 hypothesis where you say, "I see an uptick in 12 cancer in this community, and I wonder if 13 it's because of the fact that it's -- this 14 community is being exposed to X," the second 15 one being a hypothesis, the first one being 16 screening. 17 A. Uh-huh. 18 Q. Does that -- is that a fair -- 19 I mean, is that a sort of ex -- an 20 explanation we can live with for that 21 question, or is that not satisfactory? 22 MR. GRIFFIS: Objection to 23 form. 24 QUESTIONS BY MS. GREENWALD: 25 Q. I mean, obviously it's spoken</p>	<p>1 different question. I understand that. I'm 2 not asking you what your hypothesis is in 3 your expert report. I'm asking would you 4 consider it -- I just want to have the same 5 nomenclature. 6 A. Uh-huh. 7 Q. In your nomenclature would you 8 deem it a hypothesis to -- for just the pure 9 statement is this chemical capable of having 10 a health outcome? 11 Would that be a hypothesis in 12 your nomenclature? 13 A. Not in a statistical sense, no. 14 Q. Okay. 15 A. Because, you know, I -- you 16 know, again, you know, I know that, you know, 17 if you say I'm a statistician, you're an 18 attorney, but I'll -- you know, I can only 19 tell you what it is that I'm -- you know, 20 that I do from day to day. 21 And what I'm doing here is I'm 22 assessing, you know, tumor incidence across 23 these studies for, you know, dozens of 24 different tumor types, and so the hypotheses 25 here are very specific for the trend test.</p>

Confidential - Subject to Protective Order

Page 178	Page 180
<p>1 Q. Okay. Isn't it true, though, 2 that the 12 rodent studies that have been 3 discussed today and are in your expert report 4 are general screening tests? 5 A. I don't know if -- if I would 6 say that at all because I -- that's not my 7 real purview. 8 I mean, you know, what the 9 reasons were for designing those experiments 10 are known to the scientists who design them 11 originally. I'm just looking at the data 12 that was generated by those experiments. 13 Q. This is all good. I just want 14 you to know that when I scratch things out, 15 that's all good for you. 16 A. Okay. Because when I scratch 17 things out at the university, that's not good 18 for the students. 19 Q. Scratching out, yeah, I know. 20 When the deposition's over, I'll tell you why 21 I didn't like statistics. I'm not going to 22 tell you until the deposition's over. 23 Let me just get my -- I'm 24 winding down here. Okay. I'm really nearing 25 the end here.</p>	<p>1 A. Right, we already talked about 2 it. 3 MS. GREENWALD: Right. Okay. 4 I'm going to pass the witness. 5 CROSS-EXAMINATION 6 QUESTIONS BY MR. GRIFFIS: 7 Q. All right, sir. You have 8 criticisms and responses to the critiques 9 that Dr. Portier offered in his rebuttal 10 report of your own analysis, correct? 11 A. Right. 12 Q. Including, for example, 13 criticisms of his modified Table 15 and all 14 of -- each of the specific critiques that he 15 made of your methodology and his defenses of 16 his methodology; is that right? 17 A. Yes. 18 MR. GRIFFIS: I have no further 19 questions. 20 REDIRECT EXAMINATION 21 QUESTIONS BY MS. GREENWALD: 22 Q. Okay. Whenever he does that, I 23 have a few more then. 24 So tell me what criticism you 25 have of his modified Table 15 that's not</p>
Page 179	Page 181
<p>1 Have you reached any additional 2 opinions in this litigation or in connection 3 with your work with the Hollingsworth firm 4 that are not expressed in your report? 5 A. Only the opinion that I shared 6 earlier about the nature of this pooled 7 analysis that I already kind of stepped 8 through. 9 Q. Right. 10 A. But other than that, no. 11 Q. Okay. Right. 12 So are there any opinions that 13 you intend to offer in the general causation 14 phase of this case that are not contained in 15 your expert report or that you testified 16 about today? 17 A. No, I don't think so. I mean, 18 I -- I guess the one thing I would say is 19 the -- well, scratch that. I'm just 20 repeating myself. 21 I mean, the only thing I'd have 22 to add would be the issue about the pool 23 analysis, but other than that, no. 24 Q. Which you talked about today, 25 though, earlier in your --</p>	<p>1 already contained in your testimony today or 2 that is -- well, it wouldn't have been in 3 your expert report. 4 A. Well, I guess I -- I guess I'm 5 kind of starting with his -- that Table 15 6 that was in his original report. 7 I think that some of my 8 original comments obviously stand on page 12 9 of my own expert report. 10 Q. Page 12 of yours, okay. 11 A. Yeah. 12 Q. Right. 13 So I -- I don't -- you're 14 welcome to go to 12. I just wanted to know 15 if there's anything -- I'm really responding 16 to the question you just answered -- 17 A. Uh-huh. 18 Q. -- in that I want to make sure 19 there's no additional testimony, evidence or 20 information that you would have, other than 21 what's already in your expert report and what 22 you testified about today when you talked 23 about the pooling. 24 A. Yes. 25 Q. Is there anything else that you</p>

46 (Pages 178 to 181)

Confidential - Subject to Protective Order

Page 182	Page 184
<p>1 would have to testify about at the general 2 causation hearing relating to modified 3 Table 15 that is not contained either in the 4 report that you already wrote and/or what you 5 talked about today during your deposition? 6 A. Do I have a copy of his 7 rebuttal report? I can't remember -- 8 MR. GRIFFIS: It's Exhibit 10. 9 MS. GREENWALD: Yes. 10 THE WITNESS: Oh, I see it. 11 It's right here. 12 QUESTIONS BY MS. GREENWALD: 13 Q. It's the last page of the 14 report, if that helps. Page 37. 15 A. Right. 37. 16 You know, my criticisms are an 17 extension of what I put in my expert report. 18 But the problem with this 19 Table 15, he modified Table 15. He has an 20 observed number of tumor sites that have -- 21 he says there's significant trends. They're 22 not significant. They're P values that are 23 less than .05, but they're not statistically 24 significant. 25 But anyway, he's got this</p>	<p>1 total. 2 So in other words, I feel like 3 he's kind of misrepresented in his modified 4 Table 15 what his -- what his observed versus 5 expected should be. 6 If he's going to actually do 7 analyses -- if he's going to actually do 8 analyses that involve historical controls, 9 then the number of tests that he is 10 performing is larger than the 418. It's 11 larger than what he's reporting. 12 So he's looking at -- he's 13 computing P values, you know, several 14 different ways. He's not doing it 15 consistently. 16 You know, in my case what I did 17 is I took the tumors that were reported in 18 Greim as-is, and I applied, you know, the 19 same consistent methodology in computing 20 these -- computing these P values and 21 assessing whether or not there was 22 statistical significance. 23 What he did was he took all the 24 tumors, he -- for some of them he used 25 historical controls; for some of them he</p>
Page 183	Page 185
<p>1 expected number of P values less than .05 2 versus the observed. This is kind -- you 3 know, kind of a foundational point of his 4 argument that if you look down -- and he 5 tallies everything up at the bottom. He has 6 30 observed P values less than .05. He has 7 20.9 that he would expect using his counting. 8 But the problem is that this 9 table is very deeply flawed because his 10 expected -- or his total sites, in other 11 words, is much smaller than it should be in 12 his -- in his modified table. 13 In other words, he's -- you 14 know, he's -- he has a total site -- his 15 number of total sites is equal to 418, but 16 yet he's also -- he's also reporting trend 17 tests that he -- that were less than .05 when 18 he incorporated historical controls. 19 So in other words, what he's 20 doing is he's including the 418, but he's -- 21 he's kind of -- he's kind of double-counting, 22 in other words. He's computing P values 23 using a different -- a couple of different 24 approaches, and if either one of them is less 25 than .05, then he's including them in that</p>	<p>1 didn't; for some of them he combined, you 2 know, with different studies and so on. 3 So in other words, he's 4 computing P values kind of inconsistently 5 using several different methods as opposed to 6 just one method. And so in that sense, this 7 418 and the 20.9 is completely incorrect. 8 Q. So let me just ask you to look 9 at page 50 of Dr. Portier's original 10 report -- 11 A. Okay. 12 Q. -- which is the old Table 15, 13 or the original Table 15, before modified 14 Table 15. 15 A. I'm there. 16 Q. Okay. And on all the -- other 17 than the numbers, all of the axes are the 18 same, right? The left and the top -- 19 A. It looks like it. 20 Q. -- columns are the same? 21 Okay. And you already 22 critiqued Table 15 in your expert report, 23 right? 24 A. But now he's actually changed 25 it, and it's become even more problematic</p>

Confidential - Subject to Protective Order

<p style="text-align: right;">Page 186</p> <p>1 because that number down at the bottom of 30, 2 as opposed to the 19 on page 50 in his 3 original report, that is a big difference 4 between the two. And it kind of -- it again 5 demonstrates his -- as I describe in my 6 expert report, it demonstrates his tendency 7 to just look for P values in all kinds of 8 different ways, in other words, to do the P 9 hacking that I described in my expert report, 10 to look for P values using many, many 11 different methods that are not reflected in 12 the 418 or the 20.9 next to it. 13 And so the problem has become 14 even more -- you know, has become even 15 greater in his modified Table 15 as opposed 16 to his original. 17 Q. So am I correct that your -- 18 the new critique is the new calculations, 19 essentially, that he has in modified 20 Table 15? 21 A. Yeah, but I think -- I think 22 it's really important to note that because in 23 addition to that, his new table also 24 includes -- I don't know if you look down at 25 footnote 2 --</p>	<p style="text-align: right;">Page 188</p> <p>1 beginning, which, again, is just kind of 2 the -- what I would deem as consummate P 3 hacking. 4 Q. Okay. Did you read -- I think 5 you testified, did you not, that you read 6 Dr. Portier's deposition, right? 7 A. Yes. 8 Q. And he explained this 9 recalculation and why he has these different 10 numbers in his -- in his deposition, didn't 11 he? 12 A. And that was a great 13 explanation about why it is that one person 14 would not make an executive decision about 15 where those are combined, that instead you 16 would -- you know, you would consult as a 17 part of an interdisciplinary team to make 18 that determination. 19 Q. Right. 20 But he actually explained that 21 the skin lymphoma didn't mean skin lymphoma. 22 It actually meant spleen lymphoma. It was 23 just a typo in his footnote. 24 A. Well, my understanding is 25 that --</p>
<p style="text-align: right;">Page 187</p> <p>1 Q. Yes. 2 A. -- do you see where he has -- 3 toward the very end of that footnote it says 4 "SL, skin lymphoma." 5 Q. Uh-huh. 6 A. So, you know, in other words, a 7 big critique I have of his rebuttal report is 8 that he, you know, spends some time in his 9 report pointing out that I was not, you know, 10 combining certain tumor types -- and, you 11 know, you asked me about that earlier as 12 well -- when, in fact, here, you know, he's 13 kind of including skin lymphoma based on my 14 own finding. He's including that in his 15 table without reconciling why it was -- why 16 it was he didn't combine that. 17 So in other words, again, 18 pointing to this 30 at the bottom of the 19 observed, this is really a crucial point with 20 respect to this rebuttal report. He's -- 21 he's counted these up in ways that are not 22 reflected in the 20.9 you would expect or the 23 418 that he's counting. He's computing P 24 values in all different ways and coming up 25 with an even larger total than he had at the</p>	<p style="text-align: right;">Page 189</p> <p>1 Q. And people make typos, right? 2 A. Yeah, but in his -- in his 3 rebuttal report what he pointed out was that 4 I didn't understand what the meaning of a 5 systemic tumor was, that, you know, lymphoma 6 should be combined somehow, and he's not 7 doing it here. 8 And so what that tells me is 9 that, you know, that really the bigger 10 concern is are these numbers, 418, 20.9, and 11 what they represent, that he didn't use kind 12 of a consistent approach. 13 What he did was he just kind of 14 mined P values in four or five different 15 ways, and then he totaled them up here 16 misrepresenting how that compares to what you 17 would expect. 18 Q. Did you not understand that 19 Dr. Portier was doing a modified Table 15 in 20 large measure in response to your criticism 21 of him and it's resulting from your approach 22 of only using Greim data? 23 A. Well, yeah, he used Greim data 24 in his first report as well -- 25 Q. Not exclusively.</p>

Confidential - Subject to Protective Order

Page 190

1 A. -- just as I did.
 2 Well, I think the bulk of it in
 3 the same way that I did.
 4 So, yes, I understand that he
 5 modified Table 15 in response to me, but what
 6 I'm saying is that he actually -- he actually
 7 magnified the problem from his original
 8 Table 15.
 9 Q. So just so I'm clear, other
 10 than what you just explained about table --
 11 modified Table 15 and what you talked about
 12 earlier on pooling and what's in your expert
 13 report, that's the totality of the evidence
 14 that you intend to present -- of your
 15 opinions, I'm sorry, that you -- let me start
 16 over again. Wow.
 17 Just want to make sure I'm
 18 correct that other than what you just
 19 explained, what you explained earlier on
 20 pooling and what's in your expert report,
 21 that's the totality of the opinions and the
 22 reliance of those opinions that you intend to
 23 testify about in the general causation phase
 24 of this case; is that right?
 25 A. As of right now, yeah, that's

Page 191

1 all I can say about it.
 2 MS. GREENWALD: Okay. I don't
 3 have anything else.
 4 MR. GRIFFIS: I have no further
 5 questions.
 6 MS. GREENWALD: Thank you.
 7 THE WITNESS: Thanks.
 8 VIDEOGRAPHER: Going off
 9 record. The time is 1:24.
 10 (Deposition concluded at 1:24 p.m.)
 11 -----
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25

Page 192

1 CERTIFICATE
 2
 3 I, CARRIE A. CAMPBELL, Registered
 4 Diplomate Reporter, Certified Realtime
 5 Reporter and Certified Shorthand Reporter, do
 6 hereby certify that prior to the commencement
 7 of the examination, Christopher Corcoran,
 8 Sc.D. was duly sworn by me to testify to the
 9 truth, the whole truth and nothing but the
 10 truth.
 11 I DO FURTHER CERTIFY that the
 12 foregoing is a verbatim transcript of the
 13 testimony as taken stenographically by and
 14 before me at the time, place and on the date
 15 hereinbefore set forth, to the best of my
 16 ability.
 17 I DO FURTHER CERTIFY that I am
 18 neither a relative nor employee nor attorney
 19 nor counsel of any of the parties to this
 20 action, and that I am neither a relative nor
 21 employee of such attorney or counsel, and
 22 that I am not financially interested in the
 23 action.
 24
 25
 CARRIE A. CAMPBELL,
 NCRA Registered Diplomate Reporter
 Certified Realtime Reporter
 California Certified Shorthand
 Reporter #13921
 Missouri Certified Court Reporter #859
 Illinois Certified Shorthand Reporter
 #084-004229
 Texas Certified Shorthand Reporter #9328
 Kansas Certified Court Reporter #1715
 Notary Public
 Dated: September 20, 2017

Page 193

1 INSTRUCTIONS TO WITNESS
 2
 3 Please read your deposition over
 4 carefully and make any necessary corrections.
 5 You should state the reason in the
 6 appropriate space on the errata sheet for any
 7 corrections that are made.
 8 After doing so, please sign the
 9 errata sheet and date it. You are signing
 10 same subject to the changes you have noted on
 11 the errata sheet, which will be attached to
 12 your deposition.
 13 It is imperative that you return
 14 the original errata sheet to the deposing
 15 attorney within thirty (30) days of receipt
 16 of the deposition transcript by you. If you
 17 fail to do so, the deposition transcript may
 18 be deemed to be accurate and may be used in
 19 court.
 20
 21
 22
 23
 24
 25

Confidential - Subject to Protective Order

<p>1 - - - - -</p> <p>2 E R R A T A</p> <p>3 - - - - -</p> <p>4 PAGE LINE CHANGE</p> <p>5 _____</p> <p>6 REASON: _____</p> <p>7 _____</p> <p>8 REASON: _____</p> <p>9 _____</p> <p>10 REASON: _____</p> <p>11 _____</p> <p>12 REASON: _____</p> <p>13 _____</p> <p>14 REASON: _____</p> <p>15 _____</p> <p>16 REASON: _____</p> <p>17 _____</p> <p>18 REASON: _____</p> <p>19 _____</p> <p>20 REASON: _____</p> <p>21 _____</p> <p>22 REASON: _____</p> <p>23 _____</p> <p>24 REASON: _____</p> <p>25</p>	<p>1 - - - - -</p> <p>2 LAWYER'S NOTES</p> <p>3 - - - - -</p> <p>4 PAGE LINE</p> <p>5 _____</p> <p>6 _____</p> <p>7 _____</p> <p>8 _____</p> <p>9 _____</p> <p>10 _____</p> <p>11 _____</p> <p>12 _____</p> <p>13 _____</p> <p>14 _____</p> <p>15 _____</p> <p>16 _____</p> <p>17 _____</p> <p>18 _____</p> <p>19 _____</p> <p>20 _____</p> <p>21 _____</p> <p>22 _____</p> <p>23 _____</p> <p>24 _____</p> <p>25</p>
--	--

<p>1</p> <p>2 ACKNOWLEDGMENT OF DEPONENT</p> <p>3</p> <p>4 I, _____, do</p> <p>5 hereby certify that I have read the</p> <p>6 foregoing pages, and that the same is</p> <p>7 a correct transcription of the answers</p> <p>8 given by me to the questions therein</p> <p>9 propounded, except for the corrections or</p> <p>10 changes in form or substance, if any,</p> <p>11 noted in the attached Errata Sheet.</p> <p>12</p> <p>13</p> <p>14 _____</p> <p>15 CHRISTOPHER CORCORAN, Sc.D. DATE</p> <p>16</p> <p>17</p> <p>18 Subscribed and sworn</p> <p>19 to before me this</p> <p>20 _____ day of _____, 20____.</p> <p>21 My commission expires: _____</p> <p>22 _____</p> <p>23 Notary Public</p> <p>24</p> <p>25</p>	
---	--

A	116:17 143:16 179:22	airtight 70:16	analysts 97:3 98:10	127:19
A.1-7 153:8	adding 144:18	allegedly 41:7	analyze 16:22 40:1	answers 7:10 195:7
a.m 1:13 5:9 75:22 141:19 148:12	addition 117:2 121:18 186:23	allow 130:4	72:6 99:6 123:13	anybody 32:18
ability 104:5,10,19 192:10	additional 37:10,12 56:16 68:14 69:19	allowing 144:20,21	145:4,12 149:15	anyway 182:25
absolute 125:17	69:22 113:8 179:1 181:19	allows 143:11	153:14,15 157:23	apart 45:2
absolutely 27:7 55:19 131:22	address 68:19	Alzheimer's 102:4 102:15 103:1,11	analyzed 44:8,19	apologize 45:2 80:25
academic 30:18 86:13 87:12,22	addressed 35:16 140:10,10,20	107:4	60:21 68:25 71:9	apparently 98:16
93:1 96:21	addresses 104:17	amazing 91:10	74:8 145:8 151:10	appear 95:2 101:4 106:19,23
academics 93:18 98:10 100:1	adenoma 142:4	American 169:5	155:24	APPEARANCES 3:3
acceptable 47:21 48:2	adenomas 129:6	amount 24:20 105:4,12 106:25	analyzing 23:4 25:3	appeared 47:17 68:16
accepted 70:1 123:20	adhere 108:17	amounts 90:1	27:15 29:5 32:25	appearing 6:2 153:7
access 48:11,19 54:10 171:17	adjust 61:12	analyses 24:23 32:7 37:10,12 71:23	80:14 130:3	appears 31:10 93:7 130:12
account 134:9,14 136:2 137:24	adjusted 63:15	75:2 112:17,22	137:20 173:19	appendices 64:8 145:8 147:20
141:8 143:2,5	adjusting 142:23	113:8,13,23	174:12	151:22 152:7
147:12 156:10	adjustment 61:19 156:13	114:19 137:2	and/or 41:5,7 182:4	appendix 63:17,19 63:20,21,23,23,23
158:21	adjustments 135:1	138:12 147:13	Angeles 2:9	64:2,2,22,23
accounted 136:15	Administration 96:4 169:12	149:20 156:23	animal 19:17 29:21	69:23 146:3,8,10
accounting 71:6 115:5 119:1 136:7	advance 108:3	158:6 166:4,5	55:14,24 60:7,11	153:8
136:13 156:13	advice 83:25	176:11 184:7,8	60:18,21 80:4,12	application 80:16 106:20
accounts 143:17,23 144:19	advising 85:22	analysis 16:24 19:18 23:10,15	80:17 81:5 123:11	applications 159:18
accurate 47:24 72:5 91:20 193:18	advisor 81:17 82:5 82:23	25:1 26:1,20	130:17,19 133:5	applied 62:7,9 64:4 80:7 140:24
accurately 12:22 112:3	Affiliated 67:21	28:12,21 29:3,18	153:19 169:23	144:25 159:13,22
ACKNOWLED... 4:7 195:2	affiliation 67:18	30:22 31:3 32:4,9	173:23 174:15	160:2 163:6 184:18
acronym 100:17	age 6:7 103:1,11	36:16 42:2 60:2	173:12 174:4	applies 169:22 174:20
act 19:5	age-related 102:5 102:15	63:14 64:19 65:16	animals 129:8	apply 60:17 61:8 82:17 157:18
action 192:12,14	agencies 98:11,12	65:16,20 69:15	130:22 131:10,17	176:13
actual 25:9 41:5 49:10 50:5 51:11	agency 99:20	70:21 71:6 72:10	132:22 133:24	approach 61:11 134:11 135:15
53:5 54:7 57:16	aggregate 145:13	80:8,12 81:9	173:12 174:4	137:7 189:12,21
76:18,25 77:8,9	aggregates 135:4	83:15 86:17 112:7	animals' 131:16	approaches 183:24
77:23 100:2 122:2	aging 104:3	116:12 124:12,21	132:5,21	appropriate 155:2 156:21 193:6
add 65:5 83:16	ago 19:3,4 161:25	125:12 128:9	annually 108:20	appropriately
	agree 150:12	131:19 133:15,17	answer 7:8,15,17	
	agreed 19:5	134:10 135:14	21:4 24:5 35:20	
	agreement 3:14 20:2,7 84:6	136:20 139:15,25	44:12,17 51:21	
	107:13	140:4,13,19 141:7	54:14 58:14 59:17	
	agreements 35:17	142:4 145:2,23	87:9 89:18 90:12	
	agrees 47:20	153:11 154:11	95:7 104:23	
		155:10 158:2,4	112:16,20 128:23	
		159:13 160:1	133:13,21 141:23	
		161:17,20 163:6	142:1 151:1,13	
		176:10 179:7,23	167:3,7,11 168:14	
		180:10	171:2	
		analyst 105:3	answered 41:24	
			42:20 51:17 54:12	
			56:3,11 74:4	
			87:10 89:15 144:6	
			147:1 181:16	
			answering 121:14	

118:25 120:1 168:10 approximate 14:18 15:11 88:16,20 approximately 10:2,7 18:8 23:1 24:11 83:4 arbitrary 130:8 area 30:25 80:18 104:3,3 argument 183:4 Argumentative 41:24 42:19 48:16 156:25 arises 31:18 ARISTEI 2:7 artfully 34:23 article 45:5 51:9 102:24 164:8 169:22 article's 162:8 articles 87:1 88:7 101:6,9,11 102:1 102:14,16,18,19 149:9 as-is 152:7 184:18 aside 118:2 asked 19:13,14 20:16,21 24:1 37:4 41:24 42:1 42:19 51:6,16,19 54:11 56:10 59:18 59:25 74:3 89:14 97:19 112:13,17 112:19 144:5 146:25 171:6 187:11 asking 6:25 9:8 34:21,22 36:10 50:8,9 52:4 57:20 58:7,20,21 60:24 77:3,6 89:9 122:23 123:2 128:17 139:24 160:14,15 171:7 176:17,25 177:2,3 assess 104:5,10,19	138:13 assessed 138:5 151:4 assessing 29:15 30:8,19 160:25,25 177:22 184:21 assessment 139:18 139:19 assistant 11:21 assisted 105:3 assisting 41:4 associated 59:24 77:8 Association 169:5 assume 22:19 30:13 35:5 48:5 48:25 50:17,25 52:12,14 assumed 50:21 assumption 148:22 attached 50:14 76:20 77:12 101:1 111:25 193:11 195:11 attained 163:22 attempts 168:3 attorney 177:18 192:11,13 193:15 attorney-client 21:7 attorneys 11:14 67:12 audible 7:10 audibly 7:8 audiences 96:19 August 18:17,20,22 19:24 20:6 21:17 107:8,14,16 author 101:12 author's 45:6 authority 149:7 authors 72:16 available 10:17 15:9 37:22 40:10 47:14 48:21 49:24 57:23 58:2 59:1,2 70:10,10,12 82:16	85:16 88:3,8 100:16 average 116:3,6 award 107:20,22 108:5 awards 107:19 aware 70:11 axes 185:17 <hr/> B B 145:18 146:3,10 146:21 B.1-5 153:8 back 30:4 31:6 40:21 51:5 52:18 62:2,25 72:19 75:23 78:21 84:6 89:5 90:14 106:2 106:3,5 110:22 111:18 141:20 148:14 background 40:5 79:1 139:7,10 173:6 backgrounds 157:7 bad 101:21 based 24:22 33:11 33:13 47:18 48:1 50:17 55:5,23 60:1 69:15,21,23 72:9 75:1 113:8 123:16 127:15 131:25 139:15 155:2 157:14 158:2 174:18 187:13 baseline 129:16 basically 13:12 23:8 34:17 39:24 75:3 116:9 168:22 basis 148:21 150:6 150:10 BAUM 2:7 beauty 133:7,14 beginning 65:8 188:1 behalf 4:2 6:10	40:11,17 41:1,13 42:4,16 48:7,13 92:24 109:12 111:10 147:25 152:18 believe 31:7 41:21 44:11 47:23 106:7 119:22 131:10,14 150:11 benefit 41:22 best 120:8 122:19 123:23 132:3 192:9 better 116:13 122:22 beyond 114:8 bias 172:9 big 16:1 150:9 186:3 187:7 bigger 189:9 bill 22:23 116:2 billing 33:5 90:14 bioassay 60:7,11,18 60:21 130:17,19 bioassays 80:4 153:19 169:1,23 biologists 157:10 biology 159:19 biopharmaceutic... 98:11 bit 79:1 100:23 board 90:19 body 13:23 142:17 154:2 book 79:24 86:21 86:24 87:5 100:10 born 135:5 Boston 18:2 bottom 71:25 130:24 172:22 183:5 186:1 187:18 Boulevard 2:9 Boy 104:13 Brammer 126:11 142:14 break 8:3,5,6,7,9	8:10 66:13,23 67:6,8 75:16 81:1 148:8 Brent 2:8 6:3 bright 34:5 broad 175:2 Broadway 2:5 brought 41:15 140:9 budget 108:4 build 83:16 buildings 119:19 119:23 122:2 bulk 25:20 27:22 28:3 31:19 39:13 60:2 63:17 139:4 145:22 190:2 bundle 23:12 business 85:13 96:3 96:5 159:19 BWisner@Baum... 2:8 <hr/> C C 2:1 63:20,21,23 64:2,8,22,23 145:10,17,18 146:3,21 cabin 15:22 Cache 103:6,7,8,9 105:17 calculate 13:6 16:18 calculating 151:6 calculation 65:24 calculations 60:6 60:10,14 61:14 62:5,16 63:2,6,7 64:5 151:15 186:18 calendar 36:14 California 1:1,16 2:9 5:15 192:19 call 103:20 108:1 called 85:13 96:6 calls 20:19 Campbell 1:14 5:5
---	--	--	---	--

192:3,17 cancer 38:10 80:4 104:6,11,20 169:1 175:12 capabilities 83:21 99:3,11 capable 176:21 177:9 capital 81:10 carcinogenic 3:18 162:9 carcinogenicity 45:21 104:5,9,12 104:13,18 162:12 care 161:14 career 88:13 careful 7:14 carefully 193:4 Carrie 1:14 5:5 192:3,17 carried 49:21 118:23 119:13 120:6 121:22 125:6 130:14 135:23 139:14 carry 167:21 carryover 131:2 case 1:4 5:12 17:4 17:10,14,18,21 18:13 19:6 20:4 22:20 27:16 28:8 35:17 40:12 49:5 53:20,23,24 61:21 70:6,24 71:12 112:5 113:18 114:6 120:9 123:1 143:9 147:24 148:3 156:6 159:10 160:1 161:10 166:2,20 170:6,19 173:22 174:14 179:14 184:16 190:24 cases 1:5 160:23 catching 27:7 categorical 30:22 31:3	causation 4:2 152:17 179:13 182:2 190:23 cause 104:6,10,20 caused 41:7 causing 176:21 certain 8:3,3 36:20 110:14 165:13 167:25 187:10 certainly 28:22 CERTIFICATE 4:5 192:1 Certified 1:15,17 1:18 192:3,4,18 192:19,20,20,21 192:22 certify 192:4,7,11 195:5 chance 73:13 156:16 change 44:6 69:25 72:8 74:9 75:4,15 158:5 194:4 changed 68:16 70:25 71:5,9 74:19 185:24 changes 193:10 195:10 chapters 79:24 80:7 86:22,24 87:5 100:10 characteristics 119:2 characterize 168:3 check 10:21 42:12 88:24 89:5 110:23 checked 10:16 16:22 checking 89:21 checkmark 135:25 chemical 104:6,10 104:20 175:8 176:21 177:9 cherry-picking 138:1 choice 49:3,7 51:9 53:2	choose 49:11 51:14 53:6 54:6,17 Chris 38:14 91:3 123:18 Christopher 1:11 3:11,13,15,16,17 3:24 4:1 6:6 9:1 126:2 152:16 192:5 195:15 chronic 173:23 174:15 chronic/ 162:11 chronic/carcinog... 3:20 circumstances 164:17 165:2,13 citations 47:18 149:23 150:3 cite 122:19 123:19 169:21 172:1 cited 13:3 31:24 39:1,15 53:14 123:18 132:1 141:5 149:4,9,10 170:12,15 clarification 114:13 clarify 160:3 clear 42:15 87:21 117:14 156:4 159:7 190:9 close 41:8,9 97:16 172:10 clue 102:20 coauthor 101:12 Cochran-Armita... 174:18 cognitive 102:4,15 103:1 collaboration 159:4 colleagues 81:21 collective 39:14 column 45:18 163:19 columns 185:20 combinations	155:15 combine 125:5 138:19 154:13,18 156:22 157:14 159:7 162:6,19 164:11 187:16 combined 115:8 139:25 150:8 154:15,20 155:8 157:25 185:1 188:15 189:6 combines 115:11 combining 115:4 118:20 121:21 125:15 129:12 149:1,15 161:6,11 164:7 187:10 come 12:25 99:2 123:13 130:3,5 146:11 147:19 153:23 156:18 comes 35:4 39:14 93:3 147:16 coming 187:24 commencement 192:4 commencing 1:13 comment 102:22 comments 181:8 commercial 97:9 commercially 85:16 commission 195:20 common 120:3 135:15 149:18 commonly 159:13 159:21 communication 43:15 communications 20:20 59:16 171:8 171:11 community 123:21 123:22 175:12,14 company 17:21 41:1 compare 130:21	138:17 compared 120:1,24 130:11 137:10,12 137:18 138:24 compares 189:16 comparing 126:20 comparison 173:15 174:9 compatibilities 83:17 completely 132:9 162:1 185:7 completeness 70:14 71:9 72:24 complex 105:12,14 155:9 173:10 174:3 complicated 144:13 complies 126:9 compound 137:4 138:21 139:2 compound-related 129:24 138:4,9 139:22 161:1 comprehensive 39:19 113:4 computation 30:9 116:15 compute 115:20 143:10 164:12 computed 116:3 computing 19:16 115:16 165:16 167:23 183:22 184:13,19,20 185:4 187:23 concentrated 24:18 25:11 concepts 173:17 174:11 concern 115:3 116:11 158:14,25 189:10 concerning 112:23 concerns 113:10,15 114:4
--	---	---	--	--

concluded 191:10	consistency 127:9	continued 37:6	Corcoran's 153:7	counts 68:16 69:17
conclusion 69:25	consistent 157:19	continuing 22:20	corners 92:18	70:25 71:10
conclusions 44:6	184:19 189:12	contributed 88:5	corporate 100:4	County 105:17
72:9	consistently 184:15	153:16	111:9	couple 6:18 11:6
concrete 124:24	constantly 111:15	contributions	corporation 18:2	15:18,20 68:17
132:23 166:3	consult 157:15	83:21	40:12 48:8 81:19	92:15 149:13
conditions 118:25	158:11 188:16	control 119:17,24	84:11,14 85:1	183:23
119:6,7,21 120:7	consultancy 110:10	120:8 121:6,9	91:6 109:13 110:9	course 8:17 25:8
121:12,15 122:10	111:8	123:23 124:8,9,11	111:10	48:6 52:14 88:12
122:12,13,24	consultant 68:8	124:20 125:10,11	correct 12:1 13:18	court 1:1,18 5:4,14
123:6,8,24 124:23	84:24 108:24	125:19 128:19	15:5 16:15 26:25	5:17 7:7,18 73:22
124:25 128:20	109:11 110:8	129:8 130:17,19	27:10 34:14 37:2	192:20,22 193:19
132:14 133:9	consultation	131:21,22 132:3,4	40:18 42:17 46:19	covers 21:17,24
conduct 135:14	158:17	132:25 133:3,4,8	47:2 52:13 56:1	22:11
139:11 142:8	consultations	133:9,15,17 141:9	59:3 64:16 65:24	created 91:17
conducted 43:17	112:18	controlled 120:22	70:3 72:16 79:8	creating 20:24
53:5 81:23 113:23	consulted 58:16	124:4 129:1	79:11 83:8 85:10	credence 70:8
114:21 128:13	83:25	131:15 132:9	85:11 94:3,3	credible 48:5 51:1
131:5,15 160:22	consulting 17:17	controlling 121:12	96:10 105:1,7,9	53:17 54:1 55:4
161:5	17:20,24 18:1	124:17	108:8 110:18	credit 93:25
conducting 115:19	19:5 23:23 41:2	controls 65:17	114:11,12 127:10	Critical 3:21 45:5
123:11	84:6 85:18 86:5	77:21 121:20	145:3,17 151:16	critically 134:24
confidential 1:8	108:22 109:6	129:7 132:7,20	154:5 160:17,17	criticism 136:24
20:19	110:18	144:2,3 183:18	180:10 186:17	180:24 189:20
confirms 40:25	consummate 188:2	184:8,25	190:18 195:7	criticisms 180:8,13
conflicting 72:17	contact 18:16 19:7	conventional	correction 62:8	182:16
conflicts 108:12	20:10	121:19 136:4	corrections 193:4,7	critique 186:18
confused 87:8	contacted 18:9,10	149:19	195:9	187:7
confusing 60:15	19:10	coordinated 103:14	correctly 58:14	critiqued 185:22
165:10	contacts 108:19	103:15	64:1 162:16	critiques 180:8,14
conjecture 124:6	contain 52:9,12	coordinator 103:21	correlated 3:23	CROSS-EXAMI...
connected 99:2	55:25 80:15	coordinators	81:9 86:17 91:2	180:5
connection 9:5	contained 11:11	103:19	96:12,13	crucial 187:19
10:22 17:5 18:12	31:13,22 64:6,6	copies 11:7	correlation 142:6	curious 93:15
20:4 41:5,14	70:2 79:3 164:3	copy 8:25 9:2,17	cost 97:6	current 65:1 94:22
95:23 97:16 110:9	179:14 181:1	78:13,15 91:20	counsel 2:11,17	95:5
119:8 179:2	182:3	182:6	5:16 192:12,13	currently 97:25
consensus 155:19	contains 55:11 58:8	Corcoran 1:11	count 74:12 101:15	cut 167:7
156:19	58:14 164:9	3:11,13,14,15,16	102:9 153:10	CV 79:3,14,18
consider 176:19	content 35:21	3:17 6:6,14 8:21	counted 74:24	86:19 100:25
177:4	64:11	9:1,3,13 19:19	101:16 102:2	106:3
consideration 66:6	contents 45:16	20:21 21:12 35:19	187:21	Cyrus 81:17
75:10 77:10 79:5	46:13,25 112:23	44:11,22 76:2	counter 101:21	Cytel 18:2 81:19,21
150:3,4	context 49:5 54:4	90:22 91:3 101:8	counting 183:7	84:8,11,14,25
considered 57:4,15	54:18 62:15 64:11	125:22 129:2	187:23	85:1,4,8,19,22,24
112:1 155:24	92:10 139:13	152:12,22 192:5	countless 125:3	88:12,22 89:12
161:6	continue 67:1	195:15	159:16	90:13,17 91:5

93:5 94:5 95:25 99:2 100:4,10 Cytel's 99:12	134:8 135:4,16 136:8,19 137:16 137:20 138:17,19 140:1,5,19 142:4 148:22 149:2,15 149:17 152:3 153:14 160:2 161:11 162:11,23 163:25 164:11 173:9 178:11 189:22,23	deeply 141:1 183:9 Defendant 2:17 defenses 180:15 define 165:20,21 definitively 142:5 dementia 102:4,14 103:1 demonstrate 125:2 139:21 demonstrated 142:5 demonstrates 186:5,6 depending 90:1 DEPONENT 4:7 195:2 deposed 7:20 deposes 6:9 deposing 193:14 deposition 1:10 3:13 7:24 8:9 9:18 12:8 69:11 113:12,16,21 114:5,17 116:22 117:6,8,14 155:12 160:11 170:3 182:5 188:6,10 191:10 193:3,12 193:16,17 deposition's 178:20 178:22 depression 102:17 103:3 deps@golkow.com 1:20 derive 146:24 describe 23:3 62:9 126:18 149:20 186:5 described 186:9 describing 80:19 Description 3:10 descriptions 24:2 design 125:20 178:10 designed 104:4,16 124:8	designing 173:18 174:12 178:9 details 113:21 determination 157:17 188:18 determine 135:18 137:18 determined 107:21 develop 18:4 83:8 84:19,22 87:24 developed 82:15,25 developing 80:19 85:9,9 development 83:11 develops 154:1 diagnosed 151:4 dialog 33:22 diets 128:12 differed 69:17 difference 72:14 73:1,17,21 74:2 132:20 134:2 150:13 186:3 differences 115:6 117:16,22 118:5 118:22 119:4,14 127:13 134:9 135:1,20 136:2,7 136:13 142:9,23 142:25 143:18 150:16 163:23 different 34:22 52:5 70:17 77:3 92:7 97:6 105:15 115:4 117:6 118:23,24,25 119:6,6,17,18,20 119:21,21,23,23 120:4,5,6,6,7,12 120:20 121:3,15 121:23,24 122:2,2 122:4,9,12 123:6 123:8,25,25 124:1 124:2,23 125:6,7 125:7,8 127:2,3,7 127:8,15 128:12 128:13,15,18,19	128:22 129:15 130:3,5,6,13 132:6,7 133:25 134:8 135:6,7,7,8 135:17 136:14,21 143:19 144:23 148:19 149:2,16 149:17 159:18,22 161:3,12 166:13 167:24 173:16 174:9 176:11,12 177:1,24 183:23 183:23 184:14 185:2,5 186:8,11 187:24 188:9 189:14 differential 97:20 Diplomate 1:15 192:3,18 DIRECT 6:12 directly 82:12 86:11 94:9 105:6 disagree 153:1,4 disclose 109:10 disclosed 108:23 112:24 discovery 35:15,18 60:8,12,18 61:9 61:10,11 62:5,7 63:3,16 64:12 164:17,25 165:12 165:14,17,21,24 166:6 167:4,11,19 168:2,8,9,15,24 169:23 discuss 67:4,6 discussed 65:7 172:16 178:3 discussing 142:13 discussion 74:19 disease 103:11 107:4 diseases 173:11 174:3 disproving 168:11 dissertation 170:13 distinction 95:8
--	--	--	--	--

distinguish 151:8 151:14	16:23	easy 132:25 133:3,4 143:13,15 144:8	100:9	158:23 162:7,20
distinguished 152:5	double-counting 183:21	ECCA 169:16	environment 119:17,24 120:11	168:6 181:19
distribution 145:14	dozens 101:20	educational 97:8	121:7 122:14	190:13
District 1:1,1 5:14	111:16 177:23	effect 129:24 138:4 138:10,21 139:22	131:21 132:5	ex 175:19
5:15	Dr 3:11,13 4:1 6:14	142:25 143:12,16	environmental 123:24 128:20	exact 96:13 155:23
doctoral 82:10	9:1,3 20:21 32:25	143:22 147:10	132:14	exactly 15:15 16:4
89:23 96:16	33:14 35:3,6,19	161:1 162:7,20	environments 120:22 135:6	19:8 25:15 32:2
doctors 157:8	37:13,16 38:14	164:13 166:23	EPA 40:7 168:23	67:15 72:21 76:14
document 1:5 9:16	39:11,16,20 44:11	168:6	169:6	76:22 78:4 92:1
84:23 91:12 92:19	44:20 48:6,24	effects 115:20	epidemiological 103:24	92:10 107:18
152:10 171:9	50:19 52:15 53:16	136:14 142:12	epidemiology 100:21 107:3	116:13 132:12
documentation 86:15 87:14	65:16 76:2 78:14	effort 24:18 36:3	159:14	135:13
documents 10:12	101:8 113:6,16	efforts 103:22	equal 183:15	examination 6:12
10:13 11:9 39:6	114:4 117:5	120:8 123:23	errata 4:6 193:6,9	60:3 155:2 180:20
49:19 149:8	121:18 122:20	132:3	193:11,14 195:11	192:5
152:11 170:23	124:15 125:13	EFSA 169:9	error 166:25	EXAMINATIONS 3:4
171:5,12,15,16	126:2,18 127:2	Egret 100:11,12,13	especially 113:11	examines 38:9
doing 23:15,23	129:2 131:19	either 23:10 72:24	173:18 174:11	example 29:9 35:2
25:20 30:3 32:6	133:1 134:13,24	103:1 136:16	ESQ 2:3,4,8,13,14	40:6 48:12 98:14
36:6 41:21 42:5	135:3 136:25	149:8,9 182:3	essentially 144:17	117:18 126:10
54:19 71:24 89:23	138:13 139:20	183:24	186:19	138:23 140:8,10
94:4,13 104:18	143:14 147:21,23	electronic 11:5,9	establishment 97:10	140:11,21 141:5
125:14,15 136:21	149:9,23 150:4	11:24	estimate 33:3,24	154:7,10 159:25
137:25 140:25	152:16,22 153:5,7	else's 49:9	59:22 143:12	180:12
144:18 156:11,14	155:11,21 158:4	employed 80:3	European 169:11	examples 80:20
158:22 163:1	158:15 159:8	employee 90:16	evaluate 83:19	81:5 96:18 99:6
166:4 167:14	161:15 162:24	192:11,13	138:3 147:9	122:17
177:21 183:20	164:14 170:2,7	employment 42:7	evaluated 12:17	exchange 171:11
184:14 189:7,19	174:17 180:9	93:25	33:14 71:4 80:4	excited 91:8
193:8	185:9 188:6	ends 158:15	evaluation 3:18	exclude 102:13,16
door 141:15	189:19	enormous 15:15	32:9 66:19 68:12	128:3,8 129:15
dose 113:23 114:18	dramatically 128:15	24:20	138:11,11 158:23	130:7
115:18,20,23	drawing 3:19	enter 24:21	162:9	exclusively 189:25
116:7,10,22 118:1	162:10	entered 20:7 78:3	everybody 47:19	Excuse 14:8 44:10
118:1,3 130:4	dropped 156:2	entire 72:20 73:13	48:1 50:25 52:1	64:24
136:14 142:12,16	duly 6:7 192:5	102:21 135:12	56:18,19	executive 157:13
142:25 143:12	<hr/> E <hr/>	entirely 124:4	everybody's 53:25	188:14
144:15,21 147:10	E 2:1,1,19,19 194:1	160:21	evidence 137:23	exhibit 8:21,25 9:3
147:13 161:1	earlier 59:25 66:1	entirety 32:16	138:3,14 139:22	9:13,17,22 19:19
doses 115:9,12,21	74:23 145:11	entitled 162:8	150:5 155:5	20:17 25:22 32:12
127:3,7	179:6,25 187:11	entries 23:7 25:24		40:21 44:22 45:4
dosing 104:17	190:12,19	26:16,23 28:9,16		56:21,21 79:7
double 62:2	ease 21:21	29:10 33:13 34:14		90:22,25 101:2
double-checked	easily 159:20	34:25		125:22 126:1
		entry 36:13 57:9		152:12 163:12
				182:8

exhibits 3:9 8:17 21:12 24:10	151:21 153:13 154:12 155:22	factor 69:3	final 156:7	flout 134:25
exist 11:25	158:7,7 170:3,6	factors 133:18 134:15	financially 192:13	focus 174:6
exists 165:14,19	170:21,24 176:24	factually 134:2	find 65:2 66:12 95:13 105:22	focused 28:23 29:23 63:17 100:20
expect 167:24 183:7 187:22 189:17	177:3 178:3 179:15 181:3,9,21 182:17 185:22	fail 193:17	155:17 175:8	follow 113:13
expected 164:17 165:2,13,25 183:1 183:10 184:5	186:6,9 190:12,20	faintest 102:20	finding 165:4 172:15 187:14	following 110:13 147:15
experience 23:22 32:6 150:2	expertise 19:16 30:21,23 31:2,17	fair 50:21 83:24 149:11 166:10 167:10 175:18	findings 163:3 164:18,19 166:1 166:22 168:22 172:10	follows 6:10 12:15
experiment 80:14 125:16 135:10	explains 81:14 117:12 122:21 126:19 134:17	false 60:7,8,11,17 61:8,10,11 62:5,7 63:3,15 64:12	fine 11:3 66:25	food 131:16 132:21 133:4,23 169:11
experiments 12:18 38:12 39:7 118:23 120:5,5 121:22 123:11 124:8 125:6,21 135:2 168:5 173:19 174:13 178:9,12	138:16 145:25 146:16,23 147:16 149:24	164:16,24 165:12 165:14,17,21,23 166:5,8,9,14,15 166:21 167:4,11 167:19 168:2,7,9 168:15,24 169:22	finish 7:14,17 111:5 133:12 141:23	footnote 186:25 187:3 188:23
expert 3:11,24 8:25 9:4 12:5 13:3 17:5 19:6 20:24 23:14 25:14 26:1 26:20,24 27:16,19 27:21 28:4,11,18 29:6,7,23 32:13 32:25 33:23 34:17 36:22,24 38:13 39:20 41:2 46:10 56:24 57:3 60:22 61:2,13 68:15 69:3,6,9 73:16 74:7,15 78:14 79:4 95:8 104:24 105:24 112:2,5,14 112:21,24 113:3 114:9,12,16 115:3 116:18,19 117:7,9 117:11 119:9 124:14 125:14 126:1,19 128:10 129:14 134:12,17 134:20 146:5 147:24 148:4 149:11,21 150:21	explained 116:20 117:9,13 188:8,20 190:10,19,19	familiar 150:16	finished 111:21 152:10	Force 67:20,23
	explains 128:24	61:8,10,11 62:5,7 63:3,15 64:12 164:16,24 165:12 165:14,17,21,23 166:5,8,9,14,15 166:21 167:4,11 167:19 168:2,7,9 168:15,24 169:22	firm 10:5 18:10 19:7,24 20:3,16 48:13 107:14 109:12 170:22 179:3	foregoing 192:8 195:6
	explanation 128:14 128:25 132:23 175:20 188:13	far 21:1 22:24 31:16 40:16 45:13 49:17,18	first 6:7,20 8:15 17:24 18:15,18 19:23 20:9 29:14 29:14 31:10 40:24 45:6 56:24 60:4 61:17 82:18 117:19 118:2 127:25 131:7 134:22,23 135:18 137:20 139:5 142:4,22 147:6,9 165:8 175:15 189:24	format 16:21
	explored 113:20	fast 6:20,21	142:4,22 147:6,9 165:8 175:15 189:24	formally 127:8,12 127:25 128:4 135:19
	exposed 130:22 175:14	fault 22:1 26:9,11 62:24	fit 143:8 144:14	formal 84:18 127:11 128:5 130:13 135:24 142:9
	expressed 115:2 179:4	fax 1:20	fits 144:15	format 16:21
	extending 65:9	FDA 97:2,4 98:15 98:16 99:10,11,22	five 38:12 39:8 57:4 60:4 92:5 102:7 138:8 146:9 189:14	formally 127:8,12 127:25 128:4 135:19
	extension 182:17	February 22:2 110:8	flawed 114:22 115:1 140:7 141:1 183:9	forth 112:8 192:9
	extent 20:19 112:12	fed 135:6	flaws 117:3	Foster 147:21,23
	extreme 115:9,18 116:7	federal 98:11,12 99:20 105:11	flip 172:24	found 48:2 82:14 91:8 92:9 116:9 142:14 172:19
	eyeball 130:10	feeding 38:11 39:7	Floor 2:5	foundational 183:3
	eyeballed 127:13 127:16 135:24	feel 184:2		founder 81:19
	F	felt 82:15 171:16		four 27:9,11,14,23 28:9,16 60:4 92:17,18 139:5 145:20 189:14
	facilities 122:7 128:13	fields 125:4		fourteen 3:20
	fact 27:20 47:7 50:15 137:25 143:24 149:18 166:23 175:13 187:12	figure 105:22		framework 175:5
		file 11:24 111:17		freely 48:21
		filed 109:20		
		files 10:18,21 11:5 11:9,15 13:11		
		fill 36:19		
		filtered 16:24		

front 16:4,8 77:24	glyphosate 3:19	184:6,7 191:8	119:15 125:24	112:10 114:8
full 76:3 106:11	17:6,9 37:25	GOLDMAN 2:7	137:5 140:3	119:10 137:3
131:1 173:9	38:10 41:8 52:2	Golkow 1:19 2:20	141:16,24 144:9	139:1 141:13
funded 95:14	52:21 67:20,23	5:6	147:4 148:9,16	144:5 146:25
105:19 106:25	147:10 162:10	good 24:25 30:17	152:8,14 159:1	148:7 151:17
funding 93:3,4	163:4	33:24 66:12 70:20	163:14 164:15	156:24 163:13
105:13 107:20	go 6:21 8:4 10:11	120:2 178:13,15	171:4,13 174:5	170:25 171:2,10
funds 84:24	30:11 33:10,12,19	178:17	175:24 180:3,21	173:24 175:22
further 85:9	33:25 34:8 40:21	gotten 26:12 54:14	182:9,12 191:2,6	180:6,18 182:8
113:19 128:11	45:11 47:15 51:5	107:24 108:7	Greim 3:21 13:3,5	191:4
180:18 191:4	52:18 56:23 57:2	133:21	13:6,8,12,16,16	group 78:5 92:16
192:7,11	57:5,7,9 72:19	government 99:25	13:16,18,24 14:2	132:15,16
	78:21 88:24 89:5	graduate 81:18,22	14:4 15:9 16:9,15	groups 115:10,13
G	90:14 92:9 93:19	88:18	16:20 24:12,19,22	115:19,23 116:7
G 2:19	101:14 102:9,21	grant 85:4 86:5,8	25:3,11 35:2	116:10 142:10
Gates 116:2	106:5 110:22	94:5,6,10,12,14	39:10,17,17,18,23	guess 10:16 13:10
general 4:1 24:1	111:18 120:19	94:17,18 95:13	43:6,11 44:21	13:23 33:1,21
152:17 174:22	121:16 126:23	105:11,12,18	45:7,12 47:4,20	34:21 38:22 40:8
175:1 176:20	130:23 131:1	106:16,19 107:17	47:24 48:22 49:12	42:6 44:3 50:6
178:4 179:13	134:19,22 146:5	107:19 108:1,8	49:24 50:4,14	54:1 61:17 65:5
182:1 190:23	153:1 171:19	grants 84:18 85:7	52:20 55:1,4,13	86:5 89:7,9 95:4
generally 36:13	172:20,21 181:14	85:14 94:20,22	56:14,17 57:17	102:8 165:24,25
49:4 101:17 139:9	goes 8:18 21:2	95:1,4,5,9 96:6,7	58:4,8,13 59:23	166:2 175:2
173:9	105:13	104:23 105:1,6,20	60:3,7,11,19,25	179:18 181:4,4
generate 35:8	going 6:25 8:16,24	106:1,5,11	61:4 69:18,21	guys 67:4 171:8
generated 79:10	9:7 12:6 16:1	great 12:3 152:19	70:3 71:13 72:13	
94:24 178:12	19:23 21:15,21,22	172:5 188:12	72:17,25 75:2	H
geneticists 157:10	22:5 30:12,18	greater 115:24	76:10,20 77:13	H 2:19
genetics 159:19	31:6 33:7,8 44:25	186:15	78:12 151:7,11,24	hacking 186:9
geographic 104:3	45:4 52:17 61:17	green 108:7	152:1 153:17	188:3
getting 49:9 51:11	62:21 65:2 66:11	Greenwald 2:3 3:5	154:15,21 155:3,7	half 31:11
53:4	70:19 75:20 77:22	3:7 5:19,19 6:13	157:21,24 160:7	Hampton 1:12
give 7:10 9:2 22:8	78:21 89:21 90:2	6:16 8:23 9:15	161:16,19,24	hand 19:25 51:24
24:1 33:3,24	91:4 101:18	14:13 19:21 21:5	162:25 163:17	76:14
62:14 70:8 78:10	102:11 104:22	21:11,14 23:20	184:18 189:22,23	hand-enter 51:24
83:25 89:1,11,20	108:21 113:2	24:7 29:1 36:8	grievously 136:9	hand-entered
92:11 93:19 96:18	125:25 131:11	37:23 38:7 39:3	Griffis 2:13 3:6	16:20 39:24
96:19 105:23	137:12 138:19	42:8 43:1 44:13	5:23,23 14:8	handful 74:18
106:6,8 116:8	141:17 148:10,18	44:24 49:2 51:18	20:18 21:3 23:18	handle 149:19
122:17 138:17	152:15 155:14	52:11 54:9,13,15	24:4 28:13 35:14	handled 131:17
152:24 159:24	156:9 157:14,21	56:13 58:10 59:21	37:18 38:4,20	132:22 133:6,24
given 22:24 29:14	157:22 158:12,20	65:21 66:14,17,22	41:23 42:18 44:10	handwritten 34:12
74:17 80:14 92:2	159:5 167:2,16,17	67:3,7,9 74:11	48:15 51:16 54:8	34:16
92:7,14 96:8,11	167:21,24,25	75:16 76:1 80:25	54:11 56:10 58:5	handy 9:11
127:2,7 156:16	169:18 171:25	81:7 89:16 90:24	59:15 64:24 66:11	happened 53:9,11
195:8	172:24 175:5,10	109:8,21 111:20	66:24 74:3 89:14	53:13,18 79:17
glad 7:25	178:21 180:4	113:14 114:11,23	109:2,14 111:12	happening 116:7

happens 30:21 72:7 87:22 108:20 132:13 139:11	73:4,5,6,7,18,19 73:20,24	176:14,18,20,22 176:23 177:2,8,11	74:8 129:12 135:9 143:22 149:5 153:10	instances 166:7 167:5
happy 51:21	historical 65:17	hypothesis-driven 174:23	includes 186:24	Institutes 84:19 93:4
hard 11:7 34:3	121:20 183:18 184:8,25	hypothetical 53:8 55:7	including 50:19 53:16 149:2	institution 97:9
Harrison 2:19 5:3	history 32:10 90:13 90:15 95:3	hypothetically 54:3	180:12 183:20,25 187:13,14	INSTRUCTIONS 193:1
head 7:8,9 16:5 43:22 68:4 73:10 80:22 88:24 89:8 98:4 99:23 103:4 122:22 169:25 172:18	HLLP 41:3,4	<hr/> I <hr/>	inconsistently 185:4	intend 179:13 190:14,22
health 84:19 93:4 102:16 173:12 176:21 177:10	Hogan 56:9 57:13 57:17,22,25 58:4 58:16,25 59:12 76:4,11,18,25 77:9	IARC 17:13 19:15 29:14,16 30:1,5 30:13 31:7,14,23 31:25 32:1 39:11 40:2	incorrect 152:11 185:7	interaction 170:16
health-related 103:2	hold 101:18	Idea 88:15 98:24	increase 142:15,20	interested 65:11 97:4 99:1 192:13
hear 170:11	Hollingsworth 2:13 5:24 10:5 18:10 18:19 19:7,11,24 20:3,16 40:14,20 40:25 41:18 42:1 42:6,7,13 48:13 48:19 56:7 59:7 59:10 67:13 107:13 108:25 109:6,12 110:19 111:9,9 170:22 179:3	Ideally 155:13	independent 42:2 53:22	interesting 44:4 53:8 168:22
heard 18:18 67:19 67:23 148:1 170:6	hope 120:16	identification 8:22 9:14 19:20 21:13 44:23 90:23 125:23 152:13	INDEX 3:1	internal 33:22
hearing 182:2	hour 35:11 66:12	identified 151:7	indicated 5:7	Internet 91:9,19
heavily 173:17 174:10	hours 33:18 35:12 36:19 59:23	identify 172:13	indirect 94:11	interruption 80:24
HEDLUND 2:7	huge 83:20	Illinois 1:16 192:20	indirectly 83:12 94:4	introduce 5:16
held 1:11	humans 173:11 174:4	illustrate 80:21 140:25	individual 12:17 15:1 55:14 160:20	introduced 6:15
Helmut 3:21 45:7	hundred 15:18 101:10,19,22,23 102:2 142:17	illustrates 158:9	individual-level 58:2,20	invading 21:7
help 32:18 42:1 44:1 78:11 83:7 95:6 110:4 136:22 157:16 170:23	hundreds 12:16 14:3,20 61:21 70:22,22 71:3,3 72:2 76:7 138:7 139:12,12 158:21 165:16 166:4 167:21,22 168:18 176:7	illustrating 132:12	industry 17:25	investigating 72:1 72:2
helped 82:2 84:22 100:22 105:2	hypothesees 177:24	imagine 55:3	inflate 116:5,5	investigators 160:16
helps 53:16 93:22 93:22 110:2 144:15 182:14	hypothesis 168:11 175:11,15 176:5	immaterial 124:18	influence 115:22 115:24,25	invoice 3:15,16,17 21:16,23 22:3,6 26:8 27:12 35:5 36:18
hepatocellular 129:6		impact 116:14	influences 115:15	invoiced 37:3
herbicide 3:19 162:10		impacts 71:24	information 67:25 76:24 80:16 109:24 110:12 111:4 161:6 164:9 181:20	invoices 23:3 28:7 28:10,17 29:3 33:2,11,20 34:8 35:9 36:1,3,11 42:10 60:2
hereinbefore 192:9		imperative 193:13	informed 110:17	invoicing 40:19 89:6 90:13
high 34:6 87:24		implement 88:2 84:21	inherent 122:14	involve 80:3 105:14 184:8
higher 115:12,21 115:23 116:9 142:6		implemented 81:25 158:10	initial 43:13 113:7 158:6	involved 125:20
highly 142:6		important 158:10 186:22	initially 28:4 29:13	involving 25:10 41:6 157:6
hired 123:12 170:5		incidence 3:20 75:13 115:22 156:1 162:11 163:24 177:22	initiated 103:23	issue 65:18 70:21 71:2 97:17 123:1
histopathological		incidents 65:12	injuries 41:7	
		include 55:13	Inn 1:12	
		included 68:18 69:5,19,23 70:13 71:19,20 72:23	innovation 85:14 96:5	
			innovative 85:15	

159:6,25 161:10 179:22 issues 6:19 8:1 30:8 66:2 102:3,5,16 103:2 items 11:6 iterating 28:22	34:8 36:19 48:18 52:4 60:15 63:14 68:25 69:14 70:10 72:12 77:24 83:16 83:19 87:22 88:6 93:20 97:5 98:12 99:2 100:21 103:14,21 108:20 109:18 110:2 115:10 116:1,4,6 116:14 118:11 124:18 129:18 130:2 135:14,20 138:2 139:4,8 143:22 150:15 151:4 154:15 155:9 157:19 158:9,24 160:25 161:9 162:6 165:18 175:2 179:7 181:5 183:2 183:3,21,21 184:3 185:4 186:4 187:13 188:1 189:11,13 kinds 32:6 119:3 155:15 157:6 159:18 186:7 Kirby 2:13 5:23 Klaus 66:10,19 67:14 68:8 knew 73:17 Knezevich 29:24 30:6,15 31:8 43:13,20 46:21,22 56:9 57:12,16,22 57:25 58:4,9,16 58:25 59:12 76:3 76:11,18,25 77:2 77:9 knock 141:14 know 6:14 8:5 13:21 14:22,23 15:25 16:1,22 17:8 18:23 19:9 24:24 25:8,16,20 27:25 28:21,23	29:17 30:17,19,20 30:21,23 31:16,17 32:5,7 33:3,20,21 33:21,25 34:18,24 35:7,23 36:5 37:21 39:4,14,22 39:24 40:16 43:9 43:16,18 44:16,18 46:5 47:18 48:2 48:18,18,20 49:18 49:19,22 50:3,12 50:13,20 51:3,24 52:1,15,23,25 53:7,11,15,19 54:5,16 55:1 57:2 59:8 61:11 65:6 67:22 68:7,13,23 68:24,25 69:14,18 70:7,8,15,25 71:8 72:1,5,20,21 73:22 74:7,16,16 74:23 75:4 76:12 77:1,4,22,24 78:3 80:10,11,18,22 81:4 82:18,21 83:12,15,18,20 84:22 86:5,13 87:11,22,23,25 88:21 89:4,6 90:1 90:15 92:10 93:2 93:16,17,18,21 94:9,24 95:13 96:16 97:1,11,12 97:16,19,20,21 98:1,9,18,20,22 99:3,9,10,12,13 99:24,25 100:1,2 100:3 101:14 102:8 104:2,22 106:10 107:18 108:10,14,15,16 108:18 109:17,19 110:21 113:5,19 114:20 116:2,4,13 117:14 120:9 121:11 122:18,19 123:10,14,16,17	123:19,20,21,25 124:2,6,7 125:2 127:14 128:19,24 129:23 130:9,12 131:6 132:6,10,11 133:23 134:1,1 135:22 137:19,21 137:22 138:4 139:4,7,7,16,20 139:24 140:8 142:14,16 144:14 144:17,21 145:13 145:22 146:10 147:21,23 148:2 149:1,3,12,16,25 150:18,25 151:3,3 151:3 152:6 155:6 155:11,20,21 156:5,5,8,15 157:7 158:6,15,22 159:5,6,8,9,20 160:18,25 161:4,6 162:4 163:5 164:8 164:12 166:2,3 167:17 168:13,14 168:15,21,23 169:3,6,9,14,16 170:1,18 171:5 174:16,19,20 176:2,4,6,7,10,12 176:24 177:15,16 177:16,16,16,18 177:19,22,23 178:5,8,14,19 181:14 182:16 183:3,14 184:13 184:16,18 185:2 186:14,24 187:6,8 187:9,11,12 188:16 189:5,9 knowing 68:6 97:5 knowledge 39:13 118:6 120:4 known 178:10 Kumar 68:21 69:20 72:12,25 74:13	L
J				L 2:3 lab 119:13 123:24 123:24 laboratories 118:24 120:21 121:25 122:3 128:18 laboratory 119:7 119:25 121:7 122:16,25 129:1 labs 119:17 121:3 Lance 2:19 5:3 language 32:21 Lankas 43:25 46:10 56:8 large 103:10 104:1 105:12 189:20 largely 33:5 173:4 173:8 larger 76:17,21 77:11 128:6,6 184:10,11 187:25 late 70:11 75:7 81:22 82:24 83:2 100:22 latest 18:23 lawful 6:7 lawsuit 6:17 LAWYER'S 4:8 196:1 lead 103:21 120:12 learned 7:24 leave 9:9 led 84:20 95:25 96:1 left 12:7 185:18 left-hand 45:18 legal 8:18 lesion 17:1 let's 10:24 16:10 33:7 40:21 51:4 61:23 62:18 63:4 72:5,7 110:7 113:25 117:18 118:1,1,2 121:16
J 3:24 4:1 126:2 152:17 January 21:16,18 24:16,17 25:4 110:7,13 jkalas@hollings... 2:15 job 11:21 123:9 124:19 155:4 John 2:14 5:25 19:12 journal 88:7 101:5 101:11 journals 87:1,16 172:8 judgment 48:1 53:23 July 22:12,18,21 79:11,15				
K				
Kalas 2:14 5:25,25 19:12 Kansas 1:18 192:22 keep 10:18 11:5 35:8,10 93:23 keeping 87:4 keeps 73:23 kept 36:1,14 key 94:9 131:24 kgriffis@holling... 2:14 kill 16:6 kilogram 142:17 kind 23:23 28:20 29:20 30:2,16,24 31:19 33:19,25				

121:17 141:13 147:2 letter 19:23 21:2 40:22,25 42:23 level 34:6 Liability 1:3 5:11 life 98:3 176:10 light 108:7 121:10 line 38:3,18 39:9 63:8,10,13 64:16 67:1 69:13 71:25 118:19 123:4 124:23 134:22 141:11 142:3 144:15 146:6 147:3,18 172:4,7 194:4 196:3 lines 12:7,12 62:12 130:25 141:3 list 10:15 11:5 29:24 88:7 99:14 101:5 102:21 112:1,3 123:19 132:2 149:5 156:7 158:15 listed 27:11 94:9,22 152:6,7 listening 44:16 127:21,22,22 lists 100:4 150:4,4 literature 123:17 123:18 149:1 172:14 litigation 1:4,19 2:20 5:6,11 9:2,5 23:24 41:6,8,14 42:5 49:5 54:5,19 109:1 179:2 little 79:1 87:8 100:23 124:17 live 6:21 175:20 liver 142:4 LLP 2:13 5:24 41:1 111:10 locations 120:7 124:1 125:7 Logan 1:12	logistic 143:9,16,22 145:1 159:12,16 160:1,16 161:13 161:16,20 163:6 164:6 logo 93:6,15 95:21 long 8:4 19:4,8 longer 100:14 look 12:12 14:1 24:9,15 25:21 26:15 28:6 30:12 31:23 45:7,15 46:7 47:16 49:18 56:20 65:3 68:21 69:10 77:23 95:12 100:25 126:15 130:4 137:20,22 141:4 147:6 155:4 157:21 163:7,18 171:25 173:5 183:4 185:8 186:7 186:10,24 looked 15:24 32:3 34:19 40:2 43:13 52:2 67:16 75:8 97:14 99:16,19 100:7 119:8 140:6 142:11 looking 12:10 13:23 23:14 28:24 29:15,20,25 31:13 33:22 35:2 51:9 52:19 54:25 61:20 70:23 135:16 141:10,10 142:24 145:14 163:16 167:15 175:7 176:7 178:11 184:12 looks 46:9 47:3 91:15,20 94:22 101:20 185:19 Los 2:9 lost 120:25 lot 9:8 18:6 25:8 32:5 33:18 34:15 40:4 47:8 96:11	103:22 105:14 loud 131:7 lower 115:12 lunch 148:8,18 LUXENBERG 2:2 lymphoma 154:8 187:4,13 188:21 188:21,22 189:5 <hr/> M <hr/> M 2:14 magnified 190:7 main 1:12 132:8 maintain 93:20 making 134:25 malignant 154:8 manual 81:11,16 82:3 85:23 86:3,7 86:12,16,20 87:14 manufactures 17:22 manuscript 163:21 manuscripts 39:6 mark 8:16,24 9:10 9:17 19:22,23 21:15,22,22 22:6 44:25 45:4 90:25 125:25 152:9,15 marked 8:21 9:13 19:19 21:13 33:11 44:22 90:22 125:22 152:12 154:12 markedly 128:21 market 98:23 marketed 98:8,9 marking 8:16 22:13 152:11 material 14:4 16:15 30:7 31:22 35:3 40:5 59:9 66:6 76:19 77:11 132:2 139:16 159:9 materials 24:13 30:2 31:24 57:3 59:24 77:8,11	79:5 111:23 112:1 112:4 123:19 132:1 149:5 matter 71:12,21 112:21 120:19 124:6 134:6 matters 71:15 MDL 1:3 5:12 35:16 mean 14:19 16:3 26:2 27:13 29:4 29:12 31:18 33:1 33:7,17 34:2,14 35:11 36:22 38:23 38:24,25 39:12 44:4,6 47:13,17 47:22 53:20 57:15 67:16 72:1 74:17 76:21 78:2 79:19 80:6 82:22 84:2 86:4 87:15,21 88:17,23 89:4 90:11 97:15 102:6 102:21 104:1 106:18 107:19 108:2 111:16 113:2 114:10 115:10 117:24,25 119:18 121:9,15 122:1,11,13 123:5 123:7 131:9 132:13 133:16 135:12 144:11 145:12 150:20 151:1 155:2,4,20 157:4,11 158:3 174:25 175:19,25 178:8 179:17,21 188:21 meaning 189:4 means 29:5 39:25 153:22 meant 30:5 164:7 188:22 measurable 125:9 measure 168:8 189:20	measured 135:7 measures 167:20 media 172:8 medical 157:7 medicine 173:13 meeting 23:11 Mehta 81:18 member 90:20 memory 33:16 34:12 65:1 103:10 mention 29:8 65:13 65:14 mentioned 22:3 37:25 62:8 63:5 65:12,18 66:4 92:18 95:9 106:15 155:11 170:1 mentioning 23:13 mentions 46:14 66:8 100:10 merely 123:2 messed 26:7 met 82:23 148:2 170:9 metastatic 153:9 method 174:20 185:6 methodologically 156:22 157:3 methodologies 80:20 methodology 80:3 134:15 143:6 146:23 157:19 180:15,16 184:19 methods 80:13,17 80:21 81:24 130:2 163:20 164:2,3 185:5 186:11 mice 17:2 38:12 39:8 68:22 120:10 120:19,21 124:3 129:19 135:3 138:8 148:23 mid-August 20:10 middle 127:4 141:25
---	--	--	--	---

milligrams 142:17	111:10 147:25	78:16 95:19 127:8	58:24 66:5 71:23	175:25 181:8
million 104:25	Monsanto's 42:4	needed 58:15 162:3	76:15 77:5 88:3	occasions 65:13
105:5,22	Monsanto-spons...	162:17 171:16	138:17 155:23	92:15
millions 168:19	43:11,14,20	negative 164:19	156:2,9,11 158:5	occupied 77:2
mind 10:24 46:7	month 25:5 31:10	neither 192:11,12	158:19 174:2,7	occurs 109:24
69:7 118:7	31:11 34:1,1,6,6	neoplasm 163:23	182:20 183:1,15	odds 142:15
mine 149:24	111:17	never 36:4 51:18	184:9 186:1	offer 179:13
mined 189:14	months 19:9 34:4	84:17 130:14	numbering 57:1	offered 180:9
minute 22:7 36:6,7	60:4 79:17 108:2	148:2 176:9	numbers 70:1	office 10:19
36:10,10 51:4	108:8	nevermind 98:6	71:13,21 72:17	Oh 22:16 27:6
52:18 61:24 84:7	morning 45:13	new 2:5,5 6:21	75:5,11 98:19	44:13,15 59:20
95:10 126:15	motivated 72:21	83:21 84:3 91:2	100:2 106:11	62:23 71:15 74:5
minutes 95:12	mouse 12:19 46:14	99:4,4 186:18,18	146:15,17,19,24	100:13 111:6
miscite 171:22	69:20 120:18,20	186:23	185:17 188:10	118:14 121:11
misrepresented	135:5 146:9	NIH 84:24 85:4,8	189:10	127:18 140:14
184:3	move 21:8 51:4	86:5,8 94:5,6 95:2		157:1 182:10
misrepresenting	62:19 148:19	95:12,23 105:1,11	O	okay 6:23,24 7:4,5
189:16	multi-task 127:23	105:20 106:24	O 2:19	7:11,19,23 8:12
Missouri 1:17	multiple 13:17 14:3	108:10	Objection 14:9	8:13 9:7,12,16
192:20	42:20 50:18 54:12	NIH's 95:21	20:18 23:18 24:4	10:1,7,11,18 11:8
Misstates 28:14	61:12,19 62:15	NIH-funded	28:13 35:14 37:18	11:13,20,23 12:3
48:16 109:3	65:6,14,19 66:2	105:18	38:4,20 41:23	14:10,21 15:11
151:18	147:13 156:13,17	nomenclature	42:18 48:15 51:16	16:11,17 17:16
model 133:8 136:3	multiplicity 156:12	177:5,7,12	54:8,11 56:10	18:5,20 19:4,10
143:8,17,23	N	noon 148:7	58:5 59:15 64:25	19:22 20:6,15
144:14,14,15,19	N 2:1	North 1:12	74:3 89:14 109:2	21:10,15 22:5,19
144:24 174:19	N.W 2:15	Northern 1:1 5:14	109:14 111:12	23:1,21 25:4
modified 180:13,25	name 5:3 6:16 45:6	Notary 192:22	112:10 119:10	26:13 27:13 28:6
182:2,19 183:12	91:5 103:7 106:18	195:22	137:3 139:1 144:5	29:2,8 31:15,21
184:3 185:13	144:24 148:1	note 186:22	146:25 151:17	35:10 36:9 37:9
186:15,19 189:19	162:14	noted 163:20	156:24 170:25	38:17 40:11 41:12
190:5,11	named 106:16	193:10 195:11	173:24 175:22	43:2 44:9,25
modules 84:21	National 84:19	notes 4:8 34:13,16	obligation 108:11	45:15 46:12,24
moment 141:14	93:3	34:25 35:8,15,21	109:23	47:4,10 50:20
money 88:11	natural 28:20	35:22,25 36:4	observational	51:3 52:17,24
monograph 17:13	159:11	196:1	104:2	57:6 58:3,11,22
19:15 30:13	nature 179:6	notice 3:12 9:18	observe 128:21	59:11,20 61:25
Monsanto 2:17	NCRA 192:18	23:2 107:20,22,24	166:19	62:1,11,18 63:11
5:24 6:1 17:17	nearing 178:24	128:11	observed 12:18	66:5,22 67:19
40:12,17 41:1,4,6	nearly 55:1,2,21	noticed 92:17	17:2 166:22	68:5,7,10 69:2
41:14,15,19,22	132:16	noticing 22:9	182:20 183:2,6	72:4 75:16,23
42:17 43:5,22	necessarily 156:8	notion 175:9	184:4 187:19	77:16,19 78:1,7
44:1 45:25 46:3	necessary 47:15	November 25:18	obtain 58:9	78:23,25 79:2,16
46:18 47:1,11	55:8 61:19 62:16	number 5:12,13	obtained 61:4	79:23 81:8,14
48:7,14,20 56:6	160:21 193:4	12:25 13:14 15:15	obvious 128:14	82:8,13 83:1,2,23
58:18 59:2,5 68:8	need 8:5,8 21:3	16:12,13 24:23	obviously 16:3	84:5,13 85:3,7,12
108:25 109:4,12		26:4 46:16 47:18	22:21 170:3	85:17,21 86:7,23

87:20 91:15,18,22 93:6,9,12 94:12 94:16 95:6,11,18 95:21 96:2,14 99:16 100:9,18,24 101:8,24 102:10 102:12 103:12,18 105:5,21 106:2,22 107:10,12,23 109:9 110:16 111:2 113:25 114:25 118:15 119:5,16 120:14 122:8,23 126:16 126:17 127:24 129:10 130:23 131:3 133:19 138:15 142:2 143:1 145:20 147:5 148:13,17 149:6 150:1,23 151:13 152:15 153:3,18,25 154:11,17 159:24 165:11 166:24,24 167:1,9,20 168:4 169:14,18,20 171:19,24 172:2,3 172:19,23 173:1,3 173:22 177:14 178:1,16,24 179:11 180:3,22 181:10 185:11,16 185:21 188:4 191:2 old 103:11 185:12 once 108:3 117:13 ones 43:22,23 56:17 96:4 ongoing 108:11 109:22 online 163:25 opinion 70:15 71:11 74:10 150:7 153:13 179:5 opinions 69:3,15 70:6 113:18 179:2	179:12 190:15,21 190:22 opposed 138:1 185:5 186:2,15 optimal 104:17 oral 3:12 order 1:8 158:22 organ 154:2 organ-specific 153:20,25 organizations 92:18 original 33:15 35:4 43:16 49:16,19,23 50:2 52:10,13 53:14 55:11,21,22 55:23 72:12 73:4 73:4,18 152:2 153:16 155:22 160:15 181:6,8 185:9,13 186:3,16 190:7 193:14 originally 51:6 161:5 178:11 outcome 175:8 176:22 177:10 outcome's 175:10 outcomes 80:5 outline 135:13 outlined 61:12 124:14 140:23 outside 36:11 37:20 54:18 112:13 overall 13:23 69:25 71:6 74:9 75:10 162:7,7,20,20 overarching 71:2 158:13,24 overseen 104:9 overtones 173:14 owned 84:8 <hr/> P <hr/> P 2:1,1,19 30:9 63:16,18 64:18 115:15,20 116:14 138:1 139:13,15	143:11 145:14 146:18 153:10 164:13 165:17 166:3,7,16,16,17 166:19,22 167:6,6 167:12,15,22 168:1,19 182:22 183:1,6,22 184:13 184:20 185:4 186:7,8,10 187:23 188:2 189:14 P.C 2:2 p.m 191:10 package 81:25 83:22 88:9 100:13 100:15,19 packages 88:1 page 3:2,10 12:4,9 14:16 38:6,8,8 39:23 56:23,25 57:7 61:17,23 62:8,11,13,13,17 63:4,22 64:10,14 64:15 69:13,13 74:14,20 75:4 81:8 86:18 94:17 94:19 95:2 105:24 106:7,9 118:13 123:4 126:8,12,24 127:4 130:23 132:10,11 134:19 135:22 138:17 140:9,11,11,14,15 140:21 141:5 146:6 147:3,17 153:2,5 163:17 171:19 172:2,21 172:22 181:8,10 182:13,14 185:9 186:2 194:4 196:3 pages 9:22 14:3,4 14:17 15:12,16 57:4 61:18 62:6 63:24 64:3,17 65:4,7 76:3,7,7,10 76:23,24 77:2,5 79:8,23 100:25	101:4 111:24 126:25 145:17 195:6 paid 37:1 42:9 84:23 86:2,11 88:12 89:22 90:5 90:8 94:6 paper 10:18,21 13:6,17,18,25 14:2,5 16:9,15 25:16 43:11 45:12 47:5,15,19,24 48:22 49:8 50:4 50:15 51:10,21 53:1,1,2,4 54:6,21 55:9,9,10 57:13 57:22 59:23 67:11 67:17 68:11,24 69:1,2 70:2,9 72:20,21 73:13 76:10 77:13 151:7 151:11 161:17,21 162:5,18 163:1,8 163:10,17,18 170:12 paperclip 45:3 papers 24:12 48:11 79:20 111:17 170:15 paragraph 63:10 63:13 64:15 126:10,15 127:4 127:12 128:24 135:13 141:11 147:8 163:19 paragraphs 75:5 146:12 147:16 paren 41:8,9 81:11 parenthetical 173:15 parse 121:17 part 28:20 30:23 33:16 55:18 68:20 82:4,8 83:10 86:8 94:2,6 104:1 105:21 111:22 113:17,17 124:12	124:20 125:12 126:12 159:11 165:8,9 188:17 participating 86:15 87:13 particular 59:12 78:19 106:13 122:25 124:24 170:23 particularly 29:18 38:11 173:10 174:2 parties 192:12 parts 82:2 86:11 pass 180:4 pathologist 156:17 158:11 pathologists 155:17 156:18 157:16 158:17 pathology 55:14,17 56:1 68:14 150:21 151:2 pattern 104:17 pause 141:13 payments 89:12 PC 2:7 Pearl 2:4 5:21 pedigrees 107:5 peer-reviewed 86:20,25 87:2,16 101:5,11 102:14 102:18,19,24 169:22 172:14 pen 25:16 pending 8:8 113:19 people 48:23 52:24 52:25 82:17 83:14 88:9 99:1,14 124:7 189:1 people's 54:25 percent 77:20 129:3 132:16,17 132:19 141:8 142:15,20 143:3 144:4 perform 42:2 112:7
--	---	--	---	---

112:18 performed 24:24 37:9,11 63:6 104:8 performing 184:10 period 21:17 22:1 22:12 24:25 107:20 120:17 121:6 periodically 110:22 person 48:12 53:5 91:5 105:13 106:17 188:13 person's 54:6 personally 34:3 personnel 94:10 105:15 pesticides 17:22 ph 1:20 Ph.D 3:24 82:5,9 phase 179:14 190:23 phenomena 174:4 phenomenon 173:11 phone 6:3 108:1 phrase 123:4 physical 122:4,5 pick 53:12 117:11 pieces 58:23 place 116:8 192:9 places 64:3 66:3 115:9,24 119:20 119:23 120:20 130:6 plaintiff 23:14 25:25 26:19,24 27:16,19,21 28:11 28:18 plaintiffs 2:11 4:2 5:20,22 6:4,10,17 41:16 152:18 Plaintiffs' 3:12 planet 159:17 please 7:2 12:5 57:10 59:17 122:17 164:22	193:3,8 plus 116:20 point 98:3 110:11 118:10,19 124:19 127:1 129:13 134:23 156:7,10 183:3 187:19 pointed 123:10 132:11 140:7 143:14 189:3 pointing 66:3 128:9 187:9,18 policy 93:13,17 pool 128:8 131:19 134:24 138:12 179:22 pooled 65:20 113:24,24 114:19 116:23 117:3 137:1 179:6 pooling 117:5 118:20 121:21 137:16 162:23 181:23 190:12,20 pools 115:16 poor 167:3 pore 33:1,9 Portier 3:24 4:1 38:14 39:1,16,20 44:20 48:3,6,24 50:19 52:15 53:16 55:5 113:16 114:4 117:5 121:18 122:20 123:18 124:15 125:13 126:2,18 127:2 133:1 134:13 135:3 136:25 138:13 139:20 143:14 149:4,9 152:17 155:11,21 158:15 161:15 162:24 164:14 170:2,7 174:17 180:9 189:19 Portier's 32:25 33:14 35:3,6	37:13,16 39:11 40:7 65:16 78:14 113:6 131:19 134:24 149:23 150:4 153:5 158:4 159:8 185:9 188:6 position 53:21 positions 79:22 positive 164:18 165:3 166:10,14 166:15,21 172:9 172:15 positives 166:8 possible 39:25 81:6 119:16 128:17 post-Weber 67:7 potential 3:19 41:5 108:12 134:9 150:1 162:9 173:16 174:10 potentially 168:22 PowerPoint 91:1 91:16 94:13 PP 81:11 practice 121:19 125:18 136:5,10 175:3 practicing 54:24 Pralay 91:7 preceding 146:12 146:13 147:7,7 preconceived 175:9 preliminary 6:18 7:25 preparation 112:4 170:21 171:14 prepare 170:24 171:16 prepared 9:4 38:14 90:12 91:11,14,16 91:23 preparing 81:16 85:23 present 99:13 112:5 116:3 190:14 presentation 91:1	91:16 92:2,12 presentations 92:3 92:7,14 93:19,24 96:9,12,20 presented 44:21 55:22 97:2 99:11 presenting 163:2 presumably 20:8 pretty 33:24 34:4 144:8 149:14 previous 75:5 prices 98:3 pricing 97:13,22 primary 150:13,16 150:19,24 151:8 151:15 152:4 printed 14:12 prior 17:4 109:3 158:6 170:5 192:4 priori 157:20 prioritized 34:19 private 110:9 privilege 21:8 privileged 35:17 112:15 171:12 probability 173:18 174:12,19 probably 20:11 25:17 33:24 60:4 82:24 98:2 100:6 108:6 159:20 probertson@wei... 2:4 problem 81:3 117:15 131:18 139:10 182:18 183:8 186:13 190:7 problematic 185:25 problems 161:14 procedure 117:3 130:15 procedures 113:24 114:20 116:23 134:24 process 70:11	159:11 produce 11:13 13:13 100:14 123:15 produced 13:2 28:7 29:6 49:17,20 152:2 production 9:23 10:14,23 11:10,16 Products 1:3 5:11 profession 168:17 169:4 professional 79:21 88:13 program 82:6,9,10 project 90:4 projects 81:20 90:2 157:5 prominence 116:8 promise 68:2 pronounce 91:4 proper 139:25 properly 137:14 proportion 24:25 166:6 167:5,25 168:4 proportions 127:16 proposing 136:21 propounded 195:9 PROTECTIVE 1:8 provide 41:2 provided 11:19 13:9,24 32:22 40:6 55:1 95:24 113:22 proving 168:11 psychiatrists 157:8 psychologists 157:8 Public 192:22 195:22 publication 39:18 publications 80:2 87:2,16 172:14 publish 86:14 87:13 published 38:25 79:20,25 86:20
---	---	---	---	--

88:6 102:19,25 162:5,18 170:13 pure 177:8 purpose 68:11,23 130:16,18 purposes 11:25 41:3 101:24 purview 178:7 put 16:7 22:16 25:16 53:21 93:14 118:1,2 136:8 175:5 182:17	109:21 111:20 113:14 114:23 119:15 125:24 137:5 140:3 141:24 144:9 147:4,7 148:16 152:8,14 159:1 164:15 169:19 171:13 173:12 174:5 175:24 180:6,19,21 182:12 191:5 195:8 quick 148:17 quite 58:7 170:2 quote 41:9 172:9 172:10	rats 17:2 38:12 39:8 118:2 120:10 120:18 129:20 142:7 raw 55:2 re-reviewed 69:1 reached 179:1 reaching 70:5,6 71:11 read 10:15,25 12:22 17:13 30:18 32:3,4 40:4 42:22 42:22 47:4 72:20 73:13 126:5,16 127:5 129:2 131:7 135:12 148:4 159:9 161:23 162:1 188:4,5 193:3 195:5 reading 28:24 31:12 49:8 reads 40:24 153:6 real 178:7 realize 77:4 176:1 realized 72:16 really 15:25 17:11 32:2 44:5 48:18 54:2 69:25 71:24 72:13 81:4 83:20 89:4 95:19 97:14 99:18 104:14 113:22 116:13 123:2 134:6 136:9 148:3 150:15 151:2 156:6 168:13 176:17 178:24 181:15 186:22 187:19 189:9 Realtime 1:15 192:3,18 reanalysis 72:4,23 74:6 reanalyzed 73:3,18 reason 54:1 68:20 94:7,21 127:17 128:2,7 129:14	130:7 131:9,13 153:1,4 193:5 194:6,8,10,12,14 194:16,18,20,22 194:24 reasons 129:11 132:8 178:9 reassure 53:17 rebuttal 4:1 35:6 37:13,16 78:15 113:6 143:14 149:10 152:16 153:6 156:3 158:8 180:9 182:7 187:7 187:20 189:3 recalculation 188:9 recall 14:19,22 15:15,23 32:2,24 43:21 56:4 68:3 73:2,9,11 76:2,9 76:16 77:6,16,25 91:11,22 99:21 111:2 161:18,19 receipt 193:15 receive 10:1,4,8 43:2 received 27:21 47:19 59:9 76:19 77:10 104:25 106:12 107:17 113:6 receiving 37:16 recipient 106:16 recollection 30:4 34:5 44:2 recommended 168:17 169:4 reconciling 187:15 record 5:2 33:5 36:2,21 75:21,22 75:24 93:21,23 141:18,19,21 148:11,12,14 191:9 records 88:25 89:5 89:6 recreate 33:20	90:14 REDIRECT 180:20 reevaluated 68:18 reevaluation 69:24 refer 13:15 38:2,18 118:8 134:16 referee 86:25 refereed 88:7 reference 23:11 26:24 39:9 47:1 57:12 81:9 83:5,6 111:23 referenced 39:11 43:10 86:18 references 29:17 referred 27:18,25 28:18 64:15 96:7 referring 12:6 29:16 57:17 117:17 139:17 reflect 28:10 34:13 35:1 36:3 75:6 reflected 20:17 33:5 96:10 186:11 187:22 reflects 27:20 34:18 36:24 refresh 44:2 regard 75:10 109:3 112:16,20 regardless 97:23 158:14 regards 5:10 Registered 1:14 192:3,18 regression 143:9 143:16,23 145:1 159:13,16 160:1 160:16 161:13,17 161:20 163:6 164:6 rejecting 164:18,19 165:3 relate 102:3,25 related 30:1,7 92:3 159:10
Q quality 131:16 133:5,23 quantity 165:19 question 7:2,15,16 8:7 24:5 26:14 30:17 34:22 50:10 51:5,19 52:18 54:14 55:3 58:12 60:16 66:15 70:20 72:3 77:4 97:20 111:5 120:3,16 121:14 127:20 133:20 148:17 151:14 164:21 165:9 167:3 168:14 171:3 175:21 176:16,20 177:1 181:16 questioning 67:2 111:22 questions 6:13 7:1 8:23 9:8,15 14:13 18:6 19:21 21:14 23:20 24:7 29:1 36:8 37:23 38:7 39:3 42:8 43:1 44:24 49:2 52:11 54:9,15 56:13 58:10 59:17,21 65:21 66:17 67:9 74:11 76:1 81:7 89:16 90:12,24 95:7 101:25 109:8	R R 2:1,8,19,19 194:1 194:1 raised 135:6 range 89:1,11,21 rat 12:19 45:21 117:19 119:7 126:20,20 133:25 135:4,22 138:8,23 145:3,4 146:7 148:23 rate 60:8,12,18 61:9,10,11 62:6,8 63:3,16 64:12 77:20 128:6 129:19 130:11 132:15,19 143:3 144:22 164:17,25 165:12,14,17,22 165:24 166:6,10 166:14,15,21,21 167:4,11,20 168:3 168:8,9,15,24 169:23 rates 78:5 120:13 128:15 129:16 130:6 132:7 141:8 143:25 ratio 165:25			

relates 1:5 80:12 relating 39:6 76:11 85:24 102:17 116:21 182:2 relative 77:15 192:11,12 relatively 96:17 115:12 reliance 190:22 relied 39:20 52:1 52:24 relies 173:17 174:10 religion 102:17 103:2 rely 56:18,19 relying 30:24 52:6 52:7,8 149:8 remainder 46:13 remember 16:5 67:17 76:6,14 77:14 78:4 92:15 98:4 100:17 155:23 182:7 reminder 110:1 repeat 164:22 repeating 179:20 rephrase 7:3 50:10 105:10 report 3:11,24 4:1 8:25 9:4 12:5 13:3 17:5 20:24 23:11,14 25:2,14 26:1,20,24 27:19 27:22 28:5,12,19 29:3,6,7,14,16,18 29:23 30:1,5 31:14,23,25 32:4 32:13,15,19,22,25 33:15,23 34:17 35:4,6 36:22,24 37:13,17 38:1,9,9 38:13 39:2,11 40:1,3,7,7 46:11 48:3 49:6 56:1,25 57:3 60:22 61:2 61:13,15 62:22	63:1,12,13 64:20 68:1,14,15,18,21 69:4,6,9 73:16 74:7,15 78:13,14 78:15 79:4,10 94:25 95:8 101:1 104:25 105:24 112:2,8,14,22,24 113:3,7 114:10,12 114:16 115:3 116:18,20 117:7 117:10,11 118:8 118:14 119:9 123:5 124:14 125:14 126:1,5,19 126:24 128:10 129:14 134:12,17 134:20 138:16 140:9,16,22 141:6 143:15 146:5 147:24 148:5 149:10,10,11,21 149:23 151:22 152:16 153:6 154:12 155:22 156:3 158:7,8,8 160:10 170:4,22 170:24 171:14,17 171:20 172:15,17 176:24 177:3 178:3 179:4,15 180:10 181:3,6,9 181:21 182:4,7,14 182:17 185:10,22 186:3,6,9 187:7,9 187:20 189:3,24 190:13,20 reported 63:19 64:19 69:17 71:1 74:13,24 113:11 151:11,21,24,25 152:3 153:15 154:14 155:6,7,21 157:23,25 160:7 163:24 184:17 reporter 1:15,16,17 1:18 5:4,17 7:7,18	73:23 192:3,4,4 192:18,18,19,20 192:20,21,22 reporting 23:5 183:16 184:11 reports 27:16 39:20 55:17 159:8 160:11 represent 5:5 6:17 87:1 189:11 representation 18:13 representing 41:4 41:19 represents 103:13 reproduce 34:8,11 request 10:14,22 11:10,16 108:7 112:15 requested 10:13 requests 9:23 111:16 require 79:18 required 11:18 140:2 requirement 108:11 requirements 108:16 110:15 requires 139:24 161:13 176:18 research 17:6 23:15 26:1,20 28:11,12 30:25 31:9 37:15 49:11 54:19 80:19 81:20 81:23 85:14 96:6 108:22 119:25 research/reading 29:9,11 30:5 researched 31:2,5 researchers 108:12 135:8 172:7 researching 27:15 resilience 107:4 respect 65:15,20 87:17 122:25	138:23 187:20 responding 10:22 181:15 response 77:20 78:4 113:23 114:18 115:20 116:23 128:6 129:4 130:5,11 132:15 136:14 142:12,25 143:12 144:16,21 147:10 147:13 161:1 189:20 190:5 responses 180:8 responsive 10:12 11:10,15 rest 44:17 result 115:24 168:1 resulting 189:21 results 28:25 29:6 29:22 30:20 39:1 50:5 63:14 64:6,7 64:18 145:21,22 146:1,2,7,9,11 147:19 162:6,19 168:5 retained 17:9,14 24:3 41:2 retainer 42:23 84:13,18 retention 3:14 20:2 40:22 107:13 return 193:13 review 15:7 16:14 19:14 35:5 37:24 38:17,23 39:19 69:10 101:9 reviewed 15:13 19:18 38:13 39:5 39:21,22 40:9 61:1 66:18 76:4 112:4 reviewing 24:12 27:14,23 31:22,25 37:12,21 53:2 54:21 59:23 reviews 3:21 45:5	53:3 rgreenwald@wei... 2:3 right 7:12 8:14,20 12:2 13:19 15:3 16:10 17:15 18:5 18:7 19:1 20:11 20:12,13 21:22 22:21,25 23:5,16 23:22,24,25 24:6 24:8 26:12,13 27:7 28:8 30:14 32:14 36:17 40:12 40:23 42:22 46:12 46:17,20 47:5,8 48:14 50:21 57:8 57:13 61:2 62:3 64:9,12,23 66:16 66:20 72:18 75:18 78:9 79:4,9 82:7 82:11 84:9,15 85:4,5,20 86:24 87:3,18 89:24 93:8 95:19 99:8 100:24 101:6,7,13 101:18 105:8,9 107:1,2,14,17 111:25 112:2,2 116:23,24 122:23 126:6 131:20,22 133:16 141:16 145:16 148:20 149:7 152:21 154:2,8,13,19,22 160:7,8,12,13 162:12,21 163:6 163:19 170:20 173:7 179:9,11 180:1,3,7,11,16 181:12 182:11,15 185:18,23 188:6 188:19 189:1 190:24,25 risk 38:11 107:4 174:10 risks 173:16 Robertson 2:4 5:21
---	--	--	---	---

5:21 Robin 2:3 5:19 6:16 rodent 3:20 38:10 104:4,9,18 162:12 172:16 178:2 rodents 135:5 role 148:2 157:15 roles 93:25 roughly 101:23 Roundup 1:3 5:11 41:7 Ruecker 43:25 56:8 rule 8:6	187:3 SBA 96:2 SBIR 96:7 Sc.D 1:11 3:11 6:6 192:5 195:15 school 81:18 science 125:4 sciences 159:22 scientific 172:8 scientists 43:17 49:16,20 50:18 52:16 53:15 55:6 152:2 153:16 157:6 161:4 178:10 scope 112:14 scratch 178:14,16 179:19 Scratching 178:19 screen 5:8 screening 168:12 174:23 175:1,16 178:4 searched 11:8 searching 10:12 second 9:16 22:8 105:23 106:6,8,17 114:24 136:1 142:24 147:12 152:24 165:6 171:21 175:14 secondary 150:13 150:17 151:8,15 152:4 153:9 Secondly 128:2 section 61:16 62:10 65:9,10,15,19 79:24 134:20 139:17,19 140:1 173:6 sections 65:22 139:5 see 9:24 10:24 12:20 26:21 38:15 41:10 44:4 45:20 45:22 46:14 63:4 68:22 72:7 92:22	111:18 115:23 167:16 172:11 173:20 175:11 182:10 187:2 seen 9:19 49:12 91:12 98:2 152:21 164:5 Senchaudhuri 91:7 send 110:1 sense 15:23 40:8 51:2 80:12 95:5 177:13 185:6 sent 59:18 109:18 sentence 40:24 121:16 123:3 129:3 131:2 153:5 167:2 separate 86:25 87:5 107:21 separately 151:5 152:1,6 September 1:7 5:8 18:23,24 31:6 107:7 108:8 114:6 192:23 series 9:23 served 83:18 90:19 106:1 services 1:19 2:20 5:6 41:3 set 76:17 77:11 108:3,4 112:8 140:5 166:17 192:9 sets 70:18 115:4,16 140:1 162:23 setting 94:24 96:24 97:1 157:12 165:15 settings 159:23 176:12 seven 38:11 39:7 119:7 138:8 145:3 145:4 146:7 shake 7:8,9 shared 179:5 sheet 193:6,9,11,14	195:11 sheets 50:1 short 167:10 Shorthand 1:17 192:4,19,20,21 show 35:5 53:21 62:22 63:2 99:2,6 showed 140:21 shown 12:16 shows 78:17 sic 21:23 159:21 sign 193:8 signed 84:17 107:12 significance 163:22 184:22 significant 28:1 117:4 142:6 166:20 182:21,22 182:24 significantly 130:12 signing 193:9 similar 92:14 similarities 135:2 simple 50:9 120:16 simply 128:3,8 135:3 simultaneously 61:22 single 65:2 135:10 147:11 169:21 sir 180:7 sit 33:25 41:20 47:23 50:3,12 77:7 89:10 102:23 110:16 131:14 133:11,22 152:25 155:16 156:16 158:10 159:2 site 92:9 183:14 sites 17:1 153:7 182:20 183:10,15 sitting 50:7 73:2 76:16 111:3 situations 168:18 size 77:15	sizes 127:3,8 skin 187:4,13 188:21,21 SL 187:4 slightly 34:21 69:17 slow 6:22 small 85:13 96:3,5 smaller 58:23 183:11 sociology 159:19 software 18:2,4 32:8 81:19,25 83:14 84:20 85:1 87:25 88:9 91:5 97:7 somebody 30:20 49:25 160:21 sorry 21:11,25 22:8 22:16 26:4,10 27:6 28:11 37:4 37:10 38:8 40:15 44:13,15 56:4,21 60:8,13 62:13,18 62:21,23 63:22 70:5 73:24 78:7 100:4 105:23 106:5 111:6,25 114:14 127:18,19 127:22 131:11 133:12 139:18 140:14,15 142:1 152:24 153:2 157:1 160:3 164:20 167:8 171:21,22,23 172:1,20 173:2 174:6 176:3 190:15 sort 33:22 61:18 93:12 126:11 129:23 155:18 156:12,18 175:19 sound 49:1 101:13 101:17 156:22 157:3 sounds 176:3
S				
S 2:1 S-t-a-t 81:10 Safety 169:11 sake 42:4 70:14 71:8,8 72:23 salaries 116:6 salary 116:3 sample 127:3,8 SAS 88:1 satisfactory 175:21 saw 129:3,8 132:19 saying 16:13 21:6 34:11 66:1 71:12 71:22 75:3 89:10 89:19,20 110:10 120:23 121:1,2,8 125:1 127:24 131:20 132:18,24 133:6 141:2 147:19 149:12 151:20,20 154:21 190:6 says 6:9 26:19 38:9 45:20,24 46:2,18 79:10 82:20 91:1 92:19 100:11 108:1 127:2,2 128:11 129:3 163:20 164:3,5 167:20 182:21				

source 44:5 49:23 58:1	64:16 65:8 69:13 96:15 108:1	178:21	105:3,14 115:9,11 117:17,19 119:8	160:22 164:9 168:10 173:10 174:3
sources 12:24 30:24 40:10 48:4 115:4 118:21 121:22 122:20 132:1 135:7 136:3 149:2,3,4,17	118:11,11,18 130:24 139:6 141:11 142:3 146:6 147:18 181:5	StatXact 3:22 81:10,15 82:1,9 82:19 83:8,13,24 84:8,22 85:9,18 85:23,25 87:17 88:1,5,14 91:2 97:8,13,22 98:7 99:14,21 100:1,3 100:5,11	123:1,14 125:3,8 126:21 127:9 128:12,18,21 129:7,15 130:4 131:4,14 132:13 133:25 134:4,8 135:5,17,19,23 136:15 137:10,21 137:24 138:8,23 142:13,19,19 143:25 144:2,23 145:3,5,23 146:7 146:9 148:23,23 148:24 149:16 150:7 159:25 160:6,9,20 161:5 161:7,12 162:12 164:11 172:16 173:23 174:15,23 175:1 177:23 178:2 185:2	studying 28:4 47:8 129:17,22,25 stuff 8:18 subject 1:8 35:18 51:8,8 112:21 160:10 193:10 submitted 147:24 Subscribed 195:18 subsets 135:4 substance 6:19 195:10 substantial 79:16 substantive 72:9 substantively 75:15 sufficient 160:24 suggest 101:10 suite 2:9 83:13 sum 147:18 summaries 39:10 summarized 51:13 64:7 146:8,10 summarizes 49:8 51:10 69:14 summary 38:1 51:22 52:6,8 53:1 53:2 54:6,21 55:8 118:12,14 139:6 146:11 163:3,18 163:24
space 193:6 span 135:9 speak 150:6 speaking 49:4 54:3 176:5 specific 122:24 149:23 154:1 177:25 180:14 specifically 23:4,13 36:1 59:19 159:6 161:12 specified 36:5 spend 33:8 spends 187:8 spent 24:12 25:1 27:23 28:3,23 29:15 32:25 33:14 33:18 35:2 47:7 59:23 spite 120:8 123:23 125:9 132:2 spleen 188:22 spoken 175:25 sponsor 47:1 96:5 sponsored 43:5,22 spontaneous 129:19 spot 65:2 66:13 SPSS 88:1 stand 181:8 standard 130:2 standards 134:25 staple 45:1 stapling 45:2 start 7:15,16 25:13 131:12 147:3 176:5 190:15 started 25:19 starting 63:9,12	starts 63:10 108:5 126:11 131:4 172:6 state 12:15 91:3 92:19,25 93:2,7 93:10,18 103:16 111:5,7 122:6 193:5 stated 104:24 114:9 176:24 statement 177:9 States 1:1 5:14 statistical 32:7 81:24 120:3 121:19 123:22 125:12,18 128:7 130:14 133:8,15 133:17 134:10,25 136:5,10 144:13 159:21 163:20,22 163:23 164:2,2 169:5 173:6,13,17 174:11 175:3 176:13,18 177:13 184:22 statistically 166:20 176:4 182:23 statistician 54:23 86:13 87:12 93:2 103:21 123:12 124:11,19 125:19 132:25 134:5,7 144:12 151:1 157:15 175:4 176:1 177:17 statisticians 96:22 97:3 98:10,16 99:24 157:9 statistics 83:14 87:23 143:8	stood 100:17 stop 165:5 Stout 43:25 46:11 56:8 strain 120:10,18,20 strains 124:2 Street 1:12 2:15 strict 168:21 strike 10:3 131:11 strong 173:13 structure 97:7,13 97:22 student 81:22 88:19 96:16 100:22 students 96:22 178:18 studied 120:22 studies 3:21 15:2,5 15:8 19:17 37:25 38:5,10,18,21 39:14 40:9 43:3,4 43:8,10,11,17,19 43:20 44:1,7,19 44:21 46:5 47:12 50:5,16 52:3 58:17,18 81:6 103:14 104:18	studies' 119:1 study 29:23,24 30:6 31:8 38:24 39:18 43:13,14,14,25,25 45:24 46:2,10,11 46:16,22 47:2 49:10,21 51:10,13 53:5 54:7,21 55:14,18 56:8 57:16 58:17 59:12 59:13 68:21 70:18 72:15,16 74:13 76:4,18,25 77:2,9 77:17,21 78:6,18 103:9,10,19,25 104:2,5,9,12,16 105:12,17 115:6 117:16,21 118:5 125:17 128:3 129:11,21 130:7 132:19 135:3 139:12 142:7,14 143:18 144:19 145:24 156:1	sum 147:18 summaries 39:10 summarized 51:13 64:7 146:8,10 summarizes 49:8 51:10 69:14 summary 38:1 51:22 52:6,8 53:1 53:2 54:6,21 55:8 118:12,14 139:6 146:11 163:3,18 163:24 summation 36:23 supplement 13:2,8 13:22,25 16:3,20 24:19 25:3,11 39:23 43:7 47:14 47:20 49:13,25 51:23 54:25 55:4 55:10 60:3 61:5 76:10 77:12 151:12,24 152:1 154:16 155:7 157:22,24 supplemental 14:4 16:14 24:13 35:3 59:24 76:19

supplementation 84:2	T 2:13 194:1	182:5 190:11	Terrific 8:14	132:25 135:12
supplements 13:17 14:2,11,24,25 15:9 24:22 50:4 50:14 51:25 52:9 55:15 163:25	table 45:15 46:10 46:13,25 68:18 69:19,21,22 70:13 74:9 115:5 136:9 180:13,25 181:5 182:3,19,19 183:9 183:12 184:4 185:12,13,14,22 186:15,20,23 187:15 189:19 190:5,8,10,11	talking 14:5,7,11 14:25 30:14 45:12 52:20 60:14,20,22 74:18,21 78:18 80:8 89:2 94:15 105:25 118:22 119:4 120:18 137:1 139:8,8 144:11 145:16,18 158:18 161:2,11 165:16 166:16	test 19:16 30:9 31:18 64:25 115:19 127:9,11 127:25 128:4 130:13 135:24 142:9 146:6,18 160:23 174:18 176:3,13,18 177:25	179:18,21 things 7:6 10:16 20:21 52:5 77:25 88:4,5 110:21 111:15 112:13 124:5,9,12,18,20 125:8,20 128:25 133:16 176:7 178:14,17
support 4:1 93:5,5 95:25 152:17	tables 12:16 13:9 13:12,13,24 15:1 15:5,8 16:2 49:15 49:16 50:2 51:25 52:10,13,16 55:12 55:21,22 125:15 145:8 146:8,20 151:12 153:7,17 155:3 163:21,24 164:4,4	talks 65:25 tallies 183:5 tape 8:4,4 task 16:1 67:20,23 138:2 tasked 29:20 team 188:17 technical 176:3 technology 85:15 teleconference 23:12 Telephone 2:10 80:24 tell 6:8,22 8:10 12:9 16:4 24:11 24:14 63:8 73:13 94:16 102:24 108:5 114:1,3 121:14 136:3,19 138:15 146:14 163:8 177:19 178:20,22 180:24	tested 127:12 128:4 testified 113:16 114:5 116:21,25 179:15 181:22 188:5 testify 182:1 190:23 192:5 testifying 137:9,11 137:14 testimony 48:16 50:23 71:18 109:3 116:22 126:18,22 151:18 162:15 181:1,19 192:8 testing 61:12,19 62:15 65:6,14,19 66:2 tests 96:13 137:25 138:6 145:15 156:11,14 158:21 167:21 178:4 183:17 184:9 Texas 1:16 192:21 text 112:3 textbooks 149:25 150:2 thank 8:13 12:3 27:7 114:13 163:14 191:6 Thanks 20:1 21:10 21:19 22:14 45:9 75:19 126:3 152:19 191:7 thesis 89:24 thing 7:13 8:15 71:24 91:10 124:17 129:17	think 10:10 18:17 18:22 20:12 21:5 21:6 22:3,16 24:14 26:7 27:19 33:4,19,23 39:12 40:6 47:15 50:1 59:8,25 60:1 64:18 69:12,12 70:9 74:17,20 75:1 77:23 86:9 86:10 94:19,21 97:1 98:2,19,20 100:6,14,16,20,20 101:22 104:22 106:16,21 108:19 113:2 114:21 115:15 117:8 120:25 122:18,21 129:10 133:20 134:17 154:9,25 154:25 155:1,10 156:21 159:7,17 161:25 162:1,4 163:2 165:9 169:24 170:12 174:1 176:23 179:17 181:7 186:21,21 188:4 190:2 thinking 124:24 third 136:11 thirty 193:15 thought 86:23 87:6 139:21 152:10 thousand 14:21 76:7 78:3
supported 94:14 supporting 106:17 suppose 80:10 167:12,13,14 supposed 22:17 93:14 110:11 sure 7:23 11:2 12:11 18:23 19:8 21:20 25:15 39:12 45:10 50:7,22 56:22 57:19 58:7 63:25 64:1,9 66:24 67:15 71:16 71:17 79:20 81:17 89:17,20 90:15 91:19 92:1,6,8,13 106:14 110:2,20 114:7 126:4 136:12 137:13 148:9 152:20 160:5,19 162:2,16 163:9 164:23 165:7,23 166:25 167:2 168:20 174:25 176:17 181:18 190:17 Suresh 77:17,21 78:18 128:5 129:3 129:11 132:18 141:9 142:19 swear 5:18 sworn 6:7 192:5 195:18 systematic 154:4,7 154:13,18 156:22 systemic 189:5	taken 35:20,24 114:6 138:19 192:8 talk 6:20 61:18 62:14,15 64:10 78:25 98:15 117:18 118:2 134:12 159:3,6 talked 20:9 65:23 67:24 74:23 113:20 114:17 145:10 146:20 161:14 179:24 180:1 181:22	terms 31:17 79:19 79:21 108:21 121:11 132:4 166:15	thing 7:13 8:15 71:24 91:10 124:17 129:17	
T				

thousands 14:3 15:21 125:2 165:16 166:5 168:19 176:11	133:22 152:25 160:11 170:3 178:3 179:16,24 181:1,22 182:5	track 120:25 training 31:19 32:11 149:13 151:2	115:22 120:12 132:7,15,19 137:23 138:7 141:8 143:3,25	typo 188:23 typos 189:1
three 23:8 25:24 26:16 28:7 33:11 46:25 47:12 75:12 121:5 128:12 142:12 143:18,25 155:25,25 173:15	told 11:18 29:19 43:24 76:12 108:2 130:15	transcribed 13:10 transcribing 25:2 transcript 192:8 193:16,17	144:22 147:11,14 150:19,21,24 153:6 154:1,8 156:1 162:10 167:24 177:22,24 182:20 187:10 189:5	U
threshold 166:18 threw 22:11 throwing 168:21 till 37:1	tomographers 157:9	transcription 195:7 treating 51:1 135:5 treatment 78:5 115:10,13 118:1 130:21	tumors 70:22 71:1 71:3,7,25 74:12 74:18,24 75:11,13 78:3 116:9 129:8 129:19 144:3 150:14,17 151:7,9 151:10,16,23 152:4 153:9,15,19 154:5,13,18 155:6 155:24 156:23 157:23 158:5,19 184:17,24	Uh-huh 12:14 15:6 23:9 25:23 26:18 45:17 46:1,4,15 52:22 57:11,14 61:6,7 63:9 66:7,9 80:1 101:3 106:4 117:20,23 118:4 118:17 127:6 129:5 130:20 134:21 154:3 165:1 174:8 175:17 177:6 181:17 187:5
time 5:7 8:3 10:25 18:18 23:2 24:11 24:18,25 25:12 27:20,22 28:2,4 28:22,23 29:15,19 30:1 31:5 32:3,24 33:14 35:1,10 47:8 69:10 71:4 73:15 74:7 75:17 75:21,24 78:24 95:15 97:1 98:5 110:12 113:5 120:17 121:2 135:10 141:18,21 148:11,14 161:7 161:23 162:4,18 170:14 187:8 191:9 192:9	tomorrow 35:11 108:2	treatments 173:16 174:10	150:14,17 151:7,9 151:10,16,23 152:4 153:9,15,19 154:5,13,18 155:6 155:24 156:23 157:23 158:5,19 184:17,24	uncertainty 173:9 underlie 34:25 underlying 31:24 39:5 43:3 47:11 51:12 54:20 55:18 56:7 57:16,24 58:25 68:11 120:12
times 27:14,18 28:19 42:20 54:12 84:4 119:21 120:6 124:1 125:7 159:16 170:2	tools 83:14 88:2,10 99:4 135:8 159:21	trees 16:7,7 trend 19:16 30:9 31:17 115:19 138:6 145:15 146:6,18 160:23 174:18 177:25 183:16	turned 81:1 turns 115:17 two 9:22 10:9 19:9 20:8 35:12 52:5 65:22 70:17 79:17 120:20 121:3,5 129:7 142:18 143:18 144:2 147:6 173:12 186:4	understand 7:2 30:2 31:4 34:20 42:16 50:23 53:10 57:19 58:13 64:1 64:10,21,22 68:10 71:17 85:3 89:17 110:4 116:13 117:25 120:15 121:24 136:18,23 136:24 137:6 143:2,4 146:14 149:6 153:18,21 153:23 156:20 162:16,25 164:20 177:1 189:4,18 190:4
timing 110:15 titled 91:2 titles 101:9 today 7:1 9:9,18 35:10 41:20 47:23 50:4,13 69:11 73:3,8 76:17 77:7 89:11 102:23 104:14 110:17 111:3 131:14	total 105:3 137:21 156:10 183:10,14 183:15 184:1 187:25	true 28:17 77:19 102:3 159:12 164:16,24 165:25 174:22 178:1	turn 9:21 12:4 69:7 81:2 126:8,25	understand 7:2 30:2 31:4 34:20 42:16 50:23 53:10 57:19 58:13 64:1 64:10,21,22 68:10 71:17 85:3 89:17 110:4 116:13 117:25 120:15 121:24 136:18,23 136:24 137:6 143:2,4 146:14 149:6 153:18,21 153:23 156:20 162:16,25 164:20 177:1 189:4,18 190:4
	totalled 189:15 totality 150:5,9 190:13,21	truth 6:8,8,9 35:24 131:25 132:2 192:6,6,6	turned 81:1 turns 115:17 two 9:22 10:9 19:9 20:8 35:12 52:5 65:22 70:17 79:17 120:20 121:3,5 129:7 142:18 143:18 144:2 147:6 173:12 186:4	understanding 41:13,17 42:3,24 43:12 150:24 188:24
	totally 79:20 totals 58:8 toxicity 173:23 174:15	try 7:17 33:3 85:14 91:4 108:16 120:8 125:5,10 132:13 149:15 175:5	typo 23:13 24:8 78:8,19 131:16 132:21 133:4,23 144:20 147:11	undue 115:24 unique 119:1
	toxicologist 123:15 159:3	trying 15:22 31:4 128:19 129:20 131:20,24 136:18 136:23 137:6 138:13 143:1 162:6,19 164:10 168:8	types 12:17 16:25 23:8 61:21 68:17 75:12 123:13 137:23 138:7 147:14 167:24 177:24 187:10	
	toxicologists 155:17	tumor 3:19 12:17 16:25 61:21 68:17 69:17 71:9 75:12 77:20 78:8,19	typical 30:24 typically 55:17	
	toxicology 3:21 19:17 29:22 45:6 80:13,17 81:5 123:11,21 125:3 174:24			

unit 142:16	93:10,18 103:16	videographer 5:1,4	144:7 149:20	74:6 76:13 105:6
United 1:1 5:13	111:5,7 122:6	8:2 75:20,23	151:23 152:5	weren't 43:23
universities 105:15	utility 80:21 87:25	141:17,20 148:10	154:15 160:24	133:10 162:5,19
university 11:21		148:13 191:8	162:23 164:13,14	162:22,22
91:3 92:20,25	V	videotaped 1:10	175:6,9 190:3	When's 161:23
93:7,11,13,14,22	V 2:19	3:13	ways 143:19 184:14	whichever 158:19
93:23 96:23,25	Vague 37:19 38:4	violated 121:19	186:8 187:21,24	widely 88:8
103:16 108:15,24	38:20	violation 125:18	189:15	wider 88:3
109:11,23 110:12	value 30:9 63:16	virus 68:22	we'll 8:11 9:9,9	Wilshire 2:9
110:17 111:4,8	64:19 115:20	volume 24:22	45:3 62:2 80:20	winding 178:24
178:17	116:15 143:11	25:10	95:9 101:23	Wisner 2:8 6:2,3
update 83:23 86:7	153:10 164:13	W	we're 8:16 12:9	Wite-Out 50:1
108:12,18,21	166:17,19 167:6	wait 16:10 21:24	30:14 50:7 52:20	witness 5:18 14:10
109:19,23 110:7	values 63:18	22:7 95:10 110:13	60:22 70:23 71:3	19:6 21:1,10 24:6
110:11,24	115:15 138:1	walked 116:2	71:23 72:2 74:18	28:15 35:23 37:20
updated 79:13	139:13,15 145:14	want 8:10,15 9:17	74:21 75:20 77:22	38:6,22 41:25
85:22 110:3,21	146:18 165:17	16:6 18:25 34:10	80:8,19 110:2	42:21 44:15 48:17
111:3	166:3,7,16,22	39:4 50:9,10,12	137:25 141:17,20	51:20 56:12 58:6
updating 79:18	167:6,13,15,23	50:22 53:11 54:5	145:16,18 148:10	59:20 65:5 66:16
111:15	168:1,19 182:22	54:16,20 58:3	148:18 156:11,14	66:25 67:5 74:5
upper 115:10	183:1,6,22 184:13	63:25 65:1 66:23	161:2,10 167:13	75:18 81:3 109:5
uptick 175:11	184:20 185:4	67:1,22 71:16,17	167:23,24 172:24	109:16 111:14
use 12:24 13:6	186:7,10 187:24	89:7 91:18 93:20	we've 45:12 66:11	113:1 114:15
16:21 30:25 45:3	variability 124:3	95:14 106:12	112:12,17,18	119:12 126:9
50:18 55:5 60:9	143:24	120:14 126:14,23	Weber 66:8,10,19	139:3 141:22
69:14 70:19 71:13	variation 173:10	131:7 133:12,19	67:1,6,10,14 68:8	144:7 147:2
80:20 82:17 83:14	variations 120:11	134:16 150:25	68:11,21,24 69:2	151:19 157:1
88:9 98:7,17,22	various 40:9 41:15	159:2 163:7 167:1	69:15,23 70:2,24	163:16 171:1
99:14 112:1 114:2	135:4 148:22	168:20 173:5	71:14 72:4,6,11	174:1 180:4
121:20 123:3,3	vary 144:22,22	177:4 178:13	72:15,20,22,25	182:10 191:7
124:22 128:12	varying 89:25,25	181:18 190:17	73:3,17 74:13,25	193:1
132:1,14 134:13	venture 89:7	wanted 34:7,24	75:6,6,9	wonder 175:12
143:15 156:9	venues 172:9	35:7 74:23 171:4	website 99:13	wondering 38:23
158:20 161:16	verbatim 192:8	171:6 181:14	100:7	83:2
174:20 189:11	verify 44:5	wants 93:23	WEDNESDAY 1:7	Wood 142:19
useful 12:8 80:13	versa 7:16	Washington 2:16	weeks 10:10 20:8	word 38:21 73:23
82:15	version 81:11,13	wasn't 86:11 90:12	161:25	124:22 131:24
user 81:11,16 82:2	82:19,20,22 83:3	waste 78:24	weighed 75:14	words 11:23 17:12
97:23 99:21	84:3 99:4	water 131:16	weight 142:18	71:5 88:4 97:2
users 88:3 98:21	versions 83:11,16	132:21 133:5,23	148:25 155:5	104:14 114:2
100:5	83:19 85:22	way 9:10 15:18	WEITZ 2:2	123:7 128:16
uses 99:10 168:23	versus 76:19 97:9	16:7 28:2,2 37:5	welcome 181:14	130:1 137:22
169:6,15	168:11 175:10	72:24 83:12 88:19	well-accepted	139:23 142:21
usually 96:23,25	183:2 184:4	91:12 109:9	143:20 149:14	144:20 156:4,15
108:21	vice 7:15	114:21 115:1,8,14	well-understood	157:20 161:3,9
Utah 1:13 91:3	video 5:8	131:15 137:8	124:13	164:1 168:6
92:19,25 93:2,7			went 7:25 14:15	183:11,13,19,22

184:2 185:3 186:8 187:6,17 work 11:25 17:17 17:21,25 18:1 20:24 23:23 24:23 25:10 36:2,21,23 37:6 39:15 41:13 41:21 42:16 48:7 51:11,12,12 58:15 81:15 82:1,8 85:18,21,24 87:17 88:13 92:24 93:1 93:10,13,18 94:4 94:15 95:14,25 97:4 99:25 107:19 108:22 110:10,18 111:8 170:17 179:3 worked 34:2 35:10 35:11,12 36:25 81:20 88:18 157:4 working 17:4 22:20 25:13 32:7 33:17 36:19 40:11,13 41:18 48:12 51:7 82:9 85:8 works 51:10 83:13 110:5 worth 167:18 wouldn't 27:17 34:15 44:5 48:10 70:14 89:7 103:20 150:20 154:24 157:2 159:15 160:20 181:2 Wow 73:8 190:16 write 32:15 82:2 86:11 writing 25:9,14,20 29:7 32:19 86:2 143:4 writings 170:16 written 26:3 149:25 wrong 22:17 26:3 94:3 136:9 172:21 wrote 73:15 182:4	<hr/> X <hr/> X 175:14 X-a-c-t 81:10 <hr/> Y <hr/> yeah 12:2 14:14 19:3 20:12,14 21:5,25 22:10,22 26:10 27:12 30:16 47:3 52:14 55:19 56:21 57:23 58:1 63:23 64:17 66:24 74:22 77:14 79:15 81:13 82:7 84:1,4 84:10,12 85:2,6 85:11 86:9 89:19 90:1 91:14 95:3 96:11 105:4,25 106:9 107:9 112:12 118:16 120:2 122:7 131:6 136:22 141:22 142:1 143:7 144:11 145:7,12 150:9 153:23 165:23 169:13 171:10 176:2 178:19 181:11 186:21 189:2,23 190:25 year 18:18,25 19:3 26:17 33:17 60:5 83:4 88:22 89:13 90:4,6,8 92:1 110:1 121:6 years 31:20 32:5 54:24 90:7 92:5 118:24 121:23 150:2 157:5 Yep 91:21 yesterday 35:12 York 2:5,5 6:21 <hr/> Z <hr/> zero 130:11 132:17 <hr/> 0 <hr/>	05 63:19 166:8,18 166:19,23 167:9 167:16 168:1 182:23 183:1,6,17 183:25 084-004229 192:21 <hr/> 1 <hr/> 1 12:16 21:18 38:8 45:24 57:4,6 79:8 107:7 108:8 111:24,24 123:4 142:20 1,016 12:18 13:7 16:13 17:3 74:14 74:22 75:1,11 1,067,869 106:25 1.0 82:22 1:24 191:9,10 10 22:2 46:16 64:17 182:8 10,000 89:2 10:24 75:21,22 10:43 75:24 10003 2:5 1016 16:18 107,250 37:2 11 65:7 69:13 75:4 11:51 141:18,19,21 11:58 148:11,12 112 17:13 30:13 32:1 12 12:18 15:2,4 37:24 38:18 39:7 39:13 43:4,10,19 44:19,20 50:5,16 52:3 65:7 122:25 137:21 138:7 159:25 160:6,9 172:16 178:2 181:8,10,14 12:37 148:15 12100 2:9 125 3:24 12th 25:25 26:17 13 65:8 1350 2:15	13921 192:19 14 140:11,11,14 162:11 15 63:10 64:16 134:19,22 180:13 180:25 181:5 182:3,19,19 184:4 185:12,13,14,22 186:15,20 189:19 190:5,8,11 152 4:1 16 21:17 100:25 16-MD-02741 5:13 16-md-02741-VC 1:5 1665 1:12 1715 192:22 18 140:15,16 141:2 180 3:6,7 19 3:14 126:24,25 130:23,24 131:2 186:2 190 163:17 192 4:5 194 4:6 195 4:7 196 4:8 1981 45:25 1983 46:19 1990 46:3 1st 110:7,8 <hr/> 2 <hr/> 2 3:3 12:16 46:2 105:24 153:2,5 172:22 186:25 20 1:7 5:8 21:16,24 22:4,10,12,21 31:19 54:24 126:24 127:1 130:24,24 131:2 157:5 192:23 195:19 20.9 183:7 185:7 186:12 187:22 189:10 20005 2:16	2001 126:11 2009 83:4,5 2016 18:21 19:2,24 20:13 21:18 31:6 89:13 107:8,14 2017 1:7 5:9 21:17 21:18,24 22:2,2,4 22:11,12,12,21 79:11 114:6 192:23 202 2:16 2021 107:8 207-3233 2:10 20th 22:2,7,18 21 3:15,16,17 22:12 142:15 163:14 21-1 3:11 8:21,25 9:3 32:12 56:21 79:7 101:2 154:12 21-10 4:1 152:12,16 21-2 3:12 9:13,17 9:22 11:11 21-3 3:14 19:19,23 20:17 40:21 21-4 3:15 21:12,16 24:10 28:8 29:9 33:12 35:1 21-5 3:16 21:12,25 21:25 22:1 26:2,6 26:15 27:3 21-6 3:17 21:13 22:6,13 25:22 26:2 33:12 35:1 21-7 3:18 44:22 45:4 21-8 3:22 90:22,25 96:10 21-9 3:24 125:22 126:1 212 2:6 23-4 21:23 25 31:20 104:25 105:5,22 27 94:19 95:2 106:7 106:9 2741 1:3 5:12 28 63:13 79:8
--	---	---	--	--

118:19 141:3 146:6 147:18 29 79:11 123:4 124:23 141:3 29th 79:15	<hr/> 5 <hr/> 5 24:10 28:8 57:4,6 57:7 61:18 62:6 64:10 65:9 79:23 81:8 86:18 100:25 111:24 114:6 139:19 50 132:16 185:9 186:2 50,000 89:3 558-5547 2:6 5A 65:10 5B 65:15 140:1 5C 65:19 134:20 5th 2:5 26:5	90 3:22 90025 2:9 90s 81:22 100:22 917.591.5672 1:20 9328 192:21 935 81:12 950 2:9		
<hr/> 3 <hr/> 3 57:7 69:13 141:3 171:19 172:25 174:7 30 183:6 186:1 187:18 193:15 30-year 135:8 31 19:24 107:8 141:11 142:3 172:7 310 2:10 31st 20:6 107:16 32 172:4 33 12:12 126:8 127:4 132:10 135:22 140:9,21 141:5 34 12:13 345 75:12 37 94:17 182:14,15 39 57:9,18 58:24	<hr/> 6 <hr/> 6 3:5 24:10 28:8 61:17,18 62:6,8 62:11,13,13,17,19 64:10 111:24 66 66:5 6th 25:25 26:6,6,16			
<hr/> 4 <hr/> 4 62:10 79:23 139:17 172:2 418 183:15,20 184:10 185:7 186:12 187:23 189:10 419 156:2 158:19 44 3:18 450 158:18 450-plus 155:23 46 63:24 64:3 145:17 47 56:25 63:22,24 64:3 145:17 48 77:20 129:3 130:11 132:19 141:8 143:3 144:4 4th 27:2,5,8	<hr/> 7 <hr/> 7 38:3,18 39:9 163:13 700 2:5			
	<hr/> 8 <hr/> 8 3:11 81:13 82:20 83:3 147:3,3 8.0 81:11 80s 82:24 83:2 81 153:6 859 192:20 877.370.3377 1:20 895 81:11 898-5800 2:16 8th 25:25 26:16			
	<hr/> 9 <hr/> 9 3:12 12:4 38:3,19 39:9 63:4 64:15 64:17 74:14,20 146:6 147:17 9:13 1:13 5:9			

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP PRODUCTS
LIABILITY LITIGATION

Case No. 16-md-02741-VC

MDL No. 2741

This document relates to:

ALL ACTIONS

EXPERT REPORT OF DR. CHRISTOPHER D. CORCORAN, Sc.D.



1 **EVALUATION OF GLYPHOSATE EXPOSURE AND CANCER RISK IN RATS AND MICE**

2 **Dr. Chris Corcoran**
3 **Department of Mathematics and Statistics**
4 **Utah State University, Logan, UT**
5

6 **I. SUMMARY**

7 This report examines the rodent studies of glyphosate and cancer risk, particularly the seven feeding
8 experiments using rats and five using mice that were reviewed in the expert report prepared by Dr. Chris
9 Portier. The overarching question is whether these animal experiments provide a scientific basis to opine
10 that glyphosate causes cancer in rats and mice. A few critical characteristics of these studies require
11 careful consideration in addressing this question. Most crucially, the hundreds of individual tumor types
12 evaluated within each experiment across both male and female rodents make it virtually certain that
13 apparent “statistically significant” results will be observed for individual tumors that are in fact due to
14 nothing more than chance. This necessitates the use of common statistical methods that account for
15 multiple tests applied repeatedly to the same data. In addition, most of the tumor types are relatively
16 uncommon, which warrants additional prudence in choosing appropriate statistical methods. In this
17 report, I outline these issues, discussing in Section III how they are managed in everyday statistical
18 practice. In Section IV, I apply the appropriate methods to the glyphosate rodent data and find no
19 evidence whatsoever of a glyphosate effect on the risk any of the tumors evaluated across these studies
20 after accounting for multiple tests. In Section V, I consider the discussion and results in Sections III and
21 IV in the context of Dr. Portier’s expert report. Dr. Portier suggests that the glyphosate experiments do
22 provide some evidence of tumor risk among rodents. However, his statistical approaches are deeply
23 flawed, leading him to overstate his findings and seriously misrepresent the data in aggregate. These
24 flaws would prove fatal in any peer review. Most significantly, the results from the animal experiments
25 that were highlighted by Dr. Portier were handpicked because of their “statistical significance”, without
26 appropriately accounting for the large number of tests for other tumors that demonstrated no evidence of a
27 glyphosate effect. In addition, Dr. Portier violated conventional statistical practice in his use of historical
28 controls and in combining or “pooling” data from across several sources – using experiments carried out
29 during different years and in different laboratories under different conditions – without appropriately
30 accounting for these studies’ unique characteristics. In Section V we illustrate these flaws and their
31 impact on Dr. Portier’s conclusions.

32
33 **II. RESUME AND QUALIFICATIONS**

34 I am a professor of Statistics, and head of the Department of Mathematics and Statistics at Utah State
35 University (USU) in Logan, Utah. I joined the faculty as an Assistant Professor at USU in 1999, after

1 receiving a B.S. in Statistics from USU in 1995 and a doctorate in Biostatistics from Harvard University
2 in 1999. I was tenured and promoted to the rank of Associate Professor in 2005, and then promoted to the
3 rank of Professor in 2011.

4 My research interests as a biostatistician focus largely on statistical methods for categorical data
5 analysis, including the analysis of proportions and counts. My dissertation and much of my subsequent
6 work has focused particularly on so-called exact methods for categorical data, developing software tools
7 for researchers that allow them to analyze proportions and counts using exact tests for previously
8 unaddressed study designs, including settings in which data are clustered or correlated (e.g., gestational or
9 developmental toxicology studies using rats or mice), or for large-scale studies of genetics and disease.
10 Much of this work has been funded by the National Institutes of Health, and implemented in the software
11 packages StatXact and LogXact through Cytel Software Corporation (Cambridge, MA). These packages
12 have long been considered the industry standard for exact statistical analysis.

13 I have also served as a senior biostatistician for a number of large interdisciplinary research projects
14 focused on the epidemiology and genetic causes of complex disease, including Alzheimer's disease,
15 cognitive decline among the elderly, hip fracture, autism, birth defects, and cancer. I have advised
16 collaborators about study design, data management, and data analyses and the appropriate application of
17 statistical methods, and I have either led or assisted with numerous manuscripts and presentations to
18 disseminate research results. This work has likewise largely been funded by the NIH. In all, the collective
19 extramural funding for these efforts has exceeded \$25 million.

20 I have been asked examine data from the rodent glyphosate feeding experiments, and to assess any
21 evidence of potential compound-related effects on the incidence of mouse and rat tumors, and have been
22 compensated for this work at a rate of \$250/hour. Unless otherwise stated, all of my opinions are
23 expressed to a reasonable degree of scientific certainty. I reserve the right to amend or supplement my
24 report in response to any rebuttal by plaintiffs' experts or as new information becomes available. I have
25 not testified as an expert witness over the past 4 years. My curriculum vita is included as an attachment to
26 this report.

27 28 **III. STATISTICAL BACKGROUND**

29 The fields of health and medicine abound with questions that likewise often appear straightforward: What
30 is the best diet for a healthy heart? Are men or women at higher risk for a particular disease? Does a new
31 drug lengthen life for cancer patients? In collaboration with other scientists, a biostatistician's role is to
32 design experiments that address these questions, and to contribute to the analysis of the resulting
33 experimental outcomes or data. Proper statistical methodology has assumed an increasingly important
34 role in health and medicine as research has become more evidence-based. This is largely because (1) data

1 are generally full of uncertainty and variation, particularly when we study complex diseases or other
2 phenomena in humans or animals; (2) many questions in health and medicine have strong statistical
3 overtones (e.g., How common is a disease? Who is most likely to contract it?); and (3) the comparison of
4 different treatments or potential risks relies heavily on statistical concepts – especially probability – in
5 both designing and analyzing experiments.

6 As an example, suppose we pose the simple question: Does a flu vaccine work? This could be
7 answered in part by considering a study of people who are randomly assigned to two groups, one
8 receiving the treatment and the other some sort of placebo. At the study's end, the flu rates between the
9 groups would be compared to assess whether the treated subjects experienced less flu than those on
10 placebo. To continue the illustration, suppose such a study was designed with 20 patients in treatment and
11 20 in control (i.e., given placebo). Suppose further that we subsequently observe 0 flu cases (a 0% flu
12 rate) among those who are treated and 20 cases (a 100% flu rate) among controls. With such a dramatic
13 difference between the respective flu rates, common sense and intuition would strongly suggest that the
14 treatment prevents flu.

15 On the other hand, suppose that this experiment alternatively results in 5 flu cases within the
16 treatment group versus 10 in control (25% flu rate for treatment versus 50% for control). While the
17 observed flu rate in this scenario is likewise lower within the treatment group, we are clearly *less* certain
18 about declaring that the treatment works more generally. Why? Because it is more difficult to discern
19 whether this result demonstrates an advantage for treatment, or if it could be simply due to chance
20 variation between the people participating in the study. In other words, assuming that the vaccine does not
21 work at all, we would expect that the observed flu rates within the two groups would differ by chance,
22 much as we would expect that the number of heads we observe with 20 flips of a coin would be different
23 than the number we observe if we flipped the same coin an additional 20 times.

24 How can we quantify the possibility that an experimental result is due simply to chance? The role of
25 probability and statistics is especially critical in providing insight into this question. Common scientific
26 and statistical practice involves designing an experiment with two competing hypotheses in mind. For a
27 study comparing different treatments or groups, the primary hypothesis – generally referred to as the *null*
28 *hypothesis* – is that there is *no difference* between the groups. The competing or *alternative hypothesis* is
29 that there is a difference between the groups. At the end of the experiment, a probability is computed that
30 measures the evidence against the null hypothesis. This probability, called a *p-value*, represents the
31 likelihood of having observed the experimental result or data given that the null hypothesis is true. A
32 relatively smaller p-value therefore indicates that there is evidence *against* the null hypothesis, since it
33 tells us that the data are unlikely, assuming that the null is correct. On the other hand, a relatively larger p-

1 value provides no evidence against the null. The process of determining hypotheses and computing and
2 interpreting a p-value based on resulting data is called a *hypothesis test*.

3 Two generally crucial issues with regard to testing a given hypothesis are (1) how the p-value is
4 computed, and (2) how the p-value is used to make a decision about the null hypothesis. With regard to
5 (1), even for relatively straightforward experiments, such as our hypothetical flu vaccine trial, there may
6 be multiple approaches available for computing a p-value, each of which has certain advantages or
7 disadvantages – these characteristics often depend on a specific study setting, and a biostatistician’s role
8 is to evaluate the strengths and weaknesses of competing methods for any given experiment to ensure that
9 the data analysis is as accurate and reliable as possible. With regard to (2), the primary question is: How
10 small does a p-value need to be in order to determine that there is sufficient evidence against a null
11 hypothesis? A decision rule generally provides a cutoff against which the p-value is compared. For a
12 single hypothesis test, the scientific community over time has settled on a threshold of 5%, meaning that a
13 p-value less than 5% indicates sufficient evidence against the null, whereas a p-value greater than 5%
14 provides insufficient evidence. This threshold is called a *significance level*, and p-values below this level
15 are referred to as “statistically significant”. Another important role of a biostatistician is to ensure for any
16 given data analysis that the significance level is preserved. Any violation or inflation of the significance
17 level can result in greater likelihood of spurious conclusions, especially in declaring “significant”
18 treatment effects based on experimental results that are only due to chance.

19 **IV.A *Interpreting p-values in the presence of many hypothesis tests***

20 The “p-value < 0.05” decision rule is relatively straightforward for a single experiment. However, the
21 role of the p-value has become more complicated in today’s data-driven world. The fathomless ocean of
22 available data – generated from billions of dollars spent annually on research in health and medicine, and
23 from the sheer volume of electronic transactions and online activity, among other sources – along with the
24 relative ease of computing software for generating statistical analyses, necessitate some additional
25 prudence in interpreting p-values. Nearly every day, online or other media news sources tout claims about
26 an association between an exposure and an outcome, often with some implication of dramatic or broad
27 consequences for the public. Many of these results often do not hold up under additional scrutiny or
28 attempts at replication. How do these kinds of findings so readily find their way into the scientific
29 literature and popular press? Explanations may sometimes include inadequate study design or poor data,
30 but in our “big data” era the culprit is most often the amount of data available from large studies, or from
31 a large number of smaller studies that are examined simultaneously. The tendency of researchers, along
32 with scientific journals and other media venues, is a bias toward “positive” findings. This has led in turn
33 to an overreliance on p-values and statistical significance, at the frequent expense of context, especially in
34 underreporting or ignoring the large number of additional tests performed resulting in “negative” findings.

1 This issue is relatively straightforward to illustrate, given the application of hypothesis tests and p-
2 values just described. Researchers can easily draw incorrect conclusions from an analysis of a large data
3 set when many associations are examined across a large number of hypothesis tests that each look for a p-
4 value that is less than the conventional 5% significance level. Simply put, when multiple tests are
5 performed, “p-value < 0.05” outcomes will occur quite often even when there are no real effects. Note
6 that the p-value < 0.05 rule was developed relative to a single test. However, this logic breaks down when
7 multiple comparisons or tests are performed within a single analysis. With a 1-in-20 chance of a false
8 positive for a single test, we would expect to see about one false positive for every 20 tests that we
9 compute. In fact, it is straightforward to show using basic probability that there is a 64% chance of at least
10 one false positive among 20 independent tests, and a 99.4% chance of at least one false positive among
11 100 tests.

12 This so-called multiple testing issue and the general overreliance on p-values has been discussed and
13 studied extensively within the statistics and epidemiology professions. These issues have likewise been
14 paid some considerable attention over the past several years in the popular media, especially given the
15 many highly publicized findings that create an initial sensation but then fail to hold up under additional
16 study and experimentation. (As just a small sampling of this coverage, within the scientific literature see
17 “Why Most Published Research Findings Are False” by JPA Ioannidis in *PLoS One*, “Statistical Errors: *P*
18 values, the ‘gold standard’ of statistical validity, are not as reliable as many scientists assume” by R
19 Nuzzo in *Nature*, and “Evolution of Reporting *P* Values in the Biomedical Literature, 1990-2015” by D
20 Chavalarais, JD Wallach, AHT Li, and JPA Ioannidis in *JAMA*. In the popular press see “Trouble at the
21 lab”, “How science goes wrong”, and “Metaphysicians” in the *Economist*; “Science Isn’t Broken: It’s just
22 a hell of a lot harder than we give it credit for” at *538.com*; “Striking results, little reliability” in the *Los*
23 *Angeles Times*; and “New Truths Only One Can See” in the *New York Times*.)

24 Statisticians have long warned against the practice of computing a multitude of p-values – especially
25 when applying arbitrary criteria to examine the same data in various ways – in order to identify positive
26 associations. More recently, in response to this growing problem and the attention paid to it, our largest
27 and oldest professional organization, the American Statistical Association (ASA), took the unusual step in
28 2015 of producing “The ASA’s Statement on p-Values: Context, Process, and Purpose” (*The American*
29 *Statistician*), under the direction of a committee comprised of some of our most respected colleagues.
30 Several underlying principles regarding p-values are briefly emphasized in the document. In particular,
31 the committee crystallizes the ongoing issues with multiple testing by noting that

32 *P-values and related analyses should not be reported selectively. Conducting multiple analyses of*
33 *the data and reporting only those with certain p-values (typically those passing a significance*
34 *threshold) renders the reported p-values essentially uninterpretable. Cherry-picking promising*

1 *findings, also known by such terms as data dredging, significance chasing, significance questing,*
2 *selective inference, and “p-hacking,” leads to a spurious excess of statistically significant results*
3 *in the published literature and should be vigorously avoided. One need not formally carry out*
4 *multiple statistical tests for this problem to arise: Whenever a researcher chooses what to present*
5 *based on statistical results, valid interpretation of those results is severely compromised if the*
6 *reader is not informed of the choice and its basis. Researchers should disclose the number of*
7 *hypotheses explored during the study, all data collection decisions, all statistical analyses*
8 *conducted, and all p-values computed. Valid scientific conclusions based on p-values and related*
9 *statistics cannot be drawn without at least knowing how many and which analyses were conducted,*
10 *and how those analyses (including p-values) were selected for reporting.*

11
12 Of course, none of this means that all science is unreliable, or that we should give up on experimentation
13 altogether. The problem is not with research, generally, but with the overuse and misapplication of p-
14 values. The good news is that the same statisticians and scientists who have identified potential problems
15 with p-values have often also developed or proposed constructive and accessible approaches for
16 increasing the reliability of research results. In addition to the basic suggestions about disclosure quoted
17 above from the ASA report, a couple of the most common among the recurring recommendations include
18 (1) the use of multiple test corrections or what we call “false discovery rates” to adjust for a large number
19 of hypothesis tests; and (2) the reporting of actual effect sizes (in addition to p-values), along with
20 measures of uncertainty about the effect size.

21 With regard to (1), how does a biostatistician make sure that p-values < 0.05 for an analysis involving
22 many tests are not merely due to chance? This is generally accomplished by first assessing the number of
23 tests that need to be carried out, and then by computing the individual p-values using a method that
24 accounts for the number of tests. This kind of multiple testing method will yield a set of p-values that can
25 then be individually compared to the 0.05 testing level to identify truly significant findings. Such multiple
26 testing methods are readily available in any one of the most widely-used statistical analysis software
27 packages, and are illustrated in the large number of dedicated multiple testing textbooks and manuals.
28 These methods are taught as a matter of course within many university statistics curricula. In particular,
29 so-called stepwise or closed testing procedures can be readily applied to a set of many p-values computed
30 in a given analysis, adjusting the p-values to preserve the false positive rate not only for the individual
31 tests but for any combination or subset of null hypotheses under consideration. While several options are
32 available, the so-called False Discovery Rate (FDR) approach has been increasingly recommended and
33 used in statistical practice.

34 **IV. ASSESSING THE GLYPHOSATE FEEDING EXPERIMENTS**

35 Section III broadly outlined some of the crucial statistical issues that are highly relevant to the rodent
36 glyphosate feeding experiments and to the analysis provided in Dr. Portier’s expert report. Most

1 importantly, given the dozens of tumor types evaluated for both male and female rodents across the
 2 twelve studies we are considering, some sort of multiple comparison correction is imperative to avoid a
 3 very serious problem with false positives. In this section, we consider these issues in analyzing the rodent
 4 data, and summarize the results. In the next section we discuss these results in light of Dr. Portier's
 5 conclusions.

6 The available data come from 12 different experiments (7 using rats and 5 using mice) in which
 7 rodents were randomized – males and females, respectively – to increasing doses of glyphosate, then
 8 examined after their natural lifespan or at a pre-specified limit and evaluated for the presence of many

Study	Year	Strain	Glyphosate Doses (mg/kg bw/day)		# Types w/ ≥1 observed		# Types w/ ≥3 observed	
			MALE (M)	FEMALE (F)	M	F	M	F
Lankas	1981	SD	0, 3, 10, 32	0, 3, 11, 34	51	68	19	28
Stout	1990	SD	0, 89, 362, 940	0, 113, 457, 1183	45	44	17	14
Atkinson	1993	SD	0, 11, 112, 320, 1147	0, 12, 109, 347, 1134	46	35	15	11
Enemoto	1997	SD	0, 104, 354, 1127	0, 115, 393, 1247	53	37	20	12
Suresh	1996	Wistar	0, 6, 59, 595	0, 9, 89, 886	50	41	15	11
Brammer	2001	Wistar	0, 121, 361, 1214	0, 145, 437, 1498	45	44	14	15
Wood	2009	Wistar	0, 86, 285, 1077	0, 105, 349, 1382	52	40	16	14

Table 1: Summary of 7 rat glyphosate feeding experiments.

Study	Year	Strain	Glyphosate Doses (mg/kg bw/day)		# Types w/ ≥1 observed		# Types w/ ≥3 observed	
			MALE (M)	FEMALE (F)	M	F	M	F
Knezevich	1983	CD-1	0, 157, 814, 4841	0, 190, 955, 5874	57	98	16	32
Atkinson	1993	CD-1	0, 98, 297, 988	0, 102, 298, 1000	25	27	9	13
Sugimoto	1997	CD1	0, 165, 838, 4348	0, 153, 787, 4116	23	31	6	10
Kumar	2001	Swiss	0, 15, 150, 1453	0, 15, 151, 1467	19	30	8	10
Wood	2009	CD-1	0, 71, 234, 810	0, 98, 300, 1081	21	34	9	11

Table 2: Summary of 5 mouse glyphosate feeding experiments.

1 specific tumor types. These studies are summarized in Tables 1 and 2 (the totals given in these tables
2 exclude cases where proportionally few mice or rats were apparently evaluated for a given tumor type, as
3 the limited number of animals evaluated may reduce the interpretive value of the results to such a degree
4 as no conclusions may be drawn). There are two critical questions to address in evaluating the collective
5 evidence of a possible glyphosate effect on tumors among rodents. First, how do we evaluate the dose-
6 response effect of glyphosate on a single tumor type? Second, how do we account for many dose-
7 response analyses across multiple tumor types?

8 In answer to question 1, the most commonly used tool for assessing a dose-response effect is the
9 Cochran-Armitage trend test. In the context of the rodent feeding experiments, this approach provides a p-
10 value to test the null hypothesis of *no dose effect on tumor rate* versus the alternative hypothesis that the
11 *tumor rate increases with increasing dose*. This trend test is generally applicable to any experimental data
12 where subjects are randomized to increasing doses of some drug or other intervention, and then observed
13 to experience (on average) an increasing or decreasing percentage of subjects who experience the
14 outcome of interest. As with much of the analysis provided by Dr. Portier, these results are based on a
15 one-sided exact trend test – “one-sided” in that we are testing the trend in only one direction for a given
16 tumor, and “exact” in that we are using the actual probability distribution under the null hypothesis,
17 instead of a normal or bell-curve approximation (also called the “approximate” or “asymptotic” trend
18 test). The exact test is recommended when outcomes of interest are not common, which is often the case
19 across the glyphosate experiments.

20 What motivates this recommendation, and why does it matter whether we use the exact or
21 approximate p-value? While it may seem like a statistical technicality, the choice turns out to be germane
22 to the glyphosate rodent carcinogenicity question. The International Agency for Research on Cancer
23 (IARC) monograph on glyphosate used the approximate p-value to conclude that results from the
24 Knezevich experiment (included in Table 2) implicated glyphosate as a cause of kidney adenomas among
25 male mice, based on their reported approximate trend test p-value of 0.034 (without adjusting for multiple
26 tests). However, the exact one-sided test – subsequently reported by Dr. Portier in other material and
27 ultimately his expert report – yields a p-value of 0.062 for these same data. The discrepancy between the
28 approximate and exact p-values in this case illustrates why the former should be avoided when tumor
29 incidence is low. It turns out that the approximate p-value is an estimate of the actual or exact p-value,
30 and tends to be more accurate when the overall sample size is relatively larger and when relatively more
31 investigative events (in this case, tumors) are observed. In general, approximate p-values tend to
32 *underestimate* the exact p-values they are supposed to estimate. When sample sizes and numbers of
33 observed outcomes (such as tumors) are relatively large, this underestimation may not be consequential.
34 However, in cases like the glyphosate feeding experiments – where tumors are relatively less common –

1 the inaccuracy of approximate p-values when they are used can lead to a significant increase in the
2 number of false positives. In other words, because the approximate test tends to underestimate the exact,
3 we will see more “p-value < 0.05” results with the approximate test when there is actually no dose-
4 response effect. This can lead to serious exaggeration of the evidence in favor of trend effects.

5 Given the large relative error of this normal approximation for the Knezevich data, one might wonder
6 why anyone would ever use it. Normal approximations in applied research had much greater utility before
7 the widespread availability of powerful computing tools. Without some sort of special calculator or
8 software, a normal probability is relatively much easier to compute than an exact probability. Even now,
9 some analyses of counts and proportions rely on more sophisticated statistical models for which the exact
10 distribution is prohibitively difficult to compute, and so some form of normal approximation can still be
11 useful. However, for many experiments – particularly controlled experiments such as the glyphosate
12 mouse studies – exact p-values can be computed instantaneously with a desktop computer, and no
13 approximation is needed, even in cases where the sample sizes and counts are sufficiently large to justify
14 such an approximation.

15 Given appropriate computation of the trend test p-value, the second necessity is accounting for the
16 many dose-response analyses across multiple tumor types. As discussed earlier in Section III, the False
17 Discovery Rate (FDR) approach recommended by Ioannidis and others is particularly useful for these
18 data. It is a less conservative adjustment that is recommended in settings where there are hundreds or even
19 thousands of p-values under consideration. Of all multiple testing options available in this setting, the
20 FDR approach minimizes the chance that we would fail to detect an actual glyphosate-related effect. It
21 should be noted that an FDR adjustment could and should be used for any set of p-values computed to
22 assess potential glyphosate effects on tumor incidence, including any pairwise comparisons made
23 between the tumor rates of two dose groups. Such two-group comparisons are not reported here as Dr.
24 Portier’s conclusions do not appear to rely upon them, but the same multiple testing problem applies, and
25 even more so: in an experiment with four dose groups, respective comparisons of the three treatment
26 groups to control can yield up to three p-values – as opposed to one trend test p-value – for each tumor
27 type.

28 Trend test results for the 7 rat studies are summarized by the tables shown in Appendix A, and results
29 for the 5 mouse studies are similarly summarized in Appendix B. Each table contains exact one-sided p-
30 values for each study, reported by tumor type and sex, testing specifically for evidence of increasing
31 tumor probability. In addition, for those p-values < 0.05 reported and highlighted in Appendix A and
32 Appendix B, a multiple testing FDR adjustment is applied and reported in the table shown in Appendix C.

33 As shown in Tables 1 and 2, of the hundreds of individual tumor types evaluated across all 12
34 experiments, 1,016 were observed in at least one mouse or rat. Among rats, there were 13 trend test p-

1 values < 0.05 when testing for increasing incidence of each tumor, without accounting for the false
2 discovery rate. Among mice, there were 7 such trend test p-values < 0.05 without accounting for the false
3 discovery rate. All of these are highlighted in blue for easy identification in the tables contained in
4 Appendices A and B. Note that – assuming no effect of glyphosate on tumor incidence – we would
5 conservatively expect about 5% of all individual trend tests to yield p-values < 0.05 only by chance. This
6 would represent about 51 p-values < 0.05 out of the 1,016 individual cancer types for which at least one
7 tumor was observed. However, it makes sense to consider those cancer types for which three tumors were
8 observed. Given the typical study design of four dose groups with approximately 50 animals per dose,
9 about 3 tumors in total are necessary for an exact one-sided p-value no greater than 0.05. Given 345
10 tumor types across the 12 rodent studies with at least 3 observed tumors (as summarized in Tables 1 and
11 2), assuming no compound effects we would expect roughly 17.3 p-values < 0.05. In other words, given
12 the 20 observed p-values < 0.05, the overall results are entirely consistent what we should observe given
13 no compound-related effect on tumor incidence. This is analogous to flipping a coin 345 times that has a
14 5% probability of heads, and observing 20 heads with an expected number of 17.3. This result is highly
15 likely: there is actually about a 62.5% chance of observing this many independent p-values < 0.05 relative
16 to the expected proportion, given no compound-related effects.

17 In addition, when computing the trend test p-values to account for the false discovery rate, not one of
18 the 1,016 tests is statistically significant. FDR-adjusted p-values for all tumor types with individual trend
19 test p-values < 0.05 are summarized in Appendix C, and not one has a value even marginally close to
20 0.05. (Note that adjusting for multiple tests always increases the p-value, so that there is no need to report
21 FDR adjustments for any individual trend test results with p-values > 0.05.) There is no statistical
22 evidence whatsoever that glyphosate increases the risk of any of the tumors examined across these 12
23 studies.

24 I would emphasize that the results summarized above correspond to a one-sided test that only
25 evaluates the hypothesis that increased glyphosate exposure is associated with an increased rate of tumors
26 – what we would refer to as a *positive* association. However, the data may also be analyzed to evaluate a
27 *negative* association – that is, a decreased tumor rate as glyphosate exposure increases. In fact, it turns out
28 that the one-sided p-values for testing negative effects can simply be computed as 1.0 minus the one-sided
29 p-values reported in Appendices A and B. In other words, any p-value reported in Appendices A and B
30 that is larger than 0.95 represents a p-value < 0.05 for testing for a negative association. There are 13 such
31 outcomes, as summarized in Appendix D (additionally adjusted for the false discovery rate). Again, as
32 with the tests for positive associations, we would expect 5% of all 345 tumor types with at least three
33 observed tumors to likewise yield one-sided p-values < 0.05 when testing for *negative* associations. The
34 13 such results are again entirely consistent with this expected proportion: there is actually about a 24.5%

1 chance of observing this many independent p-values < 0.05 relative to the expected proportion, assuming
2 no compound-related effect.

3 Finally, I have also been made aware of a statistical reanalysis carried out by Dr. Klaus Weber of data
4 from Kumar mouse study. I have evaluated the reported data used by Dr. Weber. Some of the reported
5 tumor counts differ slightly from the data reported in Greim. My own analysis indicates that utilizing the
6 data tables reported by Dr. Weber does not substantively change my conclusions. I have included my
7 results both based on the Kumar data as reported in Greim, et al, and the data reported by Dr. Weber (see
8 Appendix B, Tables B.5 and B.6).

9 10 **V. RESULTS FROM DR. CHRIS PORTIER'S EXPERT REPORT**

11 Given that the 1,016 p-values computed across all 12 studies yield nothing more than the expected pattern
12 of false positives given no effect from glyphosate exposure, Dr. Portier nevertheless most recently asserts
13 that there is sufficient evidence glyphosate increases the risk for a handful of cancers, including liver
14 adenomas, thyroid C-cell adenomas and carcinomas, skin keratocanthomas, and kidney adenomas in male
15 rats; mammary gland adenomas and adenocarcinomas in female rats; hemangiosarcomas, kidney tumors,
16 and lymphomas among male mice; and hemangiomas among female mice. His analysis unfortunately
17 would certainly not pass the scrutiny of any meaningful peer review, and could actually be used as an
18 excellent case study in any university statistics course to illustrate the misappropriation of p-values. Most
19 critically, virtually any experienced statistician reviewing Dr. Portier's work with the animal data would
20 see immediately that his approach has led to a very serious multiple testing problem. Dr. Portier's analysis
21 is entirely dependent on p-values, arising from three types of computations: those for individual tumor
22 types by gender across each specific study (handpicked from among the more complete results contained
23 in Appendix A and Appendix B of this report), those that incorporate additional "historical control" data,
24 and those that "pool" data from across studies for a given tumor type. Dr. Portier provides a patchwork of
25 p-values from across these three sources, reporting significant findings (for increased risk, only) wherever
26 and in whatever manner they are found in order to manufacture a pattern implicating glyphosate.

27 While the multiple testing problem overarches all of these p-values, there are additional chronic flaws
28 with his use of historical controls and pooling procedures that need to be illustrated separately. These
29 three issues – multiple testing, historical controls, and pooling of data sets – are correspondingly
30 addressed in Sections V.A–V.C. Section V.D subsequently summarizes how the conclusions in Dr.
31 Portier's report have evolved from his prior work.

32 ***(V.A) The Use and Interpretation of P-Values***

1 Given the large number of animal tumors under investigation here, any analysis should consider the
2 concerns and recommendations of statisticians and researchers about the use and misuse of p-values, as
3 discussed in Section III. Unfortunately, Dr. Portier does not consider or apply even one of the common or
4 recommended remedies for this problem. In his tables summarizing results for individual rat and mouse
5 studies, he includes only what he terms as “Tumors of Interest”, which appear to be selected primarily on
6 the basis of their statistical significance within at least one of the several studies. His report makes no
7 effort to directly adjust p-values for multiple comparisons, for example by using the false discovery rate
8 approach recommended by experts in the profession. This is in spite of Dr. Portier’s brief comment on
9 page 40 of his expert report that “an adjustment for multiple comparisons is indeed warranted in
10 evaluating the outcomes of these studies.”

11 The only other mention of the multiplicity problem is the inclusion of Table 15, which Dr. Portier
12 constructed in response to comments submitted last year to the EPA by Dr. Joseph Haseman. Dr. Portier
13 has used Haseman’s tally of the expected number of false positives as a basis for demonstrating that there
14 are more significant results among male CD-1 mice than would be expected by chance, given no
15 glyphosate effects. A couple of critical differences in Dr. Portier’s approach account for his findings.
16 First, Haseman bases his own expected false positive number on the number of tumors for which there are
17 at least 3 observed cases (roughly the number required for a possibility of a p-value < 0.05). Haseman
18 confined his estimate to sites with three tumors based on the use of an exact one-sided p-value, given that
19 the study designs used for the glyphosate feeding experiments generally cannot yield a p-value < 0.05
20 unless at least three rodents are observed with a given tumor type. However, Dr. Portier is including his
21 historical control test, which (while not validated, as illustrated in the following section) can yield p-
22 values < 0.05 for *observed* tables that contain only two tumors. For example, the Sugimoto
23 hemangiosarcoma figures in male mice (0/50, 0/50, 0/50, 2/50) generates an exact one-sided trend test p-
24 value of 0.062, which is > 0.05 . When reanalyzed by Dr. Portier using historical controls his resulting p-
25 value (what he refers to as “ P_{Hist} ”) is 0.004, which is < 0.05 . In other words, when he incorporates
26 historical controls he is able to generate a p-value < 0.05 for smaller numbers of tumors in the observed
27 table. In addition, since he appears to be counting either trend test result with a p-value < 0.05 , or a “ P_{Hist} ”
28 result < 0.05 , as “positive,” he is at least doubling the number of observed tests among those tumor types
29 for which historical control data are available. These uses of historical controls explain the disparity in Dr.
30 Portier’s Table 15 between what is observed and what is expected relative to statistically significant
31 findings among male CD-1 mice.

32 However, in addition to that, such a comparison of observed and expected – while interesting for
33 exploratory purposes – does not directly address the more pressing question: is there evidence of a
34 compound-related effect with respect to any *specific* cancer type? The answer in part requires multiple

1 testing adjustments to individual p-values, such as the false discovery rate approach we use for both the
2 rat and mouse studies. As reviewed in Section III, other recommendations for balancing the overuse of p-
3 values include full disclosure of all tests performed, and the estimation of actual effect sizes along with
4 measures of effect size variability (such as confidence intervals). Dr. Portier uses neither of these
5 approaches.

6 **(V.B) *P-values Using Historical Controls***

7 The quantitative use of historical controls for the sake of establishing treatment effects within a given
8 statistical analysis is not universally accepted in experimental research. Many researchers view historical
9 controls at best as a means of laboratory quality control (to check consistency of outcome rates) or as a
10 qualitative measure before reaching any determination of causation. However, even if the historical data
11 are judged by study toxicologists to be comparable and potentially useful for inclusion with new
12 experimental data, any statistical analysis needs to be carefully planned and conducted to ensure that p-
13 values are computed appropriately. Dr. Portier's expert report helps to illustrate why. He argues that we
14 can compare prior experimental results for unexposed rats or mice to what we observe among treated
15 rodents in a given experiment. Particularly for rare or uncommon events, such as the cancer types
16 investigated for the glyphosate experiments, it may appear compelling or interesting when the number of
17 tumors observed in a treatment group is markedly higher than what we would expect given the average
18 control rate in prior experiments. However, the approach not only is not helpful for this particular
19 analysis, but is fundamentally inaccurate and is moreover applied inconsistently by Dr. Portier.

20 Most critically, underlying response rates almost always vary across different experiments, even when
21 those experiments are studying the same outcomes but using different samples at different times and in
22 different settings or laboratories. Even for the best or most consistently controlled studies, there are
23 underlying factors inherent in the sampling, the methods, the environment, and so forth, that can
24 significantly affect the likelihood of response. This is why, for example, statisticians account for study
25 differences or heterogeneity when combining data from different experiments or study sites (as discussed
26 more extensively in the following section – Section V.C – in the context of Dr. Portier's "pooled"
27 analyses).

28 Dr. Portier illustrates this with an example on page 28 of his report. In this case, he uses historical
29 controls to assess hepatocellular adenoma in the Wistar rats studied by Brammer, and cites results from
30 16 historical control groups with an underlying range in adenoma rates of 0% to nearly 18%. This
31 relatively wide range in adenoma rates, across studies using the same genetic strain of rat, is a perfect
32 example of how significantly these outcome rates can vary between experiments. However, Dr. Portier's
33 solution is simply to apply the average rate of 4.3% across the 16 studies to the results of the Brammer

1 experiment, which yielded 0/53, 2/53, 0/52, and 5/52 male rats with liver adenomas across the four
2 respective dose groups. Although Portier appears to dismiss the possibility, it is entirely possible that the
3 Brammer sample actually *did* have an underlying liver adenoma rate nearer to 18% than to 0%. In that
4 case, observing 7 liver adenomas out of 210 mice would not be at all remarkable. Because Dr. Portier
5 failed to formally account for the potential range of historical control tumor rates when generating his test
6 statistic, his resulting p-value is flawed.

7 Even assuming justification for including historical controls in his analysis (i.e., the historical controls
8 are sufficiently consistent with the given feeding experiment data), Dr. Portier's approach is deeply
9 flawed, and alarmingly inconsistent even with the recommended statistical methods cited within his own
10 sources. He appeals on page 21 of his expert report to four references as "guidelines" (numbers 30, 33,
11 34, and 66 in his citation list). The first three provide an exceptionally thin foundation for such a key
12 aspect of Dr. Portier's analysis: the first is somewhat of a self-reference (the preamble to the IARC
13 glyphosate monograph, written by a group chaired by Dr. Portier), and the second and third are regulatory
14 references specific to the EPA and the European Chemicals Agency. The fourth is an expository article
15 authored by Dr. Joseph Haseman in an environmental health journal – the only one of the four references
16 that outlines specific statistical methodology for incorporating historical controls. The Haseman paper
17 describes the heterogeneity problem described above – the tendency of different study samples to have
18 significantly different tumor rates – and proposes a sensible modeling method that accounts for these
19 differences. Dr. Portier offers no explanation for why he fails to use this approach, in spite of his citing
20 the paper in which it was suggested. Moreover, there are other references in the statistical literature that
21 specifically address the problem of incorporating historical controls. For example, Fung et al (*Canadian*
22 *Journal of Statistics*, 1996), Greim et al (*Human & Experimental Toxicology*, 2003), and Peddada et al
23 (*Journal of the American Statistical Association*, 2007), among others, all offer overviews and options for
24 a proper analysis using historical controls – none of them mentioned or utilized by Dr. Portier, in spite of
25 his citing these articles in a recently published commentary (Portier and Clausing, 2017). The common
26 principle underlying all of these methods is the need to account for differences in underlying tumor rates
27 for controls drawn from a variety of experiments. As explained more fully in the following section, the
28 general consequence of not properly adjusting for such differences is underestimation of p-values, which
29 leads to inflation of p-values < 0.05 and "statistically significant" findings due to nothing more than
30 chance. Given the hundreds of tumor types under consideration across the glyphosate rodent experiments,
31 this is a problem that should be meticulously avoided.

32 Aside from his completely incorrect analysis, the p-values computed by Dr. Portier using historical
33 controls do not change any of the substantive conclusions of the analysis, since Dr. Portier neglected to
34 account for the enormous multiple testing problem. Even when the corresponding trend test p-values in

1 Tables A1–A7 and B1–B5 of this report were replaced by Dr. Portier’s historical control-based results
2 and then adjusted with respect to the false discovery rate, none of them was significant. In addition, Dr.
3 Portier neglects to explain why he selectively highlights tests using historical data – there were apparently
4 many other tumor types for which historical control data were available but not used. It appears that such
5 results were reported by Dr. Portier primarily if they resulted in a p-value < 0.05 .

6 **(V.C) P-values From “Pooled” Analyses and Interpretation of Results Across Studies**

7 Given the multiple testing problem and the relative rarity of most all of the cancer types, there would
8 seem to be some impetus to attempt combining data from across studies. Aggregating the sample size and
9 tumor counts could potentially increase the likelihood of observing a compound-related effect, if any such
10 an effect exists. Dr. Portier’s attempts to accomplish this through his “pooled” analyses are nevertheless
11 completely unreliable. His analysis and comparative interpretations across the various experiments
12 disregard conventional statistical practice in several fundamental and egregious respects, and his approach
13 is ad hoc and inconsistently applied, without any kind of systematic analysis plan across the available
14 studies or tumor types.

15 First and most critically, Dr. Portier’s “pooled” procedures flout statistical standards by making no
16 adjustments at all for differences between experiments or for the similarities among mice within each
17 study. Dr. Portier simply aggregates data across various subsets of rat and mouse studies, treating rodents
18 born and raised in different environments, fed from different sources, measured using different tools by
19 different researchers over a 30-year span as though they were all included within a single experiment at
20 the same time. This is an astonishing violation of accepted practice that would serve as an example in any
21 relevant college class of how not to combine data from different sources.

22 Generally speaking, any combining of data across experiments such as those considered here requires
23 that (1) the experiments are comparable enough in terms of their measurements and conditions to justify
24 their inclusion in a combined analysis; and (2) if the studies are sufficiently comparable, some adjustment
25 is made for similarities or correlation of subjects within each study, as well as for differences in treatment
26 effects that are often observed. Addressing (1) is a primarily qualitative first step that usually relies on
27 some consensus among collaborating investigators with complementary expertise, who assess the
28 admissibility of available studies in terms of their comparability (e.g., that they consistently measured
29 outcomes and administered treatment doses). Without such strong justification, any attempt to
30 quantitatively combine the data from the individual studies can be unreliable. Dr. Portier has provided
31 very little information in his report about how he conducted such a review – for example, describing
32 consultations with other collaborators or sources about whether pathologies were examined consistently
33 for the handful of tumors types that he selected for his pooled analyses.

1 Putting aside the lack of a qualitative review, the “pooling” approach used by Dr. Portier to simply
2 combine data from different studies – as though they arose from the same experiment – is completely
3 inappropriate and incorrect. The underlying principle in any analysis that combines data from independent
4 studies is that the studies themselves – carried out at different times and in different settings – may be
5 distinct in ways that may or may not be measurable. These differences, often referred to in experimental
6 research as sample or study *heterogeneity*, need to be considered within the statistical analysis in order to
7 avoid bias when computing p-values. Why is this so crucial? There are two reasons to account for study
8 differences. First, ignoring them often leads to an increased chance of a false positive result. To illustrate,
9 consider an example where we have access to data for a flu vaccine that was administered to 10 large
10 nuclear families, with 5 family members in each home. For the sake of illustration, suppose that the
11 members within each of these families – for one reason or another – have the exact same response to the
12 vaccine. In other words, if one member of a given family responds to the vaccine, then *all* family
13 members respond. If one does not respond, then neither to any of the other family members. Although
14 there are 50 total individuals enrolled in this study, our *effective* sample size is only 10. In other words,
15 one family member from each home is sufficient. The other 4 give us no additional information about the
16 treatment effect, and are statistically redundant. From a statistical standpoint, naively assuming that all 50
17 individuals are somehow independent could lead to significant underestimation of the p-value testing the
18 vaccine effect, making a false positive much more likely.

19 This example is obviously extreme. In practice, we would seldom (if ever) observe that kind of perfect
20 correlation among data from a given study site or experimental source. However, in any analysis of data
21 from multiple sites or experiments, some appreciable correlation within each will exist due to variations
22 in the different sampling populations or experimental conditions. This heterogeneity will result in at least
23 some effective reduction of the sample size, in proportion to the strength of the correlation between
24 subjects within each study. Suppose that we ignore those study differences by simply aggregating the data
25 and analyzing them as though they all came from the same experiment, as Dr. Portier has done. Then p-
26 values computed to test overall treatment effects will be inaccurate. Generally speaking, they will be too
27 small, leading researchers to overstate any evidence of a treatment effect.

28 The second reason to assess and account for study differences is that the treatment effect often differs
29 between the individual studies, both with respect to the size and even the direction of the effect (e.g.,
30 increasing or decreasing trend). Another crucial step in combining datasets is to compare the effects
31 across studies, to understand how they are either alike or different with respect both to their direction and
32 magnitude. This typically involves some estimation of effect sizes, along with additional formal statistical
33 comparisons to ensure that the effects are consistent before any data from across the various studies are
34 pooled. Treatment effects in dose-response experiments are often summarized using an odds ratio or

1 relative risk, which in the case of the glyphosate experiments would estimate the relative increase or
2 decrease in the odds or risk of tumor for some given increase in glyphosate dose. For example, the so-
3 called logistic regression model that is used extensively by researchers across numerous fields
4 (particularly in biomedicine) allows researchers to estimate such odds ratios in ways that can examine
5 whether the estimated odds ratios are consistent across experiments. A logistic regression can help an
6 investigator to make a reasonable judgment about whether the observed results – expressed as odds ratios
7 relative to glyphosate dose – in two or more different experiments are significantly different. This is a
8 crucial assessment in any combined analysis that statisticians use to decide whether they are justified in
9 estimating a “common” or averaged effect across all of the studies. The important point is that such
10 methods are generally applied as a matter of course in this kind of analysis, although they are not used at
11 all by Dr. Portier.

12 In short, Dr. Portier has apparently made no reasonable effort to address study heterogeneity, either
13 with respect to the correlation of rodents within study or to differences in dose-response effects across
14 studies. The seriousness of this flaw cannot be overstated. In addition to his failure to account for the way
15 that mice and rats are correlated within the individual studies, Dr. Portier has combined data from
16 different sources without regard for the magnitude or direction of observed effects within groups. At a
17 minimum, by failing to account for within-study correlation, Dr. Portier has underestimated the actual p-
18 values – hence overstating the evidence (and increasing the chance for a false positive result) – for those
19 tumor types that he has selected for “pooled” analyses. Moreover, relying only on p-values for these
20 “pooled” analyses, even if they correctly account for study heterogeneity, masks study differences in
21 ways that can seriously undermine any possible understanding of potential compound-related effects. I
22 know of no available applied statistical text or handbook that touches on this topic that even entertains the
23 possibility that an analyst would simply combine data from various experiments as Dr. Portier has done,
24 without carefully examining and accounting for study differences. His approach can only be described as
25 naïve at best, and deliberately misleading at worst.

26 Interestingly, Dr. Portier provides two citations (numbers 92 and 93 in his report) that he uses to
27 justify his combined analyses, and that provide some guidance about how he should conduct them. They
28 are expository articles from epidemiological journals, and – while not statistical sources, strictly speaking
29 – both provide general information about how to analyze data from different sources, consistent with the
30 principles summarized above. Both emphasize the importance of evaluating and accounting for study
31 heterogeneity to avoid bias in statistical inference, and both recommend the use of logistic regression
32 models to estimate treatment effects between studies and to assess whether those effects differ
33 significantly. Neither of these sources mention the option of aggregating data in the way that Dr. Portier
34 has done. On the contrary, one of them suggests that study heterogeneity should conservatively be

1 assumed even if there is statistical evidence that it does not exist. Dr. Portier astonishingly and
2 inexplicably ignores all of this information within his own sources.

3 How does this enormous oversight specifically compromise Dr. Portier's conclusions? As just one
4 example among his several pooled analyses, consider Dr. Portier's assessment of liver adenomas among
5 rats. Relying only on his personal qualitative judgment, and without any formal statistical justification,
6 Dr. Portier chose to focus only on studies using Wistar rats (including the Brammer, Suresh, and Wood
7 studies in Table 2), and to ignore female rats altogether. (If a logistic regression model was used, the
8 analysis could readily include the other four rat studies as well as all female rats, easily accounting for
9 any possible differences between the genetic strains and genders.) The Brammer study observed counts of
10 0/53, 2/53, 0/53, 5/52, with a trend test p-value of 0.008 and an FDR-adjusted trend p-value of 0.370.
11 Note that the Suresh study resulted in 24/50, 22/50, 10/48, and 21/50 liver adenomas across the male dose
12 groups, an increasing trend that was not statistically significant (trend p-value = 0.391; FDR-adjusted
13 trend p-value = 0.715). The Wood study resulted in 0/50, 2/51, 1/51, and 1/51 liver adenomas across the
14 male dose groups, a weak increasing trend that was also not statistically significant (trend p-value =
15 0.418; FDR-adjusted trend p-value = 0.839). Even after excluding the other rat studies, along with any
16 results for females, in an argument spanning pages 32 and 33 of his report, Dr. Portier first suggests
17 pooling the Brammer, Wood, and Suresh liver adenoma data for male rats, and then arbitrarily excludes
18 the Suresh study because of its higher overall rate of liver adenomas (based again only on personal
19 judgment, without any formal statistical analysis). Dr. Portier then combines the data from Brammer and
20 Wood into a single table to produce a single trend test p-value, that he concludes demonstrates evidence
21 that glyphosate increases incidence of liver adenomas. Dr. Portier takes the same approach with
22 mammary tumors, combining only the data from Brammer and Wood, in order to generate a p-value <
23 0.05. However, he then elects to combine data from all three studies in order to obtain a p-value < 0.05
24 with respect to skin keratocanthomas. Notably, he reports that using only Brammer and Wood for skin
25 keratocanthoma does not generate a "statistically significant" p-value. This appears to be a
26 straightforward case of the "p-hacking" phenomenon discussed earlier in Section III, as he offers no
27 empirical justification for how he chooses to include or exclude the Suresh study from these additional
28 analyses.

29 Unfortunately, Dr. Portier's arbitrary and incorrect analysis renders his resulting "pooled" p-value
30 entirely meaningless. Accounting for heterogeneity and estimating study-specific effects, as
31 recommended by Dr. Portier's own sources, my own analysis of the liver adenoma data first demonstrated
32 definitively that there is highly significant correlation among rats within each study (using an exact test
33 for correlation in the StatXact software package). In addition, using a logistic regression model to
34 estimate observed effects, I found that the Brammer study indicates an odds ratio (OR) of 1.21 with

1 respect to an increased dose of 100 mg/kg (meaning a 21% increase in odds of liver adenoma for every
2 additional 100 mg/kg bw/day). The Wood study resulted in an estimated OR of 1.01 (only a 1% increase
3 in the odds of liver adenoma for an increased dose of 100 mg/kg), and the Suresh study also resulted in an
4 estimated OR of 1.01. Moreover, the logistic regression revealed that there is a highly statistically
5 significant difference in observed effects between the three studies – specifically, the effect observed in
6 Brammer is higher than the effects observed in the Wood and Suresh data. In other words, Dr. Portier
7 included two of the three studies in his “pooled” analysis that actually are demonstrably different with
8 respect to glyphosate. This further invalidates Dr. Portier’s “pooled” p-value for evaluating a common
9 potential effect across studies, which he computed using the Brammer and Wood data. Nevertheless,
10 aggregating the two datasets, without accounting for these potentially serious differences between the
11 underlying adenoma findings, Dr. Portier reports a significant “pooled” finding that is entirely driven by
12 the Brammer data. He implies that this somehow makes the result more convincing, which is a logical
13 leap equivalent to combining a gallon of paint with a gallon of paint thinner, and then selling the product
14 as two gallons of paint.

15 In addition to this conspicuous and fatal problem, Dr. Portier takes a highly inconsistent approach with
16 his “pooled” analyses that appears to focus primarily on achieving statistical significance. He “pools” and
17 “re-pools” rat and mouse data (always ignoring study heterogeneity), using different combinations of
18 studies without any predefined strategy or logical criteria. Dr. Portier’s “Joint Analysis” of the mouse
19 studies on pages 45-47 of his expert report is a particularly confusing and ad hoc jumble. To summarize
20 the arbitrary and incongruous nature of his approach:

- 21 • Dr. Portier proposes that the only neoplasms that he needs to examine for combined or “pooled”
22 analyses are the five for which at least one of the four CD-1 studies resulted in a statistically
23 significant finding. Why the dozens of others should be ignored is not explained. At the very least,
24 Dr. Portier is compounding the grievous multiple testing problem discussed earlier, since the
25 significance of the “pooled” trend test p-values that he reports are driven entirely by the five
26 individual statistically significant results. A more systematic analysis would combine data from
27 across studies for each tumor type (assuming that the tumor types are consistent, and appropriately
28 accounting for study heterogeneity); estimate a common observed effect for each tumor type, along
29 with measures of statistical significance (including p-values and confidence intervals), assuming that
30 the effect is consistent across studies; and finally account for multiple comparisons (e.g., adjust for
31 the false discovery rate) among the set of resulting p-values. However, conducting such a systematic
32 analysis would still need to be preceded by a sound qualitative toxicological analysis to ensure that
33 the studies are comparable, as discussed at the beginning of Section V.C.

- 1 • After confining himself to the CD-1 studies, Dr. Portier alternatively combines the two 18-month
2 studies, the two 24-month studies, and then all four studies together, and then for each tumor type
3 simply bases his conclusions on the one of those three that results in statistical significance. For
4 example, in the summary of his findings, he claims there is evidence that glyphosate “causes” kidney
5 tumors, after pooling all four CD-1 studies. However, he also claims there is evidence that glyphosate
6 “causes” malignant lymphomas, conveniently based on the result from “pooling” only the two 18-
7 month studies, even though there is no statistically significant effect when all four CD-1 studies are
8 used. This is internally inconsistent and another example of “p-hacking.”
- 9 • Dr. Portier’s analysis of hemangiosarcomas in males is especially troubling. After first “pooling” the
10 two 18-month studies (significant result), and then the two 24-month studies (no significant result), *he*
11 *proposes simply removing the 0/50 count observed in the highest dose group of the Knezevich study.*
12 By excluding the mice in this high dose group – none of whom were observed with any
13 hemangiosarcomas, which would suggest no effect of the test compound – Dr. Portier is then able to
14 manufacture a statistically significant p-value when he pools the 24-month studies, as well as a
15 significant p-value when pooling all four CD-1 studies. This is a breathtaking manipulation that can
16 only be charitably described as statistical malpractice.
- 17 • Dr. Portier’s summaries of the results for each of the five tumors introduce logical circularities and
18 other redundancies that artificially boost the impact of his findings. For example, consider his
19 discussion of kidney tumors. After alternately pooling the 18-month, 24-month, and all CD-1 studies,
20 Dr. Portier then compares the observed adenoma rates to historical controls. (As an aside, historical
21 controls are not considered by most statisticians or statistical sources as a valid means of establishing
22 causation, as discussed earlier. However, even using Dr. Portier’s criterion on page 21 of his report, it
23 is unclear why he uses historical controls in his analysis of the mouse studies that were not “from
24 untreated control groups from studies in the same laboratory within two to three years of the study
25 being evaluated.”) His conclusion is that, given historical control rates, the two adenomas observed in
26 each of the highest dose groups of the 24-month studies is highly improbable, and strengthens the
27 evidence of a compound-related effect. However, as discussed earlier in Section III in the context of
28 multiple hypothesis tests, this is self-evident when we are evaluating hundreds of tumor types across
29 12 studies: while such a result may be improbable for a single analysis, it is nearly certain that we
30 would observe such results for many tumors when we are computing hundreds of p-values. Dr.
31 Portier is merely providing another outstanding explanation for how a false positive arises when we
32 carry out a large number of statistical tests.

1 • Dr. Portier declares that all five mouse studies, including the four CD-1 studies and the Swiss Albino
2 study, are “useful”, but then confines his analysis to the CD-1 studies. No explanation is given for the
3 omission of the Kumar study.

4 Dr. Portier’s joint analysis of the rat studies (under “Summary – Rats” on pages 32-35 in his expert
5 report) is similarly uneven, suffering from inconsistencies similar to his mouse analyses. To highlight:

6 • As with the mouse studies, for his “pooled” analyses of rats Dr. Portier selects only those tumor types
7 with statistically significant individual p-values (unadjusted for false discovery rates). There is no
8 systematic approach applied to the dozens of other tumor types that were evaluated, and no attempt to
9 make an adjustment for multiple comparisons.

10 • Dr. Portier carried out “pooled” analyses of both liver adenomas, mammary gland tumors, and skin
11 keratocanthomas among the three studies that used Wistar rats (Brammer, Suresh, and Wood in Table
12 2). As discussed previously, for his analysis of liver adenomas Dr. Portier eliminated the Suresh study,
13 without any formal statistical justification, based only on his personal judgment that the studies cannot
14 be combined because of differences in underlying tumor rates. He likewise excluded the Suresh study
15 from his “pooled” analysis of mammary gland adenomas, but then included Suresh for testing skin
16 keratocanthomas. For all three tumor types, Dr. Portier’s arbitrary exclusion or inclusion resulted in a
17 “pooled” p-value < 0.05 . Again, as noted before, an averaged or pooled effect can be estimated even if
18 the underlying average tumor rates differ, provided that the observed effects across the studies are
19 consistent. Dr. Portier made no attempt to evaluate the latter issue, which invalidates his results.

20 21 *(V.D) Evolution of Dr. Portier’s Analyses of Animal Carcinogenicity Studies*

22 In addition to the flaws in Dr. Portier’s expert report, there are other serious questions about the
23 consistency of his approach, particularly in light of how his work has evolved. He at times appears to
24 selectively rely on analytic strategies motivated primarily by arbitrarily seeking for “statistical
25 significance” (i.e., computing more p-values < 0.05). A few illustrations:

26 • The IARC Glyphosate monograph – for which Dr. Portier served as an invited specialist – used
27 approximate trend test p-values to assess potential glyphosate effects for the Knezevich data. As
28 discussed in Section IV, approximate p-values tend to underestimate the corresponding actual p-
29 values, and thus increase the potential for “statistically significant” results that are only due to chance.
30 As outlined in the supplementary material of Dr. Portier’s expert report, criticism of the approximate
31 trend test by Dr. Joseph Haseman and others prompted Dr. Portier to rely solely on the exact test in his
32 subsequent work. However, he has resorted again to approximate p-values for some of the p-values he
33 computes using historical controls, arguing that the sample sizes justify their use. Since exact p-values
34 can be computed instantaneously using modern software, there is no good reason to use approximate

1 tests, particularly when their substantive results disagree with the exact p-values that they are merely
2 estimating.

- 3 • It is particularly puzzling that Dr. Portier has previously dismissed the rat feeding studies, declaring
4 that they provide no collective evidence that glyphosate increases cancer risk (for example, on page 11
5 of Document 9 in the supplementary material of his expert report). He offers no explanation regarding
6 why he has now decided that the statistical evidence supports such an association.
- 7 • Dr. Portier reports only results that demonstrate increasing tumor incidence for increasing glyphosate
8 dose, but mentions nothing about tumors that demonstrate decreasing risk of tumor across the
9 treatment groups. When computing one-sided p-values in the absence of any strong prior evidence in
10 favor of either a positive or negative effect, statistical convention dictates that we maintain equipoise
11 about what is observed, even if the result is counterintuitive or in a direction opposite of what we
12 would either hope for or expect.
- 13 • Dr. Portier also appears to be inconsistent in his standard for statistical significance. After quoting
14 EPA guidelines on page 20 of his expert report, establishing a significance threshold of 5%, he later
15 (on page 25) fudges somewhat to suggest that we should also consider p-values between 5% and 10%.
16 This is borne out in Tables 8 and 14, where he implies “statistical significance” by highlighting p-
17 values > 0.05 for multiple tumor sites. This further elevates the likelihood of observing false positive
18 results, even assuming his other strategies (i.e., historical controls and “pooled” analyses) were
19 actually valid.

21 **VI. Conclusion**

22 As discussed in Sections III and IV, in the context of the hundreds of tumors evaluated across all 12
23 rodent glyphosate feeding experiments, it is clear that the individual statistically significant findings
24 closely follow the pattern we would expect given that glyphosate does not increase the risk of cancer. Dr.
25 Portier’s own analysis of the rodent feeding studies violates several major foundational principles of
26 statistical practice. His entire approach is based on p-values, which he has selectively reported and used to
27 highlight those findings that are statistically significant, without applying any commonly recommended
28 methods to account for the hundreds of individual tumor types evaluated across the 12 experiments. Dr.
29 Portier has further employed other flawed strategies, including the use of historical controls and the
30 “pooling” of subsets of the data to generate additional p-values, which he has computed using inconsistent
31 and arbitrary standards. Dr. Portier’s “pooled” analyses are deeply defective, lacking any accounting for
32 study heterogeneity or differences in observed effects as recommended by Dr. Portier’s own cited
33 sources. His simple aggregating of data – as though data from disparate studies arose from the same
34 experiment – is completely inappropriate and unsupported by any credible statistical text or manual

1 regarding methods for analyzing data from multiple sources. Dr. Portier’s analytic strategy seriously
2 violates our own profession’s “Statement on p-Values: Context, Process, and Purpose” (*The American*
3 *Statistician*), referenced in Section III, which notes in part: “*P-values and related analyses should not be*
4 *reported selectively. Conducting multiple analyses of the data and reporting only those with certain p-*
5 *values (typically those passing a significance threshold) renders the reported p-values essentially*
6 *uninterpretable. Cherry-picking promising findings, also known by such terms as data dredging,*
7 *significance chasing, significance questing, selective inference, and ‘p-hacking,’ leads to a spurious*
8 *excess of statistically significant results...and should be vigorously avoided.”*

9



July 31, 2017

Christopher D. Corcoran

Date

1

TABLE A.2 – Stout Rat Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
adrenal adenoma	0.063	adrenal adenoma	0.664
adrenal chromocytoma B	0.248	adrenal chromocytoma b	0.268
adrenal chromocytoma M	0.585	adrenal chromocytoma m	0.250
adrenal ganglione	0.504	adrenal carcinoma	0.015
brain astrocytoma	0.297	brain cell tumor	0.500
bone sarcoma	0.245	cecum sarcoma	0.507
cervical astrocytoma	0.496	kidney lipoma	0.500
cervical glioma	0.747	kidney carcinoma	0.500
duodenum carcinoma	0.749	kidney hemangioma	0.750
eyes sarcoma	0.250	liver adenoma	0.922
kidney lipoma	0.938	liver carcinoma	0.167
kidney liposarcoma	0.500	liver sarcoma	0.500
kidney mesenchymal	0.500	liver giosarcoma	0.500
kidney adenoma	0.751	liver cholangioma	0.750
liver adenoma	0.016	lung adenoma	0.750
liver carcinoma	0.610	mammary gland adenoma	0.252
liver sarcoma	0.313	mammary gland carcinoma	0.770
liver neoplasm	0.500	mammary gland carcinosarcoma	0.438
mammary gland adenoma	0.282	nose carcinoma	0.500
mammary gland carcinoma	0.717	ovary granulosa	0.684
mammary gland canthoma	0.243	ovary theca	0.749
lymph node gioma	0.250	pancreas adenoma	0.962
nose adenoma	0.245	pituitary adenoma	0.996
pancreas adenoma	0.147	pituitary carcinoma	0.434
pancreas carcinoma	0.752	parathyroid adenoma	0.859
pituitary distalis	0.665	skin carcinoma	0.248
pituitary intermedia	0.251	skin zymbal's cell adenoma	0.500
prostate carcinoma	0.750	skin basal cell	0.748
parathyroid adenoma	0.243	skin clitoral gland adenoma	0.748
skin canthoma	0.077	spleen lymphoma	0.250
skin carcinoma	0.546	spleen hemangioma	0.250
skin adenocarcinoma	0.752	spleen sarcoma	0.750
skin cytoma	0.500	thyroid adenoma	0.050
skin zymbal's gland adenoma	0.498	thyroid carcinoma	0.500
skin basal cell	0.248	thyroid cystadenoma	0.438
skin papilloma	0.735	thyroid foll cell carcinoma	0.250
skin sebaceous gland adenoma	0.312	thymus lymphoma	0.937
skin fibroma	0.752	urinary papilloma	0.500
sp cord thoracic cytoma	0.500	uterus polyp	0.355
testies interstitial	0.297	uterus hamartoma	0.498

thyroid adenoma	0.067
thyroid c cell carcinoma	0.441
thyroid cystadenoma	0.407
thyroid follicular cell carcinoma	0.254
thymus lymphoma	0.479

uterus sarcoma	0.498
uterus adenoma	0.749
uterus leiomyoma	0.749
uterus fibroma	0.749

1

1 TABLE A.3(i) – Atkinson Male Rat Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
adrenals cortical adenoma	0.909	adrenals cortical carcinoma	0.269
adrenals uni phaeochromocytoma (M)	0.517	adrenals uni phaeochromocytoma (B)	0.975
adrenals uni phaeochromocytoma (B)	0.134	adrenals bi phaeochromocytoma (B)	0.736
adrenals bi phaeochromocytoma (B)	0.517	brain glioma	0.586
brain granular cell tumor	0.307	duodenum carcinoma	0.263
brain glioma	0.685	kidneys mesenchymal tumor	0.798
kidneys tubular adenoma	0.800	liver adenoma	0.235
kidneys urothelial carcinoma	0.400	lungs alveolar/bronchiolar carcinoma	0.400
liver carcinoma	0.681	lungs sarcoma	0.800
liver adenoma	0.322	mammary glands fibroadenoma	0.334
lungs squamous cell carcinoma	0.403	mammary glands met carcinoma	0.267
lungs alveolar/bronchiolar adenoma	0.763	mammary glands carcinoma	0.259
mammary glands fibroadenoma	0.303	mammary glands adenoma	0.450
mammary glands carcinoma	0.548	ovaries granulosa cell tumor	0.425
mesenteric lymph nodes haemangioma	0.819	pancreas exocrine carcinoma	0.732
pancreas exocrine adenoma	0.945	pancreas islet adenoma	0.733
pancreas islet adenoma	0.973	parathyroids adenoma	0.448
parathyroids adenoma	0.699	pituitary carcinoma	0.384
pituitary carcinoma	0.750	pituitary adenoma	0.525
pituitary adenoma	0.981	salivary glands mandibular fibroma	0.395
prostate carcinoma	0.307	skin basal cell tumor	0.428
prostate adenoma	0.307	skin sebaceous carcinoma	0.733
salivary glands parotid fibroma	0.796	skin zymbal's carcinoma	0.744
skin trichoepithelioma	0.331	skin squamous-cell carcinoma	0.583
skin basal cell tumor	0.697	skin sarcoma	0.733
skin zymbal's carcinoma	0.697	skin fibroma	0.505
skin squamous-cell carcinoma	0.303	skin lipoma	0.070
skin sarcoma	0.690	skin epithelioma	0.733
skin schwannoma	0.545	thyroids uni c-cell adenoma	0.108
skin papilloma	0.303	thyroids bi c-cell adenoma	0.927
skin fibrosarcoma	0.296	uterus stromal sarcoma	0.265
skin fibroma	0.489	uterus met endometrial carcinoma	0.584
skin dermal fibroma	0.561	uterus endometrial carcinoma	0.461
skin lipoma	0.725	uterus endometrial adenoma	0.735
skin epithelioma	0.047	uterus polyp	0.367
testes uni interstitial-cell adenoma	0.976		
testes bi interstitial-cell adenoma	0.303		
testes interstitial-cell adenoma	0.303		
thymus thymoma	0.684		
thyroids follicular carcinoma	0.310		

thyroids follicular adenoma	0.067		
thyroids uni c-cell carcinoma	0.310		
thyroids bi met c-cell carcinoma	0.310		
thyroids uni c-cell adenoma	0.400		
thyroids bi c-cell adenoma	0.310		
thyroids uni adenoma	0.310		

1

1

TABLE A.4 – Brammer Rat Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
adrenal phaeochromoytoma b	0.806	adrenal ganglioneuroma	0.498
adrenal adenoma	0.313	adrenal phaeochromocytoma	0.890
adrenal phaeochromocytoma m	0.313	brain astrocytoma	0.202
brain astrocytoma	0.438	brain meningioma	0.250
brain meningioma	0.313	brain pineal gland tumour	0.250
brain ependymoma	0.250	cervix stromal cell polyp	0.250
epididymis mesothelioma b	0.316	cervix adenocarcinoma	0.438
epididymis mesothelioma m	0.502	cervix sarcoma	0.062
heart schwannoma	0.750	cervix haemangiosarcoma	0.250
kidney haemangioma	0.250	duodenum adenocarcinoma	0.506
kidney mesenchymal tumour	0.250	duodenum leiomyoma	0.506
lacrimal gland neurofibrosarcoma	0.750	harderian gland anaplastic sarcoma	0.502
liver adenoma	0.008	ileum leiomyosarcoma	0.519
liver liposarcoma	0.250	kidney liposarcoma	0.250
lung adenocarcinoma	0.500	liver adenoma	0.250
lymph node-m haemangioma	0.687	lymph node-m haemangioma	0.762
lymph node-m haemangiosarcoma	0.814	lymph node-m haemangiosarcoma	0.432
nasal cavity fibrosarcoma	0.250	mammary gland adenocarcinoma	0.264
nasal cavity papilloma	0.250	mammary gland adenoma	0.894
nasal cavity ameloblastoma	0.500	mammary gland cystadenoma	0.519
pancreas exocrine adenoma	0.095	mammary gland fibroadenoma	0.377
pancreas exocrine adenocarcioma	0.500	nasal cavity papilloma	0.187
pancreas islet cell adenoma	0.576	nasal cavity adenoma	0.500
parathyroid gland adenoma	0.500	pancreas adenocarcinoma	0.252
pharynx carcinoma	0.753	pancreas islet cell adenoma	0.252
pituitary gland adenoma pars distalis	0.386	pituitary gland adenoma pars distalis	0.280
pituitary gland adenoma pars intermedia	0.387	salivary gland adenoma	0.751
salivary gland neurofibrosarcoma	0.254	skin squamous carcinoma	0.313
skin papilloma	0.247	skin basal cell tumour	0.250
skin basal cell tumour	0.387	skin pilomatrixoma	0.438
skin basal cell carcinoma	0.247	spleen haemangiosarcoma	0.502
skin pilomatrixoma	0.430	stomach squamous papiifoma	0.251
skin xeratoacanthoma	0.387	thymus thymoma b	0.629
skin adenoma	0.496	thymus thymoma m	0.626
skin trichofolliculoma	0.498	thymus not otherwise specified sarcoma	0.252
skin sarcoma	0.749	thyroid gland follicular cell adenoma	0.833
spleen not otherwise specified sarcoma	0.500	thyroid gland parafollicular cell adenoma	0.499
spleen not otherwise specified sarcoma	0.500	thyroid gland parafollicular cell carcinoma	0.252
testis leydig cell tumor	0.791	uterus stromal cell polyp	0.950
testis mesothelioma b	0.502	uterus adenocarcinoma	0.816

testis mesothelioma m	0.502
thymus benign thymoma	0.112
thyroid gland follicular cell adenoma	0.072
thyroid gland parafollicular cell adenoma b	0.882
thyroid gland parafollicular cell adenoma m	0.502
voluntary muscle haemangioma	0.251

uterus leiomyoma	0.438
uterus carcinoma	0.297
uterus haemangiosarcoma	0.625
uterus haemangioma	0.250

1

1

TABLE A.5 – Suresh Rat Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
salivary gland duct papinoma	0.691	stomach papilloma-forestomach	0.355
stomach adenocarcinoma	0.307	pancreas islet cell adenoma	0.355
stomach papilloma-forestomach	0.503	pancreas cholangio-carcinoma	0.638
pancreas islet cell adenoma	0.742	pancreas histiocytic sarcoma	0.638
pancreas carcinoma	0.509	liver cholangiocarcinoma	0.746
pancreas sarcoma	0.308	liver adenoma	0.922
pancreas lymphosarcoma	0.698	liver carcinoma	0.869
liver cholangiocarcinoma	0.263	liver b.d. adenoma	0.503
liver hepatocellular adenoma	0.391	liver histiocytic sarcoma	0.711
liver carcinoma	0.418	lungs bronchio alveolar adenoma	0.434
liver b.d. adenoma	0.937	lungs histiocytic sarcoma-metastatic	0.667
liver histiocytic sarcoma	0.624	lungs adenoma	0.633
liver tumour emboli	0.370	lungs fibroma	0.480
liver fibrosarcoma	0.495	lungs round cell sarcoma	0.333
liver lymphosarcoma	0.747	lungs histiocytic sarcoma	0.633
liver benign b.d. adenoma	0.253	trachea sarcoma	0.472
lungs histiocytic sarcoma	0.433	heart histiocytic sarcoma	0.594
lungs cholangiocarcinoma	0.503	heart round cell sarcoma	0.350
lungs adenocarcinoma	0.296	mediastinal lymph node histiocytic sarcoma-m	0.650
lungs hepatocellular carcinoma	0.322	mediastinal lymph node cholangiocarcinoma	0.650
lungs squamous cell carcinoma	0.704	mediastinal lymph node histiocytic sarcoma	0.482
lungs giant cell tumour	0.296	kidney lymphosarcoma	0.352
heart histiocytic sarcoma	0.445	urinary bladder carcinoma	0.350
spleen cholangiocarcinoma	0.515	uterus adenoma	0.289
mesentric lymph nodes sarcoma	0.695	uterus adenocarcinoma	0.643
mediastinal lymph node sarcoma - metastatic	0.634	uterus carcinoma	0.514
mediastinal lymph node cholangiocarcinoma	0.494	uterus leiomyosarcoma	0.289
mediastinal lymph node hepatocellular carcinoma	0.494	uterus adenoma papillary	0.514
mediastinal lymph node giant cell tumour	0.306	uterus hemangioma	0.289
mediastinal lymph node sarcoma	0.306	thyroids c cell adenoma	0.537
mandibular lymph node lymphoma	0.087	pituitary adenocarcinoma	0.684
kidneys carcinoma	0.503	pituitary adenoma	0.967
kidneys histiosarcoma	0.299	adrenals cortical cell adenoma	0.400
testes leydig cell tumor	0.182	adrenals pheochromocytoma	0.133
testes seminoma	0.296	thymus thymoma	0.755
epididymes sarcoma	0.250	mammary gland adenoma	0.538
brain squamous cell carcinoma	0.309	mammary gland adenocarcinoma	0.982
thyroids c cell adenoma	0.595	tumour/mass histiocytic sarcoma	0.658
pituitary adenocarcinoma	0.503	tumour/mass cholangiocarcinoma	0.635
pituitary adenoma	0.376	tumour/mass fibroma	0.635

adrenals cortical cell adenoma	0.922
adrenals pheochromocytoma	0.066
adrenals m. pheochromocytoma	0.213
tumour/mass squamous cell carcinoma	0.301
tumour/mass histiocytic sarcoma	0.123
tumour/mass cholangiocarcinoma	0.659
tumour/mass giant cell tumour	0.123
tumour/mass fibroma	0.315
bone sarcoma	0.694
sternum sarcoma	0.690

tumour/mass undifferentiated sarcoma	0.635

1

1

TABLE A.6 – Enemoto Rat P-Values, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
heart schwannoma	0.297	heart schwannoma	0.250
hematopoietic and lymphatic myelogenic leukemia	0.750	hematopoietic/lymphatic lymphoma	0.259
hematopoietic and lymphatic malignant lymphoma	0.813	small intestine leiomyoma	0.250
hematopoietic and lymphatic cell leukemia	0.813	large intestine histiocytoma	0.750
spleen histiocytic sarcoma	0.500	liver hepatocellular adenoma	0.813
lung adenoma	0.146	pancreas islet cell adenoma	0.812
lung squamous cell carcinoma	0.250	pancreas islet cell carcinoma	0.500
lung adenocarcinoma	0.250	kidney lipoma	0.500
stomach leiomyosarcoma	0.250	kidney trans cell carcinoma	0.750
small intestine leiomyoma	0.250	bladder papilloma	0.500
small intestine adenocarcinoma	0.250	ovary granulosa cell tumor	0.750
small intestine malignant schwannoma	0.500	ovary luteoma	0.250
liver adenoma	0.250	uterus stromal polyp	0.656
liver carcinoma	0.323	uterus granular cell tumor	0.750
pancreas acinar cell adenoma	0.120	uterus adenocarcinoma	0.750
pancreas islet cell adenoma	0.846	uterus schwannoma	0.250
pancreas islet cell carcinoma	0.250	uterus (mass not in section)	0.750
kidney adenoma	0.004	vagina polyp	0.750
kidney lipoma	0.250	vagina leiomyosarcoma	0.250
testis cell tumor	0.576	pituitary anterior adenoma	0.819
coagulating gland adenoma	0.250	pituitary anterior adenocarcinoma	0.750
pituitary anterior adenoma	0.132	thyroid follicular adenoma	0.688
pituitary adenoma (intermediate part)	0.500	thyroid c-cell adenoma	0.908
pituitary (mass not in section)	0.250	adrenal cortical adenoma	0.500
thyroid follicular adenoma	0.947	adrenal ganglioneuroma	0.500
thyroid c-cell adenoma	0.623	adrenal pheochromocytoma	0.500
thyroid follicular adenocarcinoma	0.750	cerebrum meningioma	0.500
thyroid c-cell carcinoma	0.514	cerebrum reticulosis	0.813
adrenal cortical adenoma	0.620	bone (vertebra) chordoma	0.750
adrenal pheochromocytoma	0.892	skin papilloma	0.500
adrenal cortical adenocarcinoma	0.250	skin keratoacanthoma	0.250
cerebrum glioma	0.392	skin fibroma	0.400
cerebrum malignant reticulosis	0.750	skin lipoma	0.932
cerebellum cell tumor	0.250	skin (mass not in section)	0.580
bone (femur) osteochondroma	0.250	mammary gland adenoma	0.813
bone (other) osteosarcoma	0.250	mammary gland fibroadenoma	0.106
eye schwannoma	0.750	mammary gland adenocarcinoma	0.595
skin papilloma	0.946		
skin keratoacanthoma	0.029		
skin trichoepithelioma	0.500		

1

TABLE A.7 – Wood Rat Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
adrenal cortical adenoma	0.813	adrenal cortical adenoma	0.813
adrenal cortical carcinoma	0.750	adrenal ganglioneuroma	0.250
adrenal phaeochromocytoma b	0.062	brain/spinal cord oligodendroglioma	0.750
adrenal phaeochromocytoma m	0.805	brain/spinal cord ependymoma	0.813
bone osteoma	0.250	heart schwannoma	0.938
brain/spinal cord astrocytoma	0.250	kidney clear cell carcinoma	0.250
brain/spinal cord granular cell tumour b	0.813	liver adenoma	0.392
brain/spinal cord granular cell tumour m	0.250	liver carcinoma	0.250
intestinal tract leiomyoma	0.250	liver cholangioma	0.750
intestinal trace leiomsarcoma	0.250	lymph node angioma	0.748
epididymis mesothelioma b	0.750	mammary gland fibroadenoma	0.824
epididymis mesothelioma m	0.751	mammary gland adenoma	0.062
heart schwannoma	0.500	mammary gland adenocarcinoma	0.042
kidney lipoma	0.250	ovary granulosa cell tumour	0.928
kidney tubular carcinoma	0.750	ovary granulosa-theca cell tumour	0.943
liver hepatocellular adenoma	0.418	ovary sarcoma	0.750
liver hepatocellular carcinoma	0.750	pancreas adenocarcinoma	0.250
lymph node angioma	0.357	pharynx papilloma	0.250
lymph node angiosarcoma	0.945	pituitary adenoma	0.014
nasal cavities adenoma	0.938	pituitary adenocarcinoma	0.500
pancreas islet cell adenoma	0.827	skin - subcutaneous fibroma	0.250
parathyroid adenoma	0.750	skin - subcutaneous lipoma	0.313
pituitary adenoma	0.045	skin - subcutaneous angioma	0.062
pituitary adenocarcinoma	0.750	skin - cutaneous basal cell tumour	0.750
skin - subcutaneous fibroma	0.595	skin - cutaneous carcinoma	0.250
skin - subcutaneous fibrosarcoma	0.903	skin - cutaneous papilloma	0.500
skin - subcutaneous histiocytic sarcoma	0.500	stomach papilloma	0.500
skin - subcutaneous lipoma	0.250	thymus thymoma b	0.765
skin - leiomyosarcoma	0.250	thymus carcinoma	0.250
skin - cutaneous basal cell tumor	0.750	thyroid follicular adenoma	0.372
skin- cutaneous carcinoma	0.675	thyroid follicular adenocarcinoma	0.813
skin - cutaneous keratoacanthoma	0.030	thyroid parafollicular adenoma	0.997
skin - cutaneous adenoma	0.500	thyroid parafollicular adenocarcinoma	0.500
skin - cutaneous adenocarcinoma	0.500	tongue granular cell tumor	0.250
skin - cutaneous trichoepithelioma	0.250	uterus polyp	0.221
skin - cutaneous papilloma	0.250	uterus adenocarcinoma	0.602
skin - cutaneous s.s. carcinoma	0.500	uterus sarcoma	0.438
spleen angioma	0.250	uterus leiomyoma	0.514
spleen angiosarcoma	0.750	uterus angiosarcoma	0.500
stomach papilloma	0.370	lymphoid/haemopoietic lymphoma	0.830

testis interstitial cell tumour	0.778		
thymus thymoma b	0.187		
thymus thymoma m	0.313		
thyroid adenoma	0.066		
thyroid adenocarcinoma	0.250		
thyroid parafollicular adenoma	0.823		
thyroid parafollicular adenocarcinoma	0.938		
thyroid hibernoma	0.250		
urinary bladder papilloma	0.500		
abdominal adenocarcinoma	0.500		
abdominal carcinoma	0.250		
lymphoid/haemopoietic lymphoma	0.500		

1

1 **APPENDIX B – RESULTS FOR MOUSE FEEDING STUDIES**

2

3

TABLE B.1 –Knezevich Mouse P-Values, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
brain lymphoblastic lymphosarcoma w/leuk	0.251	brain lymphoblastic lymphosarcoma w/leuk	0.251
heart lymphoblastic lymphosarcoma w/leuk	0.337	heart lymphoblastic lymphosarcoma w/leuk	0.433
lung adenoma	0.294	lung adenoma	0.999
lung adenocarcinoma	0.906	lung adenocarcinoma	0.183
lung lymphoblastic lymphosarcoma w/leuk	0.772	lung granulosa cell tumor	0.500
lung lymphoblastic lymphosarcoma	0.505	lung leiomyosarcoma	0.500
liver adenocarcinoma	0.717	lung liposarcoma	0.753
liver adenoma	0.251	lung composite lymphosarcoma	0.442
liver carcinoma	0.062	lung lymphoblastic lymphosarcoma w/leuk	0.717
liver sarcoma	0.503	lung lymphoblastic lymphosarcoma	0.253
liver liposarcoma	0.189	liver adenocarcinoma	0.828
liver composite lymphosarcoma	0.754	liver adenoma	0.497
liver lymphoblastic lymphosarcoma	0.539	liver hemangioendothelioma (M)	0.249
mesenteric sarcoma	0.492	liver leiomyosarcoma	0.497
mesenteric lymphosarcoma	0.624	liver granulocytic leukemia	0.875
mesenteric lymphoblastic lymphosarcoma (S)	0.827	liver hemangioendothelioma (S)	0.437
mesenteric lymphoblastic lymphosarcoma (M)	0.061	liver composite lymphosarcoma	0.064
mesenteric lymphoblastic lymphosarcoma w/leuk	0.492	liver lymphoblastic lymphosarcoma w/leuk	0.787
mediastinal sarcoma	0.489	liver lymphoblastic lymphosarcoma	0.061
mediastinal lymphosarcoma	0.631	mesenteric leiomyosarcoma	0.495
mediastinal lymphoblastic lymphosarcoma w/leuk (S)	0.373	mesenteric granulocytic leukemia	0.495
mediastinal lymphoblastic lymphosarcoma w/leuk (M)	0.463	mesenteric adenocarcinoma	0.747
salivary glands lymphoblastic lymphosarcoma w/leuk	0.628	mesenteric composite lymphosarcoma	0.141
spleen hemangioendothelioma	0.250	mesenteric lymphoblastic lymphosarcoma w/leuk (M)	0.522
spleen sarcoma	0.505	mesenteric lymphoblastic lymphosarcoma w/leuk (S)	0.782
spleen composite lymphosarcoma	0.631	mesenteric composite lymphosarcoma	0.141
spleen lymphoblastic lymphosarcoma w/leuk (S)	0.827	mesenteric lymphoblastic lymphosarcoma (M)	0.060
spleen lymphoblastic lymphosarcoma w/leuk (M)	0.442	mesenteric lymphoblastic lymphosarcoma (S)	0.247
stomach lymphoblastic lymphosarcoma w/leuk	0.746	mesenteric hemangioendothelioma	0.247
pancreas sarcoma	0.508	mediastinal leiomyosarcoma	0.489
pancreas lymphoblastic lymphosarcoma w/leuk	0.256	mediastinal granulocytic leukemia	0.489
ileum composite lymphosarcoma	0.733	mediastinal liposarcoma	0.761
ileum lymphoblastic lymphosarcoma w/leuk	0.733	mediastina composite lymphosarcoma	0.266
cecum lymphoblastic lymphosarcoma w/leuk	0.753	mediastinal lymphoblastic lymphosarcoma w/leuk (S)	0.717
colon composite lymphosarcoma	0.755	mediastinal lymphoblastic lymphosarcoma w/leuk (M)	0.760
kidney adenoma (using EPA reeval)	0.442	mediastinal lymphoblastic lymphosarc (M)	0.489
kidney carcinoma (using EPA reeval)	0.063	mediastinal lymphoblastic lymphosarc (S)	0.267
kidney sarcoma	0.505	salivary glands leiomyosarcoma	0.239

kidney composite lymphosarcoma	0.753	salivary lymphoblastic lymphosarcoma w/leuk	0.485
kidney lymphoblastic lymphosarcoma w/leuk	0.463	spleen hemangioendothelioma (M)	0.370
testes cell tumor	0.649	spleen hemangioma	0.250
testes lymphoblastic lymphosarcoma w/leuk (S)	0.508	spleen granulocytic leukemia	0.877
testes lymphoblastic lymphosarcoma w/leuk (M)	0.254	spleen adenocarcinoma	0.745
epididymides leiomyosarcoma	0.317	spleen hemangioendothelioma (S)	0.250
bladder histiocyticsarcoma	0.500	spleen composite lymphosarcoma (S)	0.580
bladder lymphoblastic lymphosarcoma w/leuk	0.810	spleen lymphoblastic lymphosarcoma w/leuk (S)	0.824
renal gland adenoma	0.574	spleen lymphoblastic lymphosarcoma w/leuk (M)	0.438
renal gland lymphoblastic lymphosarcoma w/leuk (U)	0.503	spleen composite lymphosarcoma (M)	0.016
renal gland lymphoblastic lymphosarcoma w/leuk (B)	0.246	spleen lymphoblastic lymphosarcoma (M)	0.250
skin/ears fibrosarcoma	0.245	spleen lymphoblastic lymphosarcoma (S)	0.250
skin/ears liposarcoma	0.245	stomach leiomyosarcoma	0.254
skin/ears composite lymphosarcoma	0.745	stomach adenocarcinoma	0.254
skin/ears lymphoblastic lymphosarcoma w/leuk	0.245	duodenum composite lymphosarcoma	0.770
eyes lymphoblastic lymphosarcoma w/leuk	0.643	pancreas granulocytic leukemia	0.508
harderian gland adenoma	0.750	pancreas composite lymphosarcoma	0.638
harderian gland liposarcoma	0.255	pancreas lymphoblastic lymphosarcoma w/leuk	0.746
marrow lymphoblastic lymphosarcoma w/leuk	0.566	jejunum composite lymphosarcoma	0.761
		ileum composite lymphosarcoma	0.758
		cecum composite lymphosarcoma	0.766
		colon composite lymphosarcoma	0.743
		colon lymphoblastic lymphosarcoma w/leuk	0.743
		kidney leiomyosarcoma	0.500
		kidney granulocytic leukemia	0.500
		kidney composite lymphosarcoma	0.395
		kidney lymphoblastic lymphosarcoma w/leuk	0.597
		kidney lymphoblastic lymphosarcoma	0.250
		bladder granulocytic leukemia	0.519
		bladder composite lymphosarcoma	0.822
		bladder lymphoblastic lymphosarcoma w/leuk	0.838
		ovaries luteoma	0.246
		ovaries teratoma	0.508
		ovaries cell tumor	0.508
		ovaries leiomyosarcoma	0.508
		ovaries adenocarcinoma	0.754
		ovaries lymphoblastic lymphosarcoma w/leuk (U)	0.508
		ovaries lymphoblastic lymphosarcoma w/leuk (B)	0.641
		ovaries composite lymphosarcoma	0.246
		uterus leiomyoma	0.619
		uterus leiomyosarcoma	0.385
		uterus sarcoma	0.505
		uterus hemangioma	0.505

1 **TABLE B.2 – Atkinson Mice Results, by Tumor Type and Adjusted for Multiple Tests.**

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
adrenals phaeochromocytoma (M)	0.486	adrenals carcinoma	0.500
adrenals carcinoma	0.486	adrenals subcap adenoma	0.750
adrenals phaeochromocytoma (B)	0.338	liver carcinoma	0.750
adrenals adenoma	0.648	liver adenoma	0.642
adrenals subcap adenoma	0.716	lungs carcinoma	0.105
brain meningioma	0.347	lungs adenoma	0.358
kidneys carcinoma	0.813	lungs (assoc) adenoma	0.072
kidneys adenoma	0.813	lungs secondary tumor	0.201
liver carcinoma	0.450	lymphoreticular sarcoma	0.575
liver adenoma	0.583	lymphoreticular lymphoma	0.475
liver (assoc) adenoma	0.077	mammary glands carcinoma	0.845
lungs carcinoma	0.456	mammary glands adenocarcinoma	0.250
lungs adenoma	0.339	ovaries granulosa cell tumor	0.750
lungs (assoc) adenoma	0.217	ovaries luteal cell tumor	0.250
pancreas adenoma	0.340	ovaries adenoma	0.062
pituitary intermediate adenoma	0.326	pancreas adenoma	0.500
prostate sarcoma	0.350	pituitary anterior adenoma	0.155
skin carcinoma	0.655	pituitary intermediate adenoma	0.250
skin sarcoma	0.641	skin carcinoma	0.187
skin papilloma	0.345	skin sarcoma	0.392
skin lipoma	0.345	skin papilloma	0.750
spinal cord ganglioneuroma	0.655	spleen sarcoma	0.250
stomach carcinoma	0.340	thyroids adenoma	0.250
testes adenoma	0.520	uterus sarcoma	0.299
vascular haemangiosarcoma (using IARC)	0.004	uterus stromal tumor	0.250
		uterus polyps	0.433
		uterus leiomyoma	0.108

2

1

TABLE B.3 – Wood Mice Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
adrenal adenoma	0.172	bone osteoma	0.750
adrenal carcinoma	0.754	bone marrow sarcoma	0.250
bone marrow lipoma	0.750	brain oligodendroglioma	0.750
brain sarcoma	0.251	harderian adenoma	0.155
brain oligodendroglioma	0.754	harderian adenocarcinoma	0.938
harderian adenoma	0.502	intestinal adenoma	0.750
kidney haemangiosarcoma	0.250	liver carcinoma	0.500
liver adenoma	0.335	liver haemangioma	0.500
liver carcinoma	0.921	liver haemangiosarcoma	0.250
liver haemangiosarcoma	0.615	lung adenoma	0.637
lung adenoma	0.926	lung adenocarcinoma	0.591
lung adenocarcinoma	0.030	mammary adenocarcinoma	0.391
seminal adenoma	0.938	mammary carcinoma	0.500
seminal leiomyosarcoma	0.250	mesenteric sarcoma	0.534
skin fibrosarcoma	0.542	ovary luteoma	0.514
spleen haemangioma	0.750	ovary haemangioma	0.250
testis cell tumor	0.938	ovary cell tumor	0.250
abdominal mesothelioma	0.250	ovary cystadenoma	0.062
abdominal sarcoma	0.250	ovary sarcoma	0.500
lymphoid/haemopoietic myeloid leukaemia	0.500	pancreas adenocarcinoma	0.750
lymphoid/haemopoietic lymphoma	0.007	pituitary adenoma	0.108
		skin haemangiosarcoma	0.500
		spleen haemangiosarcoma	0.438
		thymus sarcoma	0.250
		uterus polyp	0.170
		uterus haemangioma	0.500
		uterus leiomyoma	0.250
		uterus carcinoma	0.750
		uterus sarcoma	0.719
		uterus leiomyosarcoma	0.750
		abdominal lipoma	0.750
		lymphoid/haemopoietic myeloid leukaemia	0.250
		lymphoid/haemopoietic lymphoma	0.353
		lymphoid/haemopoietic sarcoma	0.482

2

1

TABLE B.4 – Sugimoto Mice Results, by Tumor Type and Adjusted for Multiple Tests.

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
hematopoietic & lymphatic system lymphoma	0.016	hematopoietic & lymphatic system leukemia	0.250
lymph nodes lymphoma	0.500	hematopoietic & lymphatic system lymphoma	0.307
spleen sarcoma	0.750	thymus lymphoma	0.250
lung adenoma	0.512	spleen hemangioma	0.250
lung adenocarcinoma	0.148	spleen hemangiosarcoma	0.250
intestine adenoma	0.500	spleen sarcoma	0.250
intestine adenocarcinoma	0.250	lung adenoma	0.800
liver adenoma	0.984	lung adenocarcinoma	0.597
liver hemangioma	0.750	small intestine adenoma	0.250
liver sarcoma	0.750	liver adenoma	0.735
liver carcinoma	0.391	liver hemangioma	0.250
kidney adenoma	0.062	urinary bladder leiomyoma	0.187
urinary bladder papilloma	0.751	ovary hemangioma	0.250
testis cell tumor	0.500	uterus polyp	0.751
testis hemangioma	0.750	uterus hemangioma	0.062
thyroid adenoma	0.751	uterus leiomyoma	0.370
adrenal b cell tumor	0.500	uterus sarcoma	0.500
cerebrum lipoma	0.500	uterus leiomyosarcoma	0.624
parathyroid gland adenoma	0.515	pituitary adenoma	0.500
skin papilloma	0.813	thyroid adenoma	0.751
skin hemangiosarcoma	0.062	adrenal a cell tumor	0.595
skin leiomyosarcoma	0.187	adrenal pheochromocytoma	0.751
skin osteosarcoma	0.250	bone osteoma	0.250
		parathyroid gland adenoma	0.040
		skin papilloma	0.750
		skin lipoma	0.626
		skin carcinoma	0.500
		skin liposarcoma	0.250
		skin hemangiosarcoma	0.250
		mammary gland adenoma	0.500
		mammary gland adenocarcinoma	0.814
		thoracic cavity osteosarcoma	0.400
		abdominal cavity hemangioma	0.257
		abdominal cavity osteosarcoma	0.257

2

1 **TABLE B.5 – Kumar Mice Results, by Tumor Type and Adjusted for Multiple Tests.**

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
cecum adenoma	0.648	stomach sarcoma	0.515
liver hemangiosarcoma	0.327	pancreas sarcoma	0.515
liver adenoma	0.846	liver sarcoma	0.769
liver carcinoma	0.249	liver adenoma	0.515
lungs squamous cell carcinoma	0.500	lungs endometrial stromal sarcoma	0.365
lungs broncho-alveolar adenoma	0.463	lungs broncho-alveolar adenoma	0.165
lungs broncho-alveolar carcinoma	0.347	lungs broncho-alveolar carcinoma	0.750
mesenteric hemangioma	0.431	mesenteric hemangioma	0.016
mesenteric hemangiosarcoma	0.245	mesenteric sarcoma	0.500
kidneys adenoma	0.090	kidneys sarcoma	0.511
kidneys hibernoma	0.671	bladder sarcoma	0.368
testes tumor	0.345	ovaries hemangioma	0.304
epididymes leiomyoma	0.503	ovaries sarcoma	0.735
skin carcinoma	0.791	ovaries tumor	0.304
tumor/mass hemangioma	0.304	ovaries luteoma	0.304
bone osteoma	0.582	uterus leiomyosarcoma	0.311
lymphoreticular sarcoma	0.624	uterus sarcoma	0.793
lymphoreticular lymphoma	0.064	uterus leiomyoma	0.311
lymphoreticular leukemia	0.744	pituitary adenoma	0.372
		adrenals sarcoma	0.511
		adrenals adenoma	0.363
		adrenals pheochromocytoma	0.363
		skin carcinoma	0.588
		thymus lymphoma	0.629
		mammary adenocarcinoma	0.598
		tumor/mass hemangiosarcoma	0.562
		femur osteoma	0.297
		lymph node sarcoma (M)	0.189
		lymph node sarcoma (I)	0.189
		hemolymphoreticular sarcoma	0.199
		hemolymphoreticular lymphoma	0.070
		hemolymphoreticular leukemia	0.602

2

1
2
3**TABLE B.6 – Kumar Mice Results Using Data from Weber Reanalysis, by Tumor Type and Adjusted for Multiple Tests.**

MALES		FEMALES	
TUMOR SITE AND TYPE	p	TUMOR SITE AND TYPE	p
cecum adenoma	0.750	stomach sarcoma	0.500
liver adenoma	0.846	pancreas sarcoma	0.500
liver carcinoma	0.155	liver sarcoma	0.688
lungs squamous cell carcinoma	0.500	liver adenoma	0.395
lungs broncho-alveolar adenoma	0.438	lungs endometrial stromal sarcoma	0.250
lungs broncho-alveolar carcinoma	0.250	lungs broncho-alveolar adenoma	0.069
kidneys adenoma	0.250	lungs broncho-alveolar carcinoma	0.750
kidneys hibernoma	0.750	mesenteric sarcoma	0.500
testes tumor	0.237	kidneys sarcoma	0.500
epididymes leiomyoma	0.500	bladder sarcoma	0.250
skin carcinoma	0.813	ovaries sarcoma	0.495
lymphoreticular sarcoma	0.534	ovaries tumor	0.250
lymphoreticular lymphoma	0.141	uterus leiomyosarcoma	0.250
lymphoreticular leukemia	0.830	uterus sarcoma	0.704
femur osteoma	0.750	uterus leiomyoma	0.830
hemangioma	0.261	pituitary adenoma	0.250
hemangiosarcoma	0.438	adrenals sarcoma	0.500
		adrenals adenoma	0.250
		adrenals pheochromocytoma	0.250
		skin carcinoma	0.500
		mammary adenocarcinoma	0.438
		femur osteoma	0.113
		hemolymphoreticular sarcoma	0.199
		hemolymphoreticular lymphoma	0.085
		hemolymphoreticular leukemia	0.602
		hemangioma	0.014
		hemangiosarcoma	0.750

1 **APPENDIX C – MULTIPLE TESTING ADJUSTMENTS**

2

3 **TABLE C.1 – Summary of findings with individual p-values < 0.05 for exact one-sided trend tests**

4 **for increasing tumor incidence with increased dose, computed across 1,016 total tumor types, with**

5 **multiple testing adjustment for the false discovery rate.**

Study	Rodent/Strain/Sex	Tumor Type	Exact Trend P-Value	P-Value Adjusted for False Discovery Rate
Lankas	Rat/SD/Male	Testis Cell Tumor	0.009	0.473
	Rat/SD/Female	Thyroid Cell Carcinoma	0.003	0.175
Stout	Rat/SD/Male	Liver Adenoma	0.016	0.703
	Rat/SD/Female	Adrenal Carcinoma	0.015	0.662
Atkinson	Rat/SD/Male	Skin Epithelioma	0.047	0.801
Brammer	Rat/Wistar/Male	Liver Adenoma	0.008	0.370
Enemoto	Rat/SD/Male	Kidney Adenoma	0.004	0.189
	Rat/SD/Male	Skin Keratoacanthoma	0.029	0.510
	Rat/SD/Male	Skin Basal Cell Adenoma	0.015	0.395
Wood	Rat/Wistar/Male	Pituitary Adenoma	0.045	0.684
	Rat/Wistar/Male	Skin Cutaneous Keratoacanthoma	0.030	0.684
	Rat/Wistar/Female	Mammary Gland Adenocarcinoma	0.042	0.616
	Rat/Wistar/Female	Pituitary Adenoma	0.014	0.557
Knezevich	Mouse/CD-1/Female	Spleen Composite Lymphosarcoma (M)	0.016	0.858
Atkinson	Mouse/CD-1/Male	Vascular Haemangiosarcoma	0.004	0.089
Wood	Mouse/CD-1/Male	Lung Adenocarcinoma	0.030	0.312
	Mouse/CD-1/Male	Lymphoid/Haemopoietic Lymphoma	0.007	0.139
Sugimoto	Mouse/CD-1/Male	Hematopoietic & Lymphatic System Lymphoma	0.016	0.373
	Mouse/CD-1/Female	Harderian Gland Adenoma	0.040	0.554
Kumar	Mouse/Swiss/Female	Mesenteric Hemangioma	0.016	0.468

6

1 **APPENDIX D – MULTIPLE TESTING ADJUSTMENTS**

2

3 **TABLE D.1 – Summary of findings with individual p-values < 0.05 for exact one-sided trend tests**
 4 **for decreasing tumor incidence with increased dose, computed across 1,016 total tumor types, with**
 5 **multiple testing adjustment for the false discovery rate.**

Study	Rodent/Strain/Sex	Tumor Type	Exact Trend P-Value	P-Value Adjusted for False Discovery Rate
Lankas	Rat/SD/Female	Thyroid Follicular Adenoma	0.036	0.956
Stout	Rat/SD/Female	Pancreas Adenoma	0.038	0.693
	Rat/SD/Female	Pituitary Adenoma	0.004	0.166
Atkinson	Rat/SD/Male	Pancreas Islet Adenoma	0.027	0.410
	Rat/SD/Male	Pituitary Adenoma	0.019	0.410
	Rat/SD/Male	Testes Uni Interstitial-Cell Adenoma	0.024	0.410
	Rat/SD/Female	Adrenals Uni Phaeochromocytoma (B)	0.025	0.781
Brammer	Rat/Wistar/Female	Uterus Stromal Cell Polyp	0.050	0.805
Suresh	Rat/Wistar	Pituitary Adenoma	0.033	0.671
	Rat/Wistar	Mammary Gland Adenocarcinoma	0.018	0.671
Wood	Rat/Wistar/Female	Thyroid Parafollicular Adenoma	0.003	0.120
Knezevich	Mouse/CD-1/Female	Lung Adenoma	0.001	0.056
Sugimoto	Mouse/CD-1/Male	Liver Adenoma	0.016	0.378

6

Materials Considered List

1. Aschwanden, C., *Science Isn't Broken: It's just a hell of a lot harder than we give it credit for*, Science & Health, FiveThirtyEight (Aug. 19, 2015).
2. Bailer, A. and C. Portier, *Effects of treatment-induced mortality and tumor induced mortality on tests for carcinogenicity in small samples*, 44 Biometrics 417 (1988).
3. BfR, *Assessment of IARC Monographs Volume 112 (2015); Glyphosate*, Renewal Assessment Report: Glyphosate Addendum I to RAR (2015).
4. BfR, *Toxicology and Metabolism*, Renewal Assessment Report: Glyphosate Volume 3 Annex B.6 (2015).
5. Bieler, G. and R. Williams, *Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity*, 49 Biometrics 793 (1993).
6. Blettner, M., et al., *Traditional reviews, meta-analyses and pooled analyses in epidemiology*, 28 Int'l J Epidemiology 1 (1999).
7. Brown, E., *Striking study results, little reliability*, L.A. Times, Oct. 24, 2012.
8. Chandra, M. & C. Frith, *Spontaneous neoplasms in aged CD-1 mice*, 61 Toxicology Letters 67 (1992).
9. Chandra, M. & C. Frith, *Spontaneous renal lesions in CD-1 and B6C3F1 mice*, 46 Experimental Toxicologic Pathology 189 (1994).
10. Chavalarias, D. et al., *Evolution of Reporting P Values in the Biomedical Literature, 1990-2015*, 315(11) JAMA 1141 (2016).
11. *Combating bad science: Metaphysicians*, The Economist (Mar. 15, 2014).
12. Dixon, D., et al., *Summary of chemically induced pulmonary lesions in the National Toxicology Program {NTP} toxicology and carcinogenesis studies*, 36 Toxicologic Pathology 428 (2008).
13. Dusheck, J., *Misleading p-values showing up more often in biomedical journal articles*, News Center, Stanford Medicine (Mar. 15, 2016).
14. EPA, FIFRA Scientific Advisory Panel, *Meeting Minutes and Final Report No. 2017-01, A Set of Scientific Issues Being Considered by the Environmental Protection Agency Regarding: EPA's Evaluation of the Carcinogenic Potential of Glyphosate*, (Mar. 16, 2017).
15. EPA, Memorandum from Herbert Lacayo, Statistician, Scientific Mission Support Staff, TOX/HED/OPP on Use of historical data in determining the weight of evidence from kidney tumor incidence in the Glyphosate two-year feeding study; and some remarks on false positives to Reto Engler, Chief, Scientific Mission Support Staff TOX/HED/OPP (Feb. 26, 1985).

16. EPA, Memorandum from Louis Kasza, D.V.M., Ph.D., Pathologist, Toxicology Branch, TS-769, EPA on Glyphosate – Evaluation of Kidney Tumors in Male Mice. Chronic Feeding Study to William Dykstra, Ph.D., Reviewer, Toxicology Branch, TS-769, EPA (Dec. 4, 1985).
17. EPA, Memorandum from William Dykstra, Toxicology Branch, Hazard Evaluation Division on Glyphosate; EPA Registration No. 524-308; Roundup; Additional Histopathological Evaluations of Kidneys in the Chronic Feeding Study of Glyphosate in Mice to Robert Taylor, Product Manager, Fungicide-Herbicide Branch, Registration Division (Mar. 11, 1986).
18. EPA, Office of Chemical Safety and Pollution Prevention, *Updated Statistics Performed on Animal Carcinogenicity Study Data for Glyphosate*, Regulations.gov (Sept. 12, 2016).
19. EPA, Office of Pesticide Programs, *Glyphosate Issue Paper: Evaluation of Carcinogenic Potential*, Regulations.gov (September 12, 2016).
20. Eustis, S., et al., *The utility of multiple-section sampling in the histopathological evaluation of the kidney for carcinogenicity studies*, 22 *Toxicologic Pathology* 457 (1994).
21. Expert Report of Dr. Christopher J. Portier in Support of General Causation on Behalf of Plaintiffs, In Re: Roundup Products Liability Litigation, No. 16-md-02741-VC (N.D. Cal. May 1, 2017).
22. Expert Report of Dr. Christopher J. Portier in Support of General Causation on Behalf of Plaintiffs, In Re: Roundup Products Liability Litigation, No. 16-md-02741-VC (N.D. Cal. June 27, 2017) [with accompanying Redline version].
23. Friedenreich, C., *Methods for pooled analyses of epidemiologic studies*. 4(4) *Epidemiology* 295 (1993).
24. Fung, K. et al., *A Comparison of Tests for Trend with Historical Controls in Carcinogen Bioassay*, 24 *The Canadian Journal of Statistics* 431 (1996).
25. German Federal Institute for Occupational Safety and Health, *Proposal for Harmonized Classification and Labeling: N-(phosphonomethyl)glycine; Glyphosate (ISO)*, CLH Report for Glyphosate (2016).
26. Giknis, M. and C. Clifford, *Spontaneous Neoplastic Lesions in the Crl:CD-1 (ICR)BR Mouse*, Charles River Laboratories (Mar. 2000).
27. Giknis, M. and C. Clifford, *Spontaneous Neoplastic Lesions in the Crl:CD-1 (ICR) Mouse in Control Groups from 18 Month to 2 year Studies*, Charles River Laboratories (Mar. 2005).
28. Giknis, M. and C. Clifford, *Neoplastic and Non-Neoplastic Lesions in the Charles River Wistar Hannover [Crl:WI(Han)] Rat*, Charles River Laboratories (Mar. 2011).
29. Greim, H. et al., *Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies*, 45 *Critical Reviews in Toxicology* 185 (2015) with attachments.

30. Greim, H. et al., *Evaluation of historical control data in carcinogenicity studies*, 22 *Human & Experimental Toxicology* 541 (2003).
31. Haseman, J. et al., *Use of historical control data in carcinogenicity studies in rodents*, 12 *Toxicologic Pathology* 126 (1984).
32. Haseman, J. et al., *Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies*, 25 *Toxicologic Pathology* 524 (1997).
33. Haseman, J., *Comments on the laboratory animal carcinogenicity studies evaluated in EPA's Glyphosate Issue Paper: Evaluation of Carcinogenic Potential, and an assessment of the comments by Dr. Christopher Portier on these studies*, Regulations.gov (December 7, 2016).
34. Haseman, J., *Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies*, 58 *Envtl. Health Persp.* 385 (1984).
35. International Agency for Research on Cancer (IARC), Monograph Vol. 112 on the Evaluation of Carcinogenic Risks to Humans, *Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos* (2015).
36. Ioannidis, J., *Interpretation of tests of heterogeneity and bias in meta-analysis*, 14 *J Evaluation Clinical Practices* 951 (2008).
37. Ioannidis, J., *Why Most Published Research Findings Are False*, 2(8) *PLoS Medicine* e124 (2005).
38. Johnson, G., *New Truths That Only One Can See*, N.Y. Times, Jan. 20, 2014.
39. Knezevich, A. and G. Hogan, *A Chronic Feeding Study of Glyphosate (Roundup® Technical) In Mice* (July 21, 1983).
40. Letter from Andre Varma, M.D. Chairman, Department of Community and Preventive Medicine, SUNY Stony Brook on chronic mouse feeding of Glyphosate (sic) on renal tumors to Marvin Kushner, M.D., Dean, School of Medicine, SUNY Stony Brook (Oct. 1, 1985).
41. Letter from Frank S. Serdy, Manager, Federal and State Registration Affairs, Monsanto Co. on Roundup® Herbicide EPA Reg Nos. 524-308, 524-330, 524-332, 524-339, 524-343. Chronic Mouse Study with Glyphosate to the Director, Registration Division, Office of Pesticide Programs, U.S. EPA (May 21, 1985).
42. Letter from Klaus Stemmer, M.D., Institute of Environmental Health, Univ. of Cincinnati Medical Center on Roundup® Chronic Mouse Study with Glyphosate to Timothy Long, Ph.D., Senior Product Toxicologist, Monsanto Co. (Oct. 17, 1985).
43. Letter from Marvin Kushner, M.D. on mouse kidney slides to Timothy J. Long, Ph. D., Senior Product Toxicologist, Monsanto Co. (May 11, 1985).
44. Letter from Marvin Kushner, M.D., Dean, School of Medicine, SUNY Stony Brook on kidney adenomas found in mice exposed to glyphosate to Timothy Long, Ph.D., Senior Product Toxicologist, Monsanto Co. (Oct. 3, 1985).

45. Letter from Robert A. Squire, D.V.M., Ph.D. on chronic toxicity data on Glyphosate in mice to Timothy Long, Ph.D., Senior Toxicologist, Monsanto Co. (Sept. 29, 1985).
46. Letter from Robert Olson, M.D., Ph.D. Professor of Medicine, Professor of Pharmacological Sciences, SUNY Stony Brook on glyphosate mouse kidney adenoma study to Timothy Long, Ph.D., Senior Product Toxicologist, Department of Medicine & Environmental Health, Monsanto Co. (Oct. 7, 1985).
47. Letter from Thomas F. Armstrong, Registration Manager, Monsanto Co. on Roundup® Herbicide EPA Reg. Nos. 524-308, 524-330, 524-332, 524-339, 524-343, 524-351 Addendum to Chronic Mouse Study with Glyphosate: Additional Evaluations to the Director, Registration Division, Office of Pesticide Programs, U.S. EPA (Oct. 28, 1985).
48. Nuzzo, R., *Scientific method: Statistical errors*, 506 Nature 150 (2014).
49. Peddada, S. et al., *Incorporating Historical Control Data When Comparing Tumor Incidence Rates*, 102(480) J. Am. Stat. Assoc. 1212 (2007).
50. Portier, C. and A. Bailer, *Testing for increased carcinogenicity using a survival-adjusted quantal response test*, 12 Fundamental and Applied Toxicology 731 (1989).
51. Portier, C. and D. Hoel, *Optimal design of the chronic animal bioassay*, 12 J Toxicology Envtl. Health 1 (1983).
52. Portier, C. & P. Clausing, *Re: Tarazona et al. (2017): Glyphosate toxicity and carcinogenicity: a review of the scientific basis of the European Union assessment and its difference with IARC*, Archives Toxicology (2017).
53. Portier, C. et al., *Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments*, 46 Cancer Res. 4372 (1986).
54. Portier, C. et al., *Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA)*, 70 J Epidemiology Community Health 741 (2016).
55. Portier, C., *Carcinogenicity of Glyphosate: A Systematic Review of the Available Evidence*, echa.europa.eu (Nov. 21, 2016).
56. Portier, C., *CLH Report for Glyphosate, EC Number 213-997-4*, eomsociety.org (July 8, 2016).
57. Portier, C., *Comments of C. Portier on USEPA (EPA-HQ-OPP-2016-0385-0094)*, Regulations.gov (Oct. 4, 2016).
58. Portier, C., *Response to comments prepared by Robert E. Tarone (dated October 27, 2016)*, Regulations.gov (Nov. 28, 2016).
59. *Problems with scientific research: How science goes wrong*, The Economist (Oct. 21, 2013).
60. Son, W. and C. Gopinath, *Early occurrence of spontaneous tumors in CD-1 mice and Sprague-Dawley rats*, 32 Toxicologic Pathology 371 (2004).

61. Tarone, R., *Comment submitted by R. Tarone (December 07, 2016)*, Regulations.gov (Dec. 7, 2016).
62. Tarone, R., *Comment submitted by R.E. Tarone and Response to comments prepared by Christopher Portier (dated October 4, 2016) for the glyphosate EPA SAP meeting*, Regulations.gov (Oct. 27, 2016).
63. Uno, H., et al., *A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves*, 34 *Statistics Med.* 3680 (2015).
64. *Unreliable research: Trouble at the lab*, *The Economist* (Oct. 18, 2013).
65. Wasserstein, R. & N. Lazar, *The ASA's Statement on p-Values: Context, Process, and Purpose*, 70 *The American Statistician* 129 (2016).
66. Weber, K., *Statistical Evaluation of Pre-Neoplastic and Neoplastic Lesions from Study: Study No. TOXI: 1559.CARCI-M Carcinogenicity Study with Glyphosate Technical in Swiss Albino Mice* (Jan. 23, 2017).

Christopher D. Corcoran

Utah State University

Email: [REDACTED]

Education

ScD, Harvard University, 1999.
Major: Biostatistics
Supporting Areas of Emphasis: Genetic Epidemiology

BS, Utah State University, 1995.
Major: Statistics
Supporting Areas of Emphasis: Computer Science

Professional Positions

Professor, Utah State University. (July 2011 - Present).

Associate Professor, Utah State University. (July 2005 - July 2011).

Assistant Professor, Utah State University. (August 1999 - July 2005).

Professional

Department Head, Department of Mathematics and Statistics, Utah State University. (2016 – Present)

Associate Department Head, Department of Mathematics and Statistics, Utah State University. (2014 – 2016)

Director of Graduate Studies, Department of Mathematics and Statistics, Utah State University. (2013 – 2016)

Director, Data Management and Statistics Core, Center for Epidemiologic Studies, Utah State University. (2004 - Present).

Research Fellow, Cytel Software Corporation. (2009 - 2010).

Teaching Assistant, Harvard University, Department of Biostatistics. (1995 - 1999).

Research Assistant, Dana Farber Cancer Institute, Department of Biostatistics. (1996).

Awards and Honors

Researcher of the Year, College of Science, Utah State University. (April 2012).

Researcher of the Year, Department of Mathematics and Statistics, Utah State University. (April 2012).

Teacher of the Year, Department of Mathematics and Statistics, Utah State University. (2006).

Researcher of the Year, Department of Mathematics and Statistics, Utah State University. (2005).

Top Professor, Mortar Board Honor Society, Utah State University Chapter. (2002).

Teaching Fellow, Department of Biostatistics, Harvard School of Public Health. (1996).

Academic Achievement Award, Utah State University. (1995).

NIH Cancer Research Training Grant Recipient. (1995).

Mortar Board, Utah State University. (1994).

Golden Key National Honor Society Peat Marwick Scholarship. (1993).

ACADEMIC INSTRUCTION

Teaching Experience

Utah State University

MATH 2260, Internship and Cooperative Studies, 1 course.
MATH 4910, Directed Reading and Conference, 2 courses.
MATH 5910, Directed Reading and Conference, 4 courses.
MATH 6250, Graduate Internship/Cooperative Studies, 5 courses.
MATH 6910, Directed Reading and Conference, 6 courses.
MATH 7810, Topics in Mathematics (Topic), 2 courses.
MATH 7910, College Teaching Internship, 2 courses.
MATH 7990, Continuing Graduate Advisement, 8 courses.
STAT 3000, Statistics for Scientists, 5 courses.
STAT 4250, Advanced Internship/Co-op, 1 course.
STAT 5100, Linear Regression and Time Series, 3 courses.
STAT 5120, Categorical Data Analysis, 6 courses.
STAT 5810, Topics in Statistics, 4 courses.
STAT 5820, Topics in Statistics, 1 course.
STAT 5820, 6910, Topics in Statistics, 1 course.
STAT 5970, Seminar, 3 courses.
STAT 6250, Graduate Internship/Co-op, 1 course.
STAT 6550, Statistical Computing, 1 course.
STAT 6810, Topics in Statistics (Topic), 1 course.
STAT 6820, Topics in Statistics (Topic), 1 course.
STAT 6910, Seminar in Statistics, 14 courses.
STAT 6950, Directed Reading and Conference, 1 course.
STAT 6990, Continuing Graduate Advisement, 2 courses.
STAT 7810, Topics in Statistics (Topic), 1 course.
STAT 7990, Continuing Graduate Advisement, 1 course.

Directed Student Learning

Dissertation Committee Chair, "Network Meta-Analysis," Mathematics & Statistics. (September 1, 2014 - Present).

Advised: Brinley Zabriskie

Master's Committee Chair, "Statistical Strategies for Public Database Access and Analysis," Mathematics & Statistics. (September 1, 2014 - Present).

Advised: Christina Stevens

Dissertation Committee Chair, Mathematics & Statistics. (August 2013 - Present).
Advised: Divya Nair

Dissertation Committee Chair, Mathematics & Statistics. (August 2013 - Present).
Advised: Sarah Schwartz

Master's Committee Chair, Mathematics & Statistics. (August 2013 - Present).
Advised: Michael Steelman

Master's Committee Chair, Mathematics & Statistics. (August 2012 - Present).
Advised: Jenny Clements

Dissertation Committee Member, Nutrition, Dietetics and Food Sciences. (August 2010 - Present).
Advised: Meo La

Dissertation Committee Chair, "Computational methods for family-based association tests." (August 2008 - May 2012).
Advised: William Welbourn

Master's Committee Chair, "Serum cytokine levels and risk of dementia." (2011).
Advised: Austin Bowles

Master's Committee Chair, "TBD." (2011).
Advised: Elizabeth Giles

Master's Committee Chair, "Patterns of stressful life events and Alzheimer's disease risk." (2011).
Advised: Megan Platt

Supervised Research/URF, "Effectiveness of surgical strategies for hysterectomy," Biology. (2010).
Advised: Erica Huelsmann

Master's Committee Chair, "Comparing methods for family-based association tests." (2009).
Advised: Abbie Lundgreen

Master's Committee Chair, "Heritability of cognitive change." (2009).
Advised: Colette Childs

Dissertation Committee Chair, "Small-sample inference for correlated categorical data." (2008).
Advised: Larry Cook

Master's Committee Chair, "Heritability of cognitive traits using complex pedigrees and sibships." (2008).
Advised: Cassidy Allen

Master's Committee Chair, "Multivariate analysis of longitudinal neuropsychological measures in the Cache County Memory Study." (2006).
Advised: Sarah Schwartz

Master's Committee Chair, "Computational efficiency of exact family-based association tests." (2006).
Advised: Yanwei Ouyan

Supervised Research/URF, "Nutritional risk factors for cognitive decline among the elderly,"
Biology. (2006).

Advised: Angela Dunn

Dissertation Committee Chair, "Exact family based association tests." (2004).

Advised: Kady Schneiter

Supervised Research/URF, "Cognitive decline and antioxidant, Vitamin C, and Vitamin E intake
among the elderly," Biology. (2003 - 2004).

Advised: Leila King

Supervised Research/URF, "Haplotypes of candidate genes as predictors of hip fracture in the
elderly," Biology. (2003 - 2004).

Advised: Sara Anderson

Master's Committee Chair, "Use of classification methods for dementia screening." (2003).

Advised: Leslie Toone

Supervised Research/URF, "Using patient characteristics of the demented to classify dementia
type," Mathematics & Statistics. (2003).

Advised: Kimberly Peterson

Supervised Research/URF, "Persistence of behavioral disturbances among the demented,"
Mathematics & Statistics. (2002 - 2003).

Advised: Craig Huber

Master's Committee Chair, "Correcting for left truncation bias when evaluating survival among the
elderly with dementia." (2002).

Advised: Jennifer Harrick

Supervised Research/URF, "General advising for submitting abstract regarding NIH internship
project to CUR Posters on the Hill," Mathematics & Statistics. (2002).

Advised: Randy Johnson

Supervised Research/URF, "Genetic factors in shortening time-to-onset of Alzheimer's disease,"
Mathematics & Statistics. (2002).

Advised: Sunni Mumford

Master's Committee Chair, "Operating characteristics of exact methods for correlated categorical
data." (2001).

Advised: Shea Watrin

RESEARCH & OTHER CREATIVE ACTIVITIES

Published Intellectual Contributions

Book Chapters

Book, Chapter in Scholarly Book (Published)

Corcoran, C. D., Senchaudhuri, P., Mehta, C., Patel, N. (2010). Exact Methods for Categorical
Data Analysis. In BS Everitt, CR Palmer (Ed.), *Encyclopaedic Companion to Medical
Statistics*. London: Hodder Arnold.

Book, Chapter in Non-Scholarly Book (Published)

Corcoran, C. D. (2009). Analysis of Correlated Data. *StatXact Version 8.0 User Manual* (pp. 895-935).

Book, Chapter in Scholarly Book (Published)

Cutler, A., Corcoran, C. D., Toone, L. (2005). Bagging. *Encyclopedia of Statistics in Behavioral Science*. New York: Wiley & Sons.

Book, Chapter in Scholarly Book (Published)

Corcoran, C. D., Ryan, L. M. (2002). Exact Dose-Response Inference. In M Aerts, H Geys, G Molenberghs, and LM Ryan (Ed.), *Topics in Modelling of Clustered Data* (pp. 195-206). New York: Chapman and Hall.

Book, Chapter in Scholarly Book (Published)

Corcoran, C. D. (2002). Trend tests for binary data. In AH El-Shaarawi and WW Piegorisch (Ed.), *Encyclopedia of Environments* (vol. 4, pp. 2260-2264). Chichester: John Wiley & Sons.

Book, Chapter in Non-Scholarly Book (Published)

Corcoran, C. D., Kannappan, A. R., Senchaudhuri, P., Coull, B. (1999). *Egret User Manual*. Cytel Software Corporation.

Refereed Journal Articles

Journal Article, Professional Journal (Accepted)

Rattinger, G. B., Fauth, E. B., Behrens, S., Sanders, C., Schwartz, S., Norton, M. C., Corcoran, C. D., Mullins, C. D., Lyketsos, C. G., Tschanz, J. T. (in press). Closer caregiver and care recipient relationships predict lower informal costs of dementia care. *Alzheimer's & Dementia*.

Journal Article, Professional Journal (Accepted)

Matyj, J. A., Tschanz, J. T., Rattinger, G. B., Sanders, C., Vernon, E. K., Corcoran, C. D., Kauwe, J. S., Buhusi, M. C. (in press). Sex differences in risk for Alzheimer's Disease related to neurotrophin gene polymorphisms: the Cache County Memory Study. *Journal of Gerontology: Biological Sciences*.

Journal Article, Professional Journal (Published)

Sanders, C., Behrens, S., Schwartz, S., Wengreen, H., Corcoran, C. D., Lyketos, C. G., Tschanz, J. T. (2016). Nutritional status is associated with faster cognitive decline and worse functional impairment in the progression of dementia: The Cache County Dementia Progression Study. *Journal of Alzheimer's Disease*.

Journal Article, Professional Journal (Published)

Rattinger, G. G., Fauth, E. B., Behrens, S., Sanders, C., Schwartz, S., Norton, M. C., Corcoran, C. D., Mullins, C. D., Lyketos, C. G., Tschanz, J. T. (2016). Closer caregiver and care-recipient relationships predict lower informal costs of dementia care: The Cache County Dementia Progression Study. *Alzheimer's & Dementia*, 12(8), 917-924.

Journal Article, Professional Journal (Published)

Hippen, A. A., Ebbert, M. t., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., Kauwe, J. S. (2016). Presenilin E318G variant and Alzheimer's disease risk: The Cache County Study. *BMC Genomics*, 17(Suppl 3), 438.

Journal Article, Professional Journal (Published)

Rattinger, G. G., Schwartz, S., Mullins, C. D., Corcoran, C. D., Zuckerman, I. H., Sanders, C., Norton, M. C., Fauth, E. B., Leoutsakos, J. M. S., Lyketsos, C. G., Tschanz, J. T. (2015). Dementia severity and the longitudinal costs of informal care in the Cache County population. *Alzheimer's & Dementia*, 11, 946-954.

Journal Article, Academic Journal (Published)

Snyder, C. M., Fauth, E. B., Wanzek, J., Piercy, K. W., Norton, M. C., Corcoran, C. D., Rabins, P. V., Lyketsos, C. G., Tschanz, J. T. (2015). Dementia caregivers' coping strategies and their relationship to health and well-being: The Cache County Study. *Aging & Mental Health*, 19(5), 390-399.

Journal Article, Academic Journal (Published)

Wang, L., Naj, A. C., Graham, R. R., Crane, P. K., Kunkle, B. W., Chrcag, C., Murcia, J. D., Cannon-Albright, L., Baldwin, C. T., Zetterberg, H., Blennow, K., Kukull, W. A., Faber, K. M., Schupf, N., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., et al., Yu, L. (2015). Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States. *JAMA Neurology*, 72(2), 209-216. <http://www.ncbi.nlm.nih.gov/pubmed/25531812>

Journal Article, Academic Journal (Published)

Lythgoe, C., Perkes, A., Peterson, M., Schmutz, C., Leary, M., Ebbert, E. T. W., Ridge, P. G., M., J., Munger, R. G., Corcoran, C. D., Kauwe, J. S. K. (2015). Population-based analysis of cholesteryl ester transfer protein identifies association between I405V and cognitive decline: the Cache County Study. *Neurobiology of Aging*, 36(547), e1-3.

Journal Article, Academic Journal (Published)

Rattiner, G. B., Schwartz, S., Mullins, C. D., Corcoran, C. D., Zuckerman, I. H., Sanders, C., Norton, M. C., Fauth, E. B., Leoutsakos, J. M. S., Lyketsos, C. G., Tschanz, J. T. (2015). Dementia severity and the longitudinal costs of informal care in the Cache County population. *Alzheimer's & Dementia*, 11(8), 946-954.

Journal Article, Professional Journal (Published)

Greene, D., Tschanz, J. T., Smith, K. R., Østbye, T., Corcoran, C. D., Welsh-Bohmer, K. A., Norton, M. C. (2014). Impact of offspring death on cognitive health in late life: The Cache County Study. *American Journal of Geriatric Psychiatry*, 22(11), 1307-15.

Journal Article, Professional Journal (Published)

Chuang, Y.-f., Breitner, J. C., Chiu, Y. L., Khachaturian, A., Hayden, K., Corcoran, C. D., Tschanz, J. T., Norton, M. C., Munger, R. G., Welsh-Bohmer, K. A., Zandi, P., For the Cache County Investigators (2014). Use of diuretics is associated with reduced risk of Alzheimer's disease: The Cache County Study. *Neurobiology of Aging*, 35(11), 2429-35.

Journal Article, Professional Journal (Published)

Gilbert, M., Snyder, C., Corcoran, C. D., Norton, M. C., Lyketsos, C. G., Tschanz, J. T. (2014). The association of traumatic brain injury with rate of progression of cognitive and functional impairment in a population-based cohort of Alzheimer's disease: The Cache County Dementia Progression Study. *International Psychogeriatrics*, 26(10), 1593-1601.

Journal Article, Professional Journal (Published)

Snyder, C. M., Fauth, E., Wanzek, J., Piercy, K. W., Norton, M. C., Corcoran, C. D., Rabins, P. V., Lyketsos, C. G., Tschanz, J. T. (2014). Dementia caregivers' coping strategies and their relationship to health and well-being: The Cache County Study. *Aging Mental Health*, 5, 1-10.

Journal Article, Public or Trade Journal (Published)

Ridge, P. G., Maxwell, T. J., Foutz, S. J., Bailey, M. H., Corcoran, C. D., Tschanz, J. T., Norton, M. C., Munger, R. G., O'Brien, E., Kerber, R. A., Cawthon, R. M., Kauwe, J. S. (2014). Mitochondrial genomic variation associated with higher mitochondrial copy number: The Cache County Study on Memory Health and Aging. *BMC Bioinformatics*, 15(7), S6.

Journal Article, Public or Trade Journal (Published)

Sharp, A. R., Ridge, P. G., Bailey, M. H., Boehme, K. L., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., Kauwe, J. S., Alzheimer's Disease Neuroimaging Initiative (2014).

Population substructure in Cache County, Utah: The Cache County study. *BMC Bioinformatics*, 15(7), S8.

Journal Article, Professional Journal (Published)

Ebbert, M. T., Ridge, P. G., Wilson, A. R., Sharp, A. R., Bailey, M., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., Kauwe, J. S. (2014). Population-based analysis of Alzheimer's disease risk alleles implicates genetic interactions. *Biological Psychiatry*, 75(9), 732-737.

Journal Article, Professional Journal (Published)

Peterson, D., Munger, C., Crowley, J., Corcoran, C. D., Cruchaga, C., Goate, A. M., Norton, M. C., Green, R. C., Munger, R. G., Breitner, J. C., Welsh-Bohmer, K. A., Lyketsos, C. G., Tschanz, J. T., Kauwe, J. S. (2014). Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. *Alzheimer's and Dementia*, 10(3), 366-371.

Journal Article, Professional Journal (Published)

Steinberg, M., Hess, K., Corcoran, C. D., Mielke, M. M., Norton, M. C., Breitner, J., Green, R., Leoutsakos, J.-M., Welsh-Bohmer, K., Lyketsos, C., Tschanz, J. T. (2014). Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: The Cache County Study. *International Journal of Geriatric Psychiatry*, 29(2), 153-159.

Journal Article, Professional Journal (Published)

Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., Jeng, A. T., Cooper, B., Skorupa, T., Carrell, D., Levitch, D., Hsu, S., Choi, J., Ryten, M., UK Brain Expression Consortium, Hardy, J., Ryten, M., Trabzuni, D., Weale, M. E., Ramasamy, A., Smith, C., Sassi, C., Bras, J., Gibbs, J. R., Hernandez, D. G., Lupton, M. K., Powell, J., Forabosco, P., Ridge, P. G., Corcoran, C. D., Tschanz, J. T., Norton, M. C., Munger, R. G., Schmutz, C., Leary, M., Demirci, F. Y., Bamne, M. N., Lopez, O. L., Ganguli, M., Medway, C., Turton, J., Lord, J., Braae, A., Barber, I., Brown, K., Alzheimer's Research UK Consortium, Passmore, P., Craig, D., Johnston, J., McGuinness, B., Todd, S., Heun, T., Kölsch, H., Kehoe, P. G., Hooper, N. M., Vardy, E. R., Mann, D. M., Pickering-Brown, S., Brown, K., Kalsheker, K., Lowe, J., Morgan, K., David Smith, A., Wilcock, G., Warden, D., Holmes, C., Pastor, P., Lorenzo-Betancor, O., Brkanac, Z., Scott, E., Topol, E., Morgan, K., Rogava, E., Singleton, A. B., Hardy, J., Kamboh, M. I., St. George-Hyslop, P., Cairns, N., Morris, J. C., Kauwe, J. S., Goate, A. M. (2014). Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature*, 505(7484), 550-554.

Journal Article, Professional Journal (Published)

Gonzalez Murcia, J. D., Schmutz, C., Munger, C., Perkes, A., Gustin, A., Peterson, M., Ebbert, M. T. W., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., Kauwe, J. S. K. (2013). Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-based sample: The Cache County Study. *Neurobiology of Aging*, 34(12), 2889.e11-e13.

Journal Article, Professional Journal (Published)

Wengreen, H., Munger, R. G., Nelson, C., Corcoran, C. D., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K. A. (2013). Prospective Study of DASH- and Mediterranean-style Dietary Patterns and Age-related Cognitive Change. 98(5), 1263-71.

Journal Article, Academic Journal (Published)

Wengreen, H., Munger, R. G., Cutler, A., Quach, A., Bowles, A., Corcoran, C. D., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K. (2013). Prospective study of dietary approaches to stop hypertension- and mediterranean-style dietary patterns and age-related cognitive change:

The Cache County Study on Memory, Health and Aging. *American Journal of Clinical Nutrition*, 98(5), 1263-1271.

Journal Article, Professional Journal (Published)

Piercy, K. W., Fauth, E. B., Norton, M. C., Pfister, R., Corcoran, C. D., Rabins, P. V., Lyketsos, C., Tschanz, J. T. (2013). Predictors of dementia caregiver depressive symptoms in a population: The Cache County Dementia Progression Study. *Journal of Gerontology: Psychological Sciences*, 68(6), 921-926.

Journal Article, Professional Journal (Published)

Norton, M. C., Clark, C., Fauth, E. B., Piercy, K. W., Pfister, R., Green, R. C., Corcoran, C. D., Rabins, P. V., Lyketsos, C. G., Tschanz, J. T. (2013). Caregiver personality predicts rate of cognitive decline in a community sample of persons with Alzheimer's Disease. The Dementia Progression Study. *International Psychogeriatrics*, 25(10), 1629-1637.

Journal Article, Academic Journal (Published)

Norton, M. C., Clark, C., Fauth, E. B., Piercy, K. W., Pfister, R., Green, R. C., Corcoran, C. D., Rabins, P. V., Lyketsos, C. G., Tschanz, J. T. (2013). Caregiver personality predicts rate of cognitive decline in a community sample of persons with Alzheimer's disease: The Cache County Dementia Progression Study. *International Psychogeriatrics*, 25, 1629-1637.

Journal Article, Professional Journal (Published)

Tschanz, J., Pfister, R., Steffens, D., Corcoran, C. D., Smith, K., Østbye, T., Schwartz, S., Welsh-Bohmer, K., Norton, M. C. (2013). Stressful events in late-life: Effects on cognitive decline: The Cache County Study. *International Journal of Geriatric Psychiatry*, 28, 821-830.

Journal Article, Academic Journal (Published)

Greene, D., Tschanz, J. T., Smith, K. R., Ostbye, T., Corcoran, C. D., Welsh-Bohmer, K. A., Norton, M. C. (2013). Impact of Offspring Death on Cognitive Health in Late Life: The Cache County Study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*.

Journal Article, Academic Journal (Published)

Tschanz, J. T., Pfister, R., Wanzek, J., Corcoran, C. D., Smith, K., Tschanz, B. T., Steffens, D. C., Østbye, T., Welsh-Bohmer, K. A., Norton, M. C. (2013). Stressful life events and cognitive decline in late life: moderation by education and age. The Cache County Study. *International journal of geriatric psychiatry*, 28(8), 821-30.

Journal Article, Academic Journal (Published)

Fauth, E. B., Schwartz, S., Tschanz, J. T., Ostbye, T., Corcoran, C. D., Norton, M. C. (2013). Baseline disability in activities of daily living predicts dementia risk even after controlling for global cognitive ability and depressive symptoms. *International Journal of Geriatric Psychiatry*, 28(6), 597-606.

Journal Article, Professional Journal (Published)

Peterson, D., Crowley, J., Munger, C., Corcoran, C. D., Cruchaga, C., Goate, A., Norton, M. C., Green, R., Munger, R. G., Breitner, J. C., Welsh-Bohmer, K., Lyketsos, C., Kauwe, J. S. (2013). Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. *Alzheimer's and Dementia*.

Journal Article, Academic Journal (Published)

Rabins, P. V., Schwartz, S., Black, B. S., Corcoran, C. D., Fauth, E. B., Mielke, M., Christensen, J., Lyketsos, C., Tschanz, J. T. (2013). Predictors of progression to severe Alzheimer Disease in an incidence sample. *Alzheimer's and Dementia*, 9(2), 204-207.

Journal Article, Professional Journal (Published)

Piercy, K. W., Corcoran, C. D., Fauth, E. B., Norton, M. C., Rabins, P. V., Tschanz, B. T., Deberard, M. S., Snyder, C., Smith, C., Lee, L., Lyketsos, C. G. (2013). Caregiver coping strategies predict rate of cognitive and functional decline in dementia: The Cache County Dementia Progression Study. *American Journal of Geriatric Psychiatry*, 21(1), 57-66.

Journal Article, Academic Journal (Published)

Tschanz, J. T., Piercy, K. W., Corcoran, C. D., Fauth, E. B., Norton, M. C., Rabins, P. V., Tschanz, B. T., Deberard, M. S., Snyder, C., Smith, C., Lee, L., Lyketsos, C. G. (2013). Caregiver coping strategies predict cognitive and functional decline in dementia: The Cache County Dementia Progression Study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*, 21(1), 57-66.

Journal Article, Professional Journal (Published)

Ridge, P., Maxwell, T. J., Corcoran, C. D., Norton, M. C., Tschanz, J. T., O'Brien, E., Kerber, R. A., Cawthon, R. M., Munger, R. G., Kauwe, J. S. (2012). Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6A1A/H6A1B. *PLoS*, 7(9), e45134.

Journal Article, Professional Journal (Published)

Leoutsakos, J. M., Han, D., Mielke, M., Forrester, S. N., Tschanz, J. T., Corcoran, C. D., Green, R., Norton, M. C., Welsh-Bohmer, K., Lyketsos, C. (2012). Effects of General Medical Health on Alzheimer Progression: the Cache County Dementia Progression Study. *International Journal of Psychogeriatrics*, 24(10), 1561-70.

Journal Article, Academic Journal (Published)

Leoutsakos, J. M., Han, D., Mielke, M. M., Forrester, S. N., Tschanz, J. T., Corcoran, C. D., Green, R. C., Norton, M. C., Welsh-Bohmer, K. A., Lyketsos, C. G. (2012). Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study. *International psychogeriatrics / IPA*, 24(10), 1561-70.

Journal Article, Academic Journal (Published)

Shao, H., Breitner, J. C., Whitmer, R., Wang, J., Hayden, K., Wengreen, H., Corcoran, C. D., Tschanz, J. T., Norton, M. C., Munger, R. G., Welsh-Bohmer, K., Zandi, P. (2012). Hormone Therapy and AD Dementia: New Findings from the Cache County Study. *Neurology*, 79(18), 1846-1852.

Journal Article, Professional Journal (Published)

Ridge, P. G., Maxwell, T. J., Corcoran, C. D., Norton, M. C., Tschanz, J. T., Kerber, R. A., Cawthon, R. M., Munger, R. G., Kauwe, J. S. (2012). Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6a1a/ H6a1b. The Cache County Study on Memory in Aging. *PLoS ONE*.

Journal Article, Academic Journal (Published)

Ridge, P., Maxwell, T., Corcoran, C. D., Norton, M. C., Tschanz, J. T., O'Brien, E., Kerber, R., Cawthon, R., Munger, R. G., Kauwe, J. (2012). Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6A1A/H6A1B: the Cache County Study on Memory in Aging. *PLoS One*, 7(9), e45134.

Journal Article, Professional Journal (Published)

Mielke, M. M., Leoutsakos, J. M., Corcoran, C. D., Green, R. C., Norton, M. C., Welsh-Bohmer, K. A., Tschanz, J. T., Lyketsos, C. G. (2012). Effects of FDA approved medications for Alzheimer's disease on dementia progression. *Alzheimer's and Dementia*, 8(3), 180-187.

Journal Article, Professional Journal (Published)

Rosenberg, P. B., Mielke, M. M., Leoutsakos, J. S., Lyketsos, C. G., Rabins, P. V., Zandi, P. P., Breitner, J. C., Norton, M. C., Welsh-Bohmer, K. A., Zuckerman, I. H., Rattinger, G. B., Green, R. C., Corcoran, C. D., Tschanz, J. T. (2012). The association of psychotropic medication use with the cognitive, functional and neuropsychiatric trajectory of Alzheimer's disease.

Journal Article, Academic Journal (Published)

Fauth, E. B., Hess, K., Piercy, K. W., Norton, M. C., Corcoran, C. D., Rabins, P., Lyketsos, C., Tschanz, J. T. (2012). Caregivers' relationship closeness with the person with dementia predicts both positive and negative outcomes for caregivers' physical health and psychological well-being. *Aging & mental health*, 16(6), 699-711.

Journal Article, Professional Journal (Published)

Treiber, K., Carlson, M., Corcoran, C. D., Norton, M. C., Piercy, K. W., Deberard, M. S., Stein, D. M., Foley, B. E., Welsh-Bohmer, K. A., Breitner, J. C. S., Lyketsos, C. G. (2011). Cognitive Stimulation and Cognitive and Functional Decline in Alzheimer's Disease: The Cache County Dementia Progression Study. *The Journals of Gerontology, Series B: Psychological Sciences and Social Sciences*, 66(4), 416-425.

Journal Article, Professional Journal (Published)

Norton, M. C., Smith, K. R., Ostbye, T., Tschanz, J. T., Corcoran, C. D., Schwartz, S., Skoog, I., Steffens, D. C., Welsh-Bohmer, K. A., Breitner, J. C. S. (2011). Early parental death and remarriage of widowed parents as risk factors for Alzheimer's disease. *American Journal of Geriatric Psychiatry*, 19, 814-824.

Journal Article, Professional Journal (Published)

Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K. W., Steinberg, M., Rabins, P. V., Leoutsakos, J., Welsh-Bohmer, K. A., Breitner, J. C. S., Lyketsos, C. G. (2011). Progression of cognitive, functional and neuropsychiatric symptom domains in a population cohort with Alzheimer's Dementia: The Cache County 5 dementia progression study. *American Journal of Geriatric Psychiatry*, 19, 532-542.

Journal Article, Professional Journal (Published)

Wengreen, H., Neilson, C., Munger, R. G., Corcoran, C. D. (2011). Prospective study of ready-to-eat breakfast cereal consumption and cognitive decline among elderly men and women. *Journal of Nutrition, Health and Aging*, 15(3), 202-207.

Journal Article, Academic Journal (Published)

Norton, M. C., Smith, K. R., Østbye, T., Tschanz, J. T., Schwartz, S., Corcoran, C. D., Breitner, J. C., Steffens, D. C., Skoog, I., Rabins, P. V., Welsh-Bohmer, K. A. (2011). Early parental death and remarriage of widowed parents as risk factors for Alzheimer disease: the Cache County study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*, 19(9), 814-24.

Journal Article, Academic Journal (Published)

Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K. W., Steinberg, M., Rabins, P. V., Leoutsakos, J. M., Welsh-Bohmer, K. A., Breitner, J. C., Lyketsos, C. G. (2011). Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*, 19(6), 532-42.

Journal Article, Academic Journal (Published)

Mielke, M. M., Leoutsakos, J. M., Tschanz, J. T., Green, R. C., Tripodis, Y., Corcoran, C. D., Norton, M. C., Lyketsos, C. G. (2011). Interaction between vascular factors and the APOE ε4

allele in predicting rate of progression in Alzheimer's disease. *Journal of Alzheimer's disease* : JAD, 26(1), 127-34.

Journal Article, Professional Journal (Published)

Mielke, M. M., Leoutsakos, J. M., Tschanz, J. T., Green, R. C., Tripodis, Y., Corcoran, C. D., Norton, M. C., Lyketsos, C. G. (2011). Interaction between vascular factors and the APOE E4 allele in predicting rate of progression in Alzheimer's dementia. *Journal of Alzheimer's Disease*, 26(1), 127-134.

Journal Article, Academic Journal (Published)

Norton, M., Smith, K. R., Ostbye, T., Tschanz, J. T., Corcoran, C. D., Swartz, S., Piercy, K. W., Rabins, P. V., Steffens, D. C., Skoog, I., Breitner, J. S., Welsh-Bohmer, K. A. (2010). Greater Risk of Dementia When Spouse Has Dementia? The Cache County Memory, Health and Aging Study. *Journal of the American Geriatrics Society*, 58(5), 895.

Journal Article, Academic Journal (Published)

Norton, M. C., Smith, K. R., Østbye, T., Tschanz, J. T., Corcoran, C. D., Schwartz, S., Piercy, K. W., Rabins, P. V., Steffens, D. C., Skoog, I., Breitner, J. C., Welsh-Bohmer, K. A. (2010). Greater risk of dementia when spouse has dementia? The Cache County study. *Journal of the American Geriatrics Society*, 58(5), 895-900.

Journal Article, Academic Journal (Published)

Norton, M. C., Piercy, K. W., Rabins, P. V., Green, R. C., Breitner, J. C., Ostbye, T., Corcoran, C. D., Welsh-Bohmer, K. A., Lyketsos, C. G., Tschanz, J. T. (2009). Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. *Journal of Gerontology Series B: Psychological Sciences and Social Sciences*, 64(5), 560-8.

Journal Article, Professional Journal (Published)

Hayden, K. H., Zandi, P. P., West, N. A., Tschanz, J. T., Norton, M. C., Corcoran, C. D., Breitner, J. C. S., Welsh-Bohmer, K. A. (2009). Effects of family history and APOE ε4 status on cognitive decline in the absence of AD: The Cache County Study. *Archives of Neurology*, 66, 1378-1383.

Journal Article, Academic Journal (Published)

Hayden, K. M., Zandi, P. P., West, N. A., Tschanz, J. T., Norton, M. C., Corcoran, C. D., Breitner, J. C., Welsh-Bohmer, K. A. (2009). Effects of family history and apolipoprotein E epsilon4 status on cognitive decline in the absence of Alzheimer dementia: the Cache County Study. *Archives of Neurology*, 66(11), 1378-83.

Journal Article, Professional Journal (Published)

Nelson, C., Wengreen, H., Munger, R. G., Corcoran, C. D. (2009). Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the Cache County Memory, Health and Aging Study. *Journal of Nutrition, Health, and Aging*, 13, 899-905.

Journal Article, Professional Journal (Published)

Wengreen, H., Nelson, C., Munger, R. G., Corcoran, C. D. (2009). Diet quality is associated with better cognitive test performance among aging men and women. *Journal of Nutrition*, 139, 1944-9.

Journal Article, Academic Journal (Published)

Norton, M. C., Singh, A., Skoog, I., Corcoran, C. D., Tschanz, J. T., Zandi, P. P., Breitner, J. C., Welsh-Bohmer, K. A., Steffens, D. C. (2008). Church attendance and new episodes of major depression in a community study of older adults: the Cache County Study. *Journal of Gerontology Series B: Psychological Sciences and Social Sciences*, 63(3), 129-37.

Journal Article, Academic Journal (Published)

Treiber, K. A., Lyketsos, C. G., Corcoran, C. D., Steinberg, M., Norton, M., Green, R. C., Rabins, P., Stein, D. M., Welsh-Bohmer, K. A., Breitner, J. C., Tschanz, J. T. (2008). Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study. *International Psychogeriatrics*, 20(3).

Journal Article, Academic Journal (Published)

Rosenberg, P., Mielke, M., Tschanz, J. T., Cook, L., Corcoran, C. D., Hayden, K., Norton, M. C., Rabins, P., Green, R., Welsh-Bohmer, K., Breitner, J., Munger, R. G., Lyketsos, C. (2008). Effects of cardiovascular medications on rate of functional decline in Alzheimer's Disease. *American Journal of Geriatric Psychiatry*, Nov 16(11), 883-892.

Journal Article, Professional Journal (Published)

Treiber, K. A., Lyketsos, C. G., Corcoran, C. D., Steinberg, M. D., Norton, M. C., Green, R. C., Rabins, P., Stein, D. M., Welsh-Bohmer, K. A., Breitner, J. C. S., Tschanz, J. T. (2008). Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's Disease: The Cache County Study. *International Psychogeriatrics*, 20(3), 538-553.

Journal Article, Academic Journal (Published)

Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C. D., Lyketsos, C. G., Breitner, J. C., Welsh-Bohmer, K. A. (2007). Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. *Neurology*, 69, 275-82.

Journal Article, Academic Journal (Published)

Hayden, K. M., Zandi, P. P., Khachaturian, A. S., Szekely, C. A., Fotuhi, M., Norton, M. C., Tschanz, J. T., Pieper, C. F., Corcoran, C. D., Lyketsos, C. G., Breitner, J. C., Welsh-Bohmer, K. A. (2007). Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. *Neurology*, 69, 275-82.

Journal Article, Academic Journal (Published)

Schneiter, K., Degnan, J. H., Corcoran, C. D., Xu, X., Laird, N. (2007). EFBAT: Exact Family-Based Association Tests. *BMC Genetics*, 8, 86.

Journal Article, Academic Journal (Published)

Wengreen, H., Munger, R. G., Corcoran, C. D., Zandi, P., Hayden, K., Fotuhi, M., Skoog, I., Norton, M. C., Tschanz, J. T., Breitner, J., Welsh-Bohmer, K. (2007). Antioxidant intake and cognitive function of elderly men and women: the Cache County Study. *J Nutr Health Aging*, 11(3), 230-237.

Journal Article, Academic Journal (Published)

Mielke, M., Rosenberg, P., Tschanz, J. T., Cook, L., Corcoran, C. D., Hayden, K., Norton, M. C., Rabins, P., Green, R., Welsh-Bohmer, K., Breitner, J., Munger, R. G., Lyketsos, c. (2007). Vascular factors predict rate of progression in Alzheimer disease. *Neurology*, 69(19), 1850-1858.

Journal Article, Professional Journal (Published)

Tschanz, J. T., Welsh-Bohmer, K. A., Lyketsos, C. G., Corcoran, C. D., Green, R. C., Hayden, K., Norton, M. C., Zandi, P. P., Toone, L., West, N. A., Breitner, J. C. (2006). Conversion to Dementia from Mild Cognitive Disorder. The Cache County Study. *Neurology*, 67, 229-234.

Journal Article, Academic Journal (Published)

Tschanz, J. T., Welsh-Bohmer, K. A., Lyketsos, C. G., Corcoran, C. D., Green, R. C., Hayden, K., Norton, M. C., Zandi, P. P., Toone, L., West, N. A., Breitner, J. C. (2006). Conversion to dementia from mild cognitive disorder: the Cache County Study. *Neurology*, 67(2), 229-34.

Journal Article, Academic Journal (Published)

Norton, M. C., Skoog, I., Franklin, L. M., Corcoran, C. D., Tschanz, J. T., Zandi, P. P., Breitner, J. S., Welsh-Bohmer, K. A., Steffens, D. C. (2006). Gender differences in the association between religious involvement and depression: The Cache County (Utah) Study. *Journal of Gerontology: Psych Sci*, 61(3), 129-136.

Journal Article, Professional Journal (Published)

Norton, M. C., Skoog, I., Franklin, L. M., Corcoran, C. D., Tschanz, J. T., Zandi, P. P., Breitner, J. C., Welsh-Bohmer, K. A., Steffens, D. C. (2006). Gender Differences in the Association between Religious Involvement and Depression: The Cache County (Utah) Study. *Journals of Gerontology B: Psychological Sciences*, 61, 129-136.

Journal Article, Academic Journal (Published)

Steinberg, M., Corcoran, C. D., Tschanz, J. T., Huber, C., Welsh-Bohmer, K., Norton, M. C., Zandi, P., Breitner, J. C., Steffens, D. C., Lyketsos, C. G. (2006). Risk factors for neuropsychiatric symptoms in dementia: the Cache County Study. *Int J Geriatr Psychiatry*, 21(9), 824-30.

Journal Article, Professional Journal (Published)

Norton, M. C., Skoog, I., Toone, L., Corcoran, C. D., Tschanz, J. T., Lisota, R. D., Hart, A. D., Zandi, P. P., Breitner, J. C., Welsh-Bohmer, K. A., Steffens, D. C. (2006). Three-year Incidence of First-Onset Depressive Illness in a Population Sample of Older Adults: The Cache County Study. *American Journal of Geriatric Psychiatry*, 14, 237-245.

Journal Article, Academic Journal (Published)

Norton, M. C., Skoog, I., Toone, L., Corcoran, C. D., Tschanz, J. T., Lisota, R. D., Hart, A. D., Zandi, P. P., Breitner, J. C., Welsh-Bohmer, K. A., Steffens, D. C. (2006). Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County Study. *The American Journal of Geriatric Psychiatry*, 14(3), 237-45.

Journal Article, Professional Journal (Published)

Steinberg, M., Corcoran, C. D., Tschanz, J. T., Huber, C., Welsh-Bohmer, K., Norton, M. C., Zandi, P., Breitner, J. C. S., Steffens, D. C., Lyketsos, C. G. (2006). Risk factors for neuropsychiatric symptoms in dementia: The Cache County Study. *International Journal of Geriatric Psychiatry*, 21(9), 824-830.

Journal Article, Academic Journal (Published)

Zhang, J., Munger, R. G., West, N. A., Cutler, D., Wengreen, H. J., Corcoran, C. D. (2006). Antioxidant intake and risk of osteoporotic hip fracture in Utah: an effect modified by smoking status. *American Journal of Epidemiology*, 163(1), 9-17.

Journal Article, Academic Journal (Published)

Lyketsos, C., Toone, L., Tschanz, J. T., Corcoran, C. D., Norton, M. C., Zandi, P., Munger, R. G., Breitner, J., Welsh-Bohmer, K. (2006). A population-based study of the association between coronary artery bypass graft surgery (CABG) and cognitive decline: the Cache County study. *Int J Geriatr Psychiatry*, 21(6), 509-518.

Journal Article, Professional Journal (Published)

Lyketsos, C. G., Toone, L., Tschanz, J. T., Rabins, P. V., Steinberg, M., Onyike, C. U., Corcoran, C. D., Norton, M. C., Zandi, P., Breitner, J. C., Welsh-Bohmer, K., t. C. C. S. G. (2005). A Population-based Study of Medical Co-morbidity in Early dementia and "Cognitive Impairment No Dementia" (CIND): Association with Functional and Cognitive Impairment. The Cache County Study. *American Journal of Geriatric Psychiatry*, 13, 656-664.

Journal Article, Academic Journal (Published)

Schneiter, K., Corcoran, C. D., Laird, N. (2005). An exact family based association test for a biallelic genotype. *Genetic Epidemiology*, 29(3), 185-94.

Journal Article, Academic Journal (Published)

Bastian, L. A., West, N. A., Corcoran, C. D., Munger, R. G. (2005). Number of children and the risk of obesity in older women. *Preventive Medicine*, 40, 99-104.

Journal Article, Academic Journal (Published)

Tamura, T., Munger, R. G., Corcoran, C. D., Bacayao, J. Y., Nepomuceno, B., Solon, F. (2005). Plasma zinc concentrations of mothers and the risk of nonsyndromic oral clefts in their children: a case-control study in the Philippines. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 73(9), 612-616.

Journal Article, Academic Journal (Published)

Lyketsos, C. G., Toone, L., Tschanz, J. T., Rabins, P. V., Steinberg, M., Onyike, C. U., Corcoran, C. D., Norton, M., Zandi, P., Breitner, J. C., Welsh-Bohmer, K., Anthony, J., Ostbye, T., Bigler, E., Pieper, C., Burke, J., Plassman, B., Green, R. C., Steffens, D. C., Klein, L., Leslie, C., Townsend, J. J., Wyse, B. W., Munger, R. G., Williams, M. (2005). Population-based study of medical comorbidity in early dementia and. *American Journal of Geriatric Psychiatry*, 13(8), 656-664.

Journal Article, Academic Journal (Published)

Khachaturian, A. S., Corcoran, C. D., Mayer, L. S., Zandi, P. P., Breitner, J. C. (2004). Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. *Archives of General Psychiatry*, 61(5), 518-24.

Journal Article, Academic Journal (Published)

Hayden, K. M., Khachaturian, A. S., Tschanz, J. T., Corcoran, C. D., Norton, M., Breitner, J. C. (2004). Characteristics of a two-stage screen for incident dementia. *Journal of Clinical Epidemiology*, 56(11), 1038-45.

Journal Article, Professional Journal (Published)

Tschanz, J. T., Corcoran, C. D., Skoog, I., Khachaturian, A. S., Heath, J., Hayden, K. M., Welsh-Bohmer, K. A., Calvert, T., Norton, M. C., Zandi, P., Breitner, J. C. (2004). Dementia: The Leading Predictor of Death after age 85. The Cache County Study. *Neurology*, 62, 1156-1162.

Journal Article, Academic Journal (Published)

Tschanz, J. T., Corcoran, C. D., Skoog, I., Khachaturian, A. S., Herrick, J., Hayden, K. M., Welsh-Bohmer, K. A., Calvert, T., Norton, M. C., Zandi, P., Breitner, J. C. (2004). Dementia: the leading predictor of death in a defined elderly population. *Neurology*, 62(7), 1156-62.

Journal Article, Academic Journal (Published)

Steinberg, M., Tschanz, J. T., Corcoran, C. D., Steffens, D. C., Norton, M. C., Lyketsos, C. G., Breitner, J. C. (2004). The persistence of neuropsychiatric symptoms in dementia. *International Journal of Geriatric Psychiatry*, 19(1), 19-26.

Journal Article, Professional Journal (Published)

Steinberg, M., Tschanz, J. T., Corcoran, C. D., Steffens, D. C., Norton, M. C., Lyketsos, C. G., Breitner, J. C. (2004). The Persistence of Neuropsychiatric Symptoms in Dementia: The Cache County Study. *International Journal of Geriatric Psychiatry*, 19, 19-26.

Journal Article, Academic Journal (Published)

Wengreen, H. J., Munger, R. G., West, N. A., Cutler, D., Corcoran, C. D., Zhang, J., Sassano, N. E. (2004). Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah. *Journal of Bone and Mineral Research*, 19(4), 537-545.

Journal Article, Academic Journal (Published)

Munger, R. G., Sauberlich, H. E., Corcoran, C. D., Nepomuceno, B., Daack-Hirsch, S., Solon, F. S. (2004). Maternal vitamin B-6 and folate status and risk of oral cleft birth defects in the Philippines. *Birth Defects Research Part A: Clinical and Molecular Teratology*, 70(7), 464-471.

Journal Article, Academic Journal (Published)

Steffens, D. C., Norton, M. C., Hart, A. D., Skoog, I., Corcoran, C. D., Breitner, J. C. (2003). Apolipoprotein E genotype and major depression in a community of older adults. The Cache County Study. *Psychological Medicine*, 33(3), 541-7.

Journal Article, Academic Journal (Published)

Willing, M., Munger, R. G., Beaty, T., Wengreen, H., West, N., Cutler, D., Corcoran, C. D. (2003). Bone-related genetic markers and risk of osteoporotic hip fracture in Utah men and women. *The American Journal of Human Genetics*, 73(5), 367.

Journal Article, Professional Journal (Published)

Hayden, K. M., Khachaturian, A. S., Tschanz, J. T., Corcoran, C. D., Norton, M. C., Breitner, J. C. (2003). Characteristics of a Two-Stage Screen in a Population Survey of Incident Dementia. *Journal of Clinical Epidemiology*, 56(11), 1038-1045.

Journal Article, Academic Journal (Published)

Leaf, A. N., Probert, K., Corcoran, C. D., Catalano, P. J., Trump, D. L., Harris, J. E., Davis, T. E. (2003). Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group Study. *Medical Oncology*, 20(2), 137-46.

Journal Article, Academic Journal (Published)

Corcoran, C. D., Mehta, C. R. (2002). Exact level and power of permutation, bootstrap, and asymptotic tests of trend. *Journal of Modern Applied Statistical Methods*, 1, 42-51.

Journal Article, Academic Journal (Published)

Rossi, W., Mayeux, R., Lee, J., Flaquer, A., Estrada-Nadal, L., Munger, R. G., Cawthon, R., Corcoran, C. D., Smith, K., Kerber, R., Pahor, M., Nicklas, B., Mychaleckyj, J., Ambrosius, W., Kritchevsky, S., Newman, A., Bleecker, E., Messier, S., Harris, T., Terry, D., McCormick, M., Lawler, E., Perls, T., Hadley, E. (2002). Genetic epidemiology of aging and survival outcomes. *Gerontologist*, 42(S1), 405.

Journal Article, Academic Journal (Published)

Corcoran, C. D., Ryan, L., Mehta, C. R., Senchaudhuri, P., Patel, N., Molenberghs, G. (2001). An Exact Trend Test for Correlated Binary Data. *Biometrics*, 57, 941-948.

Journal Article, Academic Journal (Published)

Corcoran, C. D., Mehta, C. R. (2001). Comments on 'Interval Estimation for a Binomial Proportion'. *Statistical Science*, 16, 122-124.

Journal Article, Academic Journal (Published)

Corcoran, C. D., Mehta, C. R., Patel, N., Senchaudhuri, P. (2001). Computational Tools for Exact Conditional Logistic Regression. *Statistics in Medicine*, 20, 2723-2739.

Journal Article, Academic Journal (Published)

Corcoran, C. D., Mehta, C. R., Senchaudhuri, P. (2000). Power Comparisons for Tests of Trend in Dose-Response Studies. *Statistics in Medicine*, 19, 3037-3050.

Non-Refereed Journal Articles

Journal Article, Academic Journal (Published)

Wang, G., Fu, G., Corcoran, C. D. (2015). A forest-based feature screening approach for large-scale genome data with complex structures. *BMC genetics*, 16(1), 148.

Journal Article, Academic Journal (Published)

Carlsen, M., Fu, G., Bushman, S., Corcoran, C. D. (2015). Exploiting Linkage Disequilibrium for Ultra High Dimensional Genome-Wide Data with an Integrated Statistical Approach. *Genetics*.

Journal Article, Academic Journal (Published)

Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J. C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J. (2013). TREM2 variants in Alzheimer's disease. *The New England journal of medicine*, 368(2), 117-27.

Journal Article, Professional Journal (Published)

Shao, H., Breitner, J. C., Whitmer, R., Szekely, C., Wang, J., Hayden, K., Wengreen, H., Corcoran, C. D., Norton, M. C., Munger, R. G., Welsh-Bohmer, K., Zandi, P. P. (2012). Hormone Therapy and Alzheimer's: New Findings from The Cache County Study. *Neurology*, 79(18), 1846-1852.

Journal Article, Academic Journal (Published)

Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C. D., Ostaszewski, B. L., Weiming, X., Levesque, G., Hyslop, P. G., Younkin, S. G., Selkoe, D. L. (1998). Additive Effects of PS1 and APP Mutations of Secretion of the 42-residue Amyloid B-protein. *Neurobiology of Diseases*, 5, 107-16.

Conference Proceedings

Conference Proceeding (Published)

Corcoran, C. D., Senchaudhuri, P., Mehta, C. R. (2002). *A computational method for exact order-restricted inference with binary data*. Alexandria, VA: Proceedings of the American Statistical Association.

Other Intellectual Contributions

Abstract (Published)

Wengreen, H., Corcoran, C. D., Cutler, A., Munger, R. G., Quach, A., Tschanz, J. T., Ward, R. E. (2012). *Erythrocyte omega-3 fatty acid concentrations and cognitive function: The Cache County Study on Memory and Aging* (4th ed., vol. 8, pp. P449). Alzheimer's & Dementia.

Abstract (Published)

Wengreen, H., Quach, A., Cutler, A., Munger, R. G., Corcoran, C. D. (2012). *Whole-grain intake and risk of all-cause mortality among elderly men and women: the Cache, County Study on Memory, Health and Aging* (1_MeetingAbstracts ed., vol. 26, pp. 119-2). The FASEB Journal.

Software (Published)

Schneiter, K., Corcoran, C. D., Laird, N., Degnan, J. (2007). *EFBAT*. www.math.usu.edu/~schneit/efbat/

Presentations Given

- Tschanz, J. T., Rattinger, G., Matyi, J., Sanders, C., Vernon, E. K., Corcoran, C. D., Kauwe, J. K., Buhusi, M. C., Gerontological Society of America Annual Meeting, "Sex differences in Neurotrophin Genes in the risk for Alzheimer's Disease," Gerontological Society of America. (2015).
- Rattinger, G. B., Matyi, J., Kauwe, J., Sanders, C., Corcoran, C. D., Norton, M. C., Munger, R. G., Buhusi, M. C., Tschanz, J. T., Alzheimer's Association International Conference, "Do medications that affect brain derived neurotrophic factor (BDNF) modify the associations between BDNF genotypes and cognitive functioning in older adults? The Cache County Study," Alzheimer's Association, Washington, D.C. (July 18, 2015 - July 23, 2015).
- Rattinger, G. B., Behrens, S., Schwartz, S., Corcoran, C. D., Piercy, K. W., Norton, M. C., Fauth, E. B., Lyketsos, C., Tschanz, J. T., Alzheimer's Association International Conference, "How do neuropsychiatric symptoms in persons with Dementia affect caregiver physical and mental health over time? The Cache County Dementia Progression Study," Alzheimer's Association, Washington, D.C. (July 18, 2015 - July 23, 2015).
- Matyi, J., Kauwe, J., Sanders, C., Rattinger, G. B., Corcoran, C. D., Norton, M. C., Munger, R. G., Buhusi, M. C., Tschanz, J. T., Alzheimer's Association International Conference, "Neurotrophin single nucleotide polymorphisms and cognitive functioning in older adults: The Cache County Study," Alzheimer's Association, Washington, DC. (July 18, 2015 - July 23, 2015).
- Tschanz, J. T., Sanders, C. J., Wengreen, H., Schwartz, S., Behrens, S., Corcoran, C. D., Lyketsos, C., Alzheimer's Association International Conference, "Nutritional status and Neuropsychiatric symptoms in Dementia: The Cache County Dementia Study," Alzheimer's Association, Washington, D.C. (July 18, 2015 - July 23, 2015).
- Sanders, C. J., Wengreen, H., Schwartz, S., Behrens, S., Corcoran, C. D., Lyketsos, C., Tschanz, J. T., Alzheimer's Association International Conference, "Nutritional status and severe Dementia, institutionalization and mortality: The Cache County Dementia Progression Study," Alzheimer's Association, Washington, D.C. (July 18, 2015 - July 23, 2015).
- Sanders, C., Wengreen, H., Schwartz, S., Behrens, S., Corcoran, C. D., Lyketsos, C. G., Tschanz, J. T., Neuropsychological Society Meeting, "Nutritional status and neuropsychological functioning in persons with dementia: The Cache County Dementia Progression Study," Neuropsychological Society, Denver, CO. (February 2015).
- Tschanz, J. T., Sanders, C., Wengreen, H., Schwartz, S., Behrens, S., Corcoran, C. D., Lyketsos, C., Annual Meeting of the Gerontological Society of America, "Nutritional status and neuropsychiatric symptoms in dementia: The Cache County Dementia Study," Gerontological Society of America, Washington DC. (November 2014 - 2014).
- Milman, L., Faroqi-Shah, Y., Corcoran, C. D., Clinical Aphasiology Conference, "Normative data for the WAB-R: A comparison of monolingual English speakers, Asian Indian-English bilinguals, and Spanish-English bilinguals.," St. Simons Island, GA. (May 29, 2014).
- Corcoran, C. D. (Invited Lecture), International Webinar, "Exact Nonparametric Inference for Correlated Categorical Data," Cytel Software Corporation. (April 7, 2014).
- Corcoran, C. D., Annual Meeting of the Utah Chapter of the American Statistical Association, "The Perils of P-Values: A Case Study in Statistical Genetics," American Statistical Association, Utah Chapter, Salt Lake City, UT. (March 25, 2014).

- Corcoran, C. D. (Presenter & Author), Boston University Department of Biostatistics Seminar, "Permutation-Based Tests and Rare Variants in Genetic Association Studies," Department of Biostatistics, Boston University, Boston University, Boston, MA. (March 20, 2014).
- Corcoran, C. D. (Presenter & Author), Brigham Young University Department of Statistics Seminar, "Doctoral Research Programs in Statistics at Utah State University," Brigham Young University, Brigham Young University, Provo, UT. (February 2014).
- Rattinger, G. B., Schwartz, S., Sanders, C., Corcoran, C. D., Fauth, E. B., Norton, M. C., Lyketsos, C. G., Tschanz, J. T., Annual Conference for the Gerontological Society of America, "Effect of caregiver relationship closeness and coping strategies on costs of care in the Cache County Dementia Progression Study Cohort," Gerontological Society of America, New Orleans, LA. (November 2013).
- Corcoran, C. D. (Presenter & Author), Food and Drug Administration Workshop, "StatXact Training Course," Food and Drug Administration, Chevy Chase, MD. (September 19, 2013).
- Corcoran, C. D. (Presenter & Author), Joint Statistical Meetings, "New StatXact Toolkit for Correlated Categorical Data," American Statistical Association and International Biometric Society, Montreal, Quebec, Canada. (July 2013 - August 2013).
- Rattinger, G. (Presenter & Author), Schwartz, S. (Author Only), Corcoran, C. D. (Author Only), Zuckerman, I. (Author Only), Mullins, D. (Author Only), Norton, M. C. (Author Only), Fauth, E. B. (Author Only), Leoutsakos, J. (Author Only), Lyketsos, C. (Author Only), (Author Only), Alzheimer's Association International Conference, "How does dementia severity affect the costs of dementia care? Effect of dementia severity on costs of care in the Cache County Dementia Progression Study Cohort," Alzheimer's Association, Boston, MA. (July 2013).
- Rattinger, G. B., Schwartz, S., Corcoran, C. D., Zuckerman, I. H., Mullins, C. D., Norton, M. C., Fauth, E. B., Leoutsakos, J. M., Lyketsos, C. G., Tschanz, J. T., Alzheimer's Association International Conference on Alzheimer's Disease, "Effect of dementia severity on costs of care in the Cache County Dementia Progression Study Cohort," Alzheimer's Association, Boston, MA. (July 2013).
- Ebbert, M. T. W., Ridge, P. G., Wilson, A. R., Sharp, A. R., Bailey, M., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., Kauwe, J. S. K., Alzheimer's Association International Conference on Alzheimer's Disease, "Late-onset Alzheimer's disease risk alleles provide evidence of important gene-gene interactions," Alzheimer's Association, Boston, MA. (July 2013).
- Norton, M. C., Munger, R. G., Tschanz, J. T., Corcoran, C. D., Smith, K. R., Alzheimer's Association International Conference on Alzheimer's Disease, "Multiple deaths of first-degree relatives during childhood predicts inflammation in late-life," Alzheimer's Association, Boston, MA. (July 2013).
- Sanders, C., Wengreen, H., Corcoran, C. D., Schwartz, S., Norton, M. C., Lyketsos, C. G., Tschanz, J. T., Alzheimer's Association International Conference on Alzheimer's Disease, "Nutritional status and progression of dementia: The Cache County Dementia Progression Study," Alzheimer's Association, Boston, MA. (July 2013).
- Tschanz, J. T., Schwartz, S., Gilbert, M., Wanzek, J., Sanders, C., Mielke, M., Corcoran, C. D., Norton, M. C., Lyketsos, C. G., Alzheimer's Association International Conference on Alzheimer's Disease, "Vascular factors as predictors of severe dementia and mortality in Alzheimer's disease," Alzheimer's Association, Boston, MA. (July 2013).

- Corcoran, C. D. (Presenter & Author), Seventh International Workshop on Simulation, "Monte Carlo Sampling Using Parallel Processing for Multiple Testing in Genetic Association Studies," University of Bologna and University of Padova, Rimini, Italy. (May 22, 2013).
- Fauth, E. B. (Presenter & Author), Schwartz, S. (Author Only), Norton, M. C. (Author Only), Corcoran, C. D. (Author Only), Piercy, K. W. (Author Only), Lyketsos, C. (Author Only), Tschanz, J. T. (Author Only), Gerontological Society of America Annual meeting, "Care Dyad Relationship Closeness Predicts Fewer Increases in Neuropsychiatric Symptoms over Time in Persons with Dementia," Gerontological Society of America, San Diego, CA. (November 17, 2012).
- Corcoran, C. D. (Presenter & Author), Joint Statistical Meetings, "Twenty-Five Years of Cytel and StatXact: Where We've Been and Where We're Going," American Statistical Association and International Biometric Society, San Diego, CA. (July 2012 - August 2012).
- Corcoran, C. D. (Presenter & Author), University of Utah Department of Family and Preventive Medicine Seminar, "Exact Tests for Correlated Data," University of Utah College of Family and Preventive Medicine, University of Utah, Salt Lake City, UT. (May 2012).
- Corcoran, C. D. (Presenter & Author), University of Utah Department of Family and Preventive Medicine Seminar, "Exact Methods in Data Analysis," University of Utah Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT. (April 2012).
- Norton, M. C., Hess, K., Corcoran, C. D., Piercy, K. W., Fauth, E. B., Rabins, P., Green, R., Lyketsos, C., Tschanz, J. T., International Conference on Alzheimer's Disease, "Caregiver Agreeableness, Neuroticism, Openness and Extraversion Associated with Rate of Cognitive Decline in Persons with Alzheimer's Disease," Paris, France. (July 2011).
- Tschanz, J. T., Corcoran, C. D. (Author Only), Norton, M. C., Piercy, K., Rabins, P. V., Fauth, E., DeBerard, M. S., Snyder, C., Smith, C., Lee, S., Morrison, A., Lyketsos, C. G., International Conference on Alzheimer's Disease and Other Disorders, "Caregiver Coping Strategies Predict Cognitive Decline in Dementia: The Cache County Dementia Progression Study," Honolulu, HI. (July 2010).
- Treiber, K. A., Carlson, M., Corcoran, C. D. (Author Only), Foley, B., Stein, D., DeBerard, M. S., Norton, M., Piercy, K., Welsh-Bohmer, K. A., Breitner, J. S., Lyketsos, C. G., Tschanz, J., International Conference on Alzheimer's Disease and Other Disorders, "Cognitive Activity and Decline in Alzheimer's Disease: The Cache County Study," Honolulu, HI. (July 2010).
- Norton, M. C., Fauth, E., Piercy, K., Corcoran, C. D. (Author Only), Hess, K., Morrison, A., Rabins, P. V., Lyketsos, C. G., Tschanz, J., International Conference on Alzheimer's Disease and Other Disorders, "Higher caregiver agreeableness predicts slower cognitive decline in persons with Alzheimer's Disease: the Dementia Progression Study," Honolulu, HI. (July 2010).
- Munger, R. G., Cawthon, R. M., Corcoran, C. D. (Author Only), Tschanz, J., Norton, M. C., Smith, K., Zandi, P., Welsh-Bohmer, K., International Conference on Alzheimer's Disease and Other Disorders, "Prospective study of mitochondrial DNA copy number and incident dementia in Cach County, UTah," Honolulu, HI. (July 2010).
- Corcoran, C. D., Pieper, C., Zandi, Z., Norton, M. N., Welsh-Bohmer, K., Breitner, J. S., Lyketsos, C. G., Tschanz, J. T., International Congress on Alzheimer's Disease, "A joint analysis of cognitive, functional, and neuropsychiatric symptom change in the Cache County Dementia Progression Study," Honolulu, HI. (July 2010).

- Corcoran, C. D. (Presenter & Author), Pieper, C., Zandi, Z., Norton, M. N., Welsh-Bohmer, K., Breitner, J. S., Lyketsos, C. G., Tschanz, J. T., International Congress on Alzheimer's Disease, "Predictors of decline in Alzheimer's: A joint analysis of cognitive, functional, and neuropsychiatric symptom change in the Cache County Dementia Progression Study," Honolulu, HI. (July 2010).
- Corcoran, C. D. (Invited Lecture), Senchaudhuri, P., Mehta, C., Invited Seminar, University of Utah Medical School, "Using the StatXact Correlated Data Module for Exact Tests with Clustered Data," Salt Lake City, UT. (February 2010).
- Corcoran, C. D. (Presenter & Author), Senchaudhuri, P., Mehta, C., Conference of the International Indian Statistical Association, "New Software Tools for Exact Tests with Correlated Data," Visakhapatnam, India. (January 2010).
- Corcoran, C. D. (Invited Lecture), Senchaudhuri, P., Invited Seminar, Brigham Young University, "Exact Tests for Contingency Tables with Correlated Data," Department of Statistics, Provo, UT. (December 2009).
- Norton, M. C., Smith, K. R., Ostbye, T., Tschanz, J. T., Corcoran, C. D. (Presenter Only), Schwartz, S., Piercy, K. W., Rabins, P. V., Steffens, D. C., Breitner, J. C., Welsh-Bohmer, K. A., International Conference on Alzheimer's Disease, "Spousal dementia caregiving as a risk factor for incident dementia," Vienna, Austria. (2009).
- Tschanz, J. T., Corcoran, C. D., Green, R. C., Munger, R. G., Mielke, M. M., Norton, M. C., Rabins, P. V., Welsh-Bohmer, K. A., Buckley, T., Breitner, J. C., Lyketsos, C. G., International Conference on Alzheimer's Disease, "Interaction between C-Reactive Protein level and APOE genotype in predicting rate of progression in Alzheimer's disease," The Cache County Dementia Progression Study, Vienna, Austria. (2009).
- Corcoran, C. D. (Invited Lecture), Munger, R. G., Cawthon, R., Invited Seminar, Harvard University, "Alzheimer's Disease Risk, Cognitive Decline, and Mitochondrial Function," Department of Biostatistics, Cambridge, MA. (October 2009).
- Norton, M. C., Smith, K. R., Ostbye, T., Tschanz, J. T., Corcoran, C. D., Schwartz, S., Piercy, K. W., Rabins, P. V., Steffens, D. C., Breitner, J. C. S., Welsh-Bohmer, K. A., International Conference on Alzheimer's Disease, "Spousal dementia caregiving as a risk factor for incident dementia: The Cache County Study.," Vienna, Austria. (July 2009).
- Corcoran, C. D. (Invited Lecture), Pieper, C., Tschanz, J., Invited Seminar, Brigham Young University, "Dynamical Correlations for Analyzing Multivariate Rates of Change, with Application to the Cache County Memory Study," Department of Statistics, Provo, UT. (January 2009).
- Tschanz, J. T., Cook, L., Corcoran, C. D., Norton, M. C., Mielke, M., Rabins, P., Welsh-Bohmer, K. A., Treiber, K., Buckley, T., Breitner, J. C., Lyketsos, C., 36th Annual Meeting of the International Neuropsychological Society, "Gender Differences in the Trajectory of Cognitive Decline in Alzheimer's Disease in the Cache County Population," Waikoloa Hawaii. (2008).
- Tschanz, J., Corcoran, C. D. (Author Only), Shao, H., Zandi, P., Norton, M., Mielke, M., Green, R., Rabins, P., Steinberg, M., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., International Conference on Alzheimer's Disease, "Neuropsychiatric Symptoms and Mortality in a Populationbased Sample of Incident Alzheimer's Disease and other Dementias: The Cache County Dementia Progression Study," Chicago, IL. (2008).
- Treiber, K., Shao, H., Zandi, P., Steinberg, M., Corcoran, C. D. (Author Only), Cook, L., Norton, M., Green, R., Piercy, K., Rabins, P., Breitner, J., Welsh-Bohmer, K., Lyketsos, C., Tschanz,

- J., International Conference on Alzheimer's Disease, "Neuropsychiatric Syndromes in Alzheimer's disease: Relationship to Cognitive and Functional Progression: The Cache County Dementia Progression Study," Chicago, IL. (2008).
- Treiber, K., Shao, H., Zandi, P., Steinberg, M., Corcoran, C. D., Cook, L., Norton, M. C., Green, R., Piercy, K. W., Rabins, P., Breitner, J. C. S., Welsh-Bohmer, K. A., Lyketsos, C., Tschanz, J. T., International Conference on Alzheimer's Disease, "Neuropsychiatric syndromes in Alzheimer's disease: Relationship to Cognitive and Functional Progression: The Cache County Dementia Progression Study," The Cache County Dementia Progression Study, Chicago, IL. (2008).
- Corcoran, C. D., Pieper, C., Zandi, p., Norton, M. C., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., Tschanz, J. T., International Conference on Alzheimer's Disease, "Modeling dementia trajectories: An application of dynamical correlations to age-related traits: The Cache County Dementia Progression Study," The Cache County Dementia Progression Study, Chicago, IL. (2008).
- Tschanz, J. T., Corcoran, C. D., Shao, H., Zandi, P., Norton, M. C., Mielke, M., Green, R., Rabins, P., Steinberg, M., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., International Conference on Alzheimer's Disease, "Neuropsychiatric Symptoms and Mortality in a Population-based Sample of Incident Alzheimer's Disease and other Dementias: The Cache County Dementia Progression Study," The Cache County Dementia Progression Study., Chicago, IL. (2008).
- Corcoran, C. D., Senchaudhuri, P., Joint Statistical Meetings, "Exact Trend Tests for Clustered 2 X C Tables," Denver, CO. (August 2008).
- Corcoran, C. D. (Presenter & Author), Pieper, C., Zandi, P., Norton, M., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., Tschanz, J., International Congress on Alzheimer's Disease, "Modeling dementia trajectories: An application of dynamical correlations to age-related traits in the Cache County Dementia Progression Study," Chicago, IL. (July 2008).
- Corcoran, C. D. (Invited Lecture), Zandi, P., Pieper, C., Tschanz, J., Invited Seminar, Harvard University, "Assessing Multiple Trajectories of Dementia Symptoms: The Cache County Dementia Progression Study," Department of Biostatistics, Cambridge, MA. (May 2008).
- Tschanz, J., Cook, L., Corcoran, C. D. (Author Only), Norton, M., Mielke, M., Rabins, P., Welsh-Bohmer, K. A., Trieber, K., Buckley, T., Breitner, J. S., Lyketsos, C., 36th Annual Meeting of the International Neuropsychological Society, "Gender Differences in the Trajectory of Cognitive Decline in Alzheimer's Disease in the Cache County Population," Waikola, Hawaii. (February 2008).
- Breitner, J. C., Khachaturian, A., Zandi, P., Hayden, K., Skoog, I., Tschanz, J. T., Norton, M. C., Munger, R. G., Welsh-Bohmer, K., Rosenberg, P., Mielke, M., Corcoran, C. D., Lyketsos, C., Rabins, P., Green, R., 11th International Congress of the International Federation of Psychiatric Epidemiology, "Cardiovascular risk factors for incidence and/or progression of Alzheimer's disease: The Cache County Studies," The Cache County Studies, Göteborg, Sweden. (2007).
- Mielke, M. M., Tschanz, J. T., Hayden, K. M., Rosenberg, P. B., Corcoran, C. D., Norton, M. C., Rabins, P. V., Green, R. C., Welsh-Bohmer, K. A., Breitner, J. C., Munger, R. G., Lyketsos, C. G., 2007 Vascular, Behavioural and Cognition (VAS-COG) Conference, "Interaction Between APOE ϵ 4 and Vascular Factors Predict Rate of Cognitive and Functional Decline in Alzheimer's Disease," San Antonio, TX. (2007).

- Mielke, M. M., Tschanz, J. T., Norton, M. C., Corcoran, C. D., Rabins, P., Steinberg, M., Carlson, M., Green, R., Breitner, J. C., Welsh-Bohmer, K., Lyketsos, C. G., Alzheimer Prevention Conference, "Use of acetylcholinesterase inhibitors and memantine in a population-based study of incident AD cases: Prevalence of use, characteristics, and relation to mortality," Washington, D.C. (2007).
- Mielke, M. M., Tschanz, J., Norton, M., Corcoran, C. D. (Author Only), Rabins, P., Steinberg, M., Carlson, M., Green, R., Breitner, J. S., Welsh-Bohmer, K., Lyketsos, C. G., Alzheimer Prevention Conference, "Use of acetylcholinesterase inhibitors and memantine in a population-based study of incident AD cases: Prevalence of use, characteristics, and relation to mortality.," Washington D.C. (2007).
- Mielke, M. M., Tschanz, J., Hayden, K. M., Rosenberg, P. B., Corcoran, C. D. (Author Only), Norton, M., Rabins, P. V., Green, R. C., Welsh-Bohmer, K. A., Breitner, J. S., Munger, R. G., Lyketsos, C. G., Vascular, Behavioural and Cognition Conference, "Interaction Between APOE epsilon4 and Vascular Factors Predict Rate of Cognitive and Functional Decline in Alzheimer's Disease," VAS-COG, San Antonio, TX. (2007).
- Tschanz, J., Shao, H., Zandi, P., Steinberg, M., Corcoran, C. D. (Author Only), Norton, M., Green, R., Piercy, K., Rabins, P., Cook, L., Lyketsos, C., 60th Annual Scientific Meeting of the Gerontological Society of America, "Neuropsychiatric syndromes in Alzheimer's disease: Association with Rate of Cognitive Progression. The Cache County Study," San Francisco, CA. (November 2007).
- Treiber, K., Tschanz, J., Corcoran, C. D. (Author Only), Stein, D., Steinberg, M., Norton, M., Green, R., Rabins, P., Piercy, K., Welsh-Bohmer, K., Lyketsos, C., 60th Annual Scientific Meeting of the Gerontological Society of America, "Point prevalence of neuropsychiatric symptoms in Alzheimer's disease and vascular dementia: The Cache County Study," San Francisco, CA. (November 2007).
- Norton, M., Tschanz, J., Ostbye, T., Corcoran, C. D. (Author Only), Cook, L., Breitner, J., Welsh-Bohmer, K. A., 60th Annual Scientific Meeting of the Gerontological Society of America, "Stressful life events and cognitive decline - The Cache County Study," San Francisco, CA. (November 2007).
- Norton, M. C., Tschanz, J. T., Ostbye, T., Corcoran, C. D., Cook, L., Breitner, J., Welsh-Bohmer, K., 60th Annual Scientific Meeting of the Gerontological Society of America, "Stressful life events and cognitive decline - The Cache County Study," The Cache County Study, San Francisco, CA. (November 2007).
- Norton, M. C., Tschanz, J. T., Ostbye, T., Corcoran, C. D. (Author Only), Breitner, J. S., Welsh-Bohmer, K. A., World Conference of Stress, "Widow(er)hood increases risk for subsequent dementia, especially for women. The Cache County Study," Budapest, Hungary. (August 2007).
- Norton, M. C., Tschanz, J. T., Ostbye, T., Corcoran, C. D., Zandi, P. P., Breitner, J. C., Welsh-Bohmer, K. A., World Conference of Stress, "Widow(er)hood increases risk for subsequent dementia, especially for women. The Cache County Study," The Cache County Study, Budapest, Hungary. (August 2007).
- Corcoran, C. D. (Presenter & Author), Pieper, C., Zandi, P., Tschanz, J., Joint Statistical Meetings, "Invited Presentation," Salt Lake City, UT. (July 2007).
- Breitner, J. S., Khachaturian, A., Zandi, P., Hayden, K., Skoog, I., Tschanz, J., Norton, M., Munger, R. G., Welsh-Bohmer, K., Rosenberg, P., Mielke, M., Corcoran, C. D. (Author Only), Lyketsos, C., Rabins, P., Green, R., 11th International Congress of the International

- Federation of Psychiatric Epidemiology, "Cardiovascular risk factors for incidence and/or progression of Alzheimer's disease: The Cache County Studies," Goteborg, Sweden. (May 3, 2007 - May 6, 2007).
- Buckley, T., Tschanz, J., Norton, M., Corcoran, C. D. (Author Only), Welsh-Bohmer, K. A., Breitner, J., International Neuropsychological Society Conference, "Metacognitive judgments and change in cognitive and functional abilities in a population of elderly individuals. The Cache County Study," Portland, OR. (February 2007).
- Buckley, T., Tschanz, J. T., Norton, M. C., Corcoran, C. D., Welsh-Bohmer, K., Breitner, J., International Neuropsychological Society Conference, "Metacognitive judgments and change in cognitive and functional abilities in a population of elderly individuals. The Cache County Study," The Cache County Study, Portland OR. (February 2007).
- Tschanz, J., Corcoran, C. D. (Author Only), Norton, M., Mielke, M., Rabins, P., Treiber, K., Welsh-Bohmer, K. A., Breitner, J., Lyketsos, C., International Neuropsychological Society Conference, "Rate of cognitive and functional decline in Alzheimer's disease in the Cache County Population," Portland, OR. (February 2007).
- Tschanz, J. T., Corcoran, C. D., Norton, M. C., Mielke, M., Rabins, P., Treiber, K., Welsh-Bohmer, K. A., Breitner, J., Lyketsos, C., the International Neuropsychological Society Conference, "Rate of cognitive and functional decline in Alzheimer's disease in the Cache County Population," Portland OR. (February 2007).
- Corcoran, C. D. (Invited Lecture), Invited Seminar, Harvard University, "Family-based Association Studies: The Cache County Study on Memory Health and Aging, and the Utah Population Database," Department of Biostatistics. (October 2006).
- Corcoran, C. D. (Presenter & Author), Senchaudhuri, P., Coull, B., Joint Statistical Meetings, "Exact Inference for Correlated Categorical Data," Seattle, WA. (August 2006).
- Corcoran, C. D. (Presenter & Author), Tschanz, J., Steinberg, M., Schwartz, S., Norton, M., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., 10th International Conference on Alzheimer's Disease and Related Disorders, "Longitudinal Course of Neuropsychiatric Symptoms in Dementia. The Cache County Study," Madrid, Spain. (July 2006).
- Corcoran, C. D., Tschanz, J. T., Steinberg, M., Schwartz, S., Norton, M. C., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., 10th International Conference on Alzheimer's Disease and Related Disorders, "Longitudinal Course of Neuropsychiatric Symptoms in Dementia. The Cache County Study," The Cache County Study. (July 2006).
- Tschanz, J. T., Cook, L., Corcoran, C. D., Norton, M. C., Mielke, M., Rosenberg, P., Buckley, T., Clay, C., Welsh-Bohmer, K., Breitner, J., C. L., 10th International Conference on Alzheimer's Disease and Related Disorders, "Vascular factors and the Rate of Cognitive Decline in Dementia. The Cache County Study," The Cache County Study. (July 2006).
- Mielke, M. M., Rosenberg, P., Tschanz, J. T., Cook, L., Corcoran, C. D., Norton, M. C., Welsh-Bohmer, K. A., Breitner, J. C., Lyketsos, C., 10th International Conference on Alzheimer's Disease and Related Disorders, "Vascular Risk Factors and Functional Decline in Dementia," the Cache County Study. (July 2006).
- Tschanz, J. T., Cook, L., Corcoran, C. D. (Author Only), Norton, M., Mielke, M., Rosenberg, P., Buckley, T., Clay, C., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., International Conference on Alzheimer's Disease and Related Disorders, "Vascular factors and the Rate of Cognitive Decline in Dementia. The Cache County Study," Madrid, Spain. (July 2006).

- Treiber, K., Tschanz, J., Corcoran, C. D. (Author Only), Stein, D., Steinberg, M., Norton, M., Welsh-Bohmer, K., Breitner, J., Lyketsos, C., International Conference on Alzheimer's Disease and Related Disorders, "Vascular Factors are Associated with Increased Risk of Neuropsychiatric Symptoms in Alzheimer's Disease. The Cache County Study," Madrid, Spain. (July 2006).
- Mielke, M. M., Rosenburg, P., Tschanz, J., Cook, L., Corcoran, C. D. (Author Only), Norton, M., Welsh-Bohmer, K. A., Breitner, J. C., Lyketsos, C., International Conference on Alzheimer's Disease and Related Disorders, "Vascular Risk Factors and Functional Decline in Dementia," Madrid, Spain. (July 2006).
- Corcoran, C. D. (Invited Lecture), Invited Seminar, University of Pennsylvania, "Family-based Association Studies: The Cache County Study on Memory Health and Aging, and the Utah Population Database," Department of Biostatistics. (March 2006).
- Corcoran, C. D. (Invited Lecture), Invited Seminar, Cytel Software Corporation, "The Exact Family Based Association Test," Cambridge, MA. (February 2006).
- Charoonruk, G., Munger, R. G., Wengreen, H., Corcoran, C. D., Hayden, K., Bastian, L., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K., Alzheimer's Association International conference on Prevention of Dementia: Early diagnosis and intervention, "Diabetes Mellitus and risk of Alzheimer's disease in the Cache County Study on Memory, Health and Aging," the Cache County Study on Memory, Health and Aging, Washington, D.C. (2005).
- Charoonruk, G., Munger, R. G., Wengreen, H., Corcoran, C. D. (Author Only), Hayden, K., Bastian, L., Tschanz, J., Norton, M., Welsh-Bohmer, K., Alzheimer's Association International conference on Prevention of Dementia: Early diagnosis and intervention, "Diabetes Mellitus and risk of Alzheimer's disease in the Cache County Study on Memory, Health and Aging," Washinton, D.C. (2005).
- Wengreen, H. J., Munger, R. G., Corcoran, C. D. (Author Only), Zandi, P., Tschanz, J., Norton, M., Welsh-Bohmer, K., Alzheimer's Association International Conference on Prevention of Dementia: Early diagnosis and intervention, "Fruit and vegetable intake and cognitive function in the elderly: The Cache County Study on Memory, Health and Aging," Washington, D.C. (2005).
- Corcoran, C. D. (Author Only), Alzheimer's Association International Conference on Prevention of Dementia: Early diagnosis and intervention, "Does Vitamine E use protect against dementia or increase the risk of mortality," Washington, D.C. (2005).
- Tschanz, J., Corcoran, C. D. (Author Only), Toone, L., Pfister, R., Welsh-Bohmer, K., Norton, M., Breitner, J., Lyketsos, C., International Neuropsychological Society Convention, "Head Injury and Trajectory of Cognitive Decline in Dementia. The Cache County Study," St. Louis, MO. (2005).
- Tschanz, J. T., Corcoran, C. D., L, T., R., P., K., W.-B., Norton, M. C., J., B., C., L., Presented at the International Neuropsychological Society Convention, "Head Injury and Trajectory of Cognitive Decline in Dementia," Presented at the International Neuropsychological Society Convention The Cache County Study. (2005).
- Wengreen, H., Munger, R. G., Corcoran, C. D., Zandi, P., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K., the Alzheimer's Association International conference on Prevention of Dementia: Early diagnosis and intervention, "Fruit and vegetable intake and cognitive function in the elderly: The Cache County Study on Memory, Health and Aging," The Cache County Study on Memory, Health and Aging, Washington, D.C. (2005).

- Schneiter, K., Corcoran, C. D., Laird, N., The Western North American Region of The International Biometric Society, "Exact Family Based-Association Tests for Multiallelic Data," International Biometric Society, Fairbanks, AK. (2005).
- Corcoran, C. D., Canadian Society of Epidemiology and Biostatistics Annual Meeting, "Exact inference for epidemiology and statistics," Toronto, ON. (July 2005).
- Norton, M., Steffens, D., Toone, L., Tschanz, J., Hayden, K., Corcoran, C. D. (Author Only), Klein, L., Zandi, P., Breitner, J. S., Welsh-Bohmer, K., Annual Meeting of the Gerontological Society of America, "Late-life Depression, Mild Cognitive Impairment, APOE and their Interactive Effects on 3-Year Conversion to Dementia.," Washington D.C. (November 2004).
- Benson-Lensegrav, T., Tschanz, J., Masters, K. S., Carlson, M. C., Corcoran, C. D. (Author Only), Lykestos, C., Heath, E., Leslie, C., Munger, R. G., Ostbye, T., Welsh-Bohmer, K., Norton, M., Hayden, L., Annual Meeting of the American Psychological Association, "Sedentary Lifestyle Increases Dementia Risk: The Cache County Study.," Honolulu, HI. (July 2004).
- Steinberg, M., Corcoran, C. D. (Author Only), Huber, C., Welsh-Bohmer, K., Zandi, P., Breitner, J. S., Tschanz, J., Lykestos, C., International Conference on Alzheimer's Disease and Related Disorders, "A Longitudinal Model for Neuropsychiatric Symptoms in Dementia: The Cache County Study," Philadelphia, PA. (July 2004).
- Toone, L., Tschanz, J., Rabins, P. V., Steinberg, M., Onyike, C., Corcoran, C. D. (Author Only), Norton, M., Welsh-Bohmer, K., Breitner, J., Zandi, P., Lykestos, C. G., International Conference on Alzheimer's Disease and Related Disorders, "A Population Based Study of Medical Co-Morbidity in Early Dementia and Mild Cognitive Syndrome: Association with Functional and Cognitive Impairment," Philadelphia, PA. (July 2004).
- Wengreen, H., Munger, R. G., Corcoran, C. D. (Author Only), Zandi, P., Tschanz, J., Norton, M., Welsh-Bohmer, K., Skoog, I., Breitner, J., International Conference on Alzheimer's Disease and Related Disorders, "Antioxidant Intake and Cognitive Function of Elderly Participants in The Cache County, Utah Study on Memory, Health and Aging.," Philadelphia, PA. (July 2004).
- Charoonruk, G., Munger, R. G., Wengreen, H., Corcoran, C. D. (Author Only), Tschanz, J., Norton, M., Bastian, L., Welsh-Bohmer, K., International Conference on Alzheimer's Disease and Related Disorders, "Diabetes Mellitus and Cognitive Decline in the Cache County Study on Memory, Helath and Aging," Philadelphia, PA. (July 2004).
- Norton, M. C., Steffens, D. C., Toone, L., Tschanz, J. T., Hayden, K., Corcoran, C. D. (Author Only), Klein, L., Zandi, P., Breitner, J. S., Welsh-Bohmer, K. A., International Conference on Alzheimer's Disease and Related Disorders, "Late-life Depression, Mild Cognitive Impairment, APOE and their Interactive Effects on 3-Year Conversion to Dementia," Philadelphia, PA. (July 2004).
- Tschanz, J., Klein, E., Trieber, K., Corcoran, C. D. (Author Only), Norton, M., Toone, L., Welsh-Bohmer, K., Steinberg, M., Munger, R. G., Pieper, C., Breitner, J., Zandi, P., Lykestos, C., International Conference on Alzheimer's Disease and Related Disorders, "Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia: Prevalence and Relationship to Cognitive and Functional Impairment," Philadelphia, PA. (July 2004).
- Klein, E., Corcoran, C. D., Tschanz, J., Norton, M., Welsh-Bohmer, K., Breitner, J., Zandi, P., Lykestos, C., International Conference on Alzheimer's Disease and Related Disorders, "Survival from Memory Symptom Onset: A Comparison of Individuals with Dementia and Cognitive Impairment. The Cache County Study," Philadelphia, PA. (July 2004).

- Klein, E., Tschanz, J., Corcoran, C. D. (Author Only), Norton, M., Welsh-Bohmer, K., Breitner, J., Zandi, P., Lyketsos, C., Society of Epidemiological Research, "Estimating Survival Duration from Memory Symptom Onset: A Comparison of Methods. The Cache County Study," Salt Lake City, UT. (June 2004).
- Norton, M., Skoog, I., Toone, L., Tschanz, J., Corcoran, C. D. (Author Only), Zandi, P., Hart, A., Breitner, J., Welsh-Bohmer, K., Steffens, D., Society of Epidemiological Research, "Improving Assessment of Incidence of First-Onset Geriatric Depression in Population-Based Studies," Salt Lake City, UT. (June 2004).
- Lensegrav-Benson, T., Lisota, R., Tschanz, J., Masters, K., Norton, M., Carlson, M., Corcoran, C. D. (Author Only), Lyketsos, C., Heath, E., Leslie, C., Munger, R. G., Ostbye, T., Welsh-Bohmer, K., Annual Meeting of the Western Psychological Association, "Physical Activity is Associated with Better Cognitive Performance," Phoenix, AZ. (April 2004).
- Corcoran, C. D. (Invited Lecture), Schneiter, K., Laird, N., Invited Seminar, University of Colorado Health Sciences Center, "Implementing an exact family based association test in the presence of two alleles," Denver, CO. (April 2004).
- Lisota, R., Steffens, D., Toone, L., Tschanz, J. T., Norton, M., Corcoran, C. D. (Author Only), Welsh-Bohmer, K. A., Breitner, J. S., Annual AAGP Meeting, "Vascular Risk Factors Predict Chronicity of Depression in the Elderly," Baltimore, MD. (February 2004).
- Schneiter, K., Corcoran, C. D., The Western North American Region of The International Biometric Society, "An Exact Approach to Family Based Association Tests Using a Network Algorithm.," The International Biometric Society, Golden, CO. (2003).
- Corcoran, C. D. (Invited Lecture), Invited Seminar, Brigham Young University, "A network algorithm for exact family based association tests," Provo, UT. (September 2003).
- Corcoran, C. D. (Author Only), Schneiter, K., Spring Meeting of the Western North America Region of the International Biometrics Society, "A Network Algorithm for Exact-Based Association Tests," Denver, CO. (June 2003).
- Corcoran, C. D. (Presenter & Author), Senchaudhuri, P., Spring Meeting, Western North America Region, "Exact Dose-Response Estimation for Clustered Binary Data," International Biometrics Society, Denver, CO. (June 2003).
- Huber, C., Steinberg, M., Tschanz, J., Corcoran, C. D. (Author Only), Posters on the Hill, "A Longitudinal Model for Behavioral Disturbances among the Elderly with Dementia: The Cache County Memory Study," Washington D.C. (April 2003).
- Norton, M. C., Steffens, D. C., Skoog, I., Corcoran, C. D. (Author Only), Welsh-Bohmer, K. A., Breitner, J. S., American Association for Geriatric Psychiatry, "Prior Minor Depression Is More Predictive of Future Episodes of Depression in the Elderly than Gender, Age, or APOE status. The Cache County Study," Honolulu, HI. (March 2003).
- Tschanz, J., Welsh-Bohmer, K., Norton, M., Corcoran, C. D. (Author Only), Breitner, J., International Neuropsychological Society 31st Annual Meeting, "Progression to Dementia in Diverse Types of Mild Cognitive Impairments of Aging," Honolulu, HI. (February 2003).
- Corcoran, C. D. (Presenter & Author), Senchaudhuri, P., Mehta, C., Joint Statistical Meeting, "Order-restricted inference for several binomials," NYC, NY. (August 2002).

- Norton, M., Tschanz, J., Corcoran, C. D., Mumford, S., Welsh-Bohmer, K., Breitner, J., International Conference on Alzheimer's Disease and Related Disorders, "Apolipoprotein E4 interacts with mild cognitive deficit to shorten time to dementia onset," Stockholm, Sweden. (July 2002).
- Tschanz, J., Norton, M., Corcoran, C. D., LaCaille, R., Welsh-Bohmer, K., Breitner, J., International Conference on Alzheimer's Disease and Related Disorders, "Cognitive screening and self-perception of memory problems predict mild cognitive impairment and dementia," Stockholm, Sweden. (July 2002).
- Corcoran, C. D. (Author Only), International Conference on Alzheimer's Disease and Related Disorders, "Differential impact of genetic and demographic variables on clinical course of dementia and Alzheimer's disease," Stockholm, Sweden. (July 2002).
- Hayden, K., Khachaturian, A., Breitner, J., Tschanz, J., Corcoran, C. D. (Author Only), Norton, M., International Conference on Alzheimer's Disease and Related Disorders, "Evaluation of performance of a two-stage screen for incident dementia," Stockholm, Sweden. (July 2002).
- Wengreen, H. J., Munger, R. G., West, N., Cutler, D., Corcoran, C. D., Zhang, J., Sassano, N. E., International Conference on Nutrition and Aging, "Protein Intake and Risk of Osteoporotic Hip Fracture in Elderly Utah Residents," Paris, France. (July 2001).
- Corcoran, C. D. (Presenter & Author), WHO Meeting for the Prevention of Craniofacial Anomalies, "Deisgn consideration for dose-response studies.," Park City, UT. (May 2001).
- West, N., Tschanz, J., Welsh-Bohmer, K., Corcoran, C. D., Wyse, B., Weight, C., Breitner, J., Annual Meeting of the International Neuropsychological Society, "Genetic and nongenetic risk factors for cognitive decline in the normal elderly," Chicago, IL. (February 2001).

Contracts, Grants and Sponsored Research

Contract

- Kauwe (Brigham Young University), Keone (Principal), Munger, Ronald G. (Supporting), Corcoran, Christopher D (Supporting), "Alzheimer's disease candidate gene genotyping: The Cache County Study," Sponsored by USTAR, State, \$42,000.00. (February 1, 2011 - May 30, 2011).

Grant

- Tschanz, Joann T (Principal), Corcoran, Christopher D (Supporting), Munger, Ronald G. (Supporting), Lefevre, Michael (Supporting), "Epidemiology of Alzheimer's Disease resilience and risk pedigrees," Sponsored by NIH, Federal, \$1,067,869.00. (September 1, 2016 - August 31, 2021).
- Corcoran, Christopher D (Supporting), Stevens, John R. (Supporting), "miRNA and colorectal cancer: Associations with tumor phenotype and survival," Sponsored by National Institutes of Health, Federal, \$1,250,000.00. (July 2012 - June 2017).
- Corcoran, Christopher D (Supporting), "Pleiotropic and interaction effects on Alzheimer's disease risk and progression," Sponsored by National Institutes of Health, Federal, \$1,250,000.00. (July 2012 - June 2017).
- Corcoran, Christopher D (Supporting), "Prenatal and Neonatal Biologic Markers for Autism," Federal, \$576,008.00. (July 2010 - June 2015).

Intellectual Contributions in Submission

Refereed Journal Articles

Milman, L., Faroqi-Shah, Y., Corcoran, C. D., Damele, D. Interpreting MMSE scores in highly proficient bilingual Asian Indian-English and Spanish-English speakers: Demographic adjustments, item analyses, and supplemental measures.

SERVICE

General Service

Department

Chairperson, Graduate Committee, August 2012 - Present.

Undergraduate Statistics Advisor, 1999 - Present.

Committee Member, Undergraduate Curriculum Committee, 2003 - 2005.

Committee Member, Graduate Committee, 2002 - 2003.

Committee Member, Undergraduate Committee, 2001 - 2002.

Other

Committee Chair, Computing Committee, 2005 - 2009.

Professional/Public

Officer, Secretary, American Statistical Association, Utah Chapter. 2002 - 2006.

Member, Sunrise Elementary School Community Council. 2002 - 2006.

Committee Member, Cache School District Building Task Force. 2003 - 2004.

Program Organizer, Bioinformatics Working Group. 2002 - 2003.

Contributing Author of User Manuals. 1999 - 2003.

Program Organizer, Statistics Brown Bag Seminar Series. 2000 - 2001.

Utah State University

Committee Member, Promotion and Tenure Central Committee, September 2014 - Present.

Committee Member, Utah State University Faculty Senate, 2007 - Present.

Committee Chair, Utah State University Faculty Senate Committee on Committees, 2008 - 2009.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP PRODUCTS
LIABILITY LITIGATION

MDL No. 2741

Case No. 16-md-02741-VC

This document relates to:
ALL ACTIONS

**PLAINTIFFS' NOTICE TO TAKE ORAL
AND VIDEOTAPED DEPOSITION OF DR.
CHRISTOPHER D. CORCORAN**

To: Monsanto Company, by and through their counsel, Hollingsworth, LLP.

Please take notice that, pursuant to Rule 30 and Rule 45 of the Federal Rules of Civil Procedure, Plaintiffs' Counsel shall take the videotaped deposition upon oral examination of **Dr. Christopher D. Corcoran on September 20, 2017** before a person duly authorized to administer oaths. The deposition shall commence at **9:00 a.m. ET at Hampton Inn, 1665 N. Main St., Logan, UT**. The conduct of the deposition, including its continuation if necessary, shall be governed by Pretrial Order No. 7: Deposition Protocol (ECF No. 103) and Rule 30 of the Federal Rules of Civil Procedure. Dr. Foster shall produce any documents identified in Schedule A attached to his Document Subpoena, at least 10 days prior to the deposition.

Dated: September 6, 2017

Respectfully submitted,

/s/ Robin Greenwald
Robin Greenwald
rgreenwald@weitzlux.com
Weitz & Luxenberg
700 Broadway
New York, NY 10003

/s/ Aimee Wagstaff
Aimee Wagstaff



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

aimee.wagstaff@andruswagstaff.com
Andrus Wagstaff, P.C.
7171 West Alaska Drive
Lakewood, CO 80226

/s/ Mike Miller
Michael Miller
mmiller@millerfirmllc.com
The Miller Firm LLC
108 Railroad Ave
Orange, VA 22960

*Co-Lead Counsel for Plaintiffs
in MDL No. 2741*

AO 88B (Rev. 02/14) Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action

UNITED STATES DISTRICT COURT

for the

Northern District of California

IN RE: ROUNDUP PRODS. LIABILITY LITIG.

Plaintiff

v.

MONSANTO COMPANY

Defendant

Civil Action No. 16-md-2741-VC

SUBPOENA TO PRODUCE DOCUMENTS, INFORMATION, OR OBJECTS
OR TO PERMIT INSPECTION OF PREMISES IN A CIVIL ACTION

To: Dr. Christopher D. Corcoran

(Name of person to whom this subpoena is directed)

Production: YOU ARE COMMANDED to produce at the time, date, and place set forth below the following documents, electronically stored information, or objects, and to permit inspection, copying, testing, or sampling of the material: SEE ATTACHED SCHEDULE A

Place: Weitz & Luxenberg, P.C., 700 Broadway, New York, NY 10003	Date and Time: 09/16/2017 5:00 pm
---	--------------------------------------

Inspection of Premises: YOU ARE COMMANDED to permit entry onto the designated premises, land, or other property possessed or controlled by you at the time, date, and location set forth below, so that the requesting party may inspect, measure, survey, photograph, test, or sample the property or any designated object or operation on it.

Place:	Date and Time:
--------	----------------

The following provisions of Fed. R. Civ. P. 45 are attached – Rule 45(c), relating to the place of compliance; Rule 45(d), relating to your protection as a person subject to a subpoena; and Rule 45(e) and (g), relating to your duty to respond to this subpoena and the potential consequences of not doing so.

Date: 09/06/2017

CLERK OF COURT

OR

/s/ Robin Greenwald

Signature of Clerk or Deputy Clerk

Attorney's signature

The name, address, e-mail address, and telephone number of the attorney representing *(name of party)* Plaintiffs, who issues or requests this subpoena, are:
Robin Greenwald, 700 Broadway, New York, NY 10003, rgreenwald@weitzlux.com, 212-558-5802

Notice to the person who issues or requests this subpoena

If this subpoena commands the production of documents, electronically stored information, or tangible things or the inspection of premises before trial, a notice and a copy of the subpoena must be served on each party in this case before it is served on the person to whom it is directed. Fed. R. Civ. P. 45(a)(4).

AO 88B (Rev. 02/14) Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action (Page 2)

Civil Action No. 16-md-2741-VC

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 45.)

I received this subpoena for *(name of individual and title, if any)* _____
on *(date)* _____.

I served the subpoena by delivering a copy to the named person as follows: _____
_____ on *(date)* _____; or

I returned the subpoena unexecuted because: _____

Unless the subpoena was issued on behalf of the United States, or one of its officers or agents, I have also
tendered to the witness the fees for one day's attendance, and the mileage allowed by law, in the amount of
\$ _____.

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____ 0.00.

I declare under penalty of perjury that this information is true.

Date: _____
_____ *Server's signature*

_____ *Printed name and title*

_____ *Server's address*

Additional information regarding attempted service, etc.:

Federal Rule of Civil Procedure 45 (c), (d), (e), and (g) (Effective 12/1/13)**(c) Place of Compliance.**

(1) For a Trial, Hearing, or Deposition. A subpoena may command a person to attend a trial, hearing, or deposition only as follows:

- (A) within 100 miles of where the person resides, is employed, or regularly transacts business in person; or
- (B) within the state where the person resides, is employed, or regularly transacts business in person, if the person
 - (i) is a party or a party's officer; or
 - (ii) is commanded to attend a trial and would not incur substantial expense.

(2) For Other Discovery. A subpoena may command:

- (A) production of documents, electronically stored information, or tangible things at a place within 100 miles of where the person resides, is employed, or regularly transacts business in person; and
- (B) inspection of premises at the premises to be inspected.

(d) Protecting a Person Subject to a Subpoena; Enforcement.

(1) Avoiding Undue Burden or Expense; Sanctions. A party or attorney responsible for issuing and serving a subpoena must take reasonable steps to avoid imposing undue burden or expense on a person subject to the subpoena. The court for the district where compliance is required must enforce this duty and impose an appropriate sanction—which may include lost earnings and reasonable attorney's fees—on a party or attorney who fails to comply.

(2) Command to Produce Materials or Permit Inspection.

(A) Appearance Not Required. A person commanded to produce documents, electronically stored information, or tangible things, or to permit the inspection of premises, need not appear in person at the place of production or inspection unless also commanded to appear for a deposition, hearing, or trial.

(B) Objections. A person commanded to produce documents or tangible things or to permit inspection may serve on the party or attorney designated in the subpoena a written objection to inspecting, copying, testing, or sampling any or all of the materials or to inspecting the premises—or to producing electronically stored information in the form or forms requested. The objection must be served before the earlier of the time specified for compliance or 14 days after the subpoena is served. If an objection is made, the following rules apply:

- (i) At any time, on notice to the commanded person, the serving party may move the court for the district where compliance is required for an order compelling production or inspection.
- (ii) These acts may be required only as directed in the order, and the order must protect a person who is neither a party nor a party's officer from significant expense resulting from compliance.

(3) Quashing or Modifying a Subpoena.

(A) When Required. On timely motion, the court for the district where compliance is required must quash or modify a subpoena that:

- (i) fails to allow a reasonable time to comply;
- (ii) requires a person to comply beyond the geographical limits specified in Rule 45(c);
- (iii) requires disclosure of privileged or other protected matter, if no exception or waiver applies; or
- (iv) subjects a person to undue burden.

(B) When Permitted. To protect a person subject to or affected by a subpoena, the court for the district where compliance is required may, on motion, quash or modify the subpoena if it requires:

- (i) disclosing a trade secret or other confidential research, development, or commercial information; or

- (ii) disclosing an unretained expert's opinion or information that does not describe specific occurrences in dispute and results from the expert's study that was not requested by a party.

(C) Specifying Conditions as an Alternative. In the circumstances described in Rule 45(d)(3)(B), the court may, instead of quashing or modifying a subpoena, order appearance or production under specified conditions if the serving party:

- (i) shows a substantial need for the testimony or material that cannot be otherwise met without undue hardship; and
- (ii) ensures that the subpoenaed person will be reasonably compensated.

(e) Duties in Responding to a Subpoena.

(1) Producing Documents or Electronically Stored Information. These procedures apply to producing documents or electronically stored information:

(A) Documents. A person responding to a subpoena to produce documents must produce them as they are kept in the ordinary course of business or must organize and label them to correspond to the categories in the demand.

(B) Form for Producing Electronically Stored Information Not Specified. If a subpoena does not specify a form for producing electronically stored information, the person responding must produce it in a form or forms in which it is ordinarily maintained or in a reasonably usable form or forms.

(C) Electronically Stored Information Produced in Only One Form. The person responding need not produce the same electronically stored information in more than one form.

(D) Inaccessible Electronically Stored Information. The person responding need not provide discovery of electronically stored information from sources that the person identifies as not reasonably accessible because of undue burden or cost. On motion to compel discovery or for a protective order, the person responding must show that the information is not reasonably accessible because of undue burden or cost. If that showing is made, the court may nonetheless order discovery from such sources if the requesting party shows good cause, considering the limitations of Rule 26(b)(2)(C). The court may specify conditions for the discovery.

(2) Claiming Privilege or Protection.

(A) Information Withheld. A person withholding subpoenaed information under a claim that it is privileged or subject to protection as trial-preparation material must:

- (i) expressly make the claim; and
- (ii) describe the nature of the withheld documents, communications, or tangible things in a manner that, without revealing information itself privileged or protected, will enable the parties to assess the claim.

(B) Information Produced. If information produced in response to a subpoena is subject to a claim of privilege or of protection as trial-preparation material, the person making the claim may notify any party that received the information of the claim and the basis for it. After being notified, a party must promptly return, sequester, or destroy the specified information and any copies it has; must not use or disclose the information until the claim is resolved; must take reasonable steps to retrieve the information if the party disclosed it before being notified; and may promptly present the information under seal to the court for the district where compliance is required for a determination of the claim. The person who produced the information must preserve the information until the claim is resolved.

(g) Contempt.

The court for the district where compliance is required—and also, after a motion is transferred, the issuing court—may hold in contempt a person who, having been served, fails without adequate excuse to obey the subpoena or an order related to it.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SCHEDULE A

DEFINITIONS

1. The term "Communication," as used in Schedule A shall include, but not be limited to, any contact or act by which information or knowledge is transmitted or conveyed between two or more persons and includes, without limitation: (1) written contact, including but not limited to letters, memoranda, PowerPoint presentations, email, text message, facsimile, internet-based meetings, or other written or electronic documents or files; (2) oral contact, whether by face-to-face meetings, internet-based meetings, video conferences, telephonic conversations, or otherwise; and (3) nonverbal acts intended to communicate or convey any meaning, understanding or other message.

2. "Documents" shall include, but not be limited to, the original and/or any non-conforming copies of any and all written, printed, typed, graphic, photographic, visual or otherwise recorded material, and all microfilm, or electronic sound recording or transcripts thereof however produced or reproduced, including non-identical copies, whether different from the original by reason of any notation made on such copies or otherwise, writings, drawings, records and recordings of every kind and description, whether inscribed by hand or by mechanical, electronic, microfilm, photographic or other means, as well as audio or visual reproduction of all statements, conversations or events including, but not limited to, agreements, bids, bonds, bulletins, calendars and appointment books, checks, circulars, communications, contracts, correspondence, statements, telegrams, receipts, returns, summaries, data books, accounting records, including ledgers, vouchers and books of account, computer printouts, information storage, media diaries and diary entries, drawings and charts,

1 including additions and revisions, estimates, evaluations, financial statements and records,
2 instructions, inter- and intra-office communications, invoices, job site reports, investigative
3 reports, audits, logs, memoranda of any type, minutes of all meetings, notes of all types, orders,
4 including change, proceed and purchase orders questionnaires and surveys, photographs, price
5 sheets, records, results of investigations, schedules including additions and revisions, statistical
6 records, reports, analyses and studies of any kind, tape recordings, including any form of any
7 recording of any telephone or other conversation, interview, conference, or meeting, and all
8 contract and working papers as well as drawings, papers and files. A reference herein to any
9 one or more of these types of documents shall be construed to include all other types of
10 documents without limitations.
11

12
13 3. Words used in the singular shall, where the context permits, include the plural, and
14 words used in the plural shall, where the context permits, include the singular.

15 4. "You" and "your" refers to the person served with and responding to these
16 requests.
17

18 5. "Roundup[®] litigation" refers to the multidistrict litigation captioned, *In re*
19 *Roundup Products Liability Litigation*, Case No. 3:16-md-02741-CV (N.D. Cal.), in
20 which individuals have asserted or will assert a claim against Monsanto Company
21 ("Monsanto") asserting that the use of Monsanto's Roundup[®]-branded products has
22 caused their non-Hodgkin's lymphoma ("NHL").
23
24
25
26
27
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

REQUESTS FOR PRODUCTION

As stated in the foregoing Notice, you are required to produce the following documents:

1. All documents provided to you, or that you have, related to the Roundup[®] and/or glyphosate and cancer including, but not limited to, NHL, that are not publicly available.
2. All studies, literature, materials, research files, publications, treatises or any other documents that are not publicly available that you have reviewed and upon which you rely and/or intend to rely upon as a basis for, or in any other way support, the opinions that you intend to offer in general causation phase of the Roundup[®] litigation, MDL 2741, or that were reviewed and/or considered by you in the course of formulating your opinions.
3. Your most recent curriculum vitae.
4. All billing records, invoices, or other documents reflecting time spent and/or fees and expenses charged by you (either directly or through your employer or other entity) in connection with the general causation phase of the Roundup[®] litigation, MDL 2741, and/or other consulting work regarding glyphosate, IARC Monograph 112, Roundup[®], Intertek Scientific & Regulatory Consultancy, other glyphosate-based products.
5. Any retainer letter, contract, agreement, or other document setting forth the retention of you to work in the Roundup[®] litigation, MDL 2741.
6. A copy of all abstracts, articles, draft articles, books or book excerpts, presentations, power points of which you are an author, co-author, drafter or editor which has as all or part of its subject matter NHL, glyphosate, Roundup[®], other glyphosate-based products

1 and/or IARC that are not publicly available. With respect to documents in this request relating to
2 IARC, the time frame for the request is limited to 2014 to the present.

3 7. All documents and communications regarding glyphosate, NHL, Roundup[®],
4 and/or other glyphosate-based products with any of the following people, agencies and/or
5 entities: Exponent, Failure Analysis Associates, CropLife America, Reuters, Glyphosate Task
6 Force, Glyphosate Expert Advisory Panel, Food and Chemical Toxicology Journal, Critical
7 Reviews in Toxicology, Joint Glyphosate Task Force, Toxicology Technical Working Group,
8 Environmental Protection Agency (EPA), European Union (EU), European Food Safety
9 Administration (EFSA), Intertek Scientific and Regulatory Consultancy, Intertek Expert Panel,
10 International Agency for Research on Cancer (IARC), , Dr. William Fleming, Dr. Warren G.
11 Foster, Dr. Jay Goodman, Dr. Lorelei Mucci, Dr. Jennifer Rider, and Dr. Thomas Rosol.
12

13
14 8. All draft and final spreadsheets, notes, tables, graphs or other documents showing
15 the mathematical computations that form the bases in the report for the p-Values set forth in
16 Appendix A, Tables A.1, A.2, A.3(i), A.4A, A.5, A.6. and A.7; the p-Values set forth in
17 Appendix B, Tables B.1, B.2, B.3, B.4, B.5, B.6; the Exact Trend P-values and “P-Value[s]
18 Adjusted for False Discovery Rate” set forth in Appendix C, Table C.1; and the Exact Trend P-
19 values and “P-Value[s] Adjusted for False Discovery Rate” set forth in Appendix D, Table D.1.
20
21

22 9. Any documents and/or correspondence related to a statistical analysis or
23 reanalysis carried out by Dr. Klaus Weber of data from the Kumar mouse study, as referenced
24 on page 11 of the report, as well as any data used for those analyses that is not contained in the
25 report or otherwise publicly available.

26
27 Dated: September 6, 2017

Respectfully submitted,

28 /s/ Robin Greenwald



Eric G. Lasker
dlr 202 898 5843
elasker@hollingsworthllp.com

August 31, 2016

PRIVILEGED AND CONFIDENTIAL

VIA ELECTRONIC MAIL

Dr. Chris Corcoran
Utah State University
3900 Old Main Hill
Logan, UT 84322

Re: Monsanto Roundup[®] Litigation

Dear Dr. Corcoran:

This letter confirms that Hollingsworth LLP (“HLLP”), on behalf of Monsanto Company (“Monsanto”), has retained you to provide expert consulting services to HLLP, for the purpose of assisting HLLP in representing Monsanto in connection with potential and/or actual litigation against Monsanto involving injuries allegedly caused by Roundup[®] and/or glyphosate (“the Litigation”). You acknowledge that you have received, and/or likely will receive, confidential information from HLLP and that you likely will generate work product (orally and/or in writing) to assist us in representing Monsanto in the Litigation. You agree that you will maintain all information exchanged between HLLP and you (whether orally or in writing) as strictly confidential and privileged, unless we inform you, at some time in the future, that certain information needs to be disclosed in the Litigation. You also agree to maintain the fact that you have been retained by HLLP as strictly confidential and privileged, unless we inform you, at some time in the future, that your identity as HLLP’s expert has been disclosed in the Litigation. Furthermore, you agree to not do any consulting or other work for any other corporation, law firm, or person with respect to any actual or potential legal claims involving Roundup[®] and/or glyphosate. You will be compensated at your standard hourly rate for time spent working with HLLP on the Litigation, namely \$250.00 per hour.



Dr. Chris Corcoran
August 31, 2016
Page 2



If you agree to these terms, please sign the letter below and send it back to me. We look forward to working with you.

Sincerely,

A handwritten signature in cursive script that reads "Eric G. Lasker" followed by a flourish.

Eric G. Lasker

SEEN AND AGREED:

By: 

Dr. Chris Corcoran

INVOICE

Christopher D. Corcoran



Date: 01/20/17
INVOICE #

Hollingsworth LLC
1350 I Street, N.W.
Washington, D.C. 20005

Hollingsworth contacts	Job	Hourly Rate	SS# or Tax ID
John Kalas, Eric Lasker	Glyphosate – Statistical Consulting	\$250	[REDACTED]

Date	Description	Hours	Line Total
08/16/16	Teleconference	1	\$250
09/14/16	Research/Reading	4	\$1000
09/17/16	Research/Reading	4	\$1000
09/19/16	Teleconference	1	\$250
10/15/16	Research/Reading	4	\$1000
10/20/16	Research/Reading	4	\$1000
10/22/16	Research and Data Analysis	6	\$1500
11/01/16	Teleconference	1	\$250
11/05/16	Data Analysis and Report	4	\$1000
11/10/16	Data Analysis and Report	5	\$1250
11/17/16	Data Analysis and Report	3	\$750
11/18/16	Data Analysis and Report	4	\$1000
11/22/16	Teleconference	1	\$250
12/06/16	Data Analysis and Report	6	\$1500
12/09/16	Data Analysis and Report	5	\$1250
12/10/16	Data Analysis and Report	5	\$1250
12/13/16	Data Analysis and Report	5	\$1250
12/14/16	Reading and Research	5	\$1250
12/15/16	Meeting in SLC UT with Eric L.	3	\$750
12/17/16	Research/Data Analysis	5	\$1250
12/21/16	Research/Data Analysis	3	\$750
12/22/16	Research/Data Analysis	4	\$1000
12/27/16	Research/Data Analysis	3	\$750
01/17/17	Research/Data Analysis	6	\$1500
01/18/17	Research/Data Analysis	4	\$1000
01/20/17	Teleconference	1	\$250
Total			\$24,250

EXHIBIT 21-4
 WIT: Corcoran
 DATE: 9-20-17
 C. Campbell, RDR CRR CSR #13921

INVOICE

Christopher D. Corcoran

[REDACTED]
[REDACTED]

Date 05/20/17
INVOICE #002

Hollingsworth LLC
1350 I Street, N.W.
Washington, D.C. 20005

Hollingsworth contacts	Job	Hourly Rate	SS# or Tax ID
John Kalas, Eric Lasker	Glyphosate – Statistical Consulting	\$250	[REDACTED]

Date	Description	Hours	Line Total
02/10/17	Data Analysis and Report	2	\$500
02/24/17	Data Analysis and Report	4	\$1000
02/25/17	Data Analysis and Report	4	\$1000
03/01/17	Data Analysis and Report	3	\$750
03/03/17	Data Analysis and Report	2	\$500
03/07/17	Data Analysis and Report	4	\$1000
03/08/17	Data Analysis and Report	5	\$1250
03/09/17	Data Analysis and Report	8	\$2000
03/10/17	Meeting in SLC UT with John K.	4	\$1000
03/15/17	Data Analysis and Report	6	\$1500
03/20/17	Data Analysis and Report	8	\$2000
04/08/17	Data Analysis and Report	9	\$2250
04/10/17	Data Analysis and Report	8	\$2000
04/12/17	Teleconference	1	\$250
04/18/17	Data Analysis and Report	6	\$1500
04/20/17	Data Analysis and Report	5	\$1250
04/22/17	Data Analysis and Report	5	\$1250
04/24/17	Data Analysis and Report	6	\$1500
04/25/17	Teleconference	1	\$250
04/27/17	Data Analysis and Report	6	\$1500
04/28/17	Teleconference	1	\$250
05/04/17	Plaintiff Expert Report – Research and Data Analysis	4	\$1000
05/05/17	Teleconference	1	\$250
05/06/17	Plaintiff Expert Report – Research and Data Analysis	4	\$1000
05/08/17	Plaintiff Expert Report – Research and Data Analysis	5	\$1250
05/12/17	Plaintiff Expert Report – Research and Data Analysis	3	\$750
05/15/17	Data Analysis and Report	8	\$2000
05/16/17	Data Analysis and Report	10	\$2500

EXHIBIT 31-5
 WIT: Corcoran
 DATE: 9-20-17
 C. Campbell, RDR CRR CSR #13921

05/17/17	Data Analysis and Report	8	\$2000
05/18/17	Data Analysis and Report	9	\$2250
05/19/17	Data Analysis and Report	10	\$2500
05/20/17	Data Analysis and Report	10	\$2500
Total			\$42,500

INVOICE

Christopher D. Corcoran

Date 05/20/17
INVOICE #002



Hollingsworth LLC
1350 I Street, N.W.
Washington, D.C. 20005

Hollingsworth contacts	Job	Hourly Rate	SS# or Tax ID
John Kalas, Eric Lasker	Glyphosate – Statistical Consulting	\$250	[REDACTED]

Date	Description	Hours	Line Total
05/21/17	Data Analysis and Report	8	\$2000
05/22/17	Data Analysis and Report	10	\$2500
05/23/17	Data Analysis and Report	10	\$2500
05/24/17	Data Analysis and Report	12	\$3000
05/25/17	Meeting with John and Eric, D.C.	6	\$1500
05/25/17	Data Analysis and Report	5	\$1250
05/26/17	Data Analysis and Report	8	\$2000
05/27/17	Data Analysis and Report	8	\$2000
05/31/17	Teleconference with John and Eric	1	\$250
06/05/17	Data Analysis and Report	8	\$2000
06/07/17	Data Analysis and Report	8	\$2000
06/09/17	Teleconference with John and Eric	1	\$250
06/10/17	Data Analysis and Report	5	\$1250
06/12/17	Data Analysis and Report	3	\$750
06/14/17	Data Analysis and Report	5	\$1250
06/15/17	Data Analysis and Report	6	\$1500
06/16/17	Data Analysis and Report	4	\$1000
06/17/17	Data Analysis and Report	5	\$1250
06/19/17	Teleconference with John and Eric	1	\$250
06/25/17	Data Analysis and Report	4	\$1000
06/26/17	Meeting with John, Logan UT	5	\$1250
07/10/17	Teleconference with John and Eric	1	\$250
07/11/17	Data Analysis and Report	5	\$1250
07/14/17	Teleconference with John and Eric	1	\$250
07/14/17	Data Analysis and Report	4	\$1000
07/15/17	Data Analysis and Report	4	\$1000
07/16/17	Data Analysis and Report	5	\$1250
07/17/17	Data Analysis and Report	4	\$1000

EXHIBIT 31-6
 WIT: Corcoran
 DATE: 9-20-17
 C. Campbell, RDR CRR CSR #13921

07/18/17	Data Analysis and Report	7	\$1750
07/19/17	Data Analysis and Report	4	\$1000
07/20/17	Meeting with John and Eric, SLC UT	4	\$1000
Total			\$40,500

REVIEW ARTICLE

Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies

Helmut Greim¹, David Saltmiras^{2,6}, Volker Mostert^{4,5}, and Christian Strupp^{3,6}

¹Technical University Munich, Arcisstr. 21, 80333 Munich, Germany, ²Monsanto Company, 800 North Lindbergh Blvd., 63167 St. Louis, MO, USA, ³ADAMA MAH BV Amsterdam NL Schaffhausen Branch, Spitalstrasse 5, 8200 Schaffhausen, Switzerland, ⁴Knoell Consult GmbH, Dynamostr. 19, 68165 Mannheim, Germany, ⁵Extera, Nelly-Sachs-Str, 37, 40764 Langenfeld, Germany, and ⁶Glyphosate Task Force, <http://www.glyphosatetaskforce.org/>

Abstract

Glyphosate, an herbicidal derivative of the amino acid glycine, was introduced to agriculture in the 1970s. Glyphosate targets and blocks a plant metabolic pathway not found in animals, the shikimate pathway, required for the synthesis of aromatic amino acids in plants. After almost forty years of commercial use, and multiple regulatory approvals including toxicology evaluations, literature reviews, and numerous human health risk assessments, the clear and consistent conclusions are that glyphosate is of low toxicological concern, and no concerns exist with respect to glyphosate use and cancer in humans. This manuscript discusses the basis for these conclusions. Most toxicological studies informing regulatory evaluations are of commercial interest and are proprietary in nature. Given the widespread attention to this molecule, the authors gained access to carcinogenicity data submitted to regulatory agencies and present overviews of each study, followed by a weight of evidence evaluation of tumor incidence data. Fourteen carcinogenicity studies (nine rat and five mouse) are evaluated for their individual reliability, and select neoplasms are identified for further evaluation across the data base. The original tumor incidence data from study reports are presented in the online data supplement. There was no evidence of a carcinogenic effect related to glyphosate treatment. The lack of a plausible mechanism, along with published epidemiology studies, which fail to demonstrate clear, statistically significant, unbiased and non-confounded associations between glyphosate and cancer of any single etiology, and a compelling weight of evidence, support the conclusion that glyphosate does not present concern with respect to carcinogenic potential in humans.

Keywords

amino acid, carcinogenicity, epidemiology, glyphosate, herbicide, mouse, neoplasm, phosphonomethylglycine, Roundup, rat, regulatory, tumor

History

Received 6 November 2014
Revised 19 December 2014
Accepted 28 December 2014
Published online 24 February 2015



Table of Contents

Abstract	185
Introduction	185
Absorption, distribution, metabolism and excretion of glyphosate	187
Toxicological properties of glyphosate	187
Genotoxicity	187
Epidemiology	187
Chronic toxicity studies	188
Dog chronic studies	188
Rat chronic studies	188
Carcinogenicity studies	190
Rat carcinogenicity	190
Study 1 (Monsanto 1981)	190
Study 2 (Monsanto 1990)	191
Study 3 (Cheminova 1993a)	192
Study 4 (Feinchemie Schwebda 1996)	193
Study 5 (Excel 1997)	194

Study 6 (Arysta Life Sciences 1997b)	194
Study 7 (Syngenta 2001)	195
Study 8 (Nufarm 2009b)	195
Study 9 Publication (Chruscielska et al. 2000a)	197
Mouse carcinogenicity	197
Study 10 (Monsanto 1983)	197
Study 11 (Cheminova 1993b)	199
Study 12 (Arysta Life Sciences 1997a)	200
Study 13 (Feinchemie Schwebda 2001)	200
Study 14 (Nufarm 2009a)	201
Discussion	202
Acknowledgements	206
Declaration of interest	206
References	206

Introduction

Glyphosate (Figure 1), an aminophosphonic analog of the natural amino acid glycine, is widely used as an herbicide for the control of annual and perennial grasses and broad-leaved weeds. Glyphosate inhibits 5-enolpyruvateshikimate-3-phosphate synthase (EPSPS), an enzyme of the aromatic acid biosynthesis pathway, which is not present in the animal kingdom. Glyphosate-based herbicide formulations (GBFs) were introduced in 1974 and are formulated with

Address for correspondence: David Saltmiras, Monsanto Company, 800 North Lindbergh Blvd., 63167 St. Louis, MO, USA. Tel: +1 (314) 684-8856. E-mail: david.a.saltmiras@monsanto.com

© 2015 The Author(s). Published by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1. Structure of glyphosate acid.

sodium-, potassium-, ammonium- and isopropyl ammonium-salt forms of the active ingredient. The bulk-manufactured active herbicide glyphosate has the synonyms glyphosate technical acid, technical grade glyphosate and glyphosate acid.

The economic importance of glyphosate for growers is high. It has been estimated that a hypothetical ban of glyphosate would lead to decreases in the production of wheat, fodder, maize and oilseeds, by 4.3–7.1%, with the result of an estimated annual welfare loss of 1.4 billion USD to society in the European Union alone (Schmitz and Harvert 2012). Furthermore, glyphosate plays an important role in integrated pest management strategies, and affords the environmental benefit of substantially reduced soil erosion resulting from no-till and reduced-till agriculture.

The long-term toxicity and carcinogenicity of glyphosate has been investigated by multiple entities including academia, registrants, and regulatory authorities, and the data generated have been evaluated in support of herbicide regulatory approvals in many world regions including the USA (US EPA 1993) and the European Union (EC 2002), and several scheduled reevaluations are currently ongoing in the USA, Canada, Japan and Europe (Germany Rapporteur Member State 2015a), with imminent conclusions.

Studies of appropriate scientific quality are the basis for regulatory decision making. Mandatory testing guidelines (TGs) exist for toxicological studies submitted for regulatory review of active substances for plant protection in many regions of the world. Such TGs have been released, *inter alia*, by the United States Environmental Protection Agency (US EPA 2012), the European Union (EU 2008), the Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF 2000), and the Organization of Economic Co-operation and Development (OECD 2012b). These TGs set quality standards for each type of study by giving guidance regarding test species, strains, and number of animals to be used, the choice of dosing, exposure duration, and parameters to be measured and observed, as well as for the reporting of results. Due to the lack of effective legal and regulatory provisions for the sharing of vertebrate study data in the past, and to guarantee the safety of technical glyphosate obtained from different processes of synthesis, several manufacturers of glyphosate had to initiate toxicological testing programs of their own. Occasionally, regulatory studies had to be repeated to reflect major changes in the underlying TG. In the case of glyphosate, this has given rise to a multitude of studies for the same toxicological endpoints, leading to the availability of an extraordinarily robust scientific study database that can be considered unique among pesticides, industrial chemicals, and pharmaceuticals. Such a remarkable volume of studies addressing the same endpoints, conducted over the last 40 years by several independent companies and laboratories while toxicology test guidelines have evolved,

warrants investigation for consistency, reliability, and application to their intended purpose; identifying potential human health hazards and setting appropriate endpoints for human health risk assessment. Studies conducted with equivalent test substances using the same TG are readily comparable and can be evaluated by regulators following standardized schemes. Minor differences in the findings reported by such repetitive studies are attributable to statistical chance, natural biological variability, type of basal diet, rate of feed consumption, animal strain differences, choice of dose levels, inter-strain genetic drift over time due to varying vendor breeding practices, changes in animal care and husbandry practices across laboratories over the years, inter-laboratory variations in clinical measurements, and differences between individual pathologist evaluation and interpretation of tissue specimens.

Glyphosate is under significant political pressure due to its widespread use, particularly in association with use on genetically modified crops. One focus area of contention has been the human safety of glyphosate, which has been repeatedly challenged by interest groups via the media, as well as select research publications in the scientific literature (Antoniou et al. 2012, Aris and Leblanc 2011, Aris and Paris 2010, Benachour and Seralini 2009, Gasnier et al. 2010, Paganelli et al. 2010, Romano et al. 2012, Romano et al. 2010). To that end, one specific publication by Seralini et al. (2012, retracted) drew significant criticism from both the toxicology and broader scientific communities (Barale-Thomas 2013, Berry 2013, de Souza and Oda 2013, Grunewald and Bury 2013, Hammond et al. 2013, Langridge 2013, Le Tien and Le Huy 2013, Ollivier 2013, Panchin 2013, Sanders et al. 2013, Schorsch 2013, Tester 2013, Trewavas 2013, Tribe 2013). After a special review of the investigators' raw data by a mutually agreed-upon expert panel, the manuscript was retracted by *Food and Chemical Toxicology* (FCT), for reasons of inconclusive data and unreliable conclusions (Hayes 2014). The Editor of the *International Journal of Toxicology* highlighted this manuscript as an example of possible failure of the peer review process in a well-respected toxicology journal with an editorial board of well-known and respected toxicologists (Brock 2014). The manuscript was later republished without peer-review in an open access journal (Seralini et al. 2014), but will not be addressed in this data evaluation due to the inappropriate study design, insufficient reporting of tumor incidence data, and the lack of a data supplementary to the manuscript.

The chronic/carcinogenicity studies discussed in this paper have been submitted to and evaluated by a variety of agencies over time, including the World Health Organization (WHO/FAO 2004b, WHO/FAO 2004a), the United States Environmental Protection Agency (US EPA 1993), the European Rapporteur Member State Germany for the initial glyphosate Annex I listing (EC 2002) and the recent European reevaluation (Germany Rapporteur Member State 2015a), as well as the ongoing reevaluations in the USA, Canada and Japan. These regulatory bodies, drawing upon internal and/or external expertise, have consistently concluded that glyphosate is devoid of carcinogenic risk to humans.

The purpose of this article is to provide the broader scientific community with insight into this large body of carcinogenicity data on glyphosate, originally generated for

regulatory purposes. Each study discussed in this review has been assigned a reliability score in Tables 3–19, following the Klimisch scoring system (Klimisch et al. 1997). In this system, a score of 1 is assigned to studies that are fully reliable based on compliance with Good Laboratory Practice (GLP) and adherence to appropriate study guidelines. A score of 2 is appropriate if some guideline requirements are not met, but if these deficiencies do not negatively affect the validity of the study for its regulatory purpose. Studies with a reliability of 3 employ a test design that is not fit for the scientific purpose of the study, due to significant scientific flaws, or the objective of the study not covering the regulatory endpoints, or both. Such studies can provide supplemental information but do not allow a stand-alone appraisal of a regulatory endpoint. No studies were assigned a reliability of 4, since each report contained sufficient information to judge the validity of the study.

This manuscript presents the robust glyphosate carcinogenicity data generated by industry. Study summaries will focus on carcinogenicity evaluation, to allow third parties the opportunity to independently evaluate the carcinogenicity data presented alongside other relevant data on carcinogenicity, i.e. genotoxicity testing and epidemiology, and facilitate a multidisciplinary carcinogenicity assessment as proposed in the literature, by recognized experts in the fields of toxicology and human health risk assessment (Adami et al. 2011).

Absorption, distribution, metabolism and excretion of glyphosate

A number of absorption, distribution, metabolism, and excretion studies (ADME) have been conducted on glyphosate for evaluation in regulatory submissions (EC 2002, US EPA 1993, WHO/FAO 2004a) and also by academic institutions (Anadon et al. 2009). Glyphosate consistently demonstrates low gastrointestinal absorption (20–40%). Its metabolism is very limited, whereby only small quantities of a single metabolite, aminomethylphosphonic acid (AMPA), are eliminated in feces. AMPA is likely produced by the limited metabolism of glyphosate by the gastrointestinal microflora, rather than via mammalian metabolism. Glyphosate is structurally akin to a phase II metabolite, a glycine-conjugate of methyl phosphonate, and thus avails itself to rapid urinary excretion. Systemic elimination is biphasic, with alpha-phase half-lives in the range of 6–14 h (Anadon et al. 2009, WHO/FAO 2004a).

Toxicological properties of glyphosate

Table 1 contains a short overview of toxicological endpoints of glyphosate that have been published in the List of Endpoints identified for glyphosate by the Rapporteur in the European Union under Regulation 1107/2009 (Germany Rapporteur Member State 2015c). Glyphosate is of low acute toxicity via all routes of exposure. Glyphosate's active ingredient, an organic acid, has an irritating effect on mucosa which is evidenced by eye irritation and effects on oral and gastrointestinal mucosa; final formulated products contain more neutral pH salt forms, as reflected in the tabulated eye irritation data reported in Table 11, on page 109 of the 2004 JMPR Toxicological Evaluation (WHO/FAO 2004a). Glyphosate is not mutagenic, not neurotoxic, and has no effect on pre-natal development and fertility at doses not exceeding the maximum tolerated dose (MTD).

Genotoxicity

Very recently, a review of the vast body of genotoxicity studies on glyphosate and GBFs has been published (Kier and Kirkland 2013), including an online data supplement presenting detailed data from 66 separate *in vitro* and *in vivo* genotoxicity assays. The authors incorporated these studies and published genotoxicity data into a weight-of-evidence analysis. The vast majority (over 98%) of the available bacterial reversion and *in vivo* mammalian micronucleus and chromosomal aberration assays were negative. Negative results for *in vitro* gene mutation and a large majority of negative results for clastogenic effect assays in mammalian cells support the conclusion that glyphosate is not genotoxic for these endpoints in mammalian test systems. DNA damage effects are reported in some instances for glyphosate at high or toxic dose levels. The compelling weight of evidence is that glyphosate and typical GBFs are negative in core assays, indicating that the reported high-dose effects are secondary to toxicity and are not due to DNA-reactive mechanisms. Mixed results were observed for micronucleus assays in non-mammalian systems, and DNA damage assays of GBFs. These effects of GBFs may also be associated with surfactants present in the formulated products. Kier and Kirkland conclude that glyphosate and its typical formulations do not present significant genotoxic risk under normal conditions of human or environmental exposures.

Epidemiology

Available epidemiological studies of glyphosate and cancer endpoints were recently reviewed (Mink et al. 2012). Seven cohort studies and fourteen case-control studies examining a potential association between glyphosate and one or more cancer outcomes were subjected to a qualitative analysis. The review found no consistent pattern of positive associations between total cancer (in adults or children) or any site-specific cancer, and exposure to glyphosate. A recent review article (Alavanja et al. 2013) cites one epidemiology study associating glyphosate use with non-Hodgkin's lymphoma (NHL), and accepts the study findings *prima facie*. However, Alavanja et al. (2013) did not highlight six other published epidemiology studies which evaluated glyphosate use and NHL, noting that any association between NHL and glyphosate use was null or not statistically significant. All seven studies were scrutinized by Mink et al. (2012). NHL is not a specific disease, as mentioned in both the epidemiology review publications above, but is rather multiple presentations of lymphoma which are simplistically classified as not being Hodgkin's lymphoma (HL). This dichotomous classification of HL/NHL was rejected by the World Health Organization in 2001, whereby 43 different lymphomas of various etiologies were precisely characterized (Berry 2010). The Bradford Hill criteria are often applied in efforts to determine whether an association between a health effect and human exposure may be deemed causal. However, an important premise often overlooked from Sir Austin Bradford Hill's famous speech of 1965, is that before applying these criteria, the observations should "reveal an association between two variables, perfectly clear-cut and beyond what we care to attribute to the play of chance" (Bradford Hill 1965). This predicate of the association being "perfectly clear-cut"

Table 1. Summary of toxicological endpoints for glyphosate (Germany Rapporteur Member State 2015c).

Endpoint	Value	Remark
Oral absorption	ca 20%	Rat, <i>in vivo</i>
Dermal absorption	< 1%	Human, <i>in vitro</i> , 0.015 g glyphosate/L
Rat LD50 oral	> 2000 mg/kg bw	
Rat LD50 dermal	> 2000 mg/kg bw	
Rat LC50 inhalation	> 5 mg/L	4-h exposure
Skin irritation	Not irritating	
Eye irritation	Acid: moderately to severely irritating Salts: slight or non-irritating	
Skin sensitization	Not sensitizing (LLNA, Magnusson-Kligman, and Buehler test)	
Genotoxicity	Not genotoxic (<i>in vitro</i> and <i>in vivo</i>)	
Chronic toxicity	BW gain, liver (organ weight ↑, clinical chemistry, histology); salivary glands (organ weight ↑, histology); stomach mucosa and bladder epithelium(histology); eye (cataracts), caecum (distention, organ weight ↑) NOAEL = 100 mg/kg bw/day (2-yr rat)	Critical study used for ADI setting
Reproductive toxicity	Reduced pup weight at parentally toxic doses. NOAEL = 300 mg/kg bw/day	
Developmental toxicity	Post-implantation loss, fetal BW & ossification ↓; effects confined to maternally toxic doses Rat NOAEL: 300 mg/kg bw/day Rabbit NOAEL: 50 mg/kg bw/day	
Delayed neurotoxicity	No relevant effects, NOAEL: 2000 mg/kg bw/day	
Acceptable Daily Intake (ADI)	0.5 mg/kg bw/day Based on developmental toxicity in rabbits	Safety factor 100
Acceptable Operator Exposure Level (AOEL)	0.1 mg/kg bw/day Based on maternal toxicity in rabbit teratogenicity study	Safety factor 100 Corrected for oral absorption of 20%

was recently highlighted as requiring statistical significance, wherein the confidence interval of a relative risk ratio is bracketed above 1.0, as well as concluding that the association may not be attributable to bias, confounding or sampling error (Woodside and Davis 2013). According to Bradford Hill, should an epidemiology study be considered to demonstrate a “perfectly clear-cut” association between glyphosate exposure and a human health outcome, only then should the Bradford Hill criteria be investigated to determine whether there is causality. To date, no such “perfectly clear-cut” association between glyphosate exposure and any cancer exists. However, investigative toxicology is an important discipline to evaluate chemicals before any human exposure occurs, and these data may inform subsequent considerations of whether associations are attributable to causality. One Bradford Hill criterion in establishing disease causality is plausibility, based on known disease etiologies. In the case of lymphoma, there are numerous etiologies for the numerous and different lymphoma diseases, and as such, each lymphoma type should be investigated for a plausible mechanism to determine whether causality may be attributed an appropriately qualified association. Another Bradford Hill criterion is identification of a biological gradient, or dose-response, which is a key consideration in the following data evaluation.

Chronic toxicity studies

Several one-year chronic studies have been undertaken in dogs and one in rats, in addition to the many chronic/carcinogenicity studies with one-year interim sacrifice groups. Current Test Guidelines (OECD, EPA, EU and JMAFF) for long-term studies clearly state that the highest dose tested should either be at the maximum tolerated dose (MTD), conventionally interpreted as a dose causing non-lethal toxicity, often noted

as reduced body weight gain of 10% or more (IUPAC 1997). For test substances with low toxicity, a top dose not exceeding 1000 mg/kg bw/day may apply, except when human exposure indicates the need for a higher dose level to be used (OECD 2012a). All human exposure estimates are well below 1 mg/kg bw/day (see Discussion section), so that 1000 mg/kg bw/day is a practical limit dose for glyphosate in carcinogenicity studies. In the original pre-guideline chronic/carcinogenicity study, rats were dosed well below the MTD (Monsanto 1981), but in many subsequent studies, they were dosed well in excess of today’s standard practice of not exceeding the dose limit.

Dog chronic studies

Five one-year oral toxicity studies have been conducted in Beagle dogs (Table 2). Studies in dogs are not designed to detect neoplastic effects; these studies are therefore not discussed in detail. Nonetheless, the histopathological investigations that are part of one-year dog studies according to OECD TG 452 did not identify (pre) neoplastic lesions related to the administration of glyphosate.

Treatment-related effects in dog studies with glyphosate were restricted to non-specific findings like small retardations in body weight gain and soft stools, which are common findings in this test species. The lowest relevant NOAEL (i.e. highest NOAEL below the lowest LOAEL) in dogs on a daily treatment regimen for one year was 500 mg/kg bw/day. These studies demonstrate that glyphosate is of very low toxicity following repeat exposures in dogs.

Rat chronic studies

The chronic toxicity potential of glyphosate acid was assessed in a 12-month feeding study (conducted in 1995 and 1996) in

Table 2. Summary of one-year toxicity studies with glyphosate.

Authors:	Monsanto (1985)
Reliability/Justification	2 Study performed according to GLP and OECD guideline requirements, with the following deviation: MTD not reached by highest dose
Substance:	Glyphosate (96.1% pure)
Species/Strain:	Dog/Beagle, groups of 6 ♂ and 6 ♀
Administration route:	Oral, capsule
Doses:	0, 20, 100, 500 mg/kg bw/day
Duration:	1 year
Findings:	≥ 500 mg/kg bw/day: NOAEL (♂ + ♀) no treatment-related effects
Authors:	Chemnova (1990)
Reliability/Justification	1 Study performed according to GLP and OECD guideline requirements, with no deviations.
Substance:	Glyphosate (98.6–99.5% pure)
Species/Strain:	Dog/Beagle, groups of 4 ♂ and 4 ♀
Administration route:	Oral, capsule
Doses:	0, 30, 300, 1000 mg/kg bw/day
Duration:	1 year
Findings:	300 mg/kg bw/day: NOAEL (♂ + ♀) 1000 mg/kg bw/day: soft, liquid stools (attributable to capsule administration); equivocal impact on body weight gain
Authors:	Nufarm (2007)
Reliability/Justification	2 Study performed according to GLP and OECD guideline requirements, with the following deviation: MTD not reached by highest dose
Substance:	Glyphosate (95.7% pure)
Species/Strain:	Dog/Beagle, groups of 4 ♂ and 4 ♀
Administration route:	Oral, capsule
Doses:	0, 30, 125, 500 mg/kg bw/day
Duration:	1 year
Findings:	≥ 500 mg/kg bw/day: NOAEL (♂ + ♀) No treatment-related effects
Authors:	Arysta Life Sciences (1997c)
Reliability/Justification	2 Study performed according to GLP and OECD guideline requirements, with the following deviation: MTD not reached by highest dose
Substance:	Glyphosate (94.6% pure)
Species/Strain:	Dog/Beagle, groups of 4 ♂ and 4 ♀
Administration route:	Oral, diet
Concentration:	0, 1600, 8000, 50 000 ppm diet (♂ about 34.1, 182, 1203 mg/kg bw/day; ♀ about 37.1, 184, 1259 mg/kg bw/day)
Duration:	1 year
Findings:	182/184 mg/kg bw/day: NOAEL (♂/♀) At high dose: loose stool, non-statistically significant retarded body weight gain, decreased urinary pH, slight and non-statistically significant focal pneumonia (♀), minor clinical chemistry changes of Cl ↑, albumin ↓, P ↓ (♀)
Authors:	Syngenta (1996a)
Reliability/Justification	1 Study performed according to GLP and OECD guideline requirements, with no deviations.
Substance:	Glyphosate (95.6% pure)
Species/Strain:	Dog/Beagle, groups of 4 ♂ and 4 ♀
Administration route:	Oral, diet
Concentration:	0, 3000, 15 000, 30 000 ppm diet (♂ about 90.9, 440, 907 mg/kg bw/day; ♀ about 92.1, 448, 926 mg/kg bw/day)
Duration:	1 year
Findings:	15 000 ppm diet: NOAEL (♀) ≥ 30 000 ppm diet: NOAEL (♂): No treatment-related effects 30 000 ppm diet: slight body weight reduction (♀)
Authors:	Syngenta (1996b)
Reliability/Justification	1 Study performed according to GLP and OECD guideline requirements, with no deviations.
Substance:	Glyphosate (95.6% pure)
Species/Strain:	Rat/Wistar Alpk: AP,SD, groups of 24 ♂ and 24 ♀
Administration route:	Oral, diet
Concentration:	0, 2000, 8000, 20 000 ppm diet (♂ about 141, 560, 1409 mg/kg bw/day; ♀ about 167, 671, 1664 mg/kg bw/day)
Duration:	1 year
Findings:	8000 ppm diet: NOAEL (♂ + ♀) 20 000 ppm diet: parotid salivary glands (focal basophilia of the acinar cells considered non-adverse adaptive response, ♂: 13/24, ♀: 15/24), body weight reduction

24 male and female Wistar rats per group, dosed at 0, 2000, 8000 and 20 000 ppm (Syngenta 1996). The mean achieved dose levels were 0, 141, 560 and 1409 mg/kg bw/day for males, and 0, 167, 671 and 1664 mg/kg bw/day for females. Spastically significant reductions in bodyweight were evident in animals receiving 20 000 ppm glyphosate acid, together with a marginal reduction in bodyweight in rats receiving 8000 ppm, but food consumption relative to controls was lower for these dose groups, suggesting reduced palatability of the diets containing

these doses of glyphosate. There were no toxicologically significant or treatment-related effects on hematology, blood and urine clinical chemistry, or organ weights (Table 2).

The treatment-related pathological finding, that is increased incidence of mild focal basophilia, and a hypertrophy of the acinar cells of the parotid salivary gland in both sexes which had received 20 000 ppm glyphosate acid, is considered an adaptive response due to oral irritation from the ingestion of glyphosate, an organic acid, in the diet. This was verified by

mode of action investigations and studies with dietary administration of citric acid, a non-toxic organic acid with irritation properties and pH dilution curve similar to those of glyphosate (Saltmiras et al. 2011), which elicited the same response in the acinar cells of the parotid salivary glands.

In conclusion, the 12-month NOAEL in rats for glyphosate acid, as determined from this study, is 8000 ppm (corresponding to 560 mg/kg bw/day in males and 671 mg/kg bw/day in females). This study does not cover neoplastic endpoints. These were addressed in a subsequent study by the same sponsor (Syngenta 2001). Consistent with the findings observed in dogs, this study demonstrates that glyphosate is of very low toxicological concern following long-term daily exposures.

Similarly, most of the following 2-year rat carcinogenicity studies included additional groups for 1-year interim sacrifice to evaluate chronic toxicity. These studies did not elucidate significant toxicological concerns for chronic dietary exposures to glyphosate in rats in multiple expert reviews by governmental agencies and several technical branches of the World Health Organization including the Joint Meeting on Pesticide Residues Toxicological Evaluations (WHO/FAO 2004a).

Carcinogenicity studies

Chronic/carcinogenicity tests are designed to simulate lifetime exposures to an individual chemical and represent the most robust *in vivo* assay to evaluate the effects of chronic exposure including carcinogenicity. These models are biological systems with natural background variability due to tumor formation as a natural consequence of aging. Glyphosate was found to have no carcinogenic potential, which is reflected in the data showing only background noise of spontaneous tumors across the wide range of doses. Normal biological variability should display various tumor types across all dose groups without an apparent dose-response. The study summaries discuss “select neoplasms”, identified by the authors as having an elevated incidence above concurrent controls across one or more dose groups, most of which lacked statistical significance and/or dose-response within an individual study. These tumors are then evaluated in the context of the whole data set, to provide a robust weight of evidence overview for the doses spanning several orders of magnitude. While not all studies have select neoplasms identified in the individual study summary tables, select neoplasms for all studies are reported in Tables 20–23. Summary tables of the select neoplasms footnote the strain tested for each dose, to allow consideration of strain differences in spontaneous tumor susceptibility (Tables 20–23). In addition, complete tumor incidence summary tables have been extracted from the original eight rat (the published rat study, Study 9, is not included) and five mouse study reports or study files, and posted in their original format, as a comprehensive online data supplement to this manuscript.

Rat carcinogenicity

A total of nine chronic/carcinogenicity studies in the rat, including one peer-reviewed published study, were available for review. This duplication of large-scale studies in the same animal model using the same test substance is not consistent with today's broader appreciation for animal welfare and the reduction of unnecessary animal testing. However, these

studies offer the opportunity for a critical discussion of findings in individual studies in the context of the larger body of data. Wistar and Sprague Dawley were the strains used for the bioassays in rats. Seven studies were conducted under conditions of GLP, and two studies were not under GLP (Study 1, conducted before the introduction of GLP; Study 9, non-GLP). Most studies in rats were designed as combined chronic toxicity/carcinogenicity studies, with interim sacrifices after 12 months of treatment for the assessment of non-neoplastic chronic toxicity. Statistical methods are noted in the manuscript tables where statistical significance was attained. Statistical differences in neoplasm incidence summary tables are reported in the online data supplements. Chronic endpoints and NOAEL values are captured in each study summary table; however, the following study reviews focus on carcinogenicity.

Study 1 (Monsanto 1981)

An early study into the long-term effects of orally administered glyphosate in the rat was conducted between 1978 and 1980 (Monsanto 1981), prior to the adoption of international test guidelines and GLP standards (Tables 3–6). Nonetheless, the test protocol was broadly compliant with OECD TG 453 (1981). However, an MTD was not reached and the high dose was well below an acceptable dose limit of 1000 mg/kg bw/day. Therefore, this study is rated Klimisch 3 for reliability, and is considered inadequate for carcinogenicity evaluation from a regulatory perspective.

Groups of 50 male and 50 female Sprague Dawley rats were administered glyphosate acid in the diet, at concentrations of 0, 30, 100 and 300 ppm, for up to least 26 months. The mean doses achieved were 0 (control), 3, 10, and 31 mg/kg bw/day for the males, and 0 (control), 3, 11, and 34 mg/kg bw/day for the females. Study results are summarized in Table 3.

In general, the incidences of all neoplasms observed in the treated and control animals were similar, or occurred at low incidence, such that a treatment-related association could not be made. The most common tumors found were common spontaneous neoplasms, as reported in the literature relating to rat (Johnson and Gad 2008), in the pituitary glands of both control and treated animals (Table 4). In the females, mammary gland tumors were the next most common neoplasm across control and dose groups (see data Supplementary Study 1 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

Table 3. Study 1–26-month feeding study of glyphosate in rats (Monsanto 1981).

Study owner:	Monsanto (1981)
Reliability/Justification:	3 Study not performed under GLP. High-dose well below MTD. Does not conform to modern testing standards.
Substance:	Glyphosate (98.7% pure)
Species/Strain:	Rat/Sprague-Dawley, groups of 50 ♂ and 50 ♀
Administration route:	Diet
Concentration:	0, 30, 100, 300 ppm diet (♂ about 0, 3, 10, 31 mg/kg bw/day ♀ about 0, 3, 11, 34 mg/kg bw/day)
Duration:	26 months
Findings:	≥ 300 ppm diet; NOAEL (♂ + ♀) No treatment-related effects
Select neoplasms:	Pituitary adenoma, Testes interstitial cell

Table 4. Study 1 – Pituitary tumor findings.

Tumors	Dose group (mg/kg bw/day)							
	Males				Females			
	0	3.05	10.3	31.49	0	3.37	11.22	34.02
<u>Pituitary tumors</u>	Number of animals/total number examined (% per group)							
Adenomas - B	16/48 (33)	19/49 (39)	20/48 (42)	18/47 (38)	34/48 (70)	29/48 (60)	31/50 (62)	26/49 (53)
Carcinomas - M	3/48 (6)	2/49 (4)	3/48 (6)	1/47 (2)	8/48 (17)	7/48 (14)	5/48 (19)	12/49 (24)
Combined	19/48 (40)	21/49 (43)	23/48 (48)	19/47 (40)	42/48 (88)	36/48 (75)	36/50 (72)	38/49 (78)

B benign, M malignant

The incidence of interstitial cell tumors of the testes in male rats in both the scheduled terminal sacrifice animals, as well as for all animals, suggested a possible treatment-related finding, and was presented along with contemporary historical control data for comparison (Tables 5 and 6). It was noted that at 12 months, the incidence of interstitial tumors was near zero; however, in animals aged 24–29 months at necropsy, the incidence increased to approximately 10%. The historical control data for chronic toxicity and carcinogenicity from 5 studies terminated at 24–29 months showed background levels of interstitial cell tumors comparable to those found at the highest dose in the study. Furthermore, the reported incidences in all dose groups reflect the normal range of interstitial cell tumors in rat testes, reported in the Registry of Industrial Toxicology Animal Data (Nolte et al. 2011). The incidence of interstitial cell hyperplasia did not provide evidence of a pre-neoplastic lesion. The investigators noted that at terminal sacrifice, the incidence of interstitial cell tumor was 15.4% (4/26), while the range in control animals from 5 contemporary studies (historical controls) was 6.2% (4/65) to 27.3% (3/11), with an overall mean value of 9.6% (16/166). When all animals on test are included, the incidence for the high-dose males was 12% (6/50), compared to a contemporary historical control range of 3.4% (4/116) to 6.7% (5/75), with a mean of 4.5% (24/535). The concurrent control incidence of interstitial cell tumors (0%) was not representative of the normal background incidence noted in contemporary historical control data. Therefore, the data suggest that the incidence in treated rats is within the normal biological variation observed for interstitial cell tumors at this site in this strain of rat. When evaluated in the context of the full data set for male rats (Table 20), a dose-response is clearly absent for the 25 doses evaluated in rats, ranging from 3 to 1290 mg/kg bw/day, which demonstrates that this tumor is clearly not a consequence of glyphosate exposure.

In conclusion, glyphosate was not considered carcinogenic in Sprague Dawley rats following continuous dietary exposure of up to 300 ppm, corresponding to 31 and 34 mg/kg bw/day in males and females, respectively, which is consistent with evaluations by the US EPA (US EPA 1993), the original Annex I listing in Europe (EC 2002), and WHO/FAO (WHO/FAO 2004a).

Based on the low doses tested in Study 1, Monsanto was obliged to conduct a second chronic/carcinogenicity study in rats (Study 2, discussed below) in accordance with OECD TG 453 (1981), which had been developed and instituted after this initial study was conducted.

Study 2 (Monsanto 1990)

In response to evolving regulatory requirements, this study was conducted in accordance with the contemporary version of OECD TG 453 (Monsanto 1990). The chronic toxicity and carcinogenic potential of glyphosate were assessed in a 24-month feeding study in 50 male and 50 female Sprague Dawley rats, dosed with 0, 2000, 8000 and 20 000 ppm (equivalent to mean achieved dose levels of 0, 89, 362 and 940 mg/kg bw/day for males and 0, 113, 457 and 1183 mg/kg bw/day for females (Table 7). In addition, 10 rats per sex per dose were included for interim sacrifice after 12 months. Observations covered clinical signs, ophthalmic examinations, body weight, food consumption, hematology, clinical chemistry and urinalysis, as well as organ weights, necropsy, and histopathological examination. This study was rated Klimisch I for reliability.

Treatment-related findings in this study were significantly reduced body weight in high-dose females, as well as increased liver weight in high-dose males and females, and a slight increase in incidence of cataract lens changes in high-dose males, which was not statistically significant for eye lesions confirmed by histopathology (Table 7). The body weight changes confirm that the MTD was achieved in the highest dose group. Benign thyroid C-cell adenomas were statistically higher than controls in the mid-dose terminally sacrificed males, but when pooled with unscheduled deaths, no statistically significant increase was noted. Benign pancreas islet cell adenomas were not statistically higher for the unscheduled or scheduled deaths, but when combined, were statistically higher than controls in the low and high dose males. In both cases, the benign tumors did not exhibit a dose-response, and did not progress to carcinomas, and thus the US EPA concluded that these tumors were not related to the administration

Table 5. Study 1 – Interstitial cell tumor findings in the testes.

Tumors	Dose (mg/kg bw/day)			
	0	3.05	10.3	31.49
<u>Interstitial cell tumor – B</u>	Number of animals/total number examined (% per group)			
Terminal sacrifice	0/15 (0)	2/26 (7.7)	1/16 (6.3)	4/26 (15.4)
All Animals	0/50 (0)	3/50 (6)	1/50 (2)	6/50 (12)
<u>Interstitial cell hyperplasia</u>	Number of animals (% per group)			
Terminal sacrifice	1/15 (6.7)	1/26 (3.8)	0/16 (0)	0/26 (0)
All Animals	1/50 (2)	1/50 (2)	1/50 (2)	0/50 (0)

B benign, M malignant

Table 6. Study 1 – Summary of the contemporary historical control data for interstitial cell tumors in the testes of rats in chronic toxicity studies.

	Study 1	Study 2	Study 3	Study 4	Study 5	Range
	Number of control animals/total number examined (% per study)					
Terminal sacrifice	4/65 (6.2)	3/11 (27.3)	3/26 (11.5)	3/24 (12.5)	3/40 (7.5)	6.2–27.3%
All animals	4/116 (3.4)	5/75 (6.7)	4/113 (3.5)	6/113 (5.3)	5/118 (4.2)	3.4–6.7%

of glyphosate (US EPA 1993). These neoplasms, in addition to skin keratoacanthoma in males, a common rat tumor, were selected for further weight of evidence evaluation (Tables 20 and 21). No evidence of a glyphosate-induced carcinogenic effect was noted in either sex (see data Supplementary Study 2 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

In conclusion, glyphosate was not carcinogenic in Sprague Dawley rats following continuous dietary exposure of up to 20000 ppm for 24 months, corresponding to 940 and 1183 mg/kg bw/day in males and females, respectively, which is consistent with evaluations by the US EPA (US EPA 1993), European Authorities (EC 2002), and WHO/FAO (WHO/FAO 2004a).

Study 3 (Cheminova 1993a)

The chronic toxicity and carcinogenic potential of glyphosate technical acid were assessed in a 104-week feeding study in

male and female Sprague Dawley rats (Cheminova 1993a). The study was conducted between 1990 and 1992. Groups of 50 rats per sex received daily dietary doses of 0, 10, 100, 300, or 1000 mg/kg bw/day of glyphosate technical acid for 24 months (Table 8). Five additional groups of 35 rats per sex, receiving daily dietary doses of 0, 10, 100, 300 or 1000 mg/kg bw/day, were included for interim sacrifice at the 12th month for evaluation of chronic toxicity. The dietary glyphosate levels were adjusted weekly to ensure that animals were receiving the intended dose levels at all times. This study was rated Klimisch 1 for reliability.

At 1000 mg/kg bw/day, female mean liver weights were decreased, while males and females had statistically significant reductions in body weight throughout the study, confirming that the MTD was achieved (Table 8). Neoplasms were noted in control and treated groups, but dose-responses were not evident, and no statistically significant increases versus controls were noted for any tumor type ($p < 0.05$). No treatment-related neoplastic lesions were observed at termination.

Table 7. Study 2 – Two-year feeding study of glyphosate in rats (Monsanto 1990).

Study owner:		Monsanto (1990)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations.				
Substance:	Glyphosate (96.5% pure)				
Species/Strain:	Rat/Sprague-Dawley, groups of 50 ♂ and 50 ♀ (10 rats per sex per dose were included for interim sacrifice after 12 months).				
Administration route:	Diet				
Concentration:	0, 2000, 8000, 20 000 ppm diet (♂ about 0, 89, 362, 940 mg/kg bw/day; ♀ about 0, 113, 457, 1183 mg/kg bw/day)				
Duration:	2 years				
Findings:	8000 ppm diet: NOAEL (♂+♀) 20 000 ppm diet: cataracts (♂), > 20% reduced cumulative body weight gain through months 18–20 (♀), 13% increased liver weight (♂). Local effects: inflammation of gastric mucosa				
Select neoplasms:	Pancreatic islet cell adenoma, skin keratoacanthoma (males), thyroid C cell adenoma				
Tumor	Dose (mg/kg bw/day)				
Males	0	89	362	940	
Findings for dead and moribund sacrificed animals					
Pancreas: Islet cell adenoma – B	1/34 (3%)	4/28 (14%)	2/33 (6%)	4/32 (13%)	
Skin: Keratoacanthoma – B	0/36	1/31 (3%)	2/33 (6%)	1/32 (3%)	
Thyroid: C cell adenoma – B	0/36	2/29 (7%)	1/31 (3%)	1/33 (3%)	
Thyroid: C cell carcinoma – M	0/36	1/29 (3%)	2/31 (6%)	1/33 (3%)	
Findings for animals sacrificed at termination					
Pancreas: Islet cell adenoma – B	0/14	4/19 (21%)	3/17 (6%)	3/17 (6%)	
Skin: Keratoacanthoma – B	0/13	2/19 (11%)	2/17 (12%)	2/17 (12%)	
Thyroid: C cell adenoma – B	0/14	2/19 (11%)	*7/17 (41%)	4/17 (24%)	
Thyroid: C cell carcinoma – M	0/14	0/19	0/17	0/17	
Females	0	113	457	1183	
Findings for dead and moribund sacrificed animals					
Pancreas: Islet cell adenoma – B	3/28 (11%)	0/28	3/33 (9%)	0/31	
Thyroid: C cell adenoma – B	0/28	0/28	1/33 (3%)	2/32 (6%)	
Thyroid: C cell carcinoma – M	0/28	0/28	1/33 (3%)	0/32	
Findings for animals sacrificed at termination					
Pancreas: Islet cell adenoma – B	2/22 (9%)	1/22 (5%)	1/17 (6%)	0/18	
Thyroid: C cell adenoma – B	2/22 (9%)	2/22 (9%)	5/17 (29%)	4/18 (22%)	
Thyroid: C cell carcinoma – M	0/22	0/22	0/17	0/18	

B benign, M malignant

*Statistically higher than controls ($p < 0.05$, Fisher's Exact Test with the Bonferroni Inequality).

DOI 10.3109/10408444.2014.1003423

Glyphosate – Fourteen carcinogenicity studies 193

Table 8. Study 3 – Two-year feeding study of glyphosate in rats (Cheminova 1993a).

Study owner:	Cheminova (1993a)
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations.
Substance:	Glyphosate (98.7–98.9% pure)
Species/Strain:	Rat/Sprague-Dawley, groups of 50 ♂ and 50 ♀ (additional groups of 35 ♂ and 35 ♀ per dose were included for 1-year interim sacrifice)
Administration route:	Diet
Achieved dose:	♂ + ♀: 0, 10, 100, 300, 1000 mg/kg bw/day (weekly adjustment of dietary concentration for the first 13 weeks and 4-weekly thereafter)
Duration:	2 years
Findings:	300 mg/kg bw/day: NOAEL (♂ + ♀) 1000 mg/kg bw/day: body weights ↓, urinary pH ↓, salivary glands (histopathology, organ weight ↑); evidence of weak liver toxicity (alkaline phosphatase ↑, ♀; organ weight ↓)
Select neoplasms:	No neoplasms from this study were identified for further consideration.

and no select neoplasms were identified in this study for further consideration (see data Supplementary Study 3 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>). Glyphosate was not considered carcinogenic in male and female Sprague Dawley rats following 104 weeks of continuous dietary exposure of up to 1000 mg/kg bw/day, the limit dose, which is consistent with evaluations by the European Authorities (EC 2002, Germany Rapporteur Member State 2015b) and WHO/FAO (WHO/FAO 2004a).

Study 4 (Feinchemie Schwebda 1996)

A 2-year bioassay in the Wistar rat used dietary glyphosate levels of 0, 100, 1000, and 10 000 ppm (Feinchemie Schwebda 1996). Groups of 50 rats per sex were fed for 24 months. The mean achieved dose levels were 0, 7.4,

73.9, and 740.6 mg/kg bw/day (Table 9). This study was rated Klimisch I for reliability.

In addition, one vehicle control with ten rats per sex and one high dose (10 000 ppm) group with 20 rats per sex were included for interim sacrifice after one year of treatment, to study non-neoplastic histopathological changes. The mean achieved dose level in the treated group was 764.8 mg/kg bw/day. Observations covered clinical signs, body weight, food consumption, hematology, clinical chemistry, and urinalysis, as well as organ weights, necropsy, and histopathological examination.

There were no treatment-related deaths or clinical signs in any of the dose-groups. Moreover, there were no treatment-related effects on body weight gain or food consumption noted. This suggests that the MTD may not have been reached by the applied dosing regimen.

There was some background variation in the incidences of benign tumors (e.g. reduced tumor incidence in low and mid-dose males, increased tumor incidence in mid-dose females), which was considered incidental in absence of a dose-response relationship (see data Supplementary Study 4 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

The different liver tumors observed in the dead and moribund sacrificed and terminally sacrificed rats included hepatocellular adenoma, intrahepatic bile duct adenomas, cholangiocarcinoma, hepatocellular carcinoma, histiocytic sarcoma, fibrosarcoma, and lymphosarcoma. Among these, hepatocellular adenomas and carcinomas occurred more frequently, as often observed in aging rats (Thoolen et al. 2010). These tumors appeared to be incidental and not compound-related, as their frequency of occurrence was not dependent on dose. Hepatocellular adenomas and carcinomas were considered select neoplasms (Table 9), based on increased incidence above controls for total animals, albeit non-dose

Table 9. Study 4 – Two-year feeding study of glyphosate in rats (Feinchemie Schwebda 1996).

Study owner:	Feinchemie Schwebda (1996)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations.			
Substance:	Glyphosate (96.0–96.8% pure)			
Species/Strain:	Rat/Wistar, groups of 50 ♂ and 50 ♀			
Administration route:	Diet			
Concentration:	0, 100, 1000, 10 000 ppm diet (♂ about 0, 6.3, 59.4, 595 mg/kg bw/day; ♀ about 0, 8.6, 88.5, 886 mg/kg bw/day)			
Duration:	2 years			
Findings:	10 000 ppm diet: ≥ NOAEL (♂ + ♀) Only mild effects on clinical chemistry (liver enzymes), without histopathological changes.			
Select neoplasms:	Hepatocellular adenoma, hepatocellular carcinoma			
Tumor	Dose (mg/kg bw/day)			
Males	0	7.4	73.9	741
Findings for dead and moribund sacrificed animals				
Hepatocellular adenoma – B	9/30 (30%)	9/30 (30%)	6/32 (19%)	6/21 (29%)
Hepatocellular carcinoma – M	12/30 (40%)	12/30 (40%)	9/32 (28%)	5/21 (24%)
Findings for animals sacrificed at termination				
Hepatocellular adenoma – B	15/20 (75%)	13/20 (65%)	4/16 (25%)	15/20 (75%)
Hepatocellular carcinoma – M	9/20 (45%)	16/20 (80%)	9/16 (56%)	19/29 (66%)
Females	0	7.4	73.9	741
Findings for dead and moribund sacrificed animals				
Hepatocellular adenoma – B	2/26 (8%)	8/23 (3%)	3/17 (18%)	5/29 (17%)
Hepatocellular carcinoma – M	4/26 (15%)	4/23 (17%)	2/17 (12%)	5/29 (17%)
Findings for animals sacrificed at termination				
Hepatocellular adenoma – B	16/24 (67%)	10/25 (40%)	16/32 (50%)	8/21 (38%)
Hepatocellular carcinoma – M	6/24 (25%)	11/25 (44%)	12/32 (38%)	4/21 (19%)

B benign, M malignant

responsive, for adenoma in mid-dose females, carcinoma in low- and high-dose males, and carcinoma in low- and mid-dose females. These liver neoplasms are considered in the weight of evidence evaluation (Tables 20 and 21).

The study report concluded that glyphosate technical acid was not carcinogenic in Wistar rats following continuous dietary exposure of up to 595 and 886 mg/kg bw/day in males and females, respectively, for 24 months, which is consistent with evaluations by the European Authorities (EC 2002, Germany Rapporteur Member State 2015b).

Study 5 (Excel 1997)

A 2-year feeding study in the Sprague Dawley rats (Excel 1997) featured dietary concentrations of 0, 3000, 15 000, and 25 000 ppm glyphosate technical acid. Groups of 50 rats per sex were fed for 24 months, and mean dose levels of 0, 150, 780 and 1290 mg/kg bw/day (males) and 0, 210, 1060 and 1740 mg/kg bw/day (females) were achieved (Table 10).

In addition, 20 rats/sex/group were included for interim sacrifice at week-52, to study non-neoplastic histopathological changes with a different high-dose level of 30 000 ppm. The dietary doses correspond to 180, 920 and 1920 mg/kg bw/day (males) and 240, 1130 and 2540 mg/kg bw/day (females), for 3000, 15 000 and 30 000 ppm, respectively. Thus, a limit dose above 1000 mg/kg bw/day was achieved.

The study report notes that glyphosate technical acid was not carcinogenic in Sprague Dawley rats following continuous dietary exposure to up to 1290 mg/kg bw/day, and 1740 mg/kg bw/day for males and females, respectively, for 24 months. However, this study was rated Klimisch 3 for reliability (Germany Rapporteur Member State 2015b), and therefore, is considered unreliable for carcinogenicity evaluation based on lower than expected background tumor incidences (see data Supplementary Study 5 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>). In addition, the test substance was not adequately characterized, and several deviations from the OECD Test Guideline 453 were noted.

Study 6 (Arysta Life Sciences 1997b)

A combined chronic toxicity/carcinogenicity study in Sprague Dawley rats (Arysta Life Sciences 1997b) was conducted between December 1994 and December 1996. The rats were fed 0, 3000, 10 000, and 30 000 ppm glyphosate for two years (equivalent to 0, 104, 354 and 1127 mg/kg bw/day for males and 0, 115, 393 and 1247 mg/kg bw/day for females (Table 11). Thus, a limit dose was achieved, and the MTD was noted at the high dose in males and females with decreased body weight, increased cecum weight, distention of the cecum, loose stool and skin lesions. In addition, 30 rats/sex/group were included for interim sacrifice at 26, 52 and 78 weeks, to study non-neoplastic histopathological changes. Observations covered clinical signs, body weight, food consumption, hematology, clinical chemistry, and urinalysis, as well as organ weights, necropsy, and histopathological examination. This study was rated Klimisch 1 for reliability.

Non-statistically significant increases versus controls ($p < 0.05$) were noted for pituitary adenomas, skin keratoacanthoma in high-dose males, and mammary gland fibroadenoma in low and mid-dose females (Table 11). These neoplasms were considered for the weight of evidence evaluation (Tables 20 and 21), and the full tumor summary data are available online (see data Supplementary Study 6 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>). As mentioned under Study 1, pituitary and mammary tumors are common spontaneous neoplasms in aging rats (Johnson and Gad 2008), and skin keratoacanthoma is noted as one of the most common spontaneous benign neoplasms in male Sprague Dawley rats (Chandra et al. 1992). The study report concluded that glyphosate was not carcinogenic in Sprague Dawley rats following continuous dietary exposure to up to 30 000 ppm for 24 months, corresponding to 1127 mg/kg bw/day and 1247 mg/kg bw/day for males and females, respectively, which is consistent with the recent evaluation in Europe under the Annex I Renewal of glyphosate (Germany Rapporteur Member State 2015b).

Table 10. Study 5 – Two-year feeding study of glyphosate in rats (Excel 1997).

Study owner:	Excel (1997)			
Reliability/Justification:	3 Test substance not characterized and other deviations from OECD 453, lower than expected background tumor incidence			
Substance:	Glyphosate (no purity reported)			
Species/Strain:	Rat/Sprague-Dawley, groups of 50 ♂ and 50 ♀, additional groups of 20 rats per sex and group were included for interim sacrifice after 52 weeks			
Administration route:	Diet			
Concentration:	2-year group: 0, 3000, 15 000, 25 000 ppm diet (♂ about 0, 150, 780, 1290 mg/kg bw/day; ♀ about 0, 210, 1060, 1740 mg/kg bw/day) 1-year group: 0, 3000, 15 000, 30 000 ppm diet (♂ about 0, 180, 920, 1920 mg/kg bw/day; ♀ about 0, 240, 1130, 2540 mg/kg bw/day)			
Duration:	2 years			
Findings:	≥ 25 000 ppm diet: NOAEL (♂ + ♀) Only mild toxic effects, such as clinical chemistry of questionable relevance in aged rats, without correlating histopathological organ changes.			
Select neoplasms:	No neoplasms from this study were identified for further consideration. Low background tumor incidence indicates low study reliability with no relevant increases in the incidence of tumors.			
Males	Dose (mg/kg bw/day)			
Mortality	0	150	740.6	1290
Females	16/50 (32%)	17/50 (34%)	18/50 (36%)	23/50 (46%)
Males	Dose (mg/kg bw/day)			
Mortality	0	210	1060	1740
Females	19/50 (38%)	20/50 (40%)	20/50 (40%)	25/50 (50%)

Table 11. Study 6 – Two-year feeding study of glyphosate in rats (Arysta Life Sciences 1997b).

Study owner:	Arysta Life Sciences (1997b)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations.			
Substance:	Glyphosate (94.6–97.6% pure)			
Species/Strain:	Rat/Sprague-Dawley, groups of 50 ♂ and 50 ♀; satellite groups of 30 ♂ and 30 ♀ for interim investigations			
Administration route:	Diet			
Concentration:	0, 3000, 10 000, 30 000 ppm diet (♂ about 0, 104, 354, 1127 mg/kg bw/day; ♀ about 0, 115, 393, 1247 mg/kg bw/day)			
Duration:	2 years			
Findings:	3000 ppm diet: NOAEL (♂+♀) 10 000 ppm diet: cecum weight ↑, distension of cecum, loose stool, follicular hyperkeratosis and/or folliculitis/follicular abscess of the skin, body weight ↓			
Select neoplasms:	Pituitary adenoma, skin keratoacanthoma (males), mammary gland fibroadenoma (females)			
Tumor	Dose (mg/kg bw/day)			
Males	0	104	354	1127
Findings for dead and moribund sacrificed animals (Table 25–10)				
Pituitary anterior adenoma – B	22/32 (69%)	21/30 (70%)	*14/32 (44%)	18/21 (86%)
Skin keratoacanthoma – B	2/32 (6%)	1/30 (3%)	0/32	1/21 (5%)
Findings for animals sacrificed at termination (after 104 weeks, Table 25–8)				
Lung adenoma – B	0/18	2/20 (10%)	1/18 (6%)	3/29 (10%)
Pituitary anterior adenoma – B	13/18 (72%)	14/20 (70%)	13/18 (72%)	21/29 (72%)
Pituitary adenoma in intermediate part – B	0/18	1/20 (5%)	0/18	0/29 (0%)
Skin keratoacanthoma – B	1/18 (6%)	2/20 (10%)	0/18	6/29 (21%)
Tumor	Dose (mg/kg bw/day)			
Females	0	115	393	1247
Findings for dead and moribund sacrificed animals				
Pituitary anterior adenoma – B	34/35 (97%)	29/31 (94%)	28/33 (82%)	31/36 (86%)
Thyroid follicular adenoma – B	0/35	2/31 (6%)	0/32	0/36
Mammary gland fibroadenoma – B	13/35 (37%)	14/31 (45%)	12/34 (35%)	20/36 (56%)
Findings for animals sacrificed at termination				
Pituitary anterior adenoma – B	12/15 (80%)	19/19 (100%)	12/16 (75%)	13/14 (93%)
Mammary gland fibroadenoma – B	10/15 (67%)	13/19 (68%)	12/16 (75%)	10/14 (71%)

B benign, M malignant

*Statistically lower than controls ($p < 0.05$).

Study 7 (Syngenta 2001)

The same rat model that was used in the previously discussed 12-month chronic rat study (Syngenta 1996b) was also employed in a 2-year feeding study (Syngenta 2001). A group of 52 male and 52 female Wistar rats received 0, 2000, 6000 or 20 000 ppm via feed (Table 12). The mean achieved dose levels were 0, 121, 361 and 1214 mg/kg bw/day for males, and 0, 145, 437 and 1498 mg/kg bw/day for females. Thus, a limit dose was achieved. In addition, three satellite groups with 12 rats per sex each were included for interim sacrifice after 12 months of treatment, to investigate potential non-neoplastic histopathological changes. Observations covered clinical signs, body weight, food consumption, hematology, clinical chemistry, and urinalysis, as well as organ weights, necropsy, and histopathological examination. This study was rated Klimisch 1 for reliability.

Treatment-related findings in this study were found in the liver and kidney, and were confined to animals (predominantly males) fed 20 000 ppm glyphosate acid. There were a number of changes in males and females fed 20 000 ppm glyphosate acid, notably renal papillary necrosis, prostatitis, periodontal inflammation, urinary acidosis, and hematuria, which may be attributed to the acidity of the test substance. Slight increases in proliferative cholangitis and hepatitis were noted in males at 20 000 ppm. Despite the findings at 20 000 ppm, survival was better in males fed 20 000 ppm than in the controls and lower dose groups. This improved survival was associated with a decreased severity of renal glomerular nephropathy and a 5% reduction in body weight (see data Supplementary Study 7 to be found online at [\[informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423\]\(http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423\), for neoplastic and non-neoplastic findings\).](http://</p>
</div>
<div data-bbox=)

A small increase in the incidence of hepatocellular adenoma was observed in males fed 20 000 ppm glyphosate acid. While not statistically significant using the Fisher's exact test, the difference was statistically significant for total male rats using the Peto Test for trend. However, there was no evidence of pre-neoplastic foci, no evidence of progression to adenocarcinomas, and no dose-response. In addition, the incidence was within the laboratory's historical control range for tumors of this type in the liver (Table 12). Therefore, the increased incidence was considered not to be related to treatment, yet these were considered select neoplasms (Table 12) and evaluated in context of the complete data set (Tables 20 and 21).

The study report concluded that glyphosate acid was not carcinogenic in the Wistar rats following continuous dietary exposure to up to 20 000 ppm for 24 months, at 1214 and 1498 mg/kg bw/day in males and females, respectively, which is consistent with the WHO/FAO review (WHO/FAO 2004a) and the recent evaluation in Europe under the Annex I Renewal of glyphosate (Germany Rapporteur Member State 2015b).

Study 8 (Nufarm 2009b)

The most recent study in this series of regulatory studies investigating the potential carcinogenicity of glyphosate in rats was conducted from September 2005 through March 2008 (Nufarm 2009b). The study was conducted by feeding dietary concentrations of 0, 1500, 5000 and 15 000 ppm glyphosate to groups of 51 Wistar rats per sex. To ensure that a received limit dose of 1000 mg/kg bw/day overall was achieved, the highest dose level was progressively increased to 24 000 ppm.

Table 12. Study 7 – Two-year feeding study of glyphosate in rats (Syngenta 2001).

Study owner:	Syngenta (2001)			
Reliability/Justification	1 Study performed according to GLP and OECD guideline requirements, with no deviations.			
Substance:	Glyphosate (97.6% pure)			
Species/Strain	Rat/Wistar Alpk: AP ₁ SD, groups of 52 ♂ and 52 ♀ (additional 12 animals per sex and dose for 1-year interim sacrifice)			
Administration route:	Diet			
Concentration:	0, 2000, 6000, 20 000 ppm diet (♂ about 0, 121, 361, 1214 mg/kg bw/day; ♀ about 0, 145, 437, 1498 mg/kg bw/day)			
Duration:	2 years			
Findings:	6000 ppm diet: NOAEL (♂+♀) 20 000 ppm diet: Kidney and liver findings. Increased survival due to reduction in CPN, prostatitis, periodontal inflammation			
Select neoplasms:	Hepatocellular adenoma (males), not a statistically significant increase for the high dose using the Fisher's exact test, but statistically significant using Peto trend analysis			
		Dose (mg/kg bw/day)		
Males	0	121	361	1214
Liver				
Hepatocyte fat vacuolation	6	7	11	11
Hepatitis	3	4	2	5
Kidney				
		Dose (mg/kg bw/day)		
Females	0	145	437	1498
Liver				
Hepatocyte fat vacuolation	7	5	6	6
Hepatitis	6	5	4	4
Tumors:		Dose (mg/kg bw/day)		
Males	0	121	361	1214
Findings for dead and moribund sacrificed animals				
*Hepatocellular adenoma – B	0/37	2/36 (6%)	0/35	3/26 (12%)
Hepatocellular carcinoma – M	0/37	0/36	0/35	0/26
Findings for animals sacrificed at termination				
*Hepatocellular adenoma – B	0/16	0/17	0/18	2/26 (8%)
Hepatocellular carcinoma – M	0/16	0/17	0/18	0/26

B benign, M malignant

*Historical Control Range: 0–11.5% total males with hepatocellular adenoma, 26 studies, 1984–2003

Mean dose levels of 86/105, 285/349, and 1077/1382 mg glyphosate/kg bw/day (males/females) were achieved (Table 13). This study was rated Klimisch 1 for reliability.

Non-neoplastic findings included transient liver enzyme activity for mid-dose males and high-dose males and females, and equivocal nephrocalcinosis depositions at the high-dose. Histopathology noted a statistically significant increase in

adipose infiltration of the bone marrow in high-dose males compared to controls, suggestive of myeloid hypoplasia, which may be considered a stress response (Everds et al. 2013).

Skin keratoacanthoma in males and mammary gland adenocarcinoma in females (Table 13) were considered for evaluation in the context of the weight of evidence for rat tumor incidence (Tables 20 and 21), wherein dose-

Table 13. Study 8 – Two-year feeding study of glyphosate in rats (Nufarm 2009b).

Study owner:	Nufarm (2009a)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations			
Substance:	Glyphosate (95.7% pure)			
Species/Strain:	Rat/Wistar, groups of 51 ♂ and 51 ♀			
Administration route:	Diet			
Concentration:	0, 3000, 10 000, 15 000 ppm diet, the top dose was progressively increased to reach 24 000 ppm diet by Week-40 (♂ about 0, 84, 285, 1077 mg/kg bw/day; ♀ about 0, 105, 349, 1382 mg/kg bw/day)			
Duration:	2 years			
Findings:	≥ 1077/1382 mg/kg bw/day: NOAEL (♂/♀) Transient liver enzyme activity for mid-dose males and high-dose males and females; equivocal nephrocalcinosis depositions at the high-dose males and females; increased adipose infiltration of the bone marrow in high-dose males			
Select neoplasms:	Skin keratoacanthoma (males), mammary gland adenocarcinoma			
Tumor			Dose (mg/kg bw/day)	
Males	0	84	285	1077
Findings for all animals				
Skin keratoacanthoma – B	2/51 (4%)	3/51 (6%)	0/51	6/51 (12%)
			Dose (mg/kg bw/day)	
Females	0	105	349	1382
Findings for all animals				
Mammary gland adenocarcinoma – M	2/51 (4%)	3/51 (6%)	1/51 (2%)	6/51 (12%)

B benign, M malignant

responses were not evident. Tumor incidence summary data have been tabulated (see data Supplementary Study 8 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>). Microscopic evaluation of tissues did not reveal any indications of neoplastic lesions caused by glyphosate treatment. The study report concluded that glyphosate acid was not carcinogenic in Wistar rats following continuous dietary exposure to up to 24 000 ppm for 24 months, at 1077 and 1382 mg/kg bw/day in males and females, respectively, which is consistent with the recent evaluation in Europe under the Annex I Renewal of glyphosate (Germany Rapporteur Member State 2015b).

Study 9 Publication (Chruscielska et al. 2000a)

A two-year combined chronic toxicity and carcinogenicity study in Wistar rats was published by academic researchers from Warsaw, Poland. The study was conducted as a drinking-water study in Wistar-RIZ rats according to OECD TG 453. The test material was a 13.85% aqueous formulation of glyphosate as its ammonium salt (equivalent to 12.6% glyphosate acid). However, the ammonium salt of glyphosate tested is not commercially available, and the concentration of active ingredient suggests that a glyphosate-formulated product was tested; this is supported by a concurrent genotoxicity publication by the same lead author (Chruscielska et al. 2000b), previously reviewed by Kier and Kirkland (Kier and Kirkland 2013), in which a glyphosate formulation, Perzocyd, was tested. Deficiencies noted with respect to OECD TG 453 include insufficient dosing to elicit toxic effects, inadequate test material characterization, no reporting of water/feed consumption, body weights and diet composition, and no individual animal data. Although the manuscript reporting deficiencies may have been included in the study, they were not reported in the manuscript, and could warrant a Klimisch reliability score of 4 (not assignable), but the low doses employed in this study justify a Klimisch reliability score of 3.

The test material was administered in water at glyphosate salt concentrations of 0, 300, 900, and 2700 mg/L. Each dose group consisted of 85 animals per sex. Ten animals per sex and dose were sacrificed after 6, 12, and 18 months of exposure, for evaluation of general toxicity. The remaining 55 animals per sex and dose were scheduled for sacrifice after 2 years of exposure.

Water consumption was claimed to have been measured, but these data have not been reported. To estimate the glyphosate doses received via drinking water, the assumed default water consumptions were 50 and 57 mL/kg bw/day by male and female rats, respectively (Gold et al. 1984). Using these standard figures and the glyphosate content of the tested formulation (12.6%), daily doses are estimated at 0, 1.9, 5.7, and 17 mg of glyphosate/kg bw/day for males and 0, 2.2, 6.5, and 19 mg of glyphosate/kg bw/day for females. As this study appears to have tested a formulated product, data were not included in the weight of evidence review (Tables 20 and 21), but given the very low glyphosate doses and reported low tumor incidence, these were of no consequence to the overall data review.

Exposure to glyphosate ammonium salt had no effect on body weight, appearance and behavior, and hematological parameters, which is consistent with glyphosate chronic toxicity data regulatory reviews. Even though there seems to be a trend towards higher 2-year mortality in treated females

(Table 14), this difference had no statistical significance according to the authors. There were sporadic alterations of clinical-chemical and urinalysis parameters, but not in a consistent fashion over time and without dose-dependence. These alterations were not interpreted as treatment-related. There was no effect of glyphosate on the incidence of neoplastic lesions (Table 14). Thus, the NOAEL for chronic toxicity and carcinogenicity in this study was greater than or equal to 17 and 19 mg glyphosate/kg bw/day, in males and females, respectively.

Due to the lack of systemic effects in the highest dose group, the MTD was not reached by this study. Judging from other rat studies reviewed here, the MTD is likely to be greater than 1000 mg/kg bw/day. Thus, the top glyphosate dose of an estimated 19 mg/kg bw/day in this study is too low to satisfy regulatory validity criteria for a carcinogenicity study.

Mouse carcinogenicity

There are a total of five carcinogenicity studies with glyphosate in mice, that have been submitted to support glyphosate Annex I renewal in the European Union. All but the oldest study (Study 10) were considered reliable without restriction, and were performed under conditions of GLP following OECD TGs. Most studies were conducted in the CD-1 strain. Each study was sponsored by a different manufacturer. In each case, technical grade glyphosate was administered via diet for at least 18 months. Select neoplasms, mostly lymphoreticular, liver and lung, are summarized for all mouse chronic studies in Tables 22 and 23. These neoplasms are widely recognized as occurring spontaneously in aging mice (Gad et al. 2008, Son and Gopinath 2004). Lymphomas have been recognized for many years as one of the most common, if not the most common category of spontaneous neoplastic lesions in aging mice (Brayton et al. 2012, Gad et al. 2008, Son and Gopinath 2004). The subclassification of malignant lymphomas is not a typical diagnostic feature in rodent studies, likely due to either expense and/or feasibility. It is, however, important to recognize that lymphomas are not a single type of neoplasm, rather they are a grouping of different neoplasms arising from different pathogeneses, and should be considered as different diseases (Bradley et al. 2012). As is the case for NHL in humans, these different immune system neoplasms are clustered together based on manifestation in lymphocytes, despite their very different etiologies; for example, the most common subset of NHL lymphomas clustered together as "diffuse large B cell lymphomas", have for many years been considered multiple clinical-pathologic entities (Armitage 1997), and therefore may be considered attributable to different modes of action. Chronic endpoints and NOAEL values are captured in each study summary table; however, the following study reviews focus on carcinogenicity.

Study 10 (Monsanto 1983)

The first chronic-carcinogenicity mouse study with glyphosate was conducted between March 1980 and March 1982 (Monsanto 1983), prior to the institution of GLP (Table 15). The study design was essentially in compliance with OECD TG 451 for carcinogenicity studies, adopted in 1981, when

Table 14. Publication, Study 9 – Two-year drinking water study in rats with 13.85% glyphosate ammonium salt (Chruscielska et al. 2000a).

Authors:	Chruscielska et al. (2000a)							
Reliability/Justification:	3 Study not performed according to GLP, but according to OECD TG 453, with the following deficiencies: Reporting deficits (water and feed consumption, body weights, diet composition, individual animal data, substance composition, purity, and stability) Highest dose did not elicit toxicity							
Substance:	Ammonium salt of glyphosate, 13.85% solution							
Species/Strain:	Rat/Wistar -RIZ outbred, 85 ♂ and 85 ♀ per dose group. 10 ♂ and 10 ♀ each were sacrificed after 6, 12, and 18 months of exposure.							
Administration route:	Drinking water							
Concentration:	0, 300, 900, and 2700 mg/L Estimated glyphosate intake: ♂: 0, 1.9, 5.7, and 17 mg/kg bw/day. ♀: 0, 2.2, 6.5, and 19 mg/kg bw/day, based on assumed water consumptions of 50/57 mL/kg bw/day (♂/♀), (Gold, et al. 1984)							
Duration:	2 years							
Findings:	17/19 mg glyphosate/kg bw/day; NOAEL (♂/♀) No treatment-related effects							
Tumors reported for 85 rats/sex/dose:	No increase in the incidence of tumors attributable to glyphosate administration							
	Estimated dose (mg/kg bw/day)							
	0		1.9/2.2		5.7/6.5		17/19	
	♂	♀	♂	♀	♂	♀	♂	♀
Two-year mortality	42%	38%	42%	45%	54%	53%	44%	60%
Lungs								
Lymphoma	2	–	2	–	1	–	3	1
Histiocytoma	–	–	–	–	–	–	–	1
Adenocarcinoma	1	–	–	–	–	–	–	–
Histiocytoma, malignant	–	1	–	–	1	–	–	–
Spleen, leukemia	0	–	2	–	0	–	1	–
Kidneys, Fibrous histiocytoma	–	–	–	–	–	–	1	–
Pituitary gland								
Adenoma	4	10	4	6	2	8	0	3
Adenoma, malignant (assumed to be carcinoma)	0	1	0	3	1	2	1	5
Carcinoma	0	–	0	–	1	–	0	–
Thyroid								
Adenoma	1	1	1	2	0	0	3	3
Carcinoma	0	–	1	–	0	–	0	–
Uterus, cervix carcinoma	–	0	–	0	–	0	–	1
Uterus, body, histiocytoma	–	3	–	1	–	0	–	1
Mammary gland								
Fibroma	–	0	–	0	–	0	–	0
Fibroadenoma	–	3	–	2	–	3	–	3
Adrenal medulla, adenoma	1	2	2	2	1	2	0	2
Thymus, lymphoma	0	–	0	–	0	–	1	–
Testis, Leydigoma	–	–	3	–	6	–	1	–
Subcutaneous tissue								
Fibroma	0	–	1	–	1	–	3	–
Lipoma	–	–	–	–	–	–	–	1
Cystadenoma	–	1	–	–	–	–	–	–
Lymph nodes								
Lymphoma	0	–	0	–	0	–	1	–
Lymphoma, malignant	–	1	–	–	–	–	–	–
Skin, carcinoma	2	–	–	–	–	–	–	–
Prostate, adenoma	1	–	–	–	–	–	–	–

the study was already ongoing. Groups of 50 male and female CD-1 mice received glyphosate at dietary levels of 1000, 5000, and 30 000 ppm, over a period of nearly two years. The mean achieved doses were 157/190, 814/955, and 4841/5874 mg/kg bw/day in males and females, respectively, exceeding the limit dose. Based on this study predating both GLP and OECD TG 451, a reliability score of Klimisch 2 has been assigned.

In addition to post-mortem pathological examinations after terminal sacrifice, hematological investigations were performed on 10 mice per sex and dose at months 12 and 18, and on 12 male animals/group, as well as all surviving females at scheduled termination.

Two non-neoplastic histological changes affecting the liver and urinary bladder were assumed to be treatment-related. There was a higher incidence of centrilobular hepatocyte

hypertrophy in high-dose males, and a more frequent occurrence of slight-to-mild bladder epithelial hyperplasia in the mid and high dose; however, a clear dose-response was lacking. Tumor incidences, which did not significantly increase with dose, were mostly bronchiolar-alveolar, hepatocellular, or lymphoreticular, all of which are commonly noted spontaneously occurring tumors in aging mice (Table 15). Lymphoreticular tumors combined for males and females totaled 7, 12, 10 and 12 for control, low, mid- and high-dose groups respectively, and were not considered as being related to test substance.

A more frequent occurrence of slight-to-mild bladder epithelial hyperplasia was observed in the mid and high-dose groups; however, clear dose-response was lacking (Table 15) and no urinary bladder neoplasms were noted at these doses (see data Supplementary Study 10 to be found online at <http://>

Table 15. Study 10 – Two-year feeding study with glyphosate in mice (Monsanto 1983).

Study owner:	Monsanto (1983)			
Reliability/Justification:	2 Study was performed prior to institution of GLP and OECD guideline requirements			
Substance:	Glyphosate (99.7% pure)			
Species/Strain:	Mouse/CD-1, groups of 50 ♂ and 50 ♀			
Administration route:	Diet			
Concentration:	0, 1000, 5000, 10 000 ppm diet (♂ about 0, 157, 814, 4841 mg/kg bw/day; ♀ about 0, 190, 955, 5874 mg/kg bw/day)			
Duration:	24 months			
Findings:	1000 ppm diet: NOAEL (♂ + ♀) 5000 ppm diet: body weight ↓, histological changes in liver and urinary bladder (slight to mild epithelial hyperplasia in males at mid and high doses)			
Select neoplasms:	Lymphoreticular neoplasms, bronchiolar-alveolar adenocarcinoma			
Males	0	157	814	4841
	Dose (mg/kg bw/day)			
Lymphoreticular system				
Lymphoblastic lymphosarcoma with leukemia – M	1/48 (2%)	4/49 (8%)	3/50 (6%)	2/49 (4%)
Lymphoblastic lymphosarcoma without leukemia – M	0/48	1/49 (2%)	0/50 (0%)	0/49
Composite lymphosarcoma – M	1/48 (2%)	0/49	1/50 (2%)	0/49
Histiocytic sarcoma – M	0/48	1/49 (2%)	0/50	0/49
Total lymphoreticular neoplasms [#]	2/48 (4%)	6/49 (12%)	4/50 (8%)	2/49 (4%)
Females	0	190	955	5873
	Dose (mg/kg bw/day)			
Lymphoreticular system				
Lymphoblastic lymphosarcoma with leukemia – M	1/50 (2%)	4/48 (8%)	5/49 (10%)	1/49 (2%)
Lymphoblastic lymphosarcoma without leukemia – M	0/50 (0%)	1/48 (2%)	0/49 (0%)	3/49 (6%)
Composite lymphosarcoma – M	4/50 (8%)	1/48 (2%)	1/49 (2%)	6/49 (12%)
Histiocytic sarcoma – M	0/50 (0%)	0/48 (0%)	0/49 (0%)	0/49 (0%)
[#] Total lymphoreticular neoplasms	5/50 (10%)	6/48 (13%)	6/49 (12%)	10/49 (20%)

[#]Sum of lymphoblastic lymphosarcoma, composite lymphosarcoma, and histiocytic sarcoma.

M malignant

informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423). Benign renal tubule adenomas were noted in mid- and high-dose males at incidences of 1/50 and 3/50 respectively. These neoplasms were not observed in females, lacked statistical significance, and were considered spontaneous and unrelated to glyphosate administration by the study pathologists; this neoplasm, while not seen in the concurrent control group, had previously been noted in control male CD-1 mice of comparable age by the author of the study. As an additional measure of diligence, a Pathology Working Group was convened, and it concluded that the absence of any pre-neoplastic kidney lesion in all male animals provided sufficient evidence that this finding was spurious and not related to glyphosate administration. This is reflected in the US EPA review of glyphosate (US EPA 1993). This neoplasm was not observed in the other four mouse carcinogenicity studies discussed.

The author of the study also reported a trend towards a non-statistically significant increased occurrence of lymphoreticular neoplasia in treated female mice (Table 15). However, these consisted of three different categories of lymphoreticular neoplasms. Regulatory reviews confirmed that there is no apparent dose-dependence for these endpoints (EC 2002, US EPA 1993, WHO/FAO 2004a). Summary tables of incidence of neoplastic findings are available (see data Supplementary Study 10 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

Glyphosate was reported as not carcinogenic in CD-1 mice up to doses well in excess of the limit dose for carcinogenicity testing, which is consistent with evaluations by the US EPA (US EPA 1993), European Commission (EC 2002), recent EU Annex I Renewal evaluation by the Rapporteur (Germany Rapporteur Member State 2015b), and WHO/FAO (WHO/FAO 2004a).

Study 11 (Cheminova 1993b)

Another carcinogenicity bioassay in mice was conducted between December 1989 and December 1991 (Table 16) (Cheminova 1993b). In this assay, 50 male and 50 female CD-1 mice per dose group received glyphosate via their diet over a period of approximately two years. This treatment period is 6 months longer than the 18 months stipulated for mice by OECD TG 451 (1981 version). The dietary levels were adjusted regularly to achieve constant dose levels of 0, 100, 300 and 1000 mg/kg bw/day, achieving the limit dose. This study was rated Klimisch 1 for reliability.

Slight non-statistically significant increases in bronchiolar-alveolar adenomas were noted for all male dose groups above controls in a non-dose-responsive manner. Bronchiolar-alveolar neoplasms are evaluated in the context of the full data set (Tables 22 and 23), demonstrating a lack of dose-response across doses ranging from approximately 15 mg/kg bw/day to 5000 mg/kg bw/day. Although the number of pituitary adenomas were low and considered incidental, they were conservatively included in the select neoplasms, based on being slightly higher in high dose females than concurrent controls (Table 16). The data summary of all histological findings, including tumor incidence, is available (see data Supplementary Study 11 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

There were no statistically significant increases in the occurrence of any tumor type in this study. The observed variations did not show a dose relationship, and were within the range of historical control data. Glyphosate was determined to be not carcinogenic to CD-1 mice at up to 1000 mg/kg bw/day, which is consistent with evaluations by the European Commission (EC 2002) and WHO/FAO (WHO/FAO 2004a).

Table 16. Study 11 – Two-year feeding study with glyphosate in mice (Cheminova 1993b).

Study owner:	Cheminova (1993b)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements			
Substance:	Glyphosate (98.6% pure)			
Species/Strain:	Mouse/CD-1, groups of 50 ♂ and 50 ♀			
Administration route:	Diet			
Concentration:	♂ + ♀: 0, 100, 300, 1000 mg/kg bw/day (regular adjustment of dietary concentration)			
Duration:	24 months			
Findings:	≥ 1000 mg/kg bw/day: NOAEL (♂ + ♀) no treatment-related effects			
Select neoplasms:	Bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma, pituitary adenoma (females)			
Males	Dose (mg/kg bw/day)			
	0	10	300	1000
Bronchiolar-alveolar adenoma – B	9/50 (18%)	15/50 (30%)	11/50 (22%)	13/50 (26%)
Bronchiolar-alveolar carcinoma – M	10/50 (20%)	7/50 (14%)	8/50 (16%)	9/50 (18%)
Females	Dose (mg/kg bw/day)			
	0	100	300	1000
Bronchiolar-alveolar adenoma – B	7/50 (14%)	3/50 (6%)	3/50 (6%)	6/50 (12%)
Bronchiolar-alveolar carcinoma – M	3/50 (6%)	2/50 (4%)	1/50 (2%)	5/50 (10%)
Pituitary adenoma – B	1/41 (2%)	0/32	0/23	3/43 (6%)

B benign, M malignant

Study 12 (Arysta Life Sciences 1997a)

An 18-month feeding study in ICR-CD-1 mice, conducted between February 1995 and September 1996, investigated higher doses by admixing 1600, 8000, or 40 000 ppm glyphosate into the diet fed to groups of 50 male and 50 female mice per dose (Arysta Life Sciences 1997a). The calculated test substance intake was 165/153, 838/787, and 4348/4116 mg/kg bw/day (males/females, Table 17), exceeding the limit dose. This study was rated Klimisch 1 for reliability.

Histopathological examinations did not show statistically significant increases for any type of neoplastic lesion in all treatment groups of both sexes (see data Supplementary Study 12 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>). Select neoplasms evaluated across the data set with some non-

statistically significant increases above concurrent controls included lymphoma and lung tumors, all of which lacked a clear dose-response. Glyphosate was considered not carcinogenic in CD-1 mice up to doses well in excess of the limit dose for carcinogenicity testing, which is consistent with the recent evaluation in Europe under the Annex I Renewal of glyphosate (Germany Rapporteur Member State 2015b).

Study 13 (Feinchemie Schwebda 2001)

An 18-month feeding study in Swiss albino mice (Feinchemie Schwebda 2001), conducted between December 1997 and June 1999, featured treatment groups, each with 50 animals per sex, receiving 100, 1000, and 10000 ppm technical grade glyphosate

Table 17. Study 12 – Two-year feeding study with glyphosate in mice (Arysta Life Sciences 1997a).

Study owner:	Arysta Life Sciences (1997b)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations.			
Substance:	Glyphosate (94.6–97.6% pure)			
Species/Strain:	Mouse/CD-1, groups of 50 ♂ and 50 ♀			
Administration route:	Diet			
Concentration:	♂: 1600, 8000, or 40 000 ppm diet (♂ about 0. 165, 838, 4348 mg/kg bw/day; ♀ about 0. 153, 787, 4116 mg/kg bw/day)			
Duration:	18 months			
Findings:	8000/1600 ppm diet: NOAEL (♂/♀) 8000 ppm diet (♀): retarded growth 40 000 ppm diet: pale-colored skin ♂, loose stool, retarded growth, reduced food consumption and food efficiency, cecum distension and increased absolute and relative cecum weight, without histopathological findings of increased incidence of anal prolapse, consistent with histopathological erosion/ulcer of the anus			
Select neoplasms:	Lung adenoma, lung adenocarcinoma, lymphoma			
Males	Dose (mg/kg bw/day)			
	0	165	838	4348
Lung adenoma – B	8/50 (16%)	14/50 (28%)	13/50 (26%)	11/50 (11%)
Lung adenocarcinoma – M	1/50 (2%)	1/50 (2%)	6/50 (12%)	4/50 (8%)
Lymphoma – M	2/50 (4%)	2/50 (4%)	0/50	6/50 (12%)
Females	Dose (mg/kg bw/day)			
	0	153	787	4116
Lung adenoma – B	8/50 (16%)	5/50 (10%)	12/50 (24%)	5/50 (10%)
Lung adenocarcinoma – M	1/50 (2%)	2/50 (4%)	3/50 (6%)	1/50 (2%)
Lymphoma – M	6/50 (12%)	4/50 (8%)	8/50 (16%)	7/50 (14%)

B benign, M malignant

Table 18. Study 13–18-Month feeding study with glyphosate in mice (Feinchemie Schwebda 2001).

Study owner:	Feinchemie Schwebda (2001)					
Reliability/Justification	2 Study performed according to GLP and OECD guideline requirements, with no deviations, but possible viral infection may have confounded interpretation of results					
Substance:	Glyphosate (> 95% pure)					
Species/Strain	Mouse/Swiss albino, groups of 50 ♂ and 50 ♀					
Administration route:	Diet					
Concentration:	0, 100, 1000, 10 000 ppm diet (♂ about 0, 14.5, 150, 1454 mg/kg bw/day; ♀ about 0, 15.0, 151, 1467 mg/kg bw/day)					
Duration:	18 months					
Findings:	1000 ppm diet: NOAEL (♂+♀) 10 000 ppm diet (♂+♀): increased mortality					
Select neoplasms:	Bronchiolar/alveolar adenoma, lymphoma					
	Historical controls		Dose (mg/kg bw/day)			
			0	14.5	150	1454
Males						
Mortality	§11/50–27/50		¶22/50 (6)	20/50 (6)	22/50 (8)	27/50 (8)
Findings for dead and moribund sacrificed animals						
Lymphoma – M	¶20/75	26.7% [0–44]	9/22 (41.0%)	*12/20 (60.0%)	*13/22 (59.0%)	13/27 (48.0%)
Findings in animals sacrificed at termination						
Lymphoma – M	26/175	14.9% [8–24]	1/28 (3.6%)	3/30 (10.0%)	3/28 (10.7%)	*6/23 (26.1%)
Total animals						
Lymphoma – M	46/250	18.4% [6–30]	10/50 (20.0%)	15/50 (30.0%)	16/50 (32.0%)	*19/50 (38.0%)
	Historical controls		Dose (mg/kg bw/day)			
			0	15.0	151	1467
Females						
Mortality	12/50–20/50		16/50 (7)	16/50 (7)	20/50 (2)	20/50 (3)
Findings for dead and moribund sacrificed animals						
Bronchiolar/alveolar adenoma – B	–	–	0/16	0/16	1/20 (5%)	2/20 (10%)
Lymphoma – M	49/77	63.6% [0–100]	9/16 (56.0%)	10/16 (63.0%)	13/20 (65.0%)	12/20 (60.0%)
Findings in animals sacrificed at termination						
Bronchiolar/alveolar adenoma – B			1/34 (3%)	0/0	1/1 (100%)	1/30 (3%)
Lymphoma – M	50/175	28.9% [20–43]	9/34 (26.5%)	10/30 (29.4%)	6/30 (20.0%)	*13/28 (43.3%)
Total animals						
Bronchiolar/alveolar adenoma – B			1/50 (2%)	0/16	2/21 (10%)	3/50 (6%)
Lymphoma – M	99/250	39.6% [14–58]	18/50 (36.0%)	20/50 (40.0%)	19/50 (38.0%)	*25/50 (50.0%)

B benign, M malignant.

§Nine studies, performed by the same laboratory in the timeframe encompassing the study summarized here.

¶(Number of animals killed in extremis).

*Five studies, conducted in the same laboratory between 1996 and 1999.

*Statistically higher than concurrent controls ($p < 0.05$).

in the diet. Control mice received a plain diet. The calculated test substance intake was 14.5/15.0, 150/151, 1454/1467 mg/kg bw/day (males/females, Table 18), exceeding the limit dose, as reflected in elevated mortality in the high dose groups. This study was rated Klimisch 2 for reliability, based on speculation of a viral infection within the colony, discussed below.

Based on the slightly higher mortality and lower survival rates in the high dose groups, the NOAEL was considered 1000 ppm (151 mg/kg bw/day). There were no treatment-related effects on clinical signs, behavior, eyes, body weight, body weight gain, food consumption, and differential white blood cell counts in both sexes. Gross pathology, organ weight data, and histopathological examination demonstrated no treatment-related effects. An increase in the number of malignant lymphomas, the most common spontaneously occurring tumor category in the mouse, was statistically significant in the high-dose groups compared to controls (Table 18). The Germany Rapporteur Member State concluded that the malignant lymphoma increase in high-dose males was inconclusive but unrelated to treatment in the context of similar higher dosed studies (Germany Rapporteur Member State 2015b), and considered this endpoint irrelevant to carcinogenic risk in humans (Germany Rapporteur Member State

2015a). Whether or not a viral component (Tadesse-Heath et al. 2000) may have contributed to this endpoint, the finding was considered incidental background variation based on historical control data, and in agreement with the study director. As in Study 11, bronchiolar-alveolar adenoma was also considered a select neoplasm for evaluation in the broader data set (Tables 22 and 23), and as previously discussed, demonstrates a lack of dose-response across doses ranging from approximately 15 mg/kg bw/day to 5000 mg/kg bw/day. Summary tables of all histopathological neoplastic findings are available (see data Supplementary Study 13 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

Technical grade glyphosate was reported as not carcinogenic in Swiss albino mice, following continuous dietary exposure of up to 1460 mg/kg bw/day (average for both sexes) for 18 months. The NOAEL for general chronic toxicity was 151 mg/kg bw/day for both sexes combined.

Study 14 (Nufarm 2009a)

The most recent mouse carcinogenicity assay was conducted between October 2005 and November 2007 (Nufarm 2009a).

Table 19. Study 14–18-Month feeding study with glyphosate in mice (Nufarm 2009a).

Study owner:	Nufarm (2009b)			
Reliability/Justification:	1 Study performed according to GLP and OECD guideline requirements, with no deviations			
Substance:	Glyphosate (94.6–97.6% pure)			
Species/Strain:	mouse/CD-1, groups of 51 ♂ and 51 ♀			
Administration route:	Diet			
Concentration:	0, 500, 1500, and 5000 ppm diet (♂ about 0, 0, 71.4, 234, 810 mg/kg bw/day; ♀ about 0, 97.9, 300, 1081 mg/kg bw/day)			
Duration:	18 months			
Findings:	≥ 5000 ppm diet: NOAEL (♂/♀) No treatment-related effects			
Select neoplasms:	Bronchiolar-alveolar adenoma, Bronchiolar-alveolar adenocarcinoma, hepatocellular adenoma (males), hepatocellular carcinoma (males), lymphoma, pituitary adenoma (females)			
		Dose (mg/kg bw/day)		
	0	157	814	4841
Males				
Bronchiolar-alveolar adenoma – B	9/51 (18%)	7/51 (14%)	9/51 (18%)	4/51 (8%)
Bronchiolar-alveolar adenocarcinoma – M	5/51 (10%)	5/51 (10%)	7/51 (14%)	11/51 (22%)
Hepatocellular adenoma – B	1/51 (2%)	1/51 (2%)	4/51 (8%)	2/51 (4%)
Hepatocellular carcinoma – M	6/51 (12%)	11/51 (22%)	7/51 (14%)	4/51 (8%)
Lymphoma – M	0/51	1/50 (2%)	2/51 (4%)	5/51 (10%)
		Dose (mg/kg bw/day)		
	0	190	955	5873
Females				
Bronchiolar-alveolar adenoma – B	2/51 (4%)	4/51 (8%)	2/51 (4%)	2/51 (4%)
Bronchiolar-alveolar adenocarcinoma – M	5/51 (10%)	2/51 (4%)	2/51 (4%)	3/51 (6%)
Lymphoma – M	11/51 (22%)	8/51 (16)	10/51 (20%)	11/51 (22%)
Pituitary adenoma – B	0/51	1/50 (2%)	0/51	2/51 (4%)

B benign, M malignant

Groups of 51 CD-1 mice per sex received daily dietary doses of 0, 500, 1500, and 5000 ppm technical grade glyphosate (equivalent to an average intake of 85, 267 and 946 mg/kg bw/day, Table 19). The MTD was apparently not reached in the high-dose group, which is more indicative of low general toxicity of the test substance rather than a flaw in the study design. The NOAEL for chronic toxicity was 810 mg/kg bw/day for male mice and 1081 mg/kg bw/day for female mice, the highest dosage tested. Despite not quite achieving a limit dose in males, this study was arguably rated Klimisch 1 for reliability.

Several increases in common spontaneous mouse neoplasms in male mice were noted. Non-dose-response increases were noted for hepatocellular adenoma and carcinoma in males, and dose-responses were noted for bronchiolar-alveolar adenocarcinoma and malignant lymphoma in males, but not females. Pituitary adenoma incidences were low, and considered incidental in low and high-dose females, although they were slightly higher than controls (Table 19). These neoplasms were all evaluated in context of the broader data set (Tables 22 and 23). The summary of neoplastic findings is available (see data Supplementary Study 14 to be found online at <http://informahealthcare.com/doi/abs/10.3109/10408444.2014.1003423>).

Glyphosate was considered not carcinogenic in the CD-1 mice, following continuous average dietary exposure for males and females, to quantities up to 945.6 mg/kg bw/day for 18 months, which is consistent with the recent evaluation in Europe under the Annex I Renewal of glyphosate (Germany Rapporteur Member State 2015b).

Discussion

An extraordinarily large volume of animal data has been compiled to evaluate the carcinogenic potential of glyphosate.

The expected normal biological variability for spontaneous tumor formation is reflected across this extensive data set (Tables 20–23). However, no specific neoplasm stands out as a consequence of glyphosate exposures. While some individual studies may note an increase in a specific neoplasm at the high dose, the pooled data fail to identify any consistent pattern of neoplasm formation, demonstrating that the effect is not reproducible and not treatment-related. The lack of a dose-response across the several orders of magnitude suggests that no individual tumor of single etiology is attributable to glyphosate administration.

Glyphosate has undergone repeated and extensive review by the United States Environmental Protection Agency (US EPA 1993), the European Union (EC 2002, Germany Rapporteur Member State 2015b) and the World Health Organization/Food and Agriculture Organization of the United Nations (WHO/FAO 2004b, WHO/FAO 2004a). With regard to potential carcinogenic effects of glyphosate, the unanimous outcome of these reviews has been that the data provide sufficient evidence to conclude that glyphosate should not be considered a carcinogen. Genotoxicity studies with glyphosate, conducted under conditions stipulated by internationally accepted testing guidelines and GLP, as reviewed in 2000 (Williams et al. 2000) and recently updated (Kier and Kirkland 2013), indicate that glyphosate clearly does not exhibit the properties of a DNA-reactive genotoxic carcinogen. This lack of mutagenicity rules out an important concern for carcinogenicity.

Mink et al. published a review of the available epidemiological studies that investigated possible associations between glyphosate and cancer diagnosed in humans (Mink et al. 2012). No evidence was found for a statistically significant positive association between cancer and exposure to glyphosate. While one Agricultural Health Study (AHS) publication mentions a “suggested association” between glyphosate use and multiple myeloma (De Roos et al. 2005), a later summary of AHS

Table 20. Summary of select neoplasms in male rats (Studies 1–8).

Select neoplasm	Tumor Incidence/number of animals examined, by dose (mg/kg bw/day)											
	Controls – 0 [% range for studies]	^a 3	^a 7.4	^a 10	^a 10	^a 31	^a 73.9	^b 86	^b 89	^c 100	^f 104	^g 121
Pancreas islet cell adenoma	20/397 [0–14]	5/49	0/30	2/50	1/24	2/50	0/32	1/51	8/57	2/17	1/75	2/64
Pituitary adenoma	153/398 [6–57]	19/49	4/30	20/48	12/24	18/47	3/31	11/51	32/58	8/19	41/75	17/63
Pituitary carcinoma	4/98 [2–6]	2/49	NF	3/48	1/24	1/47	NF	NF	NF	0/19	NF	NF
Testes interstitial cell (Leydig)	14/447 [0–8]	3/50	0/37	1/50	1/25	6/50	2/32	3/51	0/60	0/19	2/75	2/63
Thyroid C cell adenoma	35/391 [4–18]	1/49	0/26	0/49	1/21	2/49	1/29	*1/51	5/58	1/17	10/74	*1/63
Hepatocellular adenoma	30/351 [0–48]	NF	22/50	NF	1/50	NF	10/48	2/51	2/60	1/49	0/75	2/64
Hepatocellular carcinoma	22/384 [0–42]	0/50	28/50	1/50	1/50	2/50	18/48	0/51	2/60	1/49	1/75	NF
Benign keratoacanthoma (skin)	8/250 [2–5]	NF	NF	NF	NF	NF	NF	3/51	3/60	NF	3/75	0/64

Select neoplasm	Tumor Incidence/number of animals examined, by dose (mg/kg bw/day)													
	^e 150	^b 285	^c 300	^f 354	^g 361	^b 362	^d 740.6	^e 780	^b 940	^e 1000	^h 1077	^f 1127	^g 1214	^g 1290
Pancreas islet cell adenoma	NF	2/51	2/21	1/80	0/64	5/60	1/49	NF	7/59	1/49	1/51	1/78	1/64	NF
Pituitary adenoma	NF	10/51	7/21	33/80	18/64	34/58	5/49	NF	32/59	17/50	20/51	42/78	19/63	NF
Pituitary carcinoma	NF	NF	1/21	NF	NF	NF	NF	NF	NF	0/50	NF	NF	NF	NF
Testes interstitial cell (Leydig)	1/49	1/51	0/21	0/80	2/63	3/60	3/50	2/49	2/60	2/50	1/51	2/78	2/64	0/47
Thyroid C cell adenoma	NF	*0/51	2/21	5/79	*1/63	8/58	1/50	NF	7/60	8/49	*3/51	6/78	*0/64	NF
Hepatocellular adenoma	NF	0/51	2/50	2/80	0/64	3/60	21/50	NF	8/60	2/50	1/51	1/78	5/64	NF
Hepatocellular carcinoma	1/49	0/51	0/50	2/80	NF	1/60	24/50	0/49	2/60	0/50	0/51	1/78	NF	0/47
Benign keratoacanthoma (skin)	NF	0/51	NF	0/80	1/64	4/60	NF	NF	5/59	NF	6/51	7/78	1/63	NF

^aStudy 1 (Monsanto) (CD) SD rats, rated unreliable for carcinogenicity evaluation.^bStudy 2 (Monsanto) (CD) SD rats, including interim sacrifice groups.^cStudy 3 (Chemnova) SD rats.^dStudy 4 (Feinchemic Schwebda) Wistar rats.^eStudy 5 (Excel) SD rats, rated unreliable for carcinogenicity evaluation.^fStudy 6 (Arysta Life Sciences) Crj:CD SD rats, including interim sacrifice groups.^gStudy 7 (Syngenta) Alpk:AP₁SD Wistar rats, including interim sacrifice groups.^hStudy 8 (Nufarm) Wistar Han Crj:WI rats.

*Recorded as parafollicular adenoma.

NF not found/not reported

Table 21. Summary of select neoplasms in female rats (Studies 1–8).

Select neoplasm	Tumor Incidence/number of animals examined, by dose (mg/kg bw/day)											
	Controls – 0 [% range for studies]	^a 3	^a 7.4	^a 10	^a 11	^a 34	^d 73.9	^e 100	^b 105	^b 113	^f 115	^g 145
Pancreas islet cell adenoma	11/397 [0–9]	1/50	0/23	2/27	1/50	0/49	0/16	2/29	0/51	1/60	2/79	0/63
Pituitary adenoma	246/397 [14–78]	29/48	13/33	19/28	31/50	26/49	7/23	19/29	23/51	48/60	54/79	44/63
Pituitary carcinoma	16/155 [2–17]	7/48	NF	5/28	5/50	12/49	NF	5/28	NF	0/60	NF	NF
Thyroid C cell adenoma	25/302 [3% – 16%]	3/49	0/24	1/27	6/50	3/47	1/17	1/29	*1/51	2/60	7/78	*0/63
Hepatocellular adenoma	22/302 [0–36]	NF	18/48	1/50	NF	NF	19/49	3/50	0/51	2/60	1/79	0/64
Hepatocellular carcinoma	14/210 [0–20]	0/50	15/48	0/50	0/50	2/50	14/49	0/50	0/51	0/60	NF	NF
Mammary gland fibroadenoma	113/384 [6–58]	16/46	NF	12/28	20/48	16/44	NF	17/29	9/51	*24/54	30/79	4/63
Mammary gland adenocarcinoma	40/334 [2–22]	6/46	0/30	NF	5/48	8/44	0/33	NF	3/51	-10/54	8/79	0/63

Select neoplasm	Tumor Incidence/number of animals examined, by dose (mg/kg bw/day)													
	^e 210	^c 300	^b 349	^f 393	^g 437	^b 457	^d 740.6	^e 1000	^e 1060	^b 1183	^f 1247	^h 1382	^g 1498	^g 1740
Pancreas islet cell adenoma	NF	2/29	0/51	1/78	1/64	4/60	1/49	1/49	NF	0/59	1/78	0/51	0/64	NF
Pituitary adenoma	NF	25/30	16/51	47/77	46/63	46/60	6/50	34/49	NF	34/59	52/78	32/51	49/64	NF
Pituitary carcinoma	NF	2/30	NF	NF	NF	0/60	NF	7/49	NF	1/59	NF	NF	NF	NF
Thyroid C cell adenoma	NF	2/29	*1/50	8/76	*0/64	6/60	1/47	7/49	NF	6/60	4/78	*0/51	*2/64	NF
Hepatocellular adenoma	NF	1/50	1/51	0/78	1/64	6/60	13/50	2/50	NF	1/60	0/78	1/51	0/64	NF
Hepatocellular carcinoma	NF	0/50	1/51	NF	NF	1/60	9/50	0/50	NF	2/60	NF	0/51	NF	NF
Mammary gland fibroadenoma	1/22	19/30	7/51	27/77	6/64	*27/59	NF	29/50	5/22	*28/57	30/78	5/51	5/64	5/50
Mammary gland adenocarcinoma	0/22	NF	1/51	11/77	0/64	-14/59	0/48	NF	0/22	-9/57	8/78	6/51	2/64	0/50

^aStudy 1 (Monsanto) (CD) SD rats, rated unreliable for carcinogenicity evaluation.^bStudy 2 (Monsanto) (CD) SD rats, including interim sacrifice groups.^cStudy 3 (Chemnova) SD rats.^dStudy 4 (Feinchemic Schwebda) Wistar rats.^eStudy 5 (Excel) SD rats, rated unreliable for carcinogenicity evaluation.^fStudy 6 (Arysta Life Sciences) Crj:CD SD rats, including interim sacrifice groups.^gStudy 7 (Syngenta) Alpk:AP₁SD Wistar rats, including interim sacrifice groups.^hStudy 8 (Nufarm) Wistar Han Crj:WI rats.

*Recorded as adenoma/adenofibroma/fibroma.

-Recorded as carcinoma/adenocarcinoma.

NF not found/not reported.

Table 22. Summary of select neoplasms in male mice (Studies 10–14).

Select neoplasm	Tumor incidence/number of animals examined, by dose (mg/kg bw/day)							
	Controls – 0 [% range for studies]	^a 14.5	^c 85	^b 100	^d 150	^a 157	^e 165	^e 267
Bronchiolar-alveolar adenoma	31/249 [10–18]	2/22	[§] 7/51	15/50	0/22	9/50	[§] 14/50	[§] 9/51
Bronchiolar-alveolar adenocarcinoma	10/149 [2–10]	NF	[§] 5/51	NF	NF	3/50	[§] 1/50	[§] 7/51
Bronchiolar-alveolar carcinoma	10/100 [0–20]	0/22	NF	7/50	0/22	NF	NF	NF
Hepatocellular adenoma	27/250 [0–28]	5/25	1/51	12/50	3/28	0/50	15/50	4/51
Hepatocellular carcinoma	15/250 [0–16]	0/25	11/51	5/50	0/28	0/50	1/50	7/51
Malignant lymphoma	16/205 [0–100]	15/50	1/51	2/4	16/50	[*] 5/50	2/50	2/51
Myeloid leukemia	3/101 [0–6]	1/50	1/51	NF	1/50	NF	NF	0/51

Select neoplasm	Tumor incidence/number of animals examined, by dose (mg/kg bw/day)							
	^b 300	^a 814	^c 838	^e 946	^b 1000	^d 1454	^e 4348	^a 4841
Bronchiolar-alveolar adenoma	11/50	9/50	[§] 13/50	[§] 4/51	13/50	1/50	[§] 11/50	9/50
Bronchiolar-alveolar adenocarcinoma	NF	2/50	[§] 6/50	[§] 11/51	NF	NF	[§] 4/50	1/50
Bronchiolar-alveolar carcinoma	8/50	NF	NF	NF	9/50	1/50	NF	NF
Hepatocellular adenoma	11/50	1/50	15/50	2/51	9/50	3/50	7/50	0/50
Hepatocellular carcinoma	6/50	0/50	3/50	4/51	7/50	2/50	1/50	2/50
Malignant lymphoma	1/1	[*] 4/50	0/50	5/51	6/8	19/50	6/50	[*] 2/50
Myeloid leukemia	NF	NF	NF	0/51	NF	1/50	NF	NF

^aStudy 10 (Monsanto) CD-1 mice.^bStudy 11 (Cheminova) CD-1 mice.^cStudy 12 (Arysta Life Science) CD-1 mice.^dStudy 13 (Feinchemic Schwebda) Swiss albino mice.^eStudy 14 (Nufarm) CD-1 mice.[§]Recorded as lung rather than bronchiolar-alveolar.^{*}Recorded as sum of malignant lymphoblastic lymphosarcoma with leukemia, lymphoblastic lymphosarcoma without leukemia and composite lymphosarcoma.[‡]Recorded as lymphoblastic lymphosarcoma with leukemia.

NF not found/not reported.

results note that there were no associations between glyphosate use and a number of cancers, including lymphohematopoietic cancers, leukemia, NHL, and multiple myeloma (Weichenthal et al. 2010). A subsequent reanalysis of AHS data obtained under the Freedom of Information Act notes no suggestion of an association between glyphosate use and multiple myeloma, with a relative risk of 1.1 and 95% and a confidence interval of 0.5–2.9 (Sorahan 2012). A recent review paper (Alavanja et al.

2013) cites another epidemiology study claiming an association between glyphosate use and NHL (Eriksson et al. 2008), but this research is strongly criticized in the recent Reevaluation Assessment Report for glyphosate Annex I Renewal in Europe (Germany Rapporteur Member State 2015b), highlighting potential referral bias, selection bias, uncontrolled confounding, limited data usage contrary to claims of including all new cases (living cases only, rather than living

Table 23. Summary of select neoplasms in female mice (Studies 10–14).

Select neoplasm	Tumor incidence/number of animals examined, by dose (mg/kg bw/day)							
	Controls – 0 [% range for studies]	^d 15.0	^c 85	^b 100	^d 151	^c 153	^a 190	^e 267
Bronchiolar-alveolar adenoma	28/250 [2–20]	0/16	[§] 4/51	3/49	2/21	[§] 5/50	9/50	[§] 2/51
Bronchiolar-alveolar adenocarcinoma	2/99 [2]	NF	[§] 2/51	NF	NF	[§] 2/50	3/50	[§] 2/51
Bronchiolar-alveolar carcinoma	9/151 [2–10]	0/16	NF	2/49	0/20	NF	NF	NF
Malignant lymphoma	54/215 [10–100]	20/50	8/51	12/15	19/50	4/50	[#] 6/50	10/51
Myeloid leukemia	2/156 [0–4]	1/50	0/51	NF	2/50	0/50	NF	1/51
Pituitary adenoma	1/232 [0–2]	0/16	1/51	0/32	0/17	1/50	0/21	0/51

Select neoplasm	Tumor incidence/number of animals examined, by dose (mg/kg bw/day)							
	^b 300	^c 787	^e 946	^a 955	^b 1000	^d 1467	^e 4116	^a 5874
Bronchiolar-alveolar adenoma	3/50	[§] 12/50	[§] 2/51	10/49	6/50	3/50	[§] 5/50	1/50
Bronchiolar-alveolar adenocarcinoma	NF	[§] 3/50	[§] 3/51	4/49	NF	NF	[§] 1/50	4/50
Bronchiolar-alveolar carcinoma	1/50	NF	NF	NF	5/50	0/50	NF	NF
Malignant lymphoma	9/12	8/50	11/51	[#] 6/50	13/14	25/50	7/50	[#] 10/50
Myeloid leukemia	NF	0/50	0/51	NF	NF	1/50	1/50	NF
Pituitary adenoma	0/23	0/50	2/51	0/44	–3/50	1/48	0/50	0/37

^aStudy 10 (Monsanto) CD-1 mice.^bStudy 11 (Cheminova) CD-1 mice.^cStudy 12 (Arysta Life Science) CD-1 mice.^dStudy 13 (Feinchemic Schwebda) Swiss albino mice.^eStudy 14 (Nufarm) CD-1 mice.[§]Recorded as lung rather than bronchiolar-alveolar.[#]Recorded as sum of lymphoblastic lymphosarcoma with leukemia, lymphoblastic lymphosarcoma without leukemia and composite lymphosarcoma.[‡]2 animals in anterior lobe, 1 animal in intermediate lobe.

NF not found/not reported.

plus dead), and questionable definition/interpretation of dose-response. It is important to note that the Eriksson et al. study did detect statistically significant positive associations for small lymphocytic lymphoma/chronic lymphocytic leukemia and "unspecified NHL", while the following lymphomas were not statistically significantly associated with glyphosate use: B-cell lymphomas, grade I-III follicular lymphoma, diffuse large B-cell lymphoma, other specified B-cell lymphomas, unspecified B cell lymphomas, and T-cell lymphomas (Eriksson et al. 2008). As previously discussed, statistically significant associations need to be evaluated further for study bias, confounders and sampling error, before expending resources and energy on further evaluation of potential causality.

Epidemiological investigations face the difficulty of reliably determining the magnitude of exposure to the chemical in question, while ruling out confounders like co-exposure to other chemicals, and environmental and lifestyle factors. In contrast, carcinogenicity studies in experimental animals, when conducted according to appropriate testing guidelines, are designed in a fashion that allows a direct association between observed effects and substance exposure, yet the relevance of observed findings to humans is an important consideration. This manuscript collectively presents the scientific community with carcinogenicity results from a remarkably large body of data from fourteen long-term carcinogenicity studies on glyphosate.

Glyphosate is of very low acute toxicity with an oral LD₅₀ in the rat in excess of 5000 mg/kg of body weight. The sub-chronic NOAEL is 400 mg/kg bw/day, and is based on effects that do not impair long-term survival (WHO/FAO 2004b, WHO/FAO 2004a). This allows administration of very high glyphosate doses to rodents for a prolonged time. Dietary levels of up to 30 000 and 40 000 milligrams of glyphosate per kilogram of diet have been administered to rats and mice, respectively, in chronic feeding studies covering their expected lifespan without apparent effects on longevity.

One of the most critical aspects of designing a carcinogenicity study is the choice of dose levels, especially the top dose, at either the limit dose or MTD. The relevant OECD TGs 451 and 453 for carcinogenicity studies propose a body

weight depression of approximately 10% as evidence for systemic toxicity. This is equivalent to the concept of the MTD, which is discussed in a supporting OECD guidance document (OECD 2012b). For chemicals which are well tolerated by the experimental animal, where no dose-limiting toxicity is observed, the respective OECD guidance suggests 1000 mg/kg bw/day as the highest dose level (OECD 2012a). Many of the carcinogenicity studies performed in rats and mice with glyphosate have been conducted with the high dose group receiving levels of glyphosate at, or in excess of the limit dose because of its very low toxicity following repeat exposure. Following this extensive testing, even at very high exposure levels, there was no evidence of a carcinogenic effect related to glyphosate treatment. The select neoplasms highlighted in Tables 20–23 show normal biological background levels of spontaneous neoplasms, with lack of dose-response across the data sets. The combined studies clearly indicate that glyphosate's carcinogenic potential is extremely low or non-existent in animal models up to very high doses.

By way of comparison, the worst-case calculated human dietary exposure to glyphosate, the Theoretical Maximum Daily Intake (TMDI) is 0.14 mg/kg bw/day (EFSA 2012). Systemic exposure of operators, as assessed for the EU reapproval of glyphosate, is predicted to be between 0.0034 (German BBA model, tractor-mounted ground-boom sprayer) and 0.226 mg/kg bw/day (UK POEM, hand-held-spraying to low targets, data not shown). The model estimates are supported by human biomonitoring data in farmers showing systemic exposures of 0.004 and 0.0001 mg/kg/day for worst-case and mean acute doses, respectively (Acquavella et al. 2004). The high doses in chronic rodent studies at which no evidence of carcinogenicity is demonstrated are at least hundreds of thousands fold greater than peak human systemic exposure levels. Clearly, there is no scientific basis for concern of carcinogenic risk to humans resulting from glyphosate exposure.

With over 40 years of scientific research on glyphosate, no compelling evidence exists for a mechanism for glyphosate to cause cancer. Mammalian metabolism does not activate glyphosate to a toxic metabolite (Anadon et al. 2009, WHO/FAO 2004a). The lack of glyphosate DNA reactivity supports the




Figure 2. Likelihood of glyphosate carcinogenicity based on experimental and epidemiological data; a causal inference grid as proposed by Adami et al. (2011) to utilize both toxicological and epidemiological data.

lack of potential for an initiation event for carcinogenesis (Kier and Kirkland 2013). Clearly, there is a lack of potential for glyphosate to induce hormonal oncogenesis, based on both the tumor incidence data presented and the unequivocal evidence that glyphosate is not an endocrine disruptor (Bailey et al. 2013, Levine et al. 2012, Saltmiras and Tobia 2012, Webb et al. 2013, Williams et al. 2012).

The absence of test substance-related neoplastic findings in a total of 14 rodent cancer bioassays with glyphosate is in stark contrast to the recent dramatic media reports, internet postings, and YouTube videos of rat tumors, hypothesized to be caused by treatment with maize containing glyphosate residue or drinking water spiked with a glyphosate formulation (Seralini et al. 2014). Such reports, under the scrutiny of the global scientific community, demand greater data transparency and accountability within the peer review process.

The absence of a glyphosate-related mechanism for carcinogenesis, the huge volume of genotoxicity data studies indicating no likely mutagenic or DNA-reactive potential (Kier and Kirkland 2013), combined with the lack of epidemiological evidence for glyphosate-induced cancer (Mink et al. 2012), and the lack of carcinogenicity in multiple rodent carcinogenicity assays, are depicted in a causal inference grid in Figure 2, as put forth by Adami et al. (Adami et al. 2011). The overwhelming weight of the available evidence, demonstrating a lack of both biological plausibility and epidemiological effects, draws a compelling conclusion that glyphosate's carcinogenic potential is extremely low or non-existent.

Acknowledgements

Special thanks go to Elizabeth Webb, Monsanto Toxicologist, for her detailed attention to document and data table formatting and as the reference library curator. Quality control and review of data transcription were valued services provided by Carrie Leigh Logan and Aparna Desai Nemali, Monsanto Quality Assurance Specialists.

Declaration of interest

The employment affiliation of the authors is as shown on the cover page. Volker Mostert was an employee of the consulting group, Dr. Knoell Consult GmbH, involved in the preparation of the recent glyphosate Annex I Renewal dossier for the Glyphosate Task Force (GTF; a consortium of European glyphosate registrants <http://www.glyphosatetaskforce.org/>). Helmut Greim was funded as an independent consultant for his expert contributions to this manuscript. David Saltmiras and Christian Strupp are employed by member companies of the GTF, Monsanto and ADAMA Agriculture B.V. (formerly Feinchemie Schwebda GmbH) respectively. David Saltmiras is also Chair of the Toxicology Technical Working Group of the GTF. Christian Strupp is an expert member of the Toxicology Technical Working Group of the GTF. Monsanto Company was the original producer and marketer of glyphosate formulations. The authors had sole responsibility for the writing and content of the paper and the interpretations and opinions expressed in the paper are those of the authors and may not necessarily be those of the member companies of the Glyphosate Task Force.

References

- Acquavella JF, Alexander BH, Mandel JS, Gustin C, Baker B, Chapman P, Bleeke M. (2004). Glyphosate biomonitoring for farmers and their families: Results from the farm family exposure study. *Environ Health Perspect*, 112, 321–6.
- Adami HO, Berry SC, Breckenridge CB, Smith LL, Swenberg JA, Trichopoulos D, et al. (2011). Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. *Toxicol Sci*, 122, 223–34.
- Alavanja MC, Ross MK, Bonner MR. (2013). Increased cancer burden among pesticide applicators and others due to pesticide exposure. *CA Cancer J Clin*, 63, 120–42.
- Anadon A, Martinez-Larranaga MR, Martinez MA, Castellano VJ, Martinez M, Martin MT, et al. (2009). Toxicokinetics of glyphosate and its metabolite aminomethyl phosphonic acid in rats. *Toxicol Lett*, 190, 91–5.
- Antoniou M, Habib M, Howard C, Jennings R, Leifert C, Nodari R, et al. (2012). Teratogenic effects of glyphosate-based herbicides: divergence of regulatory decisions from scientific evidence. *J Environ Anal Toxicol*, 34, 006.
- Aris A, Leblanc S. (2011). Maternal and fetal exposure to pesticides associated to genetically modified foods in Eastern Townships of Quebec, Canada. *Reprod Toxicol*, 31, 528–33.
- Aris A, Paris K. (2010). [Hypothetical link between endometriosis and xenobiotics-associated genetically modified food]. *Gynecol Obstet Fertil*, 38, 747–53.
- Armitage JO. (1997). The changing classification of non-Hodgkin's lymphomas. *CA Cancer J Clin*, 47, 323–5.
- Arysta Life Sciences. (1997a). HR-001: 18-Month Oral Oncogenicity Study in Mice. Tokyo, Japan: The Institute of Environmental Toxicology.
- Arysta Life Sciences. (1997b). HR-001: 24-Month Oral Chronic Toxicity and Oncogenicity Study in Rats. Kodaira-shi, Tokyo, Japan: The Institute of Environmental Toxicology.
- Arysta Life Sciences. (1997c). HR-001: 12-Month Oral Chronic Toxicity Study in Dogs. IET 94-0157
- Bailey J, Hauswirth J, Stump D. (2013). No evidence of endocrine disruption by glyphosate in male and female pubertal assays (Conference Abstract PS 1937). *The Toxicologist (supplement to Toxicological Sciences)*, 132, 412.
- Barale-Thomas E. (2013). The SFPT feels compelled to point out weaknesses in the paper by Seralini et al. (2012). *Food Chem Toxicol*, 53, 473–4.
- Benachour N, Seralini GE. (2009). Glyphosate formulations induce apoptosis and necrosis in human umbilical, embryonic, and placental cells. *Chem Res Toxicol*, 22, 97–105.
- Berry C. (2013). Adverse effects in a feeding study of a GM derived corn in rats. *Food Chem Toxicol*, 53, 445–6.
- Berry CL. (2010). Relativism, regulation and the dangers of indifferent science: the Sir Roy Cameron lecture of the Royal College of Pathologists. *Toxicology*, 267, 7–13.
- Bradford Hill A. (1965). The environment and disease: association or causation? *Proc R Soc Med*, 58, 295–300.
- Bradley A, Mukaratirwa S, Petersen-Jones M. (2012). Incidences and range of spontaneous findings in the lymphoid and haemopoietic system of control Charles River CD-1 mice (CrI: CD-1(ICR) BR) used in chronic toxicity studies. *Toxicol Pathol*, 40, 375–81.
- Brayton CP, Treuting PM, Ward JM. (2012). Pathobiology of aging mice and GEM: background strains and experimental design. *Vet Pathol*, 49, 85–105.
- Brock WJ. (2014). Strengthening the peer review process for the International Journal of Toxicology. *Int J Toxicol*, 33, 351–2.
- Chandra M, Riley MG, Johnson DE. (1992). Spontaneous neoplasms in aged Sprague-Dawley rats. *Arch Toxicol*, 66, 496–502.
- Cheminova. (1990). Glyphosate: 52 Week Oral Toxicity Study in Dogs. Inveresk Research International Report No.: 7502. Cheminova report No.: 52 GLY.
- Cheminova. (1993a). Glyphosate – 104 Week Combined Chronic Feeding/Oncogenicity Study in Rats with 52 Week Interim Kill (Results After 104 Weeks). Tranent, UK: Inveresk Research International, Ltd.
- Cheminova. (1993b). Glyphosate; 104 week dietary carcinogenicity study in mice. Tranent, UK: Inveresk Research International, Ltd.
- Chruscielska K, Brzezinski J, Kita K, Kalhorn D, Kita I, Graffstein B, et al. (2000a). Glyphosate – evaluation of chronic activity and possible

- far-reaching effects. Part 1. Studies on chronic toxicity. *Pestycydy* (Warsaw), 3-4, 11-20.
- Chruscielska K, Graffstein B, Szarapinska-Kwaszewska J, Brzezinski J, Kalhorn D. (2000b). Glyphosate: Evaluation of chronic activity and possible far-reaching effects. Part 2. Studies on mutagenic activity. *Pestycydy* (Warsaw) 3-4, 21-5.
- De Roos AJ, Blair A, Rusiecki JA, Hoppin JA, Svec M, Dosemeci M, et al. (2005). Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study. *Environ Health Perspect*, 113, 49-54. doi:10.1289/ehp.7340.
- de Souza I., Oda LM. (2013). Letter to the editor. *Food Chem Toxicol*, 53, 440.
- EC. (2002). Review report for the active substance glyphosate. European Commission, Directorate E – Food Safety: plant health, animal health and welfare, international questions, E1-Plant health.
- EFSA. (2012). Reasoned Opinion – Modification of the existing MRL for glyphosate in lentils. *EFSA J*, 10, 2250.
- Eriksson M, Hardell L, Carlberg M, Akerman M. (2008). Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. *Int J Cancer*, 123, 1657-63.
- EU. (2008). Council Regulation (EC) No 440/2008. Available at: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:142:0001-0739:en:PDF>. Accessed on November 13, 2012
- Everds NE, Snyder PW, Bailey KL, Bolon B, Creasy DM, Foley GL, et al. (2013). Interpreting stress responses during routine toxicity studies: a review of the biology, impact, and assessment. *Toxicol Pathol*, 41, 560-614.
- Excel. (1997). Combined Chronic Toxicity/Carcinogenicity Study of Glyphosate Technical in Sprague Dawley Rats, Pune, India: Indian Institute of Toxicology.
- Feinchemie Schwebda. (1996). Combined Chronic Toxicity and Carcinogenicity Study with Glyphosate Technical in Wistar Rats. Bangalore, India: Rallis India, Ltd.
- Feinchemie Schwebda. (2001). Carcinogenicity Study with Glyphosate Technical in Swiss Albino Mice. Bangalore, India: Rallis India, Ltd.
- Gad SC, Frith CH, Goodman DG, Boysen BG. (2008). Chapter 2. The Mouse. In: Gad, SC, Ed. *Animal Models in Toxicology*, Second Edition. Informa Health Care USA, Inc. ISBN-13: 978-0-8247-5407-5, ISBN-10: 0-8247-5407-7.
- Gasnier C, Benachour N, Clair E, Travert C, Langlois F, Laurant C, et al. (2010). Dgl1 protects against cell death provoked by glyphosate-based herbicides in human liver cell lines. *J Occup Med Toxicol*, 5, 29.
- Germany Rapporteur Member State. (2015a). Glyphosate Renewal Assessment Report. Volume 1. Report and Proposed Decision. Revised 29th, January 2015.
- Germany Rapporteur Member State. (2015b). Glyphosate Renewal Assessment Report. Volume 3, Annex B.6.1 Toxicology and Metabolism. Revised 29th, January 2015.
- Germany Rapporteur Member State. (2015c). List of Endpoints. Active Substance Glyphosate. Report and Proposed Decision. Revised 29th, January 2015.
- Gold LS, Sawyer CB, Magaw R, Backman GM, de Veciana M, Levinson R, et al. (1984). A carcinogenic potency database of the standardized results of animal bioassays. *Environ Health Perspect*, 58, 9-319.
- Grunewald W, Bury J. (2013). Comment on "Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize" by Seralini et al. *Food Chem Toxicol*, 53, 447-8.
- Hammond B, Goldstein DA, Salmiras D. (2013). Response to original research article, in press, corrected proof, "Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize". *Food Chem Toxicol*, 53, 459-64.
- Hayes AW. (2014). Reply to letter to the editor: Editor in Chief of *Food and Chemical Toxicology* answers questions on retraction. *Food Chem Toxicol*, 65, 394-5.
- IUPAC. (1997). *Compendium of Chemical Terminology*, 2nd ed. (the "Gold Book"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). XML on-line corrected version: <http://goldbook.iupac.org> (2006-) created by M. Nic, J. Jirat, B. Kosata; updates compiled by A. Jenkins. ISBN 0-9678550-9-8. doi:10.1351/goldbook. (<http://goldbook.iupac.org/M03771.html>).
- JMAFF. (2000). Data Requirements for Supporting Registration of Pesticides. Appendix, Section 2-1-15. Available at: <http://www.acs.famc.go.jp/eng/shinsei/8147annex.pdf>. Accessed on March 8, 2013.
- Johnson MD, Gad SC. (2008). Chapter 3. The Rat. In: Gad, SC, Ed. *Animal Models in Toxicology*, Second Edition. Informa Health Care USA, Inc. ISBN-13: 978-0-8247-5407-5, ISBN-10: 0-8247-5407-7.
- Kier LD, Kirkland DJ. (2013). Review of genotoxicity studies of glyphosate and glyphosate-based formulations. *Crit Rev Toxicol*, 43, 283-315.
- Klimisch HJ, Andreae M, Tillmann U. (1997). A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. *Regul Toxicol Pharmacol*, 25, 1-5.
- Langridge P. (2013). Problems lie at several levels and bring into serious question the quality and standard of the editorial processes in your journal. *Food Chem Toxicol*, 53, 441.
- Le Tien D, Le Huy H. (2013). Comments on "Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize". *Food Chem Toxicol*, 53, 443-4.
- Levine S, Salmiras D, Webb E, Holmes C, Mortensen S, Honnegger J, Bailey J. (2012). Tier 1 EDSP Assays and Regulatory Safety Studies Provide a Weight of Evidence that Glyphosate is Not an Endocrine Disruptor (Conference Abstract 529). Abstract Book for SETAC North America 33rd Annual Meeting. Long Beach, California. November 11-15, 2012.
- Mink PJ, Mandel JS, Scurman BK, Lundin JJ. (2012). Epidemiologic studies of glyphosate and cancer: a review. *Regul Toxicol Pharmacol*, 63, 440-52.
- Monsanto. (1981). A Lifetime Feeding Study of Glyphosate (ROUNDUP Technical) in Rats. East Millstone, New Jersey, USA: Bio/dynamics Inc.
- Monsanto. (1983). A Chronic Feeding Study of Glyphosate (Roundup® Technical) in Mice. East Millstone, New Jersey, USA: Bio/dynamics, Inc.
- Monsanto. (1985). Twelve-month Study of Glyphosate administered by Gelatin Capsule to Beagle Dogs. Monsanto report ML-83-137.
- Monsanto. (1990). Chronic Study of Glyphosate Administered in Feed to Albino Rats. St. Louis, MO, USA: Monsanto Agricultural Company.
- Nolte T, Rittinghausen S, Kellner R, Karbe E, Kittel B, Rinke M, Deschl U. (2011). RITA-Registry of Industrial Toxicology Animal data: the application of historical control data for Leydig cell tumors in rats. *Exp Toxicol Pathol*, 63, 645-56.
- Nufarm. (2007). Glyphosate technical: 52-week Toxicity Study by Oral Route (Capsule) in Beagle Dogs. Study No. 29647 TCC.
- Nufarm. (2009a). Glyphosate Technical: Dietary Carcinogenicity Study in the Mouse. Derbyshire, UK: Harlan Laboratories Ltd.
- Nufarm. (2009b). Glyphosate Technical: Dietary Combined Chronic Toxicity/Carcinogenicity in the Rat. Shardlow, Derbyshire, UK: Harlan Laboratories Ltd.
- OECD. (2012a). Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies, Supporting Test Guidelines 451, 452 and 453, 2nd Edition. Available at: [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO\(2011\)47&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2011)47&doclanguage=en). Accessed on 20th, January 2015.
- OECD. (2012b). OECD Guidelines for the Testing of Chemicals, Section 4 - Health Effects. Available at: http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-4-health-effects_20745788. Accessed on 20th, January 2015.
- Ollivier L. (2013). A comment on "Seralini, G.-E., et al., Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize. *Food Chem Toxicol*. (2012)". *Food Chem Toxicol*, 53, 458.
- Paganelli A, Guazzo V, Acosta H, Lopez SL, Carnasco AE. (2010). Glyphosate-based herbicides produce teratogenic effects on vertebrates by impairing retinoic acid signaling. *Chem Res Toxicol*, 23, 1586-95.
- Panchin AY. (2013). Toxicity of Roundup-tolerant genetically modified maize is not supported by statistical tests. *Food Chem Toxicol*, 53, 475.
- Romano MA, Romano RM, Santos LD, Wlanczewski P, Campos DA, de Souza PB, et al. (2012). Glyphosate impairs male offspring reproductive development by disrupting gonadotropin expression. *Arch Toxicol*, 86, 663-73.
- Romano RM, Romano MA, Bernardi MM, Furtado PV, Oliveira CA. (2010). Prepubertal exposure to commercial formulation of the herbicide glyphosate alters testosterone levels and testicular morphology. *Arch Toxicol*, 84, 309-17.

- Saltmirus D, Remick A, Haas M. (2011). Repeat dietary administration of an organic acid causes salivary gland alterations. *Toxicol Lett*, 205S, S233.
- Saltmirus D, Tobia A. (2012). No evidence of endocrine disruption by glyphosate in Hershberger and Uterotrophic assays (Conference Abstract PS 2198). *The Toxicologist* (supplement to Toxicological Sciences), 126, 474.
- Sanders D, Kamoun S, Williams B, Festing M. (2013). Re: Seralini, G.-E., et al. Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize. *Food Chem. Toxicol.* (2012). *Food Chem Toxicol*, 53, 450–3.
- Schmitz P, Harvert H. (2012). Die ökonomische Bedeutung des Wirkstoffes Glyphosat für den Ackerbau in Deutschland [Agro-Economic Analysis of the use of Glyphosate in Germany]. *J Kulturpflanzen*, 64, 150–62.
- Schorsch F. (2013). Serious inadequacies regarding the pathology data presented in the paper by Seralini et al. (2012). *Food Chem Toxicol*, 53, 465–6.
- Seralini GE, Clair E, Mesnage R, Gress S, Defarge N, Malatesta M, et al. (2014). Republished study: long-term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize. *Environ Sci Eur* [Online], 26, 14.
- Son WC, Gopinath C. (2004). Early occurrence of spontaneous tumors in CD-1 mice and Sprague-Dawley rats. *Toxicol Pathol*, 32, 371–4.
- Sorahan T. (2012). Multiple myeloma and glyphosate use: a re-analysis of US Agricultural Health Study data. Abstract P27-02. *Toxicol Lett*, 211S, S127.
- Syngenta. (1996a). *Glyphosate Acid: 1 Year Dietary Toxicity Study in Dogs*. Alderley Park, Macclesfield, Cheshire, UK: Central Toxicology Laboratory.
- Syngenta. (1996b). *Glyphosate Acid: One Year Dietary Toxicity Study in Rats*. CTL/P/5143.
- Syngenta. (2001). *Glyphosate Acid: Two Year Dietary Toxicity and Oncogenicity Study in Rats*. Central Toxicology Laboratory, Alderley Park Macclesfield, Cheshire, UK: Syngenta.
- Taddesse-Heath L, Chattopadhyay SK, Dillehay DL, Lander MR, Nagashfar Z, Morse HC, III, Hartley JW. (2000). Lymphomas and high-level expression of murine leukemia viruses in CFW mice. *J Virol*, 74, 6832–7.
- Tester M. (2013). It does not become the quality of a journal such as *Food and Chemical Toxicology* to publish such poor work. *Food Chem Toxicol*, 53, 457.
- Thoolen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Nolte T, et al. (2010). Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. *Toxicol Pathol*, 38, 5S–81S.
- Trewavas A. (2013). Science requires the dispassionate presentation of information. *Food Chem Toxicol*, 53, 449.
- Tribe D. (2013). My comments about the paper do not adequately describe the serious failures that have occurred in the peer review process at FCT. *Food Chem Toxicol*, 53, 467–72.
- US EPA. (1993). Reregistration eligibility decision (RED): glyphosate. United States Environmental Protection Agency, Office of Prevention, Pesticides, and Toxic Substances. Washington, DC, USA.
- US EPA. (2012). OCSPP Harmonized Test Guidelines - Series 870 - Health Effects Test Guidelines. Available at: http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series870.htm. Accessed on November 13, 2012.
- Webb E, Saltmirus D, Levine S. (2013). Endocrine Disruptor Screening Program (EDSP) Tier 1 In Vitro Assays Indicate Glyphosate Does Not Interact with Estrogen and Androgen Receptor Nor Inhibit Steroidogenesis (Poster abstract P500. American College of Toxicology 33rd Annual Meeting, November 4–7, 2012). *Int J Toxicol*, 32, 77.
- Weichenthal S, Moase C, Chan P. (2010). A review of pesticide exposure and cancer incidence in the Agricultural Health Study cohort. *Environ Health Perspect*, 118, 1117–25.
- WHO/FAO. (2004a). Pesticides residues in food – 2004. Part II Toxicological Evaluations. Joint meeting of the FAO Panel of Experts on pesticide residues in food and the environment and the WHO Core Assessment Group (JMPR). World Health Organization/Food and Agriculture Organization of the United Nations, Rome, Italy. <http://www.inchem.org/documents/jmpr/jmmono/v2004pr01.pdf>. Accessed on 20th, January 2015.
- WHO/FAO. (2004b). Pesticides residues in food – 2004. Report of the joint meeting of the FAO Panel of Experts on pesticide residues in food and the environment and the WHO Core Assessment Group on Pesticide Residues (JMPR). World Health Organization/Food and Agriculture Organization of the United Nations, Rome, Italy. http://www.fao.org/fileadmin/templates/agphome/documents/Pests_Pesticides/JMPR/Reports_1991-2006/report2004jmpr.pdf. Accessed on 20th, January 2015.
- Williams AL, Watson RE, DeSesso JM. (2012). Developmental and reproductive outcomes in humans and animals after glyphosate exposure: a critical analysis. *J Toxicol Environ Health B Crit Rev*, 15, 39–96.
- Williams GM, Kroes R, Munro IC. (2000). Safety evaluation and risk assessment of the herbicide Roundup and its active ingredient, glyphosate, for humans. *Regul Toxicol Pharmacol*, 31, 117–65.
- Woodside FC, Davis AG. (2013). The Bradford Hill Criteria: The Forgotten Predicate. *Thomas Jefferson Law Rev*, 35, 103–25.

Supplementary material available online

Data Supplementary Study 1–14.



New StatXact Toolkit for Correlated Data

Chris Corcoran – Utah State University

Pralay Senchaudhuri – Cytel Software Corporation



National Institutes of Health

The Nation's Medical Research Agency

U.S. Small Business Administration



Your Small Business Resource

EXHIBIT	21-8
WIT:	Corcoran
DATE:	9-20-17
C. Campbell, RDR CRR CSR #13921	

Example 1 – Developmental Toxicology Experiment with Multinomial Response

Response counts for 48 litters of mice with respect to (Dead, Malformed, Normal):

Dose=0.0 g/kg			Dose=3.0 g/kg		
(1,0,7)	(0,0,14)	(0,0,13)	(0,4,3)	(1,9,1)	(0,4,8)
(0,0,10)	(0,1,15)	(1,0,14)	(1,11,0)	(0,7,3)	(0,9,1)
(1,0,10)	(0,0,12)	(0,0,11)	(0,3,1)	(0,7,0)	(0,1,3)
(0,0,8)	(1,0,6)	(0,0,15)	(0,12,0)	(2,12,0)	(0,11,3)
(0,0,12)	(0,0,12)	(0,0,13)	(0,5,6)	(0,4,8)	(0,5,7)
(0,0,10)	(0,0,10)	(1,0,11)	(2,3,9)	(0,9,1)	(0,0,9)
(0,0,12)	(0,0,13)	(1,0,14)	(0,5,4)	(0,2,5)	(1,3,9)
(0,0,13)	(0,0,13)	(1,0,14)	(0,2,5)	(0,1,11)	
(0,0,14)					

TOTAL: (2.3%, 0.3%, 97.4%)

(3.0%, 55.6%, 41.5%)

Example 2 – Genetics of Alzheimer’s Disease (AD)

Sibships of size 3 from the Cache County Study on Memory, Health, and Aging.
Question: dose-response effect with respect to number of APOE ϵ 4 alleles?

Family		# ϵ 4 Alleles		
		0	1	2
1	AD	0	0	0
	No AD	1	2	0
2	AD	0	1	0
	No AD	0	2	0
		⋮		
20	AD	0	0	1
	No AD	2	0	0

Overall: 1/33 (2.6%) AD rate for 0 ϵ 4, 8/21 (38.1%) for 1 ϵ 4, and 1/1 (100.0%) for 2 ϵ 4.

Example 3 – Congenital Ophthalmologic Defects

Number of rejected corneal grafts out of total grafts received among 9 children with congenital hereditary endothelial dystrophy (CHED). With all four rejections observed in the older age group, what can we say about the effect of age on the probability of rejection?

Age at Diagnosis (years)	
< 3	≥ 3
0/2	0/2
0/2	1/2
0/2	1/2
0/2	1/1
	1/1


Fisher's Exact Test



R.A. Fisher (1890-1962)

An analogue of the chi-square test of independence for a two-way table. With an exact test, we do not need to rely on the assumption of large-sample normality (in particular, a large-sample chi-square distribution).

Sampling and Permutation Tests



Question: What's the probability that you reach into this bin to pull out 4 balls at random, and two of them are red?

Answer: There are ${}_{11}C_4$ total ways of choosing 4 balls from 11, where order doesn't matter. Of these possibilities, there are $({}_6C_2)({}_5C_2)$ ways of choosing exactly two red and two black. So

$$P(\text{Two Red}) = \frac{({}_6C_2)({}_5C_2)}{({}_{11}C_4)}.$$

Hypergeometric Distribution

In general, suppose that we have a bin with N balls, of which r are red and $N - r$ are black. We select m balls from the bin. What's the probability that we observe exactly x balls in this sample?

From the previous slide, we can see the answer is

 The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

or the hypergeometric mass function.

The Tea-Tasting Experiment

How does this relate to exact inference? While having tea with some colleagues, a woman in Fisher's company claimed that she could tell by taste if a cup of tea had been prepared with the tea poured first or the milk.



Fisher proposed the following experiment: present the woman with 8 cups of tea in random order, four of which had tea added first and four milk.

What if she picked four correctly? Three? Would either case provide evidence that her claim had merit?

Computing a Probability for this Experiment

To summarize the result of this experiment, we can use a 2 x 2 table, like this:

Truth	Decision		Total
	Tea first	Milk first	
Tea First	3	1	4
Milk First	1	3	4
Total	4	4	8

What's the probability of this result? Suppose we assume the number of tea-first cups is fixed. If the woman's claim is false, then picking tea-first cups correctly is like picking four red balls at random out of a bag containing a fixed number of red and black.

What's the "exact" p-value?

Assuming that the taster can't tell the difference (the null hypothesis), each possible table has associated with it a hypergeometric probability.

Note that assuming a fixed number of tea-first cups, these are the following potential outcomes of the experiment:

0	4	1	3	2	2	3	1	4	0
4	0	3	1	2	2	1	3	0	4
0.014		0.229		0.514		0.229		0.014	


As always, the p-value represents the probability that an outcome is as extreme as the observed result, given the null hypothesis is true. In this case:

$$P\text{-value} = P(\text{Pick 3 correctly}) + P(\text{Pick 4 Correctly}) = 0.229 + 0.014 = 0.243.$$

Quadratic Exponential Model (QEM)

Gourieroux (1984), Zhao and Prentice (1990)

- Loglinear model with all three-way and higher association parameters set to zero.
- For clustered binomial data (with N clusters, indexed by i):




Comparing Response Rates With Respect to Fixed Factors

- Alternative formulation using -1/1 coding for failure/success (Molenberghs and Ryan, 1999):

$$P(Y_i | n_i, \theta, \delta) = \binom{n_i}{S_i} \exp \{ \theta S_i + \delta S_i (n_i - S_i) + A(n_i; \theta, \delta) \}$$

- Using logit link:


$$P(Y_i | n_i, x_i, \beta_0, \beta_1, \delta) = \binom{n_i}{S_i} \exp \{ \beta_0 S_i + \beta_1 x_i S_i + \delta S_i (n_i - S_i) + A(n_i, x_i; \beta_0, \beta_1, \delta) \}$$



Value of fixed
factor

Likelihood and Conditioning

$$\left[\prod_{i=1}^N \binom{n_i}{S_i} \right] \exp \{ \beta_0 T_0 + \beta_1 T_1 + \delta U + \sum_i A(n_i, x_i; \beta_0, \beta_1, \delta) \}$$



EXACT TEST (Corcoran et al., 2001):

- Condition on sufficient statistics T_0 and U (and cluster sizes) to eliminate nuisance parameters β_0 and δ . Denote this set of tables by Γ .
- Order all tables in Γ according to test statistic $T_1 = \sum_i x_i S_i$.
- Under the hypothesis of no group differences (i.e., $\beta_1 = 0$), distribution of T_1 is a hypergeometric distribution, free of all unknown parameters.

Illustration: Corneal Graft Data

Reject	Age Group, or $I\{< 3 \text{ years}\}$									Total
	0	0	0	0	1	1	1	1	1	
Yes	0	0	0	0	0	1	1	1	1	4
No	2	2	2	2	2	1	1	0	0	12
Total	2	2	2	2	2	2	2	1	1	16

Observed Sufficient Statistics: $t_0 = 4, t_1 = 4, u = 2$

2	2	0	0	0	0	0	0	0
0	0	2	2	2	2	2	1	1



$t_0 = 4, u = 0$



1	2	0	0	1	0	0	0	0
1	0	2	2	1	2	2	1	1




$t_0 = 4, u = 2$



Comparing Two Ordered Multinomials with Clustering

- We have C categories, with N clusters.
- An exponential-family likelihood (adapted from Heagerty and Zeger, 1996):

$$\left[\prod_{i=1}^N \binom{n_i}{y_{i1} \dots y_{iC}} \right] \exp \left\{ \sum_{j=1}^C \beta_j \sum_{i=1}^N y_{ij} + \sum_{j < k} \delta_{jk} \sum_{i=1}^N y_{ij} y_{ik} + \sum_{i=1}^N A_i(\beta_1, \dots, \beta_C, \delta_{12}, \dots, \delta_{C-1,C}, n_i) \right\}$$



- Use Wilcoxon-type test statistic $T = \sum_{i,j} u_j y_{ij} I(\text{ith cluster in treatment group})$.
 - u_j 's represent increasing scores across multinomial categories.
 - $I(\cdot)$ is an indicator function.

Within-Cluster Covariates

- For both ordered binomials and multinomials, conditioning on the sufficient statistics is the same.
- Need to also condition on numbers of subjects within each cluster assigned to each treatment group.
- Test statistics change slightly: for both binomials and multinomials we need to sum over subgroups within cluster – defined by treatment level.


Computational Efficiency

- For dementia data: thousands of tables.
- Explicit enumeration too inefficient.
- Implicit enumeration: network algorithm.

Network Example

Suppose there are 6 clusters, divided equally in three dose groups, with cluster sizes (1,2,1,2,2,1), and observed number of responses (0,0,0,1,2,1).

Sufficient statistics are given by $T_0 = 4$ and $U = 5$. For dose scores of 0, 1, and 2, the test statistic is given by $T_1 = 6$.



Correlated Data Procedures in StatXact

SBIR Phases I and II: correlated data module for StatXact.

Clustered-data analogues:

- trend tests for ordered binomials and two ordered multinomials,
- Kruskal-Wallis test,
- Fisher's exact test,
- stratified 2×2 tables.

Also:

- Exact test for clustering,
- Exact trend test for multiple binomial outcomes.

Example 1 – Developmental Toxicology Experiment with Multinomial Response

Response counts for 48 litters of mice with respect to (Dead, Malformed, Normal):


Dose=0.0 g/kg			Dose=3.0 g/kg		
(1,0,7)	(0,0,14)	(0,0,13)	(0,4,3)	(1,9,1)	(0,4,8)
(0,0,10)	(0,1,15)	(1,0,14)	(1,11,0)	(0,7,3)	(0,9,1)
(1,0,10)	(0,0,12)	(0,0,11)	(0,3,1)	(0,7,0)	(0,1,3)
(0,0,8)	(1,0,6)	(0,0,15)	(0,12,0)	(2,12,0)	(0,11,3)
(0,0,12)	(0,0,12)	(0,0,13)	(0,5,6)	(0,4,8)	(0,5,7)
(0,0,10)	(0,0,10)	(1,0,11)	(2,3,9)	(0,9,1)	(0,0,9)
(0,0,12)	(0,0,13)	(1,0,14)	(0,5,4)	(0,2,5)	(1,3,9)
(0,0,13)	(0,0,13)	(1,0,14)	(0,2,5)	(0,1,11)	
(0,0,14)					

TOTAL: (2.3%, 0.3%, 97.4%)

(3.0%, 55.6%, 41.5%)

Example 1 – Developmental Toxicology

Permutation distribution of Wilcoxon statistic:



Example 2 – Genetics of Alzheimer’s Disease (AD)


Sibships of size 3 from the Cache County Study on Memory, Health, and Aging.
Question: dose-response effect with respect to number of APOE ϵ 4 alleles?

Family		# ϵ 4 Alleles		
		0	1	2
1	AD	0	0	0
	No AD	1	2	0
2	AD	0	1	0
	No AD	0	2	0
		⋮		
20	AD	0	0	1
	No AD	2	0	0

Overall: 1/33 (2.6%) AD rate for 0 ϵ 4, 8/21 (38.1%) for 1 ϵ 4, and 1/1 (100.0%) for 2 ϵ 4.

Example 2 – Genetics of Alzheimer’s

Permutation distribution of trend statistic:



Alternatives

- Under independence:
 - p -value is 1.92E-12 for toxicology data.
 - p -value is 0.00011 for Alzheimer's data.
- What if we stratify on cluster?
 - p -value is 0.012 for Alzheimer's data.

Do we still have to worry about small samples and asymptotic approximations?

Many “big data” problems are really just a large samples of small data problems

Genomewide association studies with high-density SNP panels:

- *1M (or more) hypothesis tests – none of these two-way tables produce highly discrete testing distributions?*
- *Bonferroni-corrected p-values – is it reasonable to use a chi-square approximation for a critical region of 10^{-8} ?*

Thanks to...

- The NIH: National Institute of Research Resources award RR019052.
- Cytel Software Corporation.

Expert Report
Christopher J. Portier, Ph.D.

Charge

Glyphosate acid is a colorless, odorless, crystalline solid. Glyphosate is the term used to describe the salt that is formulated by combining the deprotonated glyphosate acid and a cation (isopropylamine, ammonium, or sodium). This expert report is intended to review the available scientific evidence relating to the potential of glyphosate and glyphosate-based formulations (GBFs), including Roundup®, to cause Non-Hodgkin's Lymphoma (NHL) in humans.

Qualifications

I received an undergraduate degree in mathematics in 1977 from Nicholls State University and a Master's degree and Ph.D. in biostatistics from the University of North Carolina School of Public Health in 1979 and 1981 respectively. My Ph.D. thesis addressed the optimal way to design a two-year rodent carcinogenicity study to assess the ability of a chemical to cause cancer^[1, 2]; the optimal dosing pattern from my thesis is still used by most researchers. My first employment following my doctoral degree was a joint appointment at the National Institute of Environmental Health Sciences (NIEHS) and the National Toxicology Program (NTP) to conduct research on the design and analysis of experiments generally employed in toxicology. After 5 years with NIEHS/NTP, I developed my own research group which eventually became the Laboratory of Quantitative and Computational Biology and then the Laboratory of Computational Biology and Risk Assessment (LCBRA). One highlight during this period was the development of the Poly-3 Test for survival adjustment of data from two-year carcinogenicity studies in rodents^[3, 4]; this test is used as the main method of analysis of these studies by the NTP and many others. We also did a complete analysis of the historical controls animals from the NTP studies^[5, 6]. The LCBRA focused on the application of computational tools to identify chemicals that are toxic to humans, to develop tools for understanding the mechanisms underlying those toxicities and to quantify the risks to humans associated with these toxicities. The main toxicological focus of the LCBRA was cancer and my laboratory developed many methods for applying multistage models to animal cancer data and implemented the use of these models in several experimental settings^[7-19]. In my last few years at the NIEHS/NTP, my research focus expanded to the development of tools for evaluating the response of complex experimental and human systems to chemicals^[20-24] and the name of the laboratory shifted to Environmental Systems Biology.

Over my 32 years with the NIEHS/NTP, I was involved in numerous national priority issues that went beyond my individual research activities. After Congress asked NIEHS to work with the Vietnamese government to address the hazards associated with Agent Orange use during the Vietnamese War, I was given the responsibility of working with



my counterparts in Vietnam to build a research program in this area^[25]. Congress also tasked NIEHS with developing a research program (EMF-RAPID) to address concerns about the risks to humans from exposure to power lines and to report back to Congress on what we found. I was in charge of evaluating all research developed under this program and was responsible for the final recommendations to Congress on this issue^[26-28].

While at the NIEHS/NTP, I also had administrative positions that relate to my qualifications. From 2000 to 2006 I was the Director of the Environmental Toxicology Program (ETP) at NIEHS. The ETP included all of the toxicology research laboratories within the NIEHS Intramural Research Program. It was my responsibility to ensure the research being done was pertinent to the mission of the NIEHS, addressing high priority concerns about toxic substances and human health and that the NIEHS had adequate resources to complete this research.

During this time I was also Associate Director of the NTP, a position in which I was the scientific and administrative director of the NTP (The Director of the NTP was also the NIEHS Director and gave me complete autonomy in the management and science of the NTP). These two positions were historically always combined at the NIEHS and the NTP so that one person was in charge of all toxicological research at the NIEHS/NTP. The NTP is the world's largest toxicology program, routinely having 15 to 25 active two-year carcinogenicity studies, numerous genetic toxicology studies and many other toxicological studies being conducted at any given time. The NTP two-year carcinogenicity studies and their technical reports are also considered the "gold standard" of cancer studies due to their extreme high quality, their tremendous utility in evaluating human health hazards and the rigor and transparency they bring to the evaluation of the data. All data from NTP two-year cancer studies are publicly available including data on individual animals and images from the pathology review of each animal. The NTP is also home to the Report on Carcinogens, the US Department of Health and Human Services official list of what is known or reasonably anticipated to be carcinogenic to humans. It was my responsibility to decide what items eventually went onto this list while I was Associate Director of the NTP. In 2006, I became an Associate Director of the NIEHS, a senior advisor to the director and the director of the Office of Risk Assessment Research (ORAR). ORAR focused on stimulating new research areas on the evaluation of health risks from the environment and addressed major risk assessment issues on behalf of the NIEHS/NTP. For example, in this capacity, I lead a multiagency effort to understand the health risks to humans from climate change and to develop a research program in this area^[29].

I left the NIEHS/NTP in 2010 to become the Director of the National Center for Environmental Health (NCEH) at the Centers for Disease Control and Prevention and simultaneously Director of the Agency for Toxic Substances and Disease Registry (ATSDR). NCEH does research and supports activities aimed at reducing the impact of environmental hazards on public health. One well-respected research effort of the NCEH is the National Biomonitoring Program. This program tests for the presence of hundreds of chemicals in human blood and urine in a national sample of people in the

United States. ATSDR advises the Environmental Protection Agency (EPA) and communities on the potential health impacts from toxic waste dump sites (superfund sites). ATSDR is required by law to produce ToxProfiles. These are comprehensive reviews of the scientific literature for specific chemicals generally found at superfund sites. They also provide an assessment of the safety of these chemicals. As part of my activities at ATSDR, I began a modernization of the ToxProfiles to use systematic review methods in their assessments; this effort was linked to a similar effort that I had helped to implement at the NIEHS/NTP.

Aside from my official duties in my various federal jobs, I also served on numerous national and international science advisory panels. Most notable, for my qualifications for this statement, are my serving as Chair from 2005 to 2010 of the Subcommittee on Toxics and Risk of the President's National Science and Technology Council, member and chair of EPA's Science Advisory Panel from 1998 to 2003 (focused specifically on advising their pesticides program) and chair of the International Agency for Research on Cancer (IARC) advisory group that updated and improved its rules for reviewing scientific data to ensure that conclusions on the carcinogenicity of human exposures are the best possible (Preamble)^[30]. As part of my work on science advisory panels, I have served on EPA's Science Advisory Board, as an advisor to the Australian Health Council on risk assessment methods, as an advisor to the Korean Food and Drug Administration on toxicological methods, and served on several World Health Organization (WHO) International Program on Chemical Safety scientific panels dealing with risk assessment. Besides the guidelines for evaluating cancer hazards used by the IARC, I have either chaired or served as a member of scientific panels developing guidance documents for other organizations including the EPA.

I have received numerous awards, most notably the Outstanding Practitioner Award from the International Society for Risk Analysis and the Paper of the Year Award (twice) from the Society of Toxicology Risk Assessment Specialty Section. I am a fellow of the American Statistical Association, the International Statistical Institute, the World Innovation Foundation and the Ramazzini Institute. I have published over 250 peer-reviewed scientific papers, book chapters and technical documents on topics in toxicology and risk assessment.

Finally, I have served on numerous national and international committees tasked with evaluating the risk and/or hazard of specific environmental chemicals, including glyphosate. For example, I have contributed to risk assessments for EPA, the Food and Drug Administration, the Centers for Disease Control and Prevention, the National Institutes of Health, the WHO and IARC.

Reliance List

During the course of my preparation for this report, I have reviewed the following materials:

- a. All epidemiological data relating to the ability of glyphosate formulations to cause NHL in humans.

- b. Scientific papers on the cellular origins of NHL
- c. Peer-reviewed scientific data relating to the carcinogenicity, genotoxicity and oxidative stress caused by glyphosate
- d. Technical reports relating to the carcinogenicity of glyphosate provided by the defendant to the lawyers for the plaintiff
- e. The USEPA, the European Food Safety Authority (EFSA), the German Federal Institute for Risk Assessment, the European Chemical Agency, the IARC and the WHO/Food and Agriculture Organization Joint Meeting on Pesticide Residues reviews of the scientific literature relating to the potential for glyphosate to cause cancer.
- f. Technical documents available from EFSA regarding animal carcinogenicity data on glyphosate prepared by organizations other than the defendant
- g. Various other documents produced in the litigation

A complete list of my reliance materials is at the end of this report.

Methodology for Causality Evaluation

The evaluation of whether glyphosate and/or GBFs can cause NHL in humans requires the review and synthesis of scientific evidence from studies of human populations (epidemiology), animal cancer studies, and studies investigating the mechanisms through which chemicals cause cancer. Many different approaches^[31, 32] are used to synthesize these three areas of science to answer the question “Does this chemical cause cancer in humans?” In any of these three science areas, the quality of the individual studies has to be assessed and summarized to make certain the studies included in the overall assessment are done appropriately. Once the quality of the individual studies has been assessed, a judgment needs to be made concerning the degree to which the studies support a finding of cancer in humans. To do this, the EPA, IARC, the European Chemical Agency (EChA), the US Report on Carcinogens, and many others use guidelines^[30, 33-35] that rely upon aspects of the criteria for causality developed by Hill (1965)^[36].

Hill listed nine (9) aspects of epidemiological studies and the related science that one should consider in assessing causality. The presence or absence of any of these aspects is neither sufficient nor necessary for drawing inferences of causality. Instead, the nine aspects serve as means to answer the question of whether other explanations are more credible than a causal inference. As noted by Hill:

“None of my nine viewpoints can bring indisputable evidence for or against the cause-and-effect hypothesis and none can be required as a sine qua non. What they can do, with greater or less strength, is to help us to make up our minds on the fundamental question — is there any other way of explaining the set of facts before us, is there any other answer equally, or more, likely than cause and effect?”

The nine aspects cited by Hill include consistency of the observed association, strength

of the observed association, biological plausibility, biological gradient, temporal relationship of the observed association, specificity of the observed association, coherence, evidence from human experimentation and analogy. These are briefly described below.

An inference of causality is strengthened when several of the studies show a **consistent positive association** between cancer and the exposure. This addresses the key issue of replication of studies which is critical in most scientific debates. If studies are discordant, differences in study quality, potential confounding, potential bias and statistical power are considered to better understand that discordance.

An inference of causality is strengthened when the **strength of the observed association** in several studies are large and precise. These large, precise associations lessen the possibility that the observed associations are due to chance or bias. A small increase in risk of getting cancer does not preclude a causal inference since issues such as potency and exposure level may reduce the ability of a study to identify larger risks. Meta-analyses provide an objective evaluation of the strength of the observed association across several studies with modest risks to help clarify strength of the observed associations.

An inference of causality is strengthened when there is data supporting **biological plausibility** demonstrated through experimental evidence. Animal carcinogenicity studies, in which tumor incidence is evaluated in experimental animals exposed to pure glyphosate, play a major role in establishing biological plausibility. There are numerous types of mechanisms that can lead to cancer^[37], most of which can be demonstrated through experimental studies in animals, human cells, animal cells, and/or other experimental systems. Occasionally, occupational, accidental or unintended exposures to humans allow researchers to evaluate mechanisms using direct human evidence.

An inference of causality is strengthened when there is a **biological gradient** showing a reasonable pattern of changing risk with changes in exposure (e.g. risk increases with increasing exposure or with longer exposure). In many epidemiological studies, this aspect cannot be examined due to limitations in the study design or due to a lack of clarity in the presentation of the results. When a study does address an exposure-response relationship, failure to find a relationship can be due to a small range of exposures, insufficient sample size or a changing exposure magnitude over time that has not been accounted for.

An inference of causality is strengthened when there is a **temporal relationship** in which the exposure comes before the cancer. This aspect is necessary to show causality; if it is not present, a causal inference is not plausible. Because the latency period for cancers can be long (years), evaluation of studies should consider whether the exposure occurred sufficiently long ago to be associated with cancer development.

An inference of causality is strengthened when the exposure is **specific** for a given cancer. This would mean that the disease endpoint being studied is only due to the cause being assessed. This issue is seldom applicable and, since NHL has other causes, specificity is not applicable to the determination of causality for glyphosate.

An inference of causality is strengthened when other lines of experimental evidence are **coherent** with a causal interpretation of the association seen in the epidemiological evidence. To evaluate coherence, information from animal carcinogenicity studies, mechanistic investigations and information on the metabolism of the chemical being studied would be considered.

An inference of causality is strengthened when there is **experimental evidence in humans** supporting a causal interpretation. Seldom is this type of information available when addressing the toxicity of chemicals. However, experiments in which an individual reduces or limits exposures and the risk of cancer is reduced would carry considerable weight in the evaluation (e.g. studies evaluating the cancer risks of people who stop cigarette smoking compared with continuing smoking have demonstrated reduced lung cancer risks). No such data are available for glyphosate.

Finally, an inference of causality is strengthened when there are other chemical agents with **analogous** structures showing similar effects in humans and/or animals and/or showing similar biological impacts in mechanistic studies. No such data are available for glyphosate.

The most logical approach to developing an inference of causality is to step through each of the aspects of causality developed by Hill (1965)^[36] and apply them to the available data for glyphosate and for glyphosate formulations. This is done in the sections that follow.

Consistency of the Associations seen in Human Epidemiological Studies

Relevant Epidemiology Studies

In their meta-analysis, **Chang and Delzell (2016)**^[38] performed a systematic literature search of all scientific literature up to June, 2015, to identify all epidemiological studies that were pertinent to evaluating an association between glyphosate and NHL. They identified 12 relevant epidemiology studies^[39-50]. Their search agrees with all current reviews of glyphosate and I will use their findings from the literature up until 2015. To cover from June 2015 to the present (April 1, 2017), I used their searching algorithm and identified 117 additional published studies, none of which were new epidemiology studies. These same 12 studies will be considered for use in this evaluation. Other experts will be discussing the studies as well as their strengths and their weaknesses; I will focus on using the results of these studies in evaluating causality so I will only briefly describe each study.

Cantor et al. (1992)^[39] did an in-person interview study comparing 622 white men, newly diagnosed with NHL, to 1245 population-based controls in Iowa and Minnesota. They originally identified 780 cases, of which 694 (89%) were interviewed. After pathology review, only 622 were found to have NHL, the remaining cases having leukemia or other diseases. Three different sources of controls were used, random digit dialing (76.7% response rate), Health Care Financing Administration rolls (79% response

rate) and deceased controls with eligible proxies (77% response rate). Both cases and controls were questioned regarding their use of agricultural products including Roundup® and any other glyphosate-based formulations. For deceased or incompetent controls (184) and cases (number not given), proxy interviews were done with a close relative. When cases in farmers were compared to cases in non-farmer controls, 26 cases (out of 266) and 49 controls (out of 547) had handled herbicides containing glyphosate yielding an odds ratio¹ (OR) of 1.1 (95% confidence interval 0.7-1.9). This analysis controlled for vital status, age, state, cigarette smoking status, family history of lymphopoietic cancer, high-risk occupations and high-risk exposures in a logistic analysis. The authors noted there was “minimal evidence for confounding of results for any single pesticide by exposure to pesticides belonging to other chemical families.” Because the exposure is determined based on interviews in cases and controls, this study has the potential for recall bias². However, the authors note that the bias could both increase or decrease the OR because of non-differential exposure misclassification³ because of difficulties in accurate recall of past pesticide exposures for both controls and treated individuals. This study will not be included separately into the evaluation since it overlaps with **De Roos et al. (2003)**^[43]

Two additional studies conducted by **Zahm et al. (1990)**^[51] in Nebraska and **Hoar et al. (1986)**^[52] in Kansas collected information on pesticide and herbicide use, but did not report specifically on the effects of glyphosate. **De Roos et al. (2003)**^[43] pooled the data from these two studies with the data from **Cantor et al. (1992)**^[39] to examine pesticide exposure to glyphosate in farming as risk factors for NHL. The three case-control studies^[39, 51, 52] had slightly different designs. The design for the Minnesota study^[39] is

¹ The odds ratio (OR) is calculated as the proportion of exposed cases with disease to exposed controls divided by the proportion of non-exposed cases to non-exposed controls. For rare diseases, this value approximates the population risk ratio (PRR) which is the probability of having the disease in exposed individuals divided by the probability of having the disease in non-exposed individuals. If the PRR is 1, then there is no difference in the probability of having the disease regardless of your exposure. Values of PRR greater than 1 imply the risk is higher in the exposed population. Because the OR is an estimate of the PRR for rare diseases, it is usually accompanied by a 95% confidence interval that describes the probable range of the estimate. If the OR is greater than 1, then the exposure is associated with the disease. If the lower 95% confidence bound for the OR is greater than 1, this is typically used to say the association is statistically significant.

² Recall bias occurs when cases are more likely to say they are exposed to glyphosate than controls or when controls are more likely to say they are exposed to glyphosate than cases. The recall must be different for the cases than the controls for this to cause a bias; errors in recalling past exposures that happen for both cases and controls would not be recall bias.

³ Non-differential exposure misclassification occurs when the probability of an error in determining whether an individual is exposed or not is the same for both cases and controls.

provided directly above. In Nebraska^[51], the cases were identified through the Nebraska Lymphoma Study Group and area hospitals for 66 counties and included all white men and women diagnosed with NHL between July 1, 1983 and June 30, 1986. Controls were obtained by random-digit dialing, Medicare records or state mortality files depending upon age and vital status. All study participants were over age 21 and even though this study included a few women, they were excluded from the **De Roos et al. (2003)** analysis. The response rates for cases and controls were 91% and 87% respectively. In Kansas^[52], cases were randomly sampled from a registry at the University of Kansas of white men, over age 21, diagnosed between 1979 and 1981. The response rates for cases and controls were 96% and 94% respectively. Controls were population-based matched on age and vital status. As for the Nebraska study, controls for live cases were obtained from Medicare records for cases 65+ and by random-digit dialing for cases <65 years; controls for deceased patients came from state mortality records. The resulting pooled case-control study had 870 cases and 2569 controls (for analyzing the relationship between glyphosate and NHL, there were only 650 cases and 1933 controls following exclusion of subjects with missing data). For any glyphosate exposure, there were 36 exposed cases and 61 exposed controls with an OR (95% confidence interval) of 2.1 (1.1-4.0) in a logistic regression analysis controlling for all other pesticides reported, age and study site. The authors also analyzed the data using a Bayesian hierarchical regression analysis yielding an OR (95% confidence interval) of 1.6 (0.9-2.8) controlling for the same parameters as the logistic regression. They also conducted an analysis of "potentially carcinogenic" pesticides which included glyphosate. When just one of these pesticides was used by subjects, the logistic regression OR was 1.6 (0.8-3.1), two to four pesticides yielded an OR of 2.7 (0.7 to 10.8) and when more than five were used, the OR was 25.9 (1.5-450.2) in the logistic regression analysis and 1.1 (0.8-1.7), 1.3 (0.7-2.3) and 2.0 (0.8-5.2) respectively for the Bayesian analysis. Removing glyphosate from the list of "potentially carcinogenic" pesticides yielded equivalent ORs of 1.2 for one pesticide, 1.2 for two to four pesticides and 1.1 for five or more pesticides. The authors note that the positive results seen in their study are not likely due to recall bias since there were few associations seen over the 47 pesticides they studied. Also, although some of the positive results could be due to chance, the use of the hierarchical regression analysis theoretically decreases the chance of false positive findings. In the Kansas study^[52], suppliers for 110 subjects with farming experience were identified and provided information on the subjects' crops and pesticide purchases. In general, the suppliers reported less pesticide use than the subjects of the study with no consistent differences in agreement rates between cases and controls. The agreement between suppliers and subjects improved when pesticide use during the last 10 years was considered. This supports a reduced role of recall bias in these studies and a possible role of non-differential exposure misclassification. The reduced ORs when using the Bayesian analysis as compared to the logistic regression is not surprising because the authors used a non-informative prior rather than a less conservative prior. In addition, adjustment for 47 pesticides is also likely to reduce the significance of the observed ORs for pesticides that are associated with NHL as demonstrated by the analysis of "potentially carcinogenic" pesticides (this model is possibly over-parameterized since it

includes over 47 dependent variables for only 36 exposed cases; this can significantly reduce the ORs and increase the confidence bounds). This pooled case-control study is the strongest study with sufficient power (3.8% of subjects exposed) and will be included in the evaluation of causation.

Lee et al. (2004)^[44] pooled data from **Zahm et al. (1990)**^[51] and **Cantor et al. (1992)**^[39] (previously described) to evaluate whether asthma acts as an effect modifier of the association between glyphosate exposure and NHL. Women were included in this analysis whereas **De Roos et al. (2003)**^[43] excluded women. The final study published by Lee included 872 cases and 2336 controls of which 45 cases and 132 controls had been told by their doctors they had asthma. The OR of association between glyphosate and NHL in non-asthmatics was 1.4 (0.98-2.1) and 1.2 (0.4-3.3) in asthmatics when controlling for age, vital status and state (geographical location). This study completely overlaps with the study by **De Roos et al. (2003)**^[43] with the exception of the inclusion of the few women in the study by **Zahm et al. (1990)**^[51]. Since this study only looks at effect modification due to asthma, it does not contribute to the overall evaluation of causality and it will be excluded from further evaluations.

Nordstrom et al. (1998)^[40] conducted a population-based case-control study of hairy cell leukemia (HCL); a subtype of B-cell NHL in Sweden that included an evaluation of exposures to glyphosate. The study included 111 men with NHL reported to the Swedish Cancer Registry between 1987 and 1992 (with one patient from 1993 accidentally included). Controls (400 in total) were drawn from the National Population Registry matched for age and county with the cases. The response rates were 91% for cases (10 refused to participate out of the original 121) and 83% (84 controls refused to participate out of 484 selected). Almost all questionnaires were answered by the subject of the study (4 cases and 5 controls were answered by proxies). The study reported an OR for glyphosate exposure and HCL of 3.1 (0.8-12) controlling only for age. This study had very limited power for detecting an association because there were only four cases and five controls with glyphosate exposure (1.8% of the total study population). In addition, because they failed to adjust for other exposures, the potential for confounding in this study is greater than those presented previously. The authors noted that they attempted to minimize recall bias by only using living cases in the analysis. Also, even though matching was performed to identify the controls, this matching was not used in the final analysis. This study was later used in a pooled analysis of HCL and NHL^[42] and will not be considered independently in the evaluation for causation but will be used in the context of the pooled analysis.

Hardell and Eriksson (1999)^[41] conducted a population-based case-control study of all male patients older than 25 years diagnosed with NHL between 1987 and 1990 in the four most northern counties of Sweden. After excluding misdiagnosed cases, they included 442 cases of which 404 answered their questionnaire (most by proxy) for a response rate of 91%; 192 of these cases were deceased. For each living case, two male matched controls were chosen from the National Population Registry and matched on age and county. For each deceased case, two male controls were chosen from the National Registry for Causes of Death, matched for age and year of death. The response

rate for the controls was 84% (741 out of 884 identified). Study subjects were sent a detailed questionnaire and, in most cases, this was supplemented with a phone interview. A complete working history was obtained with questions regarding exposure to numerous chemicals to avoid a focus on pesticides and organic solvents, the focus of the study. Exposure was defined as at least one full day of exposure more than one year before diagnosis. For glyphosate exposure, the authors identified four cases and three controls with exposures and a univariate OR of 2.3 (0.4-13). A multivariate analysis of both glyphosate and phenoxy herbicides produced an OR of 5.8 (0.6-54). The study has limited power for detecting an effect because the exposure frequency is very low (0.6% exposed). This study was later used in a pooled analysis of HCL and NHL^[42] and will not be considered independently in the evaluation for causation but will be used in the context of the pooled analysis.

Hardell et al. (2002)^[42] conducted a pooled analysis of NHL and HCL by combining the studies of **Nordstrom et al. (1998)**^[40] and **Hardell and Eriksson (1999)**^[41]. This study fully overlaps with the previous two studies. The analysis controlling for age, study, county and vital status yielded an OR of 3.04 (1.08-8.52) based on eight exposed cases and eight exposed controls. A more extensive analysis additionally controlled for other pesticides and yielded a smaller OR of 1.85 (0.55-6.20). As for the study by **De Roos et al. (2003)**, the analysis may be over-parameterized (more than eight dependent variables with only eight exposed cases) which could lead to a reduction in the ORs and larger confidence bounds. Even with the pooled data, **Hardell et al. (2002)** had limited power to detect an effect because the exposure frequency for cases and controls was very low (1% exposed). This study is a valid case-control study and will be used in the evaluation of causality.

In a later study, **Eriksson et al. (2008)**^[46] conducted a population-based case-control study where cases were identified as NHL patients aged 18-74 years diagnosed in four major hospitals in Sweden from December 1, 1999 until April 30, 2002. In total, 995 cases were identified as matching the study parameters with 910 (91%) answering the questionnaire shortly after diagnosis. All cases were classified into subgroups with 810 B-cell, 53 T-cell, and 38 unspecified lymphomas. Controls (1,108) were randomly selected from the population registry and matched on health service, region, sex and age and interviewed in several periods during the conduct of the study; 1,016 controls responded to the questionnaire (92% response rate). Study subjects were sent a detailed questionnaire and, in many cases, a phone interview followed. Exposure was defined as at least one full day of exposure more than one year before diagnosis. The univariate analysis, adjusting for age, sex and year of diagnosis (cases) or enrollment (control) yielded an OR of 2.02 (1.10-3.71) based on 29 exposed cases and 18 exposed controls. When cases and controls were divided into those with ≤ 10 days per year exposure and those with > 10 days per year exposure, the ORs were 1.69 (0.70-4.07) and 2.36 (1.04-5.37) respectively. When diagnoses were grouped into various subtypes of NHL, the results did not change dramatically except for small lymphocytic lymphoma and chronic lymphocytic lymphoma which showed an increased OR of 3.35 (1.42-7.89). A multivariate analysis of glyphosate controlling for other agents with statistically

increased odds ratios and/or odds ratios greater than 1.5 yielded an OR of 1.51 (0.77-2.94). In a similar analysis to the multivariate analysis, latency periods of one to ten years showed an OR of 1.11 (0.24-5.08) and >10 years had an OR of 2.26 (1.16-4.40). This study was much larger than the previous Swedish studies (2.3% exposed) and, although there may have been confounding from other pesticides, this was addressed in the multivariate analysis and the latency analysis. This study is a valid case-control study and will be used in the evaluation of causality.

McDuffie et al. (2001)^[50] recruited incidence cases of NHL in men 19 years or older from six Canadian provinces with a first diagnosis between September 1, 1991 and December 31, 1994. Each provincial Cancer Registry or, in the case of Quebec, hospital, had a target number of cases and ended recruitment when the case number was reached. Controls were men 19 years or older selected at random from provincial health insurance records, computerized telephone listings or voter registration lists, depending upon the province. Cases and controls were sent questionnaires with surrogates ineligible to answer the questionnaires for deceased cases or controls. Each subject who reported 10 hours per year or more of pesticide exposure and a random sample of 15% who reported less exposure were interviewed by telephone to obtain details on pesticide use. A pilot study was conducted to obtain an improved version of the telephone interview questionnaire used by **Hoar et al. (1986)**^[52] and **Zahm et al. (1990)**^[51] that would provide accurate pesticide exposure assessment in the form of a screening questionnaire and a telephone interview questionnaire. This was followed by a validation study (27 farmers) where the final questionnaires used to screen and include potential cases and controls were administered and the answers regarding pesticide usage showed excellent concordance with purchases through their local agrochemical supplier. The screening questionnaire was returned by 517 cases of NHL (67.1% response rate) and 1506 controls (48% response rate). Following analysis of the screening questionnaire, the telephone interview was administered to 179 cases and 456 controls to obtain more detailed exposure information. The OR for glyphosate exposure and NHL was 1.26 (0.87-1.80) stratified by age group and province of residence and the OR was 1.20 (0.83-1.74) when the analysis also controlled for significant medical variables (51 exposed cases and 133 exposed controls). An exposure-response evaluation was performed where the OR for exposure between zero to two days per year was 1.0 (0.63-1.57) and for greater than two days per year was 2.12 (1.20-3.73) with the latter group having 23 exposed cases and 36 exposed controls. This study had excellent sample size and power (8.1% of subjects exposed), but a low response rate to the screening questionnaire. Also, by adjusting for significant medical variables, this study ruled out many confounders but did not adjust for other pesticide exposures. The effort to validate the recall of pesticide usage for farmers supports a lack of recall bias in the study. This study is a valid case-control study and will be used in the evaluation of causality.

Hohenadel et al. (2011)^[48] re-analyzed the data of **McDuffie et al. (2001)**^[50] to specifically investigate the impact of exposure to multiple pesticides on NHL. Four cases of NHL were excluded from this evaluation following a pathology review. They reported associations with the use of glyphosate with and without malathion but not with

glyphosate overall. The OR for glyphosate (ever used) without malathion (ever used) was 0.92 (0.54-1.55) and the OR for glyphosate (ever used) with malathion (ever used) was 2.1 (1.31-3.37). **Chang and Delzell (2016)**^[38] combined the ORs from the glyphosate only analysis with the glyphosate and malathion analyses using random-effects meta-analysis to get a combined OR for glyphosate of 1.4 (0.62-3.15). This study was specifically targeted to interactions of various pesticides and does not substantively contribute to an evaluation of glyphosate. Since it is a refined analysis of **McDuffie et al. (2001)**^[50], it will be included in the evaluation of causation only in the context of the combined analysis provided by **Chang and Delzell (2016)**.

Orsi et al. (2009)^[47] conducted a hospital-based case-control study of men and women diagnosed with lymphoid neoplasms in five hospitals in France between 2000 and 2004 who were aged 20-75 years (the abstract gives the age range as 18-75 years). All diagnoses were cytologically or histologically confirmed. The evaluation only included men and questionnaires/interviews were completed by 491 cases (95.7% response rate) which included 244 cases with NHL. Controls were patients in the same hospital (mostly orthopedic or rheumatological patients) with no prior history of lymphoid neoplasms and excluding patients admitted to the hospital for cancer or a disease directly related to occupation, smoking or alcohol abuse. The controls were matched to cases by hospital and age. Of the 501 candidate controls, 456 participated (91% response). Exposure was evaluated differently for subjects who had non-occupational exposures from those who had occupational exposures. For both, the subjects had to fill out a questionnaire/interview on occupations and home gardening pesticide exposures. For those who had worked professionally as farmers or gardeners for at least 6 months, a specific agricultural occupational questionnaire/interview was administered and exposure was determined on the basis of this extra data. The OR for occupational use of glyphosate and NHL was 1.0 (0.5-2.2) with 12 exposed cases and 24 exposed controls stratified by age and center category. A further analysis was done by individual subtypes of NHL with an OR of 1.0 (0.3-2.7) for diffuse large cell lymphoma, 1.4 (0.4-5.2) for follicular lymphoma, 0.4 (0.1-1.8) for chronic lymphocytic leukemia (CLL) and 1.8 (0.3-9.3) for HCL. No separate analysis of non-occupational use of glyphosate was provided, nor does it seem specific data on glyphosate usage was ascertained for subjects who were not professional farmers or gardeners. This could lead to non-differential misclassification of exposure which could reduce the ORs of the study. Barring this, the sample size was sufficient to detect an effect (5.3% with occupational exposure) and this study will be included in the evaluation of causality.

Cocco et al. (2013)^[49] evaluated data from a multi-center case-control study of lymphoid neoplasms in six European countries from 1998 to 2004. Cases included only adult patients diagnosed with lymphoma during the study period drawn from participating centers. Controls were either selected by sampling from the general population on sex, age group, and residence area (Germany, Italy), or from hospital controls matched to the patient excluding patients with cancer, infectious diseases, and immunodeficiency diseases (Czech Republic, France, Ireland, Spain). The study included 2348 lymphoma cases (88% participation) and 2462 controls (81% response rate in hospital-based controls and 52% in population-based controls). Exposures were derived using an

occupational exposure matrix developed by industrial hygienists and occupational experts from the research centers. Only 35 individuals (cases and controls not broken out) in the study were exposed to carbamates (glyphosate was grouped with the carbamates). No results were provided for NHL and the only OR provided for glyphosate was for B-cell lymphoma where the OR was 3.1 (0.6-17.1) based on four exposed cases and two exposed controls. No information was provided on the total number of cases for each type of lymphoma evaluated. This study has very limited power to evaluate an association between NHL and glyphosate and provides only information on B-cell lymphomas with very few exposed cases and controls. As has been done by most researchers evaluating these data, this study will receive very little weight in the evaluation of causality.

De Roos et al. (2005)^[45] reported results on the association of glyphosate and cancer incidence from the Agricultural Health Study (AHS), a prospective cohort study in Iowa and North Carolina, which included 57,311 private and commercial applicators who were licensed to apply restricted-use pesticides at the time of enrollment. Recruitment occurred between 1993 and 1997 and cohort members were matched to cancer registry files to identify cases and the National Death Index (1999) to ascertain vital status. Incident cancers were identified from the date on enrollment until 31 December, 2001, with the average follow-up time being 6.7 years. Comprehensive use data was obtained by self-administered questionnaire for 22 pesticides, ever/never use for 28 additional pesticides, and general information on work practices. Applicators were given a second self-administered questionnaire on occupational exposures and lifestyle factors. They used three exposure metrics in their analyses: a) ever personally mixed or applied pesticides containing glyphosate; b) cumulative exposure days of use of glyphosate (years of use times days per year); and c) intensity weighted cumulative exposure days (years of use times days per year times intensity of use). Persons whose first primary tumor occurred before the time of enrollment (1074) were excluded from the analysis as were those who were lost to follow-up (298), did not provide age information (7) or information on glyphosate use (1678) leaving 54,315 subjects for inclusion. There were 92 cohort members with a diagnosis of NHL during the study period of which 77.2% had ever used glyphosate resulting in a rate ratio⁴ (RR) of 1.2 (0.7-1.9) when controlling for age and an RR of 1.1 (0.7-1.9) when controlling for age, lifestyle factors, demographics and five other pesticides for which cumulative-exposure-day variables were most highly associated with glyphosate cumulative-exposure-days (2,4-D, alachlor, atrazine, metalochlor, and trifluralin) or, for chemicals with only ever/never exposure information that were most highly associated with glyphosate ever/never use (benomyl, maneb, paraquat, carbaryl and diazinon). When cumulative exposure days in exposed individuals are divided into tertiles and RRs examined using the lowest exposed tertile as

⁴ The rate ratio (RR) is estimated as the incidence in the exposed population divided by the incidence in the unexposed population. Incidence is calculated as the number of events in a fixed period of time divided by the person years at risk. Unlike the OR, the RR does not require the assumption of a rare disease to serve as a good estimate of the population risk ratio (PRR).

the reference group, the RRs drop with values of 0.7 (0.4-1.4) and 0.9 (0.5-1.6) for tertiles 2 and 3 respectively controlling for demographic and lifestyle factors and other pesticides (30,699 subjects). When intensity-weighted exposure days are examined again using exposed tertile 1 as the reference group, the RRs drop with values of 0.6 (0.3-1.1) and 0.8 (0.5-1.4) for tertiles 2 and 3 intensity-weighted exposure days respectively controlling for demographic and lifestyle factors and other pesticides (30,699 subjects). Analyses are not shown for the evaluation of the exposed tertiles against never exposed because the authors felt that never exposed and exposed subjects differed in terms of socio-economic factors and other exposures like smoking^[45].

This is a typical cohort study, but has some limitations in terms of its interpretation. The majority (75.5%) of subjects in the cohort reported having ever personally mixed or applied products containing glyphosate and was composed primarily of male, middle-aged, private applicators. For glyphosate, reliability of the answers by subjects on the use of glyphosate between the first and second questionnaire were evaluated in the AHS^[53]: 82% agreement for whether they had ever mixed or applied glyphosate, 53% agreement on years mixed or applied, and 62% agreement on days per year mixed or applied and 62% agreement on decade first applied. They saw no differences in over versus under reporting between the two questionnaires suggesting this could lead to non-differential exposure bias and reduce the RRs in this study. Another weakness, noted by the authors, is that the small number of incident cases during follow-up period hindered precise effect estimates. Also, the high frequency of exposure to many pesticides (e.g. 73.8% were exposed to 2,4-D) means subjects unexposed to glyphosate were likely to be exposed to other agents that may also induce NHL, reducing the RRs. Also, as noted by the EPA's FIFRA Science Advisory Panel (SAP)^[54] in their review of the EPA's issue paper on the carcinogenicity of glyphosate and as noted in a critique^[55] of the European Food Safety Agency's risk assessment for glyphosate, the follow-up time in this cohort study may not be long enough to produce a sufficient sample size for evaluation of the association between NHL and glyphosate. Like other studies, this study has few exposed cases and controls, but the authors adjust their analysis for many other pesticides which could reduce ORs and increase confidence bounds limiting the ability of the study to show positive results. This study could also suffer from a survival bias because pesticide applicators were recruited as case participants after their exposure had begun and those with a cancer prior to enrollment were excluded.

This study will be included in the evaluation of causality.

Consistency of Associations

Hill (1965)^[36] defines consistency as the answer "yes" to the question "Has it repeatedly been observed by different persons, in different places, circumstances and times?" For these studies, the answer is indeed yes.

If the population relative risk (PRR) for an association of glyphosate with NHL were equal to 1 (no effect), then one would expect very few statistically significant results in multiple studies and that about half of the studies would have ORs or RRs below one

and half above one. As noted by both the **IARC Monograph 112 (2015)**^[56] and by **Chang and Delzell (2016)**^[38], when comparing studies, the most reasonable comparison is to use the most-fully-adjusted risk estimates. I will mostly limit my comments to these most-fully-adjusted risk estimates.

Consistency of the associations across several epidemiology studies is not simply a matter of seeing how many were statistically significant and how many were not but must also address the consistency of the direction of the responses. Figure 1 shows a forest plot of all ORs and RRs from the epidemiology studies discussed previously. Each horizontal line in the forest plot shows the mean estimate of the OR/RR as a black square and the 95% confidence interval around this estimate as whiskers extending left and right from the black square.


The first obvious conclusion to be drawn from Figure 1 is that all of the mean OR/RR estimates (black squares) are consistently ≥ 1 . This implies that all of the studies are pointing in the same direction toward a positive effect. In their meta-analyses, **Schinasi and Leon (2014)**^[57], **IARC (2015)**^[56] and **Chang and Delzell (2016)**^[38] all identified 6 papers (highlighted in red in Figure 1) as being the most reliable for evaluation of the ability for glyphosate to induce NHL in people: **McDuffie et al. (2001)**^[50], **Hardell et al. (2002)**^[42], **De Roos et al. (2003)**^[43] and **(2005)**^[45], **Eriksson et al. (2008)**^[46] and **Orsi et al. (2009)**^[47]. I will refer to these papers as the six core epidemiology studies. As noted above, if the true underlying risk ratio was 1 (no effect), you would expect about half of the findings to be below 1 and half to be equal to 1 or greater. Using only the results from the 6 core studies, you can see that all are ≥ 1 ; the probability of this happening is $(0.5)^6$ or 0.016, strongly suggesting the studies do not agree with an underlying PRR=1 and that they consistently support a positive effect.

A second way in which consistency can be evaluated is to combine the individual studies using meta-analysis to obtain a combined analysis using both the ORs and the RR (CRR) and test for heterogeneity in the studies. The meta-analysis done by **Chang and Delzell (2016)** includes the same analysis as that done by the **IARC (2015)** and is an improvement over **Schinasi and Leon (2014)**, so I will focus my comments on using the **Chang and Delzell (2016)** meta-analysis. **Chang and Delzell (2016)** did four separate meta-analyses on the glyphosate epidemiology studies using two different methods (random-effects and fixed-effects models). In their first analysis (model 1)⁵, they combined the most-fully-adjusted risk estimates from the six core studies to yield a CRR of 1.27 (1.01-1.59) for both random-effects and fixed-effects models supporting an association between NHL and glyphosate exposure in these studies. In a second analysis (model 2), they replace the results of the Bayesian analysis in **De Roos et al. (2003)** with the results of the logistic regression analysis and get the same CRR of 1.30 (1.03-1.64) for both random-effects and fixed-effects models. In a third analysis (model 3), they replace from model 1 the **McDuffie et al. (2001)** results in with a combined meta-

⁵ **Chang and Delzell (2016)** provided only one significant digit to the right of the decimal point in their confidence bounds; the EPA SAP (2017) re-calculated models 1-4 of **Chang and Delzell (2016)** to provide two significant digits – these are presented here.

analytic result they derived from analyses by **Hohenadel et al. (2011)** (this study reanalyzed the same data as **McDuffie et al. (2001)**, splitting results between asthmatics and non-asthmatics) resulting in a CRR of 1.32 (1.00-1.73) for both random-effects and fixed-effects models. Finally, in a fourth analysis (model 4), they use model 3 but replaced the Bayesian analysis in **De Roos et al. (2003)** with the logistic regression analysis yielding a CRR of 1.37 (1.04-1.82) for both random-effects and fixed-effects models. In essence, none of the different meta-analyses rejected the notion of a combined, statistically significant positive effect.

Figure 1: Odds Ratios and Rate Ratios from the most-fully-adjusted risk estimates from selected epidemiology studies and from the meta-analyses of **Chang and Delzell (2016)**^[38]. “RR” refers to the OR or RR from the study, “Lower” refers to the 95% lower bound, “Upper” to the 95% upper bound and “Weight” refers to the weight applied to that specific study in Model 1 of the meta-analysis (Table 3 in Chang and Delzell). For **De Roos et al. (2003)**, the first row is for the Bayesian model analysis and the second row, labelled “logistic regression” is from the logistic model analysis.



As stated above, another way to evaluate consistency in the epidemiological data would be to evaluate the heterogeneity in the studies. Heterogeneity may be due to differences in participants, outcomes, exposure metrics, methods for questioning study subjects, sex of the subjects, etc. **Chang and Delzell (2016)** formally tested for heterogeneity of the responses from the six core studies using Cochran’s Q statistic and the I^2 statistic^[58]. For models 1 to 4, the p-values from Cochran’s Q test are 0.84, 0.59, 0.85, and 0.63 respectively (typically you reject the concept of homogenous studies in favor of heterogeneous studies if $p < 0.10$). The I^2 statistic for all four models are 0.0% (values for I^2 can range from 0-100% with concern for heterogeneity above 50%). The fact that the fixed-effects models and random-effects models gave the same results also supports a lack of heterogeneity in the data. There is no indication of heterogeneity in these six core studies. Lack of heterogeneity supports the interpretation of the meta-analyses as showing a positive association and strong consistency of the findings across the six core studies.

Chang and Delzell (2016) also evaluated the association between subtypes of NHL and glyphosate exposure where possible. For B-cell lymphomas, they combined the results of **Eriksson et al. (2008)**^[46] with those of **Cocco et al. (2013)**^[49] and saw a CRR (random-effects and fixed-effects) of 2.0 (1.1-3.6) with an I^2 of 0 and a Cochran's Q test p-value of 0.58. For diffuse large B-cell lymphomas, they combined the results of **Eriksson et al. (2008)**^[46] with those of **Orsi et al. (2009)**^[47] and saw a CRR (random-effects and fixed-effects) of 1.1 (0.5-2.3) with an I^2 of 0 and a Cochran's Q test p-value of 0.79. For combined chronic lymphocytic leukemia and small lymphocytic lymphoma, they combined the results of **Eriksson et al. (2008)**^[46] with those of **Orsi et al. (2009)**^[47] and saw a CRR using the random-effects model of 1.3 (0.2-10) and for the fixed effects model 1.9 (0.9-4.0) with an I^2 of 83.7% and a Cochran's Q test p-value of 0.01. For follicular lymphomas, they combined the results of **Eriksson et al. (2008)**^[46] with those of **Orsi et al. (2009)**^[47] and saw a CRR (random-effects and fixed-effects) of 1.7 (0.7-3.9) with an I^2 of 0 and a Cochran's Q test p-value of 0.73. And finally, for HCL, they combined the results of **Nordstrom et al. (1998)**^[40] with those of **Orsi et al. (2009)**^[47] and saw a CRR (random-effects and fixed-effects) of 2.5 (0.9-7.3) with an I^2 of 0 and a Cochran's Q test p-value of 0.63. These subtype analyses are based upon small numbers of cases and only two studies making them unreliable, when considered individually, to address the question of consistency in the data. However, when they are combined with the results for the meta-analyses of the core studies of NHL, these studies add support to the conclusion that these data are consistent.

Chang and Delzell (2016) also performed a sensitivity analysis by only doing meta-analyses on studies with similar characteristics. Using only the five case-control studies, the CRR was 1.3 (1.0-1.7). Breaking them into the type of control used, there were four studies using population controls with a CRR of 1.4 (1.0-1.8). There were four studies with males only with a CRR of 1.3 (1.0-1.7) and two studies with males and females with a CRR of 1.2 (0.8-1.8). Three studies were done in North America with a CRR of 1.2 (1.0-1.6), three in Europe with a CRR of 1.3 (0.8-2.1); two of the three studies were in Sweden with a CRR of 1.6 (0.9-2.8). All of the resulting meta CRRs were the same for the fixed-effects model and the random-effects model. This sensitivity analysis shows that the results do not differ significantly from the main CRR for the six core studies combined adding support to the findings being consistent across the different studies.

In case-control studies, selection bias arises when the reasons cases and controls choose to participate in the study could lead to systematic biases that might result in a positive or negative finding independent of the exposure being studied. For example, if cases with exposure are more likely to participate than controls with exposure, the result would be higher OR values; however, this difference has to be differential and not simply a difference in participation rates. It is possible that in a few of these studies, the method by which controls were selected could contribute to selection bias that might lead to increased ORs. However, given the diverse types of cases and controls used in the five core case-control studies, this is unlikely to explain the consistent findings seen from these studies. It is also possible that the lack of complete data on cases versus controls could result in selection bias if the reasons for not completing the questionnaire/interview are different between cases and controls and relates to

exposure. There is no indication of this type of selection bias in these reports, and this is unlikely to explain the consistency seen in these data.

Exposure misclassification can lead to increases or decreases in the OR or RR values seen in both case-control and cohort studies. For example, in case-control studies, if cases are more likely to say they were exposed to glyphosate than controls, this would inflate the OR values; this is one type of recall bias. This type of bias is less likely in cohort studies. In all six of the core studies, this issue was discussed by the authors. In every case, they concluded there was bound to be some exposure misclassification, but that it was most likely non-differential, meaning that the misclassification was random; this would likely reduce the OR/RRs seen in the studies rather than increase them.

Confounding occurs when there is an exposure or some other factor that is tightly associated with both glyphosate exposure and NHL diagnosis that, if controlled for, could explain the results. The most likely source of confounding in these studies would be exposures to other pesticides. Four^[42, 43, 45, 46] of the six core studies controlled for exposure to other pesticides and saw basically the same findings as the other two studies. Another concern for confounding would be if the cases had immune deficiencies that could be linked to NHL; in all of the case-control studies, such cases were excluded. Finally, other agricultural exposures (e.g. animals, other chemicals, infectious agents) could be correlated with glyphosate exposure and may be linked to NHL; none of the studies controlled for these factors. However, not all exposed cases were farmers; if confounding via other agricultural exposures is occurring, it is not possible to determine the magnitude or direction of such an effect from these data.

In conclusion, we have six core epidemiology studies done on two different continents by four different research groups using different designs, questionnaires and study populations that are highly consistent with no obvious bias or confounding that would explain the results. **There is a consistency of associations across the six core studies.**

Strength of the Association seen in Human Epidemiological Studies

To explain strength of association, Hill (1965) gives the classic example of John Snow and the cholera epidemic of 1855 where the risk ratio of dying if you drank water from the Southwark and Vauxhall Company (polluted by sewage) compared to drinking from the Lambeth Company water (sewage free) was 14. Yet, for the six core studies, the OR/RR ranges from 1.0 to 1.85 for the most-fully-adjusted risk estimates and to 2.1 if you include the fully adjusted risk estimate from De Roos et al. (2003)^[45] using logistic regression. These are moderate OR/RR estimates making it conceivable they are individually due to either chance or bias. Thus, with the exception of the logistic regression analysis in De Roos et al. (2003)^[45], none of the core studies demonstrate large, precise risks as envisioned by Hill (2016)^[36]. However, Hill (1965) was not expressing himself in statistical terms where the significance of an association is dependent upon the precision of the observations. If the statistical variation around an OR/RR estimate is large relative to the estimate itself, the estimate is not very precise

and generally would not be statistically significant. The result from the study by **Hardell and Eriksson (1999)** shown in Figure 1 is an example of an estimate with very large statistical variation. On the other hand, a very small (in value), precise OR or RR estimate could be statistically significant and prove important in deciding causation. The meta-analyses shown in Figure 1 all demonstrate estimates of OR/RR that are significantly different from 1 rejecting the concept that the overall association is due to chance. The statistically significant estimate of the OR/RR for B-cell lymphomas in the meta-analysis support this finding as well.

In summary, we have six core epidemiology studies that all show approximately the same, modest increase in OR/RR that, when combined, demonstrate a significant strength of association. **There is a strong association across the six core studies**

Biological Plausibility

The range of data one can use to determine biological plausibility is quite diverse and can be exceptionally complicated. For simplicity, it can be divided into the types of assays that can be used in this evaluation: animal cancer bioassays, toxicokinetic studies, studies from accidental exposures in humans, and studies of specific biological mechanisms in animals or cells derived from humans or animals. Animal cancer bioassays are intended to test whether glyphosate can cause cancers in mammals, thus supporting the concept that the chemical could cause cancer in humans. Toxicokinetic studies provide insight into the degree to which glyphosate is absorbed by humans, distributed to various organs in the body, what happens to the chemical once it is in the body (metabolism), and, finally, how it is eliminated from the body. Studies from accidental exposures in humans can provide some information on the effects of glyphosate through changes in the chemistry and cellular structure of human blood. Studies of biological mechanisms are generally addressing what effects the chemical may have on human and animal cells under controlled, laboratory conditions. Some of the studies in this section were done with technical grade (virtually pure) glyphosate and some with the glyphosate formulations that humans encounter in occupational and environmental settings. I will summarize the literature in each of these areas and offer an opinion to their support of biological plausibility of NHL in humans.

Animal Cancer Bioassays

Typical animal cancer bioassays will expose animals (generally rats or mice) to a chemical for a substantial proportion of the animal's life (generally 2 years) then kill the animal and examine its organs and tissues for tumors. There are guidelines on how to conduct and analyze these studies. Typically, chemical registrants conduct cancer bioassays for pesticide approval pursuant to guidelines developed under the guidance of the Organization for Economic Cooperation and Development (OECD^[59]). Other groups^[30, 33, 34] provide guidance on how to analyze these studies based upon methodology papers from the published literature. These studies are conducted in a way that controls for everything in the animal's environment (e.g., food type, water quality, how often the animals are handled) leaving only the exposure to explain

differences in tumor formation between control and exposed animals. Even then, non-cancer endpoints can also be modified by the chemical and these may have an impact on tumor rates in the animals (e.g., survival, death from some other toxic effect of the chemical); these must be accounted for when reaching conclusions from the study.

Studies generally use four groups of animals, one group receiving no exposure (control) and the remaining three groups are test animals, with each group receiving different dose exposures to the chemical^[60]. Doses generally above human experience are used in animal carcinogenicity studies because only relatively small numbers of animals are being used to evaluate risk for a large human population and because even the best known human carcinogens do not cause cancer in large fractions (say 20%) of the human population. The basic underlying premise of this design consideration is that, as the dose increases, so does the risk of getting a tumor. By exposing animals to the highest dose possible, you increase the ability of the study to identify a risk if one is present. However, one must be careful not to use a dose that is so high it will cause cancers by processes that would never work at lower doses. To avoid this, studies are designed around a maximum tolerated dose (MTD) or limit dose. This dose is generally determined based upon a subchronic study (90 days) in the same animals and is usually the maximum dose that can be tolerated by the animals without any signs of significant toxicity in the exposed animals (e.g., weight loss, tissue damage). The OECD and EPA provide guidelines^[33, 59] on how to choose this top dose. These guidelines are in general agreement with the scientific literature^[60].

The guidelines also address the methods by which the data should be analyzed. For example, the EPA guidelines^[61] state that:

"A trend test such as the Cochran-Armitage test (Snedecor and Cochran, 1967) asks whether the results in all dose groups together increase as dose increases. A pairwise comparison test such as the Fisher exact test (Fisher, 1950) asks whether an incidence in one dose group is increased over that of the control group. By convention, for both tests a statistically significant comparison is one for which p is less than 0.05 that the increased incidence is due to chance. Significance in either kind of test is sufficient to reject the hypothesis that chance accounts for the result."

In fact, most guidelines and peer-reviewed publications come to the same conclusion^[30, 59, 60, 62] on what tests to use, as did EPA's FIFRA Scientific Advisory Panel (SAP) in their review of the EPA's issue paper of the carcinogenicity of glyphosate^[54]. The US National Toxicology Program (NTP) uses both a trend test^[3, 4, 63] and Fisher's exact test for analyzing carcinogenicity data. Unless otherwise noted in this document, all p-values presented in this section on animal cancer studies were recalculated on my computer and are the exact one-sided p-values for the Fisher test (p_{Fisher}) and/or the Cochran-Armitage linear trend test (p_{Trend}) where appropriate. In cases where the data is pooled and the numbers of tumors are large, the approximate p-value based upon the normal distribution is used for the trend test to avoid excessive computation time; these are noted as p_{TrendA} . The approximation (p_{TrendA}) is generally equivalent to the exact p-value (p_{Trend}) when there are more than 10 animals with tumors^[64].

To avoid doing large numbers of tests and over-analyzing the data, my comments will generally rely upon the use of the trend test with the results from Fisher's exact test serving as a descriptive discussion of the findings. This is in agreement with SAP comments^[54] and is generally accepted in the evaluation of animal cancer studies.

Even with the high doses used in these studies, it is sometimes necessary to use "historical controls" to evaluate a given response. Historical controls are generally the historical collection of tumor responses from untreated control groups from studies in the same laboratory within two to three years of the study being evaluated^[30, 34, 59, 65, 66]. Evaluation of the data using the historical controls should be done rigorously to correctly evaluate the responses seen in a given study. Where a valid historical control dataset was available, I used the mean tumor response in the controls to calculate the probability of observing the trend seen in the study or a more significant trend if the true probability of response is the historical control average; this is labeled p_{Hist} . In all cases, the guidelines and literature support the use of the control in the current study as the most appropriate control group to use unless there is a specific need to address historical responses. Many guidelines^[30, 33, 34, 67] suggest historical controls be used for evaluating rare tumors and findings in assays that appear to be unusual. It is explicitly noted that significant increases in tumors over what is seen in the concurrent control should not be rejected simply because the tumors are in the range of the historical controls^[30]. Nor is it recommended to reject significant increases in tumor responses because the control response is on the low end of the historical range. Animals are randomly assigned to control and exposure groups and any low response in controls is likely to also reflect similar response patterns in treated animals. This is in agreement with SAP comments^[54] on the EPA issue paper on glyphosate^[61] and with all guidelines for analyzing animal carcinogenicity data.

There are 13 animal carcinogenicity studies in rats^[68-80] and eight in mice^[81-88]. Only two studies^[71, 77] appear in the peer-reviewed literature; the remaining studies are partially available through several sources. For three of the rat studies^[70, 74, 78] and two mouse studies^[83, 86], technical reports from the performing laboratory are available from documents provided by the registrant. For the remaining unpublished studies, data was obtained from the EPA review of glyphosate^[61], the European Food Safety Authority review of glyphosate^[89, 90] and supplemental material from a review of the carcinogenicity of glyphosate by a panel of scientists on behalf of Monsanto^[91].

Many additional endpoints, other than cancer incidence and related toxicities, were evaluated in these studies; I will only provide comments on the tumor incidence data and related data where relevant to the cancer findings.

It is unusual to have multiple carcinogenicity studies in the same experimental animal model arising from different laboratories. Methods for the combined analysis of multiple animal cancer bioassays are not available in the scientific literature. However, pooled analyses, as conducted in epidemiology^[92, 93] are applicable for combining animal carcinogenicity studies. The basic concept is to pool all data from the same sex/species/strain into one study and analyze it appropriately. The basic steps are: 1) select the studies to be pooled; 2) merge the data for analysis; 3) estimate study specific

effects; 4) estimate pooled effects; 5) explain the differences between the pooled effects and the individual study effects; 6) do a sensitivity analysis if possible. These steps will be used to analyze pooled data from animal carcinogenicity studies where pooling is done by sex, species, strain and duration of exposure to limit heterogeneity across pooled studies. In their recommendations to the EPA regarding EPA's issue paper on the carcinogenicity of glyphosate^[54], the FIFRA Science Advisory panel strongly supported the use of a pooled analysis to address the question of consistency citing my comments to the EPA^[94].

Rat Studies

Reyna and Gordon (1974)^[76] exposed Albino rats (probably Sprague-Dawley) to ammonium salt of glyphosate (13.85% purity) in a two-year chronic feeding study. Only EPA^[61] reported on this study and provided no details other than to report there were approximately 70 animals per group and there was insufficient reporting on the histopathology findings. Insufficient detail is available on this study.

This study is inadequate for use in deciding on causality.

Burnett et al. (1979)^[70] exposed male and female albino rats to an aqueous monosodium salt solution of glyphosate by oral intubation (purity not given). There were 90 animals per group and doses were 0, 3, 10 and 30 mg/kg/day for 24 months. EPA^[61] reported that no histopathological alterations were observed; no additional information was available on this study. This study had severely reduced sensitivity to observe any cancer findings because the highest dose used in this study is very low compared to the MTDs in the other rat studies. This study does not contribute to the evaluation of cancer causation in laboratory animals and will be excluded from any further discussion.

Lankas et al. (1981)^[74] exposed groups of 50 male and 50 female Sprague-Dawley rats to glyphosate (98.7% purity) in feed (see Table 1 for doses) for 26 months. This study is not in concordance with OECD guidelines (they were not available at the time of this study), but as noted by EFSA^[89], it was in general accordance with the 1981 OECD guidelines. Information on this study was available from EPA^[61], EFSA^[89], Greim et al.^[91], the original study report from Bio/dynamics Inc.^[95] and memos from Monsanto to EPA provided by Monsanto.

There were no survival differences in this study and there was no indication that the highest dose used exceeded the maximum-tolerated dose.

Table 1 shows the statistically significant trend in testicular interstitial cell tumors that was observed ($p_{Trend}=0.009$). Historical controls were provided in the study report for five studies with response rates of 4/116, 5/75, 4/113, 6/113 and 5/118 for a mean response of 4.5% (24/535). Comparing this historical control mean to the observed response yields $p_{Hist}=0.006$, showing that this result is significant, even when comparing it to the historical control dataset. **Lankas et al. (1981)** argued that the tumor rates at sacrifice were not statistically significant from control suggesting this finding is not related to glyphosate. However, by reducing the numbers of animals to only those at

terminal sacrifice, the power to find an effect was significantly reduced. Also, if the tumor increases the animal's chances of dying, then some animals with tumors will die early, which could bias results only seen at terminal sacrifice. This type of analysis is simply never done; it appears to have been developed for this case to dismiss the effects seen in the study. **Lankas et al. (1981)** also suggested the control response was low compared to the historical rates, but the concurrent control is always the best control group to use unless it is clearly flawed^[33, 34, 59]; in this case, there was no apparent problem with the controls because the probability of seeing 0/50 if the true background response is 4.5% is about 10% and this control group is not significantly different than the historical controls. **EFSA^[89]** noted rates for interstitial cell hyperplasia (a potential precursor for the interstitial cell tumors) and saw no dose-response trend (Table 1). However, these very low rates would suggest that the tumors arising in the 10 animals that did get interstitial cell tumors are independent of a mechanism involving interstitial cell hyperplasia. The tumor response for interstitial cell tumors was not monotonic (tumor rates increasing as dose increases), but was still within statistical variation. The EPA SAP agrees, concluding that "requiring visual confirmation of a monotonic trend in scatter plots of data ... is known to be a poor way of assessing trend"^[54].

An increase in Thyroid C-cell carcinomas (Table 1) was observed in female rats ($p_{Trend}=0.003$) but combining adenomas and carcinomas was only marginally significant ($p_{Trend}=0.072$). Independent pathologists brought in by Monsanto argued these tumors were not treatment related. The authors provided historical control data for both carcinomas and carcinomas combined with adenomas from nine control groups with mean responses of $4/453=0.9\%$ for carcinomas and $46/453=10.2\%$ for the combined tumors. The significance of both results was unchanged using the historical control data.

The authors also mentioned that the incidence of lymphocytic hyperplasia in the thymus and lymph nodes were slightly elevated above controls ($p_{Trend}=0.143$). The middle dose group was significantly different from controls ($p_{Fisher}=0.018$).

This study also had a statistically significant increase in pancreatic islet cell tumors in the lowest dose ($p_{Fisher}=0.028$) in males (Table 1), but not any of the other doses; the trend test was not significant ($p_{Trend}=0.312$).

The highest dose used in this study in Sprague-Dawley rats is far below the MTD. Even though **EFSA^[89]** noted that this study was in general accordance with the 1981 OECD guidelines, they dismissed it for not meeting current guidelines due to the low-doses used. **EPA^[61]** also excluded this study from consideration. However, the study saw an increase in testicular tumors in males and Thyroid C-cell carcinomas in females that should be carefully evaluated in determining causality. Also, this is the study with the longest exposure (26 months) and provides unique information to the overall evaluation.

Additional tumors seen to have significant increases in other studies using Sprague-Dawley Rats are also included in Table 1.

Table 1: Tumors of interest in male and female Sprague-Dawley rats the 26-month feeding study of Lankas (1981)^[74]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	3.05	10.30	31.49	
	Female	0	3.37	11.22	34.02	
Testicular interstitial cell tumors	Male	0/50	3/50	1/50	6/50**	P _{Trend} =0.009 P _{Hist} =0.006
Interstitial cell hyperplasia	Male	1/50	1/50	1/50	0/50	P _{Trend} =0.830
Thyroid C-cell Carcinomas	Female	1/47	0/49	2/50	6/47	P _{Trend} =0.003 P _{Hist} <0.001
Thyroid C-cell Adenomas and Carcinomas	Female	6/47	3/49	8/50	9/47	P _{Trend} =0.072 P _{Hist} =0.072
Pancreas Islet Cell Tumors	Male	0/50	5/50*	2/50	3/50	P _{Trend} =0.312
lymphocytic hyperplasia, thymus and lymph nodes	Female	27/50	35/50	38/50*	35/50	P _{Trend} =0.143
Thyroid C-cell Adenomas and Carcinomas	Male	1/47	2/49	4/49	4/49	P _{Trend} =0.122
Thyroid Follicular-cell Adenoma	Male	5/47	1/49	2/49	2/49	P _{Trend} =0.748
Liver Neoplastic Nodule	Male	3/50	5/50	1/50	3/10	P _{Trend} =0.630
Kidney Adenoma	Male	1/50	5/50	0/50	0/50	P _{Trend} =0.979

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

In conclusion, this study shows positive result for testes interstitial cell tumors and hepatocellular adenomas in male Sprague-Dawley rats and a positive response for thyroid c-cell carcinomas in female Sprague-Dawley rats and will be included in the overall evaluation of causation.

Stout and Ruecker (1990)^[78] exposed groups of 50 male and 50 female Sprague-Dawley rats to glyphosate (98.7% purity) in feed (see Table 2 for doses) for 24 months. This study was done under OECD guidelines.

There were no survival differences in this study and there was no indication that the highest dose used exceeded the maximum-tolerated dose.

Pancreatic islet cell tumors were increased in all dose groups relative to the controls in male rats and statistically significant for the lowest (p_{Fisher}=0.015) and highest (p_{Fisher}=0.032) dose groups (Table 2). However, these rates include the 10 animals that were sacrificed at one year. Due to the short duration of exposure, the rats terminated at one year were likely not at risk of developing this tumor; it is very unusual to include these animals in the final tumor counts (EPA^[61] also excluded these animals). In the pathology tables for this study, there were no tumors in any of the 10 animals at the interim sacrifice. Removing these 10 animals does not alter the p-values for trend or

Fisher's exact test. Historical control data for this tumor in this laboratory was reported as 23/432 or 5.3%^[96] and a trend comparison against this control rate was not significant ($p_{\text{hist}}=0.15$). The lack of a trend is driven by the up and down nature of the response. Assuming the historical rate of 5.3% is correct, the chances of seeing eight or more tumors in 47 animals is 0.003. Similarly, for the mid- and high-doses, this probability is 0.124 and 0.014, respectively. Females did not show an increase in this tumor. The authors provided a table with the combined results for pancreatic islet-cell adenomas and carcinomas from this study with the tumor counts from the **Lankas et al. (1981)**^[74] study arguing the results do not show a dose-related increase. Animals studied for 26 months versus 24 months can have very different responses to the same chemical and very different control incidence.

In male rats, there was a statistically significant trend ($p_{\text{Trend}}=0.015$) after removal of interim-sacrificed animals for hepatocellular adenomas but a significant increase for adenomas and carcinomas combined ($p_{\text{Trend}}=0.05$, Table 2) and not in females (not shown). Liver carcinomas are generally also provided in a separate analysis, but these data were not provided by the authors (the data would suggest the hepatocellular carcinomas would have a negative trend).

There was also a significant increase in thyroid C-cell adenomas in the female rats ($p_{\text{Trend}}=0.049$) and a marginal increase⁶ in adenomas and carcinomas combined ($p_{\text{Trend}}=0.052$) regardless of whether interim sacrificed animals are included (Table 2). In males, the trend for adenomas was $p_{\text{Trend}}=0.084$ and for adenomas and carcinomas was $p_{\text{Trend}}=0.091$. Adenomas were seen in male rats at the interim sacrifice demonstrating that male rats at the interim sacrifice were at risk for this tumor. If these animals are added back into the analysis, the trend test in males has $p_{\text{Trend}}=0.063$ for adenomas and $p_{\text{Trend}}=0.068$ for adenomas and carcinomas combined.

Several other tumors demonstrating significant findings in other studies of Sprague-Dawley rats are included in Table 2 and do not show significant effects.

In conclusion, the finding of an increased incidence of pancreatic islet-cell tumors in this study cannot easily be ruled out as a chance finding. Findings of significant increases in liver adenomas in male rats with no increases in carcinomas could be due to chance. The findings of significant increases in thyroid c-cell tumors in males and females should be compared with other studies. This study will be included in the overall evaluation of causation.

⁶ In statistics, it is common to refer to p-values in the range of $0.10 > p\text{-value} > 0.05$ as marginal when the target p-value is ≤ 0.05 ; this is done to avoid missing trends in data reflected by almost significant findings

Table 2: Tumors of interest in male and female Sprague-Dawley rats from the 24-month feeding study of Stout and Ruecker (1990)^[78]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	89	362	940	
	Female	0	113	457	1183	
Pancreas Islet Cell Tumors (with interim sacrifice)	Male	1/58	8/57*	5/60	7/59*	P _{Trend} =0.147 P _{Hist} =0.140
Pancreas Islet Cell Tumors (without interim sacrifice)	Male	1/48	8/47*	5/50	7/49*	P _{Trend} =0.147 P _{Hist} =0.150
Hepatocellular adenomas (without interim sacrifice)	Male	3/50	2/50	3/50	8/50	P _{Trend} =0.015
Hepatocellular Adenomas and Carcinomas (without interim sacrifice)	Male	6/50	4/50	4/50	10/50	P _{Trend} =0.050
Thyroid C-Cell Adenomas (with interim sacrifice)	Female	2/60	2/60	6/60	6/60	P _{Trend} =0.050
Thyroid C-Cell Adenomas (without interim sacrifice)	Female	2/50	2/50	6/50	6/50	P _{Trend} =0.049
Thyroid C-Cell Adenomas and Carcinomas (with interim sacrifice)	Female	2/60	2/60	7/60	6/60	P _{Trend} =0.053
Thyroid C-Cell Adenomas and Carcinomas (without interim sacrifice)	Female	2/50	2/50	7/50	6/50	P _{Trend} =0.052
Thyroid C-Cell Adenomas (with interim sacrifice)	Male	2/60	4/60	8/60	7/60	P _{Trend} =0.063
Thyroid C-Cell Adenomas (without interim sacrifice)	Male	0/50	4/50	8/50**	5/50*	P _{Trend} =0.084
Thyroid C-Cell Adenomas and Carcinomas (with interim sacrifice)	Male	2/60	6/60	8/60*	8/60*	P _{Trend} =0.068
Thyroid C-Cell Adenomas and Carcinomas (without interim sacrifice)	Male	0/50	6/50*	8/50**	6/50*	P _{Trend} =0.091
Testis Interstitial Cell Tumors	Male	2/50	0/50	3/50	2/50	P _{Trend} =0.296
Kidney Adenomas	Males	0/50	2/50	0/50	0/50	P _{Trend} =0.813
Thyroid Follicular Adenoma/Carcinoma	Males	2/50	1/48	3/48	3/50	P _{Trend} =0.225

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Atkinson et al. (1993)^[68] conducted a combined chronic toxicity/carcinogenicity study of glyphosate (98.9% pure). They used 50 Sprague-Dawley rats in each group for both sexes with dietary exposures given in Table 3. An additional 35 rats/sex/dose were included for interim sacrifices.

There were no survival differences in this study and there was no indication that the highest dose used exceeded the maximum-tolerated dose.

Table 3: Tumors of interest in male and female Sprague-Dawley rats from the 24-month feeding study of Atkinson et al. (1993)^[68]

Tumor	Sex	Doses (mg/kg/day)					p-values
	Male	0	11	112	320	1147	
	Female	0	12	109	347	1134	
Thyroid Follicular Adenomas and Carcinomas	Male	0/50	0/21	0/17	2/21	2/49	P _{Trend} =0.099
Thyroid Follicular Adenomas and Carcinomas (adding terminal sacrifice animals to denominator)	Male	0/50	0/50	0/50	2/50	2/49	P _{Trend} =0.034
Thyroid C-cell Adenomas and Carcinomas	Female	8/50	1/27	1/29	1/29	7/49	P _{Trend} =0.197
Thyroid C-cell Adenomas and Carcinomas	Male	9/50	1/21	1/17	2/21	9/49	P _{Trend} =0.183
Testes Interstitial Cell Tumors	Male	3/50	1/25	0/19	0/21	2/50	P _{Trend} =0.580
Kidney Adenomas	Males	1/50	0/50	0/50	0/50	0/50	P _{Trend} =1
Hepatocellular Adenomas	Males	2/50	1/50	1/50	2/50	3/50	P _{Trend} =0.155
Pancreas Islet-Cell Adenoma	Male	0/50	0/50	0/50	0/50	1/50	P _{Trend} =0.200

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

The authors reported no significant effects, as do **EPA**^[61] and **EFSA**^[89]. The study did not do detailed histopathological examination on all animals in all groups for every tumor type, but did examine all control and high dose animals, all animals that died before study termination and animals showing macroscopic tumors at study termination; liver, kidney and lungs were examined for all animals. This severely weakens the study for addressing dose-response trends. However, in reviewing the pathology tables provided in **Greim et al. (2015)**^[91], thyroid follicular adenomas and carcinomas were found to be marginally significant (p_{Trend}=0.099) by the trend test. If the three middle exposure groups had seen no other tumors and the denominators were the entire 50 animals on study, the trend analysis becomes significant (p_{Trend}=0.034).

Without examination of the animals free of gross tumors at terminal sacrifice, the findings from this study will be given less weight in the overall evaluation of causation.

Brammer (2001)^[69] conducted a two-year carcinogenicity study in Wistar rats in which groups of 52 animals were exposed to glyphosate (97.6% pure) at doses provided in

Table 4. An additional 12 animals were sacrificed at one-year.

A significant positive trend in survival was noted by the EPA ($p=0.03$), however this trend was not accomplished using a Kaplan-Meier test^[97] (the appropriate test), but simply a test relating to the percent surviving to terminal sacrifice. There was no indication that the highest dose used exceeded the maximum-tolerated dose.

EPA^[61], but not EFSA^[89], noted there was a statistically significant trend of hepatocellular adenomas in male rats with the highest dose also being statistically significant from the control. Trend analysis gives $p_{Trend}=0.008$ and the Fisher's exact test comparison of high dose to control is $p_{Fisher}=0.027$. EPA dismissed this finding as potentially due to a slight difference in the number of animals at the terminal sacrifice in this study versus controls. However, no formal statistical evaluation of survival is provided and it cannot be assumed from these numbers that survival was significantly impacted in these animals. Greim et al. (2015)^[91] used slightly different numbers for this tumor because three animals (one in the control group, one in the low-dose group and one in the mid-dose group) in the interim sacrifice group died before their sacrifice time and, from the pathology tables provided in their paper, these could not be separated from others. These numbers have been included in Table 4, but it does not change the significance of the findings. Greim et al. (2015)^[91] dismissed these findings, partly because of the same survival argument used by the EPA and partly because they had a historical control dataset where the range of historical response was from 0-11.5%; they did not provide the mean response or the individual tumor responses for these historical controls. As mentioned earlier, dismissing results because they are in the range of the historical controls is an unacceptable method for using historical controls to evaluate a study, and in this case, there is no reason to question the concurrent controls.

Table 4: Tumors of interest in male and female Wistar rats from the 24-month feeding study of Brammer (2001)^[69]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	121	361	1214	
	Female	0	145	437	1498	
Hepatocellular Adenoma	Male	0/52	2/52	0/52	5/52*	$P_{Trend}=0.008$
Hepatocellular Adenoma (from Greim et al., 2015 ^[91])	Male	0/53	2/53	0/53	5/52*	$P_{Trend}=0.008$ $P_{Hist}=0.006$
Mammary Gland Adenomas and Adenocarcinomas	Female	3/51	2/51	0/51	2/51	$P_{Trend}=0.575$
Skin Keratocanthoma	Male	1/51	0/51	1/51	1/51	$P_{Trend}=0.392$

*- $p_{Fisher}<0.05$, **- $p_{Fisher}<0.01$

I obtained historical control data from 16 control groups in Wistar rats from Charles River Laboratories for the years 2003 to 2011^[98]. Although these are outside of the optimal time range for the animals used in the Brammer (2001) study, they can serve as an illustration of why using a range can be misleading. There were 52 liver adenomas

seen in 1217 control animals for a mean response of 4.27% with a range of 0% to 17.5% (individual study findings of 6/100, 0/60, 1/60, 1/50, 1/80, 14/112, 1/65, 0/60, 21/120, 0/50, 1/50, 2/60, 0/50, 1/100, 1/150, 2/50; 13 studies with $\leq 2\%$ response). Assuming the underlying probability of having a tumor in controls is 4.27%, $p_{\text{Hist}}=0.006$ (Table 4). Thus, even though the responses seen in **Brammer (2001)** are in the range of the historical controls, the trend is highly significant when historical controls are used appropriately. **Greim et al. (2015)** also mentioned findings of increased toxicity at the high dose for which they provided numbers for only hepatocyte fat vacuolation and hepatitis; none of these findings were statistically significant by any test.

In conclusion, this study shows a positive result for hepatocellular adenomas in male Wistar rats and will be included in the overall evaluation of causation.

Pavkov and Wyand (1987)^[75] exposed Sprague-Dawley rats to glyphosate trimesium salt (sulfosate, 56.2% pure) in feed for two years. Eighty animals/sex were tested in the control, low-dose and mid-dose groups, and 90/sex were tested in the high dose group. Doses of 0, 4.2, 21.2 and 41.8 mg/kg/day were used in males and 0, 5.4, 27, and 55.7 mg/kg/day in females. This study showed no significant findings according to EPA^[61]. No details were given beyond that simple statement and no others reported on this study. The doses in this study are far below the MTD so this study would have reduced sensitivity to detect an effect if one existed. This study also used a different chemical than the other Sprague-Dawley rat studies and is not comparable on that basis.

This study is not acceptable for use in the evaluation of causality due to the lack of details about the study.

Suresh, (1996)^[79] exposed Wistar rats to glyphosate (96.8% pure) in feed for two years. Fifty animals/sex were tested in four exposure groups shown in Table 5.

There were no survival differences in this study and there was no indication that the highest dose used exceeded the maximum-tolerated dose.

EPA^[61] concluded there were no tumors increased due to glyphosate exposure in this study and EFSA^[89] concluded that, "[n]one of the significant microscopic changes, increased and decreased incidences (in liver, spleen, lymph nodes, adrenals, thymus, gonads, uterus, mammary gland) observed have shown dose relationship, hence appeared to be incidental and not related to the treatment with the test compound." (page 491). **Greim et al. (2015)**^[91] provided data on hepatocellular adenomas and carcinomas in both sexes but none of these showed significant trends or pairwise tests (Table 5). However, there was another study with a strong significant trend in hepatocellular adenomas in Wistar rats^[69] so these are also included in Table 5 for comparison. No other tumors were mentioned by any other group and an examination of the grouped pathology tables provided by **Greim et al. (2015)** show an increase in mammary gland adenomas at the mid-dose ($p_{\text{Fisher}}=0.017$) but no significant trend. However, there was another study with a strong significant trend in mammary gland adenomas and adenocarcinomas combined in Wistar rats^[80] so these are also included in Table 5 for comparison. Like the **Atkinson et al. (1993)**^[68] study, **Suresh (1996)** did not do full pathology on all of the animals in the interim exposure groups making

interpretation of this study problematic.

This study will be included in the overall evaluation of causation.

Table 5: Tumors of interest in male and female Wistar rats from the 24-month feeding study of Suresh(1996)^[79]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	6.3	59.4	595.2	
	Female	0	8.6	88.5	886	
Mammary Gland Adenoma and Carcinoma	Female	5/40	3/28	8/33	2/48	P _{Trend} =0.970
Hepatocellular Adenoma	Male	24/50	22/50	10/50	21/50	P _{Trend} =0.374
Skin Keratocanthoma	Male	0/50	0/50	0/50	0/50	P _{Trend} =1

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Enemoto (1997)^[72] exposed Sprague-Dawley rats to glyphosate (95.7% pure) in feed for two years. Fifty animals/sex were tested in four exposure groups (see Table 6). In addition, 10 animals per exposure group were exposed for 1 year and another 10 for 18 months at which point they were sacrificed and examined. These interim sacrifice animals (1 year and 18 months) are included in the analysis if tumors were seen in these groups.

There were no survival differences in this study and there was no indication that the highest dose exceeded the maximum-tolerated dose.

EPA and EFSA both found no significant changes in tumors in any group. **Greim et al. (2015)** again provide tables for a number of tumors, none of which show significant effects except for the incidence of kidney adenomas in male rats (p_{Trend}=0.004, Table 6). Examining the pathology tables provided in **Greim et al. (2015)** reveals no additional tumors showing an increase in tumor incidence with dose. A different study^[74] in Sprague-Dawley rats demonstrated a strong significant trend in mammary gland adenomas, thyroid C-cell carcinomas, skin Keratocanthomas and testicular interstitial cell tumors so these are also included in Table 6 for comparison.

This study showed a significant increase in kidney adenomas and will be included in the overall evaluation of causation.

Table 6: Tumors of interest in male and female Sprague-Dawley rats from the 24-month feeding study of Enemoto (1997)^[72]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	104	354	1127	
	Female	0	115	393	1247	
Mammary Gland Adenoma	Female	23/50	27/50	24/50	30/50	P _{Trend} =0.106
Kidney Adenoma	Male	0/50	0/50	0/50	4/50	P _{Trend} =0.004
Thyroid C-cell Adenomas/Carcinomas	Female	4/60	7/60	8/60	4/60	P _{Trend} =0.692
Thyroid C-cell Adenomas/Carcinomas	Male	8/70	10/70	6/70	7/70	P _{Trend} =0.697
Thyroid Follicular-cell Adenomas/Carcinomas	Male	4/70	2/70	1/70	0/70	P _{Trend} =0.990
Testes Interstitial Cell Tumors	Male	3/49	2/50	0/50	2/50	P _{Trend} =0.594
Hepatocellular Adenomas	Male	1/60	0/60	2/60	1/60	P _{Trend} =0.371
Skin Keratoacanthoma	Male	3/50	3/50	0/50	6/50	P _{Trend} =0.065
Pancreas Islet-Cell Adenoma	Male	4/50	1/50	2/50	1/50	P _{Trend} =0.844

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Wood et al. (2009)^[80] exposed Wistar rats to glyphosate (94.7% to 97.6% pure) in feed for two years. Fifty-one animals/sex were tested in four exposure groups at doses shown in Table 7.

No survival differences were seen in this study.

EFSA^[89] found no dose-related tumor increases while **EPA**^[61] noted an increase in mammary gland adenomas and adenocarcinomas combined with p_{Trend}=0.062 for adenomas, p_{Trend}=0.042 for adenocarcinomas and p_{Trend}=0.007 for the combined tumors (Table 7). EPA concluded there was no progression from adenoma to adenocarcinoma and argued the increase was not glyphosate related. This conclusion is contradicted by the fact that 6 animals in control and the lower dose groups got carcinomas with no adenomas in any of the animals in these groups. It seems likely that, in this case, mammary gland adenocarcinomas can arise without the presence of any adenomas.

Greim et al (2015)^[91] also noted an increase in skin keratoacanthoma in males (p_{Trend}=0.030). Review of the pathology tables identified no other tumors with increased tumor rates as a function of dose. There was another study with a strong significant trend in hepatocellular adenomas in Wistar rats^[69] so this tumor is also included in Table 7 for comparison.

This study showed an increase in mammary tumors in females and skin keratoacanthomas in males and will be used in the evaluation of causality.

Table 7: Tumors of interest in male and female Wistar rats from the 24-month feeding study of Wood et al. (2009)^[80]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	85.5	285.2	1077.4	
	Female	0	104.5	348.6	1381.9	
Mammary Gland Adenomas	Female	0/51	0/51	0/51	2/51	P _{Trend} =0.062
Mammary Gland Adenocarcinomas	Female	2/51	3/51	1/51	6/51	P _{Trend} =0.042
Mammary Gland Adenomas and Adenocarcinomas	Female	2/51	3/51	1/51	8/51*	P _{Trend} =0.007
Skin Keratocanthoma	Male	2/51	3/51	0/51	6/51	P _{Trend} =0.030
Hepatocellular Adenoma	Male	0/51	2/51	1/51	1/51	P _{Trend} =0.418

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Excel (1997)^[73] exposed Sprague-Dawley rats to glyphosate (purity not given) in feed for two years. Fifty-one animals/sex were tested in four exposure groups at doses of 0, 150, 780 and 1290 mg/kg/day in males and 0, 210, 1060 and 1740 mg/kg/day in females.

EPA^[61], **EFSA**^[89] and **Greim et al. (2015)**^[91] had concerns with the quality of this study, the characterization of the chemical being used and with tumor rates in this strain of animals being too low. The Supplemental Material from **Greim et al. (2015)** on this study shows no significant increase in any tumor and virtually all animals having no tumors in controls and treated animals.

This study is inadequate for use in deciding on causality for the same reasons given by the **EPA**, **EFSA** and **Greim et al. (2015)**.

Chruscielska, K. (2000)^[71] exposed Wistar rats to glyphosate as a 13.8% solution (purity not given) in drinking water for two years. According to **Greim et al. (2015)**^[91], this appears to be the glyphosate formulation Perzocyd. Eighty-five animals/sex were tested in four exposure groups. The authors listed the doses as control, 300 mg/L, 900 mg/L and 2700 mg/L in drinking water. **Greim et al. (2015)**^[91] estimated the intake of glyphosate to be 0, 1.9, 5.7 and 17 mg/kg/day for females and 0, 2.2, 6.5, and 19 mg/kg/day in males. There was a slight increase in malignant adenomas of the pituitary gland and an opposite decrease in pituitary adenomas suggesting no effect or potentially a promotional effect in which adenomas are promoted to carcinomas by glyphosate. No other increased tumor responses were reported in the manuscript. Because of the low exposures, this study is an inadequate challenge to the animals (the highest dose is far below the MTD). The reporting of this study is very limited and the overall quality of the work cannot be evaluated.

This study is inadequate for use in deciding on causality.

Seralini, G. E., et al. (2014)^[77] exposed Sprague-Dawley rats to the glyphosate formulation Roundup in drinking water for two years as part of a broader experiment on

Roundup-Ready Corn. Ten animals/sex were tested in four exposure groups at doses of 0, 0.00005, 400 and 22500 mg/L in females. The authors reported an increase in the incidence of mammary gland tumors (mainly fibroadenomas and adenocarcinomas) in female rats with incidences of 5/10 for control and 9/10, 10/10, 9/10 ($p_{\text{Fisher}}=0.016$) in the low-, mid- and high-doses groups respectively. It is difficult to assess the quality of this study due to limited reporting on the histopathological descriptions of the tumors and the very small sample size.

This study will not be used in the evaluation of causality.

Joint Analysis - Rats

Table 8 summarizes the significance for all tumors of interest in rats.

Brammer (2001)^[69] saw a significant increase in hepatocellular adenomas in male Wistar rats with increasing dose ($p_{\text{Trend}}=0.008$, Table 4). The other two acceptable studies in Wistar rats (**Wood et al. (2009)**^[80] and **Suresh (1996)**^[79]) did not see significant increases (Tables 5 and 7). On the basis of statistical significance, these studies are inconsistent. To reject these findings based upon only 1/3 being positive is the same as rejecting a coin as being fair if, in three flips of the coin, the result is one head and two tails; it simply is not possible and there is a better way to address these findings. Given different doses and different sample sizes, we need to formally test for consistency in these studies. **Suresh (1996)** saw 48% response for hepatocellular adenomas in controls whereas the other two studies saw no tumors in the control animals. Thus, although all three studies are in Wistar rats, **Suresh (1996)** has a significantly different control response from the other two. **Suresh (1996)** did not give a substrain for the Wistar rats used, but **Brammer (2001)** and **Wood et al. (2009)** used different substrains. All three studies used different diets and were conducted in different facilities. Thus, there is no obvious explanation for the dramatically different rates in **Suresh (1996)**. It is known that the same strain of rats from different laboratories can have markedly different control tumor responses. Because they have similar control response, **Brammer (2001)** and **Wood et al. (2009)** can be pooled into a single study to ask the question "Does the significant trend for **Brammer (2001)** disappear when it is pooled with the negative study of **Wood et al. (2009)**?" The analysis of the pooled studies yields $p_{\text{Trend}}=0.013$ supporting the conclusion that glyphosate causes hepatocellular adenomas in Wistar rats with similar background responses.

Wood et al. (2009)^[80] saw a significant increase in mammary gland adenomas and adenocarcinomas ($p_{\text{Trend}}=0.007$, Table 7) in females that was not seen in the other two studies (Tables 4 and 6). The background rates in these studies differ only slightly and a pooled analysis of all three studies yields $p_{\text{TrendA}}=0.459$, suggesting that combining the data eliminates the dose-response trend seen in **Wood et al. (2009)**. However, if the Wistar rats used in **Suresh (1996)** differed in their response for hepatocellular adenomas, they may differ for this tumor as well. Combining only **Wood et al. (2009)** with **Brammer (2001)** results in $p_{\text{Trend}}=0.037$. Given the mixed results from the pooling for this tumor I conclude there is limited support for the notion that glyphosate can cause mammary gland adenomas and adenocarcinomas in Wistar rats.

Wood et al. (2009)^[80] saw a significant increase in skin keratocanthomas ($p_{Trend}=0.030$, Table 7) in males that was not seen in the other two studies (Tables 4 and 6). The background rates in these studies differ only slightly and a pooled analysis of all three studies yields $p_{TrendA}=0.010$, suggesting that combining the data does not eliminate the dose-response trend seen in **Wood et al. (2009)**. Combining only **Wood et al. (2009)** with **Brammer (2001)** results in $p_{Trend}=0.053$. Given the results from the pooling for this tumor I conclude there is support for the notion that glyphosate can cause skin keratocanthomas in Wistar rats.

In Sprague-Dawley rats, there were four studies that were acceptable for inclusion in the evaluation of causality with one^[74] yielding strong positive responses for thyroid C-cell carcinomas in females and testicular interstitial tumors and hepatocellular adenomas in males and another^[72] yielding a strong result for kidney adenomas in males. **Lankas (1981)**^[74] saw a significant increase in thyroid C-cell carcinomas in female rats exposed to glyphosate ($p_{Trend}=0.003$, Table 1) and a marginal increase in C-cell adenomas and carcinomas combined ($p_{Trend}=0.072$, $p_{hist}=0.072$, Table 1; two of the other three studies also saw marginal results for thyroid C-cell adenomas and carcinomas in females (Tables 2 and 3). A pooled analysis using all four studies yields $p_{TrendA}=0.390$. This pooled analysis does not support the results seen in **Lankas (1981)**. However, the **Lankas (1981)** study was for 26 months and the other three were for 24 months; the C-cell carcinomas could be a result of the longer exposure period even though the dose is substantially lower in this study compared to the other two. From these data, I conclude that the evidence is weak that glyphosate causes thyroid C-cell tumors in female Sprague-Dawley rats.

Thyroid C-cell adenomas and carcinomas combined, in males, show marginally significant dose-response trends in **Stout and Ruecker (1990)**, Table 2) but not in the remaining three studies. Pooling all four studies yields a significant trend of $p_{TrendA}=0.041$. From these data, I conclude that there is evidence is that glyphosate causes thyroid C-cell tumors in male Sprague-Dawley rats.

Thyroid follicular-cell adenomas and carcinomas combined, in males, show a significant dose-response trend in **Atkinson et al. (1993)**, Table 3) but not in the remaining three studies;. Pooling all four studies yields no significant trend with $p_{TrendA}=0.618$. From these data, I conclude that there is no evidence that glyphosate causes thyroid follicular-cell tumors in male Sprague-Dawley rats.

Hepatocellular adenomas, in males, show a significant dose-response trend in **Stout and Ruecker (1990)**, Table 2) but not in the remaining three studies. Pooling all four studies yields a marginally significant trend with $p_{Trend}=0.073$. From these data, I conclude that there is limited evidence that glyphosate causes thyroid follicular-cell tumors in male Sprague-Dawley rats.

Table 8: Summary of significance tests for 5 tumors from 7 studies in Rats

Study	Strain	Neoplasm							
		Hepato-cellular Adenomas (males)	Mammary Gland Tumors (females)	Skin Kerato-canthoma (males)	Thyroid C-Cell Tumors (females)	Thyroid C-Cell Tumors (males)	Thyroid Follicular Cell Tumors (males)	Testis Interstitial Cell Tumors (male)	Kidney Adenomas (males)
Brammer (2001) ^[69]	Wistar	+++ ¹	-						
Wood (2009) ^[80]		-	+++	++					
Suresh (1996) ^[79]		-	-						
Pooled Wistar Rats		++ ²	++ ²	+++					
Lankas (1981) ^[74]	Sprague Dawley	- ³			+	-	-	+++	-
Enemoto (1997) ^[72]		-			-	-	-	-	+++
Atkinson et al. (1993) ^[68]		-			-	-	++	-	-
Stout and Ruecker (1990)		++			-	+	-	-	-
Pooled Sprague-Dawley Rats		+			-	++	-	-	++ ⁴

¹entries are p_{Trend}/p_{Hist} with values: - $p>0.1$, + $0.1\geq p>0.05$, ++ $0.05\geq p>0.01$, +++ $p\leq 0.01$; ²pooling results from **Brammer (2001)** and **Wood (2009)** only; ³liver neoplastic nodules; ⁴excluding **Lankas (1981)**

Another significant trend seen in Sprague-Dawley rats is the finding of testes interstitial cell tumors from **Lankas (1981)**^[74] ($P_{Trend}=0.009$, Table 1); the other three studies were negative for this tumor (Tables 2, 3 and 6). Combining the other three studies with that of **Lankas (1981)** for testes interstitial tumors results in a p-value for trend that is clearly non-significant ($p_{TrendA}=0.608$). However, as noted above, the **Lankas (1981)** study was for 26 months and the other two were for 24 months; the tumors could be a result of the longer exposure period even though the dose is substantially lower in this study compared to **Stout and Ruecker (1990)**, **Atkinson et al.(1993)** and **Enemoto (1997)**.

The final tumor in Sprague-Dawley rats showing a strong significant trend is kidney

adenomas in males from the study by **Enemoto (1997)**^[72] ($P_{Trend}=0.004$, Table 6). The kidney tumor data is not significant for the studies by **Lankas (1981)**^[74] (Table 1), **Atkinson et al. (1993)**^[99] (Table 3) and **Stout and Ruecker (1990)**^[78] (Table 2). Pooling the **Enemoto (1997)** study with that of **Lankas (1981)**^[74], **Stout and Ruecker (1990)** and **Atkinson et al. (1993)** yields $p_{TrendA}=0.201$. Removing the 26-month study by **Lankas (1981)**^[74] yields a p-value for the three combined 24-month studies of $p_{Trend}=0.031$; thus, the association between glyphosate and kidney adenomas in male Sprague-Dawley rats is supported by these data, even with the difficulty associated with interpreting the results in the low- and mid-doses in the **Atkinson et al. (1993)** study. There is evidence to support an increase in kidney tumors in male Sprague-Dawley rats exposed to glyphosate.

In summary, there is evidence that glyphosate causes hepatocellular adenomas and skin keratocanthomas in male Wistar rats, mammary gland adenomas and adenocarcinomas in female Wistar rats and kidney adenomas and thyroid C-cell adenomas and carcinomas in male Sprague-Dawley rats. There is limited evidence glyphosate causes hepatocellular adenomas in male Sprague-Dawley rats.

Mouse Studies

Reyna and Gordon (1974)^[86] exposed Swiss White mice to glyphosate (>97% purity) in feed for 16 months in males and 18 months in females. Fifty animals/group/sex were tested in three exposure groups; control, 17 mg/kg and 50 mg/kg. Only 10 animals per group were examined for histopathological changes.

There was no impact on survival of administration of glyphosate and no indication that the high dose exceeded the MTD.

No significant increases were seen in any tumor from this study. However, given the small sample size for histopathological evaluation and the low doses used for this study, this study is inadequate.

This study will not be used in the evaluation of causality.

Knezevich and Hogan, (1983)^[83] exposed CD-1 mice to glyphosate (99.8% pure) in feed for two years. Fifty animals/group/sex were tested in four exposure groups (see Table 9).

There were no survival differences in this study and there was no indication that the highest dose used exceeded the MTD.

EPA^[100] found a significant increase in kidney tubular cell adenomas in male mice based upon the original pathology done from the study and this analysis is shown in Table 9 ($p_{Trend}=0.019$). Kidney tubular cell adenomas are very rare tumors in CD-1 mice so it is important to compare these results with the historical controls. No historical controls were available from the laboratory that conducted **Knezevich and Hogan, (1983)** so IARC, EPA and EFSA all used historical control databases from published studies in the

literature^[101-103]. These studies have virtually identical rates for the important tumors seen in CD-1 mice; I will use the study by **Giknis and Clifford (2000)**^[102] since it best covers the range of studies we have for CD-1 mice. For studies of approximately two years, the mean historical tumor response in controls is 0.27%. Applying this control response rate to the kidney adenomas yields $p_{\text{Hist}}=0.005$, strengthening the significance of the evaluation against the concurrent control. EPA originally used a similar analysis and reached the same conclusions. However, in 1985, the registrant had a group of pathologists review the kidney slides. Using additional kidney sections from this study, the pathologists identified an additional adenoma in the control animals and changed the classification for three adenomas to carcinomas (Table 9). With these changes, the adenomas no longer have a significant trend ($p_{\text{Trend}}=0.442$, $p_{\text{Hist}}=0.121$) but carcinomas have a marginally significant trend against concurrent controls and a clearly significant trend using historical controls ($p_{\text{Trend}}=0.063$, $p_{\text{Hist}}=0.002$, historical control rate of 0.15%). These historical control rates may not apply to this analysis because the reevaluation of the kidney tumors considered additional sections and no information is available on how additional sections affect historical control rates in this strain of mice; differences have been seen in other settings^[104]. The incidence of combined carcinomas and adenomas has the same marginal significance against the concurrent control and significance against the historical controls ($p_{\text{Trend}}=0.065$, $p_{\text{Hist}}=0.011$, historical control rate of 0.44%). However, there was considerable disagreement on whether the one adenoma in the control group was correctly diagnosed^[105]. Removing this one adenoma from the control group results in $p_{\text{Trend}}=0.019$ and $p_{\text{Hist}}=0.005$.

Other CD-1 mouse studies have seen increases in malignant lymphomas, hemangiosarcomas and lung adenocarcinomas (males) and hemangiomas (females). Evaluations of those tumors for this study yields results that are not significant; for malignant lymphoma, $p_{\text{Trend}}=0.754$, $p_{\text{Hist}}=0.767$, with the historical control rate equal 6.2%, for hemangiosarcomas $p_{\text{Trend}}=0.503$, $p_{\text{Hist}}=0.591$, with the historical control rate equal to 2.5%, for lung adenocarcinomas $p_{\text{Trend}}=0.918$, $p_{\text{Hist}}=0.899$, with the historical control rate equal to 9.2% and for hemangiomas $p_{\text{Trend}}=0.631$. No other tumors were found in this study.

The EPA^[61] has produced many different arguments to dismiss the findings of renal tumors from this study. One argument is that the pathology working group requested by the EPA in 1986 concluded these lesions were not glyphosate related because “1) renal tubular cell tumors are spontaneous lesions for which there is a paucity of historical control data for this mouse stock; 2) there was no statistical significance in a pairwise comparison of treated groups with the concurrent controls and there was no evidence of a statistically significant linear trend; 3) multiple renal tumors were not found in any animal; and 4) compound-related nephrotoxic lesions, including pre-neoplastic changes, were not present in male mice in this study.” Reason number one no longer exists as there are two very good historical control databases for CD-1 mice^[101, 102]. The second reason, while technically correct, is not supportable since the Agency’s own guidelines for evaluating carcinogenicity studies state that “Significance in

either kind of test [trend or pair-wise] is sufficient to reject the hypothesis that chance accounts for the result.” The third reason is also weak since one would not expect (nor require) multiple tumors to appear when dealing with a rare tumor. For the fourth point, EPA provides data on the rate of bilateral chronic interstitial nephritis in the study which it considers to show no statistically significant results although the trend test is highly significant ($p_{Trend}=0.006$, Table 9). EPA then states, without reference, that “chronic interstitial nephritis is not considered to be a precursor lesion for tubular neoplasms”. I could find no published research to either support or refute this statement. However, chronic interstitial nephritis is an inflammation of the interstitial tissue surrounding the glomeruli and tubules in the kidney. Inflammation is well known

Table 9: Tumors of interest in male and female CD-1 mice from the 24-month feeding study of Knezevich and Hogan (1983)^[83]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	157	814	4841	
	Female	0	190	955	5874	
Kidney Adenoma ¹ (original pathology)	Male	0/49	0/49	1/50	3/50	$P_{Trend}=0.019$ $P_{Hist}=0.005$
Kidney Adenoma (EPA pathology)	Male	1/49	0/49	0/50	1/50	$P_{Trend}=0.442$ $P_{Hist}=0.121$
Kidney Carcinoma ² (EPA pathology)u	Male	0/49	0/49	1/50	2/50	$P_{Trend}=0.063$ $P_{Hist}=0.002$
Kidney Adenoma and Carcinoma Combined ³ (EPA pathology)	Male	1/49	0/49	1/50	3/50	$P_{Trend}=0.065$ $P_{Hist}=0.011$
Malignant Lymphoma ⁴	Male	2/49	5/49	4/50	2/50	$P_{Trend}=0.754$ $P_{Hist}=0.767$
Hemangiosarcoma ⁵	Male	0/50	0/49	1/50	0/50	$P_{Trend}=0.503$ $P_{Hist}=0.591$
Bilateral Chronic Interstitial Nephritis	Male	5/49	1/49	7/50	11/50	$P_{Trend}=0.006$
Hemangioma ⁶	Female	0/49	1/49	1/50	0/50	$P_{Trend}=0.631$
Lung Adenocarcinoma ⁷	Male	4/48	3/50	2/50	1/50	$P_{Trend}=0.918$ $P_{Hist}=0.899$

*- $p_{Fisher}<0.05$, **- $p_{Fisher}<0.01$, ¹historical rate=0.27%, ²historical rate=0.15%, ³historical rate=0.44%, ⁴historical rate=6.2%, ⁵historical rate=2.5%, ⁶No Historical Controls, ⁷Historical rate=9.2%

to play an important role in kidney cancer^[106] and many other cancers so this argument also fails to support rejection of these findings.

In summary, this study shows a positive result for kidney tumors in male CD-1 mice and will be included in the overall evaluation of causation.

Atkinson, et al., (1993)^[81] exposed CD-1 mice to glyphosate (>97% purity) in feed for two years. Fifty animals/group/sex were tested in four exposure groups (see Table 10).

There was no impact on survival of administration of glyphosate and no indication that the high dose exceeded the MTD.

Table 10: Tumors of interest in male and female CD-1 mice from the 24-month feeding study of **Atkinson et al. (1993)**^[81]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	98	297	988	
	Female	0	102	298	1000	
Kidney Adenoma and Carcinoma Combined ¹	Male	2/50	2/50	0/50	0/50	P _{Trend} =0.981 P _{Hist} =1
Malignant Lymphoma ²	Male	4/50	2/50	1/50	6/50	P _{Trend} =0.087 P _{Hist} =0.085
Hemangiosarcoma ³	Male	0/50	0/50	0/50	4/50	P _{Trend} =0.004 P _{Hist} =0.001
Hemangioma ⁴	Female	0/50	0/50	0/50	0/50	P _{Trend} =1
Lung Adenocarcinoma ⁵	Male	10/50	7/50	8/50	9/50	P _{Trend} =0.456 P _{Hist} =0.449

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01, ¹historical rate=0.44%, ²historical rate=6.2%, ³historical rate=2.5%, ⁴No historical control rate, ⁵Historical rate=9.2%

Hemangiosarcomas were the only tumors showing a significant trend in this study (P_{Trend}=0.004, P_{Hist}=0.001, Table 10). Also shown in Table 10 are the results for malignant lymphomas, kidney tumors and lung adenocarcinomas (males) and hemangioma (females); there is a marginal trend for malignant lymphomas (P_{Trend}=0.087, P_{Hist}=0.085) and no trend for kidney tumors.

The EPA^[61] concluded the findings in this study were not treatment related based upon the tumors appearing only in the high dose group, a lack of statistical significance between the response in this group and control response and that these tumors are commonly observed in mice as both spontaneous and treatment related effects. There is no scientific support for excluding positive findings in the highest dose group, a view also held by the SAP^[54]. I have already commented on how EPA's guidelines treat trend tests and Fisher's Exact test results, although in this case, the value of the comparison of the highest exposure group to controls, p_{Fisher}=0.059, is marginally significant. The argument regarding the frequency of this tumor in controls is addressed directly by the evaluation against the historical control rates; if these rates were high enough to exclude this finding, P_{Hist} would have been above 0.05 instead of 0.001. The mean

historical control incidence of hemangiosarcomas in controls from two-year cancer bioassays in CD-1 mice is 2.5% and the response seen in the high-dose group is 8.9%. The SAP^[54] stated very clearly that the practice, being used by the EPA, of negating a positive finding because of historical control data was not acceptable^[54]. (page 63). The EPA Cancer Guidelines^[33] state this very clearly “...statistically significant increases in tumors should not be discounted simply because incidence rates in the treated groups are within the range of historical controls or because incidence rates in the concurrent controls are somewhat lower than average.”

In summary, this study shows a positive result for hemangiosarcomas in male CD-1 mice and will be included in the overall evaluation of causation.

Wood et al., (2009)^[88] exposed CD-1 mice to glyphosate (95.7% pure) in feed for 80 weeks. Fifty-one animals/groups/sex were tested in four exposure groups (see Table 11).

There was no effect on survival and no information suggesting the study exceeded the MTD.

No increase in kidney tumors or hemangiosarcomas (males) or hemangiomas (females) were seen in this study. There was a monotonic increase in lung adenocarcinomas ($p_{Trend}=0.028$, $p_{Hist}=0.031$) in males and a monotonic increase in malignant lymphomas ($p_{Trend}=0.007$, $p_{Hist}=0.007$) in males. The historical control incidence for this study is different from the earlier studies because this study is only for 80 weeks instead of 104 weeks (two years); the historical control rate for malignant lymphomas in CD-1 mice after 80 weeks is 2.6% instead of 6.2%, the historical control rate at two years^[102].

For lung adenocarcinomas, the EPA^[61] again argued a lack of significance for pairwise comparisons (in violation of its guidelines) and that there was no evidence of progression from adenomas to carcinomas. Even though there was no increase in lung adenomas as a function of exposure, it is possible to have an increase in lung adenocarcinomas without an associated increase in adenomas^[107]. For malignant lymphomas, EPA notes that there was a statistically significant response and that the high dose was significantly different from control ($p_{Fisher}=0.028$), but then uses an argument based upon the number of analyses done in this study to adjust the Fisher Exact test p-value to 0.082 (an adjustment for multiple comparisons is indeed warranted in evaluating the outcomes of these animal cancer studies, this will be addressed later in my report in the evaluation of all of the studies combined).

The EPA^[61] uses historical control data^[103, 108] to exclude the malignant lymphomas and cite a mean response of 4.5% and a range of 1.5% to 21.7%. **Son and Gopinath (2004)**^[108] saw 21 animals out of 1453 examined prior to 80 weeks with lung adenocarcinomas (1.4%). **Giknis and Clifford (2005)**^[103] saw a mean rate of 4.5% with a range of 0% to 21.7% in 52 studies which included mostly 78 week controls (26 studies) and 104 week controls (21 studies). Including only studies of 80 weeks or less, the rate in **Giknis and Clifford (2005)** is 37/1372=2.7% with a range of 0% to 14%. **Giknis and Clifford (2000)**^[102] (the reference I have been citing) did a similar evaluation, using mostly the same data as their 2005 paper and saw an average tumor incidence before

80 weeks of 2.6% with a range of 0% to 14%. Based upon its flawed interpretation of the **Giknis and Clifford (2005)** historical controls, EPA argues that the incidence of concurrent controls in the study was low (it was 0%) and rejected the positive finding. In fact, of the 26 studies in the 18-month control groups evaluated by **Giknis and Clifford (2005)**, eight (31%) had response of 0% and eight (31%) had only one tumor. The evaluation used by the EPA is incorrect. In addition, as noted earlier, the use of historical control data to negate a positive finding is not supported by **EPA's guidelines**^[33, 54] or its **SAP**^[54].

There was an increase in the number of animals with multiple malignant tumors ($P_{Trend}=0.046$)

In summary, this study shows a positive result for malignant lymphomas and lung adenocarcinomas in male CD-1 mice and will be included in the overall evaluation of causation.

Table 11: Tumors of interest in male and female CD-1 mice from the 18-month feeding study of **Wood et al. (2009)**^[88]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	71.4	234.2	810	
	Female	0	97.9	299.5	1081.2	
Kidney Adenoma ¹	Male	0/51	0/51	0/51	0/51	$P_{Trend}=1$
Malignant Lymphoma ²	Male	0/51	1/51	2/51	5/51*	$P_{Trend}=0.007$ $P_{Hist}=0.007$
Hemangiosarcoma	Male	0/51	0/51	0/51	0/51	$P_{Trend}=1$
Lung Adenocarcinoma ³	Male	5/51	5/51	7/51	11/51	$p_{Trend}=0.028$ $P_{Hist}=0.031$
Hemangioma ⁴	Female	0/51	2/51	0/51	1/51	$p_{Trend}=0.438$
Animals with Malignant Neoplasms	Male	14/51	20/51	17/51	20/51	$P_{Trend}=0.203$
Animals with Malignant Neoplasms	Female	23/51	15/51	17/51	18/51	$P_{Trend}=0.628$
Animals with multiple malignant tumors	Male	1/51	2/51	3/51	5/51	$P_{Trend}=0.046$

*- $p_{Fisher}<0.05$, **- $p_{Fisher}<0.01$, ¹historical rate=0.44%, ²historical rate=2.6%, ³Historical rate=2.5%, ⁴No Historical Control Rate

Sugimoto (1997)^[87] exposed CD-1 mice to glyphosate (94.61-95.67% pure) in feed for two years. Fifty animals/group/sex were tested in four exposure groups (see Table 12).

There were no effects of treatment on survival and no indication the highest dose had exceeded the MTD.

Kidney adenomas ($p_{Trend}=0.062$, $p_{Hist}=0.005$), malignant lymphomas ($p_{Trend}=0.016$,

$p_{\text{Hist}}=0.017$) and hemangiosarcomas ($p_{\text{Trend}}=0.062$, $p_{\text{Hist}}=0.004$) in male mice and hemangiomas ($p_{\text{Trend}}=0.002$) in female mice all showed increased tumor incidence with increasing dose. The evaluation of lung adenocarcinomas in males showed no significant dose-related trend ($p_{\text{Trend}}=0.148$, $p_{\text{Hist}}=0.140$). This study also had an increase in animals with any malignancy in males ($p_{\text{Trend}}=0.001$) but not in females ($p_{\text{Trend}}=0.362$). Note that no hemangiosarcomas were seen in the 26 control groups evaluated by **Giknis and Clifford (2000)** so the development of an estimate of the historical control response is difficult (if the historical control rate is 0, then any observed response other than 0 has a p-value of 0). The fact that this tumor was never seen in the historical controls should strongly support any positive finding as being significant. However, to still allow for a test using historical control data, I used the historical control estimate of the mean response that would result in a 5% chance of seeing no tumors in 1149 animals. This estimated historical control response value was 0.0026. This value was used in the analysis for hemangiosarcomas in male CD-1 mice exposed for 18 months ($p_{\text{Hist}} < 0.001$).

Table 12: Tumors of interest in male and female CD-1 mice from the 18-month feeding study of **Sugimoto (1997)**^[87]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	165	838.1	4348	
	Female	0	153.2	786.8	4116	
Kidney Adenoma ¹	Male	0/50	0/50	0/50	2/50	$P_{\text{Trend}}=0.062$ $P_{\text{Hist}}=0.005$
Malignant Lymphoma ²	Male	2/50	2/50	0/50	6/50	$P_{\text{Trend}}=0.016$ $P_{\text{Hist}}=0.017$
Hemangiosarcoma ³	Male	0/50	0/50	0/50	2/50	$P_{\text{Trend}}=0.062$ $P_{\text{Hist}}=0.004$
Hemangioma ⁴	Female	0/50	0/50	2/50	5/50*	$P_{\text{Trend}}=0.002$
Lung Adenocarcinoma ⁵	Male	1/50	1/50	6/50	4/50	$P_{\text{Trend}}=0.148$ $P_{\text{Hist}}=0.140$
Number of animals with Malignant Neoplasms	Male	5/50	5/50	11/50	16/50**	$P_{\text{Trend}}=0.001$
Number of animals with Malignant Neoplasms	Female	9/50	13/50	16/50	13/50	$P_{\text{Trend}}=0.362$

*- $p_{\text{Fisher}} < 0.05$, **- $p_{\text{Fisher}} < 0.01$, ¹historical rate=0.44%, ²historical rate=2.6%, ³historical rate=0/1424 (0.26% - 95% confidence limit), ⁴No Historical Control Rate, ⁵Historical rate=2.5%

EPA^[61] only addressed the hemangiomas in the female mice and did not note any other significant effects. For the females, EPA argued that the high dose was approximately four times higher than the current recommended high dose from the **OECD guidelines**^[109]. This study was correctly designed under the previous guidelines (the limit was <5% in feed) and there is no indication that this dose exceeded the MTD. The EPA also argued that when the p-value for Fisher's Exact test was adjusted for multiple comparisons, the new p-value for the high-dose group for hemangiomas was 0.055.

For the hemangiosarcomas in males, none of the 26 historical control groups examined by **Giknis and Clifford (2000)** had hemangiosarcomas, making this a very rare tumor in males prior to 80 weeks on study. The malignant lymphomas in males are statistically significant against both the concurrent controls and the historical controls. Finally, there is clearly an overall increase of malignancies in the males.

In summary, this study shows a positive result for kidney adenomas, malignant lymphomas and hemangiosarcomas in male CD-1 mice, hemangiomas in female CD-1 mice and an overall increase in malignancies as a function of exposure in male CD-1 mice. This study will be included in the overall evaluation of causation.

Kumar (2001)^[84] exposed Swiss Albino mice to glyphosate (>95% purity) in feed for two years. Fifty animals/group/sex were tested in four exposure groups (see Table 13).

The survival was decreased in the highest exposure group but this was not statistically significant and there was no other data indicating the MTD was exceeded for this study.

Kidney adenomas ($p_{Trend}=0.062$) and malignant lymphomas ($p_{Trend}=0.064$, $p_{Hist}=0.070$) in male mice demonstrated marginal statistical significance and hemangiosarcomas ($p_{Trend}=0.500$) in male mice demonstrated no statistical significance. In this study, not all animals in the low- and mid- dose groups were evaluated for kidney tumors, so a second analysis was done based on only the animals examined in these two groups ($p_{Trend}=0.088$). No historical control data was available for hemangiosarcomas and kidney adenomas in Swiss Albino mice. For the malignant lymphomas, EFSA provided a historical control data set showing a mean response of 46/250=0.184 (18.4%) with a range of 6% to 30%. Using this historical control data, the trend is only marginally significant ($p_{Hist}=0.070$). I have some concern that the responses at two of the doses are outside of the historical control range and the third dose is at the upper limit of the historical control range. However, this is a small historical control dataset for a tumor with a relatively high background tumor rate, thus placing too much emphasis on this historical control population is not warranted.

In a recent memo, Martens (2017)^[110] asserts that the incidence counts for malignant lymphomas and kidney adenomas appearing in Greim et al. (2015)^[91] and EFSA (2013)^[89] are incorrect and provides different rates (shown in Table 13). The p-values for both of these tumors are reduced using the incidence counts from the Martens memo. However, it should be noted that if the counts for malignant lymphomas in the Martens (2017) memo are correct, then all three exposure groups have responses outside of the range of the historical controls. It is unclear from Greim et al. (2015), EFSA or Martens (2017) which tumor incidence counts are correct.

There was a significant increase in hemangiomas (any tissue) in female mice ($p_{Trend}=0.004$).

In summary, this study shows support for an increase for malignant lymphomas and kidney adenomas as a function of exposure in male Swiss Albino mice and an increase in hemangiomas in female Swiss Albino mice. This study will be included in the overall

Table 13: Tumors of interest in male and female Swiss Albino mice from the 18-month feeding study of **Kumar (2001)**^[84]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	14.5	149.7	1453	
	Female	0	15	151.2	1466.8	
Kidney Adenoma (only tissues examined microscopically)	Male	0/50	0/26	1/22	2/50	P _{Trend} =0.088
Kidney Adenoma (as reported by Greim et al.)	Male	0/50	0/50	1/50	2/50	P _{Trend} =0.062
Kidney Adenoma (as reported by Martens)	Male	0/50	0/50	0/50	1/50	P _{Trend} =0.250
Malignant Lymphoma ¹ (as reported by Greim et al.)	Male	10/50	15/50	16/50	19/50	P _{Trend} =0.064 P _{Hist} =0.070
Malignant Lymphoma ¹ (as reported by Martens)	Male	10/50	16/50	18/50	19/50*	P _{Trend} =0.141 P _{Hist} =0.150
Hemangiosarcoma	Male	0/50	0/50	2/50	0/50	P _{Trend} =0.500
Hemangioma (any tissue)	Female	1/50	0/50	0/50	5/50	P _{Trend} =0.004

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01, ¹Historical control rate=0.184 (46/250 mice)

evaluation of causation.

Pavkov and Turner (1987)^[85] exposed CD-1 mice to glyphosate trimesium salt (56.2%) and 1% propylene glycol (wet weight vehicle) in feed for two years. Eighty animals/sex/group were tested in control, low- and mid-dose groups and 90 animals/sex were tested at the high dose. Exposure levels were 0, 11.7, 118 and 991 mg/kg/day in males and 0, 16, 159 and 1341 mg/kg/day in females. EPA^[61] lists this study as completely negative for any cancer findings. No details on this study are provided by the EPA nor is it listed in the **Greim et al. (2015)**^[91] manuscript. There was limited information on this study in a Data Evaluation Report from EPA (accession number 4021 40-06) that discussed findings from this study. EPA noted that body weight and food consumption were reduced in the highest exposure group, but the actual amounts of these reductions were not available. They also noted that the authors failed to make it clear that the tumors reported in the study had been histopathologically validated. Data was presented for tumors in the livers and lungs of male mice and the lungs of female mice. No other data is provided.

This study is not acceptable for inclusion in the evaluation of causation due to the lack of information on the tumor incidence in tissues other than liver and lung.

George et al. (2010)^[82] exposed groups of 20 male Swiss Albino mice to a glyphosate

formulation (Roundup Original, 36g/L glyphosate) at a dose of 25 mg/kg (glyphosate equivalent dose) topically three times per week, topically once followed one week later by 12-o-tetradecanoylphorbol-13-acetate (TPA) three times per week, topically three times per week for three weeks followed one week later by TPA three times per week, or a single topical application of 7,12-dimethyl-benz[a]anthracene (DMBA) followed one week later by topical application of glyphosate three times per week for a total period of 32 weeks. Appropriate untreated, DMBA-treated, and TPA-treated controls were included. The group exposed to DMBA followed by glyphosate demonstrated a significant increase ($p < 0.05$) in the number of animals with tumors (40% of the treated animals versus no tumors in the controls) indicating glyphosate has a promotional effect on carcinogenesis in the two-stage model in skin. This study addresses the question of whether glyphosate is more likely to cause skin tumors through initiation (starting the cancer process) or promotion (moving the process along after it starts). This study supports the overall concept that glyphosate can have an impact on tumor incidence.

EPA^[61] discounted this study because it included only 20 animals per group, tested only males and did not conduct a histopathological analysis. It is hard to understand how EPA could reject a positive finding using 20 mice; typically one would ignore a negative study that had too few animals as not having sufficient statistical power to see an effect but never reject positive findings for this reason. Also, 20 animals per group is common for skin-painting initiation-promotion studies like the one presented here. Doing a study in only males is not a reason to ignore the positive findings in a study. Finally, in initiation-promotion studies of mouse skin, histopathological evaluation would be done if one were interested in separating papillomas from carcinomas. It is highly unlikely that the lesions seen in 40% of the DMBA/glyphosate treated mice were not papillomas or carcinomas.

Some members of the EPA SAP noted^[54] that the rodent data were consistent with glyphosate acting as a tumor promoter but, because “[t]here has been no direct test of this hypothesis (such as in a standard initiation-promotion bioassay)...,” this “conclusion was speculative.” (page #). Because the EPA dismissed this study without any discussion, the SAP did not recognize there was an initiation-promotion supporting a promotional effect of glyphosate.

This study is included in the evaluation of causality as support for a promotional effect of glyphosate on some tumors.

Joint Analysis - Mouse

In their evaluation of the mouse studies, EPA^[61] and EFSA^[89] chose to challenge the results in each study separately, dismiss the studies as showing no effect, and never compared results across the various studies. In response to the evaluation done by the IARC^[30], EFSA^[90] extracted the original data and did trend tests on kidney tumors, malignant lymphomas and hemangiosarcomas in male mice in five of the mouse studies, the same five studies I consider acceptable for a causation analysis. Rather than formally evaluate these cancer responses for consistency by pooling the data where appropriate, EPA and EFSA simply produced a table with the responses for each dose

group in each study and concluded (subjectively) they were inconsistent. In addition, EPA and EFSA argued that doses above 1000 mg/kg/day (there are only two of these) were outside the range of what would be tested today under OECD guidelines and should be excluded. I will now address both points.

In CD-1 mice, there are four useful animal carcinogenicity studies and one study in Swiss Albino mice. As with the rats, consistency across studies can be addressed in two ways. The first is by simply looking at the overall findings to evaluate where they agree or disagree in terms of statistical significance. Table 14 summarizes the positive and negative findings for all five cancers in which at least one study in CD-1 mice showed a significant trend. It is clear that not every tumor shows a positive trend with glyphosate exposure in every study. For hemangiosarcomas in males, there are clear positive findings in the studies by **Sugimoto (1997)** and **Atkinson et al. (1993)** and non-significant responses in **Wood et al. (2009)** and **Knezevich and Hogan (1983)**. In females, hemangiosarcomas are only present in the study by **Sugimoto (1997)**. Malignant lymphomas in males are clearly positive in two studies^[87, 88] and marginally positive in a third^[81] but negative in the fourth^[83]. Both of the strong positive studies exposed animals for 18 months. Kidney tumors in males are positive in two studies^[83, 87] and negative in the remaining two^[81, 88]. Lung adenocarcinomas in males are only positive in the study by **Wood et al. (2009)**. **Sugimoto (1997)** had four clearly positive associations between tumors and glyphosate while the others had two or less.

Table 14: Summary of significance tests for 5 tumors from 4 studies in CD-1 Mice

Study	Months on Study	Neoplasm				
		Hemangio-sarcoma (male)	Hemangioma (female)	Malignant Lymphoma (male)	Kidney Tumor (male)	Lung Adeno-carcinoma (male)
Sugimoto 1997 ^[87]	18	+ /+++ ¹	+++	++/++	+ /+++	-/-
Wood 2009 ^[88]	18	-/-	-	+++ /+++	-/-	++/++
Sugimoto & Wood Pooled		++/+++	+++	+++ /+++	++/+++	-/-
Atkinson 1993 ^[81]	24	+++ /+++	-	+ /+	-/-	-/-
Knezevich 1983 ^[83]	24	-/-	-	-/-	+ /++	-/-
Atkinson & Knezevich Pooled		-/-	-	-/-	+ /+	-/-
All CD-1 Studies Pooled		++/++	++/++	+ /+	+++ /+++	-/-

¹entries are p_{Trend}/p_{Hist} with values: - $p > 0.1$, + $0.1 \geq p > 0.05$, ++ $0.05 \geq p > 0.01$, +++ $p \leq 0.01$

As seen for the rat studies, this simple evaluation of the positive versus negative findings fails to resolve the issue of which findings are driving the overall responses in these data. To do this, I will again pool the studies. Table 14 summarizes the pooled analyses.

For kidney tumors in males, pooling the two 18-month studies yields significant increases in incidence ($p_{Trend}=0.015$, $p_{Hist}=0.003$) and pooling of the two year studies shows marginal significance ($p_{Trend}=0.081$, $p_{Hist}=0.054$). Pooling all four studies results in ($p_{Trend}=0.005$, $p_{Hist}=0.007$), thus the positive trend remains. **Knezevich and Hogan (1983)** saw a 4% response for kidney carcinomas in their highest exposure group. The largest response seen for kidney carcinomas in controls in 48 studies by **Giknis and Clifford (2000)** and in 52 studies by **Giknis and Clifford (2005)** was 2% and in the control groups from 11 two-year cancer studies, **Chandra and Frith (1992)**^[101] saw only one animal out of 725 with a kidney carcinoma. In 46 control datasets, **Giknis and Clifford (2000)** saw 39 control groups with no adenomas, five with one adenoma and two with two adenomas; both 24-month studies saw two adenomas in the highest exposure group, a very rare finding. To better illustrate, there are 16 groups of animals in the four studies. For any one group, there is a 2/44 or 4.3% chance of getting a response 4% or larger. The chances of randomly getting 3 or more such responses in 16 groups is 2.9% and the chances of two of these being in any two of the four highest exposure groups is 0.01. In summary, the strong finding in two of the four studies, the positive finding when all four studies are pooled and the very low probability that this is due to chance when compared to historical controls support the conclusion that glyphosate causes kidney tumors in male mice.

For malignant lymphomas in males, pooling the two 18-month studies, **Sugimoto (1997)** and **Wood et al. (2009)**, results in a significant trend ($p_{Trend}=0.005$, $p_{Hist}=0.006$). Pooling the two 24-month studies, **Knezevich and Hogan (1983)** and **Atkinson et al. (1993)**, yields ($p_{Trend}=0.653$, $p_{Hist}=0.649$). The main differences between these two findings is in the control response; the pooled control response at 24 months is 6/99 (6%) versus 2/101 at 18 months (2%). This is expected since, in the absence of any exposure, tumor rates increase as a function of age^[5]. **Giknis and Clifford (2000)** show a control response at 18 months of 4% and a control response at 24 months of 6% (matching the value for the pooled studies). Pooling all four studies results in ($p_{TrendA}=0.073$, $p_{Hist}=0.080$). However, the responses seen for malignant lymphomas in controls by **Giknis and Clifford (2000)** show only one historical control group in twenty-six 18-month groups with 10% or higher response. The responses at the high doses (10% and 12%) in the two 18-month studies are very unlikely to have arisen by chance. There are eight groups of animals in the two studies. For any one group, there is a 1/26 or 3.8% chance of getting a response of at least 10% based on the 26 control groups from **Giknis and Clifford (2000)**. The chances of getting two or more such responses in eight groups is 0.035 and the chances of these being in three of the four highest exposure groups is 0.004. For the 24-month studies, the higher background rate makes it difficult to identify a small change in incidence, thus the findings in the 24-month studies and the 18-month studies are not inconsistent. In summary, the very strong findings in the 18-month studies, the very strong positive findings when the two 18-month studies are pooled, the low probability that the responses seen in the 18-month studies are due to chance, and the

marginal increase in malignant lymphomas in the 18-month study in Swiss Albino mice^[84] support the conclusion that glyphosate causes malignant lymphoma in male mice.

For hemangiosarcomas in males, pooling the two 18-month studies results in a significant trend ($p_{Trend}=0.015$, $p_{Hist}=0.002$). Pooling the two 24-month studies yields ($p_{Trend}=0.490$, $p_{Hist}=0.429$). The main difference between these two findings is the 0/50 response in animals exposed at 4841 mg/kg/day in the study by **Knezevich and Hogan (1983)**. Removing this one exposure group in the pooled 24-month analysis yields ($p_{Trend}<0.001$, $p_{Hist}<0.001$). Pooling all four studies results in ($p_{Trend}=0.045$, $p_{Hist}=0.043$). No hemangiomas were seen in controls groups from twenty-six 18-month studies by **Giknis and Clifford (2000)** so the two hemangiosarcomas seen in the high dose group in the study by **Sugimoto (1997)** are biologically very significant. For the 24-month historical controls, only two out of 20 control groups had a response greater than 8%. In summary, the very strong findings in the 18-month studies, the positive finding when all four studies are pooled and the low probability that the responses seen in the 18-month studies are due to chance support the conclusion that glyphosate causes hemangiosarcomas in male CD-1 mice.

For hemangiomas in females, pooling the two 18-month studies results in a significant trend ($p_{Trend}=0.001$). Pooling the two-year studies results in $p_{Trend}=0.424$. Pooling all four studies results in $p_{Trend}=0.018$. In summary, the very strong findings in one 18-month study, the positive finding when all four studies are pooled and the low probability that the responses seen in the **Sugimoto (1997)** study are due to chance, support the conclusion that glyphosate causes hemangiomas in female CD-1 mice.

For lung adenocarcinomas in male CD-1 mice, pooling the two 18-month studies results shows no significant trend ($p_{Trend}=0.417$, $p_{Hist}=0.126$). Pooling the two 24 month studies yields ($p_{TrendA}=0.985$, $p_{Hist}=0.993$). Pooling all four studies results in ($p_{TrendA}=0.937$, $p_{Hist}=0.744$). In summary, the moderate findings in one 24 month study, and the negative finding when any studies are pooled suggest that the linkage between glyphosate and lung adenocarcinomas in male CD-1 mice is due to chance.

The one study in Swiss Albino mice^[84] was effectively negative for all endpoints except malignant lymphomas and kidney adenomas where marginally significant tumor responses were seen. Considering the findings for kidney adenomas in CD-1 mice, glyphosate may also cause kidney adenomas in male Swiss Albino mice from the study of **Kumar (2001)**.

To summarize the findings in mice, glyphosate causes hemangiosarcomas, kidney tumors and malignant lymphomas in male CD-1 mice and hemangiomas in female CD-1 mice after 18 months of exposure, kidney tumors in male CD-1 mice after 24 months exposure and possibly kidney adenomas in male Swiss albino mice. When 18-month and 24-month studies are pooled, there is a significant increase in hemangiosarcomas in male mice, hemangiomas in female mice and kidney tumors in male mice.

Discussion and Summary Animal Carcinogenicity Studies

As noted earlier, there has been a suggestion that using doses substantially larger than 1000 mg/kg/day exceeds the current limit dose set by the OECD. The only place in the **OECD guidance**^[67] that addresses a dose of 1000 mg/kg/day is in paragraph 23 which reads:

“For the chronic toxicity phase of the study, a full study using three dose levels may not be considered necessary, if it can be anticipated that a test at one dose level, equivalent to at least 1000 mg/kg body weight/day, is unlikely to produce adverse effects. This should be based on information from preliminary studies and a consideration that toxicity would not be expected, based upon data from structurally related substances. A limit of 1000 mg/kg body weight/day may apply except when human exposure indicates the need for a higher dose level to be used.”

This language does not preclude the use of a dose exceeding 1000 mg/kg/day nor does it advocate ignoring such doses when evaluating the results of an animal carcinogenicity study. In fact, the reasons for excluding a dose in an animal carcinogenicity study are clearly outlined in paragraph 90 within **OECD guidance**^[59] and reads:

“If the main objective of the study is to identify a cancer hazard, there is broad acceptance that the top dose should ideally provide some signs of toxicity such as slight depression of body weight gain (not more than 10%), without causing e.g., tissue necrosis or metabolic saturation and without substantially altering normal life span due to effects other than tumours. Excessive toxicity at the top dose level (or any other dose level) may compromise the usefulness of the study and/or quality of data generated. Criteria that have evolved for the selection of an adequate top dose level include: (in particular) toxicokinetics; saturation of absorption; results of previous repeated dose toxicity studies; the MOA and the MTD.”

While one study has a slight decrease in body-weight gain, there are no indications in any other studies of an exceedance in dose that would support ignoring the findings from any exposure group.

EPA^[33] uses a slightly different criteria to determine which dose to include or exclude based on an earlier OECD document. These are spelled out in EPA’s guideline document for carcinogenicity risk assessment^[33]

“Other signs of treatment-related toxicity associated with an excessive high dose may include (a) significant reduction of body weight gain (e.g., greater than 10%), (b) significant increases in abnormal behavioral and clinical signs, (c) significant changes in hematology or clinical chemistry, (d) saturation of absorption and detoxification mechanisms, or (e) marked changes in organ weight, morphology, and histopathology. It should be noted that practical upper limits have been established to avoid the use of excessively high doses in long-term carcinogenicity studies of environmental chemicals (e.g., 5% of the test substance in the feed for dietary studies or 1 g/kg body weight for oral gavage studies [OECD, 1981]).” As before, this applies to only one study presented in this review.

Both of these guidelines make good scientific sense. In the 12 acceptable rodent carcinogenicity studies included in this evaluation, no study had sufficient toxicity at the highest dose to justify removing the highest dose from the analysis. Hence, the analyses presented here did not drop the doses >1000 mg/kg/day. This is also supported by one member of the EPA's SAP^[54].

Twenty chronic rodent carcinogenicity studies have been done using glyphosate as the test compound. Eight of these studies are unacceptable for use in an evaluation of causality leaving seven studies in rats and five studies in mice. Because of the large number of evaluations done in an individual animal carcinogenicity study, there is concern that the false-positive rates could be exaggerated. For example, if 20 evaluations are done and a finding is deemed significant if $p_{Trend} < 0.05$, then you would expect that $20 * 0.05 = 1$ evaluation would be positive simply due to chance.

Table 15: Observed versus expected tumor sites with significant trends in the 12 acceptable rodent carcinogenicity studies using glyphosate.

Species	Strain	Sex	Total Sites ¹	Exp. <0.05	Obs. <0.05	Tumors ² p<0.05	Exp. <0.01	Obs. <0.01	Tumors p<0.01
Rat (7 studies)	Sprague-Dawley (4 studies)	M	86	4.3	4	TICT, TFAC, KA, HA	0.9	2	TICT, KA
		F	102	5.1	1	TCCC	1.0	1	TCCC
	Wistar (3 studies)	M	64.5	3.2	2	HA, SK	0.6	1	HA
		F	76.5	3.8	2	MC, MAC	0.8	1	MAC
Mouse (5 studies)	CD-1 (4 studies)	M	42	2.1	8	KA, KC, KAC, HS(2) ³ , ML(2), LAC	0.4	5	KA, KC, HS(2), ML
		F	60	3	1	H	0.6	1	H
	Albino (1 study)	M	10.5	0.5	0		0.1	0	
		F	15	0.8	1	H	0.2	1	H
Rats (7 studies)	All (7 studies)	M	150.5	7.5	6	TICT, KA, HA(2), TFAC, SK	1.5	3	TICT, KA, HA
		F	178.5	8.9	3	TCCC, MC, MAC	1.8	2	TCCC, MAC
		Both	329	16.5	9	TICT, KA, HA(2), TFAC, SK, TCCC, MC, MAC	3.3	5	TICT, KA, HA, TCCC, MAC
Mice (5 studies)	All (5 studies)	M	52.5	2.6	8	KA, KC, KAC, HS(2), ML(2), LAC	0.5	5	KA, KC, HS(2), ML
		F	75	3.8	2	H(2)	0.7	2	H(2)
		Both	127.5	6.4	10	KA, KC, KAC, HS(2) ³ , H(2), ML(2), LAC	1.3	7	KA, KC, HS(2), H(2), ML
All (12 studies)	All (12 studies)	M	203	10.1	14	TICT, KA(2), HA(2), TFAC, SK, KC, KAC, HS(2), ML(2), LAC	2.0	8	TICT, HA, KA(2), KC, HS(2), ML
		F	253.5	12.7	5	TCCC, MC, MAC, H(2)	2.5	4	TCCC, MAC, H(2)
		Both	456.5	22.8	19	TICT, KA(2), HA(2), TFAC, SK, KC, KAC, HS(2), H, ML(2), LAC, TCCC, MC, MAC	4.6	12	TICT, HA, KA(2), KC, HS(2), H(2), ML, TCCC, MAC

¹ Number of sites examined is based upon suggestions by Dr. J. Haseman in his written testimony to the EPA; male mice – 10.5 sites; female mice – 15 sites; male rats – 21.5 sites; female rats – 25.5 sites

² Tumor abbreviations are: KA – kidney adenoma; KC – kidney carcinoma; KAC – kidney adenoma or carcinoma; HS – hemangiosarcoma; H – hemangioma; HA – hepatocellular adenoma; LAC – lung adenoma or adenocarcinoma; ML – malignant lymphoma; MC – mammary gland carcinoma; MAC – mammary gland adenoma or carcinoma; TCCC – thyroid C-cell carcinoma; TFAC

– thyroid follicular cell adenoma or carcinoma; TICT – testes interstitial cell tumor; SK – skin keratocanthoma
³(x): x studies with this result

The EPA asked the SAP to comment on its evaluation of glyphosate^[61] at a meeting in Washington, DC in December 2016^[54]. Many comments were received from outside experts at this meeting; one such set of comments came from Dr. J. K. **Haseman (2016)**^[111]. **Haseman (2016)** directly addressed the false-positive error rate and concluded that the results seen in these studies were due to chance. He did this by deciding how many evaluations were likely for each study (broken into sex-by-species groups) and then aggregating the findings. He concluded that the effective number of analyses were 10.5 in male mice, 15 for female mice, 21.5 for male rats, and 25.5 for female rats. **Haseman (2016)** made two assumptions in his analysis that are not valid. The first was that all of the possible trend tests had been done on all of the sites he considered reasonable for such an evaluation. He identified eight positive findings. However, EPA had not evaluated all of the sites nor had they considered doing a formal analysis using historical control data. EPA identified eight sex/species groups that had at most one positive tumor finding using the trend test with $p_{Trend} \leq 0.05$. In Tables 1-14 above, I have identified 19 tumors with $p_{Trend} \leq 0.05$ or $p_{Hist} \leq 0.05$ and 12 with $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ (Table 15). Secondly, Dr. Haseman assumed one could aggregate all the studies into one large analysis of Type-1 error. However, inference in these studies is always made by sex/species/strain (e.g. glyphosate causes hemangiosarcomas in male CD-1 mice; not glyphosate causes cancer in rodents), and the analysis should have been done by grouping each separately. Table 15 shows these analyses as well as the aggregated analysis for all of the acceptable studies.

With the exception of male Sprague-Dawley rats, the observed number of tumors are at or near the expected number for the different sex/strain groups in rats (Table 15). For male Sprague-Dawley rats, 0.8 cases with $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ are expected and two were observed ($p=0.21$). In female CD-1 mice and Swiss Albino mice, the expected and observed numbers are approximately equal. However, in male CD-1 mice, there were 2.1 tumors expected for $p_{Trend} \leq 0.05$ or $p_{Hist} \leq 0.05$ and eight were observed ($p < 0.001$) and there were 0.4 expected for $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ and five were observed ($p < 0.001$). This clearly could not have occurred by chance alone. Even if one incorrectly groups all sexes and species together, there are 4.6 expected responses for $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ and 12 observed ($p < 0.001$). Thus, chance does not explain the positive results seen in these studies.

Conclusion for Animal Carcinogenicity Studies

There are several general issues that pertain to all animal carcinogenicity studies. There is considerable genetic variability across animal strains both over time and space. It is difficult to compare experiments done in different laboratories even when using the same strain of animal. This is obvious when you examine the rates for hepatocellular adenomas in Wistar rats across the three studies using this strain. Thus, each study

should be considered separately with regard to the findings in that study before being compared across studies.

The use of a p-value of 0.05 as the cut off for increasing tumor incidence does not account for trends in the data across multiple studies. Three studies with marginal responses of 6-8% in a given tumor could, when pooled for analysis, lead to highly significant findings. This issue is well-recognized in epidemiology but not usually considered in toxicology because of a lack of replicate studies. This case is fairly unique because of the larger number of studies available for analysis and requires a more rigorous evaluation of the data such as the pooled analysis presented in this report.

Pooling of the data for the evaluation of replicate studies makes sense as it addresses the question “Does the data as a whole support a finding of increased cancer incidence in these studies?” Some toxicologists may argue that the studies are not replicates and hence cannot be pooled. But if they are not replicates, then they cannot be compared to see if there is consistency across the studies. This is because there may be some subtle change from one study to another that leads to a positive finding in one study but a negative finding in other studies. Thus, either the studies are not good replicates so you cannot compare across studies and you cannot pool them, or they are good replicates so you can compare across studies and you can pool them. There is no argument that would support a comparison across studies that is appropriate when pooling is inappropriate.

There were seven rat studies and five mouse studies that were of sufficient quality and with sufficient details available for inclusion in this evaluation.

Glyphosate has been demonstrated to cause cancer in two strains of rats and one strain of mice. Glyphosate causes hepatocellular adenomas in male Wistar rats and, to a lesser degree, in male Sprague-Dawley rats, mammary gland adenomas and adenocarcinomas in female Wistar rats, skin keratocanthomas in male Wistar rats, and kidney adenomas and thyroid C-cell adenomas and carcinomas in male Sprague-Dawley rats. Glyphosate causes hemangiosarcomas, kidney tumors and malignant lymphomas in male CD-1 mice and hemangiomas in female CD-1 mice and possibly causes malignant lymphomas, kidney adenomas in male Swiss albino mice and hemangiomas in female Swiss albino mice. Thus, glyphosate causes cancer in mammals.

Mechanisms Relating to Carcinogenicity

Many human carcinogens act via a variety of mechanisms causing various biological changes, taking cells through multiple stages from functioning normally to becoming invasive with little or no growth control (carcinogenic). **Hanahan and Weinberg (2011)**^[112] identified morphological changes in cells as they progress through this multistage process and correlated these with genetic alterations to develop what they refer to as the “hallmarks of cancer.” These hallmarks deal with the entire process of carcinogenesis and not necessarily with the reasons that cells begin this process or the early stages in the process where normal protective systems within the cells remove

potentially cancerous cells from the body. While tumors that arise from a chemical insult to the cell may be distinct from other tumors by mutational analysis, they all exhibit the hallmarks as described by **Hanahan and Weinberg (2011)**.

Systematic review of all data on the mechanisms by which a chemical causes cancer is complicated by the absence of widely accepted methods for evaluating mechanistic data to arrive at an objective conclusion on human hazards associated with carcinogenesis. Such systematic methods exist in other contexts^[113], but are only now being accepted as a means of evaluating literature in toxicological evaluations^[114-117].

In this portion of the report, I am focusing on the mechanisms that can cause cancer. **Smith et al. (2015)**^[37] discussed the use of systematic review methods in identifying and using key information from the literature to characterize the mechanisms by which a chemical causes cancer. They identified 10 “Key Characteristics of Cancer” useful in facilitating a systematic and uniform approach to evaluating mechanistic data relevant to carcinogens. These 10 characteristics are presented in Table 16 (copied from Table 1 of **Smith et al. (2015)**^[37]). While there is limited evidence on glyphosate for most of the key characteristics, genotoxicity (characteristic two) and oxidative stress (characteristic five) have sufficient evidence to warrant a full review.

Genotoxicity

Genotoxicity refers to the ability of an agent (chemical or otherwise) to damage the genetic material within a cell, thus increasing the risks for a mutation. Genotoxic substances interact with the genetic material, including DNA sequence and structure, to damage cells. DNA damage can occur in several different ways, including single- and double-strand breaks, cross-links between DNA bases and proteins, formation of micronuclei and chemical additions to the DNA.

Just because a chemical can damage DNA does not mean it will cause mutations. So, while all chemicals that cause mutations are genotoxic, all genotoxic chemicals are not necessarily mutagens. Does that mean that the genotoxicity of a chemical can be ignored if all assays used for identifying mutations in cells following exposure to a chemical are negative? The answer to that question is no and is tied to the limitations in tests for mutagenicity (the ability of a chemical to cause mutations in a cell). It is unusual to see an evaluation of the sequence of the entire genome before exposure with the same sequence after exposure to determine if the genome has been altered (mutation). There are assays that can evaluate a critical set of genes that have previously been associated with cancer outcomes (e.g. cancer oncogenes), but these are seldom applied. In general, mutagenicity tests are limited in the numbers of genes they actually screen and the manner in which these screens work.

Because screening for mutagenicity is limited in scope, any genetic damage caused by chemicals should raise concerns because of the possibility of a mutation arising from that genetic damage. In what follows, I will systematically review the scientific findings available for evaluating the genotoxic potential of glyphosate. This will be divided into six separate sources of data based on the biological source of that data: (1) data from exposed humans, (2) data from exposed human cells in a laboratory setting, (3) data

from exposed mammals (non-human), (4) data from exposed cells of mammals (non-human) in the laboratory, (5) data from non-mammalian animals and others, and (5) data from cells from non-mammalian animals and others. These six areas are based upon the priorities one would apply to the data in terms of impacts. Seeing genotoxicity in humans is more important than seeing genotoxicity in other mammals, which is more important than seeing genotoxicity in non-mammalian systems. In addition, seeing genotoxicity in whole, living organisms (*in vivo*) carries greater weight than seeing responses in cells in the laboratory (*in vitro*). Basically, the closer the findings are to real, living human beings, the more weight they should be given.

Table 16: Key characteristics of carcinogens, **Smith et al. (2016)**^[37]

Characteristic	Examples of relevant evidence
1. Is electrophilic or can be metabolically activated	Parent compound or metabolite with an electrophilic structure (e.g., epoxide, quinone), formation of DNA and protein adducts
2. Is genotoxic	DNA damage (DNA strand breaks, DNA–protein cross-links, unscheduled DNA synthesis), intercalation, gene mutations, cytogenetic changes (e.g., chromosome aberrations, micronuclei)
3. Alters DNA repair or causes genomic instability	Alterations of DNA replication or repair (e.g., topoisomerase II, base-excision or double-strand break repair)
4. Induces epigenetic alterations	DNA methylation, histone modification, microRNA expression
5. Induces oxidative stress	Oxygen radicals, oxidative stress, oxidative damage to macromolecules (e.g., DNA, lipids)
6. Induces chronic inflammation	Elevated white blood cells, myeloperoxidase activity, altered cytokine and/or chemokine production
7. Is immunosuppressive	Decreased immunosurveillance, immune system dysfunction
8. Modulates receptor-mediated effects	Receptor in/activation (e.g., ER, PPAR, AhR) or modulation of endogenous ligands (including hormones)
9. Causes immortalization	Inhibition of senescence, cell transformation
10. Alters cell proliferation, cell death or nutrient supply	Increased proliferation, decreased apoptosis, changes in growth factors, energetics and signaling pathways related to cellular replication or cell cycle control, angiogenesis

Abbreviations: AhR, aryl hydrocarbon receptor; ER, estrogen receptor; PPAR, peroxisome proliferator–activated receptor. Any of the 10 characteristics in this table could interact with any other (e.g., oxidative stress, DNA damage, and chronic inflammation), which when combined provides stronger evidence for a cancer mechanism than would oxidative stress alone.

The data being included in this review come from the peer-reviewed scientific literature, the summaries of reports in regulatory documents that are proprietary and for which I have limited access to the original work, and reports from industry that are proprietary to which I have been given greater access. All of these studies are included in the overall evaluation of causation.

Genotoxicity in Humans *in-vivo*

Three studies have evaluated the potential genotoxicity of glyphosate formulations in exposed humans. **Paz-y-Miño et al. (2007)**^[118] analyzed the blood of 24 exposed individuals (living within 3 kilometers of spraying) and 21 unexposed individuals (living 80 kilometers away from the spraying area) for DNA damage using the comet assay. All study subjects were from Ecuador and none of the controls or exposed individuals smoked, drank alcohol, took non-prescription drugs or had been exposed to pesticides during the course of their normal daily lives. Exposed and control individuals did some cultivating and harvesting but without pesticides or herbicides. Exposed individuals were analyzed within two months of spraying for the eradication of plants associated with illegal narcotics. An average of 200 cells per person were ranked between 0-400 depending on the amount of DNA in the comet's tail in order to calculate the mean amount of DNA damage. There was a significant difference between the mean total migration level of exposed individuals to controls ($p < 0.001$). Data was given for each individual classified into five groups based upon the amount of DNA in the comet's tail. There was clearly a shift in the distribution of DNA in cells with the controls never seeing scores in the top two categories while all but three exposed had some scores in the top two categories. In essence, some of the DNA had been fragmented by the exposure.

In a second study by the same group, **Paz-y-Miño et al. (2011)**^[119] evaluated the karyotypes (the chromosome count of the individuals and any alterations to the chromosomes as seen under a microscope) of 92 people living in 10 communities in northern Ecuador. Controls were from areas without spraying and both controls and exposed subjects had no history of exposure to smoking or other genotoxic compounds. This study saw no changes between controls and exposed subjects for 182 karyotypes evaluated.

Bolognesi et al. (2009)^[120] studied women of reproductive age and their spouses in five areas of Colombia, four of which are subject to spraying for either narcotics control or sugar cane growing. There were 60 subjects from the Santa Marta area (organic coffee is grown without the use of pesticides), 52 from Boyaca (manual spraying for illicit drugs), 58 from Putumayo (aerial spraying for illicit drugs using a glyphosate formulation), 63 from Nariño (same exposure as Putumayo) and 28 from Valle del Cauca (aerial spraying of Roundup 747 (74.7% glyphosate) without additional adjuvant for sugar cane maturation). All subjects were interviewed with a standardized questionnaire designed to obtain information about current health status, health history, lifestyle and potential exposure to possible confounding factors (smoking, use of medicinal products, severe infections or viral diseases during the last six months, recent vaccinations, presence of known indoor/outdoor pollutants, exposure to diagnostic x-rays, and previous radio- or chemotherapy). In Santa Marta, blood samples were taken

once, during the initial interview. In Boyaca, blood samples were taken at the initial interview and 1 month later. In Nariño, Putumayo and Valle del Cauca, blood samples were taken at the initial interview, within five days after spraying and 4 months later. In lymphocytes, binucleated cells with micronuclei (BNMN) were lowest in Santa Marta and similar in the four exposed regions prior to exposure. Statistically significant increases in BMNM in Nariño, Putumayo and Valle del Cauca were seen between first and second sampling. The mean BMNM in Nariño and Putumayo was greater in respondents who self-reported direct contact with sprayed fields, but differences were not statistically significant. Multiple linear regression demonstrated statistically significant increases in BMNM in all four exposed regions post exposure when compared to pre-exposure and controlling for all other variables ($p < 0.001$). The largest total change in mean BMNM values pre-exposure compared to immediate post exposure occurred in Valle del Cauca where spraying is done using Roundup with no additional adjuvant.

Kier (2015)^[121] identified 16 additional studies of pesticide use that included some exposure to glyphosate. Eleven of the 16 studies demonstrated some degree of genotoxicity in the human populations studied but did not adequately attribute the exposure primarily to glyphosate so they are not included in this review.

In summary, two of the three studies in which genotoxicity endpoints were evaluated in humans in areas with exposure to glyphosate spraying showed statistically increased changes in DNA damage in blood. In the strongest study, in three areas where chromosomal damage (micronuclei) was examined in individuals pre- and post-spraying (<5 days) showed statistically significant increases. In one other area where post-exposure damage was measured one month after exposure, there was little change.

Genotoxicity in Human Cells (*in vitro*)

Studies have explored the *in vitro* genotoxicity of glyphosate using a variety of different cell types (lymphocytes, fibroblasts, and immortalized cells from cancers of the larynx, mouth, blood and liver) using several different assays for markers of genotoxicity with or without metabolic activation.

Mladinic et al. (2009)^[122] induced DNA strand breaks (comet assay) from exposure to glyphosate (purity not given) in lymphocytes from three healthy human donors (questionnaire used to exclude genotoxic exposures) at concentrations of 3.5, 92.8 and 580 $\mu\text{g}/\text{ml}$ with S9 activation and saw effects at only the highest doses for cells without S9 activation.

Alvarez-Moya et al. (2014)^[123] conducted a similar study using lymphocytes from human volunteers (questionnaire used to exclude genotoxic exposures) and exposure to glyphosate (96% purity) at concentrations of 0.12, 1.2, 12 and 120 $\mu\text{g}/\text{ml}$. A significant increase in DNA strand breaks (comet assay) was seen for all exposure groups with a clear dose-response relationship without metabolic activation (metabolic activation was not tested).

Using human HEP-2 cells, **Manas et al. (2009)**^[124] induced DNA damage (comet assay) by

glyphosate (96% pure) at all concentrations ranging from 676 µg/ml to 1270 µg/ml (no S9 activation tested). Cell viability at the highest concentration was below 80% and values at the other concentrations were not given.

Monroy et al. (2005)^[125] induced significant DNA damage (comet assay) in fibroblast GM 38 cells at concentrations of glyphosate (technical grade, purity not given) ranging from 676 µg/ml to 1000 µg/ml with a clear dose-response pattern. Over this same concentration range, they also saw concentration-dependent decreases in cell viability at all doses making the comet assay results difficult to interpret. In a similar analysis in the same paper, using fibrosarcoma HT1080 cells, they also saw concentration-dependent DNA damage and loss of cell viability. Activation by S9 was not used in either experiment.

Lueken et al. (2004)^[126] induced DNA damage (comet assay) in fibroblasts GM 5757 at a concentration of glyphosate (98.4% purity) of 12,680 µg/ml in combination with exposure to 40 or 50 mM H₂O₂. Activation by S9 was not used in this experiment. According to the authors, cell viability at this exposure level was above 80%.

Koller et al. (2012)^[127] significantly induced DNA damage (comet assay) in human TR146 cells (buccal carcinoma cells) from exposure to glyphosate (>95% purity) in a dose-dependent fashion at concentrations of 20 and 40 µg/ml. Above 40 µg/ml, there was a significant increase in tail intensity relative to controls, but the actual amount increased did not change as the dose increased (plateau). Using Roundup (Ultra Max) the authors saw virtually the same level of DNA damage at 20 and 40 µg/ml, but the concentration response continued to increase above that exposure. These experiments did not use S9 activation. They also used the CBMN assay in the same system to evaluate the total number of micronuclei in binucleated cells (MNI), the number of binucleated cells with micronuclei (BN-MNI), the number of nuclear buds (NB) and the number of nucleoplasmic bridges (NPB) caused by glyphosate and Roundup exposure. Two endpoints (NB, NPB) had significant increases at concentrations of 10, 15 and 20 µg/ml and two (MNI, BN-MNI) were significantly elevated for concentrations of 15 and 20 µg/ml. Equivalent Roundup exposures resulted in significant increases in all four measures of DNA damage at 10, 15 and 20 µg/ml. The results for the Roundup were greater than for glyphosate alone.

Gasnier et al. (2009)^[128] exposed cells from the hepatoma cell line HepG2 to glyphosate (purity not given) and four glyphosate formulations. Only one glyphosate formulation was tested for DNA damage (comet assay) and they saw significant effects at equivalent concentrations of 0.05 µg/ml to 4 µg/ml of glyphosate (p-values not given). No p-values are provided and presentation of the results does not provide a clear means to compare these results with other studies. This study will not be used in the evaluation.

Manas et al. (2009)^[124] obtained human blood samples from three healthy, non-smoking women and three healthy men with no history of pesticide exposure. Lymphocytes were cultured with glyphosate (96% purity) at concentrations of 34, 203, and 1015 µg/ml with no statistically significant changes in chromatid breaks,

chromosome breaks, chromatid gaps, chromosome gaps, dicentrics, acentric fragments, or endoreduplication.

Mladinic et al. (2009)^[129] used blood from three non-smoking, healthy volunteers to evaluate the formation of micronuclei, nuclear buds and nucleoplasmic bridges as a function of exposure to glyphosate (98% purity). Significant changes in micronuclei were seen following exposure to glyphosate at 92.8 and 580 µg/ml in S9 activated cells, but not those without metabolic activation. Changes in nuclear buds were seen at 580 µg/ml for both S9 activated and non-activated cells while significant changes in nucleoplasmic bridges were seen only at 580 µg/ml in S9 activated cells. This study contained a positive control (ethyl methanesulfonate at 200 µg/ml) which was also negative in all assays, many times showing effects below that seen for glyphosate.

Bolognesi et al. (1997)^[130] obtained blood from two healthy female donors and exposed it to glyphosate (99.9% purity) or a Roundup formulation (30.4% glyphosate). At concentrations of 1000, 3000 and 6000 µg/ml of glyphosate and at 100 and 330 µg/ml of glyphosate formulation, significant changes in sister chromatid exchanges (SCEs) were seen. At 330 µg/ml, a non-significant increase in SCEs was seen for glyphosate alone that was approximately 20% below that seen for an equivalent glyphosate exposure from the Roundup formulation. This study did not consider S9 activation.

Lioi et al. (1998)^[124, 131] obtained blood from three healthy donors and exposed it to glyphosate (>98% purity). At concentrations of 1.4, 2.9, and 8.7 µg/ml of glyphosate, significant changes in sister chromatid exchanges (SCEs) and chromosomal aberrations were seen. This study did not consider S9 activation.

Vigfusson and Vyse (1980)^[132] exposed cultured human lymphocytes from two people to Roundup (% glyphosate unknown) at concentrations of 250, 2500 and 25000 µg/ml. Results for the highest concentration were not provided due to lack of cell growth in culture. SCEs were shown to be significantly increased for the remaining two concentrations in one donor and only for the lowest concentration in the other. While the relative SCE counts seen in this paper are similar to those from **Bolognesi et al. (1997)**, the absolute counts in the controls are roughly three times higher in this study. This study did not consider S9 activation.

Genotoxicity in Non-Human Mammals (*in vivo*)

Bolognesi et al. (1997)^[130] exposed groups of three Swiss CD-1 male mice by intraperitoneal (IP) injection with a single dose of glyphosate (99.9% purity, 300 mg/kg) or Roundup (900 mg/kg, equivalent to 270 mg/kg glyphosate). Animals were sacrificed at four and 24 hours after injection and livers and kidney were removed to obtain crude nuclei from the adhering tissues. Both tissues demonstrated significant increases in DNA single-strand breaks ($p < 0.05$) at four hours for both glyphosate and Roundup with no discernable difference between the responses. At 24 hours, the presence of strand breaks was reduced and no longer statistically significant from controls.

Peluso et al. (1998)^[133] exposed groups of six (controls, lowest doses of glyphosate-salt and Roundup) or three Swiss CD-1 mice (males and females, specific numbers not

specified, liver and kidney tissues combined for analysis) to the isopropylammonium salt of glyphosate or Roundup (30.4% isopropylammonium salt of glyphosate) for 24 hours. DNA adducts (^{32}P -DNA post labeling) were not evident in mice exposed to the glyphosate-salt alone in either liver or kidney, but were present in liver and kidney at all tested doses of Roundup showing a dose-response pattern.

Rank et al. (1993)^[134] exposed male and female NMRI mice (three to five per sex) to glyphosate isopropylamine salt (purity not specified) and Roundup (480 g glyphosate isopropylamine salt per liter) by intraperitoneal injection. After 24 or 48 hours (only 24 hours for Roundup), polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 1000 cells. No significant increases were seen for any concentration in glyphosate-exposed animals (100, 150 and 200 mg/kg) or Roundup-exposed animals (133 and 200 mg/kg glyphosate equivalent dose). The positive controls, while not statistically significant, showed an increase in micronuclei.

Bolognesi et al (1997)^[130] exposed groups of three, four or six male Swiss CD-1 mice to glyphosate (99.9% purity) and Roundup (30.4% glyphosate) by intraperitoneal injection in two equal doses given 24 hours apart. After six or 24 hours following the last exposure, polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 1000 cells. Mice given two doses of 150 mg/kg of glyphosate showed a non-significant increase in micronuclei at 6 hours and a significant increase at 24 hours. In contrast, mice given two doses of 225 mg/kg glyphosate equivalent of Roundup showed a significant increase in micronuclei at both six and 24 hours. The relative differences in mean absolute increase (subtract mean response in controls) in micronuclei between glyphosate and Roundup at 24 hours was 3.6 whereas the relative difference in glyphosate equivalent dose was 1.5 indicating a greater effect of the glyphosate formulation.

Manas et al. (2009)^[124] exposed groups of male and female Balb C mice (group size not given, tissues combined for analysis) to glyphosate (96% purity) by intraperitoneal injection in two equal doses given 24 hours apart. Twenty-four hours post exposure, polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 1000 cells. No significant increases were seen at doses of 50 mg/kg and 100 mg/kg in glyphosate-exposed animals but a significant increase was seen at 400 mg/kg. The positive controls showed a statistically significant increase in micronuclei (roughly three times the control rate).

Dimitrov et al. (2006)^[135] exposed groups of eight male C57BL mice (tissues combined for analysis) to Roundup (41% glyphosate) via gavage at a dose of 1080 mg/kg. At 6, 24, 72, 96, or 120 hours post exposure, polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 4000 cells (500 per animal). No significant increases were seen. They also looked for chromosomal damage in these animals and saw no significant increases. The positive controls showed a statistically significant increase in micronuclei.

Prasad et al. (2009)^[136] exposed groups of 15 male Swiss CD-1 mice to Roundup (30.4% glyphosate) by IP injection at doses of 25 and 50 mg/kg. At 24, 48 or 72 hours post

exposure, polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 2000 cells per animal, five animals per sacrifice. Micronuclei counts were significantly increased ($p < 0.05$) at all doses at all times relative to controls. In addition, the number of cells with chromosomal aberrations was significantly increased for all doses at all times. The control rate of micronuclei was similar to that of **Bolognesi et al. (1997)**, but about 50% greater response for a dose that was approximately 10 times smaller.

Grisolia et al. (2002)^[137] exposed groups of Swiss mice (sex and sample size not given) to Roundup (480 g glyphosate isopropylamine salt per liter) by IP injection at doses of 50, 100 and 200 mg/kg Roundup in two doses separated by 24 hours. At 24 hours post exposure, polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 2000 cells per animal. Micronuclei counts were not increased at any dose. This exposure appears to be the same formulation of Roundup used in the study by **Rank et al. (1993)** which was also negative.

Coutinho do Nascimento and Grisolia (2000)^[138] exposed groups of six male mice (strain not given) to Roundup (% glyphosate not given) by IP injection at doses of 50, 100 and 200 mg/kg in two doses separated by 24 hours. At 24 hours post exposure, polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 1000 cells per animal. A significant increase in micronuclei were seen at a dose of 85 mg/kg. No increase was seen at 42 or 170 mg/kg.

Cavusoglu et al. (2011)^[139] exposed groups of six Swiss albino mice by IP injection with a single dose of glyphosate formulation (RoundupUltra Max, 450 g/l glyphosate, 50 mg/kg glyphosate equivalent dose). Animals were sacrificed at three days after injection. Micronuclei in normochromatic erythrocytes were counted from a sample of 1000 cells per animal. There was a significant increase in micronuclei in erythrocytes ($p < 0.05$). *G. bilboa* eliminated these effects.

Chan and Mahler (1992)^[140] exposed groups of 10 male and female B6C3F₁ mice to glyphosate (98.6% purity) in feed at doses of 0, 507, 1065, 2273, 4776, and 10780 mg/kg in males and 0, 753, 1411, 2707, 5846, and 11977 mg/kg in females for 13 weeks. At sacrifice, polychromatic erythrocytes from peripheral blood were extracted and micronuclei counted from a sample of 10,000 cells. No significant increases were seen at any of the tested doses.

Li and Long (1988)^[141] exposed groups of 18 male and female Sprague-Dawley rats to glyphosate (98% purity) by IP injection at a dose of 1000 mg/kg. At 6, 12 and 24 hours post treatment, 6 animals of each sex were sacrificed and polychromatic erythrocytes from bone marrow were extracted and micronuclei counted from a sample of 50 cells per animal. The percentage of cells with chromosomal aberrations was not increased at any time point following exposure.

Genotoxicity in Non-Human Mammalian Cells (*in vitro*)

Li and Long (1988)^[141] incubated Chinese hamster ovary cells (CHO-K1BH4) with glyphosate (98% purity) for three hours at concentrations of 5, 10, 50 and 100 mg/ml.

Cells were then plated using 200 cells per sample in triplicate and incubated for 8-12 days. Colonies were then counted and results expressed as mutant frequency. No positive results were seen in any experimental group with or without S9 activation. It is not clear why there is such a large difference in the incubation times in the various groups in this experiment, nor is it clear which groups incubated longer. In a second study in the same publication, non-induced primary rat hepatocytes (Fischer 344) were incubated with seven concentrations of glyphosate (12.5 ng/ml to 125 µg/ml) for 18-20 hours. No significant increases were seen for net grains per nucleus at any exposure concentration. There was a four-fold increase in the lowest exposure groups relative to controls and then every other treated group was below the control response. This is a very unusual finding and could be due to the way in which the data is adjusted for net grains in cytoplasm. The authors calculated net grains per nucleus by subtracting the highest cytoplasmic count from the nuclear count; if cytoplasmic count is increased by glyphosate this could bias the findings making any increase in nuclear count disappear. No data is provided to resolve this issue.

Roustan et al. (2014)^[142] incubated Chinese hamster ovary cells (CHO-K1) with glyphosate (purity not provided) for three hours at concentrations of 2, 5, 10, 15, 17.5, 20, and 22.5 mg/ml. Cells were then plated using 200 cells per sample in triplicate and incubated for 24 hours. For each exposure concentration, 2000 bi-nucleated cells were examined for micronuclei. No positive results were seen in any experimental group without S9 activation but the four highest exposure groups were significant with a clear concentration-response pattern when S9 activation was present.

Lioi et al. (1998)^[131] exposed lymphocytes from three unrelated healthy cows to glyphosate (>98% purity) for 72 hours to concentrations of 3, 14.4 and 28.7 µg/ml without S9 activation. Chromosomal aberrations scored from 150 cells were significantly increased ($P < 0.05$) for all exposure concentrations of glyphosate with a clear concentration-response pattern. Similarly, SCEs per cell were increased at all concentrations ($p < 0.05$) but no concentration response pattern was evident.

Sivikova and Dianovsky (2006)^[143] exposed lymphocytes from two healthy young bovine bulls to glyphosate formulation (62% glyphosate) for 2, 24 and 48 hours using concentrations of 4.7, 9.5, 23.6, 47.3, 94.6 and 190 µg/ml without S9 activation. Chromosomal aberrations scored from 100 cells were not significantly increased ($P < 0.05$) without S9 activation for any 24-hour exposure concentration of glyphosate (2- and 48-hours exposures were not done). SCEs per cell were increased at all 24-hour exposure concentrations ($p < 0.05$) except the lowest concentration. At 48-hours, significant increases of SCEs per cell were seen at concentrations at or above 47.3 µg/ml (2-hour exposures were not done). Finally, after two hours of exposure with S9 activation, significant effects were seen at 5 and 10 µg/ml but not at 15 µg/ml (24- and 48-hour exposures were not done for S9 activation).

Holeckova (2006)^[144] exposed lymphocytes from two healthy young bovine bulls to glyphosate formulation (62% glyphosate) for 24 hours to concentrations ranging from 28 to 1120 µmol/L without S9 activation. A significant increase in polyploidy was observed at 56 µmol/L, all other comparisons were without significance. However, this

one finding cannot be easily dismissed because all exposure groups above this concentration had too few cells for evaluation. This study did not consider S9 activation.

Genotoxicity in Non-Human Systems (*in vivo* and *in vitro*)

Four studies^[123, 145-147] in fish have seen positive results for genotoxicity (DNA strand breaks, different assays) following exposure to glyphosate. In addition, one study^[148] in oyster sperm and embryos exposed to glyphosate saw no increase in DNA damage (comet assay) and one study^[149] in two strains of *Drosophila melanogaster* showed an increase in mutations (wing spot test) at the higher doses of exposure.

Fourteen studies^[137, 145, 147, 150-160] in multiple fish species evaluated the relationship between various glyphosate formulations and genotoxicity with all studies showing positive results for various endpoints (DNA strand breaks, micronucleus formation, and chromosomal aberrations). Two of the studies^[150, 152] were negative for micronucleus formation after exposure to glyphosate formulations and one of these^[150] was also negative for chromosomal aberrations but both were positive in other markers of genotoxicity. Two studies^[161, 162] demonstrated genotoxicity (DNA strand breaks, micronuclei) in caiman from *in-vivo* exposure to a glyphosate formulation. Three studies^[163-165] demonstrated genotoxicity (DNA strand breaks, micronucleus formation) in frogs or tadpoles from exposure to glyphosate formulations. One study^[148] in oyster sperm and embryos, one study^[166] in clams and one study^[167] in mussels exposed to a glyphosate formulation saw no increase in DNA damage (comet assay). One study^[168] in snails saw increased DNA damage (comet assay) following exposure to a glyphosate formulation. Two studies^[169, 170] in worms saw mixed results for DNA damage (comet assay) with one of these studies^[169] showing a positive result for micronucleus formation. One study^[171] in *Drosophila melanogaster* showed an increase in sex-linked recessive lethal mutations.

In the published literature, five studies evaluated the impact of glyphosate in *in vitro* systems. Two of these studies^[172, 173] looked at genotoxicity of glyphosate in combination with UVB radiation and saw significant increases in DNA strand breaks (FADU assay) in bacteria without metabolic activation. One study^[174] in eukaryote fish saw a significant increase in DNA strand breaks (comet assay) without S9 activation. Another study^[141] showed no increase in reverse mutations in two strains of bacteria with and without S9 activation.

Williams et al. (2000)^[175] summarized the literature regarding the use of reverse mutation assays in *S. typhimurium* (Ames Test). Four studies using glyphosate and five studies of glyphosate formulations were all negative. They cited one study^[134] of a glyphosate formulation that was positive with S9 activation and negative without S9 activation. However, this study was positive with S9 activation in TA100 cells, negative with S9 activation in TA98 cells, negative without S9 activation for TA100 cells and positive without activation for TA98 cells. They also summarized two studies of glyphosate in *e. coli* that were negative with and without activation.

Two additional studies^[141, 176] of glyphosate using reverse mutation assays are available

from the scientific literature, both of which are negative.

Regulatory Studies

EFSA^[89] cited 14 reverse mutation assays in *S. typhimurium* (Ames Test), most of which were tested in strains TA 98, 100, 1535, 1537 (Table B.6.4-1). All 14 studies are listed as negative by EFSA. Actual data is provided for only one of the 14 studies and this study is clearly negative. EPA^[61] cited 27 reverse mutation assays in *S. typhimurium* (Ames Test), most of which were tested in strains TA 98, 100, 1535, 1537 (EPA Table 5.1). All 27 studies are listed as negative. No data is provided for any of the studies. **Kier and Kirkland (2013)**^[177] cited results from 18 bacterial reverse mutation assays of glyphosate and 16 of glyphosate formulations. Tabulated results and background information were provided for all 34 studies. Six studies of glyphosate alone demonstrated positive findings in one or more groups.

EFSA^[89] cites three studies of gene mutations in mammalian cells, all of which are listed as negative (EFSA Table B.6.4-5), two use the mouse lymphoma assay, and one uses the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyl transferase (CHO/HGPRT) mutation assay. EPA^[61] cites four studies, three of which appear to be the same as those cited by EFSA (EPA Table 5.2) and the fourth is another mouse lymphoma assay. All four are listed as negative. **Kier and Kirkland (2013)**^[177] cite two of the mouse lymphoma studies and provide tabulated data. Neither study shows any indication of a statistically significant increase in mutation frequency at the thymidine kinase locus of L5178 mouse lymphoma tk(+/-) cells.

EFSA^[89] cites one *in vitro* study of DNA damage and repair in mammalian cells which is listed as negative (EFSA Table B.6.4-6). This study is of unscheduled DNA synthesis (UDS assay) in primary rat lymphocytes. They also list five studies of chromosome aberrations (EFSA Table B.6.4-8), which are characterized as negative. Two studies are in human lymphocytes and two are in Chinese hamster lung (CHL) cells. Data for one of the studies in CHL is provided in tabular form and is clearly negative. EPA^[61] cites eight *in vitro* studies of chromosome aberrations in mammalian cells (EPA Table 5.3); two of these studies match studies in the EFSA report. Four of the studies are from the literature^[124, 131, 143, 178] and are reviewed above. Surprisingly, EPA refers to the study by **Manas et al. (2009)**^[124] as negative although it was clearly positive in the comet assay. Additionally, EPA refers to the study by **Sivikova and Dainovsky (2006)**^[143] as negative even though they saw clear effects of glyphosate on SCEs. Basically, all four of the literature studies cited by EPA are positive yet EPA lists only two of the four as positive. The remaining four studies are noted as negative; however, no data is supplied for these studies. **Kier and Kirkland (2013)**^[177] cites eight literature studies (all reviewed above) and three regulatory studies with glyphosate exposure. The three regulatory studies are listed as negative, and the data are available as a table in the supplement material to **Kier and Kirkland (2013)**; these studies are negative at all tested concentrations in CHL cells; one matches the study data provided by EFSA^[89].

EFSA^[89] cites nine micronucleus assays, three in Swiss Albino mice, two in NMRI mice, two in CD-1 mice, one in Sprague-Dawley rats, and one in CD rats (EFSA Table B.6.4-12). They list one study in Swiss Albino mice as weakly positive in males, one study in CD-1 mice as positive at the highest dose (data for this study is provided) and all other studies as negative. They discard one study with low doses in male Swiss mice, but the tables provided for this study show a clearly significant result at the highest dose used (30 mg/kg) and clear dose-response. They provide data for two of the negative studies which indicate these studies were indeed negative. EPA^[61] (EPA Table 5.5) cites 20 micronucleus assays, four are available in the scientific literature and three are reviewed above (the fourth reference^[179] was unavailable to me at the time of preparation of this report). The remaining 16 studies include six studies in Swiss Albino mice, four studies in CD-1 mice, three studies in NMRI mice, two studies in Sprague-Dawley rats and one study in Wistar rats. Since EFSA does not provide names associated with their micronucleus studies, I cannot determine if any of the studies cited by the EPA are the same as those cited by EFSA. EPA lists two of the literature studies as positive and two as negative (matching my reviews for the three studies I have access to) and all but one of the regulatory studies as negative (the one positive study was in Swiss-Albino mice). **Kier and Kirkland (2013)**^[177] cite 12 regulatory micronucleus assays of glyphosate and provide data tables for all 12. All 12 of these studies are cited by EPA. **Kier and Kirkland (2013)** list 11 studies as negative and one as inconclusive. However, four of the studies show positive effects in at least one sex-by-treatment group. One of these four studies they list as inconclusive and the remaining three studies are determined to be negative because the response is within the range of the historical controls. As was discussed for the animal carcinogenicity studies, the correct group to use is the concurrent control. **Kier and Kirkland (2013)**^[177] also cite 12 regulatory studies and three literature studies where animals are exposed to a glyphosate formulation. Two of the literature studies are reviewed above and the remaining study^[179] was unavailable. Data for the 12 regulatory studies are all provided in tables by **Kier and Kirkland (2013)** and show two positive studies in CD-1 mice and negative studies for the remaining 10.

Summary for Genotoxicity

This is a complicated area from which to draw a conclusion due to the diversity of the studies available (there are multiple species, multiple strains within a species, multiple cell types from multiple species, differing lengths of exposure, differing times of evaluation after exposure, differing exposures, numerous markers of genotoxicity, and finally both glyphosate and multiple different glyphosate formulations). There are three studies that evaluate the genotoxicity of glyphosate in humans directly, 36 experiments in eight strains of mice, three studies in rats, nine studies in human lymphocytes and four studies in other human cells, 12 studies in non-human mammalian cell lines (two using mouse cells, five using hamster cells, two using rat cells and three using cells from cows), a large number of studies in a wide variety of non-mammalian species, and a plethora of studies, mostly identical, in bacteria.

Some conclusions are straightforward"; glyphosate does not appear to cause reverse mutations for histidine synthesis in *Salmonella typhimurium*, regardless of whether

these reverse mutations are due to frameshift mutations or point mutations. I am cautious in this determination because there were several studies with positive results, but no clear pattern is evident. There is ample evidence supporting the conclusion that glyphosate formulations and glyphosate can cause genotoxicity in non-mammalian animal species. This clearly indicates that both glyphosate and the formulations are able to cause injury to DNA. So while findings of genotoxicity in these species do not speak directly to the hazard potential in humans, they do support a cause for concern.

The more important studies are those that have been done using mammalian systems, human cells and direct human contact. Table 16 summarizes these studies in a simple framework that allows all of the experimental data to be seen in one glance. This table does not address the subtlety needed to interpret any one study, but simply demonstrates when a study produced positive versus negative results.

Clearly, for *in vitro* evaluations in human cells, the majority of the studies have produced positive results. There was only one regulatory study evaluating glyphosate genotoxicity in human lymphocytes from healthy volunteers and that study was negative. The study was not significantly different from the other six studies in this category, five of which produced positive results. The majority of these studies used either the comet assay (a simple way for measuring any type of DNA strand break) or methods that counted specific types of strand breaks in the cells (e.g. SCEs, micronuclei, nuclear buds and nucleoplasmic bridges). From these assays, we can conclude there is DNA damage. For glyphosate formulations, there are only three studies in humans *in vivo*, two of which were positive.

The magnitude of the concentrations used in these studies could potentially lead to false positives if the glyphosate is causing cytotoxicity in the cells. All six studies using the comet assay were positive with no study showing a negative response below 10 µg/ml and mixed results below that with positive results at 0.12 and 3.5 µg/ml and negative results at 2.91 and 10 µg/ml. In general, the comet assays provide strong support for genotoxicity.

The four studies that directly addressed specific types of strand breaks in cells following exposure to glyphosate showed markedly different responses across the various concentrations used. **Manas et al. (2009)** saw no changes in chromatid breaks, chromosome breaks, chromatid gaps, chromosome gaps, dicentrics, acentric fragments or endoreduplication over the range of concentrations 3.4-1015 µg/ml. In contrast, **Lioi et al. (1998)** saw changes in SCEs over concentrations ranging from 1.4 to 8.7 µg/ml. Both studies were done in lymphocytes from volunteers. **Mladinic et al. (2009)** saw significant changes in micronuclei above 92.8 µg/ml and **Bolognesi et al. (1997)** saw positive changes in SCEs above 1000 µg/ml but not at 330 µg/ml. While changes have been seen in three of the four studies, the actual concentrations in which the changes are seen is not consistent across studies. I conclude that glyphosate causes DNA strand breaks, which is indicative of genotoxicity.

The micronucleus assays in rodents examining glyphosate genotoxicity are either all positive in one strain or all negative in one strain with the exception of the three studies

in CD-1 mice and four studies in Swiss Albino mice. For the positive studies, we can ask the question of whether, in this strain, the actual number of micronuclei are consistent.

Table 17: Summary of *in vivo* and *in vitro* genotoxicity studies of glyphosate and glyphosate formulations in mammals¹

<i>In vivo or in vitro</i>	Species	Cell type or tissue	Glyphosate ²		Glyphosate Formulations	
			Number Positive	Number Negative	Number Positive	Number Negative
<i>In vivo</i>	Humans	Peripheral blood			2	1
<i>in vitro</i>	Humans	lymphocytes	5	2(1)	2	
		Hep 2	1			
		GM 38 HT1080	1			
		GM 5757	1			
		TR146	1		1	
<i>In vivo</i>	Swiss CD-1 Mouse	Liver/Kidney	1	1	2	
<i>In vivo</i> (micro-nucleus assay)	NMRI mouse	Erythrocytes		4(3)		2(1)
	Swiss CD-1 mouse		1		2	
	Balb C mouse		1			
	B6C3F ₁ mouse			1		
	Swiss mouse		1(1)			3(2)
	CD-1 mouse		2(2)	1(1)	2 (2)	6 (6)
	Swiss albino mouse		1(1)	3(3)	1	
	C57BL mouse					1
	Mouse (not specified)				1	
	Rats (all)			2(1)		1(1)
<i>In vitro</i>	Mouse	L5178 lymphoma		2(2)		
	Chinese hamster	Lung		3(3)		
	Chinese hamster	ovary	1	1		
	Fischer rat	liver		1		

	Rat	Lymphocytes		1(1)		
	Bovine	Lymphocytes	1		2	

¹each entry in the table corresponds to a single study where a study is positive if at least one valid positive finding emerged from the study $p < 0.05$; entries in the table are only for studies where data was available to review including data from EFSA¹⁸⁹¹ and Kier and Kirkland (2000)¹¹⁷⁷; ²numbers are the total number of studies in this category, numbers in parentheses are the subset of studies that are regulatory studies

In Swiss Albino mice, all four studies were done with males and females. Exposures were by oral gavage for the positive study (in female mice) and IP injection by the negative studies. The positive study was at 5000 mg/kg and the highest dose in any of the negative studies was 3024 mg/kg. Finally, the control response in the positive study was 6.7 micronucleated PCE per 1000 PCE whereas the controls in the three negative studies were between 0 and 0.6 micronucleated PCE per 1000 PCE. Any of these differences could easily explain the differences in response so the positive result in Swiss Albino mice should be accepted.

For CD-1 mice, the one negative micronucleus study was by oral gavage in males and females at a single dose of 5000 mg/kg. One of the positive studies was also by oral gavage in males at a single dose of 2000 mg/kg. Because of the nature of statistical noise, these two studies could both occur whether there is a true effect or not. For the other positive study, the dose was by IP injection in male mice with a positive response at 600 mg/kg that was more than double the response of the controls. These data support the finding that glyphosate can cause micronuclei in male CD-1 mice, which is indicative of genotoxicity.

The remaining *in vitro* assays in mammalian cells exposed to glyphosate show mixed results. The mouse lymphoma assay and the Chinese hamster ovary assays are looking for specific mutations that will allow these cells to grow in culture. The Chinese hamster lung, the two rat assays and the assay in bovine lymphocytes are measuring DNA damage and provide mixed results. In general, these responses appear to be negative with the exception of those seen in bovine lymphocytes that appear to show a positive increase in SCEs following exposure to glyphosate.

For glyphosate formulations, the main difference between the findings for glyphosate and those for the glyphosate formulations is the direct evidence for genotoxicity in humans and the micronucleus assays in Swiss mice. The observation of genotoxicity in humans following exposure to glyphosate formulations must carry the greatest weight in the overall analysis and two of the three studies were positive with the strongest study by **Bolognesi et al. (2009)**¹¹²⁰ showing the strongest response.

For the Swiss mouse studies of micronuclei, the fact that all three studies are negative for glyphosate formulations while one study is positive for glyphosate creates a clear disagreement. The positive study is an oral gavage study with an effect seen in male mice at 30 mg/kg/day. The two negative regulatory studies for glyphosate formulations were done at 2000 mg/kg (about 500 mg/kg glyphosate equivalent), were also oral

gavage studies and were replicates done in the same laboratory at different times. The remaining negative study used glyphosate formulation doses of 50-200 mg/kg (25-100 mg/kg glyphosate equivalent) but was done by intraperitoneal injection. With the exception of the different routes of exposure, the differences between these studies cannot be resolved.


In this case, a pooled analysis of the data is not possible because in almost every case, no one study is a clear replicate of another. Instead, the appropriate approach would be to do a meta-analysis and evaluate which aspects of the experimental designs are important to producing positive findings of genotoxicity. The studies with the most data for this type of analysis are the various *in vivo* assays of micronucleus formation. **Ghisi et al. (2016)**^[180] did a systematic search to identify all published studies evaluating the ability of glyphosate or glyphosate formulations to induce micronuclei *in vivo*. The authors also used the data from **Kier and Kirkland (2013)**^[177] summarized above. An experiment, in their evaluation, was defined by sex/species/route/form of glyphosate so that some studies doing both sexes using glyphosate and a glyphosate formulation will enter multiple times into the analysis. They identified 93 experiments from which it was possible to do a meta-analysis. Data were extracted for each study and the log ratio of the mean of each experimental group to the mean control response (E+) was used to evaluate effect sizes in the meta-analysis. For this meta-analytic mean, a value below zero suggests no genotoxicity while a value above zero suggests increased genotoxicity. A test of heterogeneity (Cochran's Q statistic discussed earlier for the epidemiological data) was also evaluated.

Figure 2 is a reprint of Figure 1 from the study by **Ghisi et al. (2016)**^[180] and is a forest plot from all studies they evaluated for glyphosate and glyphosate formulations. It is clear from this plot that the predominant response is positive in these data with an overall grand mean response across all studies of $E+=1.37$ and a 95% confidence interval of (1.356-1.381) (this is highly statistically significant with a $p<0.0001$). The Q_t value for the grand mean was also statistically significant suggesting there are other explanatory variables in the data that would help to explain the overall variance.

Categorical variables were then used to make comparisons across the various strata in the data to identify which experimental conditions show the largest impacts on the mean response. Mammalian species presented a higher mean effect ($E+=1.379$; 1.366-1.391) than non-mammalian species ($E+=0.740$; 0.641-0.840). Glyphosate formulations showed a greater mean response ($E+=1.388$; 1.375-1.400) than did glyphosate ($E+=0.121$; 0.021-0.221), but both were significantly greater than zero. The mean response in studies using only male animals ($E+=1.833$; 1.819-1.847) was significantly different from zero as were studies using both males and females ($E+=0.674$; 0.523-0.825) whereas the mean response in studies using only females ($E+=0.088$; -0.153-0.328) was not. Peer-reviewed studies had higher mean response ($E+=1.394$; 1.381-1.407) compared to regulatory studies ($E+=0.114$; 0.027-0.202), but both means were significantly greater than zero, indicating an overall genotoxic effect. Other variables were examined such as length of exposure and magnitude of exposure that had very little impact on the overall findings.

The meta-analysis by Ghisi et al. (2016)^[180] provides strong support for the hypothesis that exposure to glyphosate and glyphosate formulations increases the formation of micronuclei *in vivo*. This means that glyphosate and glyphosate formulations are damaging DNA in living, functioning organisms with intact DNA repair capacity strengthening the finding that glyphosate is genotoxic to humans.

Figure 2: Forest plot of studies evaluating micronucleus frequency in glyphosate exposure, arranged by effects size. The plot shows the estimate of the response ratio and 95% confidence interval (CI) of each experiment included in the meta-analysis. The number beside the bars represents the reference number of each experiment as in Table 1 of Ghisi et al. (2016)^[180]. Grand Mean is the overall mean effects size of all studies. [Reprinted from Ghisi et al. (2016)^[180]]



From a simply statistical perspective, there is another way in which one can decide if the positive findings in the micronucleus assays in the mice are due to chance. For the glyphosate studies, if one adds up all of the individual experimental groups, there are 79 total groups which correspond to 79 statistical tests. Assuming the critical testing level is 0.05 for all of the tests, one would expect to see just under four positive findings, yet six are observed. For the glyphosate formulations, there were 70 experimental groups so one expects 3.5 positive findings yet 12 are observed ($p < 0.01$). Overall, there were a total of 149 experimental groups examined in mice for micronucleus formation and we observed 18 (7.5 expected, $p < 0.01$). Repeating this analysis on the basis of studies instead of experimental groups, there were 15 studies for glyphosate (expected number is 0.75 positive) yet six positive were observed ($p < 0.01$). For the glyphosate formulations, there were 18 studies (expected number is 0.9 positive) yet six positive

are observed ($p < 0.01$). Now expanding to all 69 studies presented in Table 17, there were 33 positive studies, but the expectation is a mere 3.5 ($p < 0.01$).

It is clear that both glyphosate and glyphosate formulations have genotoxic potential. But which is worse? Of the 69 experiments in Table 17, there were eight experiments from five research publications that addressed both glyphosate and a glyphosate formulation in the same laboratory. Of these, two were negative for both glyphosate and the formulation and do not contribute to a discussion of relative potency. The remaining six can provide some guidance on the relative potency of glyphosate to glyphosate formulations. In **Koller et al. (2007)**^[127], tail intensity for the comet assay were virtually identical when the amount of glyphosate in the formulation was compared to the results using glyphosate alone. In the same paper, micronuclei and related biomarkers were consistently higher in the glyphosate formulation by 10-20%. In **Bolognesi et al. (1997)**, DNA strand breaks in liver and kidney in Swiss CD-1 mice were virtually identical under equivalent doses of glyphosate and glyphosate formulations. In their micronucleus assay, the glyphosate formulation was approximately 50% more potent. Finally, **Bolognesi et al. (1997)**, in their analysis of SCEs in human lymphocytes, the glyphosate formulation was approximately twice as effective as glyphosate alone. In **Peluso et al. (1988)**^[133], DNA adducts in livers and kidneys were only seen in mice treated with the glyphosate formulation, so these findings are not likely to be due to glyphosate. The data suggest a small increase in the potential for genotoxicity for glyphosate formulations relative to the genotoxicity one would see with glyphosate alone.

In summary, the data support a conclusion that both glyphosate and glyphosate formulations are genotoxic. Thus, there is a reasonable mechanism supporting the increases in tumors caused by glyphosate and glyphosate formulations in humans and animals.

Oxidative Stress

Oxidative stress refers to an imbalance between the production of reactive oxygen species (free radicals) in a cell and the antioxidant defenses the cell has in place to prevent this. Oxidative stress has been linked to both the causes and consequences of several diseases^[181-186] including cancer^[37, 187-191]. Multiple biomarkers exist for oxidative stress; the most common being the increased antioxidant enzyme activity, depletion of glutathione or increases in lipid peroxidation. In addition, many studies evaluating oxidative stress used antioxidants following exposure to glyphosate to demonstrate that the effect of the oxidative stress can be diminished.

Oxidative Stress in Human Cells (*in vitro*)

Mladinic et al. (2009)^[122] examined the induction of oxidative stress from exposure to glyphosate (98% purity) in lymphocytes from three healthy human donors (questionnaires were used to exclude other genotoxic exposures) at concentrations of 0.5, 2.91, 3.5, 92.8 and 580 $\mu\text{g}/\text{ml}$. Cells with and without S9 activation saw increases in total antioxidant capacity at only the highest dose for cells without S9 activation although a clear concentration response pattern was seen with S9 activation.

Kwiatkowska et al. (2014)^[192] examined the induction of oxidative stress from exposure to glyphosate (purity not given) in erythrocytes obtained from healthy donors in the Blood Bank of Lodz, Poland. Erythrocytes were exposed to concentrations of 1.7, 8.4, 17, 42.3, 85 and 845 µg/ml and incubated for 1 hour. Oxidative stress (oxidation of dihydrorhodamine 123) was significantly increased at 42.3, 85 and 845 µg/l with a clear concentration-response pattern.

Chaufan et al. (2014)^[193] examined the induction of oxidative stress from exposure to glyphosate (95% purity) and Roundup UltraMax (74.7% glyphosate) in HepG2 cells (human hepatoma cell line). Exposure concentrations were 900 µg/ml for glyphosate and 40 µg/ml for the glyphosate formulation. After incubation for 24 hours, oxidative stress (expressed as the activity of superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and glutathione-S-transferase (GST)) was significantly increased ($p < 0.05$) for the glyphosate formulation (increased SOD activity) but not for glyphosate alone.

Coalova et al. (2014)^[194] examined the induction of oxidative stress from exposure to a glyphosate formulation (Atanor, 48% glyphosate) or with a surfactant (Impacto) in Hep-2 cells (human epithelial cell line). Exposure concentrations were 376.4 µg/ml for Atanor, 12.1 µg/ml for Impacto and 180.2 µg/ml for a mixture of the two. After incubation for 24 hours, oxidative stress (measured as activity of SOD, CAT, GSH, and GST) was significantly increased for Impacto, Atanor and the mixture (CAT and GSH only, $p < 0.05$ or $p < 0.01$).

Gehin et al. (2005)^[195] examined the induction of oxidative stress from exposure to glyphosate (purity unknown) and a glyphosate formulation (Roundup 3 plus, 21% glyphosate) in HaCaT cells (human keratinocyte cell line). Glyphosate induced cytotoxicity in the cells which was reduced or eliminated by antioxidants. The authors attributed the cytotoxicity to oxidative stress.

Elie-Caille et al. (2010)^[196] examined the induction of oxidative stress from exposure to glyphosate (purity unknown) in HaCaT cells (human keratinocyte cell line). Exposure concentrations ranged from 1700 µg/l to almost 12,000 µg/ml. Glyphosate induced cytotoxicity in the cells and increased hydrogen peroxide H₂O₂ (dichlorodihydrofluorescein diacetate assay). This study used exceptionally high concentrations that may be inducing cytotoxicity by means that are independent of the oxidative stress observed. Measuring oxidative stress using the dichlorodihydrofluorescein diacetate assay has limitations^[197, 198].

George and Shukla (2013)^[199] examined the induction of oxidative stress from exposure to a glyphosate formulation (Roundup Original, 41% glyphosate) in HaCaT cells (human keratinocyte cell line). Exposure concentration ranged from 1.7 µg/ml to 17,000 µg/ml and exposure was for 24 hours. Glyphosate significantly induced the formation of reactive oxygen species (dichlorodihydrofluorescein diacetate assay) at all exposures in a concentration-dependent fashion. Prior treatment of the cells with N-Acetylcysteine reduced the impact of glyphosate, but did not eliminate it. Measuring oxidative stress using dichlorodihydrofluorescein diacetate has limitations^[197, 198] that affect the clear

interpretation of these results.

Oxidative Stress in Non-Human Mammals (*in vivo*)

Bolognesi et al. (1997)^[130] exposed groups of three Swiss CD-1 male mice by IP injection with a single dose of glyphosate (99.9% purity, 300 mg/kg) or Roundup (900 mg/kg, equivalent to 270 mg/kg glyphosate). Animals were sacrificed at eight and 24 hours after injection and livers and kidney were removed to obtain crude nuclei from the adhering tissues. Samples of liver and kidneys from these mice were evaluated for levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) which is a biomarker of oxidative stress^[200]. There was a significant increase in the liver of 8-OHdG at 24 hours following glyphosate exposure, but not at eight hours and not in the kidney. At both eight hours and 24 hours, Roundup increased 8-OHdG in the kidneys, but the mild increase seen in the liver at 24 hours was not significant.

Cavusoglu et al. (2011)^[139] exposed groups of six Swiss albino mice by IP injection of a glyphosate formulation (RoundupUltra Max, 450 g/l glyphosate, 50 mg/kg formulation). At the end of dosing, animals were fasted overnight then sacrificed. There was a significant increase in malondialdehyde in both liver and kidney and a significant decrease in GSH in liver and kidney from exposure to the glyphosate formulation. *G. bilboa* eliminated these effects.

Jasper et al. (2012)^[201] exposed groups of 10 male and 10 female Swiss albino mice via oral gavage for 15 days to a glyphosate formulation (Roundup Original, 41% glyphosate, 50 mg/kg glyphosate equivalent dose). Animals were sacrificed at three days after injection. There was a significant increase in thiobarbituric acid-reactive substances (TBARS) in the liver for both male and female mice at both doses ($p < 0.05$). The concentration of non-protein thiols was elevated in both dose groups for males and for the high dose only in females (no dose-response was seen for this endpoint).

Astiz et al. (2009)^[202] exposed groups of four male Wistar rats by IP injection to a single dose of glyphosate (purity unknown, 10 mg/kg). Animals were injected three times per week for five weeks and then sacrificed. Thiobarbituric acid-reactive substances (TBARS assay), protein carbonyls (PCOSs), total glutathione levels, individual glutathione levels, SOD and CAT were all measured as biomarkers for oxidative stress in plasma, brain, liver and kidney. Glyphosate significantly increased TBARS in all tissues ($p < 0.01$), total glutathione in brain ($p < 0.01$), SOD in liver and brain ($p < 0.01$) and CAT in brain. In a follow-up report^[203], they demonstrate that lipoic acid eliminates or severely reduces the impacts of glyphosate on the brain.

Cattani et al. (2014)^[204] exposed groups of four pregnant Wistar rats to glyphosate formulation (Roundup Original, 360 g/L glyphosate) in drinking water from gestational days 5-15 at a dose of 71.4mg/kg. Fifteen day-old pups (2 per dam) were examined for oxidative stress markers in the hippocampus. Pups had a significant increase in TBARS ($p < 0.05$) and a significant decrease in GSH ($p < 0.01$).

George et al. (2010)^[82] exposed groups of four Swiss albino mice to a glyphosate formulation (Roundup Original, 36g/L glyphosate) at a dose of 50 mg/kg (glyphosate

equivalent dose) via a single topical application. Proteomic analysis of skin from the treated animals saw alterations in SOD1, CA III and PRX II, proteins known to play a role in the management of oxidative stress.

Oxidative Stress in Non-Mammalian Systems

As for genotoxicity, oxidative stress from exposure to glyphosate and glyphosate formulations have been studied in various aquatic organisms; reviewed in **Slaninova et al. (2009)**^[205]. Many of the studies reviewed by **Slaninova et al. (2009)** showed associations with glyphosate and oxidative stress in various organs. Since that review, additional studies have been completed that also demonstrate a positive association between glyphosate and oxidative stress^[147, 156-159, 206-217].

Summary for Oxidative Stress

Seven studies addressed oxidative stress in human cells and another six studies addressed it in mammalian systems. In lymphocytes and erythrocytes from healthy donors, oxidative stress was detected as low as 580 µg/ml in lymphocytes and at 42.3 µg/ml in erythrocytes. In Hep-G2 cells, no increased oxidative stress was seen for a single concentration of 900 µg/l. In two studies in HaCat cells, glyphosate induced oxidative stress in a continuous model fit to the results in one study and at the lowest concentration (1700 µg/ml) in the other. The most convincing studies in human cells for oxidative stress are the two studies in human blood.

In Swiss CD-1 male mice, increased oxidative stress was seen in the liver at 24 hours, but not at four hours after injection of 300 mg/kg glyphosate. No increase was seen in the kidney. In Wistar rats, repeated IP dosing with glyphosate lead to increased oxidative stress in multiple organs using multiple biomarkers. Thus, all of the laboratory studies demonstrated oxidative stress with a significant finding in the rat study.

In Hep-G2 cells, a glyphosate formulation demonstrated a robust increase in oxidative stress at 40 µg/ml. Given the negative response in this cell line for glyphosate alone, it must be concluded that this response is not due to glyphosate. In HEP-2 cells, a glyphosate formulation demonstrated a robust increase in oxidative stress via multiple biomarkers at 376 µg/ml and when a surfactant is added, at 180.2 µg/ml. In HaCaT cells, a glyphosate formulation demonstrated significant increases in oxidative stress from doses starting as low as 1.7 µg/ml in a concentration-dependent fashion. No studies were available in human lymphocytes.

In Swiss CD-1 mice, a glyphosate formulation significantly increased oxidative stress in the kidney but only demonstrated a mild (non-significant) increase in the liver. This study evaluated oxidative stress at two different time points following exposure and saw responses that differed over time. The strong increase in the liver for glyphosate but not glyphosate formulation, suggests a complicated response pattern for pure glyphosate versus the formulation that could be linked to the time since exposure. In Swiss Albino mice, a glyphosate formulation demonstrated increased oxidative stress by two separate biomarkers in both the liver and the kidney. In a second study in Swiss albino mice using a different biomarker but a similar dose, increased oxidative stress

was seen in both the liver and the kidney. In Wistar rat pups exposed in utero, an increase in oxidative stress was seen in the hippocampus. In Swiss albino mice, topical application of a glyphosate formulation to the skin resulted in a proteomic fingerprint suggesting oxidative stress was increased.

Though there are fewer studies for oxidative stress than there are for genotoxicity, the robust response seen here in human cells and in rodent studies clearly supports a role for both glyphosate and glyphosate formulations in inducing oxidative stress. Thus, there is a second reasonable mechanism through which the tumors seen in humans and those seen in animals can be caused by glyphosate and glyphosate formulations.

Summary for Biological Plausibility

In the evaluation of causality, the evidence for biological plausibility is overwhelming. Glyphosate clearly causes multiple cancers in mice, two cancers in the hematopoietic system similar to what is seen in humans, causes cancer in rats, is genotoxic and induces oxidative stress. The findings are clear for both glyphosate alone and for glyphosate formulations. **There is strong support for biological plausibility in support of a causal association of glyphosate and glyphosate formulations with NHL.**

Biological Gradient

Only three of the epidemiological studies provided information on biological gradients in their publications.

Eriksson et al. (2008)^[46] divided their cases and controls into those with ≤ 10 days per year of exposure and those with > 10 days per year of exposure. The ORs were calculated using a multivariate analysis that included agents with statistically significant increased OR, or with an OR > 1.50 and at least 10 exposed subjects. ORs for glyphosate were 1.69 (0.70-4.07) for ≤ 10 days per year and 2.36 (1.04-5.37) for > 10 days per year. In their multivariate analysis, latency periods of 1-10 years showed an OR of 1.11 (0.24-5.08) and > 10 years had an OR of 2.26 (1.16-4.40). Thus, they show an increase with intensity of exposure and with latency.

McDuffie et al. (2001)^[50], using a conditional logistic regression analysis controlling for major chemical classes of pesticides and all other covariates with $p < 0.05$, the OR for ≤ 2 days per year of exposure was 1.0 (0.63-1.57) and for > 2 days per year, the OR was 2.12 (1.20-3.73). Thus, they show an increase with intensity of exposure.

De Roos et al. (2005)^[45] used three exposure metrics in their analyses: a) ever personally mixed or applied pesticides containing glyphosate; b) cumulative exposure days of use of glyphosate (years of use times days per year); and c) intensity weighted cumulative exposure days (years of use times days per year times intensity of use). For exposure measurements b and c, they divided the respondents into tertiles chosen *a priori* to avoid having sparse data when dealing with rare tumors. For cumulative exposure days and using the lowest exposed tertile as the reference group, the RRs drop with values of 0.7 (0.4-1.4) and 0.9 (0.5-1.6) for tertiles 2 and 3 respectively adjusted for demographic and lifestyle factors and other pesticides (30,699 subjects). When

intensity-weighted exposure days are examined, the RRs drop with values of 0.6 (0.3-1.1) and 0.8 (0.5-1.4) for tertiles 2 and 3, respectively adjusted for demographic and lifestyle factors and other pesticides (30,699 subjects). Thus, they do not see a biological gradient in their responses. However, the high frequency of exposure to many pesticides (e.g. 73.8% were exposed to 2,4-D) means subjects with low exposure to glyphosate were likely to be exposed to other agents that may also induce NHL; this could reduce the RRs in the higher exposure classes because it would inflate the RR in the low-exposure referent group.

Eriksson et al. (2008)^[46] and **McDuffie et al. (2001)**^[50] had consistent results for intensity of exposure per year (≤ 2 days per year, OR=1.0; ≤ 10 days per year, OR=1.69; > 2 days per year, OR=2.12; > 10 days per year, OR=2.26). It is not possible to resolve the remaining differences between these three studies nor is it easy to argue that one study has more weight on this question than any other. The studies use different measures of exposure or time since exposure, are done on different populations and have different statistical power to detect a trend.

In rodent carcinogenicity studies, there is clear evidence of a biological gradient.

In general, there is support that a biological gradient exists for the epidemiological data and thus support from this aspect of the Bradford-Hill evaluation.

Temporal Relationship

Exposure must come before the cancers occur otherwise the epidemiology studies are useless. In this case, it is clear that exposure came before the onset of NHL. **The need for a temporal relationship in the data supporting a causal association between glyphosate and NHL is satisfied.**

Specificity

There are other causes of NHL^[218-221] so this group of cancers is not specific to glyphosate. **There is little support for specificity.**

Coherence

Humans, coming into contact with glyphosate, can absorb the compound into their bodies where it has been measured in blood and in urine^[56, 222-226]. In laboratory animals, absorption, distribution and elimination of glyphosate and glyphosate compounds have been studied^[140, 227] and show that glyphosate gets into the animal's bodies, distributes to numerous organs and is eliminated in urine. The animal cancer studies clearly demonstrate that glyphosate in mammals can have toxic effects.

Mouse models have long served as surrogates for humans in understanding and developing treatments for many diseases. The same holds true for lymphoid tumors seen in humans. For over 30 years, mouse models have been studied and evaluated as surrogates for NHL^[228-232]. These publications and the associated classification systems for humans and mice indicate a close linkage between the diseases in humans and mice.

Thus, coherence is supported by the increased risk of malignant lymphomas in CD-1 mice, the marginal increase in these tumors in Swiss mice and the strong similarity between malignant lymphomas in mice and NHL in humans.

There is strong support for coherence in the data supporting a causal association of glyphosate and glyphosate formulations with NHL.

Experimental Evidence in Humans

There is no experimental evidence in humans since purposely exposing humans to a pesticide, especially one that is probably carcinogenic, is not ethical and would never pass review by a human subject's advisory board.

Analogy

I am unaware of any analogous compounds from the scientific literature. This, however, is not an area where I have sufficient background to express an opinion.

Summary

Table 18 summarizes the information for each of Hill's aspects of causality. For these data, causality is strengthened because the available epidemiological studies show a consistent positive association between cancer and the exposure. The studies do not show different responses with some studies being positive and others negative, nor do they show any heterogeneity when analyzed together. And, in answer to Hill's question, the relationship between NHL and glyphosate exposure has been observed by different persons, in different places, circumstances, and times.

Causality is strengthened for these data because the strength of the observed associations, when evaluated simultaneously, are statistically significant, the findings are uni-directional and the results are unlikely to be due to chance. Even though none of the individual studies provide relative risks or odds ratios that are large and precise, the meta-analysis has objectively shown that the observed association across these studies is significant and supports a positive association between NHL and glyphosate.

Biological plausibility is strongly supported by the animal carcinogenicity data and the mechanistic data on genotoxicity and oxidative stress. When addressing biological plausibility, the first question generally asked is "Can you show that glyphosate causes cancers in experimental animals?" In this case, the answer to that question is clearly yes. Glyphosate has been demonstrated to cause cancer in two strains of rats and one strain of mice. Glyphosate has been demonstrated to cause cancer in two strains of rats and one strain of mice. Glyphosate causes hepatocellular adenomas in male Wistar rats and, to a lesser degree, in male Sprague-Dawley rats, mammary gland adenomas and adenocarcinomas in female Wistar rats, skin keratocanthomas in male Wistar rats, and kidney adenomas and thyroid C-cell adenomas and carcinomas in male Sprague-Dawley rats. Glyphosate causes hemangiosarcomas, kidney tumors and malignant lymphomas in male CD-1 mice and hemangiomas in female CD-1 mice and possibly

causes malignant lymphomas, kidney adenomas in male Swiss albino mice and hemangiomas in female Swiss albino mice. Thus, glyphosate causes cancer in mammals. Thus, it is biologically plausible that glyphosate alone can cause cancer in mammals.

The next question generally asked is “Does the mechanism by which glyphosate causes cancer in experimental animals also work in humans?” The best understood mechanism by which chemicals cause cancer in both humans and animals is through damaging DNA that leads to mutations in cells that then leads to uncontrolled cellular replication and eventually cancer. It is absolutely clear from the available scientific data that both glyphosate and glyphosate formulations are genotoxic. This has been amply demonstrated in humans that were exposed to glyphosate, in human cells *in vitro*, in experimental animal models and their cells *in vitro* and *in vivo*, and in wildlife. One way in which DNA can be damaged is through the presence of free oxygen radicals that overwhelm a cell’s antioxidant defenses. Glyphosate induces this type of oxidative stress, providing additional support for a biological mechanism that works in humans.

Table 18: Summary conclusions for Hill’s nine aspects of epidemiological data and related science

Aspect	Conclusion	Reason
Consistency of the observed association	Strong	Multiple studies, all are positive, meta-analysis shows little heterogeneity, different research teams, different continents, different questionnaires, no obvious bias or confounding
Strength of the observed association	Strong	Six core epidemiology studies all show the same modest increase, significant meta-analyses
Biological plausibility	Very Strong	Multiple cancers in multiple species, not due to chance, increased risk of rare tumors, convincing evidence for genotoxicity and oxidative stress
Biological gradient	Moderate	Clearly seen in the two case-control studies that evaluated it, not seen in the cohort study
Temporal relationship of the observed association	Satisfied	Exposure clearly came before cancers
Specificity of the observed association	Not needed	NHL has other causes, this does not subtract from the causal argument
Coherence	Strong	Glyphosate is absorbed, distributed and excreted from the body, cancers seen in the mice have strong similarity to human NHL
Evidence from human experimentation	No data	No studies are available
Analogy	No data	No studies available in the literature

In general, there is support that a biological gradient exists for the epidemiological data and thus support from this aspect of the Bradford-Hill evaluation. Glyphosate ORs increased with time since first exposure and with intensity of use per year in the two case-control studies that evaluated at least one of these issues.

There is clearly the proper temporal relationship with the exposure coming before the cancers.

The human evidence is coherent. The basic findings in humans agree with the animal evidence for absorption, distribution and elimination of glyphosate. Also, one of the tumors seen in mice has almost the same etiology as NHL.

NHL is not specific to glyphosate exposure. There is no experimental evidence in humans and I did not find any references where researchers looked for analogous compounds with similar toxicity.

Hill (1965)^[36] asks "*is there any other way of explaining the set of facts before us, is there any other answer equally, or more, likely than cause and effect?*" There is no better way of explaining the scientific evidence relating glyphosate to an increase in NHL in humans than cause and effect.

In my opinion, glyphosate probably causes NHL and, given the human, animal and experimental evidence, I assert that, to a reasonable degree of scientific certainty, the probability that glyphosate causes NHL is high.

The IARC Assessment of Glyphosate

In March 2015, the International Agency for Research on Cancer (an agency of the World Health Organization) brought together seventeen scientists (the Working Group) to evaluate the scientific evidence on whether glyphosate can cause cancer in humans. This group also contained one invited specialist (myself) to aid the Working Group (WG) in going through the science but who was not allowed to join discussions on the final conclusion or write any part of the document. The Working Group concluded that glyphosate falls in the category "*probably carcinogenic to humans (Group 2A)*"^[56].

The IARC preamble^[30] guides Working Groups on how to evaluate scientific literature to determine if something is a hazard. All Working Groups follow these guidelines and this process is accepted worldwide as a proper way to evaluate the literature for a hazard (e.g., the European Chemical Agency cites the IARC review process as guidance and then uses the exact same wording as IARC does to guide their own hazard evaluation process^[34]).

The WG examined the epidemiological data and classified it as "*limited evidence of carcinogenicity,*" which is defined to mean "*a positive association has been observed between exposure to the agent and cancer for which a causal interpretation is considered to be credible, but chance, bias or confounding could not be ruled out with*

reasonable confidence." This is a precise and clear description of the strength of the evidence from the epidemiological studies.

The WG examined the evidence from animal carcinogenicity studies and classified it as "*sufficient evidence of carcinogenicity,*" which IARC defines as: "*a causal relationship has been established between the agent and an increased incidence of malignant neoplasms or of an appropriate combination of benign and malignant neoplasms in (a) two or more species of animals or (b) two or more independent studies in one species carried out at different times or in different laboratories or under different protocols. A single study in one species and sex might be considered to provide sufficient evidence of carcinogenicity when malignant neoplasms occur to an unusual degree with regard to incidence, site, type of tumour or age at onset, or when there are strong findings of tumours at multiple sites.*" Based on the data available to IARC at the time of their review and the restrictions placed on the studies they can review by the Preamble, this conclusion is justified and correct.

One of the major criticisms of the WG review was that the WG did not review all of the animal carcinogenicity data that was available to the regulatory bodies and thus came to the wrong conclusions on the animal cancer data. In this review, I evaluated all 19 animal carcinogenicity experiments that have been collectively mentioned by any agency that reviews glyphosate. Where possible, I have analyzed the original data and used sound statistical methods to test for significant increases in cancer incidence in animals exposed to glyphosate. My conclusion is that the WG would have called this data "*sufficient evidence*" to support their findings despite not reviewing the additional studies analyzed herein. Despite the fact the industry kept these studies confidential, nothing contained in the withheld studies would have changed the WG conclusion.

On the mechanistic data, the IARC Working Group reviewed the same data that I reviewed, but I also evaluated, where possible, the proprietary data supporting the regulatory decisions. Where possible, I reanalyzed that data to be certain the results being presented were accurate. The IARC Working Group, using the guidelines set forth in their Preamble, declared strong support for the biological mechanisms of genotoxicity and oxidative stress. As I have shown here, there is strong support for these two mechanisms, even with the proprietary evidence from the industry studies. Thus, the IARC Working Group reached the correct conclusion.

To decide on a final classification for a compound, the IARC Preamble provides guidance on how the classification of the three areas are to be used. If the data in humans is "*limited*" and the data from animal carcinogenicity studies is "*sufficient,*" the discussions should begin with Class 2A, "*the agent is probably carcinogenic to humans.*" Then, given the overall quality of the data set, the strength of the evidence from the mechanistic studies and any additional scientific issues that need to be considered, the Working Group will determine whether the data justifies a different category. In this case, the Working Group concluded 2A was the right category and I still believe the evidence supports that finding.

The EPA Assessment of Glyphosate

Like IARC, the EPA has guidelines that are to be followed when evaluating scientific literature and making a determination about the carcinogenic potential of a chemical. Those guidelines have been developed over many years and are based on sound scientific guidance that myself and many other scientists have provided to the Agency. For their evaluation of glyphosate, the Agency did not follow their own guidelines, nor did they follow sound scientific practice. This opinion is consistent with the review done by the **EPA FIFRA Scientific Advisory Panel**^[54]. In addition, the Agency failed to find all of the relevant animal cancer studies and misinterpreted several of them. The major problems with the Agency evaluation are:

- Misinterpretation of the epidemiological evidence, confusing the potential for bias and potential for confounding with real bias and real confounding, allowing them to give almost no weight to the case-control studies in favor of the one cohort study;
- Misinterpretation of the findings in the meta-analysis;
- Failure to properly use historical controls in the analysis of the animal carcinogenicity studies; declaring a significant finding as not due to the compound if it is in the range of the historical controls;
- Failure to analyze all tumors in all studies relying upon the industry submissions to have done this correctly;
- Failure to follow their guidelines on what constitutes a positive finding, disregarding significant trend tests when no corresponding pairwise comparisons are also significant;
- Disregarding positive findings in doses that are clearly not above the maximum dose the animals could be given with compromising the integrity of the study;
- Using unreasonable arguments about the overall false positive rates in the study without actually doing an analysis of this issue;
- Failing to recognize the similar findings in similar studies and to do a pooled analysis to determine if the negative effects in one study cancel out the positive effects in another;
- Giving very little weight to studies from the literature and relying almost entirely on studies provided by industry that have not undergone peer review for both quality and, more importantly in some cases, interpretation of the findings; and
- Comparing results across different species and strains for the animal cancer studies and the mechanistic studies with little regard for unique findings in any one study and consistent findings across multiple studies.

Similar comments apply to the evaluation done by the **European Food Safety Authority**^[89] and the **European Chemical Agency**^[233]. My detailed comments to these

agencies on their risk assessments are attached. There were comments to my comments to EPA by other scientists and I also responded to those comments in the EPA docket for glyphosate. These are also included in the attached Appendices.



Dr. Christopher J. Portier

Cited References

1. Portier, C. and D. Hoel, *Optimal design of the chronic animal bioassay*. J Toxicol Environ Health, 1983. **12**(1): p. 1-19.
2. Portier, C.J. and D.G. Hoel, *Design of the Chronic Animal Bioassay for Goodness of Fit to Multistage Models*. Biometrics, 1983. **39**(3): p. 809-809.
3. Bailer, A.J. and C.J. Portier, *Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples*. Biometrics, 1988. **44**(2): p. 417-31.
4. Portier, C.J. and A.J. Bailer, *Testing for increased carcinogenicity using a survival-adjusted quantal response test*. Fundam Appl Toxicol, 1989. **12**(4): p. 731-7.
5. Portier, C.J., J.C. Hedges, and D.G. Hoel, *Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments*. Cancer Res, 1986. **46**(9): p. 4372-8.
6. Portier, C.J. and A.J. Bailer, *2-Stage Models of Tumor-Incidence for Historical Control Animals in the National Toxicology Programs Carcinogenicity Experiments*. Journal of Toxicology and Environmental Health, 1989. **27**(1): p. 21-45.
7. Portier, C.J. and L. Edler, *Two-stage models of carcinogenesis, classification of agents, and design of experiments*. Fundam Appl Toxicol, 1990. **14**(3): p. 444-60.
8. Portier, C.J., et al., *Biologically based models for risk assessment*. IARC Sci Publ, 1990(104): p. 20-8.
9. Kopp-Schneider, A. and C.J. Portier, *Distinguishing between models of carcinogenesis: the role of clonal expansion*. Fundam Appl Toxicol, 1991. **17**(3): p. 601-13.
10. Kopp-Schneider, A., C.J. Portier, and F. Rippmann, *The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments*. Math Biosci, 1991. **105**(2): p. 139-66.
11. Kopp-Schneider, A., C.J. Portier, and F. Rippmann, *The Application of a Multistage Model That Incorporates DNA Damage and Repair to the Analysis of Initiation Promotion Experiments*. Mathematical Biosciences, 1991. **105**(2): p. 139-166.
12. Kopp-Schneider, A. and C.J. Portier, *Birth and Death Differentiation Rates of Papillomas in Mouse Skin*. Carcinogenesis, 1992. **13**(6): p. 973-978.

13. Portier, C.J., A. Kopp-Schneider, and C.D. Sherman, *Using Cell Replication Data in Mathematical-Modeling in Carcinogenesis*. Environmental Health Perspectives, 1993. **101**: p. 79-86.
14. Kopp-Schneider, A., C.J. Portier, and C.D. Sherman, *The Exact Formula for Tumor-Incidence in the 2-Stage Model*. Risk Analysis, 1994. **14**(6): p. 1079-1080.
15. Portier, C., et al., *Modeling the number and size of hepatic focal lesions following exposure to 2378-TCDD*. Organohalogen Compounds, 1994. **21**: p. 393-397.
16. Kopp-Schneider, A. and C.J. Portier, *Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages*. Carcinogenesis, 1995. **16**(1): p. 53-9.
17. Portier, C.J., A. Kopp-Schneider, and C.D. Sherman, *Calculating tumor incidence rates in stochastic models of carcinogenesis*. Mathematical Biosciences, 1996. **135**(2): p. 129-146.
18. Portier, C.J., et al., *Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD*. Toxicology and Applied Pharmacology, 1996. **138**(1): p. 20-30.
19. Kopp-Schneider, A., C. Portier, and P. Bannasch, *A model for hepatocarcinogenesis treating phenotypical changes in focal hepatocellular lesions as epigenetic events*. Math Biosci, 1998. **148**(2): p. 181-204.
20. Toyoshiba, H., et al., *Gene interaction network analysis suggests differences between high and low doses of acetaminophen*. Toxicol Appl Pharmacol, 2006. **215**(3): p. 306-16.
21. Gohlke, J.M. and C.J. Portier, *The forest for the trees: a systems approach to human health research*. Environ Health Perspect, 2007. **115**(9): p. 1261-3.
22. Gohlke, J.M., et al., *Genetic and environmental pathways to complex diseases*. BMC Syst Biol, 2009. **3**: p. 46.
23. Gohlke, J.M., et al., *Estimating the global public health implications of electricity and coal consumption*. Environ Health Perspect, 2011. **119**(6): p. 821-6.
24. Aylward, L.L., et al., *Evaluation of biomonitoring data from the CDC National Exposure Report in a risk assessment context: perspectives across chemicals*. Environ Health Perspect, 2013. **121**(3): p. 287-94.
25. Trong, I. and C. Portier. *Proceedings of the Viet Nam – United States Scientific Conferences on Human Health and Environmental Effects of Agent Orange/Dioxin, Part 1 and 2*. 2002. Ha Noi, Vietnam: US National Institute of Environmental Sciences and the Government of Vietnam.
26. Portier, C.J. and M.S. Wolfe, eds. *EMF Science Review Symposium Breakout Group Report for Epidemiology Research Findings*. 1998, National Institute of Environmental Health Sciences: Research Triangle Park, North Carolina.
27. Portier, C.J. and M.S. Wolfe, eds. *EMF Science Review Symposium Breakout Group Report for Clinical and In Vivo Laboratory Findings*. NIH Publication Number 98-4400. 1998, National Institute of Environmental Health Sciences: Research Triangle Park, North Carolina.
28. Portier, C.J. and M.S. Wolfe, eds. *Assessment of Health Effects from Exposure to Power-Line Frequency Electric and Magnetic Fields*. NIH Publication Number 98-

3981. 1998, National Institute of Environmental Health Sciences: Research Triangle Park, North Carolina. 508.
29. Portier, C.J., et al., *A Human Health Perspective on Climate Change*, N.I.o.E.H.S. Health and Human Services, Editor. 2010, Environmental Health Perspectives: Research Triangle Park, NC72.
 30. IARC. *Preamble to the IARC Monographs*. 2006 [cited 2017 3/8/17]; Available from: <http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf>.
 31. National Research Council. *Science and Judgment in Risk Assessment*. 1994, Washington (DC): National Academy of Sciences Press.
 32. National Research Council. *Science and Decisions: Advancing Risk Assessment*. 2009, Washington (DC): National Academies Press.
 33. USEPA, *Guidelines for Carcinogen Risk Assessment*, U.E.P. Agency, Editor. 2005: Washington DC166.
 34. European Chemicals Agency, *Guidance on the Application of the CLP Criteria: Guidance to Regulation (EC) No 1272/2008 on classification, labelling and packaging (CLP) of substances and mixtures*. 2015, European Chemicals Agency: Helsinki, Finland.
 35. National Toxicology Program. *Handbook for Preparing Report on Carcinogens Monographs*. 2015 [cited 2017 3/8/17]; Available from: https://ntp.niehs.nih.gov/ntp/roc/handbook/roc_handbook_508.pdf.
 36. Hill, A.B., *The Environment and Disease: Association or Causation?* Proc R Soc Med, 1965. **58**: p. 295-300.
 37. Smith, M.T., et al., *Key Characteristics of Carcinogens as a Basis for Organizing Data on Mechanisms of Carcinogenesis*. Environ Health Perspect, 2016. **124**(6): p. 713-21.
 38. Chang, E.T. and E. Delzell, *Systematic review and meta-analysis of glyphosate exposure and risk of lymphohematopoietic cancers*. J Environ Sci Health B, 2016: p. 1-27.
 39. Cantor, K.P., et al., *Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota*. Cancer Res, 1992. **52**(9): p. 2447-2455.
 40. Nordstrom, M., et al., *Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a case-control study*. Br.J Cancer, 1998. **77**(11): p. 2048-2052.
 41. Hardell, L. and M. Eriksson, *A case-control study of non-Hodgkin lymphoma and exposure to pesticides*. Cancer, 1999. **85**(6): p. 1353-1360.
 42. Hardell, L., M. Eriksson, and M. Nordstrom, *Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies*. Leuk.Lymphoma, 2002. **43**(5): p. 1043-1049.
 43. De Roos, A.J., et al., *Integrative assessment of multiple pesticides as risk factors for non-Hodgkin's lymphoma among men*. Occup Environ Med, 2003. **60**(9): p. E11.
 44. Lee, W.J., et al., *Non-Hodgkin's lymphoma among asthmatics exposed to pesticides*. Int J Cancer, 2004. **111**(2): p. 298-302.

45. De Roos, A.J., et al., *Cancer incidence among glyphosate-exposed pesticide applicators in the Agricultural Health Study*. Environ Health Perspect, 2005. **113**(1): p. 49-54.
46. Eriksson, M., et al., *Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis*. Int J Cancer, 2008. **123**(7): p. 1657-63.
47. Orsi, L., et al., *Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study*. Occup Environ Med, 2009. **66**(5): p. 291-8.
48. Hohenadel, K., et al., *Exposure to multiple pesticides and risk of non-Hodgkin lymphoma in men from six Canadian provinces*. Int J Environ Res Public Health, 2011. **8**(6): p. 2320-30.
49. Cocco, P., et al., *Lymphoma risk and occupational exposure to pesticides: results of the Epilymph study*. Occup Environ Med, 2013. **70**(2): p. 91-8.
50. McDuffie, H.H., et al., *Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health*. Cancer Epidemiol Biomarkers Prev, 2001. **10**(11): p. 1155-1163.
51. Zahm, S.H., et al., *A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska*. Epidemiology, 1990. **1**(5): p. 349-356.
52. Hoar, S.K., et al., *Agricultural herbicide use and risk of lymphoma and soft-tissue sarcoma*. JAMA, 1986. **256**(9): p. 1141-1147.
53. Blair, A., et al., *Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from Iowa*. Epidemiology, 2002. **13**(1): p. 94-9.
54. FIFRA Scientific Advisory Panel Meeting Minutes, *Meeting Minutes and Final Report of the December 13-16, 2016 FIFRA SAP Meeting Held to Consider and Review Scientific Issues Associated with EPA's Evaluation of the Carcinogenic Potential of Glyphosate*, O.o.P. Programs, Editor. 2017, US Environmental Protection Agency: Washington, DC101.
55. Portier, C.J., et al., *Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA)*. J Epidemiol Community Health, 2016. **70**(8): p. 741-5.
56. IARC Working Group, *Glyphosate*, In: *Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos*. 2015, IARC Monogr Prog. V. 112. p. 1-92.
57. Schinasi, L. and M.E. Leon, *Non-Hodgkin lymphoma and occupational exposure to agricultural pesticide chemical groups and active ingredients: a systematic review and meta-analysis*. Int J Environ Res Public Health, 2014. **11**(4): p. 4449-527.
58. Ioannidis, J.P., *Interpretation of tests of heterogeneity and bias in meta-analysis*. J Eval Clin Pract, 2008. **14**(5): p. 951-7.
59. OECD, *Guidance Document 116 on the Conduct and Design of Chronic Toxicity and Carcinogenicity Studies*, H.a.S.P. Environment, Editor. 2012, OECD: Paris.

60. Haseman, J.K., *Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies*. Environ Health Perspect, 1984. **58**: p. 385-92.
61. Environmental Protection Agency, *Glyphosate Issue Paper: Evaluation of Carcinogenic Potential*. 2016: Washington, DC.
62. NRC Committee to Review the Styrene Assessment in the National Toxicology Program 12th Report on Carcinogens, in *Review of the Styrene Assessment in the National Toxicology Program 12th Report on Carcinogens: Workshop Summary*. 2014, National Academies Press: Washington (DC).
63. Bieler, G.S. and R.L. Williams, *Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity*. Biometrics, 1993. **49**(3): p. 793-801.
64. Piegorsch, W.W. and A.J. Bailer, *Analyzing environmental data*. 2005, Chichester, West Sussex, England ; Hoboken, NJ: Wiley. xv, 496 p.
65. Haseman, J.K., G.A. Boorman, and J. Huff, *Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies*. Toxicol Pathol, 1997. **25**(5): p. 524-7.
66. Haseman, J.K., J. Huff, and G.A. Boorman, *Use of historical control data in carcinogenicity studies in rodents*. Toxicol Pathol, 1984. **12**(2): p. 126-35.
67. OECD, *Combined Chronic Toxicity\Carcinogenicity Studies, OECD Guidelines for Testing of Chemicals, No. 453*, OECD, Editor. 2009: Paris.
68. Atkinson, C., Strutt, A., Henderson, W., et al. , *104-Week Chronic Feeding/Oncogenicity study in rats with 52-week interim kill*. 1993.
69. Brammer., *Glyphosate Acid: Two Year Dietary Toxicity and Oncogenicity Study in Wistar Rats*. 2001: Central Toxicology Laboratory, Alderley Park Macclesfield, Cheshire, UK.
70. Burnett, P., Borders, J.,Kush, J. , *Report to Monsanto Company: Two Year Chronic Oral Toxicity Study with CP- 76100 in Albino Rats*. 1979, Industrial Bio-Test Laboratories, Inc.: on behalf of Monsanto Co.
71. Chruscielska, K.B., J.; Kita, K, et al., *Glyphosate: Evaluation of chronic activity and possible far - reaching effects - Part 1. Studies on chronic toxicity*. Pestycydy, 2000. **3-4**: p. 10.
72. Enemoto, K., *24-Month Oral Chronic Toxicity and Oncogenicity Study in Rats, Vol. 1*. 1997: The Institute of Environmental Toxicology, Kodaira-shi, Tokyo, Japan.
73. Excel, *Combined chronic toxicity/carcinogenicity study of glyphosate technical in Sprague Dawley rats*. . 1997: Indian Institute of Toxicology, Pune, India.
74. Lankas, G., P., *A Lifetime Study of Glyphosate in Rats*. 1981, Monsanto: Report No. 77-2062 prepared by Bio Dynamics, Inc.
75. Pavkov, K.L., Wyand, S. , *Two-Year Chronic Toxicity and Oncogenecity Dietary Study with SC-0224 in Rats*. 1987: Stauffer Chemical Company.
76. Reyna, M.S., Gordon, D.E. , *Two- Year Chronic Oral Toxicity Study with CP67573 in Albino Rats: Monsanto*. 1974.
77. Seralini, G.E., et al., *Republished study: long-term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize*. Environmental Sciences Europe, 2014. **26**(1): p. 14.

78. Stout, L.D.a.R., P.A., *Chronic Study of Glyphosate Administered in Feed to Albino Rats*. 1990: Monsanto.
79. Suresh, T.P., *Combined Chronic Toxicity and Carcinogenicity Study with Glyphosate Technical in Wistar Rats*. 1996, Syngenta: Toxicology Department Rallis Research Centre, Rallis India Limited.
80. Wood, E., Dunster, J., Watson, P., and Brooks, P. , *Glyphosate Technical: Dietary Combined Chronic Toxicity/Carcinogenicity Study in the Rat*. 2009: Harlan Laboratories Limited, Shardlow Business Park, Shardlow, Derbyshire DE72 2GD, UK. Study No. 2060-012. April, 23, 2009.
81. Atkinson, C., Martin, T., Hudson, P., and Robb, D., *Glyphosate: 104 week dietary carcinogenicity study in mice*. 1993: Inveresk Research International, Tranent, EH33 2NE, Scotland. IRI Project No. 438618. April 7, 1993.
82. George, J., et al., *Studies on glyphosate-induced carcinogenicity in mouse skin: a proteomic approach*. *J Proteomics*, 2010. **73**(5): p. 951-64.
83. Knezevich, A.L. and G.K. Hogan, *A chronic feeding study of glyphosate in mice: Monsanto*. 1983: Bio/Dynamic Inc., dated July 21, 1983. Report No. 77-2011. .
84. Kumar, D.P.S., *Carcinogenicity Study with Glyphosate Technical in Swiss Albino Mice*. 2001: Toxicology Department Rallis Research Centre, Rallis India Limited. Study No. TOXI: 1559.CARCI-M.
85. Pavkov, K.L., Turnier, J.C. , *Two-Year Chronic Toxicity and Oncogenecity Dietary Study with SC-0224 in Mice*. 1987: Stauffer Chemical Company.
86. Reyna, M.S. and D.E. Gordon, *18-Month Carcinogenicity Study with CP67573 in Swiss White Mice: Monsanto*. 1973: Industrial Bio-Test Laboratories, Inc.
87. Sugimoto, K., *18-Month Oral Oncogenicity Study in Mice, Vol. 1 and 2*. 1997: The Institute of Environmental Toxicology, 2-772, Suzuki-cho, Kodaira-shi, Tokyo, 187, Japan, Study No.:IET 94-0151.
88. Wood, E., Dunster, J., Watson, P., and Brooks, P. , *Glyphosate Technical: Dietary Carcinogenicity Study in the Mouse*. 2009: Harlan Laboratories Limited, Shardlow Business Park, Shardlow, Derbyshire DE72 2GD, UK. Study No. 2060-011. April, 22, 2009.
89. (BfR)., G.F.I.f.R.A., *Glyphosate Renewal Assessment Report: Toxicology and Metabolism*. 2013. V. 3. p.
90. (BfR)., G.F.I.f.R.A., *Glyphosate Renewal Assessment Report: Assessment of IARC Monographs Volume 112 (2015)*. 2015. V. 3Glyphosate Addendum I to RAR. p.
91. Greim, H., et al., *Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies*. *Crit Rev Toxicol*, 2015. **45**(3): p. 185-208.
92. Blettner, M., et al., *Traditional reviews, meta-analyses and pooled analyses in epidemiology*. *Int J Epidemiol*, 1999. **28**(1): p. 1-9.
93. Friedenreich, C.M., *Methods for pooled analyses of epidemiologic studies*. *Epidemiology*, 1993. **4**(4): p. 295-302.
94. Portier, C.J., *Comments on Glyphosate Issue Paper (EPA-HQ-OPP-2016-0385-0094)*. 2016, US EPA Docket Number (EPA-HQ-OPP-2016-0385-0094): Washington DC.

95. Hogan, g.k., *A chronic Feeding Study of Glyphosate (Roundup Technical) in Rats*. 1981, Monsanto: Bio/dynamics Inc., E. Millstone, NJ.
96. EPA, *EPA Memo Stout and Ruecker*, I. William Dykstra. Toxicology Branch, Editor. 1991. V. MRID 416438-01 Tox review 008897. p.
97. Uno, H., et al., *A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves*. Stat Med, 2015. **34**(28): p. 3680-95.
98. Giknis, M. and C. Clifford. *Neoplastic and Non-Neoplastic Lesions in the Charles River Wistar Hannover [Crl:WI(Han)] Rat*. 2011; Available from: http://www.criver.com/files/pdfs/rms/wistarhan/rm_rm_r_wistar_han_tox_data_2011.aspx.
99. Acquavella, J., et al., *Glyphosate epidemiology expert panel review: a weight of evidence systematic review of the relationship between glyphosate exposure and non-Hodgkin's lymphoma or multiple myeloma*. Crit Rev Toxicol, 2016. **46**(sup1): p. 28-43.
100. Lacayo, H., *Memorandum: Use of historical data in determining the weight of evidence from kidney tumor incidence in the Glyphosate two-year feeding study and some remarks on false positives*, S.M.S. Branch, Editor. 1985, US EPA: Washington, DCC.
101. Chandra, M. and C.H. Frith, *Spontaneous neoplasms in aged CD-1 mice*. Toxicol Lett, 1992. **61**(1): p. 67-74.
102. Giknis, M. and C. Clifford, *Spontaneous Neoplastic Lesions in the Crl:CD-1(ICR)BR Mouse*. 2000, Charles River Laboratories.
103. Giknis, M. and C. Clifford, *Spontaneous Neoplastic Lesions in the Crl:CD-1(ICR)BR Mouse in Control Groups from 18 Month to 2 year Studies*. 2005, Charles River Laboratories.
104. Eustis, S.L., et al., *The utility of multiple-section sampling in the histopathological evaluation of the kidney for carcinogenicity studies*. Toxicol Pathol, 1994. **22**(5): p. 457-72.
105. Kasza, L., *Memorandum: Glyphosate - Evaluation of Kidney Tumors in Male Mice. Chronic Feeding Study*, T.B. Branch, Editor. 1985, US EPA: Washington, DCC.
106. de Vivar Chevez, A.R., J. Finke, and R. Bukowski, *The role of inflammation in kidney cancer*. Adv Exp Med Biol, 2014. **816**: p. 197-234.
107. Dixon, D., et al., *Summary of chemically induced pulmonary lesions in the National Toxicology Program (NTP) toxicology and carcinogenesis studies*. Toxicol Pathol, 2008. **36**(3): p. 428-39.
108. Son, W.C. and C. Gopinath, *Early occurrence of spontaneous tumors in CD-1 mice and Sprague-Dawley rats*. Toxicol Pathol, 2004. **32**(4): p. 371-4.
109. OECD, *Carcinogenicity Studies, OECD Guideline for the Testing of Chemicals, No. 451*, OECD, Editor. 2009: Paris.
110. Martens, M., *Memorandum to Joe Haseman, March 2, 2017: Analysis tumor data RAC 40 meeting*, G.T. Force, Editor. 2017: Helsinki, Finland.
111. Haseman, J.K., *Comments on the laboratory animal carcinogenicity studies evaluated in EPA's Glyphosate Issue Paper: Evaluation of Carcinogenic Potential*,

- and an assessment of the comments by Dr. Christopher Portier on these studies. 2016, US EPA Docket Number (EPA-HQ-OPP-2016-0385-0094); Washington DC.
112. Hanahan, D. and R.A. Weinberg, *Hallmarks of cancer: the next generation*. Cell, 2011. **144**(5): p. 646-74.
 113. Higgins, J.P.T. and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions*. 2011, The Cochrane Collaboration.
 114. Birnbaum, L.S., et al., *Implementing systematic review at the National Toxicology Program: status and next steps*. Environ Health Perspect, 2013. **121**(4): p. A108-9.
 115. Murray, H.E. and K.A. Thayer, *Implementing systematic review in toxicological profiles: ATSDR and NIEHS/NTP collaboration*. J Environ Health, 2014. **76**(8): p. 34-5.
 116. Rooney, A.A., et al., *Systematic review and evidence integration for literature-based environmental health science assessments*. Environ Health Perspect, 2014. **122**(7): p. 711-8.
 117. Vandenberg, L.N., et al., *A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals*. Environ Health, 2016. **15**(1): p. 74.
 118. Paz-y-Miño, C., et al., *Evaluation of DNA damage in an Ecuadorian population exposed to glyphosate*. Genetics and Molecular Biology, 2007. **30**(2).
 119. Paz-y-Miño, C., et al., *Baseline determination in social, health, and genetic areas in communities affected by glyphosate aerial spraying on the northeastern Ecuadorian border*. Reviews on Environmental Health, 2011. **26**(1).
 120. Bolognesi, C., et al., *Biomonitoring of genotoxic risk in agricultural workers from five colombian regions: association to occupational exposure to glyphosate*. J Toxicol Environ Health A, 2009. **72**(15-16): p. 986-97.
 121. Kier, L.D., *Review of genotoxicity biomonitoring studies of glyphosate-based formulations*. Crit Rev Toxicol, 2015. **45**(3): p. 209-18.
 122. Mladinic, M., et al., *Evaluation of genome damage and its relation to oxidative stress induced by glyphosate in human lymphocytes in vitro*. Environ Mol Mutagen, 2009. **50**(9): p. 800-7.
 123. Alvarez-Moya, C., et al., *Comparison of the in vivo and in vitro genotoxicity of glyphosate isopropylamine salt in three different organisms*. Genet.Mol Biol, 2014. **37**(1): p. 105-110.
 124. Manas, F., et al., *Genotoxicity of glyphosate assessed by the comet assay and cytogenetic tests*. Environ Toxicol Pharmacol, 2009. **28**(1): p. 37-41.
 125. Monroy, C.M., et al., *Citotoxicidad y genotoxicidad en células humanas expuestas in vitro a glifosato*. Biomédica, 2005. **25**: p. 335-45.
 126. Lueken, A., et al., *Synergistic DNA damage by oxidative stress (induced by H2O2) and nongenotoxic environmental chemicals in human fibroblasts*. Toxicology Letters, 2004. **147**(1): p. 35-43.
 127. Koller, V.J., et al., *Cytotoxic and DNA-damaging properties of glyphosate and Roundup in human-derived buccal epithelial cells*. Arch Toxicol, 2012. **86**(5): p. 805-13.

128. Gasnier, C., et al., *Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines*. *Toxicology*, 2009. **262**(3): p. 184-91.
129. Mladinic, M., P. Perkovic, and D. Zeljezic, *Characterization of chromatin instabilities induced by glyphosate, terbuthylazine and carbofuran using cytome FISH assay*. *Toxicol Lett*, 2009. **189**(2): p. 130-7.
130. Bolognesi, C., et al., *Genotoxic Activity of Glyphosate and Its Technical Formulation Roundup*. *J. Agric. Food Chem.*, 1997. **45**: p. 1957-1962.
131. Lioi, M.B., et al., *Genotoxicity and oxidative stress induced by pesticide exposure in bovine lymphocyte cultures in vitro*. *Mutat Res*, 1998. **403**(1-2): p. 13-20.
132. Vigfusson, N.V. and E.R. Vyse, *The effect of the pesticides, Dexon, Captan and Roundup, on sister-chromatid exchanges in human lymphocytes in vitro*. *Mutat Res*, 1980. **79**(1): p. 53-57.
133. Peluso, M., et al., *32P-postlabeling detection of DNA adducts in mice treated with the herbicide Roundup*. *Environ Mol Mutagen*, 1998. **31**(1): p. 55-59.
134. Rank, J., et al., *Genotoxicity testing of the herbicide Roundup and its active ingredient glyphosate isopropylamine using the mouse bone marrow micronucleus test, Salmonella mutagenicity test, and Allium anaphase-telophase test*. *Mutat Res*, 1993. **300**(1): p. 29-36.
135. Dimitrov, B.D., et al., *Comparative genotoxicity of the herbicides Roundup, Stomp and Reglone in plant and mammalian test systems*. *Mutagenesis*, 2006. **21**(6): p. 375-82.
136. Prasad, S., et al., *Clastogenic effects of glyphosate in bone marrow cells of swiss albino mice*. *J Toxicol*, 2009. **2009**: p. 308985.
137. Grisolia, C.K., *A comparison between mouse and fish micronucleus test using cyclophosphamide, mitomycin C and various pesticides*. *Mutat Res*, 2002. **518**(2): p. 145-150.
138. Coutinho do Nascimento A and G. C., *Comparative analysis between micronuclei tests in mice and in peripheral erythrocytes of Oreochromis niloticus in evaluation of mutagenic potential of the agrotoxins deltamethrin, dicofol, glyphosate, and imazapyr*. *Pesticides: R Ecotoxicol E Meio Ambiente*, Curitiba, 2000. **10**: p. 8.
139. Cavusoglu, K., et al., *Protective effect of Ginkgo biloba L. leaf extract against glyphosate toxicity in Swiss albino mice*. *J Med Food*, 2011. **14**(10): p. 1263-72.
140. Chan, P. and J. Mahler, *Toxicity Studies of Glyphosate (CAS No. 1071836) Administered in Dosed Feed to F344/N Rats and B6C3F1 Mice*, N.T. Program, Editor. 1992: Research Triangle Park, NC.
141. Li, A.P. and T.J. Long, *An evaluation of the genotoxic potential of glyphosate*. *Fundam.Appl Toxicol*, 1988. **10**(3): p. 537-546.
142. Roustan, A., et al., *Genotoxicity of mixtures of glyphosate and atrazine and their environmental transformation products before and after photoactivation*. *Chemosphere*, 2014. **108**: p. 93-100.
143. Sivikova, K. and J. Dianovsky, *Cytogenetic effect of technical glyphosate on cultivated bovine peripheral lymphocytes*. *Int J Hyg Environ Health*, 2006. **209**(1): p. 15-20.

144. HOLEČKOVÁ, B., *EVALUATION OF THE IN VITRO EFFECT OF GLYPHOSATE-BASED HERBICIDE ON BOVINE LYMPHOCYTES USING CHROMOSOME PAINTING*. Bull Vet Inst Pulawy, 2006. **50**: p. 533-536.
145. Moreno, N.C., S.H. Sofia, and C.B. Martinez, *Genotoxic effects of the herbicide Roundup Transorb and its active ingredient glyphosate on the fish Prochilodus lineatus*. Environ Toxicol Pharmacol, 2014. **37**(1): p. 448-54.
146. Lopes, F.M., et al., *Effect of glyphosate on the sperm quality of zebrafish Danio rerio*. Aquat Toxicol, 2014. **155**: p. 322-6.
147. Guilherme, S., et al., *Are DNA-damaging effects induced by herbicide formulations (Roundup(R) and Garlon(R)) in fish transient and reversible upon cessation of exposure?* Aquat Toxicol, 2014. **155**: p. 213-21.
148. Akcha, F., C. Spagnol, and J. Rouxel, *Genotoxicity of diuron and glyphosate in oyster spermatozoa and embryos*. Aquat Toxicol, 2012. **106-107**: p. 104-13.
149. Kaya, B., et al., *Use of the Drosophila wing spot test in the genotoxicity testing of different herbicides*. Environ Mol Mutagen, 2000. **36**(1): p. 40-6.
150. Cavalcante, D.G., C.B. Martinez, and S.H. Sofia, *Genotoxic effects of Roundup on the fish Prochilodus lineatus*. Mutat Res, 2008. **655**(1-2): p. 41-6.
151. Cavas, T. and S. Konen, *Detection of cytogenetic and DNA damage in peripheral erythrocytes of goldfish (Carassius auratus) exposed to a glyphosate formulation using the micronucleus test and the comet assay*. Mutagenesis, 2007. **22**(4): p. 263-8.
152. de Castilhos Ghisi, N. and M.M. Cestari, *Genotoxic effects of the herbicide Roundup((R)) in the fish Corydoras paleatus (Jenyns 1842) after short-term, environmentally low concentration exposure*. Environ Monit Assess, 2013. **185**(4): p. 3201-7.
153. De Souza Filho, J., et al., *Mutagenicity and genotoxicity in gill erythrocyte cells of Poecilia reticulata exposed to a glyphosate formulation*. Bull Environ Contam Toxicol, 2013. **91**(5): p. 583-7.
154. Gholami-Seyedkolaei, S.J., et al., *Optimization of recovery patterns in common carp exposed to roundup using response surface methodology: evaluation of neurotoxicity and genotoxicity effects and biochemical parameters*. Ecotoxicol Environ Saf, 2013. **98**: p. 152-61.
155. Guilherme, S., et al., *European eel (Anguilla anguilla) genotoxic and pro-oxidant responses following short-term exposure to Roundup--a glyphosate-based herbicide*. Mutagenesis, 2010. **25**(5): p. 523-30.
156. Guilherme, S., et al., *Differential genotoxicity of Roundup((R)) formulation and its constituents in blood cells of fish (Anguilla anguilla): considerations on chemical interactions and DNA damaging mechanisms*. Ecotoxicology, 2012. **21**(5): p. 1381-90.
157. Marques, A., et al., *Progression of DNA damage induced by a glyphosate-based herbicide in fish (Anguilla anguilla) upon exposure and post-exposure periods--insights into the mechanisms of genotoxicity and DNA repair*. Comp Biochem Physiol C Toxicol Pharmacol, 2014. **166**: p. 126-33.

158. Marques, A., et al., *Erratum To: Progression of DNA damage induced by a glyphosate-based herbicide in fish (Anguilla anguilla) upon exposure and post-exposure periods--insights into the mechanisms of genotoxicity and DNA repair*. *Comp Biochem Physiol C Toxicol Pharmacol*, 2015. **168**: p. 1.
159. Nwani, C.D., et al., *DNA damage and oxidative stress modulatory effects of glyphosate-based herbicide in freshwater fish, Channa punctatus*. *Environ Toxicol Pharmacol*, 2013. **36**(2): p. 539-47.
160. Vera-Candioti, J., S. Soloneski, and M.L. Larramendy, *Evaluation of the genotoxic and cytotoxic effects of glyphosate-based herbicides in the ten spotted live-bearer fish *Cnesterodon decemmaculatus* (Jenyns, 1842)*. *Ecotoxicol Environ Saf*, 2013. **89**: p. 166-73.
161. Poletta, G.L., et al., *Genetic, enzymatic and developmental alterations observed in *Caiman latirostris* exposed in ovo to pesticide formulations and mixtures in an experiment simulating environmental exposure*. *Ecotoxicol Environ Saf*, 2011. **74**(4): p. 852-9.
162. Poletta, G.L., et al., *Genotoxicity of the herbicide formulation Roundup (glyphosate) in broad-snouted caiman (*Caiman latirostris*) evidenced by the Comet assay and the Micronucleus test*. *Mutat Res*, 2009. **672**(2): p. 95-102.
163. Clements, C., S. Ralph, and M. Petras, *Genotoxicity of select herbicides in *Rana catesbeiana* tadpoles using the alkaline single-cell gel DNA electrophoresis (comet) assay*. *Environ Mol Mutagen*, 1997. **29**(3): p. 277-288.
164. Meza-Joya, F.L., M.P. Ramirez-Pinilla, and J.L. Fuentes-Lorenzo, *Toxic, cytotoxic, and genotoxic effects of a glyphosate formulation (Roundup(R)SL-Cosmoflux(R)411F) in the direct-developing frog *Eleutherodactylus johnstonei**. *Environ Mol Mutagen*, 2013. **54**(5): p. 362-73.
165. Yadav, S.S., et al., *Toxic and genotoxic effects of Roundup on tadpoles of the Indian skittering frog (*Eufliectis cyanophlyctis*) in the presence and absence of predator stress*. *Aquat Toxicol*, 2013. **132-133**: p. 1-8.
166. dos Santos, K.C. and C.B. Martinez, *Genotoxic and biochemical effects of atrazine and Roundup((R)), alone and in combination, on the Asian clam *Corbicula fluminea**. *Ecotoxicol Environ Saf*, 2014. **100**: p. 7-14.
167. Conners, D.E. and M.C. Black, *Evaluation of Lethality and Genotoxicity in the Freshwater Mussel *Utterbackia imbecillis* (Bivalvia: Unionidae) Exposed Singly and in Combination to Chemicals Used in Lawn Care*. *Archives of Environmental Contamination and Toxicology*, 2004. **46**(3).
168. Mohamed, A.H., *Sublethal toxicity of Roundup to immunological and molecular aspects of *Biomphalaria alexandrina* to *Schistosoma mansoni* infection*. *Ecotoxicol Environ Saf*, 2011. **74**(4): p. 754-60.
169. Muangphra, P., W. Kwankua, and R. Gooneratne, *Genotoxic effects of glyphosate or paraquat on earthworm coelomocytes*. *Environ Toxicol*, 2014. **29**(6): p. 612-20.
170. Piola, L., et al., *Comparative toxicity of two glyphosate-based formulations to *Eisenia andrei* under laboratory conditions*. *Chemosphere*, 2013. **91**(4): p. 545-51.
171. Kale, P.G., et al., *Mutagenicity testing of nine herbicides and pesticides currently used in agriculture*. *Environ Mol Mutagen*, 1995. **25**(2): p. 148-153.

172. Chen, L., et al., *The combined effects of UV-B radiation and herbicides on photosynthesis, antioxidant enzymes and DNA damage in two bloom-forming cyanobacteria*. *Ecotoxicol Environ Saf*, 2012. **80**: p. 224-30.
173. Wang, G., et al., *Damage to DNA caused by UV-B radiation in the desert cyanobacterium *Scytonema javanicum* and the effects of exogenous chemicals on the process*. *Chemosphere*, 2012. **88**(4): p. 413-7.
174. Alvarez-Moya, C., et al., *Evaluation of genetic damage induced by glyphosate isopropylamine salt using *Tradescantia* bioassays*. *Genet.Mol Biol*, 2011. **34**(1): p. 127-130.
175. Williams, G.M., R. Kroes, and I.C. Munro, *Safety evaluation and risk assessment of the herbicide Roundup and its active ingredient, glyphosate, for humans*. *Regul Toxicol Pharmacol*, 2000. **31**(2 Pt 1): p. 117-65.
176. Moriya, M., et al., *Further mutagenicity studies on pesticides in bacterial reversion assay systems*. *Mutat Res*, 1983. **116**(3-4): p. 185-216.
177. Kier, L.D. and D.J. Kirkland, *Review of genotoxicity studies of glyphosate and glyphosate-based formulations*. *Crit Rev Toxicol*, 2013. **43**(4): p. 283-315.
178. Lioi, M.B., et al., *Cytogenetic damage and induction of pro-oxidant state in human lymphocytes exposed in vitro to glyphosate, vinclozolin, atrazine, and DPX-E9636*. *Environ Mol Mutagen*, 1998. **32**(1): p. 39-46.
179. Chruscielska, K.B., J.; Kita, K, et al., *Glyphosate: Evaluation of chronic activity and possible far - reaching effects - Part 2. Studies on Mutagenic Activity*. *Pestycydy*, 2000. **3-4**: p. 5.
180. Ghisi Nde, C., E.C. de Oliveira, and A.J. Prioli, *Does exposure to glyphosate lead to an increase in the micronuclei frequency? A systematic and meta-analytic review*. *Chemosphere*, 2016. **145**: p. 42-54.
181. Aghadavod, E., et al., *Role of Oxidative Stress and Inflammatory Factors in Diabetic Kidney Disease*. *Iran J Kidney Dis*, 2016. **10**(6): p. 337-343.
182. Kamceva, G., et al., *Cigarette Smoking and Oxidative Stress in Patients with Coronary Artery Disease*. *Open Access Maced J Med Sci*, 2016. **4**(4): p. 636-640.
183. Qureshi, M.A., Y.O. Kim, and D. Schuppan, *Hepatocellular carcinoma in nonalcoholic fatty liver disease: A link between oxidative stress and T-cell suppression*. *Hepatology*, 2016. **64**(5): p. 1794-1797.
184. Sayanthooran, S., et al., *Upregulation of Oxidative Stress Related Genes in a Chronic Kidney Disease Attributed to Specific Geographical Locations of Sri Lanka*. *Biomed Res Int*, 2016. **2016**: p. 7546265.
185. Turkmen, K., *Inflammation, oxidative stress, apoptosis, and autophagy in diabetes mellitus and diabetic kidney disease: the Four Horsemen of the Apocalypse*. *Int Urol Nephrol*, 2016.
186. Vakonaki, E., et al., *Complex interplay of DNA damage, DNA repair genes, and oxidative stress in coronary artery disease*. *Anatol J Cardiol*, 2016. **16**(12): p. 939.
187. Hecht, F., et al., *The role of oxidative stress on breast cancer development and therapy*. *Tumour Biol*, 2016. **37**(4): p. 4281-91.
188. Li, L. and F. Chen, *Oxidative stress, epigenetics, and cancer stem cells in arsenic carcinogenesis and prevention*. *Curr Pharmacol Rep*, 2016. **2**(2): p. 57-63.

189. Perse, M., *Oxidative stress in the pathogenesis of colorectal cancer: cause or consequence?* Biomed Res Int, 2013. **2013**: p. 725710.
190. Prasad, S., et al., *Oxidative Stress and Cancer: Advances and Challenges*. Oxid Med Cell Longev, 2016. **2016**: p. 5010423.
191. Toyokuni, S., *Oxidative stress as an iceberg in carcinogenesis and cancer biology*. Arch Biochem Biophys, 2016. **595**: p. 46-9.
192. Kwiatkowska, M., B. Huras, and B. Bukowska, *The effect of metabolites and impurities of glyphosate on human erythrocytes (in vitro)*. Pestic Biochem Physiol, 2014. **109**: p. 34-43.
193. Chaufan, G., I. Coalova, and C. Rios de Molina Mdel, *Glyphosate commercial formulation causes cytotoxicity, oxidative effects, and apoptosis on human cells: differences with its active ingredient*. Int J Toxicol, 2014. **33**(1): p. 29-38.
194. Coalova, I., C. Rios de Molina Mdel, and G. Chaufan, *Influence of the spray adjuvant on the toxicity effects of a glyphosate formulation*. Toxicol In Vitro, 2014. **28**(7): p. 1306-11.
195. Gehin, A., et al., *Vitamins C and E reverse effect of herbicide-induced toxicity on human epidermal cells HaCaT: a biochemometric approach*. Int J Pharm, 2005. **288**(2): p. 219-26.
196. Elie-Caille, C., et al., *Morphological damages of a glyphosate-treated human keratinocyte cell line revealed by a micro- to nanoscale microscopic investigation*. Cell Biol Toxicol, 2010. **26**(4): p. 331-9.
197. Bonini, M.G., et al., *The oxidation of 2',7'-dichlorofluorescein to reactive oxygen species: a self-fulfilling prophesy?* Free Radic Biol Med, 2006. **40**(6): p. 968-75.
198. Kalyanaraman, B., et al., *Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations*. Free Radic Biol Med, 2012. **52**(1): p. 1-6.
199. George, J. and Y. Shukla, *Emptying of Intracellular Calcium Pool and Oxidative Stress Imbalance Are Associated with the Glyphosate-Induced Proliferation in Human Skin Keratinocytes HaCaT Cells*. ISRN Dermatol, 2013. **2013**: p. 825180.
200. Valavanidis, A., T. Vlachogianni, and C. Fiotakis, *8-hydroxy-2'-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis*. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 2009. **27**(2): p. 120-39.
201. Jasper, R., et al., *Evaluation of biochemical, hematological and oxidative parameters in mice exposed to the herbicide glyphosate-Roundup((R))*. Interdiscip Toxicol, 2012. **5**(3): p. 133-40.
202. Astiz, M., M.J. de Alaniz, and C.A. Marra, *Antioxidant defense system in rats simultaneously intoxicated with agrochemicals*. Environ Toxicol Pharmacol, 2009. **28**(3): p. 465-73.
203. Astiz, M., M.J. de Alaniz, and C.A. Marra, *The oxidative damage and inflammation caused by pesticides are reverted by lipoic acid in rat brain*. Neurochem Int, 2012. **61**(7): p. 1231-41.
204. Cattani, D., et al., *Mechanisms underlying the neurotoxicity induced by glyphosate-based herbicide in immature rat hippocampus: involvement of glutamate excitotoxicity*. Toxicology, 2014. **320**: p. 34-45.

205. Slaninova, A., et al., *A review: oxidative stress in fish induced by pesticides*. Neuro.Endocrinol Lett, 2009. **30 Suppl 1**: p. 2-12.
206. Cattaneo, R., et al., *Toxicological responses of Cyprinus carpio exposed to a commercial formulation containing glyphosate*. Bull Environ Contam Toxicol, 2011. **87**(6): p. 597-602.
207. Costa, M.J., et al., *Oxidative stress biomarkers and heart function in bullfrog tadpoles exposed to Roundup Original*. Ecotoxicology, 2008. **17**(3): p. 153-63.
208. de Menezes, C.C., et al., *Roundup effects on oxidative stress parameters and recovery pattern of Rhamdia quelen*. Arch Environ Contam Toxicol, 2011. **60**(4): p. 665-71.
209. Ferreira, D., et al., *Assessment of oxidative stress in Rhamdia quelen exposed to agrichemicals*. Chemosphere, 2010. **79**(9): p. 914-21.
210. Geret, F., et al., *Effects of low-dose exposure to pesticide mixture on physiological responses of the Pacific oyster, Crassostrea gigas*. Environ Toxicol, 2013. **28**(12): p. 689-99.
211. Gluszczak, L., et al., *Acute exposure to glyphosate herbicide affects oxidative parameters in piava (Leporinus obtusidens)*. Arch Environ Contam Toxicol, 2011. **61**(4): p. 624-30.
212. Guilherme, S., et al., *DNA damage in fish (Anguilla anguilla) exposed to a glyphosate-based herbicide -- elucidation of organ-specificity and the role of oxidative stress*. Mutat Res, 2012. **743**(1-2): p. 1-9.
213. Lushchak, O.V., et al., *Low toxic herbicide Roundup induces mild oxidative stress in goldfish tissues*. Chemosphere, 2009. **76**(7): p. 932-7.
214. Modesto, K.A. and C.B. Martinez, *Roundup causes oxidative stress in liver and inhibits acetylcholinesterase in muscle and brain of the fish Prochilodus lineatus*. Chemosphere, 2010. **78**(3): p. 294-9.
215. Ortiz-Ordonez, E., et al., *Effect of Yerbimat herbicide on lipid peroxidation, catalase activity, and histological damage in gills and liver of the freshwater fish Goodea atripinnis*. Arch Environ Contam Toxicol, 2011. **61**(3): p. 443-52.
216. Sinhorin, V.D., et al., *Effects of the acute exposition to glyphosate-based herbicide on oxidative stress parameters and antioxidant responses in a hybrid Amazon fish surubim (Pseudoplatystoma sp)*. Ecotoxicol Environ Saf, 2014. **106**: p. 181-7.
217. Uren Webster, T.M., et al., *Effects of glyphosate and its formulation, roundup, on reproduction in zebrafish (Danio rerio)*. Environ Sci Technol, 2014. **48**(2): p. 1271-9.
218. Adamson, P., et al., *Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe*. Eur J Cancer, 2007. **43**(2): p. 391-401.
219. Engels, E.A., *Infectious agents as causes of non-Hodgkin lymphoma*. Cancer Epidemiol Biomarkers Prev, 2007. **16**(3): p. 401-4.
220. Hennessy, B.T., E.O. Hanrahan, and P.A. Daly, *Non-Hodgkin lymphoma: an update*. Lancet Oncol, 2004. **5**(6): p. 341-53.
221. Muller, A.M., et al., *Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology*. Ann Hematol, 2005. **84**(1): p. 1-12.

222. Acquavella, J.F., et al., *Glyphosate Biomonitoring for Farmers and Their Families: Results from the Farm Family Exposure Study*. Environmental Health Perspectives, 2003. **112**(3): p. 321-326.
223. Curwin, B.D., et al., *Urinary pesticide concentrations among children, mothers and fathers living in farm and non-farm households in Iowa*. Ann Occup Hyg, 2007. **51**(1): p. 53-65.
224. Wester, R.C., et al., *Glyphosate skin binding, absorption, residual tissue distribution, and skin decontamination*. Fundam.Appl Toxicol, 1991. **16**(4): p. 725-732.
225. Wester, R.C., D. Quan, and H.I. Maibach, *In vitro percutaneous absorption of model compounds glyphosate and malathion from cotton fabric into and through human skin*. Food Chem Toxicol, 1996. **34**(8): p. 731-735.
226. Zouaoui, K., et al., *Determination of glyphosate and AMPA in blood and urine from humans: about 13 cases of acute intoxication*. Forensic Sci Int, 2013. **226**(1-3): p. e20-5.
227. Brewster, D.W., J. Warren, and W.E. Hopkins, *Metabolism of glyphosate in Sprague-Dawley rats: tissue distribution, identification, and quantitation of glyphosate-derived materials following a single oral dose*. Fundam.Appl Toxicol, 1991. **17**(1): p. 43-51.
228. Begley, D.A., et al., *Finding mouse models of human lymphomas and leukemia's using the Jackson laboratory mouse tumor biology database*. Exp Mol Pathol, 2015. **99**(3): p. 533-6.
229. Hori, M., et al., *Non-Hodgkin lymphomas of mice*. Blood Cells Mol Dis, 2001. **27**(1): p. 217-22.
230. Morse, H.C., 3rd, J.M. Ward, and M.A. Teitell, *Mouse models of human B lymphoid neoplasms*, in *The Lymphoid Neoplasms*, I.T. Magrath, Editor. 2010, CRC Press: Boca Ratan, FL.
231. Pattengale, P.K. and C.R. Taylor, *Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias*. Am J Pathol, 1983. **113**(2): p. 237-65.
232. Ward, J.M., *Lymphomas and leukemias in mice*. Exp Toxicol Pathol, 2006. **57**(5-6): p. 377-81.
233. German Federal Institute for Occupational Safety and Health, *Proposal for Harmonized Classification and Labeling: Glyphosate*, F.O.f. Chemicals, Editor. 2016: Dortmund, Germany.

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP PRODUCTS
LIABILITY LITIGATION

MDL No. 2741

Case No. 16-md-02741-VC

This document relates to:

ALL ACTIONS

REBUTTAL REPORT OF DR. CHRISTOPHER J. PORTIER
IN SUPPORT OF GENERAL CAUSATION
ON BEHALF OF PLAINTIFFS



This rebuttal report addresses the reports of Dr. Corcoran and Dr. Foster. Because they address different issues, I address their statements separately, Dr. Corcoran first and Dr. Foster second. I do not address each issue with which I disagree; rather I identify those that I understand are appropriate for rebuttal.

REBUTTAL TO DR. CORCORAN

I. INTRODUCTION

Dr. Corcoran, in his response to my evaluation of glyphosate, demonstrates a lack of understanding of and experience with animal carcinogenicity studies. In addition, he seems to have missed some of the critical points that were made in my Expert Report, dated June 27, 2017 (hereinafter "Expert Report"). Further, he suggests an alternate analysis of the pooled data than the one I used in the Expert Report; this alternate analysis is also based on sound statistical methodology and when applied to the data set at issue here, yields effectively identical results to those in the Expert Report. These points are addressed below.

II. RESPONSE TO DR. CORCORAN'S p-VALUE COUNT

Dr. Corcoran claims that there are 1,016 p-values evaluated in the 12 animal bioassays considered acceptable for the evaluation. (Corcoran Report, at p. 9 & Tables 1 and 2). He arrives at this number by his evaluation of every neoplastic endpoint provided in the tables by **Greim et al. (2015)**^[1]. Where did these 1,016 p-values come from?

Primary tumors are cancers that develop at the anatomical site where the cancer begins. Many cancers, after developing at their primary site, can metastasize and invade other anatomical sites leading to what are referred to as secondary or metastatic tumors. In evaluating the potential for a chemical to cause cancer, the predominant interest is in the increased incidence of primary tumors, not increases in secondary tumors that arise in one place (e.g. the liver) and metastasize to invade another organ (e.g. the lung). Tumors have a specific signature, so secondary tumors found in the lung that arose from the liver will be identified as a metastatic tumor in the lung but generally would not be included in an analysis of primary tumors. Eighty-one (81) of the tumor sites appearing in Dr. Corcoran's Tables A.1-7 and B.1-5 in his Appendix are metastatic secondary tumors and should not be included in the p-value count for this analysis.

Some tumors in animal bioassays are organ-specific (e.g. hepatocellular carcinomas in liver) and some are systemic (e.g. malignant lymphomas). Systemic tumors are not analyzed separately; instead, results are combined and a single analysis is conducted on the combined results. Thus, an analysis of malignant lymphomas that are found in the lung would not be done separately from those found in a particular lymph node. There are numerous examples in Dr. Corcoran's analysis where he fails to combine systemic tumors. Instead, Dr. Corcoran erroneously conducts multiple individual analyses. Engaging in this type of data analysis is incorrect, inflates the total p-values evaluated, and fails to appreciate the significance of the reported systemic tumors that

a combined analysis demonstrates. Of special importance are the malignant lymphomas, hemangiomas, and hemangiosarcomas in mice.

Some organs in the body are made up of pairs of separate organs (e.g. kidneys, lungs, ovaries). In some of the studies analyzed by Dr. Corcoran, tumors in these organs are presented as unilateral (affecting only one side of the body) or as bilateral (affecting both sides) with separate counts given for each category. It is uncommon to analyze these categories separately, and animals with either unilateral or bilateral tumors are simply grouped together as having the tumor. Similarly, for some of the studies, Dr. Corcoran also counts animals that have a single tumor of a specific type separately from animals with multiple tumors of that same type. These also should be combined in analyses where the interest is in whether an animal got a tumor of a specific type or did not. In both of these cases, by not combining the information into a single category, important chemical-related effects can be missed and the total number of p-values is inflated.

In every well-conducted animal bioassay, the pathology generally involves the evaluation of over 40 tissues in each sex/species group from the study. Given the different types of tumors in different tissues that might arise from such a study (e.g. thyroid follicular cell carcinomas and thyroid c-cell carcinomas), there is the potential to have more than 200 different evaluations of the data from each sex/species group. A majority of these potential tumor type-by-site combinations have no tumors. In addition, many sites have only one or two tumors in all of the animals evaluated; statistical tests simply cannot detect the effect of a chemical to increase tumors in cases where so few animals have a tumor. Without the use of historical control data, it is common practice not to evaluate the tumor sites with less than three tumors and only analyze those sites with three or more tumors.

Table 1 shows the total number of primary tumor sites evaluated by Dr. Corcoran, but adjusts his data to match common practice in analyzing cancer bioassays. Table 1 adds several tumor sites that were missed by Dr. Corcoran in his tables. Table 1 also eliminates secondary tumors, combines separate counts for unilateral and bilateral tumors, combines separate counts for single and multiple tumors and eliminates individual sites for systemic tumors using only one analysis for each systemic tumor. Once the data is adjusted to correct the omissions and analytical errors, the 1,016 p-values observed by Dr. Corcoran are shown to be an inflated count of tumor analyses. As exemplified in Table 1, there are 847 possible evaluations that could have been performed on these data. Of the possible evaluations, only 319 have three or more animals with tumors and, thus, should be analyzed.

III. APPROPRIATE USE OF HISTORICAL DATA

Dr. Corcoran criticizes the application of the numbers provided by Dr. Haseman in the Expert Report since historical control data was used to evaluate some of the studies, especially those in mice. Twenty sites were evaluated using historical control data and in exactly four of those sites, the historical data changed the resulting p-value from non-significant to significant. These four are kidney carcinomas ($p_{Trend}=0.063$, $p_{Hist}=0.002$) and adenomas and carcinomas

($p_{Trend}=0.065$, $p_{Hist}=0.011$) in the study by **Knezevich and Hogan (1983)**^[2], and kidney adenomas ($p_{Trend}=0.062$, $p_{Hist}=0.005$) and hemangiosarcomas ($p_{Trend}=0.062$, $p_{Hist}=0.004$) in the **Sugimoto (1997)**^[3] study. In all four cases, the tumors are rare and all were at or close to the statistical limit of the exact trend test to identify an effect; this is the correct condition for historical control animals to make a difference in the analysis. Regardless, Dr. Corcoran implies that there is double the number of evaluations in the analysis because of the historical control evaluations. In fact, there are only 20 extra, 16 of which did not change the p-value at all.

Dr. Haseman's numbers are reasonable and come close to matching what is seen in the actual data. In male rats, there were on average 17.1 evaluations of single tumor findings in each study. Given that one would also combine tumor findings like liver adenomas and carcinomas, this is likely to add four to five additional analyses per bioassay giving 21 or 22 evaluations; Dr. Haseman chose 21.5. For female rats, there were an average of 13.4 analyses at individual sites and Dr. Haseman chose to use 25.5; this appears to be too high. Considering that females have a few more combined tumor analyses than males, I believe that 20 analyses in female rats would be more appropriate than 25.5; **Modified Table 15** (Appendix) now uses 20 tests for female rats. For male and female mice, the averages are 8.4 and 12.6, respectively, with Dr. Haseman choosing to use 10.5 and 15, again in reasonable agreement with the data. Using this arithmetic, a total of 418 possible evaluations would be done in all of these studies combined (**Modified Table 15**, Appendix), allowing almost 100 more sites than the actual count of sites with three or more animals shown in **Table 1**.

Dr. Corcoran criticizes the test used for the historical control analyses on the grounds that it does not take into account the heterogeneity that might exist across the various control groups. He references several other methods based upon statistical literature. There are several problems with this suggestion. In many cases, the methods outlined by Dr. Corcoran require the individual tumor counts from each historical control group; in many cases, only the average of the data from the historical controls is available. Where a valid historical control dataset was available, I used the mean tumor response in the controls to calculate the conditional probability of observing the trend seen in the study or a more significant trend if the true probability of response is the historical control average. Additionally, Dr. Corcoran references the manuscript by **Fung et al. (1996)**^[4] as support for his approach to historical control analysis. However, one of the analysis methods used in the Fung article is similar to the one used in the Expert Report. This method has been shown to have sound and reliable statistical characteristics when there is no extra-binomial heterogeneity in the data and to be conservative when there is heterogeneity. For hemangiosarcomas, **Giknis and Clifford (2000)**^[5] saw no tumors in 26 historical control studies (1,202 male CD-1 mice); there is no heterogeneity in these data. For kidney tumors, only the mean was provided for 46 historical control groups and only 11 animals out of 2,569 had a kidney tumor. This is broken down into seven adenomas seen in five studies and four adenocarcinomas seen in four studies; there is no heterogeneity in these data either. For the data presented here, the historical control test applied in the Expert Report was appropriate and methodologically sound. Any other reasonable statistical test applied to the four cases where historical controls changed a non-significant response to a significant response will yield effectively the same results.

IV. APPLYING LOGISTIC REGRESSION MODELING TO THE DATA SET

Dr. Corcoran criticized the pooled analysis of the data suggesting there should have been a correction for heterogeneity in the results. His long discussion of this issue, while perhaps relevant to epidemiology studies, would simply not work for animal carcinogenicity studies. In animal studies, one controls for all of the factors within a study that might make one exposure group different from any other. In pooling across multiple studies, I examined the individual experiments and only pooled data when it was clear the studies were close to identical. However, the approach suggested by Dr. Corcoran is also reasonable and it would be of value to see if the method of analysis suggested by Dr. Corcoran provides different results than the one used in the Expert Report. Thus, I reanalyzed the pooled data treating each experiment as a replicate while allowing for an effect of experiment in the evaluation (**Tables 2 and 3**). As suggested by Dr. Corcoran, the procedure used involved logistic regression modeling.

Table 2 shows four cases (highlighted in red) where the pooled analysis and the analysis using logistic regression differed in significance ($p < 0.05$). In three of the four cases, the logistic regression provided a statistically significant finding where the pooled analysis was either marginal (two cases) or not significant (one case). For thyroid C-cell tumors in male Sprague-Dawley rats, the original significant finding is no longer supported and would suggest that the marginal statistically positive finding in **Lankas (1981)**^[6] does not hold when compared to the other studies in the same sex and species and strain. In contrast, the lack of statistical significance for the pooled analyses of kidney adenomas and hepatocellular adenomas in male Sprague-Dawley rats and skin keratoacanthomas in male Wistar rats when combining **Brammer (2001)**^[7] and **Wood et al. (2009)**^[8] are reversed using logistic regression. This suggests a significant impact of glyphosate on the incidence of kidney adenomas and hepatocellular adenomas in male Sprague-Dawley rats and strengthens the finding of an increase in skin keratoacanthomas in male Wistar rats. Since kidney effects were also seen in the CD-1 mice, this strengthens the overall finding of an effect on kidney cancer rates in these animals. Since hepatocellular adenomas were also seen in Wistar rats, this strengthens that finding as well.

Four tumors in **Table 2** were not evaluated in the pooled analysis in the Expert Report; adrenal cortical carcinomas in female Sprague-Dawley rats and pituitary adenomas in male and female Wistar rats. These tumors did not appear in the Expert Report. Dr. Corcoran analyzed each of the individual tumor sites from all of the studies whereas the analysis in the Expert Report focused on tumors that were identified by regulatory authorities as increased in at least one study. Dr. Corcoran saw seven statistically significant tumor sites that were not discussed in the Expert Report. These are as follows: adrenal cortical carcinomas in female rats in the study by **Stout and Ruecker (1990)**^[9]; skin intracutaneous cornifying epitheliomas (these are the same as keratoacanthomas) in male rats from the study by **Atkinson et al. (1993)**^[10]; basal cell tumors in male rats in the study by **Enemoto (1997)**^[11]; pituitary adenomas in both male and female rats in the study by **Wood et al. (2009)**^[8]; splenic lymphosarcomas in female mice from the study by **Knezevich and Hogan (1983)**^[12]; and Harderian gland adenomas in female mice from the study by **Sugimoto (1997)**^[13]. In addition, after reviewing all of the findings in the Expert Report, it was

clear that the tumor incidence rates for skin keratoacanthomas in male rats from the study by **Enemoto (1997)**^[11] were incorrect and an additional animal with this tumor was seen in the highest exposure group. Modifications to the original tables are provided as **Modified Tables 1-7** (rats) and **Modified Tables 9-12** (mice) in the Appendix. As before, where possible, any significant increase in a tumor as a function of dose seen in one study is analyzed in all remaining studies using the same sex, species, and strain. The new statistically significant findings are highlighted in the modified tables.

Returning to **Table 2**, after pooling all of the data for adrenal cortical carcinomas in female Sprague-Dawley rats, the exact trend test statistic is not significant. Logistic regression is also not significant with a p-value of 0.984. The lack of significance in this tumor is due to the high rates for this tumor in the **Lankas (1981)**^[5] study and low rates in the remaining studies. The **Lankas (1981)**^[5] study exposed rats for 26 months and the other three studies for only 24 months explaining, to some degree, the higher background rate in the **Lankas (1981)**^[6] study (only six of the 25 cortical adenomas seen in this study occurred in rats dying before 730 days). Removing the **Lankas (1981)**^[6] study and only pooling the three 24-month studies yields a significant trend in both tests. The significant trend seen for adrenal cortical adenomas cannot be easily discarded and suggest a potential for glyphosate to also affect adrenal cortical tumors.

For pituitary tumors in female Wistar rats, the pooled analysis was significant ($p=0.005$) and logistic regression was not significant ($p=0.123$). As noted in the Expert Report, the **Suresh (1996)**^[12] study has very different control rates for pituitary tumors when compared with the other two studies. For this tumor, the categorical variable linked to the experiment by **Suresh (1996)**^[12] was statistically significant ($p<0.001$). As before, if we remove the **Suresh (1996)**^[12] study from the analysis and only pool the studies by **Brammer (2001)**^[7] and **Wood et al. (2009)**^[8], the results are statistically significant by both tests (**Table 2**). For pituitary tumors in male Wistar rats, none of the pooled analyses were significant (**Table 2**). These results would suggest there is limited support for an effect of glyphosate on pituitary adenomas in female Wistar rats.

Pooling the remaining new findings in Sprague-Dawley rats across the studies shows positive results for skin keratoacanthomas ($p_{\text{pooling}}=0.010$; $p_{\text{logistic}}=0.033$) and basal cell tumors ($p_{\text{pooling}}=0.011$; $p_{\text{logistic}}=0.020$) in males. Since the pooled results for skin keratoacanthomas in male Wistar rats was also significant ($p_{\text{pooling}}\leq 0.001$; $p_{\text{logistic}}=0.008$), there is strong support for an impact of glyphosate on skin keratoacanthomas in both male Sprague-Dawley rats and male Wistar rats.

Table 3 shows the pooled analyses for mice. None of the significant findings in the pooled analysis shown in the Expert Report were altered by the logistic regression analysis. For both hemangiosarcomas and kidney adenomas and carcinomas when pooling the 18-month studies by **Sugimoto (1997)**^[3] and **Wood et al. (2009)**^[3], the logistic regression model had difficulty

estimating the parameter for control response¹ so logistic regression was replaced with a simple linear model.

The Harderian gland adenomas seen in the study by **Sugimoto (1997)**^[3] remain significant when combined with data from the other 18-month study by **Wood et al. (2009)**^[13]. As seen in **Modified Table 11** (Appendix), there is a slight increase in Harderian gland tumors in the **Wood et al. (2009)**^[13] study. The results remain statistically significant when combined with the results from **Knezevich and Hogan (1983)**^[2]; **Atkinson (1993)**^[10] did not evaluate Harderian glands.

The one remaining significant finding when applying logistic regression is an increase in composite lymphosarcomas in the spleen in female mice in the study by **Knezevich and Hogan (1983)**^[2]. In the **International Classification of Diseases, Revision 9 (1975)**^[14] (ICD-9), lymphosarcomas were classified under the heading of “Lymphosarcoma and reticulosarcoma”. This was changed in **Revision 10 (1990)**^[15] (ICD-10) where they are no longer classified^[15]. In ICD-10, lymphosarcomas are approximately equal to lymphomas in the category of “Other specified types of non-Hodgkin lymphoma”. This is a highly relevant finding for the causality argument for non-Hodgkin lymphoma in humans. This systemic tumor should be aggregated over all tissue sites with this tumor from this study. However, that is not possible without the individual animal pathology data from the study since, like malignant lymphomas, this tumor is aggressive and any animal with one tumor of this type is likely to have many other tumors of this same type; data summarized by organ cannot be used to obtain tumor incidence of at least one tumor in each animal. The remaining studies in CD-1 mice did not use this tumor classification for any of the lymphoid tumors identified; this is probably due to the classification change identified in ICD-10.

The new **Modified Table 15** (Appendix) includes all of the tumors identified in the Expert Report and those of Dr. Corcoran. In the original **Table 15**, when an increase occurred in both adenomas and in adenomas and carcinomas, only the more malignant finding was listed. In the **Modified Table 15**, that is no longer the case and each of these tumors is counted separately. With the exception of male Sprague-Dawley rats, the observed number of tumors are at or near the expected number for the different sex/strain groups in rats (**Modified Table 15**). For male Sprague-Dawley rats, 4.3 positive tumor findings with $p_{Trend} \leq 0.05$ or $p_{Hist} \leq 0.05$ are expected and 10 are observed ($p=0.01$) while 0.8 cases with $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ are expected and two were observed ($p=0.21$). In female CD-1 mice and Swiss Albino mice, the expected and observed numbers are approximately equal. However, in male CD-1 mice, there were 2.1 tumors expected for $p_{Trend} \leq 0.05$ or $p_{Hist} \leq 0.05$ and eight were observed ($p < 0.001$) and there were 0.4 expected for $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ and five were observed ($p < 0.001$). The findings

¹ In logistic regression, modeling is done using the $\text{logit}(p)$ where p is the probability of response and modeling is done using $\text{log}\left(\frac{p}{1-p}\right) = \alpha + \beta \times \text{dose}$. If the control tumor response is 0, then $\text{log}\left(\frac{p}{1-p}\right) = -\infty$ and so the best estimate for α is also negative infinity. In these cases, numerical fitting algorithms have difficulty with estimating α which can effect the estimate and standard error of β . The general linear model has the form $p = \alpha + \beta \times \text{dose}$ and α can easily be estimated to be zero for the control response.

for male Sprague-Dawley rats and male CD-1 mice in these studies could not have occurred by chance alone. Even if one incorrectly groups all sexes and species together, there are 20.9 expected responses for $p_{Trend} \leq 0.05$ or $p_{Hist} \leq 0.05$ and 30 observed ($p=0.032$) and 4.2 expected responses for $p_{Trend} \leq 0.01$ or $p_{Hist} \leq 0.01$ and 12 observed ($p=0.001$). Thus, chance does not explain all of the positive results seen in these studies.

Dr. Corcoran makes only one comment relating to **Table 15** suggesting that the historical control evaluations explain the difference between **Table 15** and his results. As noted earlier, the use of historical control data in this instance is justified and based on sound and accepted methodology given the rarity of the four tumor sites where the historical control data made a difference. If the historical control evaluations are included in **Modified Table 15**, that adds three additional evaluations to the male rats (one with $p < 0.01$), 1 to female rats ($p < 0.001$), 0 to female mice and 18 to male mice (five with $p < 0.01$ and eight with $p < 0.05$). The number of evaluations for each group would then become 22 for male rats, no real change for female rats or female mice, and a change to 13.5 for male mice. The number of findings in the **Modified Table 15** that were significant at $p \leq 0.05$ by either test would change from 30 (expected 20.9) out of 418 reasonable analyses ($p=0.032$) to 38 (expected 22) out of 440 ($p < 0.001$). Similarly, the number of findings in the **Modified Table 15** that were significant at $p \leq 0.01$ by either test would change from 12 (expected 4.2) out of 418 reasonable analyses ($p=0.001$) to 18 (expected 4.4) out of 440 ($p < 0.001$). It is clear that incorporation of the tests using historical controls into **Modified Table 15** would make it even less likely that all of these findings are due to chance.

V. CONCLUSION

Dr. Corcoran has raised certain issues relating to the pooling of experiments that have been addressed in this response. There is no significant difference between the results from the methods proposed by Dr. Corcoran and those in the Expert Report. Both are sound methods for evaluating the overall significance of multiple animal carcinogenicity studies. Dr. Corcoran also identified several tumors that were not evaluated in the Expert Report, which are now included in my expert opinion as updated in this response. Dr. Corcoran also expressed concerns about the number of analyses and the effect of all of these analyses on false-positive error rates. As explained above, Dr. Corcoran misunderstood how analyses are conducted for animal cancer studies.

In summary, Dr. Corcoran's concerns have led to additional analyses that strengthen the case that glyphosate causes cancers in rodents, especially lymphatic and hematological cancers in male mice. The new analyses strengthen the biological plausibility, biological gradient, and coherence arguments developed by Hill (1965)^[16] supporting the conclusion that glyphosate can cause non-Hodgkin lymphoma in humans.

Table 1: Number of tumor sites with one, two, and three or more tumors in all dose groups combined from the 12 rodent studies of glyphosate

Study	Numbers of Sites with Specified Number of Tumors in All Exposure Groups					
	Exactly 1 Tumor		Exactly 2 Tumors		3 or More Tumors	
	Males	Females	Males	Females	Males	Females
Lankas (1981) S-D Rats	16	17	4	2	22	25
Stout and Ruecker (1990) S-D Rats	21	24	7	4	16	12
Atkinson et al. (1993) S-D Rats	20	16	5	3	15	9
Brammer (2001) Wistar Rats	20	20	5	5	16	13
Suresh (1996) Wistar Rats	17	20	2	3	11	9
Enemoto (1997) S-D Rats	29	18	3	5	21	12
Wood et al. (2009) Wistar Rats	27	17	2	8	19	14
Totals Rats	150	132	28	30	120	94
Average Rats	21.5	18.9	4	4.3	17.1	13.4
Knezevich and Hogan (1983) CD-1 Mice	20	44	5	7	9	17
Atkinson et al. (1993) CD-1 Mice	10	11	4	2	9	14
Wood et al. (2009) CD-1 Mice	8	14	2	2	10	13
Sugimoto (1997) CD-1 Mice	10	14	5	5	6	11
Kumar (2001) Swiss Albino Mice	4	16	3	2	8	8
Total Mice	52	99	19	18	42	63
Average Mice	10.4	19.8	3.8	3.6	8.4	12.6

Table 2: Comparison of pooled analyses with and without a correction for experiment in Rats

Studies	Sex	Tumor	General Linear Model		Original Pooled Analysis
			Slope (se)	P-value	
Lankas (1981) ^[6] Enemoto (1997) ^[11] Atkinson et al. (1993) ^[10] Stout and Ruecker (1990) ^[9] Sprague-Dawley Rats	M	Testicular Interstitial Cell Tumors	0.513 (0.517)	0.461	0.608
	F	Thyroid C-cell Adenomas and Carcinomas ²	2.95 (2.79)	0.145	0.390
	M	Thyroid C-cell Adenomas and Carcinomas	2.29 (2.78)	0.205	0.041
	M	Thyroid Follicular-cell Adenomas and Carcinomas ²	0.930 (5.49)	0.433	0.618
	M	Pancreas Islet-Cell Tumors ²	3.02 (4.07)	0.260	0.275
	M	Hepatocellular Adenomas ²	9.65 (4.30)	0.012	0.073
	M	Kidney Adenomas ²	14.3 (8.27)	0.042	0.200
	M	Kidney Adenomas (excluding Lankas, 1981)	14.7 (8.29)	0.038	0.031
	F	Adrenal Cortical Carcinoma ²	26.5 (13.6)	0.984	0.997
	M	Skin Keratoacanthoma	11.1 (4.61)	<0.001	<0.001
M	Basal Cell Tumors	23.3 (11.4)	0.020	0.011	
Brammer (2001) ^[7] Wood (2009) ^[8] Suresh (1996) ^[12] Wistar Rats	M	Hepatocellular Adenomas ²	40.0 (20.9)	0.030	0.051
	F	Mammary Gland Adenomas and Adenocarcinomas ²	2.11 (3.25)	0.258	0.459
	M	Skin Keratoacanthoma ²	10.4 (5.65)	0.033	0.010
	M	Pituitary Adenomas ²	0.266 (2.32)	0.454	0.177
	F	Pituitary Adenomas ²	1.89 (1.64)	0.123	0.005
Brammer (2001) ^[7] Wood (2009) ^[8] Wistar Rats	M	Hepatocellular Adenomas	1.32 (6.11)	0.015	0.013
	F	Mammary Gland Adenomas and Adenocarcinomas ²	7.00 (3.62)	0.027	0.037
	M	Skin Keratoacanthoma ²	10.4 (5.65)	0.033	0.053
	M	Pituitary Adenomas	0.146 (2.38)	0.476	0.503
	F	Pituitary Adenomas ²	3.34 (1.76)	0.029	0.017

Entry is multiplied by 10³ for ease in presentation; ²at least one of the categorical variables for experiment in the logistic regression analysis for these tumors was statistically significant (p<0.05)

Table 3: Comparison of pooled analyses with and without a correction for experiment in CD-1 Mice

Studies	Sex	Tumor	General Linear Model		Original Pooled Analysis
			Slope (se)	P-value	
Sugimoto 1997 ^[3] , Wood 2009 ^[13] 18 Month	M	Hemangiosarcoma ¹	7.91e-2 (1.81e-7)	<0.001	0.015
	M	Kidney Adenoma and Carcinoma ¹	7.91e-2 (1.81e-7)	<0.001	0.015
	M	Malignant Lymphoma	4.24 (1.67)	0.005	0.005
	M	Lung Adenocarcinoma ²	2.24 (1.47)	0.063	0.417
	F	Hemangioma (any tissue)	5.92 (2.293)	0.005	<0.001
	F	Harderian Gland Adenoma	3.66 (1.81)	0.021	0.005
Atkinson 1993 ^[17] , Knezevich 1983 ^[2] 24 Month	M	Hemangiosarcoma	3.58 (4.32)	0.204	0.490
	M	Kidney Adenoma and Carcinoma	2.89 (2.00)	0.075	0.081
	M	Malignant Lymphoma	-0.739 (1.53)	0.686	0.653
	M	Lung Adenocarcinoma ²	-2.28 (2.01)	0.872	0.985
	F	Hemangioma (any tissue)	-3.62 (5.88)	0.731	0.424
Sugimoto 1997 ^[3] , Wood 2009 ^[13] , Atkinson 1993 ^[17] , Knezevich 1983 ^[2]	M	Hemangiosarcoma ²	6.82 (3.72)	0.033	0.045
	M	Kidney Adenoma and Carcinoma	4.12 (1.84)	0.013	0.005
	M	Malignant Lymphoma	1.36 (1.02)	0.093	0.073
	M	Lung Adenocarcinoma ²	0.259 (1.10)	0.407	0.937
	F	Hemangioma (any tissue)	3.01 (1.61)	0.031	0.018
	F	Harderian Gland Adenoma ^{2,3}	2.77 (1.62)	0.043	0.005

Entry is multiplied by 10⁴ for ease in presentation; ¹because this tumor had a zero response in the control and low exposure groups and because the logit(0)=-infinity, the logistic regression was not appropriate in this case and a simple general linear model was used; ²at least one of the categorical variables for experiment in the logistic regression analysis for these tumors was statistically significant (p<0.05); ³ this analysis excludes the study by Atkinson et al. (1993) since they did not examine Harderian gland

REBUTTAL OF DR. FOSTER

I. INTRODUCTION

Dr. Foster dismissed 18 of the 19 statistically significant findings in the animal carcinogenicity studies identified in my Expert Report. He did not comment on the increased incidence of hemangiomas in female Swiss albino mice in the study by Kumar (2001)^[18]. Dr. Foster provided rationale for each of his dismissals based on the significant changes in tumor incidence failing to meet his criteria for a positive study. Table 4, illustrates the six categories of criteria that Dr. Foster uses to dismiss statistically significant ($p \leq 0.05$) positive findings from the 12 studies exposing rats and mice to glyphosate. Only certain categories were relevant to any one positive finding discussed in the Expert Report. The categories used by Dr. Foster are briefly described below:

Dose-Response: For several tumors, Dr. Foster, as one of his arguments, found there was no dose-response in the data.

Historical Control: Failure of the response to be outside the range of the historical control data or for the control response to be below the range of the historical control data was also an argument Dr. Foster used to dismiss studies.

Precursor Lesion: Some tumors can go through a progression from non-malignant lesions to cancer; failure to see increases in both non-malignant tumors and malignant tumors was another criterion Dr. Foster used.

Other Studies: If all of the studies did not give the same result, Dr. Foster used this as part of the criteria for dismissal.

Survival: In two studies, survival in the highest exposure group was different than in the controls, and Dr. Foster used this as part of the reason for dismissal.

Fisher Test: In several studies, Dr. Foster used a lack of statistically significant pairwise comparisons between the higher doses and controls as part of the reasoning to dismiss positive tumor findings.

Rather than going study-by-study and addressing these points, this rebuttal looks at each category separately and then discusses their impact in each study.

II. Dose-Response

Dr. Foster shows a lack of understanding of statistics in the use of this criteria. While Dr. Foster does not define what he means by a lack of dose-response, my interpretation of this concept is that as the dose increases, the probability of a tumor cannot decrease (this is known as a non-decreasing function in mathematics). As an example, if the responses from control to high dose

in a four-dose study were 2%, 3%, 5%, 7%, this would constitute clear dose-response whereas 2%, 1%, 4%, 7% would not. The problem with this criterion is that it has very significant impacts on false-positive and false-negative rates.

In any statistical analysis, there is a null hypothesis and an alternative hypothesis. In an animal carcinogenesis study, the null hypothesis means there is no impact of the chemical on the tumor rates; the alternative hypothesis means the chemical increases the tumor rates. A false-positive error occurs when one incorrectly rejects the null hypothesis and decides the chemical causes cancer when it really does not cause cancer. A false-negative error occurs when one does not reject the null hypothesis even though the chemical does cause cancer. The rates at which these errors occur for a specific test can be calculated.

So, what is the impact of requiring non-decreasing dose-response in addition to statistical significance? Using statistical simulations², it is easy to answer this question. Consider one of the examples where dose-response was part of Dr. Foster's criteria for dismissing the tumor. In the study by **Sugimoto (1997)**^[3], the control response for malignant lymphomas in male CD-1 mice was 4% and the response in the high exposure group was 12%. Let's begin by estimating the probability of a false-positive error and the impact of requiring non-decreasing dose-response.

If we assume that the true background is 4% and there is no dose-response, then we can, by random sampling on the computer, generate 1,000 datasets where each group is assumed to have a true response of 4% regardless of the dose. By random chance, these groups will sometimes result in a positive response. If we reject the null hypothesis when $p_{Trend} \leq 0.05$, the exact trend test yields a false positive rate of 5%. That is, 5% of the time, by chance, the null hypothesis will be rejected. This is exactly what should happen when a test is operating correctly. What happens then if we also require that the resulting pattern of dose-response be non-decreasing? Using the exact same simulated data, the resulting false-positive error rate now drops to 2.8%, almost half of what was expected. On the surface, one might think this is a good and acceptable outcome since the error rate has dropped, but by reducing the false-positive rate, the false-negative rate increases. Let's again look at our example.

² Statistical simulations are a critical tool for understanding the behavior of a statistical test in a specific setting. In this case, 1000 samples are drawn from a binomial distribution where the underlying probability of a tumor and the number of animals is specified; for example, the probability of a tumor is 0.04 for all of the groups when calculating the probability of a false positive error and each dose group has 50 animals in it. For each simulated data set produced, the Armitage linear trend test is applied and if the p-value is ≤ 0.05 , that simulation is given a value of 1 (positive tumor trend with increasing exposure) otherwise, it is given a value of zero. After 1000 simulations are completed, the number of cases with a value of 1 are counted and the estimated false-positive error rate is that number divided by 1000. Thus, for the case discussed above, fifty of the 1000 simulations were assigned a value of 1 and the underlying false-positive error rate is then $50/1000=0.05$ or 5%.

Table 4: Criteria used by Dr. Foster to dismiss 19 statistically significant ($p \leq 0.05$) identified using the Armitage linear trend test in proportions to evaluate 12 studies of glyphosate exposure to rats and mice

Study	Sex	Tumor	Dose-Response	Hist. Cont.	Pre-Cursor Lesion	Other Studies	Survival	Fisher Test
Lankas (1981) SD Rat	M	Testicular Tumors	x	x	x	x	x	
	F	Thyroid C-Cell			x	x		
Stout and Ruecker (1999) SD Rat	M	Liver Adenomas	x	x	x	x		
	M	Liver Adenomas and Carcinomas	x	X	x	x		
	F	Kerato-acanthoma ($p > 0.05$)		x				
	F	Thyroid C-Cell Adenomas		x				
	F	Thyroid C-Cell Adenomas and Carcinomas		x				
Brammer (2001) Wistar Rats	M	Liver Adenomas	x	x	x		x	
Wood et al. (2009) Wistar Rats	F	Mamm. Gland Adeno-carcinomas	x	x		x		
	F	Mamm. Gland Tumors	x	x		x		
	M	Kerato-acanthoma	x					x
Atkinson et al. (1993) SD Rats	M	Follicular Cell Tumors		x		x		
Enemoto (1997) SD Rats	M	Kidney Adenomas	x		x	x		x
Knezevich and Hogan (1983) CD-1 Mice	M	Kidney Tumors	x		x	x		
Atkinson (1993)	M	Hemangio-sarcoma		x		x		
Sugimoto (1997)	M	Malignant Lymphoma	x	x		x		x
	F	Hemangiomas				x		
Wood et al. (2009)	M	Malignant Lymphomas		x				
	M	Lung Adeno-carcinoma	x		x	x		x

Now, instead of assuming there is no dose-response, assume there is linear dose-response with the response in the control group is 4% and the response in the high exposure group is 12%. Since this response is linear with dose, and we use the doses for males from the **Sugimoto (1997)**^[3] study, the expected response at the four dose groups are 4% at control, 4.3% at 165 mg/kg, 5.5% at 838.1 mg/kg and 12% at 4348 mg/kg. Using these as the target responses at each dose, 1,000 studies with random error can be simulated and one can count how often the null hypothesis is not rejected and an incorrect conclusion that the chemical does not cause malignant lymphomas is accepted. Using only the trend test, without the requirement of non-decreasing dose-response, yields a false-positive error rate of 29%. This is not a bad rate for this shallow dose-response. Requiring that the dose-response be non-decreasing results in a false-positive error rate of 86%. This is unacceptable and is not surprising. Just evaluating response at control and at the lowest dose, one can see that they are almost identical in response. Thus, by random chance, one would expect the lowest dose to be below the control response about 50% of the time and each time this happens, Dr. Foster's approach would reject any positive finding in a trend test. Thus, regardless of the responses in the other exposure groups, one would accept the null hypothesis and generate a false-negative error.

Dr. Foster used this argument as one of his reasons for dismissing 11 of the 19 tumors (58%) with significant dose-response trends. His use of these criteria is not methodologically sound.

III. Historical Controls

Dr. Foster begins his discussion of the interpretation of the bioassay results by stating "*I agree with Dr. Portier that it is best to compare data with contemporary controls*". Despite this statement, Dr. Foster then goes on to use historical controls as part of his reasons for dismissing 13 of the 19 tumors (68%) in Table 4. In simple terms, rejecting a significant finding observed when comparisons are made to the concurrent control because the responses fall into the range of the historical controls is akin to replacing the concurrent control with the largest control response ever seen.

During the course of an animal study, all aspects of the animal's life are controlled; the air they breathe, the food they eat, the light-dark cycle in the laboratory, handling of the animals, etc. Certain issues are very difficult to control such as noise in the laboratory, outside radiation that may seep into the laboratory, slight differences in batches of feed from one week to the next, odors drifting in from other areas of the building, etc. For these uncontrolled variables, every animal in the study is subject to the same problems, thus the controls in the study see the same uncontrolled exposures as do the treated animals. In addition, while strains of animals may be the same, there is variability in response if the animals arise from different laboratories or are even born at different times of the year. When controls are used from another study, this allows for the possibility that uncontrolled factors from that other study could have affected those controls making their response different from the concurrent control and from the animals exposed in the current experiment. Most of the guidelines developed for animal studies clearly state that the concurrent control is the best control to use for analyzing a cancer

bioassay as noted on page 21 of the Expert Report. In fact, the IARC guidelines^[19] are explicit on the issue of using historical controls stating that

*“Formal statistical methods have been developed to incorporate historical control data into the analysis of data from a given experiment. These methods assign an appropriate weight to historical and concurrent controls on the basis of the extent of between-study and within-study variability: less weight is given to historical controls when they show a high degree of variability, and greater weight when they show little variability. **It is generally not appropriate to discount a tumour response that is significantly increased compared with concurrent controls by arguing that it falls within the range of historical controls, particularly when historical controls show high between-study variability and are, thus, of little relevance to the current experiment. In analysing results for uncommon tumours, however, the analysis may be improved by considering historical control data, particularly when between-variability is low. Historical controls should be selected to resemble the concurrent controls as closely as possible with respect to species, gender and strain, as well as other factors such as basal diet and general laboratory environment, which may affect tumour-response rates in control animals**”* (emphasis added).

The scientific reasons for not using historical control ranges to reject a positive finding are clear, but there is also a statistical reason. As the number of studies in the historical control database increases, so does the range of responses. The net effect of this is that, as the historical control dataset gets larger, one is more likely to reject a positive if one insists the response be outside the range of the historical controls. Again, going back to the example of malignant lymphomas in male mice from the study by **Sugimoto (1997)**^[3], the false positive rate is 5% when only the exact trend test is applied to the simulated data where there are no chemical-related effects in any of the dose groups. If there are 10 historical control groups with exactly the same background response as the controls (4%) and no extra-binomial variability (which could be caused by uncontrolled or different exposures), the false-positive error rate drops to 1.9% and if there are 26 historical control groups, as is the case for the **Sugimoto (1997)**^[3] study, the false-positive error rate drops to 1.1%. This results in an increase in the false-negative error rate from 29% using just the trend test results to 38% with 10 historical control groups to 50% for 30 historical control groups.

This increase in the false-negative rate is expected since one is only rejecting positive findings, never rejecting negative findings.

Dr. Foster’s discussion regarding the range of the historical control data is misleading. Again, consider the example of malignant lymphomas in male rats from the study by **Sugimoto (1997)**^[3]. Dr. Foster concludes “... the incidence of these tumors falls within the range of historical controls in the Giknis (2000) report (0-14%) cited by Dr. Portier and the range of historical controls (3-19%) from contemporaneous studies conducted at the same laboratory (BFR, 2015)”. After studying the **BFR (2015)**^[20] document, I can only find one reference to

historical controls for malignant lymphomas in male Wistar rats (page 91) which references the study by **Giknis and Clifford (2000)**^[5], showing a range of 1.45% to 21.7%. However, they misread the **Giknis and Clifford (2000)**^[5] paper, grouping 18-month controls with 24-month controls and failing to recognize there were 13 studies with no tumors in the controls making the lower range value 0%.

Figure 1 shows a histogram of the incidence rates in the twenty-six 18-month historical control groups for malignant lymphomas in male CD-1 mice from the study by **Giknis and Clifford (2000)**^[5]. It is clear from this figure that the control response from the study by **Sugimoto (1997)**^[3] is easily within the usual range of control responses for malignant lymphomas in male Wistar rats. The higher end of the historical control is driven by response in a single study that is almost double the value of the next lowest response and about five times the value of the median response. This pattern is quite common in the tumors that Dr. Foster dismisses because of historical controls. This is demonstrated by the five examples presented in **Figure 2**. In all five cases, the control tumor response is in a reasonable range of the historical control response and there is good reason to use the concurrent control group in the analysis and ignore the historical controls.

Figure 1: Incidence rates in the twenty-six 18-month historical control groups for malignant lymphomas in male CD-1 mice from the study by **Giknis and Clifford (2000)**^[1]





Figure 2: Incidence rates in the historical control groups for several tumors



Dr. Foster is also very selective in his presentation of the historical control data, not mentioning situations where the tumor response is well outside the range of the historical controls. Here are two examples:

Lankas (1981)^[6]: Testes interstitial cell tumor – historical control range 3-7% (Monsanto), 0% to 9.3% (Giknis and Clifford (2004)^[21]) – response at highest dose is 12%

Enemoto (1997)^[11]: Kidney Adenoma – historical control range 0%-4% (**Giknis and Clifford (2011)^[22]**), note 23 of 30 studies had 0% in the control group) – response at highest dose is 8%.

There were several other wrong or misleading comments in Dr. Foster's report regarding historical controls. On page 18, he mentions the average historical control rate of mammary gland tumors in female Sprague-Dawley rats (57%) and in the same sentence includes Wistar rats implying the control rate of mammary gland tumors in these animals is also large. However, according to **Giknis and Clifford (2011)^[22]** the mean response for mammary gland adenomas in female Wistar rats is 2.22% and for adenocarcinomas it is 2.96%. He also states on page 24 that the historical control data from **Giknis and Clifford (2005)^[23]** "*indicate it is unusual to have zero lymphomas in the control group*" of male Wistar rats. However, **Giknis and Clifford (2005)^[23]** show 8 of the 26 control groups (31%) from 18-month studies have no animals with a malignant lymphoma; thus having no tumors in the control group is not unusual. The actual responses for malignant lymphomas for all of the control groups in the database provided by **Giknis and Clifford (2005)^[23]** are shown in **Figure 2**.

Finally, there are four tumor sites where, used correctly, the historical control data does contribute to the interpretation of the result. These four are kidney carcinomas ($p_{Trend}=0.063$, $p_{Hist}=0.002$) and adenomas and carcinomas ($p_{Trend}=0.065$, $p_{Hist}=0.011$) in the study by **Knezevich and Hogan (1983)^[2]**, and kidney adenomas ($p_{Trend}=0.062$, $p_{Hist}=0.005$) and hemangiosarcomas ($p_{Trend}=0.062$, $p_{Hist}=0.004$) in the **Sugimoto (1997)^[3]** study. For hemangiosarcomas, **Giknis and Clifford (2000)^[5]** saw no tumors in 26 historical 18-month control studies (1,202 male CD-1 mice) making the two tumors seen in the highest dose group in the study by **Sugimoto (1997)^[3]** both statistically and biologically compelling. For kidney tumors, **Giknis and Clifford (2000)^[5]** only provide the mean tumor response for 46 historical control groups (twenty-six 18-month studies and twenty 24-month studies) and only 11 animals out of 2569 (0.4%) had a kidney tumor. This is broken down into seven adenomas seen in five studies and four adenocarcinomas seen in four studies; thus 41 control groups had no adenomas and 42 had no adenocarcinomas with the remaining four groups each having only one adenocarcinoma. Thus, the two adenomas seen in the study by **Sugimoto (1997)^[3]** and the three carcinomas seen in the study by **Knezevich and Hogan (1983)^[2]** are significant and biologically important.

Thus, Dr. Foster provides an unbalanced evaluation of the historical control data, failing to discuss it when it strengthens a significant finding and incorrectly using the range of the historical controls to reject the concurrent control group.

IV. Precursor Lesions

Dr. Foster seems to believe that virtually all tumors arise from precursor lesions like hyperplasia and adenomas and that if one does not see increases in both adenomas and carcinomas, the finding is not chemically related and can be dismissed. This is an overly simplistic view of a complicated process. For example, if one looks at human digestive tract cancers, while it is clear that many carcinomas arise from adenomas, it is also likely that some arise *de novo*^[24-26].

In humans, other organs and tissues have not been as carefully studied. In animal studies, there are numerous cases in which carcinomas and adenomas combined are increased when adenomas are not increased, many cases where adenomas are increased without an increase in carcinomas and fewer cases where only carcinomas are increased. For example, in an evaluation^[27] of 64 National Toxicology Program (NTP) carcinogenicity studies in rats and/or mice that produced alveolar/bronchiolar adenomas and/or carcinomas, there are multiple studies that the NTP labels as clear evidence of carcinogenicity or positive for carcinogenicity³ where there are only adenomas, only carcinomas or both.

Cancer is a multistage process which changes cells from being normal to being malignant through a variety of steps (**Figure 3**). In general, normal cells obtain damage to their DNA. Normally, this damage can be repaired by processes in the cell that specialize in keeping the DNA sequence from changing. If the damage to the DNA is not repaired and the cell replicates, the change in the DNA sequence can become permanent in the cell and is referred to as a mutation. Most cancers require cells to undergo several mutations before the cell will completely lose growth control and begin invading the surrounding tissue. Chemicals can affect this process at many points as cells progress from a normal state to a malignant state (**Figure 3**). Precursor lesions, like hyperplastic nodules and adenomas, are generally thought to be derived from cells that are at early stages of the carcinogenic process.

Two issues are critical in understanding what is seen in the results of an animal bioassay versus the underlying biology. First, all tumors in a glyphosate study are only observed at one time in the course of the study; when the animal dies. Thus, this entire process of multistage carcinogenesis is invisible because one does not see the adenoma in the animal and then later see the carcinoma; one only sees some animals with adenomas and others with carcinomas. Second, seldom will pathologists examine the tissue surrounding a tumor and list an animal as having both a carcinoma and an adenoma. Since carcinomas generally grow faster than adenomas, the carcinoma would be the predominant pathology and that animal would be listed as having only the carcinoma. Hence, there is a likely under-reporting of the potential number of adenomas that actually occurred.

If a chemical affects mutations or cellular replication at an early stage in this process and the final stages in the process occur spontaneously (without chemical impact), one is likely to see an increase in all of the precursor lesions as well as malignancies. As an example, suppose a chemical increases the probability of having an adenoma from 10% to 30% and the probability of an adenoma becoming a carcinoma remains constant at 30%; then, with 50 animals in each group, you would expect five adenomas in controls and 15 in the treated animals. If 30% of these adenomas progress to become malignancies, one would expect one to two animals with carcinomas in controls and four to five carcinomas in the exposed animals. Now, because the carcinoma would grow within the adenoma, one is no longer likely to count an animal with a carcinoma as having an adenoma because the cancer becomes the predominant pathology. Thus, one would likely see adenomas in three to four animals (subtract one to two from the

³ Clear evidence and positive are designations used by the National Toxicology Program for chemicals that causally induced the observed increase in tumors.

original five) in control and nine to 10 animals in the treated group (subtract five to six from the original 15).

If the tumor affects all stages of the process, then other patterns can occur. Consider the same example, but the chemical changes the rate at which adenomas become carcinomas from 20% to 60%. Now, one would expect one to two animals with carcinomas in the controls and nine animals in the treated group. The number of expected adenomas would then be three to four in controls and drop to six in the high dose group, an increase that is not likely to be significant.

If the chemical only affects the late stages (not the early stages) of cancer development, an actual decrease is seen in the adenoma counts. For example, if adenomas occur spontaneously in 30% of the animals, then with 50 animals in each group, it is expected that 15 animals in both the control and treated groups will develop adenomas. If the chemical changes the rate of conversion from adenomas to carcinomas from 20% to 60%, one would expect three tumors in the control group and nine in the treated group. Subtracting these from the adenoma counts would result in adenomas in 12 control animals and only six treated animals; a decrease.


Time also plays a role in this process. Even if the chemical is affecting all stages of the process, the final stages of tumor progression may take longer than the animal lives, resulting in an increase in adenomas without a subsequent increase in carcinomas.

Finally, genotoxic carcinogens have the capability to produce carcinomas without adenomas through rapidly inducing multiple mutations. Along these same lines, some tumors have no precursor lesions (e.g. malignant lymphomas, hemangiosarcomas)

While this is a simplistic illustration of a very complicated process, it outlines the basic reasons why any pattern is possible when one is only evaluating tumors in the animals at one point in time and counting adenomas and carcinomas.

As an illustration using real data, consider the lung adenomas and adenocarcinomas seen in male mice in the study by **Wood et al. (2009)**^[13]. Going from control to highest dose, adenoma counts were 9/51, 7/51, 9/51 and 4/51 while adenocarcinoma counts were 5/51, 5/51, 7/51 and 11/51. In not one case is there an animal listed with both of these pathologies in the lung. Unless Dr. Foster is arguing that the pathological diagnoses are wrong, this could clearly be a case where glyphosate is affecting the late stages of carcinogenesis resulting in a movement of tumors from adenomas to adenocarcinomas without increasing the incidence of the combined tumors. Looking at hepatocellular adenomas and carcinomas in males in that same study, the rates for adenomas are 1/51, 1/51, 4/51 and 2/51 while the counts for carcinomas are 6/51, 11/51, 7/51 and 4/51. Again, there were no animals with both adenomas and carcinomas and in every group, the carcinoma counts exceed the adenoma counts suggesting either carcinomas do not arise from adenomas or that adenomas are rapidly converted to carcinomas.

Figure 3: Cancer as a multistage process



V. Other Studies

Dr. Foster argues to dismiss 13 of the 19 tumors (68%) in Table 4 because the same tumor was not seen in other studies of the same sex and species. This is again a misinterpretation of what a statistical p-value means when applied to an animal carcinogenicity study. As an illustration of why this strategy could be very misleading, consider the case of four animal cancer studies where the p-values for an increase in malignant lymphomas are 0.01, 0.051, 0.051 and 0.051. This means that there is only a 1%, 5.1%, 5.1% and 5.1% chance that the null hypothesis (the chemical does not increase the cancer risk) is true. On the other hand, if the p-values would have been 0.01, 0.05, 0.05 and 0.05, Dr. Foster would then say they all gave the same answer. Reaching these two different opinions based on a difference of 0.1% in p-values does not properly portray the importance of the results. In the first case, converting the results from multiple bioassays into yes or no decisions and then concluding there is no cancer hazard if all the studies are not a yes ignores the fact that all of the studies are telling us there is a consistent increase with exposure in these hypothetical data. The entire purpose of the pooled analysis is to objectively address this question rather than merely counting positive versus negative studies. As an example, consider lung adenocarcinomas in females in the two 18-month studies in CD-1 mice. **Wood et al. (2009)** has a p-value of 0.028 whereas **Sugimoto (1997)** has a p-value of 0.148. Combined, the overall p-value is not significant ($p=0.484$) suggesting there is no effect and, in this case, I would agree with Dr. Foster. On the other hand, hemangiomas in female mice in the same two studies have p-values of 0.002 and 0.438 with the combined analysis having a p-value of 0.001; in this case, I disagree with Dr. Foster that a

positive finding and a negative finding results in a negative finding. The presumption that there is no cancer hazard whenever two or more carcinogenicity studies differ in the statistical significance of a particular tumor site is scientifically unsound and should not be used as a reason for ignoring positive findings.

VI. Survival

For two of the tumor findings, Dr. Foster argues that survival differences could allow animals in the high-dose group to live longer and could explain the significant tumor increases. The EPA disagrees with Dr. Foster regarding survival differences in the study by **Lankas (1981)**^[6]. To be even more rigorous in my analysis, I used the poly-3 test adjustment for survival differences^[28, 29] and reanalyzed the data. This test is similar to the Armitage linear trend test but adjusts the number of animals at risk of getting the tumor based upon duration of life and is commonly used to analyze bioassays by the US National Toxicology Program. Testicular tumors in male Sprague-Dawley rats from the **Lankas (1981)**^[6] study had a p-value without survival adjustment of $p_{\text{trend}}=0.009$ and with survival adjustment of $p_{\text{trend}}=0.015$. Dr. Foster's comments regarding survival differences for hepatocellular adenomas in male rats in the study by **Brammer (2001)**^[7] cannot be resolved since individual animal times of death and tumor status are not publicly available and these data were not provided by Monsanto. In essence, this is not an issue.

VI. Fisher's Test

For four tumors, Dr. Foster uses, as part of his argument for dismissal, the observation that the pairwise comparisons via Fisher's exact test were not significant even though the trend test findings were. As noted on page 20 of the Expert Report, virtually all regulatory bodies consider a positive finding in either test as sufficient evidence to reject chance as leading to the positive finding.

VIII. Summary

Dr. Foster's methods for evaluating and drawing conclusions from animal carcinogenicity studies suffers from a lack of understanding in and/or experience with statistics, a failure to understand the correct role of historical controls, a dogmatic view of adenomas and carcinomas that is not supported by either scientific theory or data, a failure to properly evaluate the same findings over multiple studies, and a lack of understanding of findings from pairwise versus trend analyses. Dr. Foster's comments do not impact my conclusion that the animal data provide strong evidence for the biological plausibility, biological gradient, and coherence arguments developed by **Hill (1965)**^[16] supporting the conclusion that glyphosate can cause non-Hodgkin lymphoma in humans.

In this Rebuttal Report, I have not provided comments on the remaining five expert reports (Dr.s Fleming, Goodman, Mucci, Rider, and Rosol) provided by Monsanto. My lack of comments on these reports does not constitute acceptance of the arguments in these reports.

It is still my opinion that glyphosate probably causes NHL based on the human, animal and experimental evidence and that, to a reasonable degree of scientific certainty, the probability that glyphosate causes NHL is high. Nothing in the reports submitted by Monsanto, including the two reports that I respond to in this rebuttal report, changes that opinion.

Compensation

I am being compensated at \$450 per hour for my expert work in this case, plus travel expenses.

A handwritten signature in black ink, appearing to read 'Chris Portier', with a horizontal line extending to the right from the end of the signature.

Dr. Christopher J. Portier

References

1. Greim, H., et al., *Evaluation of carcinogenic potential of the herbicide glyphosate, drawing on tumor incidence data from fourteen chronic/carcinogenicity rodent studies*. Crit Rev Toxicol, 2015. **45**(3): p. 185-208.
2. Knezevich, A.L. and G.K. Hogan, *A chronic feeding study of glyphosate in mice: Monsanto*. 1983: Bio/Dynamic Inc., dated July 21, 1983. Report No. 77-2011. .
3. Sugimoto, K., *18-Month Oral Oncogenicity Study in Mice, Vol. 1 and 2*. 1997: The Institute of Environmental Toxicology, 2-772, Suzuki-cho, Kodaira-shi, Tokyo, 187, Japan, Study No.:IET 94-0151.
4. Fung, K.Y., D. Krewski, and R.T. Smythe, *A Comparison of Tests for Trend with Historical Controls in Carcinogen Bioassay*. The Canadian Journal of Statistics / La Revue Canadienne de Statistique, 1996. **24**(4): p. 431-454.
5. Giknis, M. and C. Clifford, *Spontaneous Neoplastic Lesions in the Crl:CD-1(ICR)BR Mouse*. 2000, Charles River Laboratories.
6. Lankas, G., P., *A Lifetime Study of Glyphosate in Rats*. 1981, Monsanto: Report No. 77-2062 prepared by Bio Dynamics, Inc.
7. Brammer., *Glyphosate Acid: Two Year Dietary Toxicity and Oncogenicity Study in Wistar Rats*. 2001: Central Toxicology Laboratory, Alderley Park Macclesfield, Cheshire, UK.
8. Wood, E., Dunster, J., Watson, P., and Brooks, P., *Glyphosate Technical: Dietary Combined Chronic Toxicity/Carcinogenicity Study in the Rat*. 2009: Harlan Laboratories Limited, Shardlow Business Park, Shardlow, Derbyshire DE72 2GD, UK. Study No. 2060-012. April, 23, 2009.
9. Stout, L.D.a.R., P.A., *Chronic Study of Glyphosate Administered in Feed to Albino Rats*. 1990: Monsanto.
10. Atkinson, C., Strutt, A., Henderson, W., et al., *104-Week Chronic Feeding/ Oncogenicity study in rats with 52-week interim kill*. 1993.
11. Enemoto, K., *24-Month Oral Chronic Toxicity and Oncogenicity Study in Rats, Vol. 1*. 1997: The Institute of Environmental Toxicology, Kodaira-shi, Tokyo, Japan.
12. Suresh, T.P., *Combined Chronic Toxicity and Carcinogenicity Study with Glyphosate Technical in Wistar Rats*. 1996, Syngenta: Toxicology Department Rallis Research Centre, Rallis India Limited.
13. Wood, E., Dunster, J., Watson, P., and Brooks, P., *Glyphosate Technical: Dietary Carcinogenicity Study in the Mouse*. 2009: Harlan Laboratories Limited, Shardlow Business Park, Shardlow, Derbyshire DE72 2GD, UK. Study No. 2060-011. April, 22, 2009.
14. World Health Organization. *International Classification of Diseases - Version 9*. 1975 [cited 2017 August 7]; Available from: <https://www.findacode.com/icd-9/icd-9-cm-diagnosis-codes.html>.
15. World Health Organization. *International Classification of Diseases - Version 10*. 1990 [cited 2017 August 7]; Available from: {World Health Organization, 1975 #4221}.
16. Hill, A.B., *The Environment and Disease: Association or Causation?* Proc R Soc Med, 1965. **58**: p. 295-300.

17. Atkinson, C., Martin, T., Hudson, P., and Robb, D., *Glyphosate: 104 week dietary carcinogenicity study in mice*. 1993; Inveresk Research International, Tranent, EH33 2NE, Scotland. IRI Project No. 438618. April 7, 1993.
18. Kumar, D.P.S., *Carcinogenicity Study with Glyphosate Technical in Swiss Albino Mice*. 2001; Toxicology Department Rallis Research Centre, Rallis India Limited. Study No. TOXI: 1559.CARCI-M.
19. IARC. *Preamble to the IARC Monographs*. 2006 [cited 2017 3/8/17]; Available from: <http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf>.
20. (BfR), G.F.I.f.R.A., *Glyphosate Renewal Assessment Report: Assessment of IARC Monographies Volume 112 (2015)*. 2015. V. 3Glyphosate Addendum I to RAR. p.
21. Giknis, M. and C. Clifford, *Compilation of Spontaneous Neoplastic Lesions and Survival in Crl:CD (SD) Rats from Control Groups*. 2004, Charles River Laboratories.
22. Giknis, M. and C. Clifford. *Neoplastic and Non-Neoplastic Lesions in the Charles River Wistar Hannover [Crl:WI(Han)] Rat*. 2011; Available from: http://www.criver.com/files/pdfs/rms/wistarhan/rm_rm_r_wistar_han_tox_data_2011.aspx.
23. Giknis, M. and C. Clifford, *Spontaneous Neoplastic Lesions in the Crl:CD-1(ICR)BR Mouse in Control Groups from 18 Month to 2 year Studies*. 2005, Charles River Laboratories.
24. Day, D.W., *The adenoma-carcinoma sequence*. Scand J Gastroenterol Suppl, 1984. **104**: p. 99-107.
25. O'Brien, M.J. and D. Gibbons, *The adenoma-carcinoma sequence in colorectal neoplasia*. Surg Oncol Clin N Am, 1996. **5**(3): p. 513-30.
26. Baczako, K., et al., *Morphogenesis and possible precursor lesions of invasive carcinoma of the papilla of Vater: epithelial dysplasia and adenoma*. Hum Pathol, 1985. **16**(3): p. 305-10.
27. Dixon, D., et al., *Summary of chemically induced pulmonary lesions in the National Toxicology Program (NTP) toxicology and carcinogenesis studies*. Toxicol Pathol, 2008. **36**(3): p. 428-39.
28. Bailer, A.J. and C.J. Portier, *Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples*. Biometrics, 1988. **44**(2): p. 417-31.
29. Portier, C.J. and A.J. Bailer, *Testing for increased carcinogenicity using a survival-adjusted quantal response test*. Fundam Appl Toxicol, 1989. **12**(4): p. 731-7.

Appendix: Modified tables from the Expert Report**Modified Table 1:** Tumors of interest in male and female Sprague-Dawley rats the 26-month feeding study of Lankas (1981)^[6]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	3.05	10.30	31.49	
	Female	0	3.37	11.22	34.02	
Testicular interstitial cell tumors	Male	0/50	3/50	1/50	6/50**	P _{Trend} =0.009 P _{Hist} =0.006
Interstitial cell hyperplasia	Male	1/50	1/50	1/50	0/50	P _{Trend} =0.830
Thyroid C-cell Carcinomas	Female	1/47	0/49	2/50	6/47	P _{Trend} =0.003 P _{Hist} <0.001
Thyroid C-cell Adenomas and Carcinomas	Female	6/47	3/49	8/50	9/47	P _{Trend} =0.072 P _{Hist} =0.072
Pancreas Islet Cell Tumors	Male	0/50	5/50*	2/50	3/50	P _{Trend} =0.312
lymphocytic hyperplasia, thymus and lymph nodes	Female	27/50	35/50	38/50*	35/50	P _{Trend} =0.143
Thyroid C-cell Adenomas and Carcinomas	Male	1/47	2/49	4/49	4/49	P _{Trend} =0.122
Thyroid Follicular-cell Adenoma	Male	5/47	1/49	2/49	2/49	P _{Trend} =0.748
Liver Neoplastic Nodule	Male	3/50	5/50	1/50	3/10	P _{Trend} =0.630
Kidney Adenoma	Male	1/50	5/50	0/50	0/50	P _{Trend} =0.979
Adrenal Cortical Carcinoma	Female	5/50	10/50	6/50	4/49	P _{Trend} =0.851
Skin Keratoacanthoma	Male	0/49	0/48	0/49	0/49	P _{Trend} =1
Basal Cell Tumor	Male	0/49	0/48	0/49	1/49	P _{Trend} =0.251

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Modified Table 2: Tumors of interest in male and female Sprague-Dawley rats from the 24-month feeding study of **Stout and Ruecker (1990)**^[9]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	89	362	940	
	Female	0	113	457	1183	
Pancreas Islet Cell Tumors (with interim sacrifice)	Male	1/58	8/57*	5/60	7/59*	P _{Trend} =0.147 P _{Hist} =0.140
Pancreas Islet Cell Tumors (without interim sacrifice)	Male	1/48	8/47*	5/50	7/49*	P _{Trend} =0.147 P _{Hist} =0.150
Hepatocellular adenomas (without interim sacrifice)	Male	3/50	2/50	3/50	8/50	P _{Trend} =0.015
Hepatocellular Adenomas and Carcinomas (without interim sacrifice)	Male	6/50	4/50	4/50	10/50	P _{Trend} =0.050
Thyroid C-Cell Adenomas (with interim sacrifice)	Female	2/60	2/60	6/60	6/60	P _{Trend} =0.050
Thyroid C-Cell Adenomas (without interim sacrifice)	Female	2/50	2/50	6/50	6/50	P _{Trend} =0.049
Thyroid C-Cell Adenomas and Carcinomas (with interim sacrifice)	Female	2/60	2/60	7/60	6/60	P _{Trend} =0.053
Thyroid C-Cell Adenomas and Carcinomas (without interim sacrifice)	Female	2/50	2/50	7/50	6/50	P _{Trend} =0.052
Thyroid C-Cell Adenomas (with interim sacrifice)	Male	2/60	4/60	8/60	7/60	P _{Trend} =0.063
Thyroid C-Cell Adenomas (without interim sacrifice)	Male	0/50	4/50	8/50**	5/50*	P _{Trend} =0.084
Thyroid C-Cell Adenomas and Carcinomas (with interim sacrifice)	Male	2/60	6/60	8/60*	8/60*	P _{Trend} =0.068
Thyroid C-Cell Adenomas and Carcinomas (without interim sacrifice)	Male	0/50	6/50*	8/50**	6/50*	P _{Trend} =0.091
Testis Interstitial Cell Tumors	Male	2/50	0/50	3/50	2/50	P _{Trend} =0.296
Kidney Adenomas	Males	0/50	2/50	0/50	0/50	P _{Trend} =0.813
Thyroid Follicular Adenoma/Carcinoma	Males	2/50	1/48	3/48	3/50	P _{Trend} =0.225
Adrenal Cortical Carcinoma	Female	0/50	0/50	0/50	3/50	P _{Trend} =0.015
Skin Keratoacanthoma	Male	1/50	3/50	4/50	5/50	P _{Trend} =0.078
Basal Cell Tumor	Male	0/50	0/50	0/50	1/50	P _{Trend} =0.250

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Modified Table 3: Tumors of interest in male and female Sprague-Dawley rats from the 24-month feeding study of **Atkinson et al. (1993)**^[10]

Tumor	Sex	Doses (mg/kg/day)					p-values
	Male	0	11	112	320	1147	
	Female	0	12	109	347	1134	
Thyroid Follicular Adenomas and Carcinomas	Male	0/50	0/21	0/17	2/21	2/49	P _{Trend} =0.099
Thyroid Follicular Adenomas and Carcinomas (adding terminal sacrifice animals to denominator)	Male	0/50	0/50	0/50	2/50	2/49	P _{Trend} =0.034
Thyroid C-cell Adenomas and Carcinomas	Female	8/50	1/27	1/29	1/29	7/49	P _{Trend} =0.197
Thyroid C-cell Adenomas and Carcinomas	Male	9/50	1/21	1/17	2/21	9/49	P _{Trend} =0.183
Testes Interstitial Cell Tumors	Male	3/50	1/25	0/19	0/21	2/50	P _{Trend} =0.580
Kidney Adenomas	Males	1/50	0/50	0/50	0/50	0/50	p _{Trend} =1
Hepatocellular Adenomas	Males	2/50	1/50	1/50	2/50	3/50	P _{Trend} =0.155
Pancreas Islet-Cell Adenoma	Male	0/50	0/50	0/50	0/50	1/50	P _{Trend} =0.200
Skin Epithelioma (keratoacanthoma)	Male	1/50	2/25	0/19	0/21	5/50	P _{Trend} =0.047
Adrenal Cortical Carcinoma	Female	0/48	0/26	0/29	1/30	0/49	P _{Trend} =0.434
Basal Cell Tumor	Male	1/50	0/25	0/19	0/21	0/50	P _{Trend} =1

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Modified Table 4: Tumors of interest in male and female Wistar rats from the 24-month feeding study of **Brammer (2001)**^[7]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	121	361	1214	
	Female	0	145	437	1498	
Hepatocellular Adenoma	Male	0/52	2/52	0/52	5/52*	P _{Trend} =0.008
Hepatocellular Adenoma (from Greim et al., 2015 ^[11])	Male	0/53	2/53	0/53	5/52*	P _{Trend} =0.008 P _{Hist} =0.006
Mammary Gland Adenomas and Adenocarcinomas	Female	3/51	2/51	0/51	2/51	P _{Trend} =0.575
Skin Keratocanthoma	Male	1/51	0/51	1/51	1/51	P _{Trend} =0.392
Pituitary Adenoma	Male	16/63	15/62	18/63	10/62	P _{Trend} =0.922
Pituitary Adenoma	Female	42/61	40/61	42/62	45/63	P _{Trend} =0.291

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01**Modified Table 5:** Tumors of interest in male and female Wistar rats from the 24-month feeding study of **Suresh(1996)**^[12]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	6.3	59.4	595.2	
	Female	0	8.6	88.5	886	
Mammary Gland Adenoma and Carcinoma	Female	5/40	3/28	8/33	2/48	P _{Trend} =0.970
Hepatocellular Adenoma	Male	24/50	22/50	10/50	21/50	P _{Trend} =0.374
Skin Keratocanthoma	Male	0/50	0/50	0/50	0/50	P _{Trend} =1
Pituitary Adenoma	Male	3/49	4/30	3/31	5/49	P _{Trend} =0.376
Pituitary Adenoma	Female	7/49	13/33	7/23	6/50	P _{Trend} =0.967

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Modified Table 6: Tumors of interest in male and female Sprague-Dawley rats from the 24-month feeding study of **Enemoto (1997)**^[11]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	104	354	1127	
	Female	0	115	393	1247	
Mammary Gland Adenoma	Female	23/50	27/50	24/50	30/50	P _{Trend} =0.106
Kidney Adenoma	Male	0/50	0/50	0/50	4/50	P _{Trend} =0.004
Thyroid C-cell Adenomas/Carcinomas	Female	4/60	7/60	8/60	4/60	P _{Trend} =0.692
Thyroid C-cell Adenomas/Carcinomas	Male	8/70	10/70	6/70	7/70	P _{Trend} =0.697
Thyroid Follicular-cell Adenomas/Carcinomas	Male	4/70	2/70	1/70	0/70	P _{Trend} =0.990
Testes Interstitial Cell Tumors	Male	3/49	2/50	0/50	2/50	P _{Trend} =0.594
Hepatocellular Adenomas	Male	1/60	0/60	2/60	1/60	P _{Trend} =0.371
Skin Keratoacanthoma ¹	Male	3/50	3/50	0/50	7/50	P _{Trend} =0.029
Pancreas Islet-Cell Adenoma	Male	4/50	1/50	2/50	1/50	P _{Trend} =0.844
Adrenal Cortical Carcinoma	Male	0/50	0/50	0/50	0/50	P _{Trend} =1
Basal Cell Tumor	Male	0/50	0/50	0/50	3/50	P _{Trend} =0.015

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01, ¹ without interim sacrifices

Modified Table 7: Tumors of interest in male and female Wistar rats from the 24-month feeding study of **Wood et al. (2009)**^[8]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	85.5	285.2	1077.4	
	Female	0	104.5	348.6	1381.9	
Mammary Gland Adenomas	Female	0/51	0/51	0/51	2/51	P _{Trend} =0.062
Mammary Gland Adenocarcinomas	Female	2/51	3/51	1/51	6/51	P _{Trend} =0.042
Mammary Gland Adenomas and Adenocarcinomas	Female	2/51	3/51	1/51	8/51*	P _{Trend} =0.007
Skin Keratocanthoma	Male	2/51	3/51	0/51	6/51	P _{Trend} =0.030
Hepatocellular Adenoma	Male	0/51	2/51	1/51	1/51	P _{Trend} =0.418
Pituitary Adenoma	Male	16/51	11/51	10/51	20/51	P _{Trend} =0.045
Pituitary Adenoma	Female	24/51	13/51	16/51	32/51	P _{Trend} =0.014

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01

Modified Table 9: Tumors of interest in male and female CD-1 mice from the 24-month feeding study of Knezevich and Hogan (1983)^[2]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	157	814	4841	
	Female	0	190	955	5874	
Kidney Adenoma ¹ (original pathology)	Male	0/49	0/49	1/50	3/50	P _{Trend} =0.019 P _{Hist} =0.005
Kidney Adenoma (EPA pathology)	Male	1/49	0/49	0/50	1/50	P _{Trend} =0.442 P _{Hist} =0.121
Kidney Carcinoma ² (EPA pathology)	Male	0/49	0/49	1/50	2/50	P _{Trend} =0.063 P _{Hist} =0.002
Kidney Adenoma and Carcinoma Combined ³ (EPA pathology)	Male	1/49	0/49	1/50	3/50	P _{Trend} =0.065 P _{Hist} =0.011
Malignant Lymphoma ⁴	Male	2/49	5/49	4/50	2/50	P _{Trend} =0.754 P _{Hist} =0.767
Hemangiosarcoma ⁵	Male	0/50	0/49	1/50	0/50	P _{Trend} =0.503 P _{Hist} =0.591
Bilateral Chronic Interstitial Nephritis	Male	5/49	1/49	7/50	11/50	P _{Trend} =0.006
Hemangioma ⁶	Female	0/49	1/49	1/50	0/50	P _{Trend} =0.631
Lung Adenocarcinoma ⁷	Male	4/48	3/50	2/50	1/50	P _{Trend} =0.918 P _{Hist} =0.899
Harderian Gland Adenoma	Female	0/49	0/49	1/50	0/50	P _{Trend} =0.505
Spleen Composite Lymphosarcoma	Female	1/49	1/49	1/50	5/50	P _{Trend} =0.015

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01, ¹historical rate=0.27%, ²historical rate=0.15%, ³historical rate=0.44%, ⁴historical rate=6.2%, ⁵historical rate=2.5%, ⁶No Historical Controls, ⁷Historical rate=9.2%

Modified Table 10: Tumors of interest in male and female CD-1 mice from the 24-month feeding study of Atkinson et al. (1993)^[17]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	98	297	988	
	Female	0	102	298	1000	
Kidney Adenoma and Carcinoma Combined ¹	Male	2/50	2/50	0/50	0/50	P _{Trend} =0.981 P _{Hist} =1
Malignant Lymphoma ²	Male	4/50	2/50	1/50	6/50	P _{Trend} =0.087 P _{Hist} =0.085
Hemangiosarcoma ³	Male	0/50	0/50	0/50	4/50	P _{Trend} =0.004 P _{Hist} =0.001
Hemangioma ⁴	Female	0/50	0/50	0/50	0/50	P _{Trend} =1
Lung Adenocarcinoma ⁵	Male	10/50	7/50	8/50	9/50	P _{Trend} =0.456 P _{Hist} =0.449
Harderian Gland Adenoma	Female	Not examined				

*- $p_{\text{Fisher}} < 0.05$, **- $p_{\text{Fisher}} < 0.01$, ¹historical rate=0.44%, ²historical rate=6.2%, ³historical rate=2.5%, ⁴No historical control rate, ⁵Historical rate=9.2%

Modified Table 11: Tumors of interest in male and female CD-1 mice from the 18-month feeding study of Wood et al. (2009)^[13]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	71.4	234.2	810	
	Female	0	97.9	299.5	1081.2	
Kidney Adenoma ¹	Male	0/51	0/51	0/51	0/51	P _{Trend} =1
Malignant Lymphoma ²	Male	0/51	1/51	2/51	5/51*	P _{Trend} =0.007 P _{Hist} =0.007
Hemangiosarcoma	Male	0/51	0/51	0/51	0/51	P _{Trend} =1
Lung Adenocarcinoma ³	Male	5/51	5/51	7/51	11/51	p _{Trend} =0.028 P _{Hist} =0.031
Hemangioma ⁴	Female	0/51	2/51	0/51	1/51	p _{Trend} =0.438
Harderian Gland	Female	1/51	0/51	0/51	2/51	p _{Trend} =0.155
Animals with Malignant Neoplasms	Male	14/51	20/51	17/51	20/51	P _{Trend} =0.203
Animals with Malignant Neoplasms	Female	23/51	15/51	17/51	18/51	P _{Trend} =0.628
Animals with multiple malignant tumors	Male	1/51	2/51	3/51	5/51	P _{Trend} =0.046

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01, ¹historical rate=0.44%, ²historical rate=2.6%, ³Historical rate=2.5%, ⁴No Historical Control Rate

Modified Table 12: Tumors of interest in male and female CD-1 mice from the 18-month feeding study of **Sugimoto (1997)**^[3]

Tumor	Sex	Doses (mg/kg/day)				p-values
	Male	0	165	838.1	4348	
	Female	0	153.2	786.8	4116	
Kidney Adenoma ¹	Male	0/50	0/50	0/50	2/50	P _{Trend} =0.062 P _{Hist} =0.005
Malignant Lymphoma ²	Male	2/50	2/50	0/50	6/50	P _{Trend} =0.016 P _{Hist} =0.017
Hemangiosarcoma ³	Male	0/50	0/50	0/50	2/50	P _{Trend} =0.062 P _{Hist} =0.004
Hemangioma ⁴	Female	0/50	0/50	2/50	5/50*	P _{Trend} =0.002
Lung Adenocarcinoma ⁵	Male	1/50	1/50	6/50	4/50	P _{Trend} =0.148 P _{Hist} =0.140
Harderian Gland Adenoma	Female	1/50	3/50	0/50	5/50	P _{Trend} =0.040
Number of animals with Malignant Neoplasms	Male	5/50	5/50	11/50	16/50**	P _{Trend} =0.001
Number of animals with Malignant Neoplasms	Female	9/50	13/50	16/50	13/50	P _{Trend} =0.362

*- p_{Fisher}<0.05, **- p_{Fisher}<0.01, ¹historical rate=0.44%, ²historical rate=2.6%, ³historical rate=0/1424 (0.26% - 95% confidence limit), ⁴No Historical Control Rate, ⁵Historical rate=2.5%

Modified Table 15: Observed versus expected tumor sites with significant trends in the 12 acceptable rodent carcinogenicity studies using glyphosate.

Species	Strain	Sex	Total Sites ¹	Exp. <0.05	Obs. <0.05	Tumors ² p<0.05	Exp. <0.01	Obs. <0.01	Tumors p<0.01
Rat (7 studies)	Sprague-Dawley (4 studies)	M	86	4.3	9	TICT, TFAC, KA, HA, HAC, SE, SK(2) ³ , BC	0.9	2	TICT, KA
		F	80	4	3	TCCA, TCCC, AC	0.8	1	TCCC
	Wistar (3 studies)	M	64.5	3.2	3	HA, SK, PA	0.6	1	HA
		F	60	3	3	MC, MAC, PA	0.6	1	MAC
Mouse (5 studies)	CD-1 (4 studies)	M	42	2.1	8	KA, KC, KAC, HS(2), ML(2), LAC	0.4	5	KA, KC, HS(2), ML
		F	60	3	3	H, SL, HGA	0.6	1	H
	Albino (1 study)	M	10.5	0.5	0		0.1	0	
		F	15	0.8	1	H	0.2	1	H
Rats (7 studies)	All (7 studies)	M	150.5	7.5	11	TICT, TFAC, KA, HA(2), HAC, SE, SK(3), BC, PA	1.5	3	TICT, KA, HA
		F	140	7	6	TCCA, TCCC, AC, MC, MAC, PA	1.4	2	TCCC, MAC
		Both	295.5	14.5	19	TICT, TFAC, KA, HA(2), HAC, SE, SK(3), BC, PA(2), TCCA, TCCC, AC, MC, MAC	3.0	5	TICT, KA, HA, TCCC, MAC
Mice (5 studies)	All (5 studies)	M	52.5	2.6	8	KA, KC, KAC, HS(2), ML(2), LAC	0.5	5	KA, KC, HS(2), ML
		F	75	3.8	4	H(2), SL, HGA	0.7	2	H(2)
		Both	127.5	6.4	12	KA, KC, KAC, HS(2), H(2), ML(2), LAC, SL, HGA	1.3	7	KA, KC, HS(2), H(2), ML
All (12 studies)	All (12 studies)	M	203	10.1	20	TICT, TFAC, KA(2), HA(2), HAC, SE, SK(3), BC, PA, KC, KAC, HS(2), ML(2), LAC	2.0	8	TICT, HA, KA(2), KC, HS(2), ML
		F	215	10.8	10	TCCA, TCCC, MC, MAC, H(2), AC, PA, SL, HGA	2.2	4	TCCC, MAC, H(2)
		Both	418	20.9	30	TICT, TFAC, KA(2), HA(2), HAC, SE, SK(3), BC, PA(2), KC, KAC, HS(2), ML(2), LAC, TCCA, TCCC, MC, MAC, H(2), AC, SL, HGA	4.2	12	TICT, HA, KA(2), KC, HS(2), H(2), ML, TCCC, MAC

¹ Number of sites examined is based upon suggestions by Dr. J. Haseman in his written testimony to the EPA with female rats modified for fewer sites with 3 or more tumors; male mice – 10.5 sites; female mice – 15 sites; male rats – 21.5 sites; female rats – 20 sites

² Tumor abbreviations are: KA – kidney adenoma; KC – kidney carcinoma; KAC – kidney adenoma or carcinoma; HS – hemangiosarcoma; H – hemangioma; HA – hepatocellular adenoma; LAC – lung adenoma or adenocarcinoma; ML – malignant lymphoma; MC – mammary gland carcinoma; MAC – mammary gland adenoma or carcinoma; TCCA – thyroid C-cell adenoma; TCCC – thyroid C-cell carcinoma; TFAC – thyroid follicular cell adenoma or carcinoma; TICT – testes interstitial cell tumor; SK – skin keratoacanthoma; SE – skin epithelioma; AC – adrenal cortical carcinoma; BC – basal cell tumor; PA – pituitary adenoma; SL – skin lymphoma; HGA – Harderian gland adenoma

³(x): x studies with this result